Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,11221829,response rate,"5-Fluorouracil (5-FU) is one of the most widely used anticancer agents for advanced colorectal carcinoma, but its response rate is only 15%.",Dual antitumor effects of 5-fluorouracil on the cell cycle in colorectal carcinoma cells: a novel target mechanism concept for pharmacokinetic modulating chemotherapy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11221829/),%,15,726,DB00544,Fluorouracil
,16369821,systemic clearance,"The mean irinotecan systemic clearance and steady-state volume of distribution values were 14.3 l/h/m(2) and 211 l/m(2), respectively.",Pharmacokinetics and pharmacodynamics of irinotecan and its metabolites from plasma and saliva data in patients with metastatic digestive cancer receiving Folfiri regimen. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16369821/),[h·l] / [m(2],14.3,1034,DB00544,Fluorouracil
,16369821,steady-state volume of distribution,"The mean irinotecan systemic clearance and steady-state volume of distribution values were 14.3 l/h/m(2) and 211 l/m(2), respectively.",Pharmacokinetics and pharmacodynamics of irinotecan and its metabolites from plasma and saliva data in patients with metastatic digestive cancer receiving Folfiri regimen. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16369821/),[l] / [m(2],211,1035,DB00544,Fluorouracil
,16369821,saliva/plasma AUC ratios,"The saliva/plasma AUC ratios averaged 1 for irinotecan, 0.3 for SN-38, 0.17 for APC and 0.27 for NPC.",Pharmacokinetics and pharmacodynamics of irinotecan and its metabolites from plasma and saliva data in patients with metastatic digestive cancer receiving Folfiri regimen. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16369821/),,1,1036,DB00544,Fluorouracil
,16369821,saliva/plasma AUC ratios,"The saliva/plasma AUC ratios averaged 1 for irinotecan, 0.3 for SN-38, 0.17 for APC and 0.27 for NPC.",Pharmacokinetics and pharmacodynamics of irinotecan and its metabolites from plasma and saliva data in patients with metastatic digestive cancer receiving Folfiri regimen. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16369821/),,0.3,1037,DB00544,Fluorouracil
,16369821,saliva/plasma AUC ratios,"The saliva/plasma AUC ratios averaged 1 for irinotecan, 0.3 for SN-38, 0.17 for APC and 0.27 for NPC.",Pharmacokinetics and pharmacodynamics of irinotecan and its metabolites from plasma and saliva data in patients with metastatic digestive cancer receiving Folfiri regimen. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16369821/),,0.17,1038,DB00544,Fluorouracil
,16369821,saliva/plasma AUC ratios,"The saliva/plasma AUC ratios averaged 1 for irinotecan, 0.3 for SN-38, 0.17 for APC and 0.27 for NPC.",Pharmacokinetics and pharmacodynamics of irinotecan and its metabolites from plasma and saliva data in patients with metastatic digestive cancer receiving Folfiri regimen. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16369821/),,0.27,1039,DB00544,Fluorouracil
,29315736,AUC0-50,"The AUC0-50 of free platinum plasma ultrafiltrate after cycles 1-3, respectively, was 24.3, 24.7 and 25.8 μg*h/mL.",Dosing oxaliplatin in a haemodialysis patient with metastatic rectum cancer monitored by free platinum concentrations. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29315736/),[h·μg] / [ml],24.3,1183,DB00544,Fluorouracil
,29315736,AUC0-50,"The AUC0-50 of free platinum plasma ultrafiltrate after cycles 1-3, respectively, was 24.3, 24.7 and 25.8 μg*h/mL.",Dosing oxaliplatin in a haemodialysis patient with metastatic rectum cancer monitored by free platinum concentrations. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29315736/),[h·μg] / [ml],24.7,1184,DB00544,Fluorouracil
,29315736,AUC0-50,"The AUC0-50 of free platinum plasma ultrafiltrate after cycles 1-3, respectively, was 24.3, 24.7 and 25.8 μg*h/mL.",Dosing oxaliplatin in a haemodialysis patient with metastatic rectum cancer monitored by free platinum concentrations. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29315736/),[h·μg] / [ml],25.8,1185,DB00544,Fluorouracil
,29315736,Cmax,"The Cmax was, respectively, 1.3, 1.3 and 2.2 μg/mL.",Dosing oxaliplatin in a haemodialysis patient with metastatic rectum cancer monitored by free platinum concentrations. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29315736/),[μg] / [ml],1.3,1186,DB00544,Fluorouracil
,29315736,Cmax,"The Cmax was, respectively, 1.3, 1.3 and 2.2 μg/mL.",Dosing oxaliplatin in a haemodialysis patient with metastatic rectum cancer monitored by free platinum concentrations. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29315736/),[μg] / [ml],2.2,1187,DB00544,Fluorouracil
,24383625,drug-loading content,"The system was prepared under very mild conditions in an aqueous medium containing Ca(2+) and CO3(2-) ions, generating uniform pectin-based nanoparticles with an average diameter of 300 nm, and the drug-loading content of anticancer drug 5-fluorouracil (5-FU) is around 24.8%.",In vitro and in vivo evaluation of pectin-based nanoparticles for hepatocellular carcinoma drug chemotherapy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24383625/),,24.8,1657,DB00544,Fluorouracil
,23665950,objective response rate,The objective response rate was 37.5 %; six additional patients experienced no disease progression for ≥24 weeks.,Phase I study of sunitinib plus S-1 and cisplatin in Japanese patients with advanced or metastatic gastric cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23665950/),%,37.5,2167,DB00544,Fluorouracil
,23665950,progression-free survival,Median progression-free survival was 12.5 months.,Phase I study of sunitinib plus S-1 and cisplatin in Japanese patients with advanced or metastatic gastric cancer. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23665950/),month,12.5,2168,DB00544,Fluorouracil
,23665950,MTD,The MTD of sunitinib was 25 mg/day on Schedule 2/2 combined with cisplatin/S-1 in patients with advanced/metastatic gastric cancer.,Phase I study of sunitinib plus S-1 and cisplatin in Japanese patients with advanced or metastatic gastric cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23665950/),[mg] / [d],25,2169,DB00544,Fluorouracil
,11474245,response rate,"Antitumor activity was similar in the two arms and was very promising both in pretreated patients (response rate 29%; 95% confidence interval 15-46%) and in chemotherapy-naive patients (response rate 56%, complete response 9%, 95% confidence interval 40-71%).",5-fluorouracil administered as a 48-hour chronomodulated infusion in combination with leucovorin and cisplatin: a randomized phase II study in metastatic colorectal cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11474245/),%,29,2284,DB00544,Fluorouracil
,11474245,response rate,"Antitumor activity was similar in the two arms and was very promising both in pretreated patients (response rate 29%; 95% confidence interval 15-46%) and in chemotherapy-naive patients (response rate 56%, complete response 9%, 95% confidence interval 40-71%).",5-fluorouracil administered as a 48-hour chronomodulated infusion in combination with leucovorin and cisplatin: a randomized phase II study in metastatic colorectal cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11474245/),%,56,2285,DB00544,Fluorouracil
,11474245,complete response,"Antitumor activity was similar in the two arms and was very promising both in pretreated patients (response rate 29%; 95% confidence interval 15-46%) and in chemotherapy-naive patients (response rate 56%, complete response 9%, 95% confidence interval 40-71%).",5-fluorouracil administered as a 48-hour chronomodulated infusion in combination with leucovorin and cisplatin: a randomized phase II study in metastatic colorectal cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11474245/),%,9,2286,DB00544,Fluorouracil
,11474245,survival,"Median survival of the patients with and without pretreatment was 12 and 16 months, respectively.",5-fluorouracil administered as a 48-hour chronomodulated infusion in combination with leucovorin and cisplatin: a randomized phase II study in metastatic colorectal cancer. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11474245/),month,12,2287,DB00544,Fluorouracil
,11474245,survival,"Median survival of the patients with and without pretreatment was 12 and 16 months, respectively.",5-fluorouracil administered as a 48-hour chronomodulated infusion in combination with leucovorin and cisplatin: a randomized phase II study in metastatic colorectal cancer. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11474245/),month,16,2288,DB00544,Fluorouracil
,17522242,overall response rate,"The overall response rate was 19.3% (95% confidence interval, 9.2%-29.5%).",Multi-institutional phase II study of S-1 monotherapy in advanced gastric cancer with pharmacokinetic and pharmacogenomic evaluations. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17522242/),%,19.3,2590,DB00544,Fluorouracil
,17522242,time to progression,"Over a median follow-up duration of 265 days, the median time to progression and overall survival time were 126 and 264 days, respectively.",Multi-institutional phase II study of S-1 monotherapy in advanced gastric cancer with pharmacokinetic and pharmacogenomic evaluations. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17522242/),d,126,2591,DB00544,Fluorouracil
,17522242,overall survival time,"Over a median follow-up duration of 265 days, the median time to progression and overall survival time were 126 and 264 days, respectively.",Multi-institutional phase II study of S-1 monotherapy in advanced gastric cancer with pharmacokinetic and pharmacogenomic evaluations. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17522242/),d,264,2592,DB00544,Fluorouracil
,20714726,overall response rate,"On intent-to-treat analysis, the overall response rate, median progression-free and overall survival were 35.3% [95% confidence interval (CI): 19.2-51.3%], 2.9 (95% CI: 2.4-5.8) months and 9.8 (95% CI: 6.1-NA) months, respectively.",A phase II and pharmacokinetic study of first line S-1 for advanced gastric cancer in Taiwan. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20714726/),%,35.3,2674,DB00544,Fluorouracil
,20714726,overall survival,"On intent-to-treat analysis, the overall response rate, median progression-free and overall survival were 35.3% [95% confidence interval (CI): 19.2-51.3%], 2.9 (95% CI: 2.4-5.8) months and 9.8 (95% CI: 6.1-NA) months, respectively.",A phase II and pharmacokinetic study of first line S-1 for advanced gastric cancer in Taiwan. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20714726/),month,9.8,2675,DB00544,Fluorouracil
,688233,half-life,"The mean half-life was 11.4 min, and drug was essentially cleared from plasma in 1 hr.",Pharmacokinetics of fluorouracil in humans. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/688233/),min,11.4,3849,DB00544,Fluorouracil
,23595344,maximum tolerated dose,"The maximum tolerated dose of irinotecan was 350 mg/m(2) for the 0 and 1 DA groups, and 200 mg/m(2) for the 2 DA group.",A UGT1A1*28 and *6 genotype-directed phase I dose-escalation trial of irinotecan with fixed-dose capecitabine in Korean patients with metastatic colorectal cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23595344/),,350,4242,DB00544,Fluorouracil
,23595344,maximum tolerated dose,"The maximum tolerated dose of irinotecan was 350 mg/m(2) for the 0 and 1 DA groups, and 200 mg/m(2) for the 2 DA group.",A UGT1A1*28 and *6 genotype-directed phase I dose-escalation trial of irinotecan with fixed-dose capecitabine in Korean patients with metastatic colorectal cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23595344/),,200,4243,DB00544,Fluorouracil
,23595344,AUClast ratios,"For the 0, 1, and 2 DA groups, mean AUClast ratios of SN-38G to SN-38 were 7.72, 5.71, and 2.72 (P = 0.0023) and relative dose intensities at recommended dose were 85, 83, and 97 %.",A UGT1A1*28 and *6 genotype-directed phase I dose-escalation trial of irinotecan with fixed-dose capecitabine in Korean patients with metastatic colorectal cancer. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23595344/),,7.72,4244,DB00544,Fluorouracil
,23595344,AUClast ratios,"For the 0, 1, and 2 DA groups, mean AUClast ratios of SN-38G to SN-38 were 7.72, 5.71, and 2.72 (P = 0.0023) and relative dose intensities at recommended dose were 85, 83, and 97 %.",A UGT1A1*28 and *6 genotype-directed phase I dose-escalation trial of irinotecan with fixed-dose capecitabine in Korean patients with metastatic colorectal cancer. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23595344/),,5.71,4245,DB00544,Fluorouracil
,23595344,AUClast ratios,"For the 0, 1, and 2 DA groups, mean AUClast ratios of SN-38G to SN-38 were 7.72, 5.71, and 2.72 (P = 0.0023) and relative dose intensities at recommended dose were 85, 83, and 97 %.",A UGT1A1*28 and *6 genotype-directed phase I dose-escalation trial of irinotecan with fixed-dose capecitabine in Korean patients with metastatic colorectal cancer. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23595344/),,2.72,4246,DB00544,Fluorouracil
,23595344,AUClast ratios,"For the 0, 1, and 2 DA groups, mean AUClast ratios of SN-38G to SN-38 were 7.72, 5.71, and 2.72 (P = 0.0023) and relative dose intensities at recommended dose were 85, 83, and 97 %.",A UGT1A1*28 and *6 genotype-directed phase I dose-escalation trial of irinotecan with fixed-dose capecitabine in Korean patients with metastatic colorectal cancer. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23595344/),,85,4247,DB00544,Fluorouracil
,23595344,AUClast ratios,"For the 0, 1, and 2 DA groups, mean AUClast ratios of SN-38G to SN-38 were 7.72, 5.71, and 2.72 (P = 0.0023) and relative dose intensities at recommended dose were 85, 83, and 97 %.",A UGT1A1*28 and *6 genotype-directed phase I dose-escalation trial of irinotecan with fixed-dose capecitabine in Korean patients with metastatic colorectal cancer. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23595344/),,83,4248,DB00544,Fluorouracil
,23595344,AUClast ratios,"For the 0, 1, and 2 DA groups, mean AUClast ratios of SN-38G to SN-38 were 7.72, 5.71, and 2.72 (P = 0.0023) and relative dose intensities at recommended dose were 85, 83, and 97 %.",A UGT1A1*28 and *6 genotype-directed phase I dose-escalation trial of irinotecan with fixed-dose capecitabine in Korean patients with metastatic colorectal cancer. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23595344/),,97,4249,DB00544,Fluorouracil
,18260367,IC50,"Gamma-hydroxybutylic acid (GHB) and gamma-butyrolactone (GBL), the metabolites of UFT, which is an oral fluoropyrimidine, have been reported to inhibit angiogenesis with IC50 values of 25.8 ng/ml.","Pharmacokinetics of gamma-hydroxybutylic acid (GHB) and gamma-butyrolactone (GBL), the anti-angiogenic metabolites of oral fluoropyrimidine UFT, in patients with gastric cancer. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18260367/),[ng] / [ml],25.8,4462,DB00544,Fluorouracil
,18260367,concentrations,The baseline and endogenous GBL concentrations in plasma were 20.2 +/- 7.5 ng/ml for patients and 16.8 +/- 4.0 ng/ml for volunteers (P = 0.221).,"Pharmacokinetics of gamma-hydroxybutylic acid (GHB) and gamma-butyrolactone (GBL), the anti-angiogenic metabolites of oral fluoropyrimidine UFT, in patients with gastric cancer. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18260367/),[ng] / [ml],20.2,4463,DB00544,Fluorouracil
,18260367,concentrations,The baseline and endogenous GBL concentrations in plasma were 20.2 +/- 7.5 ng/ml for patients and 16.8 +/- 4.0 ng/ml for volunteers (P = 0.221).,"Pharmacokinetics of gamma-hydroxybutylic acid (GHB) and gamma-butyrolactone (GBL), the anti-angiogenic metabolites of oral fluoropyrimidine UFT, in patients with gastric cancer. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18260367/),[ng] / [ml],16.8,4464,DB00544,Fluorouracil
,18260367,C(max),"The values of C(max) for tegafur, uracil, 5-FU and GBL were 14.7 +/- 5.2 and 4.0 +/- 2.8 microg/ml, 191.2 +/- 115.3 and 147.5 +/- 57.3 ng/ml, respectively, and the values of Tmax were 1.0 +/- 0.6, 1.1 +/- 0.6, 0.9 +/- 0.6 and 1.2 +/- 0. 6 hr, respectively.","Pharmacokinetics of gamma-hydroxybutylic acid (GHB) and gamma-butyrolactone (GBL), the anti-angiogenic metabolites of oral fluoropyrimidine UFT, in patients with gastric cancer. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18260367/),[μg] / [ml],14.7,4465,DB00544,Fluorouracil
,18260367,C(max),"The values of C(max) for tegafur, uracil, 5-FU and GBL were 14.7 +/- 5.2 and 4.0 +/- 2.8 microg/ml, 191.2 +/- 115.3 and 147.5 +/- 57.3 ng/ml, respectively, and the values of Tmax were 1.0 +/- 0.6, 1.1 +/- 0.6, 0.9 +/- 0.6 and 1.2 +/- 0. 6 hr, respectively.","Pharmacokinetics of gamma-hydroxybutylic acid (GHB) and gamma-butyrolactone (GBL), the anti-angiogenic metabolites of oral fluoropyrimidine UFT, in patients with gastric cancer. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18260367/),[μg] / [ml],4.0,4466,DB00544,Fluorouracil
,18260367,C(max),"The values of C(max) for tegafur, uracil, 5-FU and GBL were 14.7 +/- 5.2 and 4.0 +/- 2.8 microg/ml, 191.2 +/- 115.3 and 147.5 +/- 57.3 ng/ml, respectively, and the values of Tmax were 1.0 +/- 0.6, 1.1 +/- 0.6, 0.9 +/- 0.6 and 1.2 +/- 0. 6 hr, respectively.","Pharmacokinetics of gamma-hydroxybutylic acid (GHB) and gamma-butyrolactone (GBL), the anti-angiogenic metabolites of oral fluoropyrimidine UFT, in patients with gastric cancer. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18260367/),[ng] / [ml],191.2,4467,DB00544,Fluorouracil
,18260367,C(max),"The values of C(max) for tegafur, uracil, 5-FU and GBL were 14.7 +/- 5.2 and 4.0 +/- 2.8 microg/ml, 191.2 +/- 115.3 and 147.5 +/- 57.3 ng/ml, respectively, and the values of Tmax were 1.0 +/- 0.6, 1.1 +/- 0.6, 0.9 +/- 0.6 and 1.2 +/- 0. 6 hr, respectively.","Pharmacokinetics of gamma-hydroxybutylic acid (GHB) and gamma-butyrolactone (GBL), the anti-angiogenic metabolites of oral fluoropyrimidine UFT, in patients with gastric cancer. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18260367/),[ng] / [ml],147.5,4468,DB00544,Fluorouracil
,18260367,Tmax,"The values of C(max) for tegafur, uracil, 5-FU and GBL were 14.7 +/- 5.2 and 4.0 +/- 2.8 microg/ml, 191.2 +/- 115.3 and 147.5 +/- 57.3 ng/ml, respectively, and the values of Tmax were 1.0 +/- 0.6, 1.1 +/- 0.6, 0.9 +/- 0.6 and 1.2 +/- 0. 6 hr, respectively.","Pharmacokinetics of gamma-hydroxybutylic acid (GHB) and gamma-butyrolactone (GBL), the anti-angiogenic metabolites of oral fluoropyrimidine UFT, in patients with gastric cancer. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18260367/),h,1.0,4469,DB00544,Fluorouracil
,18260367,Tmax,"The values of C(max) for tegafur, uracil, 5-FU and GBL were 14.7 +/- 5.2 and 4.0 +/- 2.8 microg/ml, 191.2 +/- 115.3 and 147.5 +/- 57.3 ng/ml, respectively, and the values of Tmax were 1.0 +/- 0.6, 1.1 +/- 0.6, 0.9 +/- 0.6 and 1.2 +/- 0. 6 hr, respectively.","Pharmacokinetics of gamma-hydroxybutylic acid (GHB) and gamma-butyrolactone (GBL), the anti-angiogenic metabolites of oral fluoropyrimidine UFT, in patients with gastric cancer. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18260367/),h,1.1,4470,DB00544,Fluorouracil
,18260367,Tmax,"The values of C(max) for tegafur, uracil, 5-FU and GBL were 14.7 +/- 5.2 and 4.0 +/- 2.8 microg/ml, 191.2 +/- 115.3 and 147.5 +/- 57.3 ng/ml, respectively, and the values of Tmax were 1.0 +/- 0.6, 1.1 +/- 0.6, 0.9 +/- 0.6 and 1.2 +/- 0. 6 hr, respectively.","Pharmacokinetics of gamma-hydroxybutylic acid (GHB) and gamma-butyrolactone (GBL), the anti-angiogenic metabolites of oral fluoropyrimidine UFT, in patients with gastric cancer. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18260367/),h,0.9,4471,DB00544,Fluorouracil
,18260367,Tmax,"The values of C(max) for tegafur, uracil, 5-FU and GBL were 14.7 +/- 5.2 and 4.0 +/- 2.8 microg/ml, 191.2 +/- 115.3 and 147.5 +/- 57.3 ng/ml, respectively, and the values of Tmax were 1.0 +/- 0.6, 1.1 +/- 0.6, 0.9 +/- 0.6 and 1.2 +/- 0. 6 hr, respectively.","Pharmacokinetics of gamma-hydroxybutylic acid (GHB) and gamma-butyrolactone (GBL), the anti-angiogenic metabolites of oral fluoropyrimidine UFT, in patients with gastric cancer. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18260367/),h,1.2,4472,DB00544,Fluorouracil
,24820348,RD,The RD for the phase II study was thus determined to be 90 mg/m(2).,A phase I study of capecitabine combined with CPT-11 in metastatic breast cancer pretreated with anthracyclines and taxanes. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24820348/),[mg] / [m],90,5602,DB00544,Fluorouracil
,24820348,response rate,The response rate was 41.7%.,A phase I study of capecitabine combined with CPT-11 in metastatic breast cancer pretreated with anthracyclines and taxanes. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24820348/),%,41.7,5603,DB00544,Fluorouracil
,3674768,disappearance half-life,The mean disappearance half-life of 5-FU from the peritoneal fluid was 1.6 hours with a mean permeability area product (PA) of 22.4 ml/min.,"Serum, urine and peritoneal fluid levels of 5-FU following intraperitoneal administration. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3674768/),h,1.6,5723,DB00544,Fluorouracil
,3674768,permeability area product (PA),The mean disappearance half-life of 5-FU from the peritoneal fluid was 1.6 hours with a mean permeability area product (PA) of 22.4 ml/min.,"Serum, urine and peritoneal fluid levels of 5-FU following intraperitoneal administration. ",Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3674768/),[ml] / [min],22.4,5724,DB00544,Fluorouracil
,11976834,clearance/bioavailability,"In fasted individuals, the clearance/bioavailability of 5-FU was estimated to be 5.6 l/h.",Estimation of the effect of food on the disposition of oral 5-fluorouracil in combination with eniluracil. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11976834/),[l] / [h],5.6,5767,DB00544,Fluorouracil
,11976834,absorption lag-time,The mean absorption lag-time was 0.24 h and was followed by rapid absorption of 5-FU.,Estimation of the effect of food on the disposition of oral 5-fluorouracil in combination with eniluracil. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11976834/),h,0.24,5768,DB00544,Fluorouracil
,24556590,T1/2β,"(131)I-huA33 demonstrated a mean terminal half-life and serum clearance suited to radioimmunotherapy (T1/2β, 100.24 ± 20.92 h, and clearance, 36.72 ± 8.01 mL/h).",Targeted chemoradiation in metastatic colorectal cancer: a phase I trial of 131I-huA33 with concurrent capecitabine. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/24556590/),h,100.24,5825,DB00544,Fluorouracil
,24556590,clearance,"(131)I-huA33 demonstrated a mean terminal half-life and serum clearance suited to radioimmunotherapy (T1/2β, 100.24 ± 20.92 h, and clearance, 36.72 ± 8.01 mL/h).",Targeted chemoradiation in metastatic colorectal cancer: a phase I trial of 131I-huA33 with concurrent capecitabine. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24556590/),[ml] / [h],36.72,5826,DB00544,Fluorouracil
,24556590,total tumor dose,"The mean total tumor dose was 13.8 ± 7.6 Gy (range, 5.1-26.9 Gy).",Targeted chemoradiation in metastatic colorectal cancer: a phase I trial of 131I-huA33 with concurrent capecitabine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24556590/),gy,13.8,5827,DB00544,Fluorouracil
,9586893,MTD,"The MTD was 1,657 mg/m2/d with limiting toxicities of palmar-plantar erythrodysesthesia, nausea, vomiting, vertigo, abdominal pain, diarrhea, and thrombocytopenia.",Preliminary studies of a novel oral fluoropyrimidine carbamate: capecitabine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9586893/),[mg] / [d·m2],"1,657",5941,DB00544,Fluorouracil
,12602342,AUC,"Compared to a control population, 5-FU AUC, elimination half-life, and C(max) were markedly increased (24.75 vs.","Severe 5-fluorouracil toxicity associated with a marked alteration of pharmacokinetics of 5-fluorouracil and its catabolite 5-fluoro-5,6-dihydrouracil: a case report. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12602342/),,24.75,6058,DB00544,Fluorouracil
,12602342,systemic clearance,"37.2 +/- 4.03 microg/ml, respectively) whereas systemic clearance was decreased (12 vs. 51.29 +/- 2.97 l/h/m2); also 5-FDHU AUC (3.3 vs. 12.35 +/- 0.7 h microg/ml) and C(max) (3.4 vs.","Severe 5-fluorouracil toxicity associated with a marked alteration of pharmacokinetics of 5-fluorouracil and its catabolite 5-fluoro-5,6-dihydrouracil: a case report. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12602342/),[l] / [h·m2],12,6059,DB00544,Fluorouracil
,12602342,systemic clearance,"37.2 +/- 4.03 microg/ml, respectively) whereas systemic clearance was decreased (12 vs. 51.29 +/- 2.97 l/h/m2); also 5-FDHU AUC (3.3 vs. 12.35 +/- 0.7 h microg/ml) and C(max) (3.4 vs.","Severe 5-fluorouracil toxicity associated with a marked alteration of pharmacokinetics of 5-fluorouracil and its catabolite 5-fluoro-5,6-dihydrouracil: a case report. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12602342/),[l] / [h·m2],51.29,6060,DB00544,Fluorouracil
,12602342,AUC,"37.2 +/- 4.03 microg/ml, respectively) whereas systemic clearance was decreased (12 vs. 51.29 +/- 2.97 l/h/m2); also 5-FDHU AUC (3.3 vs. 12.35 +/- 0.7 h microg/ml) and C(max) (3.4 vs.","Severe 5-fluorouracil toxicity associated with a marked alteration of pharmacokinetics of 5-fluorouracil and its catabolite 5-fluoro-5,6-dihydrouracil: a case report. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12602342/),[h·μg] / [ml],3.3,6061,DB00544,Fluorouracil
,12602342,AUC,"37.2 +/- 4.03 microg/ml, respectively) whereas systemic clearance was decreased (12 vs. 51.29 +/- 2.97 l/h/m2); also 5-FDHU AUC (3.3 vs. 12.35 +/- 0.7 h microg/ml) and C(max) (3.4 vs.","Severe 5-fluorouracil toxicity associated with a marked alteration of pharmacokinetics of 5-fluorouracil and its catabolite 5-fluoro-5,6-dihydrouracil: a case report. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12602342/),[h·μg] / [ml],12.35,6062,DB00544,Fluorouracil
,12602342,C(max),"37.2 +/- 4.03 microg/ml, respectively) whereas systemic clearance was decreased (12 vs. 51.29 +/- 2.97 l/h/m2); also 5-FDHU AUC (3.3 vs. 12.35 +/- 0.7 h microg/ml) and C(max) (3.4 vs.","Severe 5-fluorouracil toxicity associated with a marked alteration of pharmacokinetics of 5-fluorouracil and its catabolite 5-fluoro-5,6-dihydrouracil: a case report. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12602342/),,3.4,6063,DB00544,Fluorouracil
,12602342,activity,"Surprisingly, the PBMC DPD activity (110.8 pmol/min/mg protein) and urinary uracil (68.32 micromol/g urinary creatinine) were within normal range.","Severe 5-fluorouracil toxicity associated with a marked alteration of pharmacokinetics of 5-fluorouracil and its catabolite 5-fluoro-5,6-dihydrouracil: a case report. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12602342/),[pM] / [mg·min],110.8,6064,DB00544,Fluorouracil
,15853212,overall survival rate,The one-year overall survival rate was 50. 0%.,[Modified pharmacokinetic modulating chemotherapy for progressive gastric cancer accompanied by peritoneal dissemination]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15853212/),%,50. 0,6170,DB00544,Fluorouracil
,15853212,survival time,The median survival time was 311 days.,[Modified pharmacokinetic modulating chemotherapy for progressive gastric cancer accompanied by peritoneal dissemination]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15853212/),d,311,6171,DB00544,Fluorouracil
,32474564,OS,"The median PFS was 10.2 months (95%CI 8.8-14.3) and 10.0 months (95%CI 7.4-11.0), and the median OS was 29.7 months (95%CI 22.9-43.9) and 28.8 months (95%CI 18.4-ND), respectively (p = 0.3758, p = 0.8234).",Oral S-1 with 24-h Infusion of Irinotecan plus Bevacizumab versus FOLFIRI plus Bevacizumab as First-Line Chemotherapy for Metastatic Colorectal Cancer: An Open-Label Randomized Phase II Trial. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32474564/),month,29.,6333,DB00544,Fluorouracil
,32474564,OS,"The median PFS was 10.2 months (95%CI 8.8-14.3) and 10.0 months (95%CI 7.4-11.0), and the median OS was 29.7 months (95%CI 22.9-43.9) and 28.8 months (95%CI 18.4-ND), respectively (p = 0.3758, p = 0.8234).",Oral S-1 with 24-h Infusion of Irinotecan plus Bevacizumab versus FOLFIRI plus Bevacizumab as First-Line Chemotherapy for Metastatic Colorectal Cancer: An Open-Label Randomized Phase II Trial. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32474564/),month,28.8,6334,DB00544,Fluorouracil
,16968871,area under the curve (AUC),"The 5-FU area under the curve (AUC) measured at the first cycle ranged between 146 and 1236 mg x min/l and was significantly correlated with drug dose, patients' body weight (BW) and gender, females having higher AUCs.",Pharmacokinetic and demographic markers of 5-fluorouracil toxicity in 181 patients on adjuvant therapy for colorectal cancer. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16968871/),[mg·min] / [l],146 and 1236,6345,DB00544,Fluorouracil
,16968871,AUC,"AUC and age were the only covariates which discriminated between toxic (grade > or =2) and nontoxic cycles (grade <2), with an optimal AUC cut-off value of 596 mg x min/l.",Pharmacokinetic and demographic markers of 5-fluorouracil toxicity in 181 patients on adjuvant therapy for colorectal cancer. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16968871/),[mg·min] / [l],596,6346,DB00544,Fluorouracil
,16968871,AUC,"A method for calculating the initial 5-FU dose is proposed which takes into account patient BW, gender and a target AUC of 596 mg x min/l.",Pharmacokinetic and demographic markers of 5-fluorouracil toxicity in 181 patients on adjuvant therapy for colorectal cancer. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16968871/),[mg·min] / [l],596,6347,DB00544,Fluorouracil
,19060478,progression-free survival,"Median survival was 16.6 months, while median progression-free survival was 6.2 months.",A pilot human evaluation of a formulation of irinotecan and hyaluronic acid in 5-fluorouracil-refractory metastatic colorectal cancer patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19060478/),month,6.2,9310,DB00544,Fluorouracil
,19239037,half-life (t1/2),The in vitro half-life (t1/2) of P-FU in mice plasma was 32.4 h.,"[In vitro release study, in vivo evaluation of biodistribution and antitumor activity of HPMA copolymer-5-fluorouracil conjugates]. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19239037/),h,32.4,9415,DB00544,Fluorouracil
,23289150,steady state plasma concentrations (Cav),"After six days oral administration, the average steady state plasma concentrations (Cav) of tegafur, 5-fluorouracil, gimeracil, potassium oxonate and uracil were (2,425 +/- 1,172), (73.88 +/- 18.88), (162.6 +/- 70.8), (36.89 +/- 29.35) and (435.3 +/- 141.0) ng x mL(-1), respectively, and the degree of fluctuation (DF) were (1.0 +/- 0.2), (2.5 +/- 0.4), (3.1 +/- 0.8), (2.4 +/- 0.8) and (1.5 +/- 0.3), respectively.",[Pharmacokinetics of S-1 capsule in patients with advanced gastric cancer]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23289150/),[ng] / [ml],"2,425",10169,DB00544,Fluorouracil
,23289150,steady state plasma concentrations (Cav),"After six days oral administration, the average steady state plasma concentrations (Cav) of tegafur, 5-fluorouracil, gimeracil, potassium oxonate and uracil were (2,425 +/- 1,172), (73.88 +/- 18.88), (162.6 +/- 70.8), (36.89 +/- 29.35) and (435.3 +/- 141.0) ng x mL(-1), respectively, and the degree of fluctuation (DF) were (1.0 +/- 0.2), (2.5 +/- 0.4), (3.1 +/- 0.8), (2.4 +/- 0.8) and (1.5 +/- 0.3), respectively.",[Pharmacokinetics of S-1 capsule in patients with advanced gastric cancer]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23289150/),[ng] / [ml],73.88,10170,DB00544,Fluorouracil
,23289150,steady state plasma concentrations (Cav),"After six days oral administration, the average steady state plasma concentrations (Cav) of tegafur, 5-fluorouracil, gimeracil, potassium oxonate and uracil were (2,425 +/- 1,172), (73.88 +/- 18.88), (162.6 +/- 70.8), (36.89 +/- 29.35) and (435.3 +/- 141.0) ng x mL(-1), respectively, and the degree of fluctuation (DF) were (1.0 +/- 0.2), (2.5 +/- 0.4), (3.1 +/- 0.8), (2.4 +/- 0.8) and (1.5 +/- 0.3), respectively.",[Pharmacokinetics of S-1 capsule in patients with advanced gastric cancer]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23289150/),[ng] / [ml],162.6,10171,DB00544,Fluorouracil
,23289150,steady state plasma concentrations (Cav),"After six days oral administration, the average steady state plasma concentrations (Cav) of tegafur, 5-fluorouracil, gimeracil, potassium oxonate and uracil were (2,425 +/- 1,172), (73.88 +/- 18.88), (162.6 +/- 70.8), (36.89 +/- 29.35) and (435.3 +/- 141.0) ng x mL(-1), respectively, and the degree of fluctuation (DF) were (1.0 +/- 0.2), (2.5 +/- 0.4), (3.1 +/- 0.8), (2.4 +/- 0.8) and (1.5 +/- 0.3), respectively.",[Pharmacokinetics of S-1 capsule in patients with advanced gastric cancer]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23289150/),[ng] / [ml],36.89,10172,DB00544,Fluorouracil
,23289150,steady state plasma concentrations (Cav),"After six days oral administration, the average steady state plasma concentrations (Cav) of tegafur, 5-fluorouracil, gimeracil, potassium oxonate and uracil were (2,425 +/- 1,172), (73.88 +/- 18.88), (162.6 +/- 70.8), (36.89 +/- 29.35) and (435.3 +/- 141.0) ng x mL(-1), respectively, and the degree of fluctuation (DF) were (1.0 +/- 0.2), (2.5 +/- 0.4), (3.1 +/- 0.8), (2.4 +/- 0.8) and (1.5 +/- 0.3), respectively.",[Pharmacokinetics of S-1 capsule in patients with advanced gastric cancer]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23289150/),[ng] / [ml],435.3,10173,DB00544,Fluorouracil
,23289150,steady state plasma concentrations (Cav),"After six days oral administration, the average steady state plasma concentrations (Cav) of tegafur, 5-fluorouracil, gimeracil, potassium oxonate and uracil were (2,425 +/- 1,172), (73.88 +/- 18.88), (162.6 +/- 70.8), (36.89 +/- 29.35) and (435.3 +/- 141.0) ng x mL(-1), respectively, and the degree of fluctuation (DF) were (1.0 +/- 0.2), (2.5 +/- 0.4), (3.1 +/- 0.8), (2.4 +/- 0.8) and (1.5 +/- 0.3), respectively.",[Pharmacokinetics of S-1 capsule in patients with advanced gastric cancer]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23289150/),,1.0,10174,DB00544,Fluorouracil
,23289150,steady state plasma concentrations (Cav),"After six days oral administration, the average steady state plasma concentrations (Cav) of tegafur, 5-fluorouracil, gimeracil, potassium oxonate and uracil were (2,425 +/- 1,172), (73.88 +/- 18.88), (162.6 +/- 70.8), (36.89 +/- 29.35) and (435.3 +/- 141.0) ng x mL(-1), respectively, and the degree of fluctuation (DF) were (1.0 +/- 0.2), (2.5 +/- 0.4), (3.1 +/- 0.8), (2.4 +/- 0.8) and (1.5 +/- 0.3), respectively.",[Pharmacokinetics of S-1 capsule in patients with advanced gastric cancer]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23289150/),,2.5,10175,DB00544,Fluorouracil
,23289150,steady state plasma concentrations (Cav),"After six days oral administration, the average steady state plasma concentrations (Cav) of tegafur, 5-fluorouracil, gimeracil, potassium oxonate and uracil were (2,425 +/- 1,172), (73.88 +/- 18.88), (162.6 +/- 70.8), (36.89 +/- 29.35) and (435.3 +/- 141.0) ng x mL(-1), respectively, and the degree of fluctuation (DF) were (1.0 +/- 0.2), (2.5 +/- 0.4), (3.1 +/- 0.8), (2.4 +/- 0.8) and (1.5 +/- 0.3), respectively.",[Pharmacokinetics of S-1 capsule in patients with advanced gastric cancer]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23289150/),,3.1,10176,DB00544,Fluorouracil
,23289150,steady state plasma concentrations (Cav),"After six days oral administration, the average steady state plasma concentrations (Cav) of tegafur, 5-fluorouracil, gimeracil, potassium oxonate and uracil were (2,425 +/- 1,172), (73.88 +/- 18.88), (162.6 +/- 70.8), (36.89 +/- 29.35) and (435.3 +/- 141.0) ng x mL(-1), respectively, and the degree of fluctuation (DF) were (1.0 +/- 0.2), (2.5 +/- 0.4), (3.1 +/- 0.8), (2.4 +/- 0.8) and (1.5 +/- 0.3), respectively.",[Pharmacokinetics of S-1 capsule in patients with advanced gastric cancer]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23289150/),,2.4,10177,DB00544,Fluorouracil
,23289150,steady state plasma concentrations (Cav),"After six days oral administration, the average steady state plasma concentrations (Cav) of tegafur, 5-fluorouracil, gimeracil, potassium oxonate and uracil were (2,425 +/- 1,172), (73.88 +/- 18.88), (162.6 +/- 70.8), (36.89 +/- 29.35) and (435.3 +/- 141.0) ng x mL(-1), respectively, and the degree of fluctuation (DF) were (1.0 +/- 0.2), (2.5 +/- 0.4), (3.1 +/- 0.8), (2.4 +/- 0.8) and (1.5 +/- 0.3), respectively.",[Pharmacokinetics of S-1 capsule in patients with advanced gastric cancer]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23289150/),,1.5,10178,DB00544,Fluorouracil
,23289150,cumulative urine excretion percentage,"The cumulative urine excretion percentage of tegafur, 5-fluorouracil, gimeracil and potassium oxonate in urine within 48 h were (4.2 +/- 2.8) %, (4.7 +/- 1.6) %, (18.5 +/- 6.0) % and (1.7 +/- 1.2) %, repectively, after single oral administration of S-1.",[Pharmacokinetics of S-1 capsule in patients with advanced gastric cancer]. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23289150/),%,4.2,10179,DB00544,Fluorouracil
,23289150,cumulative urine excretion percentage,"The cumulative urine excretion percentage of tegafur, 5-fluorouracil, gimeracil and potassium oxonate in urine within 48 h were (4.2 +/- 2.8) %, (4.7 +/- 1.6) %, (18.5 +/- 6.0) % and (1.7 +/- 1.2) %, repectively, after single oral administration of S-1.",[Pharmacokinetics of S-1 capsule in patients with advanced gastric cancer]. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23289150/),%,4.7,10180,DB00544,Fluorouracil
,23289150,cumulative urine excretion percentage,"The cumulative urine excretion percentage of tegafur, 5-fluorouracil, gimeracil and potassium oxonate in urine within 48 h were (4.2 +/- 2.8) %, (4.7 +/- 1.6) %, (18.5 +/- 6.0) % and (1.7 +/- 1.2) %, repectively, after single oral administration of S-1.",[Pharmacokinetics of S-1 capsule in patients with advanced gastric cancer]. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23289150/),%,18.5,10181,DB00544,Fluorouracil
,23289150,cumulative urine excretion percentage,"The cumulative urine excretion percentage of tegafur, 5-fluorouracil, gimeracil and potassium oxonate in urine within 48 h were (4.2 +/- 2.8) %, (4.7 +/- 1.6) %, (18.5 +/- 6.0) % and (1.7 +/- 1.2) %, repectively, after single oral administration of S-1.",[Pharmacokinetics of S-1 capsule in patients with advanced gastric cancer]. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23289150/),%,1.7,10182,DB00544,Fluorouracil
,2525905,Half-life (t1/2),"Half-life (t1/2) values for the elimination of DFUR and 5-fluorouracil (5-FU) from plasma following DFUR (100 mg/kg) administration were about 0.80 and 0.39 hr, respectively.",Enhancing effect of bromovinyldeoxyuridine on antitumor activity of 5'-deoxy-5-fluorouridine against adenocarcinoma 755 in mice. Correlation with pharmacokinetics of plasma 5-fluorouracil levels. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2525905/),h,0.80,10188,DB00544,Fluorouracil
,2525905,Half-life (t1/2),"Half-life (t1/2) values for the elimination of DFUR and 5-fluorouracil (5-FU) from plasma following DFUR (100 mg/kg) administration were about 0.80 and 0.39 hr, respectively.",Enhancing effect of bromovinyldeoxyuridine on antitumor activity of 5'-deoxy-5-fluorouridine against adenocarcinoma 755 in mice. Correlation with pharmacokinetics of plasma 5-fluorouracil levels. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2525905/),h,0.39,10189,DB00544,Fluorouracil
,2525905,AUC (area under the curve),Plasma 5-FU AUC (area under the curve) values following oral DFUR (100 mg/kg) was 0.224 micrograms.hr/ml.,Enhancing effect of bromovinyldeoxyuridine on antitumor activity of 5'-deoxy-5-fluorouridine against adenocarcinoma 755 in mice. Correlation with pharmacokinetics of plasma 5-fluorouracil levels. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2525905/),[h·μg] / [ml],0.224,10190,DB00544,Fluorouracil
,2525905,t1/2,"If DFUR (100 mg/kg) was combined with BVDU (10 mg/kg) the t1/2 and AUC values for 5-FU increased from 0.39 to 1.24 hr, and from 0.224 to 1.699 micrograms.hr/ml, respectively.",Enhancing effect of bromovinyldeoxyuridine on antitumor activity of 5'-deoxy-5-fluorouridine against adenocarcinoma 755 in mice. Correlation with pharmacokinetics of plasma 5-fluorouracil levels. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2525905/),h,0.39,10191,DB00544,Fluorouracil
,2525905,AUC,"If DFUR (100 mg/kg) was combined with BVDU (10 mg/kg) the t1/2 and AUC values for 5-FU increased from 0.39 to 1.24 hr, and from 0.224 to 1.699 micrograms.hr/ml, respectively.",Enhancing effect of bromovinyldeoxyuridine on antitumor activity of 5'-deoxy-5-fluorouridine against adenocarcinoma 755 in mice. Correlation with pharmacokinetics of plasma 5-fluorouracil levels. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2525905/),h,1.24,10192,DB00544,Fluorouracil
,2525905,AUC,"If DFUR (100 mg/kg) was combined with BVDU (10 mg/kg) the t1/2 and AUC values for 5-FU increased from 0.39 to 1.24 hr, and from 0.224 to 1.699 micrograms.hr/ml, respectively.",Enhancing effect of bromovinyldeoxyuridine on antitumor activity of 5'-deoxy-5-fluorouridine against adenocarcinoma 755 in mice. Correlation with pharmacokinetics of plasma 5-fluorouracil levels. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2525905/),[h·μg] / [ml],0.224,10193,DB00544,Fluorouracil
,2525905,AUC,"If DFUR (100 mg/kg) was combined with BVDU (10 mg/kg) the t1/2 and AUC values for 5-FU increased from 0.39 to 1.24 hr, and from 0.224 to 1.699 micrograms.hr/ml, respectively.",Enhancing effect of bromovinyldeoxyuridine on antitumor activity of 5'-deoxy-5-fluorouridine against adenocarcinoma 755 in mice. Correlation with pharmacokinetics of plasma 5-fluorouracil levels. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2525905/),[h·μg] / [ml],1.699,10194,DB00544,Fluorouracil
,18670112,Tmax/Cmax,"Pharmacokinetic study in dogs gave Tmax/Cmax of 14 h/1.6 microg/ml and 16 h/1.7 microg/ml for total weight gain (TWG)-22% and 18% coated pellets, respectively.","Biphasic drug release: permeability and swelling of pectin/ethylcellulose films, and in vitro and in vivo correlation of film-coated pellets in dogs. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18670112/),h,14,10524,DB00544,Fluorouracil
,18670112,Tmax/Cmax,"Pharmacokinetic study in dogs gave Tmax/Cmax of 14 h/1.6 microg/ml and 16 h/1.7 microg/ml for total weight gain (TWG)-22% and 18% coated pellets, respectively.","Biphasic drug release: permeability and swelling of pectin/ethylcellulose films, and in vitro and in vivo correlation of film-coated pellets in dogs. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18670112/),h,16,10525,DB00544,Fluorouracil
,18670112,mean residence time (MRT),"The plasma 5-FU levels of the TWG-22% and 18% coated pellets were maintained at a much lower level with a mean residence time (MRT) of 18-20 h, longer than 2.1 h for 5-FU uncoated pellets, confirming delayed absorption.","Biphasic drug release: permeability and swelling of pectin/ethylcellulose films, and in vitro and in vivo correlation of film-coated pellets in dogs. ",MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18670112/),h,18-20,10526,DB00544,Fluorouracil
longer,18670112,mean residence time (MRT),"The plasma 5-FU levels of the TWG-22% and 18% coated pellets were maintained at a much lower level with a mean residence time (MRT) of 18-20 h, longer than 2.1 h for 5-FU uncoated pellets, confirming delayed absorption.","Biphasic drug release: permeability and swelling of pectin/ethylcellulose films, and in vitro and in vivo correlation of film-coated pellets in dogs. ",MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18670112/),h,2.1,10527,DB00544,Fluorouracil
,18414865,AUC,"Among patients treated with a constant capecitabine dose of 450 mg bid, there was a higher mean AUC of 5-FU in women than in men (mean +/- SD: 892 +/- 287 nM h vs. 537 +/- 182 nM h; Mann-Whitney two-tailed, P = 0.02).","Phase I clinical and pharmacokinetic study of oxaliplatin, irinotecan and capecitabine. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18414865/),h·nM,892,10721,DB00544,Fluorouracil
,18414865,AUC,"Among patients treated with a constant capecitabine dose of 450 mg bid, there was a higher mean AUC of 5-FU in women than in men (mean +/- SD: 892 +/- 287 nM h vs. 537 +/- 182 nM h; Mann-Whitney two-tailed, P = 0.02).","Phase I clinical and pharmacokinetic study of oxaliplatin, irinotecan and capecitabine. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18414865/),h·nM,537,10722,DB00544,Fluorouracil
,11002217,Maximum plasma concentrations,Maximum plasma concentrations of 5-FU in Group A reached 144.0 ng/mL and in Group B 58.7 ng/mL.,Results of pharmacokinetic modulating chemotherapy in combination with hepatic arterial 5-fluorouracil infusion and oral UFT after resection of hepatic colorectal metastases. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11002217/),[ng] / [ml],144.0,10920,DB00544,Fluorouracil
,11002217,Maximum plasma concentrations,Maximum plasma concentrations of 5-FU in Group A reached 144.0 ng/mL and in Group B 58.7 ng/mL.,Results of pharmacokinetic modulating chemotherapy in combination with hepatic arterial 5-fluorouracil infusion and oral UFT after resection of hepatic colorectal metastases. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11002217/),[ng] / [ml],58.7,10921,DB00544,Fluorouracil
,11002217,hepatic recurrence free times,(P = 0.00001) HAI-PMC drastically decreased hepatic recurrence (median hepatic recurrence free times were 34.2 months in Group A vs. 18.4 months in Group B; P = 0.00002).,Results of pharmacokinetic modulating chemotherapy in combination with hepatic arterial 5-fluorouracil infusion and oral UFT after resection of hepatic colorectal metastases. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11002217/),month,34.2,10922,DB00544,Fluorouracil
,11002217,hepatic recurrence free times,(P = 0.00001) HAI-PMC drastically decreased hepatic recurrence (median hepatic recurrence free times were 34.2 months in Group A vs. 18.4 months in Group B; P = 0.00002).,Results of pharmacokinetic modulating chemotherapy in combination with hepatic arterial 5-fluorouracil infusion and oral UFT after resection of hepatic colorectal metastases. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11002217/),month,18.4,10923,DB00544,Fluorouracil
,9748117,objective response rate,The objective response rate was comparable in the two treatment arms: 77.2% in the St-arm versus 81.7% in the PK-arm.,Clinical impact of pharmacokinetically-guided dose adaptation of 5-fluorouracil: results from a multicentric randomized trial in patients with locally advanced head and neck carcinomas. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9748117/),%,77.2,11478,DB00544,Fluorouracil
,9748117,objective response rate,The objective response rate was comparable in the two treatment arms: 77.2% in the St-arm versus 81.7% in the PK-arm.,Clinical impact of pharmacokinetically-guided dose adaptation of 5-fluorouracil: results from a multicentric randomized trial in patients with locally advanced head and neck carcinomas. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9748117/),%,81.7,11479,DB00544,Fluorouracil
,22669574,half-life,Pharmacokinetic studies of BIIB036 in tumor-bearing mice revealed a half-life of approximately three days suggesting twice a week dosing would be necessary to maintain efficacy.,The anti-Fn14 antibody BIIB036 inhibits tumor growth in xenografts and patient derived primary tumor models and enhances efficacy of chemotherapeutic agents in multiple xenograft models. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22669574/),d,three,12423,DB00544,Fluorouracil
,15014016,steady-state concentration,"Indeed, the steady-state concentration of irinotecan, SN-38, and SN-38glu were 42.7 +/- 25.2, 14.9 +/- 1.9, and 31.7 +/- 3.5 nmol/liter, respectively, and the area under the time-concentration curves of irinotecan, SN-38, and SN-38glu were 6.94 +/- 0.41, 1.92 +/- 0.30, and 4.23 +/- 0.52 hx micro mol/liter, respectively.",A phase I and pharmacokinetic study of irinotecan given as a 7-day continuous infusion in metastatic colorectal cancer patients pretreated with 5-fluorouracil or raltitrexed. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15014016/),[nM] / [l],42.7,12481,DB00544,Fluorouracil
,15014016,steady-state concentration,"Indeed, the steady-state concentration of irinotecan, SN-38, and SN-38glu were 42.7 +/- 25.2, 14.9 +/- 1.9, and 31.7 +/- 3.5 nmol/liter, respectively, and the area under the time-concentration curves of irinotecan, SN-38, and SN-38glu were 6.94 +/- 0.41, 1.92 +/- 0.30, and 4.23 +/- 0.52 hx micro mol/liter, respectively.",A phase I and pharmacokinetic study of irinotecan given as a 7-day continuous infusion in metastatic colorectal cancer patients pretreated with 5-fluorouracil or raltitrexed. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15014016/),[nM] / [l],14.9,12482,DB00544,Fluorouracil
,15014016,steady-state concentration,"Indeed, the steady-state concentration of irinotecan, SN-38, and SN-38glu were 42.7 +/- 25.2, 14.9 +/- 1.9, and 31.7 +/- 3.5 nmol/liter, respectively, and the area under the time-concentration curves of irinotecan, SN-38, and SN-38glu were 6.94 +/- 0.41, 1.92 +/- 0.30, and 4.23 +/- 0.52 hx micro mol/liter, respectively.",A phase I and pharmacokinetic study of irinotecan given as a 7-day continuous infusion in metastatic colorectal cancer patients pretreated with 5-fluorouracil or raltitrexed. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15014016/),[nM] / [l],31.7,12483,DB00544,Fluorouracil
,15014016,area under the time-concentration curves,"Indeed, the steady-state concentration of irinotecan, SN-38, and SN-38glu were 42.7 +/- 25.2, 14.9 +/- 1.9, and 31.7 +/- 3.5 nmol/liter, respectively, and the area under the time-concentration curves of irinotecan, SN-38, and SN-38glu were 6.94 +/- 0.41, 1.92 +/- 0.30, and 4.23 +/- 0.52 hx micro mol/liter, respectively.",A phase I and pharmacokinetic study of irinotecan given as a 7-day continuous infusion in metastatic colorectal cancer patients pretreated with 5-fluorouracil or raltitrexed. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15014016/),[h·μmol] / [l],6.94,12484,DB00544,Fluorouracil
,15014016,area under the time-concentration curves,"Indeed, the steady-state concentration of irinotecan, SN-38, and SN-38glu were 42.7 +/- 25.2, 14.9 +/- 1.9, and 31.7 +/- 3.5 nmol/liter, respectively, and the area under the time-concentration curves of irinotecan, SN-38, and SN-38glu were 6.94 +/- 0.41, 1.92 +/- 0.30, and 4.23 +/- 0.52 hx micro mol/liter, respectively.",A phase I and pharmacokinetic study of irinotecan given as a 7-day continuous infusion in metastatic colorectal cancer patients pretreated with 5-fluorouracil or raltitrexed. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15014016/),[h·μmol] / [l],1.92,12485,DB00544,Fluorouracil
,15014016,area under the time-concentration curves,"Indeed, the steady-state concentration of irinotecan, SN-38, and SN-38glu were 42.7 +/- 25.2, 14.9 +/- 1.9, and 31.7 +/- 3.5 nmol/liter, respectively, and the area under the time-concentration curves of irinotecan, SN-38, and SN-38glu were 6.94 +/- 0.41, 1.92 +/- 0.30, and 4.23 +/- 0.52 hx micro mol/liter, respectively.",A phase I and pharmacokinetic study of irinotecan given as a 7-day continuous infusion in metastatic colorectal cancer patients pretreated with 5-fluorouracil or raltitrexed. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15014016/),[h·μmol] / [l],4.23,12486,DB00544,Fluorouracil
,32572849,plasma ultrafiltrate Cmax,The plasma ultrafiltrate Cmax of oxaliplatin reached 1.36-1.90 µg/mL after 30 min with an AUC0-24 h of 9.6-11.7 µg/mL * h.,Systemic Pharmacokinetics of Oxaliplatin After Intraperitoneal Administration by Electrostatic Pressurized Intraperitoneal Aerosol Chemotherapy (ePIPAC) in Patients with Unresectable Colorectal Peritoneal Metastases in the CRC-PIPAC Trial. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32572849/),[μg] / [ml],1.36-1.90,12797,DB00544,Fluorouracil
,32572849,AUC0-24 h,The plasma ultrafiltrate Cmax of oxaliplatin reached 1.36-1.90 µg/mL after 30 min with an AUC0-24 h of 9.6-11.7 µg/mL * h.,Systemic Pharmacokinetics of Oxaliplatin After Intraperitoneal Administration by Electrostatic Pressurized Intraperitoneal Aerosol Chemotherapy (ePIPAC) in Patients with Unresectable Colorectal Peritoneal Metastases in the CRC-PIPAC Trial. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32572849/),[μg] / [h·ml],9.6-11.7,12798,DB00544,Fluorouracil
,32572849,plasma Cmax,The plasma Cmax reached 2.67-3.28 µg/mL after 90 min with an AUC0-24 h of 49.0-59.5 µg/mL * h.,Systemic Pharmacokinetics of Oxaliplatin After Intraperitoneal Administration by Electrostatic Pressurized Intraperitoneal Aerosol Chemotherapy (ePIPAC) in Patients with Unresectable Colorectal Peritoneal Metastases in the CRC-PIPAC Trial. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32572849/),[μg] / [ml],2.67-3.28,12799,DB00544,Fluorouracil
,32572849,AUC0-24 h,The plasma Cmax reached 2.67-3.28 µg/mL after 90 min with an AUC0-24 h of 49.0-59.5 µg/mL * h.,Systemic Pharmacokinetics of Oxaliplatin After Intraperitoneal Administration by Electrostatic Pressurized Intraperitoneal Aerosol Chemotherapy (ePIPAC) in Patients with Unresectable Colorectal Peritoneal Metastases in the CRC-PIPAC Trial. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32572849/),[μg] / [h·ml],49.0-59.5,12800,DB00544,Fluorouracil
,32572849,absorption rate constant (Ka),The absorption rate constant (Ka) was 1.13/h.,Systemic Pharmacokinetics of Oxaliplatin After Intraperitoneal Administration by Electrostatic Pressurized Intraperitoneal Aerosol Chemotherapy (ePIPAC) in Patients with Unresectable Colorectal Peritoneal Metastases in the CRC-PIPAC Trial. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32572849/),1/[h],1.13,12801,DB00544,Fluorouracil
,1581906,activity,"The mean value for DPD activity was 0.186 +/- 0.068 (SD) nmol/min/mg of protein (range, 0.058 to 0.357).",Correlation between dihydropyrimidine dehydrogenase activity in peripheral mononuclear cells and systemic clearance of fluorouracil in cancer patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1581906/),[nM] / [mg·min],0.186,12802,DB00544,Fluorouracil
,1581906,clearance,"The mean value for 5-FU clearance was 2522.6 +/- 684.2 ml/min/m2 (range, 1052 to 4029).",Correlation between dihydropyrimidine dehydrogenase activity in peripheral mononuclear cells and systemic clearance of fluorouracil in cancer patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1581906/),[ml] / [m2·min],2522.6,12803,DB00544,Fluorouracil
less,10561167,UH(2)-U ratios,Toxic side effects were observed only in patients with initial UH(2)-U ratios of less than 1.8.,"Correlation between uracil and dihydrouracil plasma ratio, fluorouracil (5-FU) pharmacokinetic parameters, and tolerance in patients with advanced colorectal cancer: A potential interest for predicting 5-FU toxicity and determining optimal 5-FU dosage. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10561167/),,1.8,13105,DB00544,Fluorouracil
greater,10561167,UH(2)-U ratios,No adverse effects were noted in patients with UH(2)-U ratios of greater than 2.25.,"Correlation between uracil and dihydrouracil plasma ratio, fluorouracil (5-FU) pharmacokinetic parameters, and tolerance in patients with advanced colorectal cancer: A potential interest for predicting 5-FU toxicity and determining optimal 5-FU dosage. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10561167/),,2.25,13106,DB00544,Fluorouracil
,11060767,oral bioavailability,"Eniluracil (ethynyluracil, GlaxoWellcome, USA), a uracil analogue, which irreversibly inhibits DPD, increases the oral bioavailability of 5-FU to 100%, facilitating uniform absorption and predictable toxicity.",Eniluracil: an irreversible inhibitor of dihydropyrimidine dehydrogenase. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11060767/),%,100,13129,DB00544,Fluorouracil
,12111108,T(1/2),"In contrast, in patients with mild and moderate renal dysfunction (CLcr 55 and 36 ml/min, respectively), the T(1/2) values of CDHP with consecutive administrations (7.6 and 15.3 h, respectively) were longer than the values with single administration (4.6 and 8.2 h, respectively).","Pharmacokinetic study of S-1, a novel oral fluorouracil antitumor agent in animal model and in patients with impaired renal function. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12111108/),h,7.6,13342,DB00544,Fluorouracil
,12111108,T(1/2),"In contrast, in patients with mild and moderate renal dysfunction (CLcr 55 and 36 ml/min, respectively), the T(1/2) values of CDHP with consecutive administrations (7.6 and 15.3 h, respectively) were longer than the values with single administration (4.6 and 8.2 h, respectively).","Pharmacokinetic study of S-1, a novel oral fluorouracil antitumor agent in animal model and in patients with impaired renal function. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12111108/),h,15.3,13343,DB00544,Fluorouracil
,12111108,T(1/2),"In contrast, in patients with mild and moderate renal dysfunction (CLcr 55 and 36 ml/min, respectively), the T(1/2) values of CDHP with consecutive administrations (7.6 and 15.3 h, respectively) were longer than the values with single administration (4.6 and 8.2 h, respectively).","Pharmacokinetic study of S-1, a novel oral fluorouracil antitumor agent in animal model and in patients with impaired renal function. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12111108/),h,4.6,13344,DB00544,Fluorouracil
,12111108,T(1/2),"In contrast, in patients with mild and moderate renal dysfunction (CLcr 55 and 36 ml/min, respectively), the T(1/2) values of CDHP with consecutive administrations (7.6 and 15.3 h, respectively) were longer than the values with single administration (4.6 and 8.2 h, respectively).","Pharmacokinetic study of S-1, a novel oral fluorouracil antitumor agent in animal model and in patients with impaired renal function. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12111108/),h,8.2,13345,DB00544,Fluorouracil
,12111108,T(1/2),The T(1/2) of 5-FU was 5.7 h with single administration and 8.5 h with consecutive administration in patients with moderate renal impairment.,"Pharmacokinetic study of S-1, a novel oral fluorouracil antitumor agent in animal model and in patients with impaired renal function. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12111108/),h,5.7,13346,DB00544,Fluorouracil
,12111108,T(1/2),The T(1/2) of 5-FU was 5.7 h with single administration and 8.5 h with consecutive administration in patients with moderate renal impairment.,"Pharmacokinetic study of S-1, a novel oral fluorouracil antitumor agent in animal model and in patients with impaired renal function. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12111108/),h,8.5,13347,DB00544,Fluorouracil
,12111108,AUC((0-infinity)),The AUC((0-infinity)) of 5-FU with consecutive administrations (3089.7 ng.h/ml) was far greater than with single administration (430.4 ng.h/ml).,"Pharmacokinetic study of S-1, a novel oral fluorouracil antitumor agent in animal model and in patients with impaired renal function. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12111108/),[h·ng] / [ml],3089.7,13348,DB00544,Fluorouracil
,12111108,AUC((0-infinity)),The AUC((0-infinity)) of 5-FU with consecutive administrations (3089.7 ng.h/ml) was far greater than with single administration (430.4 ng.h/ml).,"Pharmacokinetic study of S-1, a novel oral fluorouracil antitumor agent in animal model and in patients with impaired renal function. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12111108/),[h·ng] / [ml],430.4,13349,DB00544,Fluorouracil
,21750645,plasma concentrations,"The plasma concentrations of 5-FU at 24 hr after the start of treatment were 27.4 ng/mL and 9.4 ng/mL in the patients with and without the bolus injection, respectively.",Effects of bolus injection of 5-fluorouracil on steady-state plasma concentrations of 5-fluorouracil in Japanese patients with advanced colorectal cancer. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21750645/),[ng] / [ml],27.4,15050,DB00544,Fluorouracil
,21750645,plasma concentrations,"The plasma concentrations of 5-FU at 24 hr after the start of treatment were 27.4 ng/mL and 9.4 ng/mL in the patients with and without the bolus injection, respectively.",Effects of bolus injection of 5-fluorouracil on steady-state plasma concentrations of 5-fluorouracil in Japanese patients with advanced colorectal cancer. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21750645/),[ng] / [ml],9.4,15051,DB00544,Fluorouracil
,21750645,AUC(0-48),"At 48 hr, they were 31.3 ng/mL and 10.4 ng/mL with the AUC(0-48) values of 22.16 mg h/L and 0.65 mg h/L, respectively.",Effects of bolus injection of 5-fluorouracil on steady-state plasma concentrations of 5-fluorouracil in Japanese patients with advanced colorectal cancer. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21750645/),[h·mg] / [l],22.16,15052,DB00544,Fluorouracil
,21750645,AUC(0-48),"At 48 hr, they were 31.3 ng/mL and 10.4 ng/mL with the AUC(0-48) values of 22.16 mg h/L and 0.65 mg h/L, respectively.",Effects of bolus injection of 5-fluorouracil on steady-state plasma concentrations of 5-fluorouracil in Japanese patients with advanced colorectal cancer. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21750645/),[h·mg] / [l],0.65,15053,DB00544,Fluorouracil
,23179563,Cmax,"After administration of micro-device, the 5-Fu was absorbed into the tumor on Day 1, and Cmax (4.14 μg/g) was reached on Day 6.",In vivo distribution of 5-Fluorouracil after peritumoral implantation using a biodegradable micro-device in tumor-bearing mice. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23179563/),[μg] / [g],4.14,15358,DB00544,Fluorouracil
,23179563,half life for the elimination,The half life for the elimination was 4.48 d and the AUC was 46.78 μg × d/g.,In vivo distribution of 5-Fluorouracil after peritumoral implantation using a biodegradable micro-device in tumor-bearing mice. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/23179563/),d,4.48,15359,DB00544,Fluorouracil
,23179563,AUC,The half life for the elimination was 4.48 d and the AUC was 46.78 μg × d/g.,In vivo distribution of 5-Fluorouracil after peritumoral implantation using a biodegradable micro-device in tumor-bearing mice. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23179563/),[d·μg] / [g],46.78,15360,DB00544,Fluorouracil
,359130,half-life,"Plasma disappearance of FT was exponential, with a half-life of 8.8 hr.",Disposition and metabolism of 1-(tetrahydro-2-furanyl)-5-fluorouracil (ftorafur) in humans. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/359130/),h,8.8,15983,DB00544,Fluorouracil
,359130,cumulative urinary excretion,The cumulative urinary excretion was 20% of the administered dose in 24 hr.,Disposition and metabolism of 1-(tetrahydro-2-furanyl)-5-fluorouracil (ftorafur) in humans. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/359130/),%,20,15984,DB00544,Fluorouracil
,8955653,bioavailability,"Following oral 5-FU 10 mg/m2, the bioavailability was 122% +/- 40% (mean +/- SD), the terminal half-life (t1/2 beta) was 4.5 +/- 1.6 hours, the apparent volume of distribution (V beta) was 21.4 +/- 5.9 L/ m2, and the systemic clearance (Clsys) was 57.6 +/- 16.4 mL/min/m2.","Pharmacokinetic, oral bioavailability, and safety study of fluorouracil in patients treated with 776C85, an inactivator of dihydropyrimidine dehydrogenase. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8955653/),%,122,16442,DB00544,Fluorouracil
,8955653,terminal half-life (t1/2 beta),"Following oral 5-FU 10 mg/m2, the bioavailability was 122% +/- 40% (mean +/- SD), the terminal half-life (t1/2 beta) was 4.5 +/- 1.6 hours, the apparent volume of distribution (V beta) was 21.4 +/- 5.9 L/ m2, and the systemic clearance (Clsys) was 57.6 +/- 16.4 mL/min/m2.","Pharmacokinetic, oral bioavailability, and safety study of fluorouracil in patients treated with 776C85, an inactivator of dihydropyrimidine dehydrogenase. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8955653/),h,4.5,16443,DB00544,Fluorouracil
,8955653,apparent volume of distribution (V beta),"Following oral 5-FU 10 mg/m2, the bioavailability was 122% +/- 40% (mean +/- SD), the terminal half-life (t1/2 beta) was 4.5 +/- 1.6 hours, the apparent volume of distribution (V beta) was 21.4 +/- 5.9 L/ m2, and the systemic clearance (Clsys) was 57.6 +/- 16.4 mL/min/m2.","Pharmacokinetic, oral bioavailability, and safety study of fluorouracil in patients treated with 776C85, an inactivator of dihydropyrimidine dehydrogenase. ",Vb-Q62,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8955653/),[l] / [m2],21.4,16444,DB00544,Fluorouracil
,8955653,systemic clearance (Clsys),"Following oral 5-FU 10 mg/m2, the bioavailability was 122% +/- 40% (mean +/- SD), the terminal half-life (t1/2 beta) was 4.5 +/- 1.6 hours, the apparent volume of distribution (V beta) was 21.4 +/- 5.9 L/ m2, and the systemic clearance (Clsys) was 57.6 +/- 16.4 mL/min/m2.","Pharmacokinetic, oral bioavailability, and safety study of fluorouracil in patients treated with 776C85, an inactivator of dihydropyrimidine dehydrogenase. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8955653/),[ml] / [m2·min],57.6,16445,DB00544,Fluorouracil
,2970537,apparent half life,"After an oral administration of 5'-DFUR (800 mg/body) to patients with cancer, 5-FU in plasma peaked within 1 h and eliminated with an apparent half life of about 1 h.",Determination of 5-fluorouracil in plasma and liver after oral administration of 5'-deoxy-5-fluorouridine using gas chromatography-mass spectrometry. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2970537/),h,1,16456,DB00544,Fluorouracil
,10873073,MTD,"For patients with no prior AP radiation therapy, the MTD was determined to be 320 mg/m2, whereas those with prior AP radiation therapy had a MTD of 290 mg/m2.",Phase I dose-finding and pharmacokinetic trial of irinotecan hydrochloride (CPT-11) using a once-every-three-week dosing schedule for patients with advanced solid tumor malignancy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10873073/),[mg] / [m2],320,17617,DB00544,Fluorouracil
,10873073,MTD,"For patients with no prior AP radiation therapy, the MTD was determined to be 320 mg/m2, whereas those with prior AP radiation therapy had a MTD of 290 mg/m2.",Phase I dose-finding and pharmacokinetic trial of irinotecan hydrochloride (CPT-11) using a once-every-three-week dosing schedule for patients with advanced solid tumor malignancy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10873073/),[mg] / [m2],290,17618,DB00544,Fluorouracil
,10873073,terminal phase half-life,"Mean values of terminal phase half-life, clearance, terminal phase volume of distribution, and steady-state volume of distribution for CPT-11 were 12.4 +/- 1.8 h, 13.0 +/- 3.8 liters/h/m2, 234 +/- 83 liters/m2, and 123 +/- 38 liters/m2, respectively.",Phase I dose-finding and pharmacokinetic trial of irinotecan hydrochloride (CPT-11) using a once-every-three-week dosing schedule for patients with advanced solid tumor malignancy. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10873073/),h,12.4,17619,DB00544,Fluorouracil
,10873073,clearance,"Mean values of terminal phase half-life, clearance, terminal phase volume of distribution, and steady-state volume of distribution for CPT-11 were 12.4 +/- 1.8 h, 13.0 +/- 3.8 liters/h/m2, 234 +/- 83 liters/m2, and 123 +/- 38 liters/m2, respectively.",Phase I dose-finding and pharmacokinetic trial of irinotecan hydrochloride (CPT-11) using a once-every-three-week dosing schedule for patients with advanced solid tumor malignancy. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10873073/),[l] / [h·m2],13.0,17620,DB00544,Fluorouracil
,10873073,clearance,"Mean values of terminal phase half-life, clearance, terminal phase volume of distribution, and steady-state volume of distribution for CPT-11 were 12.4 +/- 1.8 h, 13.0 +/- 3.8 liters/h/m2, 234 +/- 83 liters/m2, and 123 +/- 38 liters/m2, respectively.",Phase I dose-finding and pharmacokinetic trial of irinotecan hydrochloride (CPT-11) using a once-every-three-week dosing schedule for patients with advanced solid tumor malignancy. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10873073/),[l] / [m2],234,17621,DB00544,Fluorouracil
,10873073,terminal phase volume of distribution,"Mean values of terminal phase half-life, clearance, terminal phase volume of distribution, and steady-state volume of distribution for CPT-11 were 12.4 +/- 1.8 h, 13.0 +/- 3.8 liters/h/m2, 234 +/- 83 liters/m2, and 123 +/- 38 liters/m2, respectively.",Phase I dose-finding and pharmacokinetic trial of irinotecan hydrochloride (CPT-11) using a once-every-three-week dosing schedule for patients with advanced solid tumor malignancy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10873073/),[l] / [h·m2],13.0,17622,DB00544,Fluorouracil
,10873073,steady-state volume of distribution,"Mean values of terminal phase half-life, clearance, terminal phase volume of distribution, and steady-state volume of distribution for CPT-11 were 12.4 +/- 1.8 h, 13.0 +/- 3.8 liters/h/m2, 234 +/- 83 liters/m2, and 123 +/- 38 liters/m2, respectively.",Phase I dose-finding and pharmacokinetic trial of irinotecan hydrochloride (CPT-11) using a once-every-three-week dosing schedule for patients with advanced solid tumor malignancy. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10873073/),[l] / [m2],123,17623,DB00544,Fluorouracil
,21339064,response duration,"The median response duration was 3.1 months (95% CI: 2.1-8.4 months), with four of five lasting for more than 3 months.",A multicentre dose-escalating study of cabazitaxel (XRP6258) in combination with capecitabine in patients with metastatic breast cancer progressing after anthracycline and taxane treatment: a phase I/II study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21339064/),month,3.1,17771,DB00544,Fluorouracil
,21339064,time to progression,Median time to progression was 4.9 months.,A multicentre dose-escalating study of cabazitaxel (XRP6258) in combination with capecitabine in patients with metastatic breast cancer progressing after anthracycline and taxane treatment: a phase I/II study. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21339064/),month,4.9,17772,DB00544,Fluorouracil
,27189323,overall response rate,The overall response rate was 54.5 %.,A phase I study of S-1 in combination with nab-paclitaxel in patients with unresectable or recurrent gastric cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27189323/),%,54.5,17773,DB00544,Fluorouracil
,16319513,MTD,"The MTD of paclitaxel was presumed to be 60 mg/m(2), because 50.0% of patients (2/4) developed DLTs (mainly grade 3 anorexia).",Phase I and pharmacokinetic study of S-1 combined with weekly paclitaxel in patients with advanced gastric cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16319513/),mg,60,17786,DB00544,Fluorouracil
,16319513,RD,"Therefore, the RD of paclitaxel was estimated to be 50 mg/m(2).",Phase I and pharmacokinetic study of S-1 combined with weekly paclitaxel in patients with advanced gastric cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16319513/),[mg] / [m(2],50,17787,DB00544,Fluorouracil
,16319513,preliminary response rate,The preliminary response rate was 62.5% (5/8) at the RD.,Phase I and pharmacokinetic study of S-1 combined with weekly paclitaxel in patients with advanced gastric cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16319513/),%,62.5,17788,DB00544,Fluorouracil
,10447576,acrophase (peak) times,"The acrophase (peak) times of the first and the second periodic component were 04 h 12 m and 00 h 25 m, respectively.",Circadian rhythm of 5-fluorouracil population pharmacokinetics in patients with metastatic colorectal cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10447576/),m,04,17972,DB00544,Fluorouracil
,10447576,acrophase (peak) times,"The acrophase (peak) times of the first and the second periodic component were 04 h 12 m and 00 h 25 m, respectively.",Circadian rhythm of 5-fluorouracil population pharmacokinetics in patients with metastatic colorectal cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10447576/),m,12,17973,DB00544,Fluorouracil
,10447576,acrophase (peak) times,"The acrophase (peak) times of the first and the second periodic component were 04 h 12 m and 00 h 25 m, respectively.",Circadian rhythm of 5-fluorouracil population pharmacokinetics in patients with metastatic colorectal cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10447576/),m,00,17974,DB00544,Fluorouracil
,10447576,acrophase (peak) times,"The acrophase (peak) times of the first and the second periodic component were 04 h 12 m and 00 h 25 m, respectively.",Circadian rhythm of 5-fluorouracil population pharmacokinetics in patients with metastatic colorectal cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10447576/),m,25,17975,DB00544,Fluorouracil
,10447576,CL(mean),"The population parameter estimates of mean clearance (CL(mean)) and initial volume of distribution (V), were as follows: the male subgroup showed a CL(mean) value twice larger (125 l/h) than the value observed in the female subgroup (65 l/h), and V = 21 l.",Circadian rhythm of 5-fluorouracil population pharmacokinetics in patients with metastatic colorectal cancer. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10447576/),[l] / [h],125,17976,DB00544,Fluorouracil
,10447576,CL(mean),"The population parameter estimates of mean clearance (CL(mean)) and initial volume of distribution (V), were as follows: the male subgroup showed a CL(mean) value twice larger (125 l/h) than the value observed in the female subgroup (65 l/h), and V = 21 l.",Circadian rhythm of 5-fluorouracil population pharmacokinetics in patients with metastatic colorectal cancer. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10447576/),[l] / [h],65,17977,DB00544,Fluorouracil
,10447576,V,"The population parameter estimates of mean clearance (CL(mean)) and initial volume of distribution (V), were as follows: the male subgroup showed a CL(mean) value twice larger (125 l/h) than the value observed in the female subgroup (65 l/h), and V = 21 l.",Circadian rhythm of 5-fluorouracil population pharmacokinetics in patients with metastatic colorectal cancer. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10447576/),l,21,17978,DB00544,Fluorouracil
,8373234,AUCs,"The AUCs in the peritoneal cavity of free CDDP and 5-FU were 63.6 micrograms.hr/ml and 925 micrograms.hr/ml, respectively.",[Pharmacokinetics following intraperitoneal sequential administration of cisplatin and fluorouracil for gastric cancer]. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8373234/),[h·μg] / [ml],63.6,18276,DB00544,Fluorouracil
,8373234,AUCs,"The AUCs in the peritoneal cavity of free CDDP and 5-FU were 63.6 micrograms.hr/ml and 925 micrograms.hr/ml, respectively.",[Pharmacokinetics following intraperitoneal sequential administration of cisplatin and fluorouracil for gastric cancer]. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8373234/),[h·μg] / [ml],925,18277,DB00544,Fluorouracil
,22978343,inter-compartmental clearance,A bimodal distribution of the inter-compartmental clearance was observed allowing two subpopulation with high (17 L/h) and low values (3.35 L/h).,Population pharmacokinetic analysis of 5-FU and 5-FDHU in colorectal cancer patients: search for biomarkers associated with gastro-intestinal toxicity. ,CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22978343/),[l] / [h],17,18340,DB00544,Fluorouracil
,22978343,inter-compartmental clearance,A bimodal distribution of the inter-compartmental clearance was observed allowing two subpopulation with high (17 L/h) and low values (3.35 L/h).,Population pharmacokinetic analysis of 5-FU and 5-FDHU in colorectal cancer patients: search for biomarkers associated with gastro-intestinal toxicity. ,CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22978343/),[l] / [h],3.35,18341,DB00544,Fluorouracil
,19238629,Objective response rates,"Objective response rates of 65% (95% confidence interval (CI): 43-82), disease stabilisation of 25% (95% CI: 11-47) and a disease control rate (CR + PR + SD) of 90% were achieved overall.","Phase I study of epirubicin, cisplatin and capecitabine plus matuzumab in previously untreated patients with advanced oesophagogastric cancer. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19238629/),%,65,18433,DB00544,Fluorouracil
,19238629,MTD,"The MTD of matuzumab in combination with ECX was 800 mg weekly, and at this DL it was well-tolerated and showed encouraging antitumour activity.","Phase I study of epirubicin, cisplatin and capecitabine plus matuzumab in previously untreated patients with advanced oesophagogastric cancer. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19238629/),mg,800,18434,DB00544,Fluorouracil
,29625079,AUC,"5FU AUC ranged from 11.3 to 37.31 mg h L-1, with 46.2% of under-dosed and 10.3% over-dosed patients.","DPD functional tests in plasma, fresh saliva and dried saliva samples as predictors of 5-fluorouracil exposure and occurrence of drug-related severe toxicity. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29625079/),[h·mg] / [l],11.3 to 37.31,19040,DB00544,Fluorouracil
,21463667,Shelf life,Shelf life of the formulation was found to be 2.83 years.,"Novel microbially triggered colon specific delivery system of 5-Fluorouracil: statistical optimization, in vitro, in vivo, cytotoxic and stability assessment. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21463667/),years,2.83,19070,DB00544,Fluorouracil
less,3735094,half-lives of hydrolysis,"The rates of hydrolysis were markedly accelerated in the presence of plasma, affording half-lives of hydrolysis less than 4 min in 80% human plasma.",Prodrugs of 5-fluorouracil. V. 1-Alkoxycarbonyl derivatives as potential prodrug forms for improved rectal or oral delivery of 5-fluorouracil. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3735094/),min,4,20201,DB00544,Fluorouracil
,3735094,absolute bioavailability,A preliminary absorption study in rabbits showed an absolute bioavailability of 5-fluorouracil of 100% following rectal administration of 1-(butoxycarbonyl)-5-fluorouracil as compared with no absorption following administration of 5-fluorouracil itself.,Prodrugs of 5-fluorouracil. V. 1-Alkoxycarbonyl derivatives as potential prodrug forms for improved rectal or oral delivery of 5-fluorouracil. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3735094/),%,100,20202,DB00544,Fluorouracil
,18451241,area under the time/concentration curve (AUC),The area under the time/concentration curve (AUC) of 5-FU was significantly lower in 58 subjects who recurred (7.5 +/- 2.9 h x mg/L) with respect to other patients (9.3 +/- 4.1 h x mg/L).,5-fluorouracil pharmacokinetics predicts disease-free survival in patients administered adjuvant chemotherapy for colorectal cancer. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18451241/),[h·mg] / [l],7.5,20231,DB00544,Fluorouracil
,18451241,area under the time/concentration curve (AUC),The area under the time/concentration curve (AUC) of 5-FU was significantly lower in 58 subjects who recurred (7.5 +/- 2.9 h x mg/L) with respect to other patients (9.3 +/- 4.1 h x mg/L).,5-fluorouracil pharmacokinetics predicts disease-free survival in patients administered adjuvant chemotherapy for colorectal cancer. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18451241/),[h·mg] / [l],9.3,20232,DB00544,Fluorouracil
lower,18451241,AUC,"Furthermore, AUC values lower than 8.4 h x mg/L together with lymph node involvement and the interruption of treatment or reduction of doses were identified as risk factors at univariate analysis.",5-fluorouracil pharmacokinetics predicts disease-free survival in patients administered adjuvant chemotherapy for colorectal cancer. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18451241/),[h·mg] / [l],8.4,20233,DB00544,Fluorouracil
,18451241,AUC,"The completion of 6 cycles of adjuvant treatment without dosage modifications was the only independent risk factor at multivariate analysis, despite a trend toward significance for 5-FU AUC values (cutoff value, 8.4 hxmg/L) was observed (P = 0.06).",5-fluorouracil pharmacokinetics predicts disease-free survival in patients administered adjuvant chemotherapy for colorectal cancer. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18451241/),[h·mg] / [l],8.4,20234,DB00544,Fluorouracil
,6437345,CT/NT ratio,The CT/NT ratio with respect to 5-FU concentration was 5.36 after UFT administration.,[Comparative pharmacokinetic study between UFT and FT-207 suppo and phase II studies in gynecological malignancies]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6437345/),,5.36,20505,DB00544,Fluorouracil
more,6418079,T/N ratio,"The concentrations of 5-FU in tumor tissue (T) were observed in most of the cases compared with those in normal tissue (N) (T/N ratio of more than 2.0 was observed in 16/23 patients), especially in the patients received higher doses of UFT-E and in the patients with GI cancers.",[Pharmacokinetics and a phase I study of tegafur-uracil enterogranules in cancer patients]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6418079/),,2.0,21510,DB00544,Fluorouracil
,8398300,response rate,"In the phase II study 28 patients were evaluable for response: three complete responses and 12 partial responses were observed (response rate 54%, 95% confidence interval, 34 to 72%).",Phase I-II study of the addition of alpha-2a interferon to 5-fluorouracil/leucovorin. Pharmacokinetic interaction of alpha-2a interferon and leucovorin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8398300/),%,54,21843,DB00544,Fluorouracil
,8951171,Ka,"With an increase in dose from 1.5 nmol/rat (low dow) to 15 mumol/rat (high dose), the Ka decreased from 5.95 to 0.55 min-1, suggesting the involvement of carrier-mediated transport.",Dose-dependent gastrointestinal absorption of 5-fluorouracil in rats in vivo. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8951171/),1/[min],5.95,21919,DB00544,Fluorouracil
,8951171,Ka,"With an increase in dose from 1.5 nmol/rat (low dow) to 15 mumol/rat (high dose), the Ka decreased from 5.95 to 0.55 min-1, suggesting the involvement of carrier-mediated transport.",Dose-dependent gastrointestinal absorption of 5-fluorouracil in rats in vivo. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8951171/),1/[min],0.55,21920,DB00544,Fluorouracil
,8951171,Kg,"Meanwhile, at both the low and high doses, the Kg values, which were unaffected by dose (0.069 and 0.082 min-1, respectively, for the low and high doses), were smaller than the Ka values by an order of magnitude or more and the recovery of 5-FU was negligible, compared with that of inulin (a nonabsorbable marker), in the most distal segment of ileum.",Dose-dependent gastrointestinal absorption of 5-fluorouracil in rats in vivo. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8951171/),1/[min],0.069,21921,DB00544,Fluorouracil
,8951171,Kg,"Meanwhile, at both the low and high doses, the Kg values, which were unaffected by dose (0.069 and 0.082 min-1, respectively, for the low and high doses), were smaller than the Ka values by an order of magnitude or more and the recovery of 5-FU was negligible, compared with that of inulin (a nonabsorbable marker), in the most distal segment of ileum.",Dose-dependent gastrointestinal absorption of 5-fluorouracil in rats in vivo. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8951171/),1/[min],0.082,21922,DB00544,Fluorouracil
,15592719,transmembrane pH gradient,(31)P-MRS showed there were significant ( p<or=0.02) increases in the hepatoma NTP/Pi ratio of 49% and transmembrane pH gradient of 0.11 units.,Investigations in vivo of the effects of carbogen breathing on 5-fluorouracil pharmacokinetics and physiology of solid rodent tumours. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15592719/),units,0.11,21989,DB00544,Fluorouracil
,26435217,maximum concentration,Thymine peaked quickly (30-45min) in plasma to a maximum concentration of 170±185μg/L (mean±SD).,Towards a test to predict 5-fluorouracil toxicity: Pharmacokinetic data for thymine and two sequential metabolites following oral thymine administration to healthy adult males. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26435217/),[μg] / [l],170,22031,DB00544,Fluorouracil
,26435217,Clearance,"Clearance was high (mean 57.9L/h/kg) exceeding normal human liver blood flow, suggesting low systemic bioavailability; urinary recovery of the thymine dose was low (<1%).",Towards a test to predict 5-fluorouracil toxicity: Pharmacokinetic data for thymine and two sequential metabolites following oral thymine administration to healthy adult males. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26435217/),[l] / [h·kg],57.9,22032,DB00544,Fluorouracil
,17565248,Cmax,"Pharmacokinetic parameters of 5-FU in the serum were as follows: Cmax, 159 .9 2+/-45.2 ng/mL, Tmax, 2.17+/-0.58 h;T1/2, 3.13+/-2.88 h; and AUC(0-8), 768.0+/-260.8 ng h/mL in the patients with the usual dose, and Cmax, 117.3+/-55.1 ng/mL; Tmax, 2.62+/-0.9 6 h; T1/2, 3.09+/-1.9 5 h and AUC(0-8), 565.9+/-216.8 ng h/mL in the patients with the decreased dose.",[Pharmacokinetics of 5-FU after S-1 oral administration for adjuvant chemotherapy in gastric cancer patients]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17565248/),[ng] / [ml],159 .9 2,22076,DB00544,Fluorouracil
,17565248,Tmax,"Pharmacokinetic parameters of 5-FU in the serum were as follows: Cmax, 159 .9 2+/-45.2 ng/mL, Tmax, 2.17+/-0.58 h;T1/2, 3.13+/-2.88 h; and AUC(0-8), 768.0+/-260.8 ng h/mL in the patients with the usual dose, and Cmax, 117.3+/-55.1 ng/mL; Tmax, 2.62+/-0.9 6 h; T1/2, 3.09+/-1.9 5 h and AUC(0-8), 565.9+/-216.8 ng h/mL in the patients with the decreased dose.",[Pharmacokinetics of 5-FU after S-1 oral administration for adjuvant chemotherapy in gastric cancer patients]. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17565248/),h,2.17,22077,DB00544,Fluorouracil
,17565248,T1/2,"Pharmacokinetic parameters of 5-FU in the serum were as follows: Cmax, 159 .9 2+/-45.2 ng/mL, Tmax, 2.17+/-0.58 h;T1/2, 3.13+/-2.88 h; and AUC(0-8), 768.0+/-260.8 ng h/mL in the patients with the usual dose, and Cmax, 117.3+/-55.1 ng/mL; Tmax, 2.62+/-0.9 6 h; T1/2, 3.09+/-1.9 5 h and AUC(0-8), 565.9+/-216.8 ng h/mL in the patients with the decreased dose.",[Pharmacokinetics of 5-FU after S-1 oral administration for adjuvant chemotherapy in gastric cancer patients]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17565248/),h,3.13,22078,DB00544,Fluorouracil
,17565248,AUC(0-8),"Pharmacokinetic parameters of 5-FU in the serum were as follows: Cmax, 159 .9 2+/-45.2 ng/mL, Tmax, 2.17+/-0.58 h;T1/2, 3.13+/-2.88 h; and AUC(0-8), 768.0+/-260.8 ng h/mL in the patients with the usual dose, and Cmax, 117.3+/-55.1 ng/mL; Tmax, 2.62+/-0.9 6 h; T1/2, 3.09+/-1.9 5 h and AUC(0-8), 565.9+/-216.8 ng h/mL in the patients with the decreased dose.",[Pharmacokinetics of 5-FU after S-1 oral administration for adjuvant chemotherapy in gastric cancer patients]. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17565248/),[h·ng] / [ml],768.0,22079,DB00544,Fluorouracil
,17565248,Cmax,"Pharmacokinetic parameters of 5-FU in the serum were as follows: Cmax, 159 .9 2+/-45.2 ng/mL, Tmax, 2.17+/-0.58 h;T1/2, 3.13+/-2.88 h; and AUC(0-8), 768.0+/-260.8 ng h/mL in the patients with the usual dose, and Cmax, 117.3+/-55.1 ng/mL; Tmax, 2.62+/-0.9 6 h; T1/2, 3.09+/-1.9 5 h and AUC(0-8), 565.9+/-216.8 ng h/mL in the patients with the decreased dose.",[Pharmacokinetics of 5-FU after S-1 oral administration for adjuvant chemotherapy in gastric cancer patients]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17565248/),[ng] / [ml],117.3,22080,DB00544,Fluorouracil
,17565248,Tmax,"Pharmacokinetic parameters of 5-FU in the serum were as follows: Cmax, 159 .9 2+/-45.2 ng/mL, Tmax, 2.17+/-0.58 h;T1/2, 3.13+/-2.88 h; and AUC(0-8), 768.0+/-260.8 ng h/mL in the patients with the usual dose, and Cmax, 117.3+/-55.1 ng/mL; Tmax, 2.62+/-0.9 6 h; T1/2, 3.09+/-1.9 5 h and AUC(0-8), 565.9+/-216.8 ng h/mL in the patients with the decreased dose.",[Pharmacokinetics of 5-FU after S-1 oral administration for adjuvant chemotherapy in gastric cancer patients]. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17565248/),h,2.62,22081,DB00544,Fluorouracil
,17565248,T1/2,"Pharmacokinetic parameters of 5-FU in the serum were as follows: Cmax, 159 .9 2+/-45.2 ng/mL, Tmax, 2.17+/-0.58 h;T1/2, 3.13+/-2.88 h; and AUC(0-8), 768.0+/-260.8 ng h/mL in the patients with the usual dose, and Cmax, 117.3+/-55.1 ng/mL; Tmax, 2.62+/-0.9 6 h; T1/2, 3.09+/-1.9 5 h and AUC(0-8), 565.9+/-216.8 ng h/mL in the patients with the decreased dose.",[Pharmacokinetics of 5-FU after S-1 oral administration for adjuvant chemotherapy in gastric cancer patients]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17565248/),h,3.09,22082,DB00544,Fluorouracil
,17565248,AUC(0-8),"Pharmacokinetic parameters of 5-FU in the serum were as follows: Cmax, 159 .9 2+/-45.2 ng/mL, Tmax, 2.17+/-0.58 h;T1/2, 3.13+/-2.88 h; and AUC(0-8), 768.0+/-260.8 ng h/mL in the patients with the usual dose, and Cmax, 117.3+/-55.1 ng/mL; Tmax, 2.62+/-0.9 6 h; T1/2, 3.09+/-1.9 5 h and AUC(0-8), 565.9+/-216.8 ng h/mL in the patients with the decreased dose.",[Pharmacokinetics of 5-FU after S-1 oral administration for adjuvant chemotherapy in gastric cancer patients]. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17565248/),[h·ng] / [ml],565.9,22083,DB00544,Fluorouracil
more,17565248,AUC,"Adverse events of more than grade 3 were recognized in 7 patients, and AUC of 6 patients were more than 800 ng h/mL.",[Pharmacokinetics of 5-FU after S-1 oral administration for adjuvant chemotherapy in gastric cancer patients]. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17565248/),[h·ng] / [ml],800,22084,DB00544,Fluorouracil
,6369203,plasma halflife,"Despite the short plasma halflife of 5-Fluorouracil (16,8 min) distinct concentrations with peak levels up to 115 nmol/ml after 30 min were observed in the effusions.",[Pharmacokinetics of 5-fluorouracil and its permeation in pleural effusions in the therapy of metastatic breast cancer]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6369203/),min,"16,8",22288,DB00544,Fluorouracil
,6369203,t 1/2,"In consequence of the rapid elimination of 5-Fluorouracil from the plasma and the comparatively slow retrograde diffusion (t 1/2 55 min) from the pleural space, the drug levels persisted longer in the effusions, than in the blood.",[Pharmacokinetics of 5-fluorouracil and its permeation in pleural effusions in the therapy of metastatic breast cancer]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6369203/),min,55,22289,DB00544,Fluorouracil
,6369203,AUC,"Thus the area under the curve of the pleural level (AUC) reached 50% (27-85%) of the corresponding plasma AUC (10,9 +/- 2,3 mumol x min x ml-1).",[Pharmacokinetics of 5-fluorouracil and its permeation in pleural effusions in the therapy of metastatic breast cancer]. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6369203/),[min·μM] / [ml],"10,9",22290,DB00544,Fluorouracil
,9499187,Drug absorption,Drug absorption from perfusate was 14.3+/-2.7 mg.,Heated intraoperative intraperitoneal mitomycin C and early postoperative intraperitoneal 5-fluorouracil: pharmacokinetic studies. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9499187/),mg,14.3,22380,DB00544,Fluorouracil
,9499187,aeras under the curve (AUC),"The mean aeras under the curve (AUC) for perfusate and plasma were, respectively, 340+/-138 and 15+/-4 microg/ml x min.",Heated intraoperative intraperitoneal mitomycin C and early postoperative intraperitoneal 5-fluorouracil: pharmacokinetic studies. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9499187/),[μg] / [min·ml],340,22381,DB00544,Fluorouracil
,9499187,aeras under the curve (AUC),"The mean aeras under the curve (AUC) for perfusate and plasma were, respectively, 340+/-138 and 15+/-4 microg/ml x min.",Heated intraoperative intraperitoneal mitomycin C and early postoperative intraperitoneal 5-fluorouracil: pharmacokinetic studies. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9499187/),[μg] / [min·ml],15,22382,DB00544,Fluorouracil
,9499187,AUC peritoneal fluid/plasma ratio,The mean AUC peritoneal fluid/plasma ratio was 23.5+/-5.8.,Heated intraoperative intraperitoneal mitomycin C and early postoperative intraperitoneal 5-fluorouracil: pharmacokinetic studies. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9499187/),,23.5,22383,DB00544,Fluorouracil
,18343925,overall response rate,"The overall response rate of PMC-cisplatin as ICT was 76%, including a complete remission rate of 23%.",Effectiveness of pharmacokinetic modulating chemotherapy combined with cisplatin as induction chemotherapy in resectable locally advanced head and neck cancer: phase II study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18343925/),%,76,23231,DB00544,Fluorouracil
,18343925,complete remission rate,"The overall response rate of PMC-cisplatin as ICT was 76%, including a complete remission rate of 23%.",Effectiveness of pharmacokinetic modulating chemotherapy combined with cisplatin as induction chemotherapy in resectable locally advanced head and neck cancer: phase II study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18343925/),%,23,23232,DB00544,Fluorouracil
,18343925,overall,"The overall organ preservation rate of the multimodality treatment was 75%, with 97% in ICT responders.",Effectiveness of pharmacokinetic modulating chemotherapy combined with cisplatin as induction chemotherapy in resectable locally advanced head and neck cancer: phase II study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18343925/),,75,23233,DB00544,Fluorouracil
,18343925,overall survival rate,The 3-year overall survival rate was 67%.,Effectiveness of pharmacokinetic modulating chemotherapy combined with cisplatin as induction chemotherapy in resectable locally advanced head and neck cancer: phase II study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18343925/),%,67,23234,DB00544,Fluorouracil
,6426396,half-time,"The blood level of FT-207 showed its peak of 35 to 37 mcg/ml at 4 hours after administration, of which half-time was 11 to 12 hours.",[Pharmacokinetics of FT-207 rectum suppository in squamous cell carcinoma of the uterine cervix. (II) Pharmacokinetics in continuous administration at a daily dose of 1 gram]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6426396/),h,11 to 12,23291,DB00544,Fluorouracil
more,6426396,half time,"The blood level of 5-FU showed its peak of 0.038 to 0.041 mcg/ml at 2 to 4 hours after administration, of which half time was more than 24 hours.",[Pharmacokinetics of FT-207 rectum suppository in squamous cell carcinoma of the uterine cervix. (II) Pharmacokinetics in continuous administration at a daily dose of 1 gram]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6426396/),h,24,23292,DB00544,Fluorouracil
,6426396,FT-207,The level of FT-207 in tumor tissue was 14.2 mcg/g which was 15 times higher than that single administration.,[Pharmacokinetics of FT-207 rectum suppository in squamous cell carcinoma of the uterine cervix. (II) Pharmacokinetics in continuous administration at a daily dose of 1 gram]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6426396/),[mcg] / [g],14.2,23293,DB00544,Fluorouracil
,15846298,terminal half-life,Pharmacokinetic studies in the mouse following intravenous injection showed that HGS-ETR1 serum concentrations were biphasic with a terminal half-life of 6.9-8.7 days and a steady-state volume of distribution of approximately 60 ml kg(-1).,"HGS-ETR1, a fully human TRAIL-receptor 1 monoclonal antibody, induces cell death in multiple tumour types in vitro and in vivo. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15846298/),d,6.9-8.7,24736,DB00544,Fluorouracil
,15846298,steady-state volume of distribution,Pharmacokinetic studies in the mouse following intravenous injection showed that HGS-ETR1 serum concentrations were biphasic with a terminal half-life of 6.9-8.7 days and a steady-state volume of distribution of approximately 60 ml kg(-1).,"HGS-ETR1, a fully human TRAIL-receptor 1 monoclonal antibody, induces cell death in multiple tumour types in vitro and in vivo. ",Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15846298/),[ml] / [kg],60,24737,DB00544,Fluorouracil
,15846298,Clearance,Clearance was 3.6-5.7 ml(-1) day(-1) kg(-1).,"HGS-ETR1, a fully human TRAIL-receptor 1 monoclonal antibody, induces cell death in multiple tumour types in vitro and in vivo. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15846298/),1/[day·kg·ml],3.6-5.7,24738,DB00544,Fluorouracil
,3943086,survival times,"The mean survival times for the control and FUra-treated mice (5 mg/kg at 1, 3, 5, and 7 days after tumor cell inoculation) were 9.7 and 12.4 days, respectively.",Effect of (E)-5-(2-bromovinyl)uracil on the catabolism and antitumor activity of 5-fluorouracil in rats and leukemic mice. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3943086/),d,9.7,24816,DB00544,Fluorouracil
,3943086,survival times,"The mean survival times for the control and FUra-treated mice (5 mg/kg at 1, 3, 5, and 7 days after tumor cell inoculation) were 9.7 and 12.4 days, respectively.",Effect of (E)-5-(2-bromovinyl)uracil on the catabolism and antitumor activity of 5-fluorouracil in rats and leukemic mice. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3943086/),d,12.4,24817,DB00544,Fluorouracil
,3943086,survival time,"When BVUra (200 mumol/kg) was administered 1 h before each injection of FUra, the mean survival time was extended to 17.1 days.",Effect of (E)-5-(2-bromovinyl)uracil on the catabolism and antitumor activity of 5-fluorouracil in rats and leukemic mice. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3943086/),d,17.1,24818,DB00544,Fluorouracil
,3943086,survival time,"When the dose of FUra was increased to 20 mg/kg, the mean survival time was 15.3 days; upon a preceding injection of BVUra the mean survival time decreased to 9.2 days.",Effect of (E)-5-(2-bromovinyl)uracil on the catabolism and antitumor activity of 5-fluorouracil in rats and leukemic mice. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3943086/),d,15.3,24819,DB00544,Fluorouracil
,3943086,survival time,"When the dose of FUra was increased to 20 mg/kg, the mean survival time was 15.3 days; upon a preceding injection of BVUra the mean survival time decreased to 9.2 days.",Effect of (E)-5-(2-bromovinyl)uracil on the catabolism and antitumor activity of 5-fluorouracil in rats and leukemic mice. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3943086/),d,9.2,24820,DB00544,Fluorouracil
,1760861,extraction rate,The HPFD extraction rate was 99%.,"Combined haemoperfusion, haemofiltration and haemodialysis for systemic detoxification in locoregional 5-fluorouracil therapy. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1760861/),%,99,24857,DB00544,Fluorouracil
,1760861,clearance,Extracorporal 5-FU clearance (89 ml/min) was 9% of total body clearance (1094 ml/min).,"Combined haemoperfusion, haemofiltration and haemodialysis for systemic detoxification in locoregional 5-fluorouracil therapy. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1760861/),[ml] / [min],89,24858,DB00544,Fluorouracil
,1760861,total body clearance,Extracorporal 5-FU clearance (89 ml/min) was 9% of total body clearance (1094 ml/min).,"Combined haemoperfusion, haemofiltration and haemodialysis for systemic detoxification in locoregional 5-fluorouracil therapy. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1760861/),[ml] / [min],1094,24859,DB00544,Fluorouracil
,1760861,fraction eliminated within,The fraction eliminated within 4 h was only 6% of the applied dose (3500-4000 mg 5-FU).,"Combined haemoperfusion, haemofiltration and haemodialysis for systemic detoxification in locoregional 5-fluorouracil therapy. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1760861/),%,6,24860,DB00544,Fluorouracil
,20857171,MTD,"The MTD of single-agent oral irinotecan was estimated to be 60 mg/m(2)/day, and DLT included diarrhea, nausea, and neutropenia.",Phase I study of oral irinotecan as a single-agent and given sequentially with capecitabine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20857171/),mg,60,25570,DB00544,Fluorouracil
,20857171,MTD,"In an initial group of patients with Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0 to 2, the MTD of sequential oral irinotecan/capecitabine was estimated to be 40/1600 mg/m(2)/day with DLT of delayed diarrhea.",Phase I study of oral irinotecan as a single-agent and given sequentially with capecitabine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20857171/),[mg] / [d·m(2)],40,25571,DB00544,Fluorouracil
,20857171,MTD,"In an initial group of patients with Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0 to 2, the MTD of sequential oral irinotecan/capecitabine was estimated to be 40/1600 mg/m(2)/day with DLT of delayed diarrhea.",Phase I study of oral irinotecan as a single-agent and given sequentially with capecitabine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20857171/),[mg] / [d·m(2)],1600,25572,DB00544,Fluorouracil
,1738182,response rate,"The response rate was 52% (complete response, 12%; partial response, 40%).",Fluorouracil combined with the pure (6S)-stereoisomer of folinic acid in high doses for treatment of patients with advanced colorectal carcinoma: a phase I-II study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1738182/),%,52,25676,DB00544,Fluorouracil
,1738182,time to disease progression,"The median time to disease progression for responding patients was 9.2 months (range, 5.9-15+ months).",Fluorouracil combined with the pure (6S)-stereoisomer of folinic acid in high doses for treatment of patients with advanced colorectal carcinoma: a phase I-II study. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1738182/),month,9.2,25677,DB00544,Fluorouracil
,1738182,half-lives: alpha,"After IV injection, (6S)-folinic acid was rapidly cleared from plasma (mean half-lives: alpha = 7.2 minutes and beta = 126 minutes).",Fluorouracil combined with the pure (6S)-stereoisomer of folinic acid in high doses for treatment of patients with advanced colorectal carcinoma: a phase I-II study. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1738182/),min,7.2,25678,DB00544,Fluorouracil
,1738182,beta,"After IV injection, (6S)-folinic acid was rapidly cleared from plasma (mean half-lives: alpha = 7.2 minutes and beta = 126 minutes).",Fluorouracil combined with the pure (6S)-stereoisomer of folinic acid in high doses for treatment of patients with advanced colorectal carcinoma: a phase I-II study. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1738182/),min,126,25679,DB00544,Fluorouracil
,22353201,maximum concentration,"The maximum concentration in plasma and the area under the plasma concentration-time curve from 0 to 9 h were respectively 55.3 ± 21.1 ng/ml and 290.2 ± 95.7 ng·hr/ml for level 1, as compared with 104.2 ± 33.5 ng/ml and 541.9 ± 232.3 ng·hr/ml for level 2.",Pharmacokinetic study of weekly (days 1-5) low-dose S-1 in patients with non-small-cell lung cancer. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22353201/),[ng] / [ml],55.3,26032,DB00544,Fluorouracil
,22353201,maximum concentration,"The maximum concentration in plasma and the area under the plasma concentration-time curve from 0 to 9 h were respectively 55.3 ± 21.1 ng/ml and 290.2 ± 95.7 ng·hr/ml for level 1, as compared with 104.2 ± 33.5 ng/ml and 541.9 ± 232.3 ng·hr/ml for level 2.",Pharmacokinetic study of weekly (days 1-5) low-dose S-1 in patients with non-small-cell lung cancer. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22353201/),[ng] / [ml],104.2,26033,DB00544,Fluorouracil
,22353201,area under the plasma concentration-time curve from 0 to 9 h,"The maximum concentration in plasma and the area under the plasma concentration-time curve from 0 to 9 h were respectively 55.3 ± 21.1 ng/ml and 290.2 ± 95.7 ng·hr/ml for level 1, as compared with 104.2 ± 33.5 ng/ml and 541.9 ± 232.3 ng·hr/ml for level 2.",Pharmacokinetic study of weekly (days 1-5) low-dose S-1 in patients with non-small-cell lung cancer. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22353201/),[h·ng] / [ml],290.2,26034,DB00544,Fluorouracil
,22353201,area under the plasma concentration-time curve from 0 to 9 h,"The maximum concentration in plasma and the area under the plasma concentration-time curve from 0 to 9 h were respectively 55.3 ± 21.1 ng/ml and 290.2 ± 95.7 ng·hr/ml for level 1, as compared with 104.2 ± 33.5 ng/ml and 541.9 ± 232.3 ng·hr/ml for level 2.",Pharmacokinetic study of weekly (days 1-5) low-dose S-1 in patients with non-small-cell lung cancer. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22353201/),[h·ng] / [ml],541.9,26035,DB00544,Fluorouracil
,2783877,peak plasma folate concentrations,"In patients with lung carcinoma, oral administration of dl-LV at 125 mg/m2 hourly for 4 hours (total dose of 500 mg/m2) gave the following peak plasma folate concentrations: dl-LV, 4.6 + 1.9 microM; 5-methyltetrahydrofolate, 4.3 + 2.1 microM; and no detectable l-LV in most cases.",Toxicity and antitumor activity of 5-fluorouracil in combination with leucovorin. Role of dose schedule and route of administration of leucovorin. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2783877/),μM,4.6,26488,DB00544,Fluorouracil
,2783877,peak plasma folate concentrations,"In patients with lung carcinoma, oral administration of dl-LV at 125 mg/m2 hourly for 4 hours (total dose of 500 mg/m2) gave the following peak plasma folate concentrations: dl-LV, 4.6 + 1.9 microM; 5-methyltetrahydrofolate, 4.3 + 2.1 microM; and no detectable l-LV in most cases.",Toxicity and antitumor activity of 5-fluorouracil in combination with leucovorin. Role of dose schedule and route of administration of leucovorin. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2783877/),μM,4.3,26489,DB00544,Fluorouracil
,25416027,IC50,"In addition, 5-FU complex encapsulation into TSLs induces a reduction of the IC50 from 115 down to 49 μM.",Formulation and pharmacokinetics of thermosensitive stealth® liposomes encapsulating 5-Fluorouracil. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25416027/),μM,115,26527,DB00544,Fluorouracil
,25416027,IC50,"In addition, 5-FU complex encapsulation into TSLs induces a reduction of the IC50 from 115 down to 49 μM.",Formulation and pharmacokinetics of thermosensitive stealth® liposomes encapsulating 5-Fluorouracil. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25416027/),μM,49,26528,DB00544,Fluorouracil
,23576486,survival times,"Median survival times were 10.1 and 7.4 months, respectively.",Approval summary: Cetuximab in combination with cisplatin or carboplatin and 5-fluorouracil for the first-line treatment of patients with recurrent locoregional or metastatic squamous cell head and neck cancer. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23576486/),month,10.1,26668,DB00544,Fluorouracil
,23576486,survival times,"Median survival times were 10.1 and 7.4 months, respectively.",Approval summary: Cetuximab in combination with cisplatin or carboplatin and 5-fluorouracil for the first-line treatment of patients with recurrent locoregional or metastatic squamous cell head and neck cancer. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23576486/),month,7.4,26669,DB00544,Fluorouracil
,23576486,PFS times,"Median PFS times were 5.5 and 3.3 months, respectively.",Approval summary: Cetuximab in combination with cisplatin or carboplatin and 5-fluorouracil for the first-line treatment of patients with recurrent locoregional or metastatic squamous cell head and neck cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23576486/),month,5.5,26670,DB00544,Fluorouracil
,23576486,PFS times,"Median PFS times were 5.5 and 3.3 months, respectively.",Approval summary: Cetuximab in combination with cisplatin or carboplatin and 5-fluorouracil for the first-line treatment of patients with recurrent locoregional or metastatic squamous cell head and neck cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23576486/),month,3.3,26671,DB00544,Fluorouracil
,23576486,Response rates,Response rates were 35.6% and 19.5% (odds ratio: 2.33; 95% CI: 1.50-3.60; p = .0001).,Approval summary: Cetuximab in combination with cisplatin or carboplatin and 5-fluorouracil for the first-line treatment of patients with recurrent locoregional or metastatic squamous cell head and neck cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23576486/),%,35.6,26672,DB00544,Fluorouracil
,23576486,Response rates,Response rates were 35.6% and 19.5% (odds ratio: 2.33; 95% CI: 1.50-3.60; p = .0001).,Approval summary: Cetuximab in combination with cisplatin or carboplatin and 5-fluorouracil for the first-line treatment of patients with recurrent locoregional or metastatic squamous cell head and neck cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23576486/),%,19.5,26673,DB00544,Fluorouracil
,15751639,Cmax,"5-FU Cmax of 600 mg/m2/day, 750 mg/m2/day and 1,200 mg/m2/day were 254, 329, 531 ng/ml, respectively.",[Pharmacokinetic modulating chemotherapy for rectal carcinoma metastases to the liver and lung--a case report]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15751639/),[ng] / [ml],254,26694,DB00544,Fluorouracil
,15751639,Cmax,"5-FU Cmax of 600 mg/m2/day, 750 mg/m2/day and 1,200 mg/m2/day were 254, 329, 531 ng/ml, respectively.",[Pharmacokinetic modulating chemotherapy for rectal carcinoma metastases to the liver and lung--a case report]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15751639/),[ng] / [ml],32,26695,DB00544,Fluorouracil
,15751639,Cmax,"5-FU Cmax of 600 mg/m2/day, 750 mg/m2/day and 1,200 mg/m2/day were 254, 329, 531 ng/ml, respectively.",[Pharmacokinetic modulating chemotherapy for rectal carcinoma metastases to the liver and lung--a case report]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15751639/),[ng] / [ml],9,26696,DB00544,Fluorouracil
,15751639,Cmax,"5-FU Cmax of 600 mg/m2/day, 750 mg/m2/day and 1,200 mg/m2/day were 254, 329, 531 ng/ml, respectively.",[Pharmacokinetic modulating chemotherapy for rectal carcinoma metastases to the liver and lung--a case report]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15751639/),[ng] / [ml],531,26697,DB00544,Fluorouracil
,7595715,overall response rate,"Among 62 previously untreated patients, two complete responses (CRs) and 18 partial responses (PRs) were observed (overall response rate, 32%; 95% confidence interval, 21% to 45%).",Doxifluridine and leucovorin: an oral treatment combination in advanced colorectal cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7595715/),%,32,27040,DB00544,Fluorouracil
,7595715,response duration,"The median response duration was 4 months (range, 2 to 13) and the median survival time, 14 months.",Doxifluridine and leucovorin: an oral treatment combination in advanced colorectal cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7595715/),month,4,27041,DB00544,Fluorouracil
,7595715,survival time,"The median response duration was 4 months (range, 2 to 13) and the median survival time, 14 months.",Doxifluridine and leucovorin: an oral treatment combination in advanced colorectal cancer. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7595715/),month,14,27042,DB00544,Fluorouracil
,7595715,response rate,"Among 46 pretreated patients, there were three CRs and three PRs (response rate, 13%; 95% confidence interval, 5% to 26%).",Doxifluridine and leucovorin: an oral treatment combination in advanced colorectal cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7595715/),%,13,27043,DB00544,Fluorouracil
,7595715,response duration,"In this group of patients, the median response duration was 4 months (range, 1 to 12) and the median survival time, 12 months.",Doxifluridine and leucovorin: an oral treatment combination in advanced colorectal cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7595715/),month,4,27044,DB00544,Fluorouracil
,7595715,survival time,"In this group of patients, the median response duration was 4 months (range, 1 to 12) and the median survival time, 12 months.",Doxifluridine and leucovorin: an oral treatment combination in advanced colorectal cancer. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7595715/),month,12,27045,DB00544,Fluorouracil
,26006331,entrapment efficiencies,Dextran microspheres showed mean entrapment efficiencies ranging between 77 and 87% and mean particle size ranging between 10 and 25 µm.,Enteric-coated epichlorohydrin crosslinked dextran microspheres for site-specific delivery to colon. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26006331/),%,77 and 87,27929,DB00544,Fluorouracil
,3719584,steady-state plasma level,The steady-state plasma level increased from 3.37 to 7.49 microM with dose increases from 1.25 to 2.25 g/m2/day.,Plasma pharmacokinetics of 5-FU given by continuous infusion with allopurinol. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3719584/),μM,3.37 to 7.49,28024,DB00544,Fluorouracil
,3719584,Clearance,Clearance ranged from 1.79 to 2.41 L/min/m2.,Plasma pharmacokinetics of 5-FU given by continuous infusion with allopurinol. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3719584/),[l] / [m2·min],1.79 to 2.41,28025,DB00544,Fluorouracil
,3315280,plasma elimination half-lives,"Cyclophosphamide plasma elimination half-lives ranged between 152 and 984 min (mean 457 min), the apparent volume of distribution between 19.1 and 62.3 1 (mean 36.1 1), and plasma clearance between 25.9 and 166.6 ml/min (mean 69.5 ml/min).",Effect of body weight on the pharmacokinetics of cyclophosphamide in breast cancer patients. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3315280/),min,457,28030,DB00544,Fluorouracil
,3315280,apparent volume of distribution,"Cyclophosphamide plasma elimination half-lives ranged between 152 and 984 min (mean 457 min), the apparent volume of distribution between 19.1 and 62.3 1 (mean 36.1 1), and plasma clearance between 25.9 and 166.6 ml/min (mean 69.5 ml/min).",Effect of body weight on the pharmacokinetics of cyclophosphamide in breast cancer patients. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3315280/),1,36.1,28031,DB00544,Fluorouracil
,3315280,plasma clearance,"Cyclophosphamide plasma elimination half-lives ranged between 152 and 984 min (mean 457 min), the apparent volume of distribution between 19.1 and 62.3 1 (mean 36.1 1), and plasma clearance between 25.9 and 166.6 ml/min (mean 69.5 ml/min).",Effect of body weight on the pharmacokinetics of cyclophosphamide in breast cancer patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3315280/),[ml] / [min],25.9 and 166.6,28032,DB00544,Fluorouracil
,3315280,plasma clearance,"Cyclophosphamide plasma elimination half-lives ranged between 152 and 984 min (mean 457 min), the apparent volume of distribution between 19.1 and 62.3 1 (mean 36.1 1), and plasma clearance between 25.9 and 166.6 ml/min (mean 69.5 ml/min).",Effect of body weight on the pharmacokinetics of cyclophosphamide in breast cancer patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3315280/),[ml] / [min],69.5,28033,DB00544,Fluorouracil
,3231913,peak,"Immediately following a 500 microgram intravitreal injection of 3H-5-fluorouridine, a peak ipsilateral vitreous concentration of 308 micrograms/ml was measured.",Uptake and clearance of 5-fluorouridine following subconjunctival and intravitreal injection. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3231913/),[μg] / [ml],308,28412,DB00544,Fluorouracil
,3231913,peak i,"Following subconjunctival injection of 5 mg 3H-5-fluorouridine (0.5 ml), peak ipsilateral anterior chamber concentration of 10.7 micrograms/ml was measured 1 hour after injection and decreased to 2.4 micrograms/ml after 12 hours.",Uptake and clearance of 5-fluorouridine following subconjunctival and intravitreal injection. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3231913/),[μg] / [ml],10.7,28413,DB00544,Fluorouracil
,3231913,peak i,"Following subconjunctival injection of 5 mg 3H-5-fluorouridine (0.5 ml), peak ipsilateral anterior chamber concentration of 10.7 micrograms/ml was measured 1 hour after injection and decreased to 2.4 micrograms/ml after 12 hours.",Uptake and clearance of 5-fluorouridine following subconjunctival and intravitreal injection. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3231913/),[μg] / [ml],2.4,28414,DB00544,Fluorouracil
,3231913,Maximum vitreal concentrations,Maximum vitreal concentrations of 1.7 micrograms/ml were measured 12 hours after injection.,Uptake and clearance of 5-fluorouridine following subconjunctival and intravitreal injection. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3231913/),[μg] / [ml],1.7,28415,DB00544,Fluorouracil
,7720172,AUC,Area-under-the-curve (AUC0-24 h) calculations resulted in an AUC value of 146.4% h for the 5-FU/epi gel formulation as compared with 45.7% h for 5-FU solution.,Antitumor effect of intratumoral administration of fluorouracil/epinephrine injectable gel in C3H mice. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7720172/),%·h,146.4,28474,DB00544,Fluorouracil
,7720172,AUC,Area-under-the-curve (AUC0-24 h) calculations resulted in an AUC value of 146.4% h for the 5-FU/epi gel formulation as compared with 45.7% h for 5-FU solution.,Antitumor effect of intratumoral administration of fluorouracil/epinephrine injectable gel in C3H mice. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7720172/),%·h,45.7,28475,DB00544,Fluorouracil
,24097815,plasma pelvic-to-systemic exposure ratio,The plasma pelvic-to-systemic exposure ratio was 18.4 based on the maximum concentration and 19.0 based on the concentration-time curve.,Negative-balance isolated pelvic perfusion in patients with incurable symptomatic rectal cancer: results and drug dose correlation to adverse events. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24097815/),,18.4,28908,DB00544,Fluorouracil
,24097815,plasma pelvic-to-systemic exposure ratio,The plasma pelvic-to-systemic exposure ratio was 18.4 based on the maximum concentration and 19.0 based on the concentration-time curve.,Negative-balance isolated pelvic perfusion in patients with incurable symptomatic rectal cancer: results and drug dose correlation to adverse events. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24097815/),,19.0,28909,DB00544,Fluorouracil
,12618890,c(max),"As intended with the prodrug design of capecitabine, FU was present in low concentrations in tumour interstitium (median c(max): 0.26 microg ml(-1)) when compared with capecitabine, DFCR, and DFUR (median c(max): 2.66, 4.22, and 2.13 microg ml(-1), respectively).",Penetration of capecitabine and its metabolites into malignant and healthy tissues of patients with advanced breast cancer. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12618890/),[μg] / [ml],0.26,30305,DB00544,Fluorouracil
,12618890,c(max),"As intended with the prodrug design of capecitabine, FU was present in low concentrations in tumour interstitium (median c(max): 0.26 microg ml(-1)) when compared with capecitabine, DFCR, and DFUR (median c(max): 2.66, 4.22, and 2.13 microg ml(-1), respectively).",Penetration of capecitabine and its metabolites into malignant and healthy tissues of patients with advanced breast cancer. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12618890/),[μg] / [ml],2.66,30306,DB00544,Fluorouracil
,12618890,c(max),"As intended with the prodrug design of capecitabine, FU was present in low concentrations in tumour interstitium (median c(max): 0.26 microg ml(-1)) when compared with capecitabine, DFCR, and DFUR (median c(max): 2.66, 4.22, and 2.13 microg ml(-1), respectively).",Penetration of capecitabine and its metabolites into malignant and healthy tissues of patients with advanced breast cancer. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12618890/),[μg] / [ml],4.22,30307,DB00544,Fluorouracil
,12618890,c(max),"As intended with the prodrug design of capecitabine, FU was present in low concentrations in tumour interstitium (median c(max): 0.26 microg ml(-1)) when compared with capecitabine, DFCR, and DFUR (median c(max): 2.66, 4.22, and 2.13 microg ml(-1), respectively).",Penetration of capecitabine and its metabolites into malignant and healthy tissues of patients with advanced breast cancer. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12618890/),[μg] / [ml],2.13,30308,DB00544,Fluorouracil
,27184460,entrapment efficiency (EE),The optimized Pae-PEG-NISVs had mean diameters of approximately 166 nm and entrapment efficiency (EE) of 61.8%.,"PEGylated niosomes-mediated drug delivery systems for Paeonol: preparation, pharmacokinetics studies and synergistic anti-tumor effects with 5-FU. ",Emax-Q15,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27184460/),%,61.8,30350,DB00544,Fluorouracil
,27184460,elimination half-lives (t1/2,"Pharmacokinetic studies in rats after i.v. injection showed that Pae-PEG-NISVs had increased elimination half-lives (t1/2, 87.5 versus 17.0 min) and increased area under the concentration-time curve (AUC0-t, 38.0 versus 19.48 μg/ml*min) compared to Paeonol solution.","PEGylated niosomes-mediated drug delivery systems for Paeonol: preparation, pharmacokinetics studies and synergistic anti-tumor effects with 5-FU. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/27184460/),min,87.5,30351,DB00544,Fluorouracil
,27184460,elimination half-lives (t1/2,"Pharmacokinetic studies in rats after i.v. injection showed that Pae-PEG-NISVs had increased elimination half-lives (t1/2, 87.5 versus 17.0 min) and increased area under the concentration-time curve (AUC0-t, 38.0 versus 19.48 μg/ml*min) compared to Paeonol solution.","PEGylated niosomes-mediated drug delivery systems for Paeonol: preparation, pharmacokinetics studies and synergistic anti-tumor effects with 5-FU. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/27184460/),min,17.0,30352,DB00544,Fluorouracil
,27184460,area under the concentration-time curve (AUC0-t,"Pharmacokinetic studies in rats after i.v. injection showed that Pae-PEG-NISVs had increased elimination half-lives (t1/2, 87.5 versus 17.0 min) and increased area under the concentration-time curve (AUC0-t, 38.0 versus 19.48 μg/ml*min) compared to Paeonol solution.","PEGylated niosomes-mediated drug delivery systems for Paeonol: preparation, pharmacokinetics studies and synergistic anti-tumor effects with 5-FU. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27184460/),[μg] / [min·ml],38.0,30353,DB00544,Fluorouracil
,27184460,area under the concentration-time curve (AUC0-t,"Pharmacokinetic studies in rats after i.v. injection showed that Pae-PEG-NISVs had increased elimination half-lives (t1/2, 87.5 versus 17.0 min) and increased area under the concentration-time curve (AUC0-t, 38.0 versus 19.48 μg/ml*min) compared to Paeonol solution.","PEGylated niosomes-mediated drug delivery systems for Paeonol: preparation, pharmacokinetics studies and synergistic anti-tumor effects with 5-FU. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27184460/),[μg] / [min·ml],19.48,30354,DB00544,Fluorouracil
,27184460,IC50,"Formulated Paeonol had superior cytotoxicity versus the free drug with IC50 values of 22.47 and 85.16 μg/mL at 24 h on HepG2 cells, respectively, and we found that low concentration of Pae-PEG-NISVs and 5-Fu in conjunction had obviously synergistic effect.","PEGylated niosomes-mediated drug delivery systems for Paeonol: preparation, pharmacokinetics studies and synergistic anti-tumor effects with 5-FU. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27184460/),[μg] / [ml],22.47,30355,DB00544,Fluorouracil
,27184460,IC50,"Formulated Paeonol had superior cytotoxicity versus the free drug with IC50 values of 22.47 and 85.16 μg/mL at 24 h on HepG2 cells, respectively, and we found that low concentration of Pae-PEG-NISVs and 5-Fu in conjunction had obviously synergistic effect.","PEGylated niosomes-mediated drug delivery systems for Paeonol: preparation, pharmacokinetics studies and synergistic anti-tumor effects with 5-FU. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27184460/),[μg] / [ml],85.16,30356,DB00544,Fluorouracil
,29798953,PFS,The median PFS at 1 year was 3.83 months in test arm and 4.6 months in reference arm.,"Comparative pharmacokinetics, efficacy, and safety of bevacizumab biosimilar to reference bevacizumab in patients with metastatic colorectal cancer. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29798953/),month,3.83,30470,DB00544,Fluorouracil
,29798953,PFS,The median PFS at 1 year was 3.83 months in test arm and 4.6 months in reference arm.,"Comparative pharmacokinetics, efficacy, and safety of bevacizumab biosimilar to reference bevacizumab in patients with metastatic colorectal cancer. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29798953/),month,4.6,30471,DB00544,Fluorouracil
,29798953,OS,The mean OS was 10.91 months in test arm and 14.68 months in reference arm.,"Comparative pharmacokinetics, efficacy, and safety of bevacizumab biosimilar to reference bevacizumab in patients with metastatic colorectal cancer. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29798953/),month,10.91,30472,DB00544,Fluorouracil
,29798953,OS,The mean OS was 10.91 months in test arm and 14.68 months in reference arm.,"Comparative pharmacokinetics, efficacy, and safety of bevacizumab biosimilar to reference bevacizumab in patients with metastatic colorectal cancer. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29798953/),month,14.68,30473,DB00544,Fluorouracil
,29798953,Tmax,The median Tmaxwas 6.00 h in both the arms.,"Comparative pharmacokinetics, efficacy, and safety of bevacizumab biosimilar to reference bevacizumab in patients with metastatic colorectal cancer. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29798953/),h,6.00,30474,DB00544,Fluorouracil
,29798953,t½,"The median t½ was 330.63 h and 226.14 h, respectively, for test and reference bevacizumab.","Comparative pharmacokinetics, efficacy, and safety of bevacizumab biosimilar to reference bevacizumab in patients with metastatic colorectal cancer. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29798953/),h,330.63,30475,DB00544,Fluorouracil
,29798953,t½,"The median t½ was 330.63 h and 226.14 h, respectively, for test and reference bevacizumab.","Comparative pharmacokinetics, efficacy, and safety of bevacizumab biosimilar to reference bevacizumab in patients with metastatic colorectal cancer. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29798953/),h,226.14,30476,DB00544,Fluorouracil
,16203781,activation ratio,"Patients with CES2 mRNA expression above the median cutoff value presented an activation ratio higher (median, 0.25; range, 0.15-0.42) than those with CES2 mRNA below the median (median, 0.20; range, 0.10-0.40; P = 0.013).",Carboxylesterase isoform 2 mRNA expression in peripheral blood mononuclear cells is a predictive marker of the irinotecan to SN38 activation step in colorectal cancer patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16203781/),,0.25,30569,DB00544,Fluorouracil
,16203781,activation ratio,"Patients with CES2 mRNA expression above the median cutoff value presented an activation ratio higher (median, 0.25; range, 0.15-0.42) than those with CES2 mRNA below the median (median, 0.20; range, 0.10-0.40; P = 0.013).",Carboxylesterase isoform 2 mRNA expression in peripheral blood mononuclear cells is a predictive marker of the irinotecan to SN38 activation step in colorectal cancer patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16203781/),,0,30570,DB00544,Fluorouracil
,16203781,AUC,"This was associated with a nonsignificant trend of 1.34-fold increase of SN38 AUC in the group of patients with high CES2 mRNA expression (mean, 1.03 +/- 0.62 versus 0.77 +/- 0.32 micromol/L hour).",Carboxylesterase isoform 2 mRNA expression in peripheral blood mononuclear cells is a predictive marker of the irinotecan to SN38 activation step in colorectal cancer patients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16203781/),[μM] / [h·l],1.03,30571,DB00544,Fluorouracil
,16203781,AUC,"This was associated with a nonsignificant trend of 1.34-fold increase of SN38 AUC in the group of patients with high CES2 mRNA expression (mean, 1.03 +/- 0.62 versus 0.77 +/- 0.32 micromol/L hour).",Carboxylesterase isoform 2 mRNA expression in peripheral blood mononuclear cells is a predictive marker of the irinotecan to SN38 activation step in colorectal cancer patients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16203781/),[μM] / [h·l],0.77,30572,DB00544,Fluorouracil
,29691300,progression-free survival (PFS),"In first-line patients (n = 36), median progression-free survival (PFS) was 9.9 months [95% confidence interval (CI), 5-13.9 months], and the overall response rate (ORR) was 50%.",Andecaliximab/GS-5745 Alone and Combined with mFOLFOX6 in Advanced Gastric and Gastroesophageal Junction Adenocarcinoma: Results from a Phase I Study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29691300/),month,9.9,31475,DB00544,Fluorouracil
,29691300,overall response rate (ORR),"In first-line patients (n = 36), median progression-free survival (PFS) was 9.9 months [95% confidence interval (CI), 5-13.9 months], and the overall response rate (ORR) was 50%.",Andecaliximab/GS-5745 Alone and Combined with mFOLFOX6 in Advanced Gastric and Gastroesophageal Junction Adenocarcinoma: Results from a Phase I Study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29691300/),%,50,31476,DB00544,Fluorouracil
,29691300,PFS,"Among all patients (n = 40), median PFS was 7.8 (90% CI, 5.5-13.9) months, and ORR was 48%, with a median duration of response of 8.4 months.",Andecaliximab/GS-5745 Alone and Combined with mFOLFOX6 in Advanced Gastric and Gastroesophageal Junction Adenocarcinoma: Results from a Phase I Study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29691300/),month,7,31477,DB00544,Fluorouracil
,30989775,area under the curve,"Those in cohorts 3 and 4 treated with an adjusted dose of S-1 showed a similar area under the curve for 5-fluorouracil (941.9 ± 275.6 and 1043.5 ± 224.8 ng/mL, respectively) compared with cohort 2 (1034.9 ± 414.3 ng/mL).",Pharmacokinetic study of the oral fluorouracil antitumor agent S-1 in patients with impaired renal function. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30989775/),[ng] / [ml],941.9,31497,DB00544,Fluorouracil
,30989775,area under the curve,"Those in cohorts 3 and 4 treated with an adjusted dose of S-1 showed a similar area under the curve for 5-fluorouracil (941.9 ± 275.6 and 1043.5 ± 224.8 ng/mL, respectively) compared with cohort 2 (1034.9 ± 414.3 ng/mL).",Pharmacokinetic study of the oral fluorouracil antitumor agent S-1 in patients with impaired renal function. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30989775/),[ng] / [ml],1043.5,31498,DB00544,Fluorouracil
,30989775,area under the curve,"Those in cohorts 3 and 4 treated with an adjusted dose of S-1 showed a similar area under the curve for 5-fluorouracil (941.9 ± 275.6 and 1043.5 ± 224.8 ng/mL, respectively) compared with cohort 2 (1034.9 ± 414.3 ng/mL).",Pharmacokinetic study of the oral fluorouracil antitumor agent S-1 in patients with impaired renal function. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30989775/),[ng] / [ml],1034.9,31499,DB00544,Fluorouracil
,29131533,PFS,"Among 29 patients treated at level 2, PFS was longer for UGT1A1 wt/*6 and wt/*28 patients than for wt/wt patients (12 vs. 8 months, P = 0.06).",A phase I/II pharmacokinetics/pharmacodynamics study of irinotecan combined with S-1 for recurrent/metastatic breast cancer in patients with selected UGT1A1 genotypes (the JBCRG-M01 study). ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29131533/),month,12,31541,DB00544,Fluorouracil
,29131533,PFS,"Among 29 patients treated at level 2, PFS was longer for UGT1A1 wt/*6 and wt/*28 patients than for wt/wt patients (12 vs. 8 months, P = 0.06).",A phase I/II pharmacokinetics/pharmacodynamics study of irinotecan combined with S-1 for recurrent/metastatic breast cancer in patients with selected UGT1A1 genotypes (the JBCRG-M01 study). ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29131533/),month,8,31542,DB00544,Fluorouracil
,3943107,Vmax,"Methods 1 and 2 gave mean Vmax and Km values which did not differ significantly; the overall mean Vmax was 2.02 microM/kg/min, and the overall mean Km was 10.9 microM.",Steady-state nonlinear pharmacokinetics of 5-fluorouracil during hepatic arterial and intravenous infusions in cancer patients. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3943107/),[μM] / [kg·min],2.02,31715,DB00544,Fluorouracil
,3943107,Km,"Methods 1 and 2 gave mean Vmax and Km values which did not differ significantly; the overall mean Vmax was 2.02 microM/kg/min, and the overall mean Km was 10.9 microM.",Steady-state nonlinear pharmacokinetics of 5-fluorouracil during hepatic arterial and intravenous infusions in cancer patients. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3943107/),μM,10.9,31716,DB00544,Fluorouracil
,3943107,Q1,"For Method 1 the mean Q1 value was 0.0803 liters/(kg X min) or 5.26 liters/min, which is the same as cardiac output, but for Method 2 the mean Q2 value was higher, namely 0.189 liters/(kg X min) or 13.0 liters/min.",Steady-state nonlinear pharmacokinetics of 5-fluorouracil during hepatic arterial and intravenous infusions in cancer patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3943107/),[l] / [kg·min],0.0803,31717,DB00544,Fluorouracil
,3943107,Q1,"For Method 1 the mean Q1 value was 0.0803 liters/(kg X min) or 5.26 liters/min, which is the same as cardiac output, but for Method 2 the mean Q2 value was higher, namely 0.189 liters/(kg X min) or 13.0 liters/min.",Steady-state nonlinear pharmacokinetics of 5-fluorouracil during hepatic arterial and intravenous infusions in cancer patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3943107/),[l] / [min],5.26,31718,DB00544,Fluorouracil
,3943107,Q2,"For Method 1 the mean Q1 value was 0.0803 liters/(kg X min) or 5.26 liters/min, which is the same as cardiac output, but for Method 2 the mean Q2 value was higher, namely 0.189 liters/(kg X min) or 13.0 liters/min.",Steady-state nonlinear pharmacokinetics of 5-fluorouracil during hepatic arterial and intravenous infusions in cancer patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3943107/),[l] / [kg·min],0.189,31719,DB00544,Fluorouracil
,3943107,Q2,"For Method 1 the mean Q1 value was 0.0803 liters/(kg X min) or 5.26 liters/min, which is the same as cardiac output, but for Method 2 the mean Q2 value was higher, namely 0.189 liters/(kg X min) or 13.0 liters/min.",Steady-state nonlinear pharmacokinetics of 5-fluorouracil during hepatic arterial and intravenous infusions in cancer patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3943107/),[l] / [min],13.0,31720,DB00544,Fluorouracil
,20427247,m/z,The mass transition ion-pair was followed as m/z 290.90-204.8 for 2-hydroxyflutamide and 198.9-128.8 for tegafur.,Determination of 2-hydroxyflutamide in human plasma by liquid chromatography-tandem mass spectrometry (LC-MS/MS): application to a bioequivalence study on Chinese volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20427247/),,290.90-204.8,31887,DB00544,Fluorouracil
,20427247,m/z,The mass transition ion-pair was followed as m/z 290.90-204.8 for 2-hydroxyflutamide and 198.9-128.8 for tegafur.,Determination of 2-hydroxyflutamide in human plasma by liquid chromatography-tandem mass spectrometry (LC-MS/MS): application to a bioequivalence study on Chinese volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20427247/),,198.9-128.8,31888,DB00544,Fluorouracil
,28395759,objective response rate,"The objective response rate was 25.8% among the 85 patients, 57.3% in patients with tumors wild type (WT) for KRAS, and 25% in those whose tumor harbored a mutant-KRAS.",A multicenter phase II study of personalized FOLFIRI-cetuximab for safe dose intensification. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28395759/),%,25.8,32507,DB00544,Fluorouracil
,28395759,objective response rate,"The objective response rate was 25.8% among the 85 patients, 57.3% in patients with tumors wild type (WT) for KRAS, and 25% in those whose tumor harbored a mutant-KRAS.",A multicenter phase II study of personalized FOLFIRI-cetuximab for safe dose intensification. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28395759/),%,57.3,32508,DB00544,Fluorouracil
,28395759,objective response rate,"The objective response rate was 25.8% among the 85 patients, 57.3% in patients with tumors wild type (WT) for KRAS, and 25% in those whose tumor harbored a mutant-KRAS.",A multicenter phase II study of personalized FOLFIRI-cetuximab for safe dose intensification. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28395759/),%,25,32509,DB00544,Fluorouracil
,28395759,progression-free survival (PFS),"Median progression-free survival (PFS) for all 85 patients was 181 days and 200, 132, and 121 days for patients with 6/6, 6/7, and 7/7 UGT1A1 genotypes, respectively; these differences were not statistically different.",A multicenter phase II study of personalized FOLFIRI-cetuximab for safe dose intensification. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28395759/),d,181,32510,DB00544,Fluorouracil
,28395759,progression-free survival (PFS),"Median progression-free survival (PFS) for all 85 patients was 181 days and 200, 132, and 121 days for patients with 6/6, 6/7, and 7/7 UGT1A1 genotypes, respectively; these differences were not statistically different.",A multicenter phase II study of personalized FOLFIRI-cetuximab for safe dose intensification. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28395759/),d,200,32511,DB00544,Fluorouracil
,28395759,progression-free survival (PFS),"Median progression-free survival (PFS) for all 85 patients was 181 days and 200, 132, and 121 days for patients with 6/6, 6/7, and 7/7 UGT1A1 genotypes, respectively; these differences were not statistically different.",A multicenter phase II study of personalized FOLFIRI-cetuximab for safe dose intensification. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28395759/),d,132,32512,DB00544,Fluorouracil
,28395759,progression-free survival (PFS),"Median progression-free survival (PFS) for all 85 patients was 181 days and 200, 132, and 121 days for patients with 6/6, 6/7, and 7/7 UGT1A1 genotypes, respectively; these differences were not statistically different.",A multicenter phase II study of personalized FOLFIRI-cetuximab for safe dose intensification. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28395759/),d,121,32513,DB00544,Fluorouracil
,11899652,overall response rate,Two (4%) patients had a complete response and 21 (45%) patients had a partial response for an overall response rate of 49% (95% confidence interval: 35%-63%).,"Paclitaxel, 5-fluorouracil, and leucovorin (TFL) in the treatment of metastatic breast cancer. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11899652/),%,49,32571,DB00544,Fluorouracil
,11899652,duration of response,"The median survival was 17.7 months, median duration of response was 8.6 months, and median time to disease progression was 6.3 months.","Paclitaxel, 5-fluorouracil, and leucovorin (TFL) in the treatment of metastatic breast cancer. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11899652/),month,8.6,32572,DB00544,Fluorouracil
,11899652,time to disease progression,"The median survival was 17.7 months, median duration of response was 8.6 months, and median time to disease progression was 6.3 months.","Paclitaxel, 5-fluorouracil, and leucovorin (TFL) in the treatment of metastatic breast cancer. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11899652/),month,6.3,32573,DB00544,Fluorouracil
,11899652,peak plasma concentrations,Responders had higher peak plasma concentrations of paclitaxel than nonresponders (4.46 vs. 2.9 micrograms/mL; P = 0.02).,"Paclitaxel, 5-fluorouracil, and leucovorin (TFL) in the treatment of metastatic breast cancer. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11899652/),[μg] / [ml],4.46,32574,DB00544,Fluorouracil
,11899652,peak plasma concentrations,Responders had higher peak plasma concentrations of paclitaxel than nonresponders (4.46 vs. 2.9 micrograms/mL; P = 0.02).,"Paclitaxel, 5-fluorouracil, and leucovorin (TFL) in the treatment of metastatic breast cancer. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11899652/),[μg] / [ml],2.9,32575,DB00544,Fluorouracil
,8956782,tumour growth delay time,The mean tumour growth delay time (the time to double in volume for treated tumours minus that for untreated tumours) was 8.1 days for five administrations of 25 mg kg-1 emitefur.,"Combined effect of clinically relevant doses of emitefur, a new 5-fluorouracil derivative, and radiation in murine tumours. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8956782/),d,8.1,32817,DB00544,Fluorouracil
,8956782,time to double in volume,The mean tumour growth delay time (the time to double in volume for treated tumours minus that for untreated tumours) was 8.1 days for five administrations of 25 mg kg-1 emitefur.,"Combined effect of clinically relevant doses of emitefur, a new 5-fluorouracil derivative, and radiation in murine tumours. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8956782/),d,8.1,32818,DB00544,Fluorouracil
,15634630,time to progression,"Median time to progression was 6 months, and median survival was 8.4 months.","A phase I-II, dose-escalating trial of ZD9331 in combination with irinotecan (CPT11) in previously pretreated metastatic colorectal cancer patients. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15634630/),month,6,32870,DB00544,Fluorouracil
,15634630,survival,"Median time to progression was 6 months, and median survival was 8.4 months.","A phase I-II, dose-escalating trial of ZD9331 in combination with irinotecan (CPT11) in previously pretreated metastatic colorectal cancer patients. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15634630/),month,8.4,32871,DB00544,Fluorouracil
,10233196,Total body clearance (CLtot),"Total body clearance (CLtot) of intravenous dFUrd decreased with increasing dose; 2.7, 2.0 and 1.3 l min-1 m-2, following doses of 600, 800 and 1000 mg m-2, respectively.",Pharmacokinetics and bioavailability of oral 5'-deoxy-5-fluorouridine in cancer patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10233196/),[l] / [(m)^2·min],2.7,32887,DB00544,Fluorouracil
,10233196,Total body clearance (CLtot),"Total body clearance (CLtot) of intravenous dFUrd decreased with increasing dose; 2.7, 2.0 and 1.3 l min-1 m-2, following doses of 600, 800 and 1000 mg m-2, respectively.",Pharmacokinetics and bioavailability of oral 5'-deoxy-5-fluorouridine in cancer patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10233196/),[l] / [(m)^2·min],2.0,32888,DB00544,Fluorouracil
,10233196,Total body clearance (CLtot),"Total body clearance (CLtot) of intravenous dFUrd decreased with increasing dose; 2.7, 2.0 and 1.3 l min-1 m-2, following doses of 600, 800 and 1000 mg m-2, respectively.",Pharmacokinetics and bioavailability of oral 5'-deoxy-5-fluorouridine in cancer patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10233196/),[l] / [(m)^2·min],1.3,32889,DB00544,Fluorouracil
less,10233196,lag time,Oral dFUrd was rapidly absorbed with a lag time of less than 20 min.,Pharmacokinetics and bioavailability of oral 5'-deoxy-5-fluorouridine in cancer patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10233196/),min,20,32890,DB00544,Fluorouracil
,10233196,"elimination half-life (t1/2, z )","The mean elimination half-life (t1/2, z ) of oral dFUrd was 32-45 min in the dose range 600-1000 mg m-2.",Pharmacokinetics and bioavailability of oral 5'-deoxy-5-fluorouridine in cancer patients. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10233196/),min,32-45,32891,DB00544,Fluorouracil
,10233196,systemic bioavailability,The mean systemic bioavailability of oral dFUrd was 34-47%.,Pharmacokinetics and bioavailability of oral 5'-deoxy-5-fluorouridine in cancer patients. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10233196/),%,34-47,32892,DB00544,Fluorouracil
,8045919,peak plasma levels,"BVdUrd was rapidly absorbed, peak plasma levels of 0.6-7.1 micrograms/ml being achieved after 1-2 h.",Inhibition of fluorouracil catabolism in cancer patients by the antiviral agent (E)-5-(2-bromovinyl)-2'-deoxyuridine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8045919/),[μg] / [ml],0.6-7.1,33244,DB00544,Fluorouracil
,8045919,total body clearance,The total body clearance of FUra was approximately 61/h and t1/2 markedly increased to 4-7 h.,Inhibition of fluorouracil catabolism in cancer patients by the antiviral agent (E)-5-(2-bromovinyl)-2'-deoxyuridine. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8045919/),1/[h],61,33245,DB00544,Fluorouracil
,8045919,t1/2,The total body clearance of FUra was approximately 61/h and t1/2 markedly increased to 4-7 h.,Inhibition of fluorouracil catabolism in cancer patients by the antiviral agent (E)-5-(2-bromovinyl)-2'-deoxyuridine. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8045919/),h,4-7,33246,DB00544,Fluorouracil
,8045919,urinary excretion,The mean urinary excretion of FUra was 50%.,Inhibition of fluorouracil catabolism in cancer patients by the antiviral agent (E)-5-(2-bromovinyl)-2'-deoxyuridine. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8045919/),%,50,33247,DB00544,Fluorouracil
,10375748,slopes of the terminal phase (K10),"The mean slopes of the terminal phase (K10) in plasma and pancreatic juice were 9.4 h-1 and 10.2 h-1, respectively (P > 0.05).",Pharmacokinetics of 5-fluorouracil and its penetration into pancreatic juice in dogs. ,"K12, K21-Q48",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10375748/),1/[h],9.4,33718,DB00544,Fluorouracil
,10375748,slopes of the terminal phase (K10),"The mean slopes of the terminal phase (K10) in plasma and pancreatic juice were 9.4 h-1 and 10.2 h-1, respectively (P > 0.05).",Pharmacokinetics of 5-fluorouracil and its penetration into pancreatic juice in dogs. ,"K12, K21-Q48",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10375748/),1/[h],10.2,33719,DB00544,Fluorouracil
,10375748,penetration index,Its penetration index was 3.39 +/- 2.84.,Pharmacokinetics of 5-fluorouracil and its penetration into pancreatic juice in dogs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10375748/),,3.39,33720,DB00544,Fluorouracil
,10592100,half-life of the terminal elimination,"It is of interest that EtdUrd pretreatment did not change the maximal plasma concentration of 5-FU; however, the half-life of the terminal elimination increased from 114.5 min to 171.2 min and thus the mean residence time of 5-FU rose significantly (P < 0.05).","5-ethyl-2'-deoxyuridine, a modulator of both antitumour action and pharmacokinetics of 5-fluorouracil. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10592100/),min,114.5,33913,DB00544,Fluorouracil
,10592100,half-life of the terminal elimination,"It is of interest that EtdUrd pretreatment did not change the maximal plasma concentration of 5-FU; however, the half-life of the terminal elimination increased from 114.5 min to 171.2 min and thus the mean residence time of 5-FU rose significantly (P < 0.05).","5-ethyl-2'-deoxyuridine, a modulator of both antitumour action and pharmacokinetics of 5-fluorouracil. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10592100/),min,171.2,33914,DB00544,Fluorouracil
,10592100,maximal concentration,"After the combined treatment, the maximal concentration of dihydro-5-fluorouracil in the plasma decreased from 61.06 microM to 29.70 microM (P < 0.01).","5-ethyl-2'-deoxyuridine, a modulator of both antitumour action and pharmacokinetics of 5-fluorouracil. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10592100/),μM,61.06,33915,DB00544,Fluorouracil
,10592100,maximal concentration,"After the combined treatment, the maximal concentration of dihydro-5-fluorouracil in the plasma decreased from 61.06 microM to 29.70 microM (P < 0.01).","5-ethyl-2'-deoxyuridine, a modulator of both antitumour action and pharmacokinetics of 5-fluorouracil. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10592100/),μM,29.70,33916,DB00544,Fluorouracil
,24382596,Response rate,Response rate was 65%; median progression-free survival 16.4 months.,"Pharmacokinetics, safety, and efficacy of FOLFIRI plus bevacizumab in Japanese colorectal cancer patients with UGT1A1 gene polymorphisms. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24382596/),%,65,33960,DB00544,Fluorouracil
,24382596,progression-free survival,Response rate was 65%; median progression-free survival 16.4 months.,"Pharmacokinetics, safety, and efficacy of FOLFIRI plus bevacizumab in Japanese colorectal cancer patients with UGT1A1 gene polymorphisms. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24382596/),month,16.4,33961,DB00544,Fluorouracil
,28763145,response rate,"Of 71 eligible patients, the response rate was 53.5%, and the disease control rate was 83.1%.","Phase II study of S-1 plus leucovorin in patients with metastatic colorectal cancer: Regimen of 1 week on, 1 week off. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28763145/),%,53.5,34211,DB00544,Fluorouracil
,28763145,progression-free survival,"Median progression-free survival and median overall survival were 6.5 and 24.3 months, respectively.","Phase II study of S-1 plus leucovorin in patients with metastatic colorectal cancer: Regimen of 1 week on, 1 week off. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28763145/),month,6.5,34212,DB00544,Fluorouracil
,28763145,overall survival,"Median progression-free survival and median overall survival were 6.5 and 24.3 months, respectively.","Phase II study of S-1 plus leucovorin in patients with metastatic colorectal cancer: Regimen of 1 week on, 1 week off. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28763145/),month,24.3,34213,DB00544,Fluorouracil
,6875817,half-life,"The half-life, however, at the 50.0-mg/kg dose (27 min) was significantly longer (p less than 0.025) than the corresponding half-life at the 25.0-mg/kg dose (22 min).","5-Fluorouracil concentrations in rat plasma, parotid saliva, and bile and protein binding in rat plasma. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6875817/),min,27,35508,DB00544,Fluorouracil
,6875817,half-life,"The half-life, however, at the 50.0-mg/kg dose (27 min) was significantly longer (p less than 0.025) than the corresponding half-life at the 25.0-mg/kg dose (22 min).","5-Fluorouracil concentrations in rat plasma, parotid saliva, and bile and protein binding in rat plasma. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6875817/),min,22,35509,DB00544,Fluorouracil
,23293114,MTD,"The MTD for afatinib in regimens A (n = 26) and B (n = 21) was determined as 20 mg and 30 mg following DLTs in five and four patients in cycle 1, respectively.","A phase Ib, open-label study to assess the safety of continuous oral treatment with afatinib in combination with two chemotherapy regimens: cisplatin plus paclitaxel and cisplatin plus 5-fluorouracil, in patients with advanced solid tumors. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23293114/),mg,20,36248,DB00544,Fluorouracil
,23293114,MTD,"The MTD for afatinib in regimens A (n = 26) and B (n = 21) was determined as 20 mg and 30 mg following DLTs in five and four patients in cycle 1, respectively.","A phase Ib, open-label study to assess the safety of continuous oral treatment with afatinib in combination with two chemotherapy regimens: cisplatin plus paclitaxel and cisplatin plus 5-fluorouracil, in patients with advanced solid tumors. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23293114/),mg,30,36249,DB00544,Fluorouracil
,23293114,MTD,The MTD of afatinib was 20 mg with cisplatin-paclitaxel and 30 mg with cisplatin-5-fluorouracil.,"A phase Ib, open-label study to assess the safety of continuous oral treatment with afatinib in combination with two chemotherapy regimens: cisplatin plus paclitaxel and cisplatin plus 5-fluorouracil, in patients with advanced solid tumors. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23293114/),mg,20,36250,DB00544,Fluorouracil
,23293114,MTD,The MTD of afatinib was 20 mg with cisplatin-paclitaxel and 30 mg with cisplatin-5-fluorouracil.,"A phase Ib, open-label study to assess the safety of continuous oral treatment with afatinib in combination with two chemotherapy regimens: cisplatin plus paclitaxel and cisplatin plus 5-fluorouracil, in patients with advanced solid tumors. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23293114/),mg,30,36251,DB00544,Fluorouracil
,16257855,t1/2,"Irinotecan and 5-FU were observed to be rapidly eliminated (t1/2 = 1 h and 0.5 h, respectively).","Concomitant administration of bevacizumab, irinotecan, 5-fluorouracil, and leucovorin: nonclinical safety and pharmacokinetics. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16257855/),h,1,36707,DB00544,Fluorouracil
,16257855,t1/2,"Irinotecan and 5-FU were observed to be rapidly eliminated (t1/2 = 1 h and 0.5 h, respectively).","Concomitant administration of bevacizumab, irinotecan, 5-fluorouracil, and leucovorin: nonclinical safety and pharmacokinetics. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16257855/),h,0.5,36708,DB00544,Fluorouracil
,10561307,activity,DPD activity in tumors from 10 untreated patients ranged from 30 to 92 pmol/min/mg of protein.,Eniluracil treatment completely inactivates dihydropyrimidine dehydrogenase in colorectal tumors. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10561307/),[pM] / [mg·min],30 to 92,37177,DB00544,Fluorouracil
,10561307,activity,"A similar pattern was observed in mononuclear cells, where median pretherapy activity was 366.5 pmol/min/mg of protein (range, 265 to 494 pmol/min/mg of protein) and was undetectable immediately before surgery.",Eniluracil treatment completely inactivates dihydropyrimidine dehydrogenase in colorectal tumors. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10561307/),[pM] / [mg·min],366.5,37178,DB00544,Fluorouracil
,12739060,plasma C(max),"The plasma C(max) values of FT, 5-FU, oxonic acid and CDHP increased dose-dependently and after 1-2 h were in the ranges 5.8-13 microM, 0.4-2.4 microM, 0.026-1.337 microM, and 1.1-3.6 microM, respectively.","Pharmacokinetics of S-1, an oral formulation of ftorafur, oxonic acid and 5-chloro-2,4-dihydroxypyridine (molar ratio 1:0.4:1) in patients with solid tumors. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12739060/),μM,5.8-13,37800,DB00544,Fluorouracil
,12739060,plasma C(max),"The plasma C(max) values of FT, 5-FU, oxonic acid and CDHP increased dose-dependently and after 1-2 h were in the ranges 5.8-13 microM, 0.4-2.4 microM, 0.026-1.337 microM, and 1.1-3.6 microM, respectively.","Pharmacokinetics of S-1, an oral formulation of ftorafur, oxonic acid and 5-chloro-2,4-dihydroxypyridine (molar ratio 1:0.4:1) in patients with solid tumors. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12739060/),μM,0.4-2.4,37801,DB00544,Fluorouracil
,12739060,plasma C(max),"The plasma C(max) values of FT, 5-FU, oxonic acid and CDHP increased dose-dependently and after 1-2 h were in the ranges 5.8-13 microM, 0.4-2.4 microM, 0.026-1.337 microM, and 1.1-3.6 microM, respectively.","Pharmacokinetics of S-1, an oral formulation of ftorafur, oxonic acid and 5-chloro-2,4-dihydroxypyridine (molar ratio 1:0.4:1) in patients with solid tumors. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12739060/),μM,0.026-1.337,37802,DB00544,Fluorouracil
,12739060,plasma C(max),"The plasma C(max) values of FT, 5-FU, oxonic acid and CDHP increased dose-dependently and after 1-2 h were in the ranges 5.8-13 microM, 0.4-2.4 microM, 0.026-1.337 microM, and 1.1-3.6 microM, respectively.","Pharmacokinetics of S-1, an oral formulation of ftorafur, oxonic acid and 5-chloro-2,4-dihydroxypyridine (molar ratio 1:0.4:1) in patients with solid tumors. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12739060/),μM,1.1-3.6,37803,DB00544,Fluorouracil
,12739060,areas under the plasma concentration curves (AUC),"The areas under the plasma concentration curves (AUC) for CDHP and uracil were in the ranges 418-1735 and 2281-8627 micromol x min/l, respectively.","Pharmacokinetics of S-1, an oral formulation of ftorafur, oxonic acid and 5-chloro-2,4-dihydroxypyridine (molar ratio 1:0.4:1) in patients with solid tumors. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12739060/),[min·μM] / [l],418-1735,37804,DB00544,Fluorouracil
,12739060,areas under the plasma concentration curves (AUC),"The areas under the plasma concentration curves (AUC) for CDHP and uracil were in the ranges 418-1735 and 2281-8627 micromol x min/l, respectively.","Pharmacokinetics of S-1, an oral formulation of ftorafur, oxonic acid and 5-chloro-2,4-dihydroxypyridine (molar ratio 1:0.4:1) in patients with solid tumors. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12739060/),[min·μM] / [l],2281-8627,37805,DB00544,Fluorouracil
,12739060,t(1/2),"The t(1/2) values were in the ranges 213-692 and 216-354 min, respectively.","Pharmacokinetics of S-1, an oral formulation of ftorafur, oxonic acid and 5-chloro-2,4-dihydroxypyridine (molar ratio 1:0.4:1) in patients with solid tumors. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12739060/),min,213-692,37806,DB00544,Fluorouracil
,12739060,t(1/2),"The t(1/2) values were in the ranges 213-692 and 216-354 min, respectively.","Pharmacokinetics of S-1, an oral formulation of ftorafur, oxonic acid and 5-chloro-2,4-dihydroxypyridine (molar ratio 1:0.4:1) in patients with solid tumors. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12739060/),min,216-354,37807,DB00544,Fluorouracil
,12739060,urinary excretion,Cumulative urinary excretion of FT was predominantly as 5-FU and was 2.2-11.9%; the urinary excretion of both fluoro-beta-alanine and uracil was generally maximal between 6 and 18 h.,"Pharmacokinetics of S-1, an oral formulation of ftorafur, oxonic acid and 5-chloro-2,4-dihydroxypyridine (molar ratio 1:0.4:1) in patients with solid tumors. ",fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12739060/),%,2.2-11.9,37808,DB00544,Fluorouracil
,15177306,Cmax,"Non-compartmental PK analysis has been applied to 5-FU and 5-FUH2 concentrations, estimating the following parameters (median values): Cmax 55.44 and 6.23 microg ml(-1), respectively, AUC(0-2 h) 11.59 and 5.94 hx microg ml(-1), CLTB 30.64 and 51.81 lh(-1) m(-2), 5-FUH2/5-FU AUC ratio 0.47 (range 0.29-1.12).",Plasma concentrations of 5-fluorouracil and its metabolites in colon cancer patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15177306/),[μg] / [ml],55.44,37970,DB00544,Fluorouracil
,15177306,Cmax,"Non-compartmental PK analysis has been applied to 5-FU and 5-FUH2 concentrations, estimating the following parameters (median values): Cmax 55.44 and 6.23 microg ml(-1), respectively, AUC(0-2 h) 11.59 and 5.94 hx microg ml(-1), CLTB 30.64 and 51.81 lh(-1) m(-2), 5-FUH2/5-FU AUC ratio 0.47 (range 0.29-1.12).",Plasma concentrations of 5-fluorouracil and its metabolites in colon cancer patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15177306/),[μg] / [ml],6.23,37971,DB00544,Fluorouracil
,15177306,AUC(0-2 h),"Non-compartmental PK analysis has been applied to 5-FU and 5-FUH2 concentrations, estimating the following parameters (median values): Cmax 55.44 and 6.23 microg ml(-1), respectively, AUC(0-2 h) 11.59 and 5.94 hx microg ml(-1), CLTB 30.64 and 51.81 lh(-1) m(-2), 5-FUH2/5-FU AUC ratio 0.47 (range 0.29-1.12).",Plasma concentrations of 5-fluorouracil and its metabolites in colon cancer patients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15177306/),[h·μg] / [ml],11.59,37972,DB00544,Fluorouracil
,15177306,AUC(0-2 h),"Non-compartmental PK analysis has been applied to 5-FU and 5-FUH2 concentrations, estimating the following parameters (median values): Cmax 55.44 and 6.23 microg ml(-1), respectively, AUC(0-2 h) 11.59 and 5.94 hx microg ml(-1), CLTB 30.64 and 51.81 lh(-1) m(-2), 5-FUH2/5-FU AUC ratio 0.47 (range 0.29-1.12).",Plasma concentrations of 5-fluorouracil and its metabolites in colon cancer patients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15177306/),[h·μg] / [ml],5.94,37973,DB00544,Fluorouracil
,15177306,CLTB,"Non-compartmental PK analysis has been applied to 5-FU and 5-FUH2 concentrations, estimating the following parameters (median values): Cmax 55.44 and 6.23 microg ml(-1), respectively, AUC(0-2 h) 11.59 and 5.94 hx microg ml(-1), CLTB 30.64 and 51.81 lh(-1) m(-2), 5-FUH2/5-FU AUC ratio 0.47 (range 0.29-1.12).",Plasma concentrations of 5-fluorouracil and its metabolites in colon cancer patients. ,CLb-Q23,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15177306/),1/[(m)^2·lh],30.64,37974,DB00544,Fluorouracil
,15177306,CLTB,"Non-compartmental PK analysis has been applied to 5-FU and 5-FUH2 concentrations, estimating the following parameters (median values): Cmax 55.44 and 6.23 microg ml(-1), respectively, AUC(0-2 h) 11.59 and 5.94 hx microg ml(-1), CLTB 30.64 and 51.81 lh(-1) m(-2), 5-FUH2/5-FU AUC ratio 0.47 (range 0.29-1.12).",Plasma concentrations of 5-fluorouracil and its metabolites in colon cancer patients. ,CLb-Q23,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15177306/),1/[(m)^2·lh],51.81,37975,DB00544,Fluorouracil
,15177306,AUC ratio,"Non-compartmental PK analysis has been applied to 5-FU and 5-FUH2 concentrations, estimating the following parameters (median values): Cmax 55.44 and 6.23 microg ml(-1), respectively, AUC(0-2 h) 11.59 and 5.94 hx microg ml(-1), CLTB 30.64 and 51.81 lh(-1) m(-2), 5-FUH2/5-FU AUC ratio 0.47 (range 0.29-1.12).",Plasma concentrations of 5-fluorouracil and its metabolites in colon cancer patients. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15177306/),,0.47,37976,DB00544,Fluorouracil
,15177306,AUC(0-2 h),"In eight subjects, we compared the PK data of the first and the fifth day of dose administration, and we found stable 5-FU values, but the 5-FUH2 disposition decreased with lower AUC(0-2 h) (7.90 hx microg ml(-1) versus 5.99 hx microg ml(-1)) and, particularly, Cmax (8.38 microg ml(-1) versus 5.50 microg ml(-1)) at day 5.",Plasma concentrations of 5-fluorouracil and its metabolites in colon cancer patients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15177306/),[h·μg] / [ml],7.90,37977,DB00544,Fluorouracil
,15177306,AUC(0-2 h),"In eight subjects, we compared the PK data of the first and the fifth day of dose administration, and we found stable 5-FU values, but the 5-FUH2 disposition decreased with lower AUC(0-2 h) (7.90 hx microg ml(-1) versus 5.99 hx microg ml(-1)) and, particularly, Cmax (8.38 microg ml(-1) versus 5.50 microg ml(-1)) at day 5.",Plasma concentrations of 5-fluorouracil and its metabolites in colon cancer patients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15177306/),[h·μg] / [ml],5.99,37978,DB00544,Fluorouracil
,15177306,Cmax,"In eight subjects, we compared the PK data of the first and the fifth day of dose administration, and we found stable 5-FU values, but the 5-FUH2 disposition decreased with lower AUC(0-2 h) (7.90 hx microg ml(-1) versus 5.99 hx microg ml(-1)) and, particularly, Cmax (8.38 microg ml(-1) versus 5.50 microg ml(-1)) at day 5.",Plasma concentrations of 5-fluorouracil and its metabolites in colon cancer patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15177306/),[μg] / [ml],8.38,37979,DB00544,Fluorouracil
,15177306,Cmax,"In eight subjects, we compared the PK data of the first and the fifth day of dose administration, and we found stable 5-FU values, but the 5-FUH2 disposition decreased with lower AUC(0-2 h) (7.90 hx microg ml(-1) versus 5.99 hx microg ml(-1)) and, particularly, Cmax (8.38 microg ml(-1) versus 5.50 microg ml(-1)) at day 5.",Plasma concentrations of 5-fluorouracil and its metabolites in colon cancer patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15177306/),[μg] / [ml],5.50,37980,DB00544,Fluorouracil
,31892325,objective response rate,"The objective response rate (complete response [CR] plus partial response [PR]) in heavily pre-treated HER2-positive MBC patients at the recommended doses of epertinib combined with trastuzumab was 67% (N = 9), with trastuzumab plus vinorelbine was 0% (N = 5) and with trastuzumab plus capecitabine was 56% (N = 9).",A phase I/II study of epertinib plus trastuzumab with or without chemotherapy in patients with HER2-positive metastatic breast cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31892325/),%,67,38013,DB00544,Fluorouracil
,31892325,objective response rate,"The objective response rate (complete response [CR] plus partial response [PR]) in heavily pre-treated HER2-positive MBC patients at the recommended doses of epertinib combined with trastuzumab was 67% (N = 9), with trastuzumab plus vinorelbine was 0% (N = 5) and with trastuzumab plus capecitabine was 56% (N = 9).",A phase I/II study of epertinib plus trastuzumab with or without chemotherapy in patients with HER2-positive metastatic breast cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31892325/),%,0,38014,DB00544,Fluorouracil
,31892325,objective response rate,"The objective response rate (complete response [CR] plus partial response [PR]) in heavily pre-treated HER2-positive MBC patients at the recommended doses of epertinib combined with trastuzumab was 67% (N = 9), with trastuzumab plus vinorelbine was 0% (N = 5) and with trastuzumab plus capecitabine was 56% (N = 9).",A phase I/II study of epertinib plus trastuzumab with or without chemotherapy in patients with HER2-positive metastatic breast cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31892325/),%,56,38015,DB00544,Fluorouracil
,21512394,response rate,"The response rate of the primary tumor (Japanese criteria) was 25.0% in arm A (12 of 48 patients) and 14.9% in arm B (seven of 47 patients), whereas the response rates according to Response Evaluation Criteria In Solid Tumors were 27.8% (10 of 36) versus 21.9% (seven of 32).",Randomized phase II trial of first-line treatment with tailored irinotecan and S-1 therapy versus S-1 monotherapy for advanced or recurrent gastric carcinoma (JFMC31-0301). ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21512394/),%,25.0,38016,DB00544,Fluorouracil
,21512394,response rate,"The response rate of the primary tumor (Japanese criteria) was 25.0% in arm A (12 of 48 patients) and 14.9% in arm B (seven of 47 patients), whereas the response rates according to Response Evaluation Criteria In Solid Tumors were 27.8% (10 of 36) versus 21.9% (seven of 32).",Randomized phase II trial of first-line treatment with tailored irinotecan and S-1 therapy versus S-1 monotherapy for advanced or recurrent gastric carcinoma (JFMC31-0301). ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21512394/),%,14.9,38017,DB00544,Fluorouracil
,21512394,response rates,"The response rate of the primary tumor (Japanese criteria) was 25.0% in arm A (12 of 48 patients) and 14.9% in arm B (seven of 47 patients), whereas the response rates according to Response Evaluation Criteria In Solid Tumors were 27.8% (10 of 36) versus 21.9% (seven of 32).",Randomized phase II trial of first-line treatment with tailored irinotecan and S-1 therapy versus S-1 monotherapy for advanced or recurrent gastric carcinoma (JFMC31-0301). ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21512394/),%,27.8,38018,DB00544,Fluorouracil
,21512394,response rates,"The response rate of the primary tumor (Japanese criteria) was 25.0% in arm A (12 of 48 patients) and 14.9% in arm B (seven of 47 patients), whereas the response rates according to Response Evaluation Criteria In Solid Tumors were 27.8% (10 of 36) versus 21.9% (seven of 32).",Randomized phase II trial of first-line treatment with tailored irinotecan and S-1 therapy versus S-1 monotherapy for advanced or recurrent gastric carcinoma (JFMC31-0301). ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21512394/),%,21.9,38019,DB00544,Fluorouracil
,18765554,conversion,The conversion of capecitabine to 5-fluorouracil was higher for the combination of EKB-569 and capecitabine (321+/-151 ng*h/mL) than for capecitabine alone (176+/-62 ng*hours/mL; P=0.0037).,A phase I study of EKB-569 in combination with capecitabine in patients with advanced colorectal cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18765554/),[h·ng] / [ml],321,38113,DB00544,Fluorouracil
,18765554,conversion,The conversion of capecitabine to 5-fluorouracil was higher for the combination of EKB-569 and capecitabine (321+/-151 ng*h/mL) than for capecitabine alone (176+/-62 ng*hours/mL; P=0.0037).,A phase I study of EKB-569 in combination with capecitabine in patients with advanced colorectal cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18765554/),[h·ng] / [ml],176,38114,DB00544,Fluorouracil
,8185345,minimum effective dose,"Clinically, the minimum effective dose of cisplatin as a modulator was thought to be 10-20 mg/body judging from experimental as well as clinical kinetic study of cisplatin.",[Pharmacokinetics and changes of reduced folate levels in tumor after administration of cisplatin]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8185345/),[mg] / [body],10-20,38946,DB00544,Fluorouracil
,11081573,bioavailability,"In the presence of eniluracil, bioavailability of 5-FU has increased to approximately 100%, the half-life is prolonged to 4 to 6 hours, and systemic clearance is reduced > 20-fold to values comparable the glomerular filtration rate (46 to 58 mL/min/m2).",Pharmacology of fluorinated pyrimidines: eniluracil. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11081573/),%,100,39248,DB00544,Fluorouracil
,11081573,half-life,"In the presence of eniluracil, bioavailability of 5-FU has increased to approximately 100%, the half-life is prolonged to 4 to 6 hours, and systemic clearance is reduced > 20-fold to values comparable the glomerular filtration rate (46 to 58 mL/min/m2).",Pharmacology of fluorinated pyrimidines: eniluracil. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11081573/),h,4 to 6,39249,DB00544,Fluorouracil
,11081573,Renal excretion,"Renal excretion (approximately 45% to 75%), instead of DPD-related catabolism, is the principal route of elimination of oral 5-FU given with eniluracil.",Pharmacology of fluorinated pyrimidines: eniluracil. ,FR-Q43,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11081573/),%,45,39250,DB00544,Fluorouracil
,11081573,Renal excretion,"Renal excretion (approximately 45% to 75%), instead of DPD-related catabolism, is the principal route of elimination of oral 5-FU given with eniluracil.",Pharmacology of fluorinated pyrimidines: eniluracil. ,FR-Q43,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11081573/),%,75,39251,DB00544,Fluorouracil
,11081573,steady-state concentrations,Chronic daily administration of oral 5-FU 1.0 mg/m2 twice daily with eniluracil 20 mg twice daily produces 5-FU steady-state concentrations (8-38 ng/mL) similar to those achieved with protracted intravenous administration on clinically relevant dose-schedules.,Pharmacology of fluorinated pyrimidines: eniluracil. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11081573/),[ng] / [ml],8-38,39252,DB00544,Fluorouracil
,1802023,area under the curve,The 5-FU concentration in the plasma was 0.024 micrograms/ml at 15 min after the intravenous injection of 400 mg of tegafur and the area under the curve of 5-FU was 0.58 micrograms.h/ml.,"A protein-bound polysaccharide immunomodulator, PSK, does not suppress the conversion from 1-(2-tetrahydrofuryl)-5-fluorouracil to 5-fluorouracil in patients with gastric cancer. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1802023/),[h·μg] / [ml],0.58,39714,DB00544,Fluorouracil
,3698165,Total levels of TS (TStot),Total levels of TS (TStot) steadily increased from a pre-5-FU treatment level of 18.8 pmol to more than 40 pmol/g at 24 h.,Sequential methotrexate/5-FU: FdUMP formation and TS inhibition in a transplantable rodent colon adenocarcinoma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3698165/),pM,18.8,40655,DB00544,Fluorouracil
more,3698165,Total levels of TS (TStot),Total levels of TS (TStot) steadily increased from a pre-5-FU treatment level of 18.8 pmol to more than 40 pmol/g at 24 h.,Sequential methotrexate/5-FU: FdUMP formation and TS inhibition in a transplantable rodent colon adenocarcinoma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3698165/),[pM] / [g],40,40656,DB00544,Fluorouracil
,12567439,maximum concentration (Cmax),"In the intravenous group, maximum concentration (Cmax) of 5-FU in the pancreas was 8.42 micrograms/g and the clearance time of the pancreas was 50 min.",[Distribution of 5-fluorouracil in plasma and pancreatic tissue of rats during the regional arterial infusion chemotherapy]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12567439/),[μg] / [g],8.42,41123,DB00544,Fluorouracil
,12567439,clearance time,"In the intravenous group, maximum concentration (Cmax) of 5-FU in the pancreas was 8.42 micrograms/g and the clearance time of the pancreas was 50 min.",[Distribution of 5-fluorouracil in plasma and pancreatic tissue of rats during the regional arterial infusion chemotherapy]. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12567439/),min,50,41124,DB00544,Fluorouracil
,12567439,Cmax,"In the regional arterial infusion group, Cmax of 5-FU in the pancreas was 20.00 micrograms/g and the clearance time of the pancreas was 90 min.",[Distribution of 5-fluorouracil in plasma and pancreatic tissue of rats during the regional arterial infusion chemotherapy]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12567439/),[μg] / [g],20.00,41125,DB00544,Fluorouracil
,12567439,clearance time,"In the regional arterial infusion group, Cmax of 5-FU in the pancreas was 20.00 micrograms/g and the clearance time of the pancreas was 90 min.",[Distribution of 5-fluorouracil in plasma and pancreatic tissue of rats during the regional arterial infusion chemotherapy]. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12567439/),min,90,41126,DB00544,Fluorouracil
,12567439,Rd,Rd was 2.42.,[Distribution of 5-fluorouracil in plasma and pancreatic tissue of rats during the regional arterial infusion chemotherapy]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12567439/),,2.42,41127,DB00544,Fluorouracil
,3717964,t1/2 beta,The t1/2 beta was 0.48 h (rabbits) and 1.74-1.91 h (mice).,[Pharmacokinetics of 1-phthalidyl-5-fluorouracil (PH-FU)]. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3717964/),h,0.48,41324,DB00544,Fluorouracil
,3717964,t1/2 beta,The t1/2 beta was 0.48 h (rabbits) and 1.74-1.91 h (mice).,[Pharmacokinetics of 1-phthalidyl-5-fluorouracil (PH-FU)]. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3717964/),h,1.74-1.91,41325,DB00544,Fluorouracil
,12827293,relative dose intensity,The median relative dose intensity was 1.28 (range 0.5-1.54) compared with the non-adapted theoretical total 5-FU dose.,Individual 5-FU dose adaptation in metastatic colorectal cancer: results of a phase II study using a bimonthly pharmacokinetically intensified LV5FU2 regimen. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12827293/),,1.28,41626,DB00544,Fluorouracil
,12827293,objective response rate,The objective response rate was 37% (95% CI 23-50%) in the intention-to-treat population and 47% (95% CI 29-65%) in the first-line per-protocol population.,Individual 5-FU dose adaptation in metastatic colorectal cancer: results of a phase II study using a bimonthly pharmacokinetically intensified LV5FU2 regimen. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12827293/),%,37,41627,DB00544,Fluorouracil
,12827293,objective response rate,The objective response rate was 37% (95% CI 23-50%) in the intention-to-treat population and 47% (95% CI 29-65%) in the first-line per-protocol population.,Individual 5-FU dose adaptation in metastatic colorectal cancer: results of a phase II study using a bimonthly pharmacokinetically intensified LV5FU2 regimen. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12827293/),%,47,41628,DB00544,Fluorouracil
,12827293,response duration,The median response duration was 10.4 months.,Individual 5-FU dose adaptation in metastatic colorectal cancer: results of a phase II study using a bimonthly pharmacokinetically intensified LV5FU2 regimen. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12827293/),month,10.4,41629,DB00544,Fluorouracil
,12827293,progression-free survival (PFS),"The median progression-free survival (PFS) and overall survival (OS) were, respectively, 7 and 18.6 months.",Individual 5-FU dose adaptation in metastatic colorectal cancer: results of a phase II study using a bimonthly pharmacokinetically intensified LV5FU2 regimen. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12827293/),month,7,41630,DB00544,Fluorouracil
,12827293,overall survival (OS),"The median progression-free survival (PFS) and overall survival (OS) were, respectively, 7 and 18.6 months.",Individual 5-FU dose adaptation in metastatic colorectal cancer: results of a phase II study using a bimonthly pharmacokinetically intensified LV5FU2 regimen. ,AUCSS-Q18,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12827293/),month,18,41631,DB00544,Fluorouracil
,12827293,PFS,"PFS and OS in first-line per-protocol patients were, respectively, 9.2 and 20 months.",Individual 5-FU dose adaptation in metastatic colorectal cancer: results of a phase II study using a bimonthly pharmacokinetically intensified LV5FU2 regimen. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12827293/),month,9.2,41632,DB00544,Fluorouracil
,12827293,PFS,"PFS and OS in first-line per-protocol patients were, respectively, 9.2 and 20 months.",Individual 5-FU dose adaptation in metastatic colorectal cancer: results of a phase II study using a bimonthly pharmacokinetically intensified LV5FU2 regimen. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12827293/),month,20,41633,DB00544,Fluorouracil
,12827293,OS,"PFS and OS in first-line per-protocol patients were, respectively, 9.2 and 20 months.",Individual 5-FU dose adaptation in metastatic colorectal cancer: results of a phase II study using a bimonthly pharmacokinetically intensified LV5FU2 regimen. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12827293/),month,20,41634,DB00544,Fluorouracil
,8201391,AUC,"Medians for averaged AUC and dose per cycle were 27,906 ng/mL h (first through third quartile, 25,398 to 31,060) and 7,000 mg (first through third quartile, 6,200 to 7,833), respectively.",Relationship between fluorouracil systemic exposure and tumor response and patient survival. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8201391/),[ng] / [h·ml],"27,906",41667,DB00544,Fluorouracil
,8201391,dose per,"Medians for averaged AUC and dose per cycle were 27,906 ng/mL h (first through third quartile, 25,398 to 31,060) and 7,000 mg (first through third quartile, 6,200 to 7,833), respectively.",Relationship between fluorouracil systemic exposure and tumor response and patient survival. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8201391/),[ng] / [h·ml],"27,906",41668,DB00544,Fluorouracil
,8201391,dose per,"Medians for averaged AUC and dose per cycle were 27,906 ng/mL h (first through third quartile, 25,398 to 31,060) and 7,000 mg (first through third quartile, 6,200 to 7,833), respectively.",Relationship between fluorouracil systemic exposure and tumor response and patient survival. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8201391/),mg,"7,000",41669,DB00544,Fluorouracil
<,27138786,AUC,"Patients with 5-fluorouracil AUC <25 mg·h/L responded unsatisfactorily to 5-fluorouracil (overall response rate [ORR] 17.5 % lower than patients with AUC 25-35, p = 0.176; and 26.1 % lower than patients with AUC >35, p = 0.031).",Pharmacokinetic and Pharmacodynamic Analyses of 5-Fluorouracil in East-Asian Patients with Nasopharyngeal Carcinoma. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27138786/),[h·mg] / [l],25,42577,DB00544,Fluorouracil
>,27138786,AUC,"Patients with 5-fluorouracil AUC <25 mg·h/L responded unsatisfactorily to 5-fluorouracil (overall response rate [ORR] 17.5 % lower than patients with AUC 25-35, p = 0.176; and 26.1 % lower than patients with AUC >35, p = 0.031).",Pharmacokinetic and Pharmacodynamic Analyses of 5-Fluorouracil in East-Asian Patients with Nasopharyngeal Carcinoma. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27138786/),,35,42578,DB00544,Fluorouracil
>,27138786,AUC,"On the other hand, patients with 5-fluorouracil AUC >35 mg·h/L experienced more 5-fluorouracil-related toxicities (a grade 3 or higher toxicity rate 57.1 % higher than patients with AUC 25-35, p < 0.001; and 60.0 % higher than AUC >35, p < 0.001).",Pharmacokinetic and Pharmacodynamic Analyses of 5-Fluorouracil in East-Asian Patients with Nasopharyngeal Carcinoma. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27138786/),[h·mg] / [l],35,42579,DB00544,Fluorouracil
,27138786,AUC,The established 5-fluorouracil therapeutic window in head and neck cancer (HNC) [AUC 25-35 mg·h/L) was verified in our study.,Pharmacokinetic and Pharmacodynamic Analyses of 5-Fluorouracil in East-Asian Patients with Nasopharyngeal Carcinoma. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27138786/),[h·mg] / [l],25-35,42580,DB00544,Fluorouracil
,12907286,peak concentration (C(max),"On oral administration of colon-targeted tablets, 5-fluorouracil started appearing in the plasma at 6 h, and reached the peak concentration (C(max) of 216+/-15 ng/ml) at 7.6+/-0.1 h (T(max)), whereas the immediate release tablets produced peak plasma concentration (C(max) of 278+/-21 ng/ml) at 0.6+/-0.01 h (T(max)).",In vivo pharmacokinetics in human volunteers: oral administered guar gum-based colon-targeted 5-fluorouracil tablets. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12907286/),[ng] / [ml],216,42606,DB00544,Fluorouracil
,12907286,T,"On oral administration of colon-targeted tablets, 5-fluorouracil started appearing in the plasma at 6 h, and reached the peak concentration (C(max) of 216+/-15 ng/ml) at 7.6+/-0.1 h (T(max)), whereas the immediate release tablets produced peak plasma concentration (C(max) of 278+/-21 ng/ml) at 0.6+/-0.01 h (T(max)).",In vivo pharmacokinetics in human volunteers: oral administered guar gum-based colon-targeted 5-fluorouracil tablets. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12907286/),h,7,42607,DB00544,Fluorouracil
,12907286,peak plasma concentration (C(max),"On oral administration of colon-targeted tablets, 5-fluorouracil started appearing in the plasma at 6 h, and reached the peak concentration (C(max) of 216+/-15 ng/ml) at 7.6+/-0.1 h (T(max)), whereas the immediate release tablets produced peak plasma concentration (C(max) of 278+/-21 ng/ml) at 0.6+/-0.01 h (T(max)).",In vivo pharmacokinetics in human volunteers: oral administered guar gum-based colon-targeted 5-fluorouracil tablets. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12907286/),[ng] / [ml],278,42608,DB00544,Fluorouracil
,12907286,T(,"On oral administration of colon-targeted tablets, 5-fluorouracil started appearing in the plasma at 6 h, and reached the peak concentration (C(max) of 216+/-15 ng/ml) at 7.6+/-0.1 h (T(max)), whereas the immediate release tablets produced peak plasma concentration (C(max) of 278+/-21 ng/ml) at 0.6+/-0.01 h (T(max)).",In vivo pharmacokinetics in human volunteers: oral administered guar gum-based colon-targeted 5-fluorouracil tablets. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12907286/),,0,42609,DB00544,Fluorouracil
,12907286,AUC(0- infinity ),"The AUC(0- infinity ) for 5-fluorouracil from colon-targeted tablet and immediate release tablet were found to be 617+/-39 and 205+/-21 ng/ml/h, respectively.",In vivo pharmacokinetics in human volunteers: oral administered guar gum-based colon-targeted 5-fluorouracil tablets. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12907286/),[ng] / [h·ml],617,42610,DB00544,Fluorouracil
,12907286,AUC(0- infinity ),"The AUC(0- infinity ) for 5-fluorouracil from colon-targeted tablet and immediate release tablet were found to be 617+/-39 and 205+/-21 ng/ml/h, respectively.",In vivo pharmacokinetics in human volunteers: oral administered guar gum-based colon-targeted 5-fluorouracil tablets. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12907286/),[ng] / [h·ml],205,42611,DB00544,Fluorouracil
,32694153,progression-free survival,"Median progression-free survival was 5.9 m [95% confidence interval (CI), 3.4-18.4], median overall survival was 9.7 m (95% CI, 7.0-14).",Phase Ib Study of Wnt Inhibitor Ipafricept with Gemcitabine and nab-paclitaxel in Patients with Previously Untreated Stage IV Pancreatic Cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32694153/),m,5.9,43180,DB00544,Fluorouracil
,32694153,overall survival,"Median progression-free survival was 5.9 m [95% confidence interval (CI), 3.4-18.4], median overall survival was 9.7 m (95% CI, 7.0-14).",Phase Ib Study of Wnt Inhibitor Ipafricept with Gemcitabine and nab-paclitaxel in Patients with Previously Untreated Stage IV Pancreatic Cancer. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32694153/),m,9.7,43181,DB00544,Fluorouracil
,11953843,area under the curve(0-->3h),The 5-fluorouracil area under the curve(0-->3h) in the index patient was 24.1 mg h l(-1) compared to 9.8+/-3.6 (range 5.4-15.3) mg h l(-1) in control patients.,Reduced 5-FU clearance in a patient with low DPD activity due to heterozygosity for a mutant allele of the DPYD gene. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11953843/),[h·mg] / [l],24.1,43593,DB00544,Fluorouracil
,11953843,area under the curve(0-->3h),The 5-fluorouracil area under the curve(0-->3h) in the index patient was 24.1 mg h l(-1) compared to 9.8+/-3.6 (range 5.4-15.3) mg h l(-1) in control patients.,Reduced 5-FU clearance in a patient with low DPD activity due to heterozygosity for a mutant allele of the DPYD gene. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11953843/),[h·mg] / [l],9.8,43594,DB00544,Fluorouracil
,11953843,clearance,The 5-fluorouracil clearance was 520 ml min(-1) vs 1293+/-302 (range 980-1780) ml min(-1) in controls.,Reduced 5-FU clearance in a patient with low DPD activity due to heterozygosity for a mutant allele of the DPYD gene. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11953843/),[ml] / [min],520,43595,DB00544,Fluorouracil
,11953843,clearance,The 5-fluorouracil clearance was 520 ml min(-1) vs 1293+/-302 (range 980-1780) ml min(-1) in controls.,Reduced 5-FU clearance in a patient with low DPD activity due to heterozygosity for a mutant allele of the DPYD gene. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11953843/),[ml] / [min],1293,43596,DB00544,Fluorouracil
,11953843,activity,"The activity of dihydropyrimidine dehydrogenase in mononuclear cells was lower in the index patient (5.5 nmol mg h(-1)) compared to the six controls (10.3+/-1.6, range 8.0-11.7 nmol mg h(-1)).",Reduced 5-FU clearance in a patient with low DPD activity due to heterozygosity for a mutant allele of the DPYD gene. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11953843/),[mg·nM] / [h],5.5,43597,DB00544,Fluorouracil
,11953843,activity,"The activity of dihydropyrimidine dehydrogenase in mononuclear cells was lower in the index patient (5.5 nmol mg h(-1)) compared to the six controls (10.3+/-1.6, range 8.0-11.7 nmol mg h(-1)).",Reduced 5-FU clearance in a patient with low DPD activity due to heterozygosity for a mutant allele of the DPYD gene. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11953843/),[mg·nM] / [h],10.3,43598,DB00544,Fluorouracil
,29291414,maximum plasma concentration,"In 5-FU-treated rats, the maximum plasma concentration, the area under the concentration-time curve of DAB after the oral administration of DABE, and the oral bioavailability of DABE were significantly decreased to 18.3%, 22.9%, and 16.3% of the respective control values.",5-Fluororacil-Induced Gastrointestinal Damage Impairs the Absorption and Anticoagulant Effects of Dabigatran Etexilate. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29291414/),%,18.3,44416,DB00544,Fluorouracil
,29291414,area under the concentration-time curve,"In 5-FU-treated rats, the maximum plasma concentration, the area under the concentration-time curve of DAB after the oral administration of DABE, and the oral bioavailability of DABE were significantly decreased to 18.3%, 22.9%, and 16.3% of the respective control values.",5-Fluororacil-Induced Gastrointestinal Damage Impairs the Absorption and Anticoagulant Effects of Dabigatran Etexilate. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29291414/),%,22.9,44417,DB00544,Fluorouracil
,29291414,area under the concentration-time curve,"In 5-FU-treated rats, the maximum plasma concentration, the area under the concentration-time curve of DAB after the oral administration of DABE, and the oral bioavailability of DABE were significantly decreased to 18.3%, 22.9%, and 16.3% of the respective control values.",5-Fluororacil-Induced Gastrointestinal Damage Impairs the Absorption and Anticoagulant Effects of Dabigatran Etexilate. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29291414/),%,16.3,44418,DB00544,Fluorouracil
,29291414,oral bioavailability,"In 5-FU-treated rats, the maximum plasma concentration, the area under the concentration-time curve of DAB after the oral administration of DABE, and the oral bioavailability of DABE were significantly decreased to 18.3%, 22.9%, and 16.3% of the respective control values.",5-Fluororacil-Induced Gastrointestinal Damage Impairs the Absorption and Anticoagulant Effects of Dabigatran Etexilate. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29291414/),%,16.3,44419,DB00544,Fluorouracil
,9188061,dose-normalized area under the curve (AUC),"The dose-normalized area under the curve (AUC) was significantly higher after administration of 100 mg/kg (1.14 +/- 0.55 mg.h/L/mg; mean +/- SD) than after 50 mg/kg (0.50 +/- 0.18 mg.h/L/mg) or 10 mg/kg (0.43 +/- 0.11 mg.h/L/mg), indicating nonlinear elimination of 5-FU in rats.",Nonlinear pharmacokinetics of 5-fluorouracil in rats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9188061/),[h·mg] / [l·mg],1.14,44890,DB00544,Fluorouracil
,9188061,dose-normalized area under the curve (AUC),"The dose-normalized area under the curve (AUC) was significantly higher after administration of 100 mg/kg (1.14 +/- 0.55 mg.h/L/mg; mean +/- SD) than after 50 mg/kg (0.50 +/- 0.18 mg.h/L/mg) or 10 mg/kg (0.43 +/- 0.11 mg.h/L/mg), indicating nonlinear elimination of 5-FU in rats.",Nonlinear pharmacokinetics of 5-fluorouracil in rats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9188061/),[h·mg] / [l·mg],0.50,44891,DB00544,Fluorouracil
,9188061,dose-normalized area under the curve (AUC),"The dose-normalized area under the curve (AUC) was significantly higher after administration of 100 mg/kg (1.14 +/- 0.55 mg.h/L/mg; mean +/- SD) than after 50 mg/kg (0.50 +/- 0.18 mg.h/L/mg) or 10 mg/kg (0.43 +/- 0.11 mg.h/L/mg), indicating nonlinear elimination of 5-FU in rats.",Nonlinear pharmacokinetics of 5-fluorouracil in rats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9188061/),[h·mg] / [l·mg],0.43,44892,DB00544,Fluorouracil
,9188061,systemic clearance,The systemic clearance of 5-FU following administration of 100 mg/kg was significantly lower (1.1 +/- 0.49 L/h/kg) than after 50 mg/kg (2.2 +/- 0.72 L/h/kg) or 10 mg/kg (2.4 +/- 0.67 L/h/kg).,Nonlinear pharmacokinetics of 5-fluorouracil in rats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9188061/),[l] / [h·kg],1.1,44893,DB00544,Fluorouracil
,9188061,systemic clearance,The systemic clearance of 5-FU following administration of 100 mg/kg was significantly lower (1.1 +/- 0.49 L/h/kg) than after 50 mg/kg (2.2 +/- 0.72 L/h/kg) or 10 mg/kg (2.4 +/- 0.67 L/h/kg).,Nonlinear pharmacokinetics of 5-fluorouracil in rats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9188061/),[l] / [h·kg],2.2,44894,DB00544,Fluorouracil
,9188061,systemic clearance,The systemic clearance of 5-FU following administration of 100 mg/kg was significantly lower (1.1 +/- 0.49 L/h/kg) than after 50 mg/kg (2.2 +/- 0.72 L/h/kg) or 10 mg/kg (2.4 +/- 0.67 L/h/kg).,Nonlinear pharmacokinetics of 5-fluorouracil in rats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9188061/),[l] / [h·kg],2.4,44895,DB00544,Fluorouracil
,9188061,renal clearance,There was no significant difference in renal clearance values between the three doses (0.47 +/- 0.26 L/h/kg).,Nonlinear pharmacokinetics of 5-fluorouracil in rats. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9188061/),[l] / [h·kg],0.47,44896,DB00544,Fluorouracil
,9188061,nonrenal clearance,"However, nonrenal clearance was significantly lower after the 100-mg/kg dose (0.77 +/- 0.2 L/h/kg) than after the 50-mg/kg (1.65 +/- 0.49 L/h/kg) and 10-mg/kg (1.87 +/- 0.75 L/h/kg) doses.",Nonlinear pharmacokinetics of 5-fluorouracil in rats. ,CLH-Q25,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9188061/),[l] / [h·kg],0.77,44897,DB00544,Fluorouracil
,9188061,nonrenal clearance,"However, nonrenal clearance was significantly lower after the 100-mg/kg dose (0.77 +/- 0.2 L/h/kg) than after the 50-mg/kg (1.65 +/- 0.49 L/h/kg) and 10-mg/kg (1.87 +/- 0.75 L/h/kg) doses.",Nonlinear pharmacokinetics of 5-fluorouracil in rats. ,CLH-Q25,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9188061/),[l] / [h·kg],1.65,44898,DB00544,Fluorouracil
,9188061,nonrenal clearance,"However, nonrenal clearance was significantly lower after the 100-mg/kg dose (0.77 +/- 0.2 L/h/kg) than after the 50-mg/kg (1.65 +/- 0.49 L/h/kg) and 10-mg/kg (1.87 +/- 0.75 L/h/kg) doses.",Nonlinear pharmacokinetics of 5-fluorouracil in rats. ,CLH-Q25,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9188061/),[l] / [h·kg],1.87,44899,DB00544,Fluorouracil
,9188061,steady-state volume of distribution,There was no significant difference between the steady-state volume of distribution values (0.91 +/- 0.36 L/kg) at the three doses.,Nonlinear pharmacokinetics of 5-fluorouracil in rats. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9188061/),[l] / [kg],0.91,44900,DB00544,Fluorouracil
,9188061,maximum volume (Vmax),"The maximum volume (Vmax) and Michaelis constant (Km) values averaged (mean +/- SE) 8.3 +/- 2.3 mg/h and 31.6 +/- 11.9 mg/L, respectively.",Nonlinear pharmacokinetics of 5-fluorouracil in rats. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9188061/),[mg] / [h],8.3,44901,DB00544,Fluorouracil
,9188061,Michaelis constant (Km),"The maximum volume (Vmax) and Michaelis constant (Km) values averaged (mean +/- SE) 8.3 +/- 2.3 mg/h and 31.6 +/- 11.9 mg/L, respectively.",Nonlinear pharmacokinetics of 5-fluorouracil in rats. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9188061/),[mg] / [l],31.6,44902,DB00544,Fluorouracil
,24013904,progression-free survival,"At a median follow-up of 106 weeks (range, 21-141 weeks), the median progression-free survival and overall survival were 11.0 weeks (95% C.I.: 5.7-16.3 weeks) and 21.0 weeks (95% C.I.: 14.3-27.7 weeks), respectively.",Phase II trial of capecitabine and everolimus (RAD001) combination in refractory gastric cancer patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24013904/),weeks,11.0,45577,DB00544,Fluorouracil
,24013904,overall survival,"At a median follow-up of 106 weeks (range, 21-141 weeks), the median progression-free survival and overall survival were 11.0 weeks (95% C.I.: 5.7-16.3 weeks) and 21.0 weeks (95% C.I.: 14.3-27.7 weeks), respectively.",Phase II trial of capecitabine and everolimus (RAD001) combination in refractory gastric cancer patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24013904/),weeks,21.0,45578,DB00544,Fluorouracil
,15663907,T(1/2Ke),"5-Fu-GCL at 80, 40, and 20 mg/kg had T(1/2Ke) of 25.8+/-4.2, 27.3+/-4.4, and 28.2+/-5.6 min; C0 of 24.9+/-4.9, 17.7+/-3.6, and 11.5+/-2.7 mg/L; and AUC of 990.0+/-45.2,622.5+/-38.3, and 340.4+/-25.6 mg x min x L(-1), respectively.",Pharmacokinetics and tissue distribution of 5-fluorouracil encapsulated by galactosylceramide liposomes in mice. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15663907/),min,25.8,45657,DB00544,Fluorouracil
,15663907,T(1/2Ke),"5-Fu-GCL at 80, 40, and 20 mg/kg had T(1/2Ke) of 25.8+/-4.2, 27.3+/-4.4, and 28.2+/-5.6 min; C0 of 24.9+/-4.9, 17.7+/-3.6, and 11.5+/-2.7 mg/L; and AUC of 990.0+/-45.2,622.5+/-38.3, and 340.4+/-25.6 mg x min x L(-1), respectively.",Pharmacokinetics and tissue distribution of 5-fluorouracil encapsulated by galactosylceramide liposomes in mice. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15663907/),min,27.3,45658,DB00544,Fluorouracil
,15663907,T(1/2Ke),"5-Fu-GCL at 80, 40, and 20 mg/kg had T(1/2Ke) of 25.8+/-4.2, 27.3+/-4.4, and 28.2+/-5.6 min; C0 of 24.9+/-4.9, 17.7+/-3.6, and 11.5+/-2.7 mg/L; and AUC of 990.0+/-45.2,622.5+/-38.3, and 340.4+/-25.6 mg x min x L(-1), respectively.",Pharmacokinetics and tissue distribution of 5-fluorouracil encapsulated by galactosylceramide liposomes in mice. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15663907/),min,28.2,45659,DB00544,Fluorouracil
,15663907,C0,"5-Fu-GCL at 80, 40, and 20 mg/kg had T(1/2Ke) of 25.8+/-4.2, 27.3+/-4.4, and 28.2+/-5.6 min; C0 of 24.9+/-4.9, 17.7+/-3.6, and 11.5+/-2.7 mg/L; and AUC of 990.0+/-45.2,622.5+/-38.3, and 340.4+/-25.6 mg x min x L(-1), respectively.",Pharmacokinetics and tissue distribution of 5-fluorouracil encapsulated by galactosylceramide liposomes in mice. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15663907/),[mg] / [l],24.9,45660,DB00544,Fluorouracil
,15663907,C0,"5-Fu-GCL at 80, 40, and 20 mg/kg had T(1/2Ke) of 25.8+/-4.2, 27.3+/-4.4, and 28.2+/-5.6 min; C0 of 24.9+/-4.9, 17.7+/-3.6, and 11.5+/-2.7 mg/L; and AUC of 990.0+/-45.2,622.5+/-38.3, and 340.4+/-25.6 mg x min x L(-1), respectively.",Pharmacokinetics and tissue distribution of 5-fluorouracil encapsulated by galactosylceramide liposomes in mice. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15663907/),[mg] / [l],17.7,45661,DB00544,Fluorouracil
,15663907,C0,"5-Fu-GCL at 80, 40, and 20 mg/kg had T(1/2Ke) of 25.8+/-4.2, 27.3+/-4.4, and 28.2+/-5.6 min; C0 of 24.9+/-4.9, 17.7+/-3.6, and 11.5+/-2.7 mg/L; and AUC of 990.0+/-45.2,622.5+/-38.3, and 340.4+/-25.6 mg x min x L(-1), respectively.",Pharmacokinetics and tissue distribution of 5-fluorouracil encapsulated by galactosylceramide liposomes in mice. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15663907/),[mg] / [l],11.5,45662,DB00544,Fluorouracil
,15663907,AUC,"5-Fu-GCL at 80, 40, and 20 mg/kg had T(1/2Ke) of 25.8+/-4.2, 27.3+/-4.4, and 28.2+/-5.6 min; C0 of 24.9+/-4.9, 17.7+/-3.6, and 11.5+/-2.7 mg/L; and AUC of 990.0+/-45.2,622.5+/-38.3, and 340.4+/-25.6 mg x min x L(-1), respectively.",Pharmacokinetics and tissue distribution of 5-fluorouracil encapsulated by galactosylceramide liposomes in mice. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15663907/),[mg·min] / [l],990.0,45663,DB00544,Fluorouracil
,15663907,AUC,"5-Fu-GCL at 80, 40, and 20 mg/kg had T(1/2Ke) of 25.8+/-4.2, 27.3+/-4.4, and 28.2+/-5.6 min; C0 of 24.9+/-4.9, 17.7+/-3.6, and 11.5+/-2.7 mg/L; and AUC of 990.0+/-45.2,622.5+/-38.3, and 340.4+/-25.6 mg x min x L(-1), respectively.",Pharmacokinetics and tissue distribution of 5-fluorouracil encapsulated by galactosylceramide liposomes in mice. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15663907/),[mg·min] / [l],622.5,45664,DB00544,Fluorouracil
,15663907,AUC,"5-Fu-GCL at 80, 40, and 20 mg/kg had T(1/2Ke) of 25.8+/-4.2, 27.3+/-4.4, and 28.2+/-5.6 min; C0 of 24.9+/-4.9, 17.7+/-3.6, and 11.5+/-2.7 mg/L; and AUC of 990.0+/-45.2,622.5+/-38.3, and 340.4+/-25.6 mg x min x L(-1), respectively.",Pharmacokinetics and tissue distribution of 5-fluorouracil encapsulated by galactosylceramide liposomes in mice. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15663907/),[mg·min] / [l],340.4,45665,DB00544,Fluorouracil
,15663907,T(1/2Ke),"In contrast free 5-Fu at 40 kg/mg had T(1/2Ke) of 15.8+/-2.2 min, C0 of 35.8+/-6.2 mg/L, AUC of 639.0+/-35.9 mg x min x L(-1).",Pharmacokinetics and tissue distribution of 5-fluorouracil encapsulated by galactosylceramide liposomes in mice. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15663907/),min,15.8,45666,DB00544,Fluorouracil
,15663907,C0,"In contrast free 5-Fu at 40 kg/mg had T(1/2Ke) of 15.8+/-2.2 min, C0 of 35.8+/-6.2 mg/L, AUC of 639.0+/-35.9 mg x min x L(-1).",Pharmacokinetics and tissue distribution of 5-fluorouracil encapsulated by galactosylceramide liposomes in mice. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15663907/),[mg] / [l],35.8,45667,DB00544,Fluorouracil
,15663907,AUC,"In contrast free 5-Fu at 40 kg/mg had T(1/2Ke) of 15.8+/-2.2 min, C0 of 35.8+/-6.2 mg/L, AUC of 639.0+/-35.9 mg x min x L(-1).",Pharmacokinetics and tissue distribution of 5-fluorouracil encapsulated by galactosylceramide liposomes in mice. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15663907/),[mg·min] / [l],639.0,45668,DB00544,Fluorouracil
,9688052,local absorption ratio (Fa),UR coadministration made the local absorption ratio (Fa) of 5'-DFUR decrease significantly from 60.1 +/- 10.5% to 38.0 +/- 18.6% of dose.,Effect of coadministered uridine on intestinal first-pass metabolism of 5'-deoxy-5-fluorouridine in conscious rats--an evaluation by method of portal-systemic concentration difference. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9688052/),,60.1,46114,DB00544,Fluorouracil
,9688052,local absorption ratio (Fa),UR coadministration made the local absorption ratio (Fa) of 5'-DFUR decrease significantly from 60.1 +/- 10.5% to 38.0 +/- 18.6% of dose.,Effect of coadministered uridine on intestinal first-pass metabolism of 5'-deoxy-5-fluorouridine in conscious rats--an evaluation by method of portal-systemic concentration difference. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9688052/),,38.0,46115,DB00544,Fluorouracil
,9688052,local absorption ratios (Fm(a)),"Though the local absorption ratios (Fm(a)) of the metabolite (5-FU) were the same between Group A and Group B (8.3 +/- 1.9 and 8.7 +/- 4.0% of 5'-DFUR, respectively), AUC of arterial 5-FU in Group B was 5 times greater than that in Group A.",Effect of coadministered uridine on intestinal first-pass metabolism of 5'-deoxy-5-fluorouridine in conscious rats--an evaluation by method of portal-systemic concentration difference. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9688052/),%,8.3,46116,DB00544,Fluorouracil
,9688052,local absorption ratios (Fm(a)),"Though the local absorption ratios (Fm(a)) of the metabolite (5-FU) were the same between Group A and Group B (8.3 +/- 1.9 and 8.7 +/- 4.0% of 5'-DFUR, respectively), AUC of arterial 5-FU in Group B was 5 times greater than that in Group A.",Effect of coadministered uridine on intestinal first-pass metabolism of 5'-deoxy-5-fluorouridine in conscious rats--an evaluation by method of portal-systemic concentration difference. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9688052/),%,8.7,46117,DB00544,Fluorouracil
,9688052,Fm(a),"UR was not detected in the portal blood, and Fm(a) of U was estimated to be 41.9 +/- 26.8% of UR in Group B.",Effect of coadministered uridine on intestinal first-pass metabolism of 5'-deoxy-5-fluorouridine in conscious rats--an evaluation by method of portal-systemic concentration difference. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9688052/),%,41.9,46118,DB00544,Fluorouracil
,27507617,MTD,Conclusions: The MTD of irinotecan in FOLFIRI plus bevacizumab is 310 mg/m2 for UGT1A1 *1/*1 patients and 260 mg/m2 for *1/*28 patients.,Genotype-Guided Dosing Study of FOLFIRI plus Bevacizumab in Patients with Metastatic Colorectal Cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27507617/),[mg] / [m2],310,47547,DB00544,Fluorouracil
,27507617,MTD,Conclusions: The MTD of irinotecan in FOLFIRI plus bevacizumab is 310 mg/m2 for UGT1A1 *1/*1 patients and 260 mg/m2 for *1/*28 patients.,Genotype-Guided Dosing Study of FOLFIRI plus Bevacizumab in Patients with Metastatic Colorectal Cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27507617/),[mg] / [m2],260,47548,DB00544,Fluorouracil
,1933851,apparent rate of formation,"The apparent rate of formation of the nucleosides/tides in the tumor, K21, changed following methotrexate pretreatment, from a value of 6.4 +/- 2.4 to 15.5 +/- 5.0.","In vivo measurements of intratumoral metabolism, modulation, and pharmacokinetics of 5-fluorouracil, using 19F nuclear magnetic resonance spectroscopy. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1933851/),,6.4,47797,DB00544,Fluorouracil
,1933851,apparent rate of formation,"The apparent rate of formation of the nucleosides/tides in the tumor, K21, changed following methotrexate pretreatment, from a value of 6.4 +/- 2.4 to 15.5 +/- 5.0.","In vivo measurements of intratumoral metabolism, modulation, and pharmacokinetics of 5-fluorouracil, using 19F nuclear magnetic resonance spectroscopy. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1933851/),,15.5,47798,DB00544,Fluorouracil
,1933851,K21,The increase of the mean K21 value (2.4) estimated in vivo correlated favorably with the increase of the levels of the fluorinated nucleosides/nucleotides (2.2) observed by in vitro analysis.,"In vivo measurements of intratumoral metabolism, modulation, and pharmacokinetics of 5-fluorouracil, using 19F nuclear magnetic resonance spectroscopy. ","K12, K21-Q48",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1933851/),,2.4,47799,DB00544,Fluorouracil
,1933851,K21,The increase of the mean K21 value (2.4) estimated in vivo correlated favorably with the increase of the levels of the fluorinated nucleosides/nucleotides (2.2) observed by in vitro analysis.,"In vivo measurements of intratumoral metabolism, modulation, and pharmacokinetics of 5-fluorouracil, using 19F nuclear magnetic resonance spectroscopy. ","K12, K21-Q48",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1933851/),,2.,47800,DB00544,Fluorouracil
,1781811,bioavailability,The bioavailability of 5FU (compared as the AUC0-60 values) is elevated to 80%.,[Pharmacokinetic aspects of the combination of interferon-alpha-2b and folic acid with fluorouracil]. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1781811/),%,80,48077,DB00544,Fluorouracil
,1781811,bioavailability,"In contrary, the combination of IFN with FA leads to a non-significant change of the 5FU pharmacokinetics, although the bioavailability is increased to 18%.",[Pharmacokinetic aspects of the combination of interferon-alpha-2b and folic acid with fluorouracil]. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1781811/),%,18,48078,DB00544,Fluorouracil
,10999043,MTD,"The MTD of 5-FU in this schedule was 700 mg/m2/week, with diarrhea dose-limiting.",Phase I and pharmacokinetic study of weekly 5-fluorouracil administered with granulocyte-macrophage colony-stimulating factor and high-dose leucovorin: a potential role for growth factor as mucosal protectant. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10999043/),[mg] / [m],700,48373,DB00544,Fluorouracil
,10073147,duration of response,"The median duration of response was 5.8 months (range, 1-23+) and median survival was 25.3 months (range, 6.2-54.7+).",A phase I/II study of continuous intra-arterial chemotherapy using an implantable reservoir for the treatment of liver metastases from breast cancer: a Japan Clinical Oncology Group (JCOG) study 9113. JCOG Breast Cancer Study Group. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10073147/),month,5.8,48689,DB00544,Fluorouracil
,10073147,survival,"The median duration of response was 5.8 months (range, 1-23+) and median survival was 25.3 months (range, 6.2-54.7+).",A phase I/II study of continuous intra-arterial chemotherapy using an implantable reservoir for the treatment of liver metastases from breast cancer: a Japan Clinical Oncology Group (JCOG) study 9113. JCOG Breast Cancer Study Group. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10073147/),month,25.3,48690,DB00544,Fluorouracil
,10971312,activity,A significantly lower median DPD activity (119 pmol min(-1) mg(-1)) was observed in the Ghanaian population.,"Evaluation of dihydropyrimidine dehydrogenase activity in South-west Asian, Kenyan and Ghanaian populations. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10971312/),[pM] / [mg·min],119,48709,DB00544,Fluorouracil
,2941256,plasma levels,"The patients who were on the FU infusion protocol during the first week showed mean FU plasma levels of 10 micrograms/ml, whereas FUDR plasma levels in the same patients, treated in the second week, were about 1 microgram/ml.",On the differential affinities of two anticancer analogues to their target. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2941256/),,1,50896,DB00544,Fluorouracil
,2941256,KD,"Kinetic consideration of the these data, however, suggested significantly differing affinities--on analogy with enzyme kinetics--of active facilitated transport mechanisms towards FUDR (KD = 4.2 X 10(-2)) and towards FU (KD = 64.2 X 10(-2)).",On the differential affinities of two anticancer analogues to their target. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2941256/),,4.2,50897,DB00544,Fluorouracil
,2941256,KD,"Kinetic consideration of the these data, however, suggested significantly differing affinities--on analogy with enzyme kinetics--of active facilitated transport mechanisms towards FUDR (KD = 4.2 X 10(-2)) and towards FU (KD = 64.2 X 10(-2)).",On the differential affinities of two anticancer analogues to their target. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2941256/),,64.2,50898,DB00544,Fluorouracil
,31658382,THY/DHT,"The median THY/DHT ratios were 6.2 (interquartile range 2.9-6.4) in cases, including the 2 patients who were DPYD heterozygous carriers.",A case-control study to assess the ability of the thymine challenge test to predict patients with severe to life threatening fluoropyrimidine-induced gastrointestinal toxicity. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31658382/),,6.2,51207,DB00544,Fluorouracil
,31658382,ratios,"The median THY/DHT ratios were 6.2 (interquartile range 2.9-6.4) in cases, including the 2 patients who were DPYD heterozygous carriers.",A case-control study to assess the ability of the thymine challenge test to predict patients with severe to life threatening fluoropyrimidine-induced gastrointestinal toxicity. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31658382/),,6.2,51208,DB00544,Fluorouracil
,23108953,PFS,"Median estimated PFS in Arms A, B, and C was 4.2, 4.9, and 5.2 months, respectively (hazard ratio for Arms A+B combined versus Arm C, 0.98; 95% CI 0.67-1.43; P = 0.92).","Phase II randomized, double-blind, placebo-controlled study of AMG 386 (trebananib) in combination with cisplatin and capecitabine in patients with metastatic gastro-oesophageal cancer. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23108953/),,4,51541,DB00544,Fluorouracil
,23108953,Objective response rates,"Objective response rates were 27% (Arm A), 43% (Arm B), and 35% (Arm C).","Phase II randomized, double-blind, placebo-controlled study of AMG 386 (trebananib) in combination with cisplatin and capecitabine in patients with metastatic gastro-oesophageal cancer. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23108953/),%,27,51542,DB00544,Fluorouracil
,23108953,Objective response rates,"Objective response rates were 27% (Arm A), 43% (Arm B), and 35% (Arm C).","Phase II randomized, double-blind, placebo-controlled study of AMG 386 (trebananib) in combination with cisplatin and capecitabine in patients with metastatic gastro-oesophageal cancer. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23108953/),%,43,51543,DB00544,Fluorouracil
,23108953,Objective response rates,"Objective response rates were 27% (Arm A), 43% (Arm B), and 35% (Arm C).","Phase II randomized, double-blind, placebo-controlled study of AMG 386 (trebananib) in combination with cisplatin and capecitabine in patients with metastatic gastro-oesophageal cancer. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23108953/),%,35,51544,DB00544,Fluorouracil
more,15025795,AUC,"Although there was no relationship between the area under the plasma concentration time curve (AUC) for the first dose of 5-FU and worst-grade toxicity during the first cycle of therapy, 3 of the 4 patients in whom the AUC on week 4 was more than equal to 5 microgram/h/mL greater than the value for the first dose experienced grade 3/4 toxicity during subsequent treatment.",Dihydropyrimidine dehydrogenase and thymidylate synthase polymorphisms and their association with 5-fluorouracil/leucovorin chemotherapy in colorectal cancer. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15025795/),[μg] / [h·ml],5,51828,DB00544,Fluorouracil
,25591799,MTD,MTD for tivozanib with mFOLFOX-6 was confirmed as 1.5 mg.,A phase Ib study of the VEGF receptor tyrosine kinase inhibitor tivozanib and modified FOLFOX-6 in patients with advanced gastrointestinal malignancies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25591799/),mg,1.5,51885,DB00544,Fluorouracil
,10663632,terminal half-life,"The pharmacokinetic parameters obtained for (-)-fTHF following the administration of (-)-fTHF only were: terminal half-life, 1.2 h; area under the curve, 10 microg.",Impact of the simultaneous administration of the (+)- and (-)-forms of formyl-tetrahydrofolic acid on plasma and intracellular pharmacokinetics of (-)-tetrahydrofolic acid. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10663632/),h,1.2,52545,DB00544,Fluorouracil
,10663632,area under the curve,"The pharmacokinetic parameters obtained for (-)-fTHF following the administration of (-)-fTHF only were: terminal half-life, 1.2 h; area under the curve, 10 microg.",Impact of the simultaneous administration of the (+)- and (-)-forms of formyl-tetrahydrofolic acid on plasma and intracellular pharmacokinetics of (-)-tetrahydrofolic acid. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10663632/),μg,10,52546,DB00544,Fluorouracil
,10663632,maximum concentration,"h/ml; maximum concentration, 12 microg/ml; clearance, 305 ml/min; volume of distribution, 19 l.",Impact of the simultaneous administration of the (+)- and (-)-forms of formyl-tetrahydrofolic acid on plasma and intracellular pharmacokinetics of (-)-tetrahydrofolic acid. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10663632/),[μg] / [ml],12,52547,DB00544,Fluorouracil
,10663632,clearance,"h/ml; maximum concentration, 12 microg/ml; clearance, 305 ml/min; volume of distribution, 19 l.",Impact of the simultaneous administration of the (+)- and (-)-forms of formyl-tetrahydrofolic acid on plasma and intracellular pharmacokinetics of (-)-tetrahydrofolic acid. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10663632/),[ml] / [min],305,52548,DB00544,Fluorouracil
,10663632,volume of distribution,"h/ml; maximum concentration, 12 microg/ml; clearance, 305 ml/min; volume of distribution, 19 l.",Impact of the simultaneous administration of the (+)- and (-)-forms of formyl-tetrahydrofolic acid on plasma and intracellular pharmacokinetics of (-)-tetrahydrofolic acid. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10663632/),l,19,52549,DB00544,Fluorouracil
,30843362,maximum tolerated dose,"Dose-limiting toxicities of grade 3 diarrhea and myelosuppression were reported for the bolus schedule at 575 mg/m2 (maximum tolerated dose 525 mg/m²), whereas none were reported for the infusional schedule.","First-in-human phase I study of infusional and bolus schedules of Deflexifol, a novel 5-fluorouracil and leucovorin formulation, after failure of standard treatment. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30843362/),[mg] / [m²],525,53379,DB00544,Fluorouracil
,30843362,Disease control rate,Disease control rate was 64% despite most patients having failed previous 5-FU regimens.,"First-in-human phase I study of infusional and bolus schedules of Deflexifol, a novel 5-fluorouracil and leucovorin formulation, after failure of standard treatment. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30843362/),%,64,53380,DB00544,Fluorouracil
>,8201390,absolute neutrophil count [ANC],"In more than 600 patient-treatments, bone marrow toxicity was negligible (mean absolute neutrophil count [ANC] > 2.0 x 10(9)/L).","Results of a clinical trial in humans with refractory cancer of the intracellular histamine antagonist, N,N-diethyl-2-[4-(phenylmethyl)phenoxy]ethanamine-HCl, in combination with various single antineoplastic agents. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8201390/),,2.0,53802,DB00544,Fluorouracil
,10203589,survival period,PMC markedly improved the median survival period (26.6 months vs. 9.2 months P<0.000001).,The usefulness of pharmacokinetic modulating chemotherapy (UFT plus 5FU) in the treatment of unresectable colorectal carcinomas. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10203589/),month,26,54240,DB00544,Fluorouracil
,10203589,survival period,PMC markedly improved the median survival period (26.6 months vs. 9.2 months P<0.000001).,The usefulness of pharmacokinetic modulating chemotherapy (UFT plus 5FU) in the treatment of unresectable colorectal carcinomas. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10203589/),month,9.2,54241,DB00544,Fluorouracil
,18172273,time to tumor progression,The median time to tumor progression was 7.7 months.,"Phase I pharmacokinetic/pharmacodynamic study of EKB-569, an irreversible inhibitor of the epidermal growth factor receptor tyrosine kinase, in combination with irinotecan, 5-fluorouracil, and leucovorin (FOLFIRI) in first-line treatment of patients with metastatic colorectal cancer. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18172273/),month,7.7,55179,DB00544,Fluorouracil
,18172273,RD,The RD of EKB-569 is 25 mg/day when combined with FOLFIRI and results in complete EGFR inhibition.,"Phase I pharmacokinetic/pharmacodynamic study of EKB-569, an irreversible inhibitor of the epidermal growth factor receptor tyrosine kinase, in combination with irinotecan, 5-fluorouracil, and leucovorin (FOLFIRI) in first-line treatment of patients with metastatic colorectal cancer. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18172273/),[mg] / [d],25,55180,DB00544,Fluorouracil
,2950266,systemic exposures,"Pharmacokinetic studies indicated that at comparable antitumor activity, systemic exposures to FUra derived from 500 mg 5'-dFUrd/kg administered by iv push, orally, or continuous iv infusion were 3.5 +/- 1.0, 3.2 +/- 1.1, and 1.5 +/- 0.3 mM X min, respectively.",Role of administration route in the therapeutic efficacy of doxifluridine. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2950266/),mM·min,3.5,55806,DB00544,Fluorouracil
,2950266,systemic exposures,"Pharmacokinetic studies indicated that at comparable antitumor activity, systemic exposures to FUra derived from 500 mg 5'-dFUrd/kg administered by iv push, orally, or continuous iv infusion were 3.5 +/- 1.0, 3.2 +/- 1.1, and 1.5 +/- 0.3 mM X min, respectively.",Role of administration route in the therapeutic efficacy of doxifluridine. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2950266/),mM·min,3.2,55807,DB00544,Fluorouracil
,2950266,systemic exposures,"Pharmacokinetic studies indicated that at comparable antitumor activity, systemic exposures to FUra derived from 500 mg 5'-dFUrd/kg administered by iv push, orally, or continuous iv infusion were 3.5 +/- 1.0, 3.2 +/- 1.1, and 1.5 +/- 0.3 mM X min, respectively.",Role of administration route in the therapeutic efficacy of doxifluridine. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2950266/),mM·min,1.5,55808,DB00544,Fluorouracil
,10902627,area under the time versus radioactivity curve,"There was substantial inhibition, after eniluracil administration, of radiotracer uptake and retention in normal liver (mean area under the time versus radioactivity curve 0.927 [SE 0.086] vs 1.857 [0.169] m2 mL(-1) s) and kidneys (1.096 [0.048] vs 5.043 [0.915] m2 mL(-1) s).",Modulation of fluorouracil tissue pharmacokinetics by eniluracil: in-vivo imaging of drug action. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10902627/),m2,0.927,56509,DB00544,Fluorouracil
,10902627,area under the time versus radioactivity curve,"There was substantial inhibition, after eniluracil administration, of radiotracer uptake and retention in normal liver (mean area under the time versus radioactivity curve 0.927 [SE 0.086] vs 1.857 [0.169] m2 mL(-1) s) and kidneys (1.096 [0.048] vs 5.043 [0.915] m2 mL(-1) s).",Modulation of fluorouracil tissue pharmacokinetics by eniluracil: in-vivo imaging of drug action. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10902627/),[s] / [ml],1.857,56510,DB00544,Fluorouracil
,10902627,area under the time versus radioactivity curve,"There was substantial inhibition, after eniluracil administration, of radiotracer uptake and retention in normal liver (mean area under the time versus radioactivity curve 0.927 [SE 0.086] vs 1.857 [0.169] m2 mL(-1) s) and kidneys (1.096 [0.048] vs 5.043 [0.915] m2 mL(-1) s).",Modulation of fluorouracil tissue pharmacokinetics by eniluracil: in-vivo imaging of drug action. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10902627/),m2,1.096,56511,DB00544,Fluorouracil
,10902627,area under the time versus radioactivity curve,"There was substantial inhibition, after eniluracil administration, of radiotracer uptake and retention in normal liver (mean area under the time versus radioactivity curve 0.927 [SE 0.086] vs 1.857 [0.169] m2 mL(-1) s) and kidneys (1.096 [0.048] vs 5.043 [0.915] m2 mL(-1) s).",Modulation of fluorouracil tissue pharmacokinetics by eniluracil: in-vivo imaging of drug action. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10902627/),[s] / [ml],5.043,56512,DB00544,Fluorouracil
,10902627,half-life,There was also an increase in plasma uracil and unmetabolised 18F-fluorouracil and an increase in the radiotracer half-life in tumours (2.3 h to >4.0 h).,Modulation of fluorouracil tissue pharmacokinetics by eniluracil: in-vivo imaging of drug action. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10902627/),h,2.3,56513,DB00544,Fluorouracil
>,10902627,half-life,There was also an increase in plasma uracil and unmetabolised 18F-fluorouracil and an increase in the radiotracer half-life in tumours (2.3 h to >4.0 h).,Modulation of fluorouracil tissue pharmacokinetics by eniluracil: in-vivo imaging of drug action. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10902627/),h,4.0,56514,DB00544,Fluorouracil
,9816177,spin-lattice relaxation time,"The spin-lattice relaxation time of FBAL in liver, measured using a variable nutation angle method, was 1.6 +/- 0.2 s (mean +/- SD; n = 5).",Quantitation of 5-fluorouracil catabolism in human liver in vivo by three-dimensional localized 19F magnetic resonance spectroscopy. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9816177/),s,1.6,56561,DB00544,Fluorouracil
,9816177,concentration,The concentration of FBAL at 60 +/- 10 min after injection was 1.0 +/- 0.2 mm in liver (mean +/- SD; n = 7).,Quantitation of 5-fluorouracil catabolism in human liver in vivo by three-dimensional localized 19F magnetic resonance spectroscopy. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9816177/),mm,1.0,56562,DB00544,Fluorouracil
,9816177,FBAL,The concentration of FBAL at 60 +/- 10 min after injection was 1.0 +/- 0.2 mm in liver (mean +/- SD; n = 7).,Quantitation of 5-fluorouracil catabolism in human liver in vivo by three-dimensional localized 19F magnetic resonance spectroscopy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9816177/),mm,1.0,56563,DB00544,Fluorouracil
,12637480,clearance,"Pharmacokinetic studies demonstrated that irinotecan clearance was reduced from 13.4 to 5.8 L/h/m(2) and area under the curve (AUC)(0-tn) was increased 2.2-fold by the coadministration of Cs. Similar significant increases in AUC(0-24h) were seen for both SN38 and SN38G (2.2-fold and 2.3-fold, respectively) in the presence of Cs.",Phase I and pharmacokinetic study of intravenous irinotecan plus oral ciclosporin in patients with fuorouracil-refractory metastatic colon cancer. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12637480/),[h·l] / [m(2],13.4 to 5.8,56588,DB00544,Fluorouracil
,9515187,peak drug plasma concentrations (Cmax),"Significant inhibition of tumour growth was obtained in mice bearing human colon cancer xenografts and given intraperitoneal zidovudine 300 to 600 mg/kg weekly in combination with methotrexate 87.5 mg/kg or intraperitoneal fluorouracil 85 mg/kg, and in pharmacokinetic studies high peak drug plasma concentrations (Cmax) of zidovudine were obtained, ranging from 610.3 to 1698.8 mumol/L.",Pharmacokinetic optimisation of the treatment of cancer with high dose zidovudine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9515187/),[μM] / [l],610.3 to 1698.8,57087,DB00544,Fluorouracil
,12452026,AUC0-->tn,"The pharmacokinetics parameters of above all the fluid were in turn: AUC0-->tn(mg.L-1.h) 3667.36, 143.82, 31.02, 26.84; alpha(h-1) 1.1076, 0.6269, 7.7923, 21.5643; beta(h-1) 0.0367, 0.0474, 0.2091, 0.2014; CL(L.h-1) 0.16, 4.92, 35.36, 39.32; T1/2 alpha(h) 0.62, 1.11, 0.09, 0.03; T1/2 beta(h) 18.88, 14.64, 3.31, 3.44; (5) The portal vein 5-fluorouracil concentration at various times were all lower than that of the preoperation, suggesting that 5-fluorouracil can pass through retroperitoneal spaces into systemic circulation.",[Pharmacokinetic study of postoperative peritoneal infusion with large bulk heated hypotonic 5-fluorouracil fluid for prevention of recurrence and hepatic metastasis of gastric cancer]. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12452026/),[h·mg] / [l],3667.36,57327,DB00544,Fluorouracil
,12452026,AUC0-->tn,"The pharmacokinetics parameters of above all the fluid were in turn: AUC0-->tn(mg.L-1.h) 3667.36, 143.82, 31.02, 26.84; alpha(h-1) 1.1076, 0.6269, 7.7923, 21.5643; beta(h-1) 0.0367, 0.0474, 0.2091, 0.2014; CL(L.h-1) 0.16, 4.92, 35.36, 39.32; T1/2 alpha(h) 0.62, 1.11, 0.09, 0.03; T1/2 beta(h) 18.88, 14.64, 3.31, 3.44; (5) The portal vein 5-fluorouracil concentration at various times were all lower than that of the preoperation, suggesting that 5-fluorouracil can pass through retroperitoneal spaces into systemic circulation.",[Pharmacokinetic study of postoperative peritoneal infusion with large bulk heated hypotonic 5-fluorouracil fluid for prevention of recurrence and hepatic metastasis of gastric cancer]. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12452026/),[h·mg] / [l],143.82,57328,DB00544,Fluorouracil
,12452026,AUC0-->tn,"The pharmacokinetics parameters of above all the fluid were in turn: AUC0-->tn(mg.L-1.h) 3667.36, 143.82, 31.02, 26.84; alpha(h-1) 1.1076, 0.6269, 7.7923, 21.5643; beta(h-1) 0.0367, 0.0474, 0.2091, 0.2014; CL(L.h-1) 0.16, 4.92, 35.36, 39.32; T1/2 alpha(h) 0.62, 1.11, 0.09, 0.03; T1/2 beta(h) 18.88, 14.64, 3.31, 3.44; (5) The portal vein 5-fluorouracil concentration at various times were all lower than that of the preoperation, suggesting that 5-fluorouracil can pass through retroperitoneal spaces into systemic circulation.",[Pharmacokinetic study of postoperative peritoneal infusion with large bulk heated hypotonic 5-fluorouracil fluid for prevention of recurrence and hepatic metastasis of gastric cancer]. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12452026/),[h·mg] / [l],31.02,57329,DB00544,Fluorouracil
,12452026,AUC0-->tn,"The pharmacokinetics parameters of above all the fluid were in turn: AUC0-->tn(mg.L-1.h) 3667.36, 143.82, 31.02, 26.84; alpha(h-1) 1.1076, 0.6269, 7.7923, 21.5643; beta(h-1) 0.0367, 0.0474, 0.2091, 0.2014; CL(L.h-1) 0.16, 4.92, 35.36, 39.32; T1/2 alpha(h) 0.62, 1.11, 0.09, 0.03; T1/2 beta(h) 18.88, 14.64, 3.31, 3.44; (5) The portal vein 5-fluorouracil concentration at various times were all lower than that of the preoperation, suggesting that 5-fluorouracil can pass through retroperitoneal spaces into systemic circulation.",[Pharmacokinetic study of postoperative peritoneal infusion with large bulk heated hypotonic 5-fluorouracil fluid for prevention of recurrence and hepatic metastasis of gastric cancer]. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12452026/),[h·mg] / [l],26.84,57330,DB00544,Fluorouracil
,12452026,alpha,"The pharmacokinetics parameters of above all the fluid were in turn: AUC0-->tn(mg.L-1.h) 3667.36, 143.82, 31.02, 26.84; alpha(h-1) 1.1076, 0.6269, 7.7923, 21.5643; beta(h-1) 0.0367, 0.0474, 0.2091, 0.2014; CL(L.h-1) 0.16, 4.92, 35.36, 39.32; T1/2 alpha(h) 0.62, 1.11, 0.09, 0.03; T1/2 beta(h) 18.88, 14.64, 3.31, 3.44; (5) The portal vein 5-fluorouracil concentration at various times were all lower than that of the preoperation, suggesting that 5-fluorouracil can pass through retroperitoneal spaces into systemic circulation.",[Pharmacokinetic study of postoperative peritoneal infusion with large bulk heated hypotonic 5-fluorouracil fluid for prevention of recurrence and hepatic metastasis of gastric cancer]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12452026/),1/[h],1.1076,57331,DB00544,Fluorouracil
,12452026,alpha,"The pharmacokinetics parameters of above all the fluid were in turn: AUC0-->tn(mg.L-1.h) 3667.36, 143.82, 31.02, 26.84; alpha(h-1) 1.1076, 0.6269, 7.7923, 21.5643; beta(h-1) 0.0367, 0.0474, 0.2091, 0.2014; CL(L.h-1) 0.16, 4.92, 35.36, 39.32; T1/2 alpha(h) 0.62, 1.11, 0.09, 0.03; T1/2 beta(h) 18.88, 14.64, 3.31, 3.44; (5) The portal vein 5-fluorouracil concentration at various times were all lower than that of the preoperation, suggesting that 5-fluorouracil can pass through retroperitoneal spaces into systemic circulation.",[Pharmacokinetic study of postoperative peritoneal infusion with large bulk heated hypotonic 5-fluorouracil fluid for prevention of recurrence and hepatic metastasis of gastric cancer]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12452026/),1/[h],0.6269,57332,DB00544,Fluorouracil
,12452026,alpha,"The pharmacokinetics parameters of above all the fluid were in turn: AUC0-->tn(mg.L-1.h) 3667.36, 143.82, 31.02, 26.84; alpha(h-1) 1.1076, 0.6269, 7.7923, 21.5643; beta(h-1) 0.0367, 0.0474, 0.2091, 0.2014; CL(L.h-1) 0.16, 4.92, 35.36, 39.32; T1/2 alpha(h) 0.62, 1.11, 0.09, 0.03; T1/2 beta(h) 18.88, 14.64, 3.31, 3.44; (5) The portal vein 5-fluorouracil concentration at various times were all lower than that of the preoperation, suggesting that 5-fluorouracil can pass through retroperitoneal spaces into systemic circulation.",[Pharmacokinetic study of postoperative peritoneal infusion with large bulk heated hypotonic 5-fluorouracil fluid for prevention of recurrence and hepatic metastasis of gastric cancer]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12452026/),1/[h],7.7923,57333,DB00544,Fluorouracil
,12452026,alpha,"The pharmacokinetics parameters of above all the fluid were in turn: AUC0-->tn(mg.L-1.h) 3667.36, 143.82, 31.02, 26.84; alpha(h-1) 1.1076, 0.6269, 7.7923, 21.5643; beta(h-1) 0.0367, 0.0474, 0.2091, 0.2014; CL(L.h-1) 0.16, 4.92, 35.36, 39.32; T1/2 alpha(h) 0.62, 1.11, 0.09, 0.03; T1/2 beta(h) 18.88, 14.64, 3.31, 3.44; (5) The portal vein 5-fluorouracil concentration at various times were all lower than that of the preoperation, suggesting that 5-fluorouracil can pass through retroperitoneal spaces into systemic circulation.",[Pharmacokinetic study of postoperative peritoneal infusion with large bulk heated hypotonic 5-fluorouracil fluid for prevention of recurrence and hepatic metastasis of gastric cancer]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12452026/),1/[h],21.5643,57334,DB00544,Fluorouracil
,12452026,beta,"The pharmacokinetics parameters of above all the fluid were in turn: AUC0-->tn(mg.L-1.h) 3667.36, 143.82, 31.02, 26.84; alpha(h-1) 1.1076, 0.6269, 7.7923, 21.5643; beta(h-1) 0.0367, 0.0474, 0.2091, 0.2014; CL(L.h-1) 0.16, 4.92, 35.36, 39.32; T1/2 alpha(h) 0.62, 1.11, 0.09, 0.03; T1/2 beta(h) 18.88, 14.64, 3.31, 3.44; (5) The portal vein 5-fluorouracil concentration at various times were all lower than that of the preoperation, suggesting that 5-fluorouracil can pass through retroperitoneal spaces into systemic circulation.",[Pharmacokinetic study of postoperative peritoneal infusion with large bulk heated hypotonic 5-fluorouracil fluid for prevention of recurrence and hepatic metastasis of gastric cancer]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12452026/),1/[h],0.0367,57335,DB00544,Fluorouracil
,12452026,beta,"The pharmacokinetics parameters of above all the fluid were in turn: AUC0-->tn(mg.L-1.h) 3667.36, 143.82, 31.02, 26.84; alpha(h-1) 1.1076, 0.6269, 7.7923, 21.5643; beta(h-1) 0.0367, 0.0474, 0.2091, 0.2014; CL(L.h-1) 0.16, 4.92, 35.36, 39.32; T1/2 alpha(h) 0.62, 1.11, 0.09, 0.03; T1/2 beta(h) 18.88, 14.64, 3.31, 3.44; (5) The portal vein 5-fluorouracil concentration at various times were all lower than that of the preoperation, suggesting that 5-fluorouracil can pass through retroperitoneal spaces into systemic circulation.",[Pharmacokinetic study of postoperative peritoneal infusion with large bulk heated hypotonic 5-fluorouracil fluid for prevention of recurrence and hepatic metastasis of gastric cancer]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12452026/),1/[h],0.0474,57336,DB00544,Fluorouracil
,12452026,beta,"The pharmacokinetics parameters of above all the fluid were in turn: AUC0-->tn(mg.L-1.h) 3667.36, 143.82, 31.02, 26.84; alpha(h-1) 1.1076, 0.6269, 7.7923, 21.5643; beta(h-1) 0.0367, 0.0474, 0.2091, 0.2014; CL(L.h-1) 0.16, 4.92, 35.36, 39.32; T1/2 alpha(h) 0.62, 1.11, 0.09, 0.03; T1/2 beta(h) 18.88, 14.64, 3.31, 3.44; (5) The portal vein 5-fluorouracil concentration at various times were all lower than that of the preoperation, suggesting that 5-fluorouracil can pass through retroperitoneal spaces into systemic circulation.",[Pharmacokinetic study of postoperative peritoneal infusion with large bulk heated hypotonic 5-fluorouracil fluid for prevention of recurrence and hepatic metastasis of gastric cancer]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12452026/),1/[h],0.2091,57337,DB00544,Fluorouracil
,12452026,beta,"The pharmacokinetics parameters of above all the fluid were in turn: AUC0-->tn(mg.L-1.h) 3667.36, 143.82, 31.02, 26.84; alpha(h-1) 1.1076, 0.6269, 7.7923, 21.5643; beta(h-1) 0.0367, 0.0474, 0.2091, 0.2014; CL(L.h-1) 0.16, 4.92, 35.36, 39.32; T1/2 alpha(h) 0.62, 1.11, 0.09, 0.03; T1/2 beta(h) 18.88, 14.64, 3.31, 3.44; (5) The portal vein 5-fluorouracil concentration at various times were all lower than that of the preoperation, suggesting that 5-fluorouracil can pass through retroperitoneal spaces into systemic circulation.",[Pharmacokinetic study of postoperative peritoneal infusion with large bulk heated hypotonic 5-fluorouracil fluid for prevention of recurrence and hepatic metastasis of gastric cancer]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12452026/),1/[h],0.2014,57338,DB00544,Fluorouracil
,12452026,CL,"The pharmacokinetics parameters of above all the fluid were in turn: AUC0-->tn(mg.L-1.h) 3667.36, 143.82, 31.02, 26.84; alpha(h-1) 1.1076, 0.6269, 7.7923, 21.5643; beta(h-1) 0.0367, 0.0474, 0.2091, 0.2014; CL(L.h-1) 0.16, 4.92, 35.36, 39.32; T1/2 alpha(h) 0.62, 1.11, 0.09, 0.03; T1/2 beta(h) 18.88, 14.64, 3.31, 3.44; (5) The portal vein 5-fluorouracil concentration at various times were all lower than that of the preoperation, suggesting that 5-fluorouracil can pass through retroperitoneal spaces into systemic circulation.",[Pharmacokinetic study of postoperative peritoneal infusion with large bulk heated hypotonic 5-fluorouracil fluid for prevention of recurrence and hepatic metastasis of gastric cancer]. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12452026/),[l] / [h],0.16,57339,DB00544,Fluorouracil
,12452026,CL,"The pharmacokinetics parameters of above all the fluid were in turn: AUC0-->tn(mg.L-1.h) 3667.36, 143.82, 31.02, 26.84; alpha(h-1) 1.1076, 0.6269, 7.7923, 21.5643; beta(h-1) 0.0367, 0.0474, 0.2091, 0.2014; CL(L.h-1) 0.16, 4.92, 35.36, 39.32; T1/2 alpha(h) 0.62, 1.11, 0.09, 0.03; T1/2 beta(h) 18.88, 14.64, 3.31, 3.44; (5) The portal vein 5-fluorouracil concentration at various times were all lower than that of the preoperation, suggesting that 5-fluorouracil can pass through retroperitoneal spaces into systemic circulation.",[Pharmacokinetic study of postoperative peritoneal infusion with large bulk heated hypotonic 5-fluorouracil fluid for prevention of recurrence and hepatic metastasis of gastric cancer]. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12452026/),[l] / [h],4.92,57340,DB00544,Fluorouracil
,12452026,CL,"The pharmacokinetics parameters of above all the fluid were in turn: AUC0-->tn(mg.L-1.h) 3667.36, 143.82, 31.02, 26.84; alpha(h-1) 1.1076, 0.6269, 7.7923, 21.5643; beta(h-1) 0.0367, 0.0474, 0.2091, 0.2014; CL(L.h-1) 0.16, 4.92, 35.36, 39.32; T1/2 alpha(h) 0.62, 1.11, 0.09, 0.03; T1/2 beta(h) 18.88, 14.64, 3.31, 3.44; (5) The portal vein 5-fluorouracil concentration at various times were all lower than that of the preoperation, suggesting that 5-fluorouracil can pass through retroperitoneal spaces into systemic circulation.",[Pharmacokinetic study of postoperative peritoneal infusion with large bulk heated hypotonic 5-fluorouracil fluid for prevention of recurrence and hepatic metastasis of gastric cancer]. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12452026/),[l] / [h],35.36,57341,DB00544,Fluorouracil
,12452026,CL,"The pharmacokinetics parameters of above all the fluid were in turn: AUC0-->tn(mg.L-1.h) 3667.36, 143.82, 31.02, 26.84; alpha(h-1) 1.1076, 0.6269, 7.7923, 21.5643; beta(h-1) 0.0367, 0.0474, 0.2091, 0.2014; CL(L.h-1) 0.16, 4.92, 35.36, 39.32; T1/2 alpha(h) 0.62, 1.11, 0.09, 0.03; T1/2 beta(h) 18.88, 14.64, 3.31, 3.44; (5) The portal vein 5-fluorouracil concentration at various times were all lower than that of the preoperation, suggesting that 5-fluorouracil can pass through retroperitoneal spaces into systemic circulation.",[Pharmacokinetic study of postoperative peritoneal infusion with large bulk heated hypotonic 5-fluorouracil fluid for prevention of recurrence and hepatic metastasis of gastric cancer]. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12452026/),[l] / [h],39.32,57342,DB00544,Fluorouracil
,12452026,T1/2 alpha,"The pharmacokinetics parameters of above all the fluid were in turn: AUC0-->tn(mg.L-1.h) 3667.36, 143.82, 31.02, 26.84; alpha(h-1) 1.1076, 0.6269, 7.7923, 21.5643; beta(h-1) 0.0367, 0.0474, 0.2091, 0.2014; CL(L.h-1) 0.16, 4.92, 35.36, 39.32; T1/2 alpha(h) 0.62, 1.11, 0.09, 0.03; T1/2 beta(h) 18.88, 14.64, 3.31, 3.44; (5) The portal vein 5-fluorouracil concentration at various times were all lower than that of the preoperation, suggesting that 5-fluorouracil can pass through retroperitoneal spaces into systemic circulation.",[Pharmacokinetic study of postoperative peritoneal infusion with large bulk heated hypotonic 5-fluorouracil fluid for prevention of recurrence and hepatic metastasis of gastric cancer]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12452026/),h,0.62,57343,DB00544,Fluorouracil
,12452026,T1/2 alpha,"The pharmacokinetics parameters of above all the fluid were in turn: AUC0-->tn(mg.L-1.h) 3667.36, 143.82, 31.02, 26.84; alpha(h-1) 1.1076, 0.6269, 7.7923, 21.5643; beta(h-1) 0.0367, 0.0474, 0.2091, 0.2014; CL(L.h-1) 0.16, 4.92, 35.36, 39.32; T1/2 alpha(h) 0.62, 1.11, 0.09, 0.03; T1/2 beta(h) 18.88, 14.64, 3.31, 3.44; (5) The portal vein 5-fluorouracil concentration at various times were all lower than that of the preoperation, suggesting that 5-fluorouracil can pass through retroperitoneal spaces into systemic circulation.",[Pharmacokinetic study of postoperative peritoneal infusion with large bulk heated hypotonic 5-fluorouracil fluid for prevention of recurrence and hepatic metastasis of gastric cancer]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12452026/),h,1.11,57344,DB00544,Fluorouracil
,12452026,T1/2 alpha,"The pharmacokinetics parameters of above all the fluid were in turn: AUC0-->tn(mg.L-1.h) 3667.36, 143.82, 31.02, 26.84; alpha(h-1) 1.1076, 0.6269, 7.7923, 21.5643; beta(h-1) 0.0367, 0.0474, 0.2091, 0.2014; CL(L.h-1) 0.16, 4.92, 35.36, 39.32; T1/2 alpha(h) 0.62, 1.11, 0.09, 0.03; T1/2 beta(h) 18.88, 14.64, 3.31, 3.44; (5) The portal vein 5-fluorouracil concentration at various times were all lower than that of the preoperation, suggesting that 5-fluorouracil can pass through retroperitoneal spaces into systemic circulation.",[Pharmacokinetic study of postoperative peritoneal infusion with large bulk heated hypotonic 5-fluorouracil fluid for prevention of recurrence and hepatic metastasis of gastric cancer]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12452026/),h,0.09,57345,DB00544,Fluorouracil
,12452026,T1/2 alpha,"The pharmacokinetics parameters of above all the fluid were in turn: AUC0-->tn(mg.L-1.h) 3667.36, 143.82, 31.02, 26.84; alpha(h-1) 1.1076, 0.6269, 7.7923, 21.5643; beta(h-1) 0.0367, 0.0474, 0.2091, 0.2014; CL(L.h-1) 0.16, 4.92, 35.36, 39.32; T1/2 alpha(h) 0.62, 1.11, 0.09, 0.03; T1/2 beta(h) 18.88, 14.64, 3.31, 3.44; (5) The portal vein 5-fluorouracil concentration at various times were all lower than that of the preoperation, suggesting that 5-fluorouracil can pass through retroperitoneal spaces into systemic circulation.",[Pharmacokinetic study of postoperative peritoneal infusion with large bulk heated hypotonic 5-fluorouracil fluid for prevention of recurrence and hepatic metastasis of gastric cancer]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12452026/),h,0.03,57346,DB00544,Fluorouracil
,12452026,T1/2 beta,"The pharmacokinetics parameters of above all the fluid were in turn: AUC0-->tn(mg.L-1.h) 3667.36, 143.82, 31.02, 26.84; alpha(h-1) 1.1076, 0.6269, 7.7923, 21.5643; beta(h-1) 0.0367, 0.0474, 0.2091, 0.2014; CL(L.h-1) 0.16, 4.92, 35.36, 39.32; T1/2 alpha(h) 0.62, 1.11, 0.09, 0.03; T1/2 beta(h) 18.88, 14.64, 3.31, 3.44; (5) The portal vein 5-fluorouracil concentration at various times were all lower than that of the preoperation, suggesting that 5-fluorouracil can pass through retroperitoneal spaces into systemic circulation.",[Pharmacokinetic study of postoperative peritoneal infusion with large bulk heated hypotonic 5-fluorouracil fluid for prevention of recurrence and hepatic metastasis of gastric cancer]. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12452026/),h,18.88,57347,DB00544,Fluorouracil
,12452026,T1/2 beta,"The pharmacokinetics parameters of above all the fluid were in turn: AUC0-->tn(mg.L-1.h) 3667.36, 143.82, 31.02, 26.84; alpha(h-1) 1.1076, 0.6269, 7.7923, 21.5643; beta(h-1) 0.0367, 0.0474, 0.2091, 0.2014; CL(L.h-1) 0.16, 4.92, 35.36, 39.32; T1/2 alpha(h) 0.62, 1.11, 0.09, 0.03; T1/2 beta(h) 18.88, 14.64, 3.31, 3.44; (5) The portal vein 5-fluorouracil concentration at various times were all lower than that of the preoperation, suggesting that 5-fluorouracil can pass through retroperitoneal spaces into systemic circulation.",[Pharmacokinetic study of postoperative peritoneal infusion with large bulk heated hypotonic 5-fluorouracil fluid for prevention of recurrence and hepatic metastasis of gastric cancer]. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12452026/),h,14.64,57348,DB00544,Fluorouracil
,12452026,T1/2 beta,"The pharmacokinetics parameters of above all the fluid were in turn: AUC0-->tn(mg.L-1.h) 3667.36, 143.82, 31.02, 26.84; alpha(h-1) 1.1076, 0.6269, 7.7923, 21.5643; beta(h-1) 0.0367, 0.0474, 0.2091, 0.2014; CL(L.h-1) 0.16, 4.92, 35.36, 39.32; T1/2 alpha(h) 0.62, 1.11, 0.09, 0.03; T1/2 beta(h) 18.88, 14.64, 3.31, 3.44; (5) The portal vein 5-fluorouracil concentration at various times were all lower than that of the preoperation, suggesting that 5-fluorouracil can pass through retroperitoneal spaces into systemic circulation.",[Pharmacokinetic study of postoperative peritoneal infusion with large bulk heated hypotonic 5-fluorouracil fluid for prevention of recurrence and hepatic metastasis of gastric cancer]. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12452026/),h,3.31,57349,DB00544,Fluorouracil
,12452026,T1/2 beta,"The pharmacokinetics parameters of above all the fluid were in turn: AUC0-->tn(mg.L-1.h) 3667.36, 143.82, 31.02, 26.84; alpha(h-1) 1.1076, 0.6269, 7.7923, 21.5643; beta(h-1) 0.0367, 0.0474, 0.2091, 0.2014; CL(L.h-1) 0.16, 4.92, 35.36, 39.32; T1/2 alpha(h) 0.62, 1.11, 0.09, 0.03; T1/2 beta(h) 18.88, 14.64, 3.31, 3.44; (5) The portal vein 5-fluorouracil concentration at various times were all lower than that of the preoperation, suggesting that 5-fluorouracil can pass through retroperitoneal spaces into systemic circulation.",[Pharmacokinetic study of postoperative peritoneal infusion with large bulk heated hypotonic 5-fluorouracil fluid for prevention of recurrence and hepatic metastasis of gastric cancer]. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12452026/),h,3.44,57350,DB00544,Fluorouracil
,16086887,ER,"The nanoparticle was uniformly spherical with average diameter of (191+/-17) nm, DL of 15.2%, and ER of 45.6%.",[Preparation and release efficiency of polylactic acid nanoparticle]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16086887/),,45,57569,DB00544,Fluorouracil
,16086887,cumulative drug release rate,The nanoparticle showed sustained release character in the experiment of in vitro drug release: the cumulative drug release rate in analog body fluid was 94.3% at the 10th day.,[Preparation and release efficiency of polylactic acid nanoparticle]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16086887/),%,94.3,57570,DB00544,Fluorouracil
,25161161,Extraction recovery,Extraction recovery ranged from 87.55 to 95.26%.,Development of a HPLC method to determine 5-fluorouracil in plasma: application in pharmacokinetics and steady-state concentration monitoring. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25161161/),%,87.55,57737,DB00544,Fluorouracil
,25161161,Extraction recovery,Extraction recovery ranged from 87.55 to 95.26%.,Development of a HPLC method to determine 5-fluorouracil in plasma: application in pharmacokinetics and steady-state concentration monitoring. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25161161/),%,95.26,57738,DB00544,Fluorouracil
,25161161,flow rate,The isocratic mobile phase composed of acetonitrile-ammonium acetate buffer (pH 3.5; 0.01M) (2.5 : 97.5 v/v) at a flow rate of 0.8 mL/min.,Development of a HPLC method to determine 5-fluorouracil in plasma: application in pharmacokinetics and steady-state concentration monitoring. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25161161/),[ml] / [min],0.8,57739,DB00544,Fluorouracil
less,25161161,Retention time,Retention time was less than 7 minutes.,Development of a HPLC method to determine 5-fluorouracil in plasma: application in pharmacokinetics and steady-state concentration monitoring. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25161161/),min,7,57740,DB00544,Fluorouracil
,30657223,progression-free survival,The median progression-free survival was 5.42 months (4.14-6.70 months) and the median overall survival was 15.59 months (11.20-19.81 months).,Phase II trial of aflibercept with FOLFIRI as a second-line treatment for Japanese patients with metastatic colorectal cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30657223/),month,5.42,57848,DB00544,Fluorouracil
,30657223,overall survival,The median progression-free survival was 5.42 months (4.14-6.70 months) and the median overall survival was 15.59 months (11.20-19.81 months).,Phase II trial of aflibercept with FOLFIRI as a second-line treatment for Japanese patients with metastatic colorectal cancer. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30657223/),month,15.59,57849,DB00544,Fluorouracil
,30657223,maximum concentration,"Free aflibercept had a mean maximum concentration (coefficient of variation) of 73.2 μg/mL (15%), clearance of 0.805 L/d (22%) and volume of distribution of 6.2 L (18%); aflibercept bound with vascular endothelial growth factor had a clearance of 0.162 L/d (9%) (N = 62).",Phase II trial of aflibercept with FOLFIRI as a second-line treatment for Japanese patients with metastatic colorectal cancer. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30657223/),[μg] / [ml],73.2,57850,DB00544,Fluorouracil
,30657223,clearance,"Free aflibercept had a mean maximum concentration (coefficient of variation) of 73.2 μg/mL (15%), clearance of 0.805 L/d (22%) and volume of distribution of 6.2 L (18%); aflibercept bound with vascular endothelial growth factor had a clearance of 0.162 L/d (9%) (N = 62).",Phase II trial of aflibercept with FOLFIRI as a second-line treatment for Japanese patients with metastatic colorectal cancer. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30657223/),[l] / [d],0.805,57851,DB00544,Fluorouracil
,30657223,volume of distribution,"Free aflibercept had a mean maximum concentration (coefficient of variation) of 73.2 μg/mL (15%), clearance of 0.805 L/d (22%) and volume of distribution of 6.2 L (18%); aflibercept bound with vascular endothelial growth factor had a clearance of 0.162 L/d (9%) (N = 62).",Phase II trial of aflibercept with FOLFIRI as a second-line treatment for Japanese patients with metastatic colorectal cancer. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30657223/),l,6.2,57852,DB00544,Fluorouracil
,30657223,clearance,"Free aflibercept had a mean maximum concentration (coefficient of variation) of 73.2 μg/mL (15%), clearance of 0.805 L/d (22%) and volume of distribution of 6.2 L (18%); aflibercept bound with vascular endothelial growth factor had a clearance of 0.162 L/d (9%) (N = 62).",Phase II trial of aflibercept with FOLFIRI as a second-line treatment for Japanese patients with metastatic colorectal cancer. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30657223/),[l] / [d],0.162,57853,DB00544,Fluorouracil
,30657223,clearance,"Aflibercept did not significantly affect the pharmacokinetics of irinotecan or 5-fluorouracil: The clearance was 11.1 L/h/m2 (28%) for irinotecan and, at steady state, 72.6 L/h/m2 (56%) for 5-fluorouracil (N = 10).",Phase II trial of aflibercept with FOLFIRI as a second-line treatment for Japanese patients with metastatic colorectal cancer. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30657223/),[l] / [h·m2],11.1,57854,DB00544,Fluorouracil
,30657223,clearance,"Aflibercept did not significantly affect the pharmacokinetics of irinotecan or 5-fluorouracil: The clearance was 11.1 L/h/m2 (28%) for irinotecan and, at steady state, 72.6 L/h/m2 (56%) for 5-fluorouracil (N = 10).",Phase II trial of aflibercept with FOLFIRI as a second-line treatment for Japanese patients with metastatic colorectal cancer. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30657223/),[l] / [h·m2],72.6,57855,DB00544,Fluorouracil
,7562916,IC50,"We prepared a series of 5-aryl-substituted analogues of 5-benzylacyclouridine (BAU), a good inhibitor of UrdPase (IC50 of 0.46 microM), to develop a compound with enhanced potency and improved pharmacokinetics.",Inhibition of uridine phosphorylase: synthesis and structure-activity relationships of aryl-substituted 5-benzyluracils and 1-[(2-hydroxyethoxy)methyl]-5-benzyluracils. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7562916/),μM,0.46,58228,DB00544,Fluorouracil
,7562916,IC50s,"The two most potent compounds, 10y (3-propoxy) and 10dd (3-sec-butoxy), were inhibitors of UrdPase with IC50s of 0.047 and 0.027 microM, respectively.",Inhibition of uridine phosphorylase: synthesis and structure-activity relationships of aryl-substituted 5-benzyluracils and 1-[(2-hydroxyethoxy)methyl]-5-benzyluracils. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7562916/),μM,0.047,58229,DB00544,Fluorouracil
,7562916,IC50s,"The two most potent compounds, 10y (3-propoxy) and 10dd (3-sec-butoxy), were inhibitors of UrdPase with IC50s of 0.047 and 0.027 microM, respectively.",Inhibition of uridine phosphorylase: synthesis and structure-activity relationships of aryl-substituted 5-benzyluracils and 1-[(2-hydroxyethoxy)methyl]-5-benzyluracils. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7562916/),μM,0.027,58230,DB00544,Fluorouracil
,21786211,overall response rate,The overall response rate was 24.0% (6PR/25).,Phase I study of irinotecan by 24-h intravenous infusion in combination with 5-fluorouracil in metastatic colorectal cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21786211/),%,24.0,58771,DB00544,Fluorouracil
,26499900,overall response rate,The overall response rate was 45 %; two patients achieved a complete response.,"Phase 1a/1b and pharmacogenetic study of docetaxel, oxaliplatin and capecitabine in patients with advanced cancer of the stomach or the gastroesophageal junction. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26499900/),%,45,59541,DB00544,Fluorouracil
,26499900,progression-free survival,"Median progression-free survival and overall survival were 6.5 months (95 % CI 5.4-7.6) and 11.0 months (95 % CI 7.9-14.1), respectively.","Phase 1a/1b and pharmacogenetic study of docetaxel, oxaliplatin and capecitabine in patients with advanced cancer of the stomach or the gastroesophageal junction. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26499900/),month,6.5,59542,DB00544,Fluorouracil
,26499900,overall survival,"Median progression-free survival and overall survival were 6.5 months (95 % CI 5.4-7.6) and 11.0 months (95 % CI 7.9-14.1), respectively.","Phase 1a/1b and pharmacogenetic study of docetaxel, oxaliplatin and capecitabine in patients with advanced cancer of the stomach or the gastroesophageal junction. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26499900/),month,11.0,59543,DB00544,Fluorouracil
,6426395,half-time,"The blood level of FT-207 showed its peak of 30 mcg/ml at 2 hours after administration, of which half-time was 9 hours.",[Pharmacokinetics of FT-207 rectum suppository in squamous cell carcinoma of the uterine cervix. (I) Pharmacokinetics in single administration at a dose of 1 gram]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6426395/),h,9,59892,DB00544,Fluorouracil
,7160054,Half-life,"Half-life values for the elimination of FU from plasma (mean, 123.5 min) were greater in each patient than for the catabolite (mean, 109.2 min).",Nonlinear pharmacokinetics for the elimination of 5-fluorouracil after intravenous administration in cancer patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7160054/),min,123.5,60313,DB00544,Fluorouracil
,7160054,Half-life,"Half-life values for the elimination of FU from plasma (mean, 123.5 min) were greater in each patient than for the catabolite (mean, 109.2 min).",Nonlinear pharmacokinetics for the elimination of 5-fluorouracil after intravenous administration in cancer patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7160054/),min,109.2,60314,DB00544,Fluorouracil
,7160054,area under the curve,"Values of the area under the curve for FU profiles varied between patients (mean +/- SE, 12.7 +/- 1.9 micrograms X h/ml) by comparison with the relatively constant values for curves of DHFU concentrations (mean +/- SE, 2.8 +/- 0.15 micrograms X h/ml).",Nonlinear pharmacokinetics for the elimination of 5-fluorouracil after intravenous administration in cancer patients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7160054/),[h·μg] / [ml],12.7,60315,DB00544,Fluorouracil
,7160054,area under the curve,"Values of the area under the curve for FU profiles varied between patients (mean +/- SE, 12.7 +/- 1.9 micrograms X h/ml) by comparison with the relatively constant values for curves of DHFU concentrations (mean +/- SE, 2.8 +/- 0.15 micrograms X h/ml).",Nonlinear pharmacokinetics for the elimination of 5-fluorouracil after intravenous administration in cancer patients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7160054/),[h·μg] / [ml],2.8,60316,DB00544,Fluorouracil
,7160054,Half-lives,"Half-lives for the elimination of FU in urine were 2.6-5.9 h, which increased to 18-44 h on multiple dosing.",Nonlinear pharmacokinetics for the elimination of 5-fluorouracil after intravenous administration in cancer patients. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7160054/),h,2.6-5.9,60317,DB00544,Fluorouracil
,7160054,Half-lives,"Half-lives for the elimination of FU in urine were 2.6-5.9 h, which increased to 18-44 h on multiple dosing.",Nonlinear pharmacokinetics for the elimination of 5-fluorouracil after intravenous administration in cancer patients. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7160054/),h,18-44,60318,DB00544,Fluorouracil
,21094191,drug-to-lipid ratios,"More specifically, in the presence of entrapped copper and PEI, externally added 5-FU can be efficiently encapsulated (>95%) in DSPC/Chol (1,2-Distearoyl-sn-Glycero-3-Phosphocholine/cholesterol; 55:45 mol%) liposomes (130-170 nm) to achieve drug-to-lipid ratios of 0.1 (mol:mol).","Development of a liposomal nanoparticle formulation of 5-fluorouracil for parenteral administration: formulation design, pharmacokinetics and efficacy. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21094191/),,0.1,60690,DB00544,Fluorouracil
,23494628,flow rate,"Chromatographic separation was accomplished by Agilent® Zorbax® SB-C18 column, with isocratic elution (5 mM ammonium acetate and methanol, 70:30, %v/v) at a flow rate of 300 μL/min.","Pharmacokinetic application of a bio-analytical LC-MS method developed for 5-fluorouracil and methotrexate in mouse plasma, brain and urine. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23494628/),[μl] / [min],300,61130,DB00544,Fluorouracil
,23494628,total run time,"The limit of quantitation for both drugs was 15.6 ng/mL (plasma and brain) and 78.1 ng/mL (urine), with interday and intraday precision and accuracy ≤15% and a total run time of 6 min.","Pharmacokinetic application of a bio-analytical LC-MS method developed for 5-fluorouracil and methotrexate in mouse plasma, brain and urine. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23494628/),min,6,61131,DB00544,Fluorouracil
,16628132,elimination clearance (CL),"The elimination clearance (CL) and the elimination clearance of the peripheral compartment (CL2) (median +/- SE) were 25.2 +/- 6.3 L/hr and 68 +/- 24.8 L/hr, respectively.",Population pharmacokinetics of oxaliplatin (85 mg/m2) in combination with 5-fluorouracil in patients with advanced colorectal cancer. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16628132/),[l] / [h],25.2,61625,DB00544,Fluorouracil
,16628132,elimination clearance of the peripheral compartment (CL2),"The elimination clearance (CL) and the elimination clearance of the peripheral compartment (CL2) (median +/- SE) were 25.2 +/- 6.3 L/hr and 68 +/- 24.8 L/hr, respectively.",Population pharmacokinetics of oxaliplatin (85 mg/m2) in combination with 5-fluorouracil in patients with advanced colorectal cancer. ,CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16628132/),[l] / [h],68,61626,DB00544,Fluorouracil
,16628132,volume of distribution (V1),The median volume of distribution (V1) was determined to be 41.6 +/- 9.4 L and the median volume of distribution of the peripheral compartment (V2) was 452.5 +/- 96.4 L.,Population pharmacokinetics of oxaliplatin (85 mg/m2) in combination with 5-fluorouracil in patients with advanced colorectal cancer. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16628132/),l,41.6,61627,DB00544,Fluorouracil
,16628132,volume of distribution of the peripheral compartment (V2),The median volume of distribution (V1) was determined to be 41.6 +/- 9.4 L and the median volume of distribution of the peripheral compartment (V2) was 452.5 +/- 96.4 L.,Population pharmacokinetics of oxaliplatin (85 mg/m2) in combination with 5-fluorouracil in patients with advanced colorectal cancer. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16628132/),l,452.5,61628,DB00544,Fluorouracil
,10213210,terminal half-life,"The levels of free platin decreased triphasically, with a mean terminal half-life of 27.3+/-10.6 h.",Oxaliplatin pharmacokinetics during a four-hour infusion. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10213210/),h,27.3,61709,DB00544,Fluorouracil
,10213210,area under the time-concentration curve,"The area under the time-concentration curve was 20.17+/-6.97 microg.h/ml and the total and renal clearances amounted to 222+/-65 and 121+/-56 ml/min, respectively.",Oxaliplatin pharmacokinetics during a four-hour infusion. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10213210/),[h·μg] / [ml],20.17,61710,DB00544,Fluorouracil
,10213210,total,"The area under the time-concentration curve was 20.17+/-6.97 microg.h/ml and the total and renal clearances amounted to 222+/-65 and 121+/-56 ml/min, respectively.",Oxaliplatin pharmacokinetics during a four-hour infusion. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10213210/),[ml] / [min],222,61711,DB00544,Fluorouracil
,10213210,renal clearances,"The area under the time-concentration curve was 20.17+/-6.97 microg.h/ml and the total and renal clearances amounted to 222+/-65 and 121+/-56 ml/min, respectively.",Oxaliplatin pharmacokinetics during a four-hour infusion. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10213210/),[ml] / [min],121,61712,DB00544,Fluorouracil
,10213210,volume of distribution,"The values for the volume of distribution and for the maximum concentration at the end of infusion were 349+/-132 liters and 1612+/-553 ng/ml, respectively.",Oxaliplatin pharmacokinetics during a four-hour infusion. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10213210/),l,349,61713,DB00544,Fluorouracil
,10213210,maximum concentration,"The values for the volume of distribution and for the maximum concentration at the end of infusion were 349+/-132 liters and 1612+/-553 ng/ml, respectively.",Oxaliplatin pharmacokinetics during a four-hour infusion. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10213210/),[ng] / [ml],1612,61714,DB00544,Fluorouracil
,24942210,clearance,Median bevacizumab clearance in AGC was 4.5 versus 3 mL/day/kg in other cancers.,Lower exposure and faster clearance of bevacizumab in gastric cancer and the impact of patient variables: analysis of individual data from AVAGAST phase III trial. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24942210/),[ml] / [d·kg],4.5,61751,DB00544,Fluorouracil
,24942210,clearance,Median bevacizumab clearance in AGC was 4.5 versus 3 mL/day/kg in other cancers.,Lower exposure and faster clearance of bevacizumab in gastric cancer and the impact of patient variables: analysis of individual data from AVAGAST phase III trial. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24942210/),[ml] / [d·kg],3,61752,DB00544,Fluorouracil
> or =,12448653,T1/2,"Partial responses to 5-FU plus leucovorin therapy were seen only in patients with a long intratumoral half-life (trapping) of 5-FU (3 PR in 11 patients with T1/2 > or = 20 minutes, compared to 0 PR in 11 patients with T1/2 < 20 minutes).",Does leucovorin alter the intratumoral pharmacokinetics of 5-fluorouracil (5-FU)? A Southwest Oncology Group study. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12448653/),min,20,61844,DB00544,Fluorouracil
<,12448653,T1/2,"Partial responses to 5-FU plus leucovorin therapy were seen only in patients with a long intratumoral half-life (trapping) of 5-FU (3 PR in 11 patients with T1/2 > or = 20 minutes, compared to 0 PR in 11 patients with T1/2 < 20 minutes).",Does leucovorin alter the intratumoral pharmacokinetics of 5-fluorouracil (5-FU)? A Southwest Oncology Group study. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12448653/),min,20,61845,DB00544,Fluorouracil
,8980409,steady-state 5-FU concentrations,Pharmacokinetic studies showed i.p. steady-state 5-FU concentrations (mean 47 500 ng ml-1) that were > 1000-fold higher than systemic venous levels (mean 30 ng ml-1).,Prolonged intraperitoneal infusion of 5-fluorouracil using a novel carrier solution. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8980409/),[ng] / [ml],47 500,62506,DB00544,Fluorouracil
,8980409,systemic,Pharmacokinetic studies showed i.p. steady-state 5-FU concentrations (mean 47 500 ng ml-1) that were > 1000-fold higher than systemic venous levels (mean 30 ng ml-1).,Prolonged intraperitoneal infusion of 5-fluorouracil using a novel carrier solution. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8980409/),[ng] / [ml],30,62507,DB00544,Fluorouracil
,20566423,objective response rate,"Among the 103 eligible patients, the 48 elderly (median age 70 range 65-80) did not differ significantly from the 55 non-elderly patients (median age 59 range 33-64) in pPK parameters (including AUC at cycle-1 and cycle-2), efficacy (objective response rate of 27% [16.1-40.9] in younger and 35% [22.2-50.5] in older patients, p = 0.4) and tolerability (33.3% of overall grade 3-4 toxicities in older patients and 34.5% in younger, p = 0.9).",Clinical impact of intesified 5-Fluorouracil-based chemotherapy using a prospective pharmacokinetically-guided dosing approach: comparative study in elderly and non-elderly patients with metastatic colorectal cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20566423/),%,27,62918,DB00544,Fluorouracil
,20566423,objective response rate,"Among the 103 eligible patients, the 48 elderly (median age 70 range 65-80) did not differ significantly from the 55 non-elderly patients (median age 59 range 33-64) in pPK parameters (including AUC at cycle-1 and cycle-2), efficacy (objective response rate of 27% [16.1-40.9] in younger and 35% [22.2-50.5] in older patients, p = 0.4) and tolerability (33.3% of overall grade 3-4 toxicities in older patients and 34.5% in younger, p = 0.9).",Clinical impact of intesified 5-Fluorouracil-based chemotherapy using a prospective pharmacokinetically-guided dosing approach: comparative study in elderly and non-elderly patients with metastatic colorectal cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20566423/),%,35,62919,DB00544,Fluorouracil
,3742709,bioavailability,Areas under the concentration-time curve for Urd showed that the bioavailability of Urd after PO administration was 7% of that after SC administration.,Comparison of the bioavailability of uridine in mice after either oral or parenteral administration. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3742709/),%,7,63265,DB00544,Fluorouracil
,7602355,Response rates,"Response rates on lymph nodes (n = 27) were 40.7% CRs, 37.1% PRs, and 22.2% treatment failures.","Phase II trial of cisplatin, fluorouracil, and pure folinic acid for locally advanced head and neck cancer: a pharmacokinetic and clinical survey. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7602355/),%,40.7,63679,DB00544,Fluorouracil
,7602355,Response rates,"Response rates on lymph nodes (n = 27) were 40.7% CRs, 37.1% PRs, and 22.2% treatment failures.","Phase II trial of cisplatin, fluorouracil, and pure folinic acid for locally advanced head and neck cancer: a pharmacokinetic and clinical survey. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7602355/),,37,63680,DB00544,Fluorouracil
,7602355,plasma concentrations,"Pharmacokinetic analysis showed a wide interpatient variability for both FU (mean, 1.01 mumol/L; range, 0.16 to 2.09), l FA (mean, 1.89, mumol/L; range, 0.52 to 7.88) and 5MTHF plasma concentrations (mean, 3.85 mumol/L; range, 1.30 to 8.11).","Phase II trial of cisplatin, fluorouracil, and pure folinic acid for locally advanced head and neck cancer: a pharmacokinetic and clinical survey. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7602355/),[μM] / [l],3.85,63681,DB00544,Fluorouracil
,25339249,total run time,"Chromatographic separation was performed on a reverse LC column within a total run time of 6.5 min, which allowed for a relatively quick analysis.",Effects of American ginseng on pharmacokinetics of 5-fluorouracil in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25339249/),min,6.5,64021,DB00544,Fluorouracil
,17166367,encapsulating efficiency,The encapsulating efficiency was about 9.3%.,[Preparation of 5-fluorouracil encapsulated in amphiphilic polysaccharide nano-micelles and its killing effect on hepatocarcinoma cell line HepG2]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17166367/),%,9.3,64373,DB00544,Fluorouracil
,17166367,in,"The in vitro inhibition rate of cell growth was similar in 5-FU/DEX-g-PLA group and naked 5-FU group (58.8% vs. 58.0%, P>0.05); the in vivo inhibition rate of tumor growth was significantly higher in 5-FU/DEX-g-PLA group than in naked 5-FU group (73.1% vs. 57.5%, P<0.05).",[Preparation of 5-fluorouracil encapsulated in amphiphilic polysaccharide nano-micelles and its killing effect on hepatocarcinoma cell line HepG2]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17166367/),%,58.8,64374,DB00544,Fluorouracil
,17166367,in,"The in vitro inhibition rate of cell growth was similar in 5-FU/DEX-g-PLA group and naked 5-FU group (58.8% vs. 58.0%, P>0.05); the in vivo inhibition rate of tumor growth was significantly higher in 5-FU/DEX-g-PLA group than in naked 5-FU group (73.1% vs. 57.5%, P<0.05).",[Preparation of 5-fluorouracil encapsulated in amphiphilic polysaccharide nano-micelles and its killing effect on hepatocarcinoma cell line HepG2]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17166367/),%,58.0,64375,DB00544,Fluorouracil
,17166367,inhibition rate,"The in vitro inhibition rate of cell growth was similar in 5-FU/DEX-g-PLA group and naked 5-FU group (58.8% vs. 58.0%, P>0.05); the in vivo inhibition rate of tumor growth was significantly higher in 5-FU/DEX-g-PLA group than in naked 5-FU group (73.1% vs. 57.5%, P<0.05).",[Preparation of 5-fluorouracil encapsulated in amphiphilic polysaccharide nano-micelles and its killing effect on hepatocarcinoma cell line HepG2]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17166367/),%,73.1,64376,DB00544,Fluorouracil
,17166367,inhibition rate,"The in vitro inhibition rate of cell growth was similar in 5-FU/DEX-g-PLA group and naked 5-FU group (58.8% vs. 58.0%, P>0.05); the in vivo inhibition rate of tumor growth was significantly higher in 5-FU/DEX-g-PLA group than in naked 5-FU group (73.1% vs. 57.5%, P<0.05).",[Preparation of 5-fluorouracil encapsulated in amphiphilic polysaccharide nano-micelles and its killing effect on hepatocarcinoma cell line HepG2]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17166367/),%,57.5,64377,DB00544,Fluorouracil
,16825251,overall response rate,"The overall response rate was 35% [95% confidence interval (CI), 23-48%], and 52% of patients had stable disease.",A phase II Study of the global dose and schedule of capecitabine in Japanese patients with metastatic colorectal cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16825251/),%,35,65409,DB00544,Fluorouracil
,16825251,time to progression,"The median time to progression was 5.5 months (95% CI, 4.2-6.7 months).",A phase II Study of the global dose and schedule of capecitabine in Japanese patients with metastatic colorectal cancer. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16825251/),month,5.5,65410,DB00544,Fluorouracil
,16825251,overall survival,"The median overall survival was 20.2 months (95% CI, 16.6-27.8 months).",A phase II Study of the global dose and schedule of capecitabine in Japanese patients with metastatic colorectal cancer. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16825251/),month,20.2,65411,DB00544,Fluorouracil
,12174918,steady-state concentration (C(SS)),"The median steady-state concentration (C(SS)) (interquartile range, 25% to 75%) for oxaliplatin 85 mg/m2 was 0.33 microg Pt/ml (0.28 to 0.38 microg Pt/ml).",Oxaliplatin biotransformation and pharmacokinetics: a pilot study to determine the possible relationship to neurotoxicity. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12174918/),[pt·μg] / [ml],0.33,65470,DB00544,Fluorouracil
,12174918,area under the curve (AUC),The area under the curve (AUC) was 0.79 microg Pt/ml/h (0.62 to 0.88 microg Pt/ml/h) and the elimination half-life was 0.32 h (0.27 to 0.46 h).,Oxaliplatin biotransformation and pharmacokinetics: a pilot study to determine the possible relationship to neurotoxicity. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12174918/),[pt·μg] / [h·ml],0.79,65471,DB00544,Fluorouracil
,12174918,elimination half-life,The area under the curve (AUC) was 0.79 microg Pt/ml/h (0.62 to 0.88 microg Pt/ml/h) and the elimination half-life was 0.32 h (0.27 to 0.46 h).,Oxaliplatin biotransformation and pharmacokinetics: a pilot study to determine the possible relationship to neurotoxicity. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12174918/),h,0.32,65472,DB00544,Fluorouracil
,12174918,C(SS),The median C(SS) for Pt(dach)Cl2 was 0.008 microg Pt/ml (0.004 to 0.014 microg Pt/ml).,Oxaliplatin biotransformation and pharmacokinetics: a pilot study to determine the possible relationship to neurotoxicity. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12174918/),[pt·μg] / [ml],0.008,65473,DB00544,Fluorouracil
,12174918,C(SS) ratio,The C(SS) ratio of oxaliplatin to Pt(dach)Cl2 was 31 (24 to 51).,Oxaliplatin biotransformation and pharmacokinetics: a pilot study to determine the possible relationship to neurotoxicity. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12174918/),,31,65474,DB00544,Fluorouracil
,8426214,maximally tolerated dose (MTD),"After decreasing the 5-FU dose to 640 mg/m2/d, the maximally tolerated dose (MTD) of IFN was 2.0 x 10(6) U/m2/d.","Cisplatin, fluorouracil, and leucovorin augmented by interferon alfa-2b in head and neck cancer: a clinical and pharmacologic analysis. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8426214/),,2,65829,DB00544,Fluorouracil
,15217941,Tmax,"Pharmacokinetic parameters for 5FU without breakfast were as follows: Tmax, 107 min; Cmax, 1.60 microm; area under the plasma concentration-time curve (AUC) 441 microm x min; and T(1/2), 104 min.",The effect of food on the pharmacokinetics of S-1 after single oral administration to patients with solid tumors. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15217941/),min,107,65983,DB00544,Fluorouracil
,15217941,Cmax,"Pharmacokinetic parameters for 5FU without breakfast were as follows: Tmax, 107 min; Cmax, 1.60 microm; area under the plasma concentration-time curve (AUC) 441 microm x min; and T(1/2), 104 min.",The effect of food on the pharmacokinetics of S-1 after single oral administration to patients with solid tumors. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15217941/),μm,1.60,65984,DB00544,Fluorouracil
,15217941,area under the plasma concentration-time curve (AUC),"Pharmacokinetic parameters for 5FU without breakfast were as follows: Tmax, 107 min; Cmax, 1.60 microm; area under the plasma concentration-time curve (AUC) 441 microm x min; and T(1/2), 104 min.",The effect of food on the pharmacokinetics of S-1 after single oral administration to patients with solid tumors. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15217941/),min·μm,441,65985,DB00544,Fluorouracil
,15217941,T(1/2),"Pharmacokinetic parameters for 5FU without breakfast were as follows: Tmax, 107 min; Cmax, 1.60 microm; area under the plasma concentration-time curve (AUC) 441 microm x min; and T(1/2), 104 min.",The effect of food on the pharmacokinetics of S-1 after single oral administration to patients with solid tumors. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15217941/),min,104,65986,DB00544,Fluorouracil
,6498850,Maximal areas under the concentration-time curve,Maximal areas under the concentration-time curve were about 5 mmol/liter/hr.,Phase I and pharmacokinetic studies of high-dose uridine intended for rescue from 5-fluorouracil toxicity. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6498850/),[mM] / [h·l],5,66112,DB00544,Fluorouracil
,6498850,terminal half-life,Uridine plasma decay curves were biphasic with a terminal half-life of 118 min.,Phase I and pharmacokinetic studies of high-dose uridine intended for rescue from 5-fluorouracil toxicity. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6498850/),min,118,66113,DB00544,Fluorouracil
,6498850,volume of distribution,"Half-life, volume of distribution (634 ml/kg), and total clearance (4.98 ml/kg/min) appeared to be independent of dose.",Phase I and pharmacokinetic studies of high-dose uridine intended for rescue from 5-fluorouracil toxicity. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6498850/),[ml] / [kg],634,66114,DB00544,Fluorouracil
,6498850,total clearance,"Half-life, volume of distribution (634 ml/kg), and total clearance (4.98 ml/kg/min) appeared to be independent of dose.",Phase I and pharmacokinetic studies of high-dose uridine intended for rescue from 5-fluorouracil toxicity. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6498850/),[ml] / [kg·min],4.98,66115,DB00544,Fluorouracil
,6498850,half-life,The plasma uracil level declined with a half-life of about 40 min after uridine levels decreased to 300 microM.,Phase I and pharmacokinetic studies of high-dose uridine intended for rescue from 5-fluorouracil toxicity. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6498850/),min,40,66116,DB00544,Fluorouracil
,6498850,Total urinary excretion,"Total urinary excretion of uridine was 24% of the dose, while the amount of uracil recovered in urine was 3.4%.",Phase I and pharmacokinetic studies of high-dose uridine intended for rescue from 5-fluorouracil toxicity. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6498850/),%,24,66117,DB00544,Fluorouracil
,6498850,Total urinary excretion,"Total urinary excretion of uridine was 24% of the dose, while the amount of uracil recovered in urine was 3.4%.",Phase I and pharmacokinetic studies of high-dose uridine intended for rescue from 5-fluorouracil toxicity. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6498850/),%,3.4,66118,DB00544,Fluorouracil
,6498850,amount,"Total urinary excretion of uridine was 24% of the dose, while the amount of uracil recovered in urine was 3.4%.",Phase I and pharmacokinetic studies of high-dose uridine intended for rescue from 5-fluorouracil toxicity. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6498850/),%,3.4,66119,DB00544,Fluorouracil
,9616292,t1/2,"A 200 mg/kg i.p. bolus dose of 5-FU was eliminated from control tumours with a t1/2 of 25.4 +/- 2 min (mean +/- SEM, n = 11), while both thymidine (500 mg/kg) and interferon (50,000 IU/mouse) significantly increased t1/2 to 36.5 +/- 6.1 (n = 5) and 48.1 +/- 13.6 min (n = 4), respectively (P = 0.04, Gabriel's ANOVA).",A pharmacokinetic and pharmacodynamic study in vivo of human HT29 tumours using 19F and 31P magnetic resonance spectroscopy. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9616292/),min,25.4,66154,DB00544,Fluorouracil
,9616292,t1/2,"A 200 mg/kg i.p. bolus dose of 5-FU was eliminated from control tumours with a t1/2 of 25.4 +/- 2 min (mean +/- SEM, n = 11), while both thymidine (500 mg/kg) and interferon (50,000 IU/mouse) significantly increased t1/2 to 36.5 +/- 6.1 (n = 5) and 48.1 +/- 13.6 min (n = 4), respectively (P = 0.04, Gabriel's ANOVA).",A pharmacokinetic and pharmacodynamic study in vivo of human HT29 tumours using 19F and 31P magnetic resonance spectroscopy. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9616292/),min,36.5,66155,DB00544,Fluorouracil
,9616292,t1/2,"A 200 mg/kg i.p. bolus dose of 5-FU was eliminated from control tumours with a t1/2 of 25.4 +/- 2 min (mean +/- SEM, n = 11), while both thymidine (500 mg/kg) and interferon (50,000 IU/mouse) significantly increased t1/2 to 36.5 +/- 6.1 (n = 5) and 48.1 +/- 13.6 min (n = 4), respectively (P = 0.04, Gabriel's ANOVA).",A pharmacokinetic and pharmacodynamic study in vivo of human HT29 tumours using 19F and 31P magnetic resonance spectroscopy. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9616292/),min,48.1,66156,DB00544,Fluorouracil
,9616292,pHint,"31P-MRS of HT29 tumours showed that 2 and 24 h after i.p. injections of interferon there was a significant increase in the pHint of 0.3 +/- 0.04 units (P = 0.002), while pHext and the tumour NTP/Pi ratio were unchanged.",A pharmacokinetic and pharmacodynamic study in vivo of human HT29 tumours using 19F and 31P magnetic resonance spectroscopy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9616292/),units,0.3,66157,DB00544,Fluorouracil
,11108533,detection limits,"Assays in blood and plasma utilised a standard Meinhardt nebuliser and spray chamber, achieving detection limits of 0.1 microg Pt/ml in 100 and 200 microl of matrix, respectively.",Validation of a highly sensitive ICP-MS method for the determination of platinum in biofluids: application to clinical pharmacokinetic studies with oxaliplatin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11108533/),[pt·μg] / [ml],0.1,66624,DB00544,Fluorouracil
,33965731,clearance,"Regarding the pharmacokinetics profile, CPBMF-223 showed clearance of 9.42 L/h/kg after intravenous administration, oral bioavailability of 13.5%, and a half-life of 0.75 h.",Targeting thymidine phosphorylase inhibition in human colorectal cancer xenografts. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33965731/),[l] / [h·kg],9.42,66823,DB00544,Fluorouracil
,33965731,oral bioavailability,"Regarding the pharmacokinetics profile, CPBMF-223 showed clearance of 9.42 L/h/kg after intravenous administration, oral bioavailability of 13.5%, and a half-life of 0.75 h.",Targeting thymidine phosphorylase inhibition in human colorectal cancer xenografts. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33965731/),%,13.5,66824,DB00544,Fluorouracil
,33965731,half-life,"Regarding the pharmacokinetics profile, CPBMF-223 showed clearance of 9.42 L/h/kg after intravenous administration, oral bioavailability of 13.5%, and a half-life of 0.75 h.",Targeting thymidine phosphorylase inhibition in human colorectal cancer xenografts. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33965731/),h,0.75,66825,DB00544,Fluorouracil
>,18077151,cytotoxicity ratios,Cell lines with low CDD expression (<1.5) had 5'DFCR/5'DFUR cytotoxicity ratios>2 and cell lines with TP/DPD<0.6 had 5'DFUR IC50>50 microM (SRB assay).,"Gene expression predicts differential capecitabine metabolism, impacting on both pharmacokinetics and antitumour activity. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18077151/),,2,66874,DB00544,Fluorouracil
>,18077151,IC50,Cell lines with low CDD expression (<1.5) had 5'DFCR/5'DFUR cytotoxicity ratios>2 and cell lines with TP/DPD<0.6 had 5'DFUR IC50>50 microM (SRB assay).,"Gene expression predicts differential capecitabine metabolism, impacting on both pharmacokinetics and antitumour activity. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18077151/),μM,50,66875,DB00544,Fluorouracil
,17138702,oral bioavailability,The oral bioavailability of FdCyd alone was approximately 4%.,"Pharmacokinetics, metabolism, and oral bioavailability of the DNA methyltransferase inhibitor 5-fluoro-2'-deoxycytidine in mice. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17138702/),%,4,66994,DB00544,Fluorouracil
,23589214,elimination half-life,Mean elimination half-life of LBY135 ± capecitabine at saturation of clearance (≥10 mg/kg) ranged between 146 h and 492 h.,"Safety, pharmacokinetics, and pharmacodynamics of the DR5 antibody LBY135 alone and in combination with capecitabine in patients with advanced solid tumors. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/23589214/),h,146,67313,DB00544,Fluorouracil
,23589214,elimination half-life,Mean elimination half-life of LBY135 ± capecitabine at saturation of clearance (≥10 mg/kg) ranged between 146 h and 492 h.,"Safety, pharmacokinetics, and pharmacodynamics of the DR5 antibody LBY135 alone and in combination with capecitabine in patients with advanced solid tumors. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/23589214/),h,492,67314,DB00544,Fluorouracil
,23334261,response rate,"The response rate was 50 % (10 of 20 patients), and the median progression-free survival (PFS) and overall survival times were 10.5 and 21.2 months, respectively.",Phase I and pharmacokinetic study of gefitinib and S-1 combination therapy for advanced adenocarcinoma of the lung. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23334261/),%,50,67587,DB00544,Fluorouracil
,23334261,progression-free survival (PFS),"The response rate was 50 % (10 of 20 patients), and the median progression-free survival (PFS) and overall survival times were 10.5 and 21.2 months, respectively.",Phase I and pharmacokinetic study of gefitinib and S-1 combination therapy for advanced adenocarcinoma of the lung. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23334261/),month,10.5,67588,DB00544,Fluorouracil
,23334261,overall survival times,"The response rate was 50 % (10 of 20 patients), and the median progression-free survival (PFS) and overall survival times were 10.5 and 21.2 months, respectively.",Phase I and pharmacokinetic study of gefitinib and S-1 combination therapy for advanced adenocarcinoma of the lung. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23334261/),month,21.2,67589,DB00544,Fluorouracil
,23334261,PFS,"In EGFR mutation-positive patients (n = 9), seven patients achieved an objective response and the median PFS was 12.4 months, whereas none with wild-type EGFR (n = 6) responded.",Phase I and pharmacokinetic study of gefitinib and S-1 combination therapy for advanced adenocarcinoma of the lung. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23334261/),month,12.4,67590,DB00544,Fluorouracil
,19337632,time of progression,The median time of progression was 9.3 months.,Clinical and pharmacokinetics study of oxaliplatin in colon cancer patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19337632/),month,9.3,68766,DB00544,Fluorouracil
,20658719,overall response rate,"The overall response rate and the median time to progression (TTP) were 53.49% and 7.1 months, respectively.",Oxaliplatin in patients with metastatic colorectal cancer: efficacy and pharmacokinetics parameters. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20658719/),%,53.49,68798,DB00544,Fluorouracil
,20658719,time to progression (TTP),"The overall response rate and the median time to progression (TTP) were 53.49% and 7.1 months, respectively.",Oxaliplatin in patients with metastatic colorectal cancer: efficacy and pharmacokinetics parameters. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20658719/),month,7.1,68799,DB00544,Fluorouracil
,20658719,area under the time-concentration curve (AUC),The area under the time-concentration curve (AUC) in UFT was 4.8 + or - 0.72 standard deviation (SD) microg h/ml and the total clearance 30.17 + or - 7.75 l/min.,Oxaliplatin in patients with metastatic colorectal cancer: efficacy and pharmacokinetics parameters. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20658719/),[h·μg] / [ml],4.8,68800,DB00544,Fluorouracil
,20658719,total clearance,The area under the time-concentration curve (AUC) in UFT was 4.8 + or - 0.72 standard deviation (SD) microg h/ml and the total clearance 30.17 + or - 7.75 l/min.,Oxaliplatin in patients with metastatic colorectal cancer: efficacy and pharmacokinetics parameters. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20658719/),[l] / [min],30.17,68801,DB00544,Fluorouracil
,20658719,volume of distribution,"The values for volume of distribution and the maximum concentration were 567 + or - 20 liters and 0.38 + or - 0.17 ug/ml, respectively.",Oxaliplatin in patients with metastatic colorectal cancer: efficacy and pharmacokinetics parameters. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20658719/),l,567,68802,DB00544,Fluorouracil
,20658719,maximum concentration,"The values for volume of distribution and the maximum concentration were 567 + or - 20 liters and 0.38 + or - 0.17 ug/ml, respectively.",Oxaliplatin in patients with metastatic colorectal cancer: efficacy and pharmacokinetics parameters. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20658719/),[ug] / [ml],0.38,68803,DB00544,Fluorouracil
,16786333,AUC(0-8),"The AUC(0-8) of 5-FU at the 30 and 35 mg/m2 dose levels were 875 +/- 212 and 894 +/- 151 h ng/ml, respectively.",Phase I and pharmacokinetic study of S-1 administered for 14 days in a 21-day cycle in patients with advanced upper gastrointestinal cancer. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16786333/),[h·ng] / [ml],875,70220,DB00544,Fluorouracil
,16786333,AUC(0-8),"The AUC(0-8) of 5-FU at the 30 and 35 mg/m2 dose levels were 875 +/- 212 and 894 +/- 151 h ng/ml, respectively.",Phase I and pharmacokinetic study of S-1 administered for 14 days in a 21-day cycle in patients with advanced upper gastrointestinal cancer. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16786333/),[h·ng] / [ml],894,70221,DB00544,Fluorouracil
,16786333,MTD,"In a 14-day dosing schedule, the MTD of S-1 was 30 mg/m2 and preliminary evidence of antitumor activity was seen in a North American population with refractory upper gastrointestinal malignancies.",Phase I and pharmacokinetic study of S-1 administered for 14 days in a 21-day cycle in patients with advanced upper gastrointestinal cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16786333/),[mg] / [m],30,70222,DB00544,Fluorouracil
,22715973,IC(50),"Compound 45a, which possesses 1,5-disubstituted 1,2,3-triazole moiety that mimics the amide bond of tert-amide-containing inhibitor 6b locked in a cis conformation showed potent inhibitory activity, and its structure-activity relationship studies led us to the discovery of highly potent inhibitors 48c and 50c (IC(50) = ~0.029 μM).","1,2,3-Triazole-containing uracil derivatives with excellent pharmacokinetics as a novel class of potent human deoxyuridine triphosphatase inhibitors. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22715973/),μM,0.029,70303,DB00544,Fluorouracil
,22715973,EC(50),These derivatives dramatically enhanced the growth inhibition activity of 5-fluoro-2'-deoxyuridine against HeLa S3 cells in vitro (EC(50) = ~0.05 μM).,"1,2,3-Triazole-containing uracil derivatives with excellent pharmacokinetics as a novel class of potent human deoxyuridine triphosphatase inhibitors. ",EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22715973/),μM,0.05,70304,DB00544,Fluorouracil
,9703846,Total-Pt concentration,"Total-Pt concentration at 120 hr, after administration was 0.54 +/- 0.14 microgram/ml.",[Pharmacokinetic analysis of low-dose intra-peritoneal cis-platinum administration]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9703846/),[μg] / [ml],0.54,71316,DB00544,Fluorouracil
,11127938,terminal half-life (t 1/2beta),"At the various study doses, the terminal half-life (t 1/2beta) of FT ranged from 3.9 to 5.9 h, the area under the concentration-versus-time curve (AUC0-6h) ranged from 16,220 to 52,446 (ng/ml)h, the total clearance (ClT) ranged from 100 to 175 ml/min, and the steady-state volume of distribution (Vd(ss)) ranged from 18.3 to 28.7 l.",Oral uracil and Ftorafur plus leucovorin: pharmacokinetics and toxicity in patients with metastatic cancer. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11127938/),h,3.9 to 5.9,71829,DB00544,Fluorouracil
,11127938,area under the concentration-versus-time curve (AUC0-6h),"At the various study doses, the terminal half-life (t 1/2beta) of FT ranged from 3.9 to 5.9 h, the area under the concentration-versus-time curve (AUC0-6h) ranged from 16,220 to 52,446 (ng/ml)h, the total clearance (ClT) ranged from 100 to 175 ml/min, and the steady-state volume of distribution (Vd(ss)) ranged from 18.3 to 28.7 l.",Oral uracil and Ftorafur plus leucovorin: pharmacokinetics and toxicity in patients with metastatic cancer. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11127938/),[ng] / [ml)h],"16,220 to 52,446",71830,DB00544,Fluorouracil
,11127938,total clearance (ClT),"At the various study doses, the terminal half-life (t 1/2beta) of FT ranged from 3.9 to 5.9 h, the area under the concentration-versus-time curve (AUC0-6h) ranged from 16,220 to 52,446 (ng/ml)h, the total clearance (ClT) ranged from 100 to 175 ml/min, and the steady-state volume of distribution (Vd(ss)) ranged from 18.3 to 28.7 l.",Oral uracil and Ftorafur plus leucovorin: pharmacokinetics and toxicity in patients with metastatic cancer. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11127938/),[ml] / [min],100 to 175,71831,DB00544,Fluorouracil
,11127938,steady-state volume of distribution (Vd(ss)),"At the various study doses, the terminal half-life (t 1/2beta) of FT ranged from 3.9 to 5.9 h, the area under the concentration-versus-time curve (AUC0-6h) ranged from 16,220 to 52,446 (ng/ml)h, the total clearance (ClT) ranged from 100 to 175 ml/min, and the steady-state volume of distribution (Vd(ss)) ranged from 18.3 to 28.7 l.",Oral uracil and Ftorafur plus leucovorin: pharmacokinetics and toxicity in patients with metastatic cancer. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11127938/),l,18.3 to 28.7,71832,DB00544,Fluorouracil
,11127938,apparent distribution half-life (t 1/2alpha),"The 5-FU generated from FT had an apparent distribution half-life (t 1/2alpha) and an apparent elimination half-life (t 1/2beta) of 0.3-1.3 h and 4.9-7.0 h, respectively.",Oral uracil and Ftorafur plus leucovorin: pharmacokinetics and toxicity in patients with metastatic cancer. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11127938/),h,0.3-1.3,71833,DB00544,Fluorouracil
,11127938,apparent elimination half-life (t 1/2beta),"The 5-FU generated from FT had an apparent distribution half-life (t 1/2alpha) and an apparent elimination half-life (t 1/2beta) of 0.3-1.3 h and 4.9-7.0 h, respectively.",Oral uracil and Ftorafur plus leucovorin: pharmacokinetics and toxicity in patients with metastatic cancer. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11127938/),h,4.9-7.0,71834,DB00544,Fluorouracil
,11127938,AUC0-6h,The AUC0-6h of 5-FU ranged from 120 to 325 (ng/ml)h.,Oral uracil and Ftorafur plus leucovorin: pharmacokinetics and toxicity in patients with metastatic cancer. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11127938/),[ng] / [ml)h],120 to 325,71835,DB00544,Fluorouracil
,11127938,t 1/2alpha,Uracil had a t 1/2alpha of 0.2-0.5 h and the level quickly returned to the endogenous level.,Oral uracil and Ftorafur plus leucovorin: pharmacokinetics and toxicity in patients with metastatic cancer. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11127938/),h,0.2-0.5,71836,DB00544,Fluorouracil
,11127938,AUC0-6h,"The AUC0-6h for uracil ranged from 605 to 3764 (ng/ml)h, the ClT ranged from 3225 to 7748 ml/min, and the Vd(ss) ranged from 341 to 1354 l.",Oral uracil and Ftorafur plus leucovorin: pharmacokinetics and toxicity in patients with metastatic cancer. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11127938/),,605 to 3764,71837,DB00544,Fluorouracil
,11127938,ClT,"The AUC0-6h for uracil ranged from 605 to 3764 (ng/ml)h, the ClT ranged from 3225 to 7748 ml/min, and the Vd(ss) ranged from 341 to 1354 l.",Oral uracil and Ftorafur plus leucovorin: pharmacokinetics and toxicity in patients with metastatic cancer. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11127938/),[ml] / [min],3225 to 7748,71838,DB00544,Fluorouracil
,11127938,Vd(ss),"The AUC0-6h for uracil ranged from 605 to 3764 (ng/ml)h, the ClT ranged from 3225 to 7748 ml/min, and the Vd(ss) ranged from 341 to 1354 l.",Oral uracil and Ftorafur plus leucovorin: pharmacokinetics and toxicity in patients with metastatic cancer. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11127938/),l,341 to 1354,71839,DB00544,Fluorouracil
,9823426,Cmax,The Cmax was 20.03 +/- 18.25 mg/l in pancreatic fluid with a Tmax of 15.6 +/- 9.5 min following i.v. administration and 49.69 +/- 20.75 mg/l in plasma.,Penetration kinetics of 5-fluorouracil into pancreatic fluid in post-pancreatoduodenectomy patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9823426/),[mg] / [l],20.03,71969,DB00544,Fluorouracil
,9823426,Tmax,The Cmax was 20.03 +/- 18.25 mg/l in pancreatic fluid with a Tmax of 15.6 +/- 9.5 min following i.v. administration and 49.69 +/- 20.75 mg/l in plasma.,Penetration kinetics of 5-fluorouracil into pancreatic fluid in post-pancreatoduodenectomy patients. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9823426/),min,15.6,71970,DB00544,Fluorouracil
,9823426,Tmax,The Cmax was 20.03 +/- 18.25 mg/l in pancreatic fluid with a Tmax of 15.6 +/- 9.5 min following i.v. administration and 49.69 +/- 20.75 mg/l in plasma.,Penetration kinetics of 5-fluorouracil into pancreatic fluid in post-pancreatoduodenectomy patients. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9823426/),[mg] / [l],49.69,71971,DB00544,Fluorouracil
,9823426,K(m),"5-FU in plasma and pancreatic fluid were all in conformity with a non-linear model with a K(m) of 1098.08 +/- 1426.57 and 11.08 +/- 6.38 mg/l, respectively.",Penetration kinetics of 5-fluorouracil into pancreatic fluid in post-pancreatoduodenectomy patients. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9823426/),[mg] / [l],1098.08,71972,DB00544,Fluorouracil
,9823426,K(m),"5-FU in plasma and pancreatic fluid were all in conformity with a non-linear model with a K(m) of 1098.08 +/- 1426.57 and 11.08 +/- 6.38 mg/l, respectively.",Penetration kinetics of 5-fluorouracil into pancreatic fluid in post-pancreatoduodenectomy patients. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9823426/),[mg] / [l],11.08,71973,DB00544,Fluorouracil
up to,9823426,penetration index,The concentrations in pancreatic fluid were similar to that observed in plasma with an average penetration index up to 1.01 +/- 0.49.,Penetration kinetics of 5-fluorouracil into pancreatic fluid in post-pancreatoduodenectomy patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9823426/),,1.01,71974,DB00544,Fluorouracil
,32060768,area under the curve (AUC),"Starting doses of carboplatin and S-1 were area under the curve (AUC) of 4 and 80 mg/m2/day, respectively.",A phase I and extension study of S-1 and carboplatin for previously untreated patients aged 75 years or more with advanced non-small cell lung cancer -TCOG 1101. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32060768/),[mg] / [d·m2],4,72083,DB00544,Fluorouracil
,32060768,area under the curve (AUC),"Starting doses of carboplatin and S-1 were area under the curve (AUC) of 4 and 80 mg/m2/day, respectively.",A phase I and extension study of S-1 and carboplatin for previously untreated patients aged 75 years or more with advanced non-small cell lung cancer -TCOG 1101. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32060768/),[mg] / [d·m2],80,72084,DB00544,Fluorouracil
,32060768,response rate,"With carboplatin and S-1 combination therapy at the recommended dose, the response rate was 30.0% [95% confidence interval (CI) 12-54%] and the disease control rate was 90.0% (95% CI 68-99%).",A phase I and extension study of S-1 and carboplatin for previously untreated patients aged 75 years or more with advanced non-small cell lung cancer -TCOG 1101. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32060768/),%,30.0,72085,DB00544,Fluorouracil
,6873549,Plasma clearance,Plasma clearance of 5-FU after an i.v. bolus injection of 15 mg/kg was individually determined and found to vary widely among patients (from 0.39 to 2.55 l/min).,[Chemotherapy of extensive digestive cancers with 5-fluorouracil: relation between the clinical response and plasma clearance of the drug]. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6873549/),[l] / [min],0.39 to 2.55,72160,DB00544,Fluorouracil
greater,6873549,clearance,A clearance greater than or equal to 0.86 l/min was seen in all the patients who did not respond to treatment.,[Chemotherapy of extensive digestive cancers with 5-fluorouracil: relation between the clinical response and plasma clearance of the drug]. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6873549/),[l] / [min],0.86,72161,DB00544,Fluorouracil
less,6873549,clearance,All patients (except one) with a partial response or a stable disease had a clearance less than or equal to 0.72 l/min.,[Chemotherapy of extensive digestive cancers with 5-fluorouracil: relation between the clinical response and plasma clearance of the drug]. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6873549/),[l] / [min],0.72,72162,DB00544,Fluorouracil
,6873549,clearance,The mean clearance of non-responders (1.40 +/- 0.21 l/min) was significantly greater (P less than 0.02) than that of partial responders or patients with stable disease (0.73 +/- 0.15 l/min).,[Chemotherapy of extensive digestive cancers with 5-fluorouracil: relation between the clinical response and plasma clearance of the drug]. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6873549/),[l] / [min],1.40,72163,DB00544,Fluorouracil
,6873549,clearance,The mean clearance of non-responders (1.40 +/- 0.21 l/min) was significantly greater (P less than 0.02) than that of partial responders or patients with stable disease (0.73 +/- 0.15 l/min).,[Chemotherapy of extensive digestive cancers with 5-fluorouracil: relation between the clinical response and plasma clearance of the drug]. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6873549/),[l] / [min],0.73,72164,DB00544,Fluorouracil
,7574781,50% lethal dose,"In mice, the 50% lethal dose value of intraperitoneal 5-FU-MS was 535 mg/kg.",[Development of 5-fluorouracil incorporated in microspheres for peritoneal carcinomatosis--animal experiments]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7574781/),[mg] / [kg],535,73080,DB00544,Fluorouracil
,7574781,50% lethal dose,"The toxicity of 5-FU-MS was less than 1/2 that of intraperitoneal 5-FU solution, of which the 50% lethal dose value was 242 mg/kg.",[Development of 5-fluorouracil incorporated in microspheres for peritoneal carcinomatosis--animal experiments]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7574781/),[mg] / [kg],242,73081,DB00544,Fluorouracil
,7989950,extraction efficiencies,"The system functioned efficiently throughout the dose range, with extraction efficiencies ranging from 64% to 91% (P < .001).",Percutaneous hepatic vein isolation and high-dose hepatic arterial infusion chemotherapy for unresectable liver tumors. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7989950/),%,64,73203,DB00544,Fluorouracil
,7989950,extraction efficiencies,"The system functioned efficiently throughout the dose range, with extraction efficiencies ranging from 64% to 91% (P < .001).",Percutaneous hepatic vein isolation and high-dose hepatic arterial infusion chemotherapy for unresectable liver tumors. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7989950/),%,91,73204,DB00544,Fluorouracil
,21447616,objective response rate,"At the MTD, non-haematologic grade 3/4 adverse events with a frequency of >10% were diarrhoea, vomiting and lethargy, and the objective response rate was 57.9% (95% confidence interval 33.5-79.7).",A phase I study of sunitinib in combination with FOLFIRI in patients with untreated metastatic colorectal cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21447616/),%,57.,73220,DB00544,Fluorouracil
,21447616,MTD,The MTD of sunitinib combined with FOLFIRI in chemotherapy-naive mCRC was 37.5 mg/day on Schedule 4/2.,A phase I study of sunitinib in combination with FOLFIRI in patients with untreated metastatic colorectal cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21447616/),[mg] / [d],37.5,73221,DB00544,Fluorouracil
,34291722,en,"The formulated nanoparticles showed a smooth morphology with smaller particle size distribution (230-550 nm), zeta potential (-15 to -18 mV) required to achieve enhanced permeation and retention effect (EPR), entrapment efficiency (%EE 12-59%).",Pharmacokinetic variables of medium molecular weight cross linked chitosan nanoparticles to enhance the bioavailability of 5-fluorouracil and reduce the acute oral toxicity. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34291722/),%,12-59,73331,DB00544,Fluorouracil
,2296605,half-life,"The tumor pool of free 5FU in those human tumors that trapped 5FU was determined to have a half-life of 0.4-2.1 hr, much longer than expected and significantly longer than the half-life of 5FU in blood (5-15 min), whereas the half-life of trapped 5FU in the VX2 tumors ranged from 1.05 to 1.22 hr.",Tumor trapping of 5-fluorouracil: in vivo 19F NMR spectroscopic pharmacokinetics in tumor-bearing humans and rabbits. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2296605/),h,0.4-2.1,73804,DB00544,Fluorouracil
,2296605,half-life,"The tumor pool of free 5FU in those human tumors that trapped 5FU was determined to have a half-life of 0.4-2.1 hr, much longer than expected and significantly longer than the half-life of 5FU in blood (5-15 min), whereas the half-life of trapped 5FU in the VX2 tumors ranged from 1.05 to 1.22 hr.",Tumor trapping of 5-fluorouracil: in vivo 19F NMR spectroscopic pharmacokinetics in tumor-bearing humans and rabbits. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2296605/),min,5-15,73805,DB00544,Fluorouracil
,2296605,half-life,"The tumor pool of free 5FU in those human tumors that trapped 5FU was determined to have a half-life of 0.4-2.1 hr, much longer than expected and significantly longer than the half-life of 5FU in blood (5-15 min), whereas the half-life of trapped 5FU in the VX2 tumors ranged from 1.05 to 1.22 hr.",Tumor trapping of 5-fluorouracil: in vivo 19F NMR spectroscopic pharmacokinetics in tumor-bearing humans and rabbits. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2296605/),h,1.05 to 1.22,73806,DB00544,Fluorouracil
,23228985,clearance (CL),"The clearance (CL), central volume of distribution (V(1)), intercompartmental clearance (Q), and the peripheral volume of distribution (V(2)) were 214 mL/day, 2,830 mL, 636 mL/day, and 2,490 mL, which correspond to a disposition and elimination half-life of 1.33 and 19.1 days, respectively.",Characterization of the long-term pharmacokinetics of bevacizumab following last dose in patients with resected stage II and III carcinoma of the colon. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23228985/),[ml] / [d],214,74560,DB00544,Fluorouracil
,23228985,central volume of distribution (V(1)),"The clearance (CL), central volume of distribution (V(1)), intercompartmental clearance (Q), and the peripheral volume of distribution (V(2)) were 214 mL/day, 2,830 mL, 636 mL/day, and 2,490 mL, which correspond to a disposition and elimination half-life of 1.33 and 19.1 days, respectively.",Characterization of the long-term pharmacokinetics of bevacizumab following last dose in patients with resected stage II and III carcinoma of the colon. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23228985/),ml,"2,830",74561,DB00544,Fluorouracil
,23228985,central volume of distribution (V(1)),"The clearance (CL), central volume of distribution (V(1)), intercompartmental clearance (Q), and the peripheral volume of distribution (V(2)) were 214 mL/day, 2,830 mL, 636 mL/day, and 2,490 mL, which correspond to a disposition and elimination half-life of 1.33 and 19.1 days, respectively.",Characterization of the long-term pharmacokinetics of bevacizumab following last dose in patients with resected stage II and III carcinoma of the colon. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23228985/),[ml] / [d],636,74562,DB00544,Fluorouracil
,23228985,intercompartmental clearance (Q),"The clearance (CL), central volume of distribution (V(1)), intercompartmental clearance (Q), and the peripheral volume of distribution (V(2)) were 214 mL/day, 2,830 mL, 636 mL/day, and 2,490 mL, which correspond to a disposition and elimination half-life of 1.33 and 19.1 days, respectively.",Characterization of the long-term pharmacokinetics of bevacizumab following last dose in patients with resected stage II and III carcinoma of the colon. ,CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23228985/),ml,"2,830",74563,DB00544,Fluorouracil
,23228985,intercompartmental clearance (Q),"The clearance (CL), central volume of distribution (V(1)), intercompartmental clearance (Q), and the peripheral volume of distribution (V(2)) were 214 mL/day, 2,830 mL, 636 mL/day, and 2,490 mL, which correspond to a disposition and elimination half-life of 1.33 and 19.1 days, respectively.",Characterization of the long-term pharmacokinetics of bevacizumab following last dose in patients with resected stage II and III carcinoma of the colon. ,CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23228985/),[ml] / [d],636,74564,DB00544,Fluorouracil
,23228985,peripheral volume of distribution (V(2)),"The clearance (CL), central volume of distribution (V(1)), intercompartmental clearance (Q), and the peripheral volume of distribution (V(2)) were 214 mL/day, 2,830 mL, 636 mL/day, and 2,490 mL, which correspond to a disposition and elimination half-life of 1.33 and 19.1 days, respectively.",Characterization of the long-term pharmacokinetics of bevacizumab following last dose in patients with resected stage II and III carcinoma of the colon. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23228985/),ml,"2,490",74565,DB00544,Fluorouracil
,23228985,disposition,"The clearance (CL), central volume of distribution (V(1)), intercompartmental clearance (Q), and the peripheral volume of distribution (V(2)) were 214 mL/day, 2,830 mL, 636 mL/day, and 2,490 mL, which correspond to a disposition and elimination half-life of 1.33 and 19.1 days, respectively.",Characterization of the long-term pharmacokinetics of bevacizumab following last dose in patients with resected stage II and III carcinoma of the colon. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23228985/),d,1.33,74566,DB00544,Fluorouracil
,23228985,elimination half-life,"The clearance (CL), central volume of distribution (V(1)), intercompartmental clearance (Q), and the peripheral volume of distribution (V(2)) were 214 mL/day, 2,830 mL, 636 mL/day, and 2,490 mL, which correspond to a disposition and elimination half-life of 1.33 and 19.1 days, respectively.",Characterization of the long-term pharmacokinetics of bevacizumab following last dose in patients with resected stage II and III carcinoma of the colon. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/23228985/),d,19.1,74567,DB00544,Fluorouracil
,24324120,response rate,The response rate was 42.1%.,Phase I pharmacokinetic study of S-1 granules and nedaplatin for advanced head and neck cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24324120/),%,42.1,74787,DB00544,Fluorouracil
>,18492358,extraction recoveries,"The extraction recoveries of 5FU and p-aminobenzoic acid (as an internal standard) are > 91.28% and 81.98%, respectively.",Determination of 5-fluorouracil in serum microsamples by a high-performance liquid chromatographic method and its application to pharmacokinetic studies in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18492358/),%,91.28,74891,DB00544,Fluorouracil
,18492358,extraction recoveries,"The extraction recoveries of 5FU and p-aminobenzoic acid (as an internal standard) are > 91.28% and 81.98%, respectively.",Determination of 5-fluorouracil in serum microsamples by a high-performance liquid chromatographic method and its application to pharmacokinetic studies in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18492358/),%,81.98,74892,DB00544,Fluorouracil
,18155370,entrapment efficiency,"The drug entrapment efficiency and loading were (88.87 +/- 3.25%) and (8.89 +/- 0.19%), respectively.",Preparation and evaluation of N(3)-O-toluyl-fluorouracil-loaded liposomes. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18155370/),%,88.87,76492,DB00544,Fluorouracil
,18155370,loading,"The drug entrapment efficiency and loading were (88.87 +/- 3.25%) and (8.89 +/- 0.19%), respectively.",Preparation and evaluation of N(3)-O-toluyl-fluorouracil-loaded liposomes. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18155370/),%,8.89,76493,DB00544,Fluorouracil
,18187954,occurrence probabilities,"Based on CRM calculation, mean DLT occurrence probabilities (90% confidence intervals in parentheses) for levels 2, 3 and 4 were 21% (8-42%), 35% (17-56%) and 56% (38-71%), respectively.",Dose-finding phase I and pharmacokinetic study of capecitabine (Xeloda) in combination with epirubicin and cyclophosphamide (CEX) in patients with inoperable or metastatic breast cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18187954/),%,21,77038,DB00544,Fluorouracil
,18187954,occurrence probabilities,"Based on CRM calculation, mean DLT occurrence probabilities (90% confidence intervals in parentheses) for levels 2, 3 and 4 were 21% (8-42%), 35% (17-56%) and 56% (38-71%), respectively.",Dose-finding phase I and pharmacokinetic study of capecitabine (Xeloda) in combination with epirubicin and cyclophosphamide (CEX) in patients with inoperable or metastatic breast cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18187954/),%,35,77039,DB00544,Fluorouracil
,18187954,occurrence probabilities,"Based on CRM calculation, mean DLT occurrence probabilities (90% confidence intervals in parentheses) for levels 2, 3 and 4 were 21% (8-42%), 35% (17-56%) and 56% (38-71%), respectively.",Dose-finding phase I and pharmacokinetic study of capecitabine (Xeloda) in combination with epirubicin and cyclophosphamide (CEX) in patients with inoperable or metastatic breast cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18187954/),%,56,77040,DB00544,Fluorouracil
,2230897,peak plasma 5-FU concentrations,"Mean peak plasma 5-FU concentrations ranged from 6.19 mumol/L to greater than 60 mumol/L, and peritoneal fluid to plasma 5-FU area under the curve (AUC) ratios ranged from 85 to 1,150.",Phase I clinical and pharmacologic study of intraperitoneal cisplatin and fluorouracil in patients with advanced intraabdominal cancer. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2230897/),[μM] / [l],6.19,77087,DB00544,Fluorouracil
greater,2230897,peak plasma 5-FU concentrations,"Mean peak plasma 5-FU concentrations ranged from 6.19 mumol/L to greater than 60 mumol/L, and peritoneal fluid to plasma 5-FU area under the curve (AUC) ratios ranged from 85 to 1,150.",Phase I clinical and pharmacologic study of intraperitoneal cisplatin and fluorouracil in patients with advanced intraabdominal cancer. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2230897/),[μM] / [l],60,77088,DB00544,Fluorouracil
,2230897,area under the curve (AUC) ratios,"Mean peak plasma 5-FU concentrations ranged from 6.19 mumol/L to greater than 60 mumol/L, and peritoneal fluid to plasma 5-FU area under the curve (AUC) ratios ranged from 85 to 1,150.",Phase I clinical and pharmacologic study of intraperitoneal cisplatin and fluorouracil in patients with advanced intraabdominal cancer. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2230897/),,85,77089,DB00544,Fluorouracil
,2230897,area under the curve (AUC) ratios,"Mean peak plasma 5-FU concentrations ranged from 6.19 mumol/L to greater than 60 mumol/L, and peritoneal fluid to plasma 5-FU area under the curve (AUC) ratios ranged from 85 to 1,150.",Phase I clinical and pharmacologic study of intraperitoneal cisplatin and fluorouracil in patients with advanced intraabdominal cancer. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2230897/),,"1,150",77090,DB00544,Fluorouracil
,8612313,Cmax,"Plasma levels of 5-FU (Cmax 1.4 +/- 1.9 microM) were comparable to those achieved with protracted venous infusions, and folate levels (Cmax 6.1 +/- 3.6 microM) were sufficient for biochemical modulation.","A phase I and pharmacokinetic study of oral uracil, ftorafur, and leucovorin in patients with advanced cancer. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8612313/),μM,1.4,77168,DB00544,Fluorouracil
,8612313,Cmax,"Plasma levels of 5-FU (Cmax 1.4 +/- 1.9 microM) were comparable to those achieved with protracted venous infusions, and folate levels (Cmax 6.1 +/- 3.6 microM) were sufficient for biochemical modulation.","A phase I and pharmacokinetic study of oral uracil, ftorafur, and leucovorin in patients with advanced cancer. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8612313/),μM,6.1,77169,DB00544,Fluorouracil
,15244247,elimination half-life,"The plasma level declined rapidly in a monophasic manner with an elimination half-life of 2.1 and 2.5 h for dose level 1 and 2, respectively The mean area under the curve (AUC(o - infinity) area under the curve to 24 h; AUC(o - infinity), area under the curve to infinity) doubled at the higher dose level.",A phase I safety and pharmacokinetic study of OGT 719 in patients with liver cancer. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15244247/),h,2.1,77482,DB00544,Fluorouracil
,15244247,elimination half-life,"The plasma level declined rapidly in a monophasic manner with an elimination half-life of 2.1 and 2.5 h for dose level 1 and 2, respectively The mean area under the curve (AUC(o - infinity) area under the curve to 24 h; AUC(o - infinity), area under the curve to infinity) doubled at the higher dose level.",A phase I safety and pharmacokinetic study of OGT 719 in patients with liver cancer. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15244247/),h,2.5,77483,DB00544,Fluorouracil
,25503423,C ss,"In Group 2 (N = 20), the patients were given dosing kinetically guided in order to reach the target range of 5-FU C ss 50-100 µg/L.",Kinetically guided neoadjuvant chemoradiotherapy based on 5-Fluorouracil in patients with locally advanced rectal cancer. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25503423/),[μg] / [l],50-100,77826,DB00544,Fluorouracil
,25503423,metabolic ratio,The individual daily dose needed to reach the target C ss should be >350 mg/m(2) (up to 600 mg/m(2)) provided that 5-FU metabolic ratio is within the range of 2.5-6 and the cumulative AUC5wks is within 50-100 mg·h/L.,Kinetically guided neoadjuvant chemoradiotherapy based on 5-Fluorouracil in patients with locally advanced rectal cancer. ,Metabolic ratio-Q4,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25503423/),,2.5-6,77827,DB00544,Fluorouracil
,25503423,cumulative AUC5wks,The individual daily dose needed to reach the target C ss should be >350 mg/m(2) (up to 600 mg/m(2)) provided that 5-FU metabolic ratio is within the range of 2.5-6 and the cumulative AUC5wks is within 50-100 mg·h/L.,Kinetically guided neoadjuvant chemoradiotherapy based on 5-Fluorouracil in patients with locally advanced rectal cancer. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25503423/),[h·mg] / [l],50-100,77828,DB00544,Fluorouracil
,16306860,plasma clearance,"The slope of the monoexponential decay of plasma concentration was significantly greater 1 hour (0.161 minutes) than 49 hours after dialysis (0.127 minutes), and plasma clearance was correspondingly higher (1.78 L/min versus 1.46 L/min).",Effect of hemodialysis on the metabolic clearance of 5-Fluorouracil in a patient with end-stage renal failure. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16306860/),[l] / [min],1.78,78105,DB00544,Fluorouracil
,16306860,plasma clearance,"The slope of the monoexponential decay of plasma concentration was significantly greater 1 hour (0.161 minutes) than 49 hours after dialysis (0.127 minutes), and plasma clearance was correspondingly higher (1.78 L/min versus 1.46 L/min).",Effect of hemodialysis on the metabolic clearance of 5-Fluorouracil in a patient with end-stage renal failure. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16306860/),[l] / [min],1.46,78106,DB00544,Fluorouracil
,16306860,volume of distribution,The volume of distribution did not change (11.1 L versus 11.5 L).,Effect of hemodialysis on the metabolic clearance of 5-Fluorouracil in a patient with end-stage renal failure. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16306860/),l,11.1,78107,DB00544,Fluorouracil
,16306860,volume of distribution,The volume of distribution did not change (11.1 L versus 11.5 L).,Effect of hemodialysis on the metabolic clearance of 5-Fluorouracil in a patient with end-stage renal failure. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16306860/),l,11.5,78108,DB00544,Fluorouracil
,31252010,permeability,"Among the directly compressed liquisolid tabs, LTP-10 exhibited highest CDR of 98.70 ± 2.68% and permeability of 61.59%.","Liquisolid system of paclitaxel using modified polysaccharides: In vitro cytotoxicity, apoptosis study, cell cycle analysis, in vitro mitochondrial membrane potential assessment, and pharmacokinetics. ",Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31252010/),%,61.59,78156,DB00544,Fluorouracil
<,31252010,IC50,The IC50 of <20 mmol/L indicated remarkable cytotoxic potential on human gastro-enteric tumor cancerous cell lines (NCI-N87).,"Liquisolid system of paclitaxel using modified polysaccharides: In vitro cytotoxicity, apoptosis study, cell cycle analysis, in vitro mitochondrial membrane potential assessment, and pharmacokinetics. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31252010/),[mM] / [l],20,78157,DB00544,Fluorouracil
,31252010,Cmax,Pharmacokinetics revealed Cmax of 536.48 ± 4.63 μg/L at 1.64 ± 0.44 h for LTP-10 indicating enhancement in bioavailability (5.43 fold) of paclitaxel on oral administration.,"Liquisolid system of paclitaxel using modified polysaccharides: In vitro cytotoxicity, apoptosis study, cell cycle analysis, in vitro mitochondrial membrane potential assessment, and pharmacokinetics. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31252010/),[μg] / [l],536.48,78158,DB00544,Fluorouracil
,30592773,molar ratio,The molar ratio tended to increase within 1.5 h (1.85 ± 0.76 at 1.5 h after administration of capecitabine) and gradually recovered to its initial level (1.00 ± 0.46).,Association between the pharmacokinetics of capecitabine and the plasma dihydrouracil to uracil ratio in rat: A surrogate biomarker for dihydropyrimidine dehydrogenase activity. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30592773/),,1.85,78391,DB00544,Fluorouracil
,30592773,molar ratio,The molar ratio tended to increase within 1.5 h (1.85 ± 0.76 at 1.5 h after administration of capecitabine) and gradually recovered to its initial level (1.00 ± 0.46).,Association between the pharmacokinetics of capecitabine and the plasma dihydrouracil to uracil ratio in rat: A surrogate biomarker for dihydropyrimidine dehydrogenase activity. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30592773/),,1.00,78392,DB00544,Fluorouracil
,8731782,constant rate,The implant released the drug at a constant rate of 1.20 micrograms/hr for over 18 days and totally biodegraded in less than 86 days.,[Biodegradable controlled-release 5-FU implant in the surgery for glaucoma. Experimental study]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8731782/),[μg] / [h],1.20,78444,DB00544,Fluorouracil
,9448112,portal blood flow rate,"The portal blood flow rate, measured using a compact electromagnetic flow-meter, was estimated to be 15.3 +/- 2.2 ml/min per body weight (250g).",Simultaneous evaluation of intestinal absorption and hepatic extraction of 5-fluorouracil using portal-systemic concentration difference by short-period double dosing in a single conscious rat. ,Q-Q54,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9448112/),[ml] / [·min],15.3,78588,DB00544,Fluorouracil
,9448112,local absorption ratio (Fa),"The local absorption ratio (Fa) and the absolute bioavailability (F) were 71.2 +/- 15.4 and 25.1 +/- 13.2%, respectively.",Simultaneous evaluation of intestinal absorption and hepatic extraction of 5-fluorouracil using portal-systemic concentration difference by short-period double dosing in a single conscious rat. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9448112/),%,71.2,78589,DB00544,Fluorouracil
,9448112,absolute bioavailability (F),"The local absorption ratio (Fa) and the absolute bioavailability (F) were 71.2 +/- 15.4 and 25.1 +/- 13.2%, respectively.",Simultaneous evaluation of intestinal absorption and hepatic extraction of 5-fluorouracil using portal-systemic concentration difference by short-period double dosing in a single conscious rat. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9448112/),%,25.1,78590,DB00544,Fluorouracil
,9448112,hepatic extraction ratio (F[H],"Consequently, the hepatic extraction ratio (F[H] = F/Fa) was estimated to be 34.9 +/- 14.4%.",Simultaneous evaluation of intestinal absorption and hepatic extraction of 5-fluorouracil using portal-systemic concentration difference by short-period double dosing in a single conscious rat. ,EH-Q39,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9448112/),%,34.9,78591,DB00544,Fluorouracil
,9448112,local absorption time (t[a]),"The mean local absorption time (t[a]) and the mean absorption time (MAT) were 37.5 +/- 15.5 and 31.4 +/- 13.7 min, respectively and they were statistically the same.",Simultaneous evaluation of intestinal absorption and hepatic extraction of 5-fluorouracil using portal-systemic concentration difference by short-period double dosing in a single conscious rat. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9448112/),min,37.5,78592,DB00544,Fluorouracil
,9448112,mean absorption time (MAT),"The mean local absorption time (t[a]) and the mean absorption time (MAT) were 37.5 +/- 15.5 and 31.4 +/- 13.7 min, respectively and they were statistically the same.",Simultaneous evaluation of intestinal absorption and hepatic extraction of 5-fluorouracil using portal-systemic concentration difference by short-period double dosing in a single conscious rat. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9448112/),min,31.4,78593,DB00544,Fluorouracil
,17453364,time to progression,"At median follow-up of 113 months, the median time to progression and median overall survival were 14 and 36 months, respectively.","Individually tailored toxicity-based 5-fluorouracil, epirubicin and cyclophosphamide (FEC) therapy of metastatic breast cancer. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17453364/),month,14,78618,DB00544,Fluorouracil
,17453364,overall survival,"At median follow-up of 113 months, the median time to progression and median overall survival were 14 and 36 months, respectively.","Individually tailored toxicity-based 5-fluorouracil, epirubicin and cyclophosphamide (FEC) therapy of metastatic breast cancer. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17453364/),month,36,78619,DB00544,Fluorouracil
,19769532,entrapment efficiency,"The average drug entrapment efficiency and loading were 74% and 10%, respectively.",Preparation and passive target of 5-fluorouracil solid lipid nanoparticles. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19769532/),%,74,78720,DB00544,Fluorouracil
,19769532,loading,"The average drug entrapment efficiency and loading were 74% and 10%, respectively.",Preparation and passive target of 5-fluorouracil solid lipid nanoparticles. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19769532/),%,10,78721,DB00544,Fluorouracil
,19769532,t(1/2beta),"Compared with the 5-FU solution (t(1/2beta), 0.593h; MRT, 0.358h) after intravenous injection to rats, the pharmacokinetic parameters of 5-FU-SLNs exhibited a longer retention time.",Preparation and passive target of 5-fluorouracil solid lipid nanoparticles. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19769532/),h,0.593,78722,DB00544,Fluorouracil
,19769532,MRT,"Compared with the 5-FU solution (t(1/2beta), 0.593h; MRT, 0.358h) after intravenous injection to rats, the pharmacokinetic parameters of 5-FU-SLNs exhibited a longer retention time.",Preparation and passive target of 5-fluorouracil solid lipid nanoparticles. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19769532/),h,0.358,78723,DB00544,Fluorouracil
,19769532,t(1/2beta),"(t(1/2beta), 4.0628h; MRT, 3.5321h).",Preparation and passive target of 5-fluorouracil solid lipid nanoparticles. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/19769532/),h,4.0628,78724,DB00544,Fluorouracil
,19769532,MRT,"(t(1/2beta), 4.0628h; MRT, 3.5321h).",Preparation and passive target of 5-fluorouracil solid lipid nanoparticles. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19769532/),h,3.5321,78725,DB00544,Fluorouracil
,10550565,t(max),There was no clinically significant difference between the t(max) for the two formulations (median 2.1 versus 2.0 h).,"Bioequivalence of two tablet formulations of capecitabine and exploration of age, gender, body surface area, and creatinine clearance as factors influencing systemic exposure in cancer patients. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10550565/),h,2.1,80078,DB00544,Fluorouracil
,10550565,t(max),There was no clinically significant difference between the t(max) for the two formulations (median 2.1 versus 2.0 h).,"Bioequivalence of two tablet formulations of capecitabine and exploration of age, gender, body surface area, and creatinine clearance as factors influencing systemic exposure in cancer patients. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10550565/),h,2.0,80079,DB00544,Fluorouracil
,10550565,overall urinary excretions,"The overall urinary excretions were 86.0% and 86.5% of the dose, respectively, and the proportion recovered as each metabolite was similar for the two formulations.","Bioequivalence of two tablet formulations of capecitabine and exploration of age, gender, body surface area, and creatinine clearance as factors influencing systemic exposure in cancer patients. ",fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10550565/),,86,80080,DB00544,Fluorouracil
,7987979,plasma concentrations,"Mean plasma concentrations of 5FU and FBAL increased significantly from the 1st day (0.42 and 1.19 micrograms/ml for 5FU and FBAL, respectively) to the 4th day of 5FU infusion (0.67 and 1.78 micrograms/ml for 5FU and FBAL, respectively).",Plasma 5-fluorouracil and alpha-fluoro-beta-alanin accumulation in lung cancer patients treated with continuous infusion of cisplatin and 5-fluorouracil. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7987979/),[μg] / [ml],0.42,80091,DB00544,Fluorouracil
,7987979,plasma concentrations,"Mean plasma concentrations of 5FU and FBAL increased significantly from the 1st day (0.42 and 1.19 micrograms/ml for 5FU and FBAL, respectively) to the 4th day of 5FU infusion (0.67 and 1.78 micrograms/ml for 5FU and FBAL, respectively).",Plasma 5-fluorouracil and alpha-fluoro-beta-alanin accumulation in lung cancer patients treated with continuous infusion of cisplatin and 5-fluorouracil. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7987979/),[μg] / [ml],1.19,80092,DB00544,Fluorouracil
,7987979,plasma concentrations,"Mean plasma concentrations of 5FU and FBAL increased significantly from the 1st day (0.42 and 1.19 micrograms/ml for 5FU and FBAL, respectively) to the 4th day of 5FU infusion (0.67 and 1.78 micrograms/ml for 5FU and FBAL, respectively).",Plasma 5-fluorouracil and alpha-fluoro-beta-alanin accumulation in lung cancer patients treated with continuous infusion of cisplatin and 5-fluorouracil. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7987979/),[μg] / [ml],0.67,80093,DB00544,Fluorouracil
,7987979,plasma concentrations,"Mean plasma concentrations of 5FU and FBAL increased significantly from the 1st day (0.42 and 1.19 micrograms/ml for 5FU and FBAL, respectively) to the 4th day of 5FU infusion (0.67 and 1.78 micrograms/ml for 5FU and FBAL, respectively).",Plasma 5-fluorouracil and alpha-fluoro-beta-alanin accumulation in lung cancer patients treated with continuous infusion of cisplatin and 5-fluorouracil. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7987979/),[μg] / [ml],1.78,80094,DB00544,Fluorouracil
,8248211,oral bioavailability,5-FU oral bioavailability was approximately 100% in rats pretreated with 5-EU.,5-Ethynyluracil (776C85): a potent modulator of the pharmacokinetics and antitumor efficacy of 5-fluorouracil. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8248211/),%,100,80139,DB00544,Fluorouracil
,22648745,MTD,"The MTD of capecitabine was 4,500 mg.",Phase I pharmacokinetic study of chronomodulated dose-intensified combination of capecitabine and oxaliplatin (XELOX) in metastatic colorectal cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22648745/),mg,"4,500",80187,DB00544,Fluorouracil
,22648745,objective response rate,"The objective response rate was 33.3 %, and median overall survival was 16.3 months (95 % CI: 11.2-18.2 months).",Phase I pharmacokinetic study of chronomodulated dose-intensified combination of capecitabine and oxaliplatin (XELOX) in metastatic colorectal cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22648745/),%,33.3,80188,DB00544,Fluorouracil
,22648745,overall survival,"The objective response rate was 33.3 %, and median overall survival was 16.3 months (95 % CI: 11.2-18.2 months).",Phase I pharmacokinetic study of chronomodulated dose-intensified combination of capecitabine and oxaliplatin (XELOX) in metastatic colorectal cancer. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22648745/),month,16.3,80189,DB00544,Fluorouracil
,2204007,F,Mean F was 0.85 +/- 0.22 (85% +/- 22%); in 1 patient F was 0.43 (43%).,Bioavailability of cyclophosphamide in the CMF regimen. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2204007/),,0.85,80611,DB00544,Fluorouracil
,2204007,F,Mean F was 0.85 +/- 0.22 (85% +/- 22%); in 1 patient F was 0.43 (43%).,Bioavailability of cyclophosphamide in the CMF regimen. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2204007/),,0.43,80612,DB00544,Fluorouracil
,2204007,F,"Furthermore, 3 patients treated with only p.o. CY had low estimated F values: 0.45, 0.49 and 0.50.",Bioavailability of cyclophosphamide in the CMF regimen. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2204007/),,0.45,80613,DB00544,Fluorouracil
,2204007,F,"Furthermore, 3 patients treated with only p.o. CY had low estimated F values: 0.45, 0.49 and 0.50.",Bioavailability of cyclophosphamide in the CMF regimen. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2204007/),,0.49,80614,DB00544,Fluorouracil
,2204007,F,"Furthermore, 3 patients treated with only p.o. CY had low estimated F values: 0.45, 0.49 and 0.50.",Bioavailability of cyclophosphamide in the CMF regimen. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2204007/),,0.50,80615,DB00544,Fluorouracil
,10228497,AUC,"The distribution of doxifluridine parameters remained the same between days 1 and 5, with an AUC that ranged between 72.2 and 74.5 mmol h/l and a C max that remained in a narrow band of 67.1 to 68.3 mmol/l.",Pharmacokinetics of oral doxifluridine in patients with colorectal cancer. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10228497/),[h·mM] / [l],72.2 and 74.5,80790,DB00544,Fluorouracil
,10228497,C max,"The distribution of doxifluridine parameters remained the same between days 1 and 5, with an AUC that ranged between 72.2 and 74.5 mmol h/l and a C max that remained in a narrow band of 67.1 to 68.3 mmol/l.",Pharmacokinetics of oral doxifluridine in patients with colorectal cancer. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10228497/),[mM] / [l],67.1 to 68.3,80791,DB00544,Fluorouracil
,10228497,AUC,"In contrast, the variability of fluorouracil parameters increased from day 1 to day 5, with an AUC of respectively 5.46 and 7.52 mmol h/l and a C max that increased from 5.81 on day 1 to 7.34 mmol/l on day 5.",Pharmacokinetics of oral doxifluridine in patients with colorectal cancer. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10228497/),[h·mM] / [l],5.46,80792,DB00544,Fluorouracil
,10228497,AUC,"In contrast, the variability of fluorouracil parameters increased from day 1 to day 5, with an AUC of respectively 5.46 and 7.52 mmol h/l and a C max that increased from 5.81 on day 1 to 7.34 mmol/l on day 5.",Pharmacokinetics of oral doxifluridine in patients with colorectal cancer. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10228497/),[h·mM] / [l],7.52,80793,DB00544,Fluorouracil
,10228497,C max,"In contrast, the variability of fluorouracil parameters increased from day 1 to day 5, with an AUC of respectively 5.46 and 7.52 mmol h/l and a C max that increased from 5.81 on day 1 to 7.34 mmol/l on day 5.",Pharmacokinetics of oral doxifluridine in patients with colorectal cancer. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10228497/),[mM] / [l],5.81,80794,DB00544,Fluorouracil
,10228497,C max,"In contrast, the variability of fluorouracil parameters increased from day 1 to day 5, with an AUC of respectively 5.46 and 7.52 mmol h/l and a C max that increased from 5.81 on day 1 to 7.34 mmol/l on day 5.",Pharmacokinetics of oral doxifluridine in patients with colorectal cancer. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10228497/),[mM] / [l],7.34,80795,DB00544,Fluorouracil
,17907289,response rate,"One patient showed complete response (CR) with disappearance of HCC and PVTT after treatment, and the two patients showed partial response (PR), response rate (CR + PR/All cases 30%).","Improved survival for hepatocellular carcinoma with portal vein tumor thrombosis treated by intra-arterial chemotherapy combining etoposide, carboplatin, epirubicin and pharmacokinetic modulating chemotherapy by 5-FU and enteric-coated tegafur/uracil: a pilot study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17907289/),%,30,81438,DB00544,Fluorouracil
,17907289,survival time,The median survival time after the therapy was 457.2 d.,"Improved survival for hepatocellular carcinoma with portal vein tumor thrombosis treated by intra-arterial chemotherapy combining etoposide, carboplatin, epirubicin and pharmacokinetic modulating chemotherapy by 5-FU and enteric-coated tegafur/uracil: a pilot study. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17907289/),d,457.2,81439,DB00544,Fluorouracil
,15553701,response rate,"The response rate was 50% (1 CR, 1 PR, and 2 SD).",[The 5-fluorouracil hepato-arterial infusion with oral UFT therapy for the hepatic and extra hepatic metastases of colorectal cancer]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15553701/),%,50,81447,DB00544,Fluorouracil
,11935216,steady-state plasma concentrations,"Both before and after the addition of OXA, the 5-FU dose was individually adjusted according to the pharmacokinetic follow-up (target steady-state plasma concentrations 2.5-3 mg/l).",Influence of oxaliplatin on 5-fluorouracil plasma clearance and clinical consequences. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11935216/),[mg] / [l],2.5-3,81636,DB00544,Fluorouracil
,11935216,plasma clearance,"5-FU plasma clearance was significantly decreased on days 8 and 15 when compared with the value on day 1 and with the values before OXA introduction using a direct paired comparison (2.36 and 2.31 l/min, respectively, vs 3.12 and 3.05 l/min; P<10(-5)).",Influence of oxaliplatin on 5-fluorouracil plasma clearance and clinical consequences. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11935216/),[l] / [min],2.36,81637,DB00544,Fluorouracil
,11935216,plasma clearance,"5-FU plasma clearance was significantly decreased on days 8 and 15 when compared with the value on day 1 and with the values before OXA introduction using a direct paired comparison (2.36 and 2.31 l/min, respectively, vs 3.12 and 3.05 l/min; P<10(-5)).",Influence of oxaliplatin on 5-fluorouracil plasma clearance and clinical consequences. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11935216/),[l] / [min],2.31,81638,DB00544,Fluorouracil
,11935216,plasma clearance,"5-FU plasma clearance was significantly decreased on days 8 and 15 when compared with the value on day 1 and with the values before OXA introduction using a direct paired comparison (2.36 and 2.31 l/min, respectively, vs 3.12 and 3.05 l/min; P<10(-5)).",Influence of oxaliplatin on 5-fluorouracil plasma clearance and clinical consequences. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11935216/),[l] / [min],3.12,81639,DB00544,Fluorouracil
,11935216,plasma clearance,"5-FU plasma clearance was significantly decreased on days 8 and 15 when compared with the value on day 1 and with the values before OXA introduction using a direct paired comparison (2.36 and 2.31 l/min, respectively, vs 3.12 and 3.05 l/min; P<10(-5)).",Influence of oxaliplatin on 5-fluorouracil plasma clearance and clinical consequences. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11935216/),[l] / [min],3.05,81640,DB00544,Fluorouracil
,11896120,steady-state plasma concentration (C(P)),"The mean +/- SD steady-state plasma concentration (C(P)) and area under the curve (AUC)(144-168h) for CVI 5-FU (104 +/- 45 ng/mL and 2,350 +/- 826 ng x h/mL, respectively) were three-fold greater than those for oral 5-FU (38.1 +/- 7.7 ng/mL and 722 +/- 182 ng x h/mL, respectively [P <.00001]).",Comparative pharmacokinetic study of continuous venous infusion fluorouracil and oral fluorouracil with eniluracil in patients with advanced solid tumors. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11896120/),[ng] / [ml],104,82231,DB00544,Fluorouracil
,11896120,steady-state plasma concentration (C(P)),"The mean +/- SD steady-state plasma concentration (C(P)) and area under the curve (AUC)(144-168h) for CVI 5-FU (104 +/- 45 ng/mL and 2,350 +/- 826 ng x h/mL, respectively) were three-fold greater than those for oral 5-FU (38.1 +/- 7.7 ng/mL and 722 +/- 182 ng x h/mL, respectively [P <.00001]).",Comparative pharmacokinetic study of continuous venous infusion fluorouracil and oral fluorouracil with eniluracil in patients with advanced solid tumors. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11896120/),[ng] / [ml],38.1,82232,DB00544,Fluorouracil
,11896120,area under the curve (AUC)(144-168h),"The mean +/- SD steady-state plasma concentration (C(P)) and area under the curve (AUC)(144-168h) for CVI 5-FU (104 +/- 45 ng/mL and 2,350 +/- 826 ng x h/mL, respectively) were three-fold greater than those for oral 5-FU (38.1 +/- 7.7 ng/mL and 722 +/- 182 ng x h/mL, respectively [P <.00001]).",Comparative pharmacokinetic study of continuous venous infusion fluorouracil and oral fluorouracil with eniluracil in patients with advanced solid tumors. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11896120/),[h·ng] / [ml],"2,350",82233,DB00544,Fluorouracil
,11896120,area under the curve (AUC)(144-168h),"The mean +/- SD steady-state plasma concentration (C(P)) and area under the curve (AUC)(144-168h) for CVI 5-FU (104 +/- 45 ng/mL and 2,350 +/- 826 ng x h/mL, respectively) were three-fold greater than those for oral 5-FU (38.1 +/- 7.7 ng/mL and 722 +/- 182 ng x h/mL, respectively [P <.00001]).",Comparative pharmacokinetic study of continuous venous infusion fluorouracil and oral fluorouracil with eniluracil in patients with advanced solid tumors. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11896120/),[h·ng] / [ml],722,82234,DB00544,Fluorouracil
,2390689,"""half times""","Following intravenous administration, 5 FU decayed with ""half times"" ranging from 5 to 17 min.",Comparison of 5-fluorouracil pharmacokinetics following intraperitoneal and intravenous administration using in vivo 19F magnetic resonance spectroscopy. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2390689/),min,5 to 17,82640,DB00544,Fluorouracil
,16719540,area under the plasma concentration-time curve (AUC),"While an increased risk of leukopenia, diarrhoea, stomatitis, and hand-foot syndrome during continuous 5-day infusions was related to fluorouracil exposures above an area under the plasma concentration-time curve (AUC) threshold of 25-30 mg.h/L, tumour response was higher when an AUC of approximately 30 mg.h/L was achieved, illustrating the extremely narrow therapeutic window of fluorouracil.",How may anticancer chemotherapy with fluorouracil be individualised? ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16719540/),[h·mg] / [l],25-30,83111,DB00544,Fluorouracil
,16719540,AUC,"While an increased risk of leukopenia, diarrhoea, stomatitis, and hand-foot syndrome during continuous 5-day infusions was related to fluorouracil exposures above an area under the plasma concentration-time curve (AUC) threshold of 25-30 mg.h/L, tumour response was higher when an AUC of approximately 30 mg.h/L was achieved, illustrating the extremely narrow therapeutic window of fluorouracil.",How may anticancer chemotherapy with fluorouracil be individualised? ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16719540/),[h·mg] / [l],30,83112,DB00544,Fluorouracil
,7799022,recovery time,"Dose-dependent, reversible, noncumulative granulocytopenia was the dose-limiting toxicity (nadir, days 6 to 9; median recovery time, 5 days).",Phase I and pharmacologic studies of the camptothecin analog irinotecan administered every 3 weeks in cancer patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7799022/),d,5,83116,DB00544,Fluorouracil
,7799022,terminal half-life,"CPT-11 plasma disposition was bi- or triphasic, with a mean terminal half-life of 14.2 +/- 0.9 hours (mean +/- SEM).",Phase I and pharmacologic studies of the camptothecin analog irinotecan administered every 3 weeks in cancer patients. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7799022/),h,14.2,83117,DB00544,Fluorouracil
,7799022,volume of distribution (Vdss),"The mean volume of distribution (Vdss) was 157 +/- 8 L/m2, and total-body clearance was 15 +/- 1 L/m2/h.",Phase I and pharmacologic studies of the camptothecin analog irinotecan administered every 3 weeks in cancer patients. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7799022/),[l] / [m2],157,83118,DB00544,Fluorouracil
,7799022,total-body clearance,"The mean volume of distribution (Vdss) was 157 +/- 8 L/m2, and total-body clearance was 15 +/- 1 L/m2/h.",Phase I and pharmacologic studies of the camptothecin analog irinotecan administered every 3 weeks in cancer patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7799022/),[l] / [h·m2],15,83119,DB00544,Fluorouracil
,7799022,apparent half-life,SN-38 plasma decay had an apparent half-life of 13.8 +/- 1.4 hours.,Phase I and pharmacologic studies of the camptothecin analog irinotecan administered every 3 weeks in cancer patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7799022/),h,13.8,83120,DB00544,Fluorouracil
,7799022,MTD,"The MTD of CPT-11 administered as a 30-minute IV infusion every 3 weeks is 600 mg/m2, with granulocytopenia being dose-limiting.",Phase I and pharmacologic studies of the camptothecin analog irinotecan administered every 3 weeks in cancer patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7799022/),,600,83121,DB00544,Fluorouracil
,3032726,rates of,The rates of FT degradation in the liver tissue homogenate were similar for four of the patients with cirrhosis (0.10 +/- 0.05 mumol/g liver protein/30 min) and four of those without it (0.13 +/- 0.05).,Hepatic conversion of 1-(tetrahydro-2-furanyl)-5-fluorouracil into 5-fluorouracil in patients with hepatocellular carcinoma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3032726/),[μM] / [·30·g·liver·min],0.10,83792,DB00544,Fluorouracil
,3032726,rates of,The rates of FT degradation in the liver tissue homogenate were similar for four of the patients with cirrhosis (0.10 +/- 0.05 mumol/g liver protein/30 min) and four of those without it (0.13 +/- 0.05).,Hepatic conversion of 1-(tetrahydro-2-furanyl)-5-fluorouracil into 5-fluorouracil in patients with hepatocellular carcinoma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3032726/),,0.13,83793,DB00544,Fluorouracil
,3032726,rates of FUra formation,"The estimated rates of FUra formation in the soluble fraction (105,000 X g supernatant fraction) from the two patients (0.1 and 0.13 nmol/mg protein/30 min) were almost identical to those from the controls (0.12 and 0.14), suggesting that the rate in the soluble fraction from HCC patients may not be as strongly affected as the rate in the microsomal fraction.",Hepatic conversion of 1-(tetrahydro-2-furanyl)-5-fluorouracil into 5-fluorouracil in patients with hepatocellular carcinoma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3032726/),[nM] / [·30·mg·min],0.1,83794,DB00544,Fluorouracil
,3032726,rates of FUra formation,"The estimated rates of FUra formation in the soluble fraction (105,000 X g supernatant fraction) from the two patients (0.1 and 0.13 nmol/mg protein/30 min) were almost identical to those from the controls (0.12 and 0.14), suggesting that the rate in the soluble fraction from HCC patients may not be as strongly affected as the rate in the microsomal fraction.",Hepatic conversion of 1-(tetrahydro-2-furanyl)-5-fluorouracil into 5-fluorouracil in patients with hepatocellular carcinoma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3032726/),[nM] / [·30·mg·min],0.13,83795,DB00544,Fluorouracil
,3032726,rates of FUra formation,"The estimated rates of FUra formation in the soluble fraction (105,000 X g supernatant fraction) from the two patients (0.1 and 0.13 nmol/mg protein/30 min) were almost identical to those from the controls (0.12 and 0.14), suggesting that the rate in the soluble fraction from HCC patients may not be as strongly affected as the rate in the microsomal fraction.",Hepatic conversion of 1-(tetrahydro-2-furanyl)-5-fluorouracil into 5-fluorouracil in patients with hepatocellular carcinoma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3032726/),,0.12,83796,DB00544,Fluorouracil
,3032726,rates of FUra formation,"The estimated rates of FUra formation in the soluble fraction (105,000 X g supernatant fraction) from the two patients (0.1 and 0.13 nmol/mg protein/30 min) were almost identical to those from the controls (0.12 and 0.14), suggesting that the rate in the soluble fraction from HCC patients may not be as strongly affected as the rate in the microsomal fraction.",Hepatic conversion of 1-(tetrahydro-2-furanyl)-5-fluorouracil into 5-fluorouracil in patients with hepatocellular carcinoma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3032726/),[nM] / [·30·mg·min],0.14,83797,DB00544,Fluorouracil
,19846076,flow rate,The probe was constantly perfused with saline solution at a flow rate of 1.0 microL/minute.,EUS-guided in vivo microdialysis of the pancreas: a novel technique with potential diagnostic and therapeutic application. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19846076/),[μl] / [min],1.0,85395,DB00544,Fluorouracil
,15150625,time to progression,"The average time to progression and overall survival of the patients was, respectively, 7.26 and 22 months.","A novel biweekly multidrug regimen of gemcitabine, oxaliplatin, 5-fluorouracil (5-FU), and folinic acid (FA) in pretreated patients with advanced colorectal carcinoma. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15150625/),month,7.26,85493,DB00544,Fluorouracil
,15150625,overall survival,"The average time to progression and overall survival of the patients was, respectively, 7.26 and 22 months.","A novel biweekly multidrug regimen of gemcitabine, oxaliplatin, 5-fluorouracil (5-FU), and folinic acid (FA) in pretreated patients with advanced colorectal carcinoma. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15150625/),month,22,85494,DB00544,Fluorouracil
,7349890,t1/2 alpha,"The serum half-life of 5-fluorouracil (5-FUra) in humans is best described as a biexponential decay function, with t1/2 alpha = 7.8 +/- 2.6 (S.E.) min and t1/2 beta = 36.8 +/- 13.5 min during initial courses of this drug alone.",Comparison of pharmacokinetics of 5-fluorouracil and 5-fluorouracil with concurrent thymidine infusions in a Phase I trial. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7349890/),min,7.8,85512,DB00544,Fluorouracil
,7349890,t1/2 beta,"The serum half-life of 5-fluorouracil (5-FUra) in humans is best described as a biexponential decay function, with t1/2 alpha = 7.8 +/- 2.6 (S.E.) min and t1/2 beta = 36.8 +/- 13.5 min during initial courses of this drug alone.",Comparison of pharmacokinetics of 5-fluorouracil and 5-fluorouracil with concurrent thymidine infusions in a Phase I trial. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7349890/),min,36.8,85513,DB00544,Fluorouracil
,24493926,cross-link time,"The central composite design was performed to optimize the preparation process as CTS:tripolyphosphate sodium (TPP) weight ratio =5:1, 5-FU:CTS weight ratio =1:1, TPP concentration =0.05% (w/v), and cross-link time =50 minutes.",Optimized synthesis of glycyrrhetinic acid-modified chitosan 5-fluorouracil nanoparticles and their characteristics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24493926/),min,50,85973,DB00544,Fluorouracil
,24493926,zeta potential,"GA-CTS/5-FU nanoparticles had a mean particle size of 193.7 nm, a polydispersity index of 0.003, a zeta potential of +27.4 mV, and a drug loading of 1.56%.",Optimized synthesis of glycyrrhetinic acid-modified chitosan 5-fluorouracil nanoparticles and their characteristics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24493926/),m,27.4,85974,DB00544,Fluorouracil
,19940012,maximum tolerated dose,Two of the four patients receiving axitinib with FOLFOX plus 5 mg/kg bevacizumab experienced dose-limiting toxicity (DLT) of inability to resume treatment for 14 days following treatment interruption (associated AE: hypertension); the maximum tolerated dose of bevacizumab in this combination was 2 mg/kg.,A phase I study of axitinib (AG-013736) in combination with bevacizumab plus chemotherapy or chemotherapy alone in patients with metastatic colorectal cancer and other solid tumors. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19940012/),,2,86414,DB00544,Fluorouracil
,19940012,objective response rate,Ten patients had RECIST-confirmed partial tumor responses (objective response rate: 33.3%).,A phase I study of axitinib (AG-013736) in combination with bevacizumab plus chemotherapy or chemotherapy alone in patients with metastatic colorectal cancer and other solid tumors. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19940012/),%,33.3,86415,DB00544,Fluorouracil
,21953502,central volume of distribution V(1),"Estimated pharmacokinetic parameters (% standard error) were as follows: central volume of distribution V(1) = 2.96 L (4%), peripheral volume of distribution V(2) = 4.65 L (6%), elimination clearance CL = 0.497 L/d (4%), distribution clearance Q = 0.836 L/d (8%), and zero-order elimination rate k(0) = 8.71 mg/d (10%).",Cetuximab pharmacokinetics influences progression-free survival of metastatic colorectal cancer patients. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21953502/),l,2.96,86539,DB00544,Fluorouracil
,21953502,peripheral volume of distribution V(2),"Estimated pharmacokinetic parameters (% standard error) were as follows: central volume of distribution V(1) = 2.96 L (4%), peripheral volume of distribution V(2) = 4.65 L (6%), elimination clearance CL = 0.497 L/d (4%), distribution clearance Q = 0.836 L/d (8%), and zero-order elimination rate k(0) = 8.71 mg/d (10%).",Cetuximab pharmacokinetics influences progression-free survival of metastatic colorectal cancer patients. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21953502/),l,4.65,86540,DB00544,Fluorouracil
,21953502,elimination clearance CL,"Estimated pharmacokinetic parameters (% standard error) were as follows: central volume of distribution V(1) = 2.96 L (4%), peripheral volume of distribution V(2) = 4.65 L (6%), elimination clearance CL = 0.497 L/d (4%), distribution clearance Q = 0.836 L/d (8%), and zero-order elimination rate k(0) = 8.71 mg/d (10%).",Cetuximab pharmacokinetics influences progression-free survival of metastatic colorectal cancer patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21953502/),[l] / [d],0.497,86541,DB00544,Fluorouracil
,21953502,distribution clearance Q,"Estimated pharmacokinetic parameters (% standard error) were as follows: central volume of distribution V(1) = 2.96 L (4%), peripheral volume of distribution V(2) = 4.65 L (6%), elimination clearance CL = 0.497 L/d (4%), distribution clearance Q = 0.836 L/d (8%), and zero-order elimination rate k(0) = 8.71 mg/d (10%).",Cetuximab pharmacokinetics influences progression-free survival of metastatic colorectal cancer patients. ,CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21953502/),[l] / [d],0.836,86542,DB00544,Fluorouracil
,21953502,zero-order elimination rate k(0),"Estimated pharmacokinetic parameters (% standard error) were as follows: central volume of distribution V(1) = 2.96 L (4%), peripheral volume of distribution V(2) = 4.65 L (6%), elimination clearance CL = 0.497 L/d (4%), distribution clearance Q = 0.836 L/d (8%), and zero-order elimination rate k(0) = 8.71 mg/d (10%).",Cetuximab pharmacokinetics influences progression-free survival of metastatic colorectal cancer patients. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21953502/),[mg] / [d],8.71,86543,DB00544,Fluorouracil
,21953502,PFS,Median PFS of patients with a cetuximab residual concentration on day 14 below median value was 3.3 months as compared with 7.8 months for the other patients (P = 0.004).,Cetuximab pharmacokinetics influences progression-free survival of metastatic colorectal cancer patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21953502/),month,3,86544,DB00544,Fluorouracil
,21953502,PFS,Median PFS of patients with a cetuximab residual concentration on day 14 below median value was 3.3 months as compared with 7.8 months for the other patients (P = 0.004).,Cetuximab pharmacokinetics influences progression-free survival of metastatic colorectal cancer patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21953502/),month,7.8,86545,DB00544,Fluorouracil
,25117066,AUC,"At cycles 1 and 4, 27.7% and 46.8% of patients achieved the target AUC (20-25 mg × hour/L), respectively (odds ratio [OR]: 2.20; p = .046).",A community-based multicenter trial of pharmacokinetically guided 5-fluorouracil dosing for personalized colorectal cancer therapy. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25117066/),[h·mg] / [l],20-25,86831,DB00544,Fluorouracil
,15596912,Objective response rate,Objective response rate in 23 evaluable patients was 39.2%.,"Intensified bimonthly cisplatin with bolus 5-fluorouracil, continuous 5-fluorouracil and high-dose leucovorin (LV5FU2) in Patients with advanced gastrointestinal carcinomas: a phase I dose-finding and pharmacokinetic study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15596912/),%,39.2,86860,DB00544,Fluorouracil
,26345166,flow rate,"Following protein precipitation with acetonitrile, the NA, NUA, and internal standard (5-fluorouracil) were separated on a Zorbax 300SB-C8 column (250 mm × 4.6 mm, 5 μm) with a mobile phase consisting of methanol-2 mM ammonium acetate (3 : 97, v/v) at a flow rate of 1 mL/min (split 1 : 1).",Quantification of Niacin and Its Metabolite Nicotinuric Acid in Human Plasma by LC-MS/MS: Application to a Clinical Trial of a Fixed Dose Combination Tablet of Niacin Extended-Release/Simvastatin (500 mg/10 mg) in Healthy Chinese Volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26345166/),[ml] / [min],1,86982,DB00544,Fluorouracil
,9607574,t1/2,"The t1/2 of BAU was 1.8-3.6 h in dogs, with bioavailability levels of 85% (30 mg/kg) and 42.5% (120 mg/kg).","Phase I clinical and pharmacological studies of benzylacyclouridine, a uridine phosphorylase inhibitor. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9607574/),h,1.8-3.6,87275,DB00544,Fluorouracil
,9607574,bioavailability,"The t1/2 of BAU was 1.8-3.6 h in dogs, with bioavailability levels of 85% (30 mg/kg) and 42.5% (120 mg/kg).","Phase I clinical and pharmacological studies of benzylacyclouridine, a uridine phosphorylase inhibitor. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9607574/),%,85,87276,DB00544,Fluorouracil
,9607574,bioavailability,"The t1/2 of BAU was 1.8-3.6 h in dogs, with bioavailability levels of 85% (30 mg/kg) and 42.5% (120 mg/kg).","Phase I clinical and pharmacological studies of benzylacyclouridine, a uridine phosphorylase inhibitor. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9607574/),%,42.5,87277,DB00544,Fluorouracil
,9607574,half-life,"In pigs, the half-life varied from 1.6 to 2.3 h, with a bioavailability of 40% at 120 mg/kg.","Phase I clinical and pharmacological studies of benzylacyclouridine, a uridine phosphorylase inhibitor. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9607574/),h,1.6 to 2.3,87278,DB00544,Fluorouracil
,9607574,bioavailability,"In pigs, the half-life varied from 1.6 to 2.3 h, with a bioavailability of 40% at 120 mg/kg.","Phase I clinical and pharmacological studies of benzylacyclouridine, a uridine phosphorylase inhibitor. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9607574/),%,40,87279,DB00544,Fluorouracil
,9607574,tissue: plasma ratio,The drug was distributed into most tissues with a tissue: plasma ratio of approximately 0.7.,"Phase I clinical and pharmacological studies of benzylacyclouridine, a uridine phosphorylase inhibitor. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9607574/),,0.7,87280,DB00544,Fluorouracil
,9607574,peak concentrations,"The pharmacokinetics of BAU were consistent with a first-order clearance, with average peak concentrations ranging from 19 microM (200 mg/m2) to 99 microM (1600 mg/m2) and tbeta1/2 ranging from 3.0 to 3.9 h at the four dose levels.","Phase I clinical and pharmacological studies of benzylacyclouridine, a uridine phosphorylase inhibitor. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9607574/),μM,19,87281,DB00544,Fluorouracil
,9607574,peak concentrations,"The pharmacokinetics of BAU were consistent with a first-order clearance, with average peak concentrations ranging from 19 microM (200 mg/m2) to 99 microM (1600 mg/m2) and tbeta1/2 ranging from 3.0 to 3.9 h at the four dose levels.","Phase I clinical and pharmacological studies of benzylacyclouridine, a uridine phosphorylase inhibitor. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9607574/),μM,99,87282,DB00544,Fluorouracil
,9607574,tbeta1/2,"The pharmacokinetics of BAU were consistent with a first-order clearance, with average peak concentrations ranging from 19 microM (200 mg/m2) to 99 microM (1600 mg/m2) and tbeta1/2 ranging from 3.0 to 3.9 h at the four dose levels.","Phase I clinical and pharmacological studies of benzylacyclouridine, a uridine phosphorylase inhibitor. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9607574/),h,3.0 to 3.9,87283,DB00544,Fluorouracil
,23082002,overall response rates,"The overall response rates for placebo-treated and vismodegib-treated patients were 51% (90% CI: 43-60) and 46% (90% CI: 37-55), respectively.",A randomized phase II trial of vismodegib versus placebo with FOLFOX or FOLFIRI and bevacizumab in patients with previously untreated metastatic colorectal cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23082002/),%,51,88444,DB00544,Fluorouracil
,23082002,overall response rates,"The overall response rates for placebo-treated and vismodegib-treated patients were 51% (90% CI: 43-60) and 46% (90% CI: 37-55), respectively.",A randomized phase II trial of vismodegib versus placebo with FOLFOX or FOLFIRI and bevacizumab in patients with previously untreated metastatic colorectal cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23082002/),%,46,88445,DB00544,Fluorouracil
,19861447,standardized uptake,"The baseline average standardized uptake value at 60 minutes, rate constant for the net irreversible transfer of radiotracer from plasma to tumor (Ki), and unit impulse response function at 60 minutes were 11.11 x 10(-5) m(2)/mL, 4.38 x 10(-2) mL plasma/min/mL tissue, and 4.93 x 10(-2)/min, respectively.",Altered tissue 3'-deoxy-3'-[18F]fluorothymidine pharmacokinetics in human breast cancer following capecitabine treatment detected by positron emission tomography. ,Uptake Volume-Q9,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19861447/),[m(2] / [ml],11.11 x 10(-5),88499,DB00544,Fluorouracil
,19861447,unit impulse response function,"The baseline average standardized uptake value at 60 minutes, rate constant for the net irreversible transfer of radiotracer from plasma to tumor (Ki), and unit impulse response function at 60 minutes were 11.11 x 10(-5) m(2)/mL, 4.38 x 10(-2) mL plasma/min/mL tissue, and 4.93 x 10(-2)/min, respectively.",Altered tissue 3'-deoxy-3'-[18F]fluorothymidine pharmacokinetics in human breast cancer following capecitabine treatment detected by positron emission tomography. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19861447/),,4.93 x 10(-2),88500,DB00544,Fluorouracil
,19861447,standardized uptake,"One hour after capecitabine administration, the standardized uptake value was 13.55 x 10(-5) m(2)/mL (P = 0.004), Ki 7.40 x 10(-2) mL plasma/min/mL tissue (P = 0.004), and impulse response function was 7.40 x 10(-2)/min (P = 0.002).",Altered tissue 3'-deoxy-3'-[18F]fluorothymidine pharmacokinetics in human breast cancer following capecitabine treatment detected by positron emission tomography. ,Uptake Volume-Q9,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19861447/),[m(2] / [ml],13.55 x 10(-5),88501,DB00544,Fluorouracil
,19861447,Ki,"One hour after capecitabine administration, the standardized uptake value was 13.55 x 10(-5) m(2)/mL (P = 0.004), Ki 7.40 x 10(-2) mL plasma/min/mL tissue (P = 0.004), and impulse response function was 7.40 x 10(-2)/min (P = 0.002).",Altered tissue 3'-deoxy-3'-[18F]fluorothymidine pharmacokinetics in human breast cancer following capecitabine treatment detected by positron emission tomography. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19861447/),[ml·plasma] / [min·ml·tissue],7.40 x 10(-2),88502,DB00544,Fluorouracil
,19861447,impulse response function,"One hour after capecitabine administration, the standardized uptake value was 13.55 x 10(-5) m(2)/mL (P = 0.004), Ki 7.40 x 10(-2) mL plasma/min/mL tissue (P = 0.004), and impulse response function was 7.40 x 10(-2)/min (P = 0.002).",Altered tissue 3'-deoxy-3'-[18F]fluorothymidine pharmacokinetics in human breast cancer following capecitabine treatment detected by positron emission tomography. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19861447/),,7.40 x 10(-2),88503,DB00544,Fluorouracil
,15505626,overall response rate,"Four patients achieved a partial response, giving an overall response rate of 21.1%.",Phase II study of S-1 in patients with advanced biliary tract cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15505626/),%,21.1,88572,DB00544,Fluorouracil
,15505626,time-to-progression,"The median time-to-progression and median overall survival period were 3.7 and 8.3 months, respectively.",Phase II study of S-1 in patients with advanced biliary tract cancer. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15505626/),month,3.7,88573,DB00544,Fluorouracil
,15505626,overall survival period,"The median time-to-progression and median overall survival period were 3.7 and 8.3 months, respectively.",Phase II study of S-1 in patients with advanced biliary tract cancer. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15505626/),month,8.3,88574,DB00544,Fluorouracil
,15699481,maximal plasma concentration,The mean maximal plasma concentration of UCN-01 was 33.5 micromol/L.,Phase I trial of the cyclin-dependent kinase inhibitor and protein kinase C inhibitor 7-hydroxystaurosporine in combination with Fluorouracil in patients with advanced solid tumors. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15699481/),[μM] / [l],33.5,89229,DB00544,Fluorouracil
,3974999,peak level,"Following a 1 mg intravitreal injection of C-14 labeled 5-FU in the phakic nonvitrectomized eye, a peak level of 664 micrograms/ml is achieved which declines to 7.8 micrograms/ml at 24 hours.",Clearance of intravitreal fluorouracil. Normal and aphakic vitrectomized eyes. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3974999/),[μg] / [ml],664,89262,DB00544,Fluorouracil
,3974999,peak level,"Following a 1 mg intravitreal injection of C-14 labeled 5-FU in the phakic nonvitrectomized eye, a peak level of 664 micrograms/ml is achieved which declines to 7.8 micrograms/ml at 24 hours.",Clearance of intravitreal fluorouracil. Normal and aphakic vitrectomized eyes. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3974999/),[μg] / [ml],7.8,89263,DB00544,Fluorouracil
,9816034,response rate,"Among 40 evaluable patients treated on this protocol, a major response (partial or complete remission) was observed in 26 patients (response rate, 62%; 95% confidence interval, 46-77).",Phase II clinical and pharmacological study of pirarubicin in combination with 5-fluorouracil and cyclophosphamide in metastatic breast cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9816034/),%,62,89354,DB00544,Fluorouracil
,9816034,alpha,"Pharmacokinetic studies revealed a triphasic elimination of pirarubicin with alpha, beta and gamma half-lives of 0.12, 1.44, and 33.9 h, respectively.",Phase II clinical and pharmacological study of pirarubicin in combination with 5-fluorouracil and cyclophosphamide in metastatic breast cancer. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9816034/),h,0.12,89355,DB00544,Fluorouracil
,9816034,beta,"Pharmacokinetic studies revealed a triphasic elimination of pirarubicin with alpha, beta and gamma half-lives of 0.12, 1.44, and 33.9 h, respectively.",Phase II clinical and pharmacological study of pirarubicin in combination with 5-fluorouracil and cyclophosphamide in metastatic breast cancer. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9816034/),h,1.44,89356,DB00544,Fluorouracil
,9816034,gamma half-lives,"Pharmacokinetic studies revealed a triphasic elimination of pirarubicin with alpha, beta and gamma half-lives of 0.12, 1.44, and 33.9 h, respectively.",Phase II clinical and pharmacological study of pirarubicin in combination with 5-fluorouracil and cyclophosphamide in metastatic breast cancer. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9816034/),h,33.9,89357,DB00544,Fluorouracil
,9816034,Total clearance of drug,Total clearance of drug was 4.2 liters.,Phase II clinical and pharmacological study of pirarubicin in combination with 5-fluorouracil and cyclophosphamide in metastatic breast cancer. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9816034/),l,4.2,89358,DB00544,Fluorouracil
,30178115,AUC (0-Tlast),"Mean measured 5FU AUC (0-Tlast) for 5FU 1 g/m2 with platinum: 35.8 h mg/L (range 28.56-44.26), mean Css 372.2 µg/L (range 297.5-461.0); 5FU 600 mg/m2 with platinum: 12.42 h mg/L (range 6.91-18.29), mean Css 111.0 µg/L (72.0-190.5) and 5FU 2400 mg/m2 as part of FOLFOX ± bevacizumab: 14.75 h mg/L (range 6.74-22.93), mean Css 320.70 µg/L (range 146.5-498.5).",Feasibility of 5-fluorouracil pharmacokinetic monitoring using the My-5FU PCM™ system in a quaternary oncology centre. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30178115/),[h·mg] / [l],35.8,90774,DB00544,Fluorouracil
,30178115,Css,"Mean measured 5FU AUC (0-Tlast) for 5FU 1 g/m2 with platinum: 35.8 h mg/L (range 28.56-44.26), mean Css 372.2 µg/L (range 297.5-461.0); 5FU 600 mg/m2 with platinum: 12.42 h mg/L (range 6.91-18.29), mean Css 111.0 µg/L (72.0-190.5) and 5FU 2400 mg/m2 as part of FOLFOX ± bevacizumab: 14.75 h mg/L (range 6.74-22.93), mean Css 320.70 µg/L (range 146.5-498.5).",Feasibility of 5-fluorouracil pharmacokinetic monitoring using the My-5FU PCM™ system in a quaternary oncology centre. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30178115/),[μg] / [l],372.2,90775,DB00544,Fluorouracil
,30178115,Css,"Mean measured 5FU AUC (0-Tlast) for 5FU 1 g/m2 with platinum: 35.8 h mg/L (range 28.56-44.26), mean Css 372.2 µg/L (range 297.5-461.0); 5FU 600 mg/m2 with platinum: 12.42 h mg/L (range 6.91-18.29), mean Css 111.0 µg/L (72.0-190.5) and 5FU 2400 mg/m2 as part of FOLFOX ± bevacizumab: 14.75 h mg/L (range 6.74-22.93), mean Css 320.70 µg/L (range 146.5-498.5).",Feasibility of 5-fluorouracil pharmacokinetic monitoring using the My-5FU PCM™ system in a quaternary oncology centre. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30178115/),[h·mg] / [l],12.42,90776,DB00544,Fluorouracil
,30178115,Css,"Mean measured 5FU AUC (0-Tlast) for 5FU 1 g/m2 with platinum: 35.8 h mg/L (range 28.56-44.26), mean Css 372.2 µg/L (range 297.5-461.0); 5FU 600 mg/m2 with platinum: 12.42 h mg/L (range 6.91-18.29), mean Css 111.0 µg/L (72.0-190.5) and 5FU 2400 mg/m2 as part of FOLFOX ± bevacizumab: 14.75 h mg/L (range 6.74-22.93), mean Css 320.70 µg/L (range 146.5-498.5).",Feasibility of 5-fluorouracil pharmacokinetic monitoring using the My-5FU PCM™ system in a quaternary oncology centre. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30178115/),[μg] / [l],111.0,90777,DB00544,Fluorouracil
,30178115,Css,"Mean measured 5FU AUC (0-Tlast) for 5FU 1 g/m2 with platinum: 35.8 h mg/L (range 28.56-44.26), mean Css 372.2 µg/L (range 297.5-461.0); 5FU 600 mg/m2 with platinum: 12.42 h mg/L (range 6.91-18.29), mean Css 111.0 µg/L (72.0-190.5) and 5FU 2400 mg/m2 as part of FOLFOX ± bevacizumab: 14.75 h mg/L (range 6.74-22.93), mean Css 320.70 µg/L (range 146.5-498.5).",Feasibility of 5-fluorouracil pharmacokinetic monitoring using the My-5FU PCM™ system in a quaternary oncology centre. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30178115/),[h·mg] / [l],14.75,90778,DB00544,Fluorouracil
,30178115,Css,"Mean measured 5FU AUC (0-Tlast) for 5FU 1 g/m2 with platinum: 35.8 h mg/L (range 28.56-44.26), mean Css 372.2 µg/L (range 297.5-461.0); 5FU 600 mg/m2 with platinum: 12.42 h mg/L (range 6.91-18.29), mean Css 111.0 µg/L (72.0-190.5) and 5FU 2400 mg/m2 as part of FOLFOX ± bevacizumab: 14.75 h mg/L (range 6.74-22.93), mean Css 320.70 µg/L (range 146.5-498.5).",Feasibility of 5-fluorouracil pharmacokinetic monitoring using the My-5FU PCM™ system in a quaternary oncology centre. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30178115/),[μg] / [l],320.70,90779,DB00544,Fluorouracil
,22460270,TTP,The TTP was not significantly prolonged in the DS arm when compared with the D only arm (DS vs D only arm: 3.9 months (95% confidence interval (CI) 2.9-4.9) vs 2.6 months (95% CI 1.8-3.5) (P=0.206).,Randomised phase II trial of docetaxel and sunitinib in patients with metastatic gastric cancer who were previously treated with fluoropyrimidine and platinum. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22460270/),month,3.9,91287,DB00544,Fluorouracil
,22460270,TTP,The TTP was not significantly prolonged in the DS arm when compared with the D only arm (DS vs D only arm: 3.9 months (95% confidence interval (CI) 2.9-4.9) vs 2.6 months (95% CI 1.8-3.5) (P=0.206).,Randomised phase II trial of docetaxel and sunitinib in patients with metastatic gastric cancer who were previously treated with fluoropyrimidine and platinum. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22460270/),month,2.6,91288,DB00544,Fluorouracil
,22460270,objective response rate,"However, the objective response rate was significantly higher in the DS arm (41.1% vs 14.3%, P=0.002).",Randomised phase II trial of docetaxel and sunitinib in patients with metastatic gastric cancer who were previously treated with fluoropyrimidine and platinum. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22460270/),%,41.1,91289,DB00544,Fluorouracil
,22460270,objective response rate,"However, the objective response rate was significantly higher in the DS arm (41.1% vs 14.3%, P=0.002).",Randomised phase II trial of docetaxel and sunitinib in patients with metastatic gastric cancer who were previously treated with fluoropyrimidine and platinum. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22460270/),%,14.3,91290,DB00544,Fluorouracil
,9188833,recovery,"The average recovery from plasma was 35, 42 and 48% for 5-FUra, 5-FUrd and 5-FdUrd, respectively.",Determination of 5-fluorouracil and its main metabolites in plasma by high-performance liquid chromatography: application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9188833/),%,35,91342,DB00544,Fluorouracil
,9188833,recovery,"The average recovery from plasma was 35, 42 and 48% for 5-FUra, 5-FUrd and 5-FdUrd, respectively.",Determination of 5-fluorouracil and its main metabolites in plasma by high-performance liquid chromatography: application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9188833/),%,42,91343,DB00544,Fluorouracil
,9188833,recovery,"The average recovery from plasma was 35, 42 and 48% for 5-FUra, 5-FUrd and 5-FdUrd, respectively.",Determination of 5-fluorouracil and its main metabolites in plasma by high-performance liquid chromatography: application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9188833/),%,48,91344,DB00544,Fluorouracil
,9188833,recovery,"Precision, expressed as C.V., ranged from 2.7 to 13% and the mean recovery from 94 to 105%.",Determination of 5-fluorouracil and its main metabolites in plasma by high-performance liquid chromatography: application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9188833/),%,94 to 105,91345,DB00544,Fluorouracil
,15844007,AUC,Median daily 5'-DFUR AUC was significantly higher for capecitabine than for 5'-DFUR (81.1 vs 32.6 mmol h/l; P = 0.01).,"Pharmacokinetic and pharmacodynamic comparison of fluoropyrimidine derivatives, capecitabine and 5'-deoxy-5-fluorouridine (5'-DFUR). ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15844007/),[h·mM] / [l],81.1,91400,DB00544,Fluorouracil
,15844007,AUC,Median daily 5'-DFUR AUC was significantly higher for capecitabine than for 5'-DFUR (81.1 vs 32.6 mmol h/l; P = 0.01).,"Pharmacokinetic and pharmacodynamic comparison of fluoropyrimidine derivatives, capecitabine and 5'-deoxy-5-fluorouridine (5'-DFUR). ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15844007/),[h·mM] / [l],32.6,91401,DB00544,Fluorouracil
,15844007,AUC,"Following treatment with 5'-DFUR, the median AUC and Cmax of 5'-DFUR tended to be higher in patients with a partial response (3.83 microg h/ml and 4.88 microg/ml) and stable disease (6.46 microg h/ml and 4.96 microg/ml) than in those with disease progression (2.53 microg h/ml and 1.36 microg/ml).","Pharmacokinetic and pharmacodynamic comparison of fluoropyrimidine derivatives, capecitabine and 5'-deoxy-5-fluorouridine (5'-DFUR). ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15844007/),[h·μg] / [ml],3.83,91402,DB00544,Fluorouracil
,15844007,AUC,"Following treatment with 5'-DFUR, the median AUC and Cmax of 5'-DFUR tended to be higher in patients with a partial response (3.83 microg h/ml and 4.88 microg/ml) and stable disease (6.46 microg h/ml and 4.96 microg/ml) than in those with disease progression (2.53 microg h/ml and 1.36 microg/ml).","Pharmacokinetic and pharmacodynamic comparison of fluoropyrimidine derivatives, capecitabine and 5'-deoxy-5-fluorouridine (5'-DFUR). ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15844007/),[h·μg] / [ml],6.46,91403,DB00544,Fluorouracil
,15844007,AUC,"Following treatment with 5'-DFUR, the median AUC and Cmax of 5'-DFUR tended to be higher in patients with a partial response (3.83 microg h/ml and 4.88 microg/ml) and stable disease (6.46 microg h/ml and 4.96 microg/ml) than in those with disease progression (2.53 microg h/ml and 1.36 microg/ml).","Pharmacokinetic and pharmacodynamic comparison of fluoropyrimidine derivatives, capecitabine and 5'-deoxy-5-fluorouridine (5'-DFUR). ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15844007/),[h·μg] / [ml],2.53,91404,DB00544,Fluorouracil
,15844007,Cmax,"Following treatment with 5'-DFUR, the median AUC and Cmax of 5'-DFUR tended to be higher in patients with a partial response (3.83 microg h/ml and 4.88 microg/ml) and stable disease (6.46 microg h/ml and 4.96 microg/ml) than in those with disease progression (2.53 microg h/ml and 1.36 microg/ml).","Pharmacokinetic and pharmacodynamic comparison of fluoropyrimidine derivatives, capecitabine and 5'-deoxy-5-fluorouridine (5'-DFUR). ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15844007/),[μg] / [ml],4.88,91405,DB00544,Fluorouracil
,15844007,Cmax,"Following treatment with 5'-DFUR, the median AUC and Cmax of 5'-DFUR tended to be higher in patients with a partial response (3.83 microg h/ml and 4.88 microg/ml) and stable disease (6.46 microg h/ml and 4.96 microg/ml) than in those with disease progression (2.53 microg h/ml and 1.36 microg/ml).","Pharmacokinetic and pharmacodynamic comparison of fluoropyrimidine derivatives, capecitabine and 5'-deoxy-5-fluorouridine (5'-DFUR). ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15844007/),[μg] / [ml],4.96,91406,DB00544,Fluorouracil
,15844007,Cmax,"Following treatment with 5'-DFUR, the median AUC and Cmax of 5'-DFUR tended to be higher in patients with a partial response (3.83 microg h/ml and 4.88 microg/ml) and stable disease (6.46 microg h/ml and 4.96 microg/ml) than in those with disease progression (2.53 microg h/ml and 1.36 microg/ml).","Pharmacokinetic and pharmacodynamic comparison of fluoropyrimidine derivatives, capecitabine and 5'-deoxy-5-fluorouridine (5'-DFUR). ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15844007/),[h·μg] / [ml],2.53,91407,DB00544,Fluorouracil
,15844007,Cmax,"Following treatment with 5'-DFUR, the median AUC and Cmax of 5'-DFUR tended to be higher in patients with a partial response (3.83 microg h/ml and 4.88 microg/ml) and stable disease (6.46 microg h/ml and 4.96 microg/ml) than in those with disease progression (2.53 microg h/ml and 1.36 microg/ml).","Pharmacokinetic and pharmacodynamic comparison of fluoropyrimidine derivatives, capecitabine and 5'-deoxy-5-fluorouridine (5'-DFUR). ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15844007/),[μg] / [ml],1.36,91408,DB00544,Fluorouracil
,7479197,total clearance,"The mean (SD) ZDV pharmacokinetic values were total clearance 1.44 (1.09) L/hr/kg, volume of distribution 2.72 (2.97) L/kg, and half-life 1.2 (0.6) hours.",Pharmacokinetics and pharmacodynamics of high-dose zidovudine administered as a continuous infusion in patients with cancer. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7479197/),[l] / [h·kg],1.44,91924,DB00544,Fluorouracil
,7479197,volume of distribution,"The mean (SD) ZDV pharmacokinetic values were total clearance 1.44 (1.09) L/hr/kg, volume of distribution 2.72 (2.97) L/kg, and half-life 1.2 (0.6) hours.",Pharmacokinetics and pharmacodynamics of high-dose zidovudine administered as a continuous infusion in patients with cancer. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7479197/),[l] / [kg],2.72,91925,DB00544,Fluorouracil
,7479197,half-life,"The mean (SD) ZDV pharmacokinetic values were total clearance 1.44 (1.09) L/hr/kg, volume of distribution 2.72 (2.97) L/kg, and half-life 1.2 (0.6) hours.",Pharmacokinetics and pharmacodynamics of high-dose zidovudine administered as a continuous infusion in patients with cancer. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7479197/),h,1.2,91926,DB00544,Fluorouracil
,16284918,K(a),"Capecitabine oral absorption was characterized by a rapid first order input (K(a)=2.1 +/- 0.3 hr(-1)) with a lag time (0.28 +/- 0.11 hr), but related inter-occasion (IOV) and inter-subject (ISV) variabilities for these parameters, 167% and 110%, indicated that this oral absorption was highly variable.",Pharmacokinetic modelling of 5-FU production from capecitabine--a population study in 40 adult patients with metastatic cancer. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16284918/),1/[hr],2.1,92790,DB00544,Fluorouracil
,16284918,lag time,"Capecitabine oral absorption was characterized by a rapid first order input (K(a)=2.1 +/- 0.3 hr(-1)) with a lag time (0.28 +/- 0.11 hr), but related inter-occasion (IOV) and inter-subject (ISV) variabilities for these parameters, 167% and 110%, indicated that this oral absorption was highly variable.",Pharmacokinetic modelling of 5-FU production from capecitabine--a population study in 40 adult patients with metastatic cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16284918/),h,0.28,92791,DB00544,Fluorouracil
,16284918,CL (CL10,"The capecitabine CL (CL10 = 218+/- 18 L/hr, ISV = 18%) and 5'-DFUR elimination rate constant (K34 = 5.3 +/- 2.0 hr(-1), ISV = 25%) were influenced by total bilirubin (BILT).",Pharmacokinetic modelling of 5-FU production from capecitabine--a population study in 40 adult patients with metastatic cancer. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16284918/),[l] / [h],218,92792,DB00544,Fluorouracil
,16284918,elimination rate constant (K34,"The capecitabine CL (CL10 = 218+/- 18 L/hr, ISV = 18%) and 5'-DFUR elimination rate constant (K34 = 5.3 +/- 2.0 hr(-1), ISV = 25%) were influenced by total bilirubin (BILT).",Pharmacokinetic modelling of 5-FU production from capecitabine--a population study in 40 adult patients with metastatic cancer. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16284918/),1/[hr],5.3,92793,DB00544,Fluorouracil
,16284918,elimination rate constant of plasma 5-FU (K40),The elimination rate constant of plasma 5-FU (K40) was 66 +/- 24 hr(-1) (ISV = 34%).,Pharmacokinetic modelling of 5-FU production from capecitabine--a population study in 40 adult patients with metastatic cancer. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16284918/),1/[hr],66,92794,DB00544,Fluorouracil
,29161913,particle size,"The particle size and % drug entrapment of the optimized batch was 494.37 ± 1.4 µm and 81.39 ± 2.9%, respectively, closer to the value predicted by Minitab 17 software.",Development and optimization of locust bean gum and sodium alginate interpenetrating polymeric network of capecitabine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29161913/),µm,494.37,92951,DB00544,Fluorouracil
,29161913,% drug entrapment,"The particle size and % drug entrapment of the optimized batch was 494.37 ± 1.4 µm and 81.39 ± 2.9%, respectively, closer to the value predicted by Minitab 17 software.",Development and optimization of locust bean gum and sodium alginate interpenetrating polymeric network of capecitabine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29161913/),%,81.39,92952,DB00544,Fluorouracil
,3829006,apparent elimination half-life,FUra plasma levels declined rapidly with an apparent elimination half-life of 12.9 +/- 7.3 min.,"Clinical pharmacokinetics of 5-fluorouracil and its metabolites in plasma, urine, and bile. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3829006/),min,12.9,94037,DB00544,Fluorouracil
,3829006,maximum peak levels,"Dihydrofluorouracil was detected within 5 min in most patients, demonstrating rapid catabolism and reached maximum peak levels of 23.7 +/- 9.9 microM at approximately 60 min.","Clinical pharmacokinetics of 5-fluorouracil and its metabolites in plasma, urine, and bile. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3829006/),μM,23.7,94038,DB00544,Fluorouracil
,3829006,apparent elimination half-life,The apparent elimination half-life of dihydrofluorouracil (61.9 +/- 39.0 min) was consistently greater than that of the unchanged drug.,"Clinical pharmacokinetics of 5-fluorouracil and its metabolites in plasma, urine, and bile. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3829006/),min,61.9,94039,DB00544,Fluorouracil
,3829006,apparent elimination half-lives,"The apparent elimination half-lives of the subsequent metabolites alpha-fluoro-beta-ureidopropionic acid and alpha-fluoro-beta-alanine were prolonged with values of 238.9 +/- 175.4 min and 1976 +/- 358 min, respectively.","Clinical pharmacokinetics of 5-fluorouracil and its metabolites in plasma, urine, and bile. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3829006/),min,238.9,94040,DB00544,Fluorouracil
,3829006,apparent elimination half-lives,"The apparent elimination half-lives of the subsequent metabolites alpha-fluoro-beta-ureidopropionic acid and alpha-fluoro-beta-alanine were prolonged with values of 238.9 +/- 175.4 min and 1976 +/- 358 min, respectively.","Clinical pharmacokinetics of 5-fluorouracil and its metabolites in plasma, urine, and bile. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3829006/),min,1976,94041,DB00544,Fluorouracil
,12657918,retention times,"The retention times of 5-FU and tegafur were 5 and 16.5 minutes, respectively, and the internal standard retention times were 11.5 and 17.5 minutes for 5-bromouracil (5-BU) and beta-hydroxyethyltheophylline, respectively.",Determination of 5-fluorouracil and its prodrug tegafur in plasma and tissue by high-performance liquid chromatography in a single injection: validation for application in clinical pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12657918/),min,5,94102,DB00544,Fluorouracil
,12657918,retention times,"The retention times of 5-FU and tegafur were 5 and 16.5 minutes, respectively, and the internal standard retention times were 11.5 and 17.5 minutes for 5-bromouracil (5-BU) and beta-hydroxyethyltheophylline, respectively.",Determination of 5-fluorouracil and its prodrug tegafur in plasma and tissue by high-performance liquid chromatography in a single injection: validation for application in clinical pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12657918/),min,16.5,94103,DB00544,Fluorouracil
,12657918,retention times,"The retention times of 5-FU and tegafur were 5 and 16.5 minutes, respectively, and the internal standard retention times were 11.5 and 17.5 minutes for 5-bromouracil (5-BU) and beta-hydroxyethyltheophylline, respectively.",Determination of 5-fluorouracil and its prodrug tegafur in plasma and tissue by high-performance liquid chromatography in a single injection: validation for application in clinical pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12657918/),min,11.5,94104,DB00544,Fluorouracil
,12657918,retention times,"The retention times of 5-FU and tegafur were 5 and 16.5 minutes, respectively, and the internal standard retention times were 11.5 and 17.5 minutes for 5-bromouracil (5-BU) and beta-hydroxyethyltheophylline, respectively.",Determination of 5-fluorouracil and its prodrug tegafur in plasma and tissue by high-performance liquid chromatography in a single injection: validation for application in clinical pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12657918/),min,17.5,94105,DB00544,Fluorouracil
,12657918,recovery,"The assay had good recovery (96.5% +/- 9.45% and 97.5% +/- 7.89% for 5-FU in plasma and tissue, respectively, and 88.5% +/- 12.17% and 104.9% +/- 8.77% for tegafur in plasma and tissue, respectively).",Determination of 5-fluorouracil and its prodrug tegafur in plasma and tissue by high-performance liquid chromatography in a single injection: validation for application in clinical pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12657918/),%,96.5,94106,DB00544,Fluorouracil
,12657918,recovery,"The assay had good recovery (96.5% +/- 9.45% and 97.5% +/- 7.89% for 5-FU in plasma and tissue, respectively, and 88.5% +/- 12.17% and 104.9% +/- 8.77% for tegafur in plasma and tissue, respectively).",Determination of 5-fluorouracil and its prodrug tegafur in plasma and tissue by high-performance liquid chromatography in a single injection: validation for application in clinical pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12657918/),%,97.5,94107,DB00544,Fluorouracil
,12657918,recovery,"The assay had good recovery (96.5% +/- 9.45% and 97.5% +/- 7.89% for 5-FU in plasma and tissue, respectively, and 88.5% +/- 12.17% and 104.9% +/- 8.77% for tegafur in plasma and tissue, respectively).",Determination of 5-fluorouracil and its prodrug tegafur in plasma and tissue by high-performance liquid chromatography in a single injection: validation for application in clinical pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12657918/),%,88.5,94108,DB00544,Fluorouracil
,12657918,recovery,"The assay had good recovery (96.5% +/- 9.45% and 97.5% +/- 7.89% for 5-FU in plasma and tissue, respectively, and 88.5% +/- 12.17% and 104.9% +/- 8.77% for tegafur in plasma and tissue, respectively).",Determination of 5-fluorouracil and its prodrug tegafur in plasma and tissue by high-performance liquid chromatography in a single injection: validation for application in clinical pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12657918/),%,104.9,94109,DB00544,Fluorouracil
,1742853,AUC ratios,"Pirarubicin's pharmacokinetics and metabolism were linear within this dose range; the metabolites identified were pirarubicinol, doxorubicin and doxorubicinol (AUC ratios of metabolite/pirarubicin were 0.6, 0.64 and 0.57 respectively).",A pharmacokinetic and pharmacodynamic study of the new anthracycline pirarubicin in breast cancer patients. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1742853/),,0.6,94338,DB00544,Fluorouracil
,1742853,AUC ratios,"Pirarubicin's pharmacokinetics and metabolism were linear within this dose range; the metabolites identified were pirarubicinol, doxorubicin and doxorubicinol (AUC ratios of metabolite/pirarubicin were 0.6, 0.64 and 0.57 respectively).",A pharmacokinetic and pharmacodynamic study of the new anthracycline pirarubicin in breast cancer patients. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1742853/),,0.64,94339,DB00544,Fluorouracil
,1742853,AUC ratios,"Pirarubicin's pharmacokinetics and metabolism were linear within this dose range; the metabolites identified were pirarubicinol, doxorubicin and doxorubicinol (AUC ratios of metabolite/pirarubicin were 0.6, 0.64 and 0.57 respectively).",A pharmacokinetic and pharmacodynamic study of the new anthracycline pirarubicin in breast cancer patients. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1742853/),,0.57,94340,DB00544,Fluorouracil
,1742853,half-lives,"Pirarubicin's decay from plasma followed a two-compartmental pattern, showing half-lives of 15.6 min and 16.6 h; the total plasma clearance of the drug was 140 l/h-1/m-2, and the total volume of distribution was 2,830 l/m2.",A pharmacokinetic and pharmacodynamic study of the new anthracycline pirarubicin in breast cancer patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1742853/),min,15.6,94341,DB00544,Fluorouracil
,1742853,half-lives,"Pirarubicin's decay from plasma followed a two-compartmental pattern, showing half-lives of 15.6 min and 16.6 h; the total plasma clearance of the drug was 140 l/h-1/m-2, and the total volume of distribution was 2,830 l/m2.",A pharmacokinetic and pharmacodynamic study of the new anthracycline pirarubicin in breast cancer patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1742853/),h,16.6,94342,DB00544,Fluorouracil
,1742853,total plasma clearance,"Pirarubicin's decay from plasma followed a two-compartmental pattern, showing half-lives of 15.6 min and 16.6 h; the total plasma clearance of the drug was 140 l/h-1/m-2, and the total volume of distribution was 2,830 l/m2.",A pharmacokinetic and pharmacodynamic study of the new anthracycline pirarubicin in breast cancer patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1742853/),[l] / [h],140,94343,DB00544,Fluorouracil
,1742853,total volume of distribution,"Pirarubicin's decay from plasma followed a two-compartmental pattern, showing half-lives of 15.6 min and 16.6 h; the total plasma clearance of the drug was 140 l/h-1/m-2, and the total volume of distribution was 2,830 l/m2.",A pharmacokinetic and pharmacodynamic study of the new anthracycline pirarubicin in breast cancer patients. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1742853/),[l] / [m2],"2,830",94344,DB00544,Fluorouracil
,16010427,maximal,"When > 0.5 M of TPI and 1 M of FTD (10 mg/kg) were co-administered, the plasma FTD levels in mice and monkeys were elevated, almost reaching a maximal and constant value of 20-30 microg/ml and 15 microg/ml, respectively.","Potentiation of the antitumor activity of alpha, alpha, alpha-trifluorothymidine by the co-administration of an inhibitor of thymidine phosphorylase at a suitable molar ratio in vivo. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16010427/),[μg] / [ml],20-30,94839,DB00544,Fluorouracil
,16010427,maximal,"When > 0.5 M of TPI and 1 M of FTD (10 mg/kg) were co-administered, the plasma FTD levels in mice and monkeys were elevated, almost reaching a maximal and constant value of 20-30 microg/ml and 15 microg/ml, respectively.","Potentiation of the antitumor activity of alpha, alpha, alpha-trifluorothymidine by the co-administration of an inhibitor of thymidine phosphorylase at a suitable molar ratio in vivo. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16010427/),[μg] / [ml],15,94840,DB00544,Fluorouracil
,16010427,constant,"When > 0.5 M of TPI and 1 M of FTD (10 mg/kg) were co-administered, the plasma FTD levels in mice and monkeys were elevated, almost reaching a maximal and constant value of 20-30 microg/ml and 15 microg/ml, respectively.","Potentiation of the antitumor activity of alpha, alpha, alpha-trifluorothymidine by the co-administration of an inhibitor of thymidine phosphorylase at a suitable molar ratio in vivo. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16010427/),[μg] / [ml],20-30,94841,DB00544,Fluorouracil
,16010427,constant,"When > 0.5 M of TPI and 1 M of FTD (10 mg/kg) were co-administered, the plasma FTD levels in mice and monkeys were elevated, almost reaching a maximal and constant value of 20-30 microg/ml and 15 microg/ml, respectively.","Potentiation of the antitumor activity of alpha, alpha, alpha-trifluorothymidine by the co-administration of an inhibitor of thymidine phosphorylase at a suitable molar ratio in vivo. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16010427/),[μg] / [ml],15,94842,DB00544,Fluorouracil
,16010427,ED50,"When human gastrointestinal cancer cell lines (DLD-1, CO-3 and AZ521) were xenografted into nude mice, the antitumor activity of FTD was augmented by the co-administration of TPI, compared to that of FTD alone, and the ED50 value, used to indicate the antitumor effect, reached a maximum value (about 25, 20, and 10 mg/kg in the DLD-1, CO-3, and AZ521 tumors, respectively) when > 0.5 M of TPI was combined with 1 M of FTD.","Potentiation of the antitumor activity of alpha, alpha, alpha-trifluorothymidine by the co-administration of an inhibitor of thymidine phosphorylase at a suitable molar ratio in vivo. ",EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16010427/),[mg] / [kg],25,94843,DB00544,Fluorouracil
,16010427,ED50,"When human gastrointestinal cancer cell lines (DLD-1, CO-3 and AZ521) were xenografted into nude mice, the antitumor activity of FTD was augmented by the co-administration of TPI, compared to that of FTD alone, and the ED50 value, used to indicate the antitumor effect, reached a maximum value (about 25, 20, and 10 mg/kg in the DLD-1, CO-3, and AZ521 tumors, respectively) when > 0.5 M of TPI was combined with 1 M of FTD.","Potentiation of the antitumor activity of alpha, alpha, alpha-trifluorothymidine by the co-administration of an inhibitor of thymidine phosphorylase at a suitable molar ratio in vivo. ",EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16010427/),[mg] / [kg],20,94844,DB00544,Fluorouracil
,16010427,ED50,"When human gastrointestinal cancer cell lines (DLD-1, CO-3 and AZ521) were xenografted into nude mice, the antitumor activity of FTD was augmented by the co-administration of TPI, compared to that of FTD alone, and the ED50 value, used to indicate the antitumor effect, reached a maximum value (about 25, 20, and 10 mg/kg in the DLD-1, CO-3, and AZ521 tumors, respectively) when > 0.5 M of TPI was combined with 1 M of FTD.","Potentiation of the antitumor activity of alpha, alpha, alpha-trifluorothymidine by the co-administration of an inhibitor of thymidine phosphorylase at a suitable molar ratio in vivo. ",EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16010427/),[mg] / [kg],10,94845,DB00544,Fluorouracil
,4015949,hepatic extraction,"For the i.a.h. route, increasing the 5-FU dose from 780 to 1000 mg m-2 day-1 caused a drop in hepatic extraction from 0.93 (0.90-0.95) to 0.44 (0.21-0.66).",Continuous 5-day regional chemotherapy by 5-fluorouracil in colon carcinoma: pharmacokinetic evaluation. ,EH-Q39,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4015949/),,0.93,95274,DB00544,Fluorouracil
,4015949,hepatic extraction,"For the i.a.h. route, increasing the 5-FU dose from 780 to 1000 mg m-2 day-1 caused a drop in hepatic extraction from 0.93 (0.90-0.95) to 0.44 (0.21-0.66).",Continuous 5-day regional chemotherapy by 5-fluorouracil in colon carcinoma: pharmacokinetic evaluation. ,EH-Q39,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4015949/),,0.44,95275,DB00544,Fluorouracil
,18441330,confirmed response rate,"The confirmed response rate for patients receiving 5-FU at standard 2000 mg/m(2) (N = 41) was 56%, with a median duration of 9.3 months.",Cetuximab in combination with weekly 5-fluorouracil/folinic acid and oxaliplatin (FUFOX) in untreated patients with advanced colorectal cancer: a phase Ib/II study of the AIO GI Group. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18441330/),%,56,95589,DB00544,Fluorouracil
,18441330,progression-free,"Median progression-free and overall survival times including all 49 patients were 8.1 (95% confidence interval 6.0-9.7) and 28.2 months, respectively.",Cetuximab in combination with weekly 5-fluorouracil/folinic acid and oxaliplatin (FUFOX) in untreated patients with advanced colorectal cancer: a phase Ib/II study of the AIO GI Group. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18441330/),month,8.1,95590,DB00544,Fluorouracil
,18441330,overall survival times,"Median progression-free and overall survival times including all 49 patients were 8.1 (95% confidence interval 6.0-9.7) and 28.2 months, respectively.",Cetuximab in combination with weekly 5-fluorouracil/folinic acid and oxaliplatin (FUFOX) in untreated patients with advanced colorectal cancer: a phase Ib/II study of the AIO GI Group. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18441330/),month,28.2,95591,DB00544,Fluorouracil
,16006750,growth inhibition rate (IR),"TS-1 alone showed antitumor activity against three tumors (growth inhibition rate (IR): SC-2 (38.6 and 40.5%), St-40 (54.5%), SC-4 (55.1%)).",Increased antitumor activity in combined treatment TS-1 and docetaxel. A preclinical study using gastric cancer xenografts. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16006750/),%,38.6,95843,DB00544,Fluorouracil
,16006750,growth inhibition rate (IR),"TS-1 alone showed antitumor activity against three tumors (growth inhibition rate (IR): SC-2 (38.6 and 40.5%), St-40 (54.5%), SC-4 (55.1%)).",Increased antitumor activity in combined treatment TS-1 and docetaxel. A preclinical study using gastric cancer xenografts. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16006750/),%,40.5,95844,DB00544,Fluorouracil
,16006750,growth inhibition rate (IR),"TS-1 alone showed antitumor activity against three tumors (growth inhibition rate (IR): SC-2 (38.6 and 40.5%), St-40 (54.5%), SC-4 (55.1%)).",Increased antitumor activity in combined treatment TS-1 and docetaxel. A preclinical study using gastric cancer xenografts. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16006750/),%,54.5,95845,DB00544,Fluorouracil
,16006750,growth inhibition rate (IR),"TS-1 alone showed antitumor activity against three tumors (growth inhibition rate (IR): SC-2 (38.6 and 40.5%), St-40 (54.5%), SC-4 (55.1%)).",Increased antitumor activity in combined treatment TS-1 and docetaxel. A preclinical study using gastric cancer xenografts. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16006750/),%,55.1,95846,DB00544,Fluorouracil
,18249110,Overall response rate,"Overall response rate was 67%, comprising two complete and 12 partial responders in 21 assessable patients.",Erlotinib in combination with capecitabine and docetaxel in patients with metastatic breast cancer: a dose-escalation study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18249110/),%,67,95867,DB00544,Fluorouracil
,1557660,serum half-life times,5-FU kinetics are characterized by short serum half-life times of 4.5 to 13 minutes.,Clinical pharmacokinetics of fluorouracil and folinic acid. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1557660/),min,4.5 to 13,96571,DB00544,Fluorouracil
,1557660,half-life,"After administration of the commercially available d,l-folinic acid (d,l-CHO-THF), the biologically inactive d-form is cleared very slowly with a median half-life of 438 +/- 63 minutes.",Clinical pharmacokinetics of fluorouracil and folinic acid. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1557660/),min,438,96572,DB00544,Fluorouracil
,1557660,elimination half-lives,l-CHO has short elimination half-lives of 56.5 +/- 10.5 minutes.,Clinical pharmacokinetics of fluorouracil and folinic acid. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1557660/),min,56.5,96573,DB00544,Fluorouracil
,1557660,body clearance,The high body clearance of 222 +/- 27 mL/min is partially caused by metabolism to l-methyltetrahydrofolic acid (l-CH3-THF).,Clinical pharmacokinetics of fluorouracil and folinic acid. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1557660/),[ml] / [min],222,96574,DB00544,Fluorouracil
,7376884,hepatic extraction ratio,The hepatic extraction ratio was calculated to 0.56 and 0.26 after the lower and the higher dose respectively indicating a saturable process.,Pharmacokinetic studies of 5-fluorouracil after oral and intravenous administration in man. ,EH-Q39,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7376884/),,0.56,96917,DB00544,Fluorouracil
,7376884,hepatic extraction ratio,The hepatic extraction ratio was calculated to 0.56 and 0.26 after the lower and the higher dose respectively indicating a saturable process.,Pharmacokinetic studies of 5-fluorouracil after oral and intravenous administration in man. ,EH-Q39,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7376884/),,0.26,96918,DB00544,Fluorouracil
,11038003,tumor standardized uptake,"With eniluracil, tumor standardized uptake values ([activity/g]/[injected activity/g body weight]) increased from 0.72 +/- 0.06 (mean +/- SEM; n = 6) to 1.57 +/- 0.20 (n = 12; P < 0.01), and tumor uptake increased by factors of 2 or more relative to plasma (P < 0.05) and bone, liver, and kidney (P < 0.01).",Blocking catabolism with eniluracil enhances PET studies of 5-[18F]fluorouracil pharmacokinetics. ,Uptake Volume-Q9,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11038003/),[activity] / [g],0.72,97072,DB00544,Fluorouracil
,11038003,tumor standardized uptake,"With eniluracil, tumor standardized uptake values ([activity/g]/[injected activity/g body weight]) increased from 0.72 +/- 0.06 (mean +/- SEM; n = 6) to 1.57 +/- 0.20 (n = 12; P < 0.01), and tumor uptake increased by factors of 2 or more relative to plasma (P < 0.05) and bone, liver, and kidney (P < 0.01).",Blocking catabolism with eniluracil enhances PET studies of 5-[18F]fluorouracil pharmacokinetics. ,Uptake Volume-Q9,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11038003/),[activity] / [g],1.57,97073,DB00544,Fluorouracil
<,8857547,activity,"In these reported cases, DPD activity in peripheral blood mononuclear cells (PBMC-DPD) was < 100 pmol/min/mg protein.",Individualizing therapy with 5-fluorouracil related to dihydropyrimidine dehydrogenase: theory and limits. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8857547/),pm,100,97410,DB00544,Fluorouracil
,7127318,Overall median survival,Overall median survival was 19.2 months.,Clinical and pharmacokinetic effects of combined warfarin and 5-flourouracil in advanced colon cancer. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7127318/),month,19.2,98067,DB00544,Fluorouracil
,22020318,PFS,"The median PFS and overall survival on the low-dose arm were 2.4 and 6.5 months, respectively.",A randomized phase II study of two doses of vorinostat in combination with 5-FU/LV in patients with refractory colorectal cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22020318/),month,2.4,99084,DB00544,Fluorouracil
,22020318,overall survival,"The median PFS and overall survival on the low-dose arm were 2.4 and 6.5 months, respectively.",A randomized phase II study of two doses of vorinostat in combination with 5-FU/LV in patients with refractory colorectal cancer. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22020318/),month,6.5,99085,DB00544,Fluorouracil
,19299904,MTD,"The MTD was determined to be 30 mg/m(2), as 2 of 3 patients developed dose-limiting toxicities, grade 3 febrile neutropenia and diarrhea.",Phase I pharmacokinetic study of weekly intravenous and intraperitoneal paclitaxel combined with S-1 for advanced gastric cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19299904/),[mg] / [m],30,99179,DB00544,Fluorouracil
,19299904,RD,"Therefore, the RD was determined to be 20 mg/m(2).",Phase I pharmacokinetic study of weekly intravenous and intraperitoneal paclitaxel combined with S-1 for advanced gastric cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19299904/),[mg] / [m(2],20,99180,DB00544,Fluorouracil
,32066346,Volume of distribution,"Volume of distribution and area under the curve of the 30% reduced L-OHP dose were 56.7 L and 30.0 μg·h/mL, respectively.",Clinical pharmacokinetics of oxaliplatin in a hemodialysis patient with advanced gastric cancer. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32066346/),l,56.7,99651,DB00544,Fluorouracil
,32066346,area under the curve,"Volume of distribution and area under the curve of the 30% reduced L-OHP dose were 56.7 L and 30.0 μg·h/mL, respectively.",Clinical pharmacokinetics of oxaliplatin in a hemodialysis patient with advanced gastric cancer. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32066346/),[h·μg] / [ml],30.0,99652,DB00544,Fluorouracil
,8376540,recoveries,The average recoveries ranged from 70% to 108%.,"Solid-phase extraction of fluoropyrimidine derivatives on a copper-modified strong cation exchanger: determination of doxifluridine, 5-fluorouracil and its main metabolites in serum by high-performance liquid chromatography with ultraviolet detection. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8376540/),%,70,99824,DB00544,Fluorouracil
,8376540,recoveries,The average recoveries ranged from 70% to 108%.,"Solid-phase extraction of fluoropyrimidine derivatives on a copper-modified strong cation exchanger: determination of doxifluridine, 5-fluorouracil and its main metabolites in serum by high-performance liquid chromatography with ultraviolet detection. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8376540/),%,108,99825,DB00544,Fluorouracil
,3940219,total-body plasma clearance,"In vivo total-body plasma clearance of cyclophosphamide, a drug metabolized by hepatic cytochrome P-450, was decreased to 53 ml/min/kg in mice that had received P388 cells 8 days earlier, as against 97.2 ml/min/kg in control mice.",Effects of advanced leukemia on hepatic drug-metabolizing activity in the mouse. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3940219/),[ml] / [kg·min],53,100079,DB00544,Fluorouracil
,3940219,total-body plasma clearance,"In vivo total-body plasma clearance of cyclophosphamide, a drug metabolized by hepatic cytochrome P-450, was decreased to 53 ml/min/kg in mice that had received P388 cells 8 days earlier, as against 97.2 ml/min/kg in control mice.",Effects of advanced leukemia on hepatic drug-metabolizing activity in the mouse. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3940219/),[ml] / [kg·min],97.2,100080,DB00544,Fluorouracil
,3940219,Total-body plasma clearance,"Total-body plasma clearance of indocyanine green was decreased to 11 ml/min/kg by 8 days after P388 cell administration, compared with 36 ml/min/kg in control mice.",Effects of advanced leukemia on hepatic drug-metabolizing activity in the mouse. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3940219/),[ml] / [kg·min],11,100081,DB00544,Fluorouracil
,3940219,Total-body plasma clearance,"Total-body plasma clearance of indocyanine green was decreased to 11 ml/min/kg by 8 days after P388 cell administration, compared with 36 ml/min/kg in control mice.",Effects of advanced leukemia on hepatic drug-metabolizing activity in the mouse. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3940219/),[ml] / [kg·min],36,100082,DB00544,Fluorouracil
,10623707,area under the time-versus-concentration curve (AUC),"The pharmacokinetics of 5-FU, assessed in 12 patients on schedule 2, were nonlinear, with the mean area under the time-versus-concentration curve (AUC) increasing from 298 +/- 44 to 962 +/- 23 micromol/L and mean clearance decreasing from 34 +/- 4 to 15.6 +/- 0.38 L/h/m(2) as the dose of 5-FU was increased from 1,250 to 1,950 mg/m(2)/wk.",Phase I and pharmacologic study of PN401 and fluorouracil in patients with advanced solid malignancies. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10623707/),[μM] / [l],298,100414,DB00544,Fluorouracil
,10623707,area under the time-versus-concentration curve (AUC),"The pharmacokinetics of 5-FU, assessed in 12 patients on schedule 2, were nonlinear, with the mean area under the time-versus-concentration curve (AUC) increasing from 298 +/- 44 to 962 +/- 23 micromol/L and mean clearance decreasing from 34 +/- 4 to 15.6 +/- 0.38 L/h/m(2) as the dose of 5-FU was increased from 1,250 to 1,950 mg/m(2)/wk.",Phase I and pharmacologic study of PN401 and fluorouracil in patients with advanced solid malignancies. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10623707/),[μM] / [l],962,100415,DB00544,Fluorouracil
,10623707,clearance,"The pharmacokinetics of 5-FU, assessed in 12 patients on schedule 2, were nonlinear, with the mean area under the time-versus-concentration curve (AUC) increasing from 298 +/- 44 to 962 +/- 23 micromol/L and mean clearance decreasing from 34 +/- 4 to 15.6 +/- 0.38 L/h/m(2) as the dose of 5-FU was increased from 1,250 to 1,950 mg/m(2)/wk.",Phase I and pharmacologic study of PN401 and fluorouracil in patients with advanced solid malignancies. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10623707/),[h·l] / [m(2],34,100416,DB00544,Fluorouracil
,10623707,clearance,"The pharmacokinetics of 5-FU, assessed in 12 patients on schedule 2, were nonlinear, with the mean area under the time-versus-concentration curve (AUC) increasing from 298 +/- 44 to 962 +/- 23 micromol/L and mean clearance decreasing from 34 +/- 4 to 15.6 +/- 0.38 L/h/m(2) as the dose of 5-FU was increased from 1,250 to 1,950 mg/m(2)/wk.",Phase I and pharmacologic study of PN401 and fluorouracil in patients with advanced solid malignancies. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10623707/),[h·l] / [m(2],15.6,100417,DB00544,Fluorouracil
greater,10623707,steady-state concentrations,"Plasma uridine concentrations increased with each of the three PN401 doses given every 2 hours, and uridine steady-state concentrations were greater than 50 micromol/L.",Phase I and pharmacologic study of PN401 and fluorouracil in patients with advanced solid malignancies. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10623707/),[μM] / [l],50,100418,DB00544,Fluorouracil
,1419604,Cl,"Significant interpatient variability for various 5-FU pharmacokinetic parameters was observed including an almost ten-fold range in 5-FU clearance (5-FU Cl, ml min-1 m-2 = 791-7769, mean 2820.7).","No effect of dose, hepatic function, or nutritional status on 5-FU clearance following continuous (5-day), 5-FU infusion. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1419604/),[ml] / [(m)^2·min],2820.7,101290,DB00544,Fluorouracil
,26666649,overall survival rate,The estimated 3-year overall survival rate was 78.0 % for the PF group and 85.7 % for the TPF group (median follow-up 3.3 years).,International randomized phase 2 study on the addition of docetaxel to the combination of cisplatin and 5-fluorouracil in the induction treatment for nasopharyngeal carcinoma in children and adolescents. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26666649/),%,78.0,101431,DB00544,Fluorouracil
,26666649,overall survival rate,The estimated 3-year overall survival rate was 78.0 % for the PF group and 85.7 % for the TPF group (median follow-up 3.3 years).,International randomized phase 2 study on the addition of docetaxel to the combination of cisplatin and 5-fluorouracil in the induction treatment for nasopharyngeal carcinoma in children and adolescents. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26666649/),%,85.7,101432,DB00544,Fluorouracil
,26666649,area under the curve,"Mean docetaxel area under the curve was 3.41 µg h/mL, compared with 3.51 µg h/mL seen in adult patients.",International randomized phase 2 study on the addition of docetaxel to the combination of cisplatin and 5-fluorouracil in the induction treatment for nasopharyngeal carcinoma in children and adolescents. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26666649/),[h·μg] / [ml],3.41,101433,DB00544,Fluorouracil
,26666649,area under the curve,"Mean docetaxel area under the curve was 3.41 µg h/mL, compared with 3.51 µg h/mL seen in adult patients.",International randomized phase 2 study on the addition of docetaxel to the combination of cisplatin and 5-fluorouracil in the induction treatment for nasopharyngeal carcinoma in children and adolescents. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26666649/),[h·μg] / [ml],3.51,101434,DB00544,Fluorouracil
,420949,clearances,(The clearances obtained with an infusion--from 5 to 60 1/min--are 10 to 60 times higher than the ones observed with a bolus--from 0.5 to 1.4 1/min.),Determination of 5-fluorouracil in plasma by GC/MS using an internal standard. Applications to pharmacokinetics. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/420949/),[1] / [min],5 to 60,101623,DB00544,Fluorouracil
,420949,clearances,(The clearances obtained with an infusion--from 5 to 60 1/min--are 10 to 60 times higher than the ones observed with a bolus--from 0.5 to 1.4 1/min.),Determination of 5-fluorouracil in plasma by GC/MS using an internal standard. Applications to pharmacokinetics. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/420949/),[1] / [min],0.5 to 1.4,101624,DB00544,Fluorouracil
,420949,bioavailability,The bioavailability of the oral form seems to be about 60 per cent and the absorption appears to be very fast.,Determination of 5-fluorouracil in plasma by GC/MS using an internal standard. Applications to pharmacokinetics. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/420949/),%,60,101625,DB00544,Fluorouracil
,7695253,total body clearance,"In monkeys, the total body clearance of 10 mg of 524W91 per kg was 0.7 +/- 0.1 liter/h/kg, and the volume of distribution at steady state was 0.8 +/- 0.02 liter/kg.","Pharmacokinetics, oral bioavailability, and metabolism in mice and cynomolgus monkeys of (2'R,5'S-)-cis-5-fluoro-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl] cytosine, an agent active against human immunodeficiency virus and human hepatitis B virus. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7695253/),[l] / [h·kg],0.7,101805,DB00544,Fluorouracil
,7695253,volume of distribution at steady state,"In monkeys, the total body clearance of 10 mg of 524W91 per kg was 0.7 +/- 0.1 liter/h/kg, and the volume of distribution at steady state was 0.8 +/- 0.02 liter/kg.","Pharmacokinetics, oral bioavailability, and metabolism in mice and cynomolgus monkeys of (2'R,5'S-)-cis-5-fluoro-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl] cytosine, an agent active against human immunodeficiency virus and human hepatitis B virus. ",Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7695253/),[l] / [kg],0.8,101806,DB00544,Fluorouracil
,7695253,terminal elimination half-life,The terminal elimination half-life was 1.0 +/- 0.2 h.,"Pharmacokinetics, oral bioavailability, and metabolism in mice and cynomolgus monkeys of (2'R,5'S-)-cis-5-fluoro-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl] cytosine, an agent active against human immunodeficiency virus and human hepatitis B virus. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7695253/),h,1.0,101807,DB00544,Fluorouracil
,7695253,absolute bioavailability,The absolute bioavailability after oral dosing was 63% +/- 4% at 10 mg/kg.,"Pharmacokinetics, oral bioavailability, and metabolism in mice and cynomolgus monkeys of (2'R,5'S-)-cis-5-fluoro-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl] cytosine, an agent active against human immunodeficiency virus and human hepatitis B virus. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7695253/),%,63,101808,DB00544,Fluorouracil
,7695253,total clearance,"In mice, the total clearance of 10 mg of 524W91 per kg was 2.3 liters/kg/h, and the volume of distribution at steady state was 0.9 liter/kg.","Pharmacokinetics, oral bioavailability, and metabolism in mice and cynomolgus monkeys of (2'R,5'S-)-cis-5-fluoro-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl] cytosine, an agent active against human immunodeficiency virus and human hepatitis B virus. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7695253/),[l] / [h·kg],2.3,101809,DB00544,Fluorouracil
,7695253,volume of distribution at steady state,"In mice, the total clearance of 10 mg of 524W91 per kg was 2.3 liters/kg/h, and the volume of distribution at steady state was 0.9 liter/kg.","Pharmacokinetics, oral bioavailability, and metabolism in mice and cynomolgus monkeys of (2'R,5'S-)-cis-5-fluoro-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl] cytosine, an agent active against human immunodeficiency virus and human hepatitis B virus. ",Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7695253/),[l] / [kg],0.9,101810,DB00544,Fluorouracil
,7695253,Absolute bioavailability,Absolute bioavailability in mice after oral dosing was 96% at a dose of 10 mg/kg.,"Pharmacokinetics, oral bioavailability, and metabolism in mice and cynomolgus monkeys of (2'R,5'S-)-cis-5-fluoro-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl] cytosine, an agent active against human immunodeficiency virus and human hepatitis B virus. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7695253/),%,96,101811,DB00544,Fluorouracil
,7695253,excre,"Monkeys excreted 41% +/- 6% of the radioactive dose in the 0- to 72-h urine, 33% +/- 10% in the feces, and 10% +/- 7% in the cage wash.","Pharmacokinetics, oral bioavailability, and metabolism in mice and cynomolgus monkeys of (2'R,5'S-)-cis-5-fluoro-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl] cytosine, an agent active against human immunodeficiency virus and human hepatitis B virus. ",fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7695253/),%,41,101812,DB00544,Fluorouracil
,7695253,excre,"Monkeys excreted 41% +/- 6% of the radioactive dose in the 0- to 72-h urine, 33% +/- 10% in the feces, and 10% +/- 7% in the cage wash.","Pharmacokinetics, oral bioavailability, and metabolism in mice and cynomolgus monkeys of (2'R,5'S-)-cis-5-fluoro-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl] cytosine, an agent active against human immunodeficiency virus and human hepatitis B virus. ",fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7695253/),%,33,101813,DB00544,Fluorouracil
,7695253,excre,"Monkeys excreted 41% +/- 6% of the radioactive dose in the 0- to 72-h urine, 33% +/- 10% in the feces, and 10% +/- 7% in the cage wash.","Pharmacokinetics, oral bioavailability, and metabolism in mice and cynomolgus monkeys of (2'R,5'S-)-cis-5-fluoro-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl] cytosine, an agent active against human immunodeficiency virus and human hepatitis B virus. ",fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7695253/),%,10,101814,DB00544,Fluorouracil
,11886004,flow-rate,The flow-rate was 2 l/min for 30 min.,Heated intra-operative intraperitoneal oxaliplatin after complete resection of peritoneal carcinomatosis: pharmacokinetics and tissue distribution. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11886004/),[l] / [min],2,101973,DB00544,Fluorouracil
,17230597,time-averaged,"After intravenous administration of 5-fluorouracil at a dose of 30 mg/kg to NARs, the time-averaged nonrenal clearance (Clnr) of the drug was significantly faster than the controls (51.3 versus 28.8 ml/min/kg), possibly due to an increase in the expression and mRNA level of CYP1A2 in NARs.",Pharmacokinetics of 5-fluorouracil in mutant Nagase analbuminemic rats: faster metabolism of 5-fluorouracil via CYP1A. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17230597/),[ml] / [kg·min],51.3,102195,DB00544,Fluorouracil
,17230597,time-averaged,"After intravenous administration of 5-fluorouracil at a dose of 30 mg/kg to NARs, the time-averaged nonrenal clearance (Clnr) of the drug was significantly faster than the controls (51.3 versus 28.8 ml/min/kg), possibly due to an increase in the expression and mRNA level of CYP1A2 in NARs.",Pharmacokinetics of 5-fluorouracil in mutant Nagase analbuminemic rats: faster metabolism of 5-fluorouracil via CYP1A. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17230597/),[ml] / [kg·min],28.8,102196,DB00544,Fluorouracil
,17230597,nonrenal clearance (Clnr),"After intravenous administration of 5-fluorouracil at a dose of 30 mg/kg to NARs, the time-averaged nonrenal clearance (Clnr) of the drug was significantly faster than the controls (51.3 versus 28.8 ml/min/kg), possibly due to an increase in the expression and mRNA level of CYP1A2 in NARs.",Pharmacokinetics of 5-fluorouracil in mutant Nagase analbuminemic rats: faster metabolism of 5-fluorouracil via CYP1A. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17230597/),[ml] / [kg·min],51.3,102197,DB00544,Fluorouracil
,17230597,nonrenal clearance (Clnr),"After intravenous administration of 5-fluorouracil at a dose of 30 mg/kg to NARs, the time-averaged nonrenal clearance (Clnr) of the drug was significantly faster than the controls (51.3 versus 28.8 ml/min/kg), possibly due to an increase in the expression and mRNA level of CYP1A2 in NARs.",Pharmacokinetics of 5-fluorouracil in mutant Nagase analbuminemic rats: faster metabolism of 5-fluorouracil via CYP1A. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17230597/),[ml] / [kg·min],28.8,102198,DB00544,Fluorouracil
,17230597,Clnr,The Clnr of 5-fluorouracil was significantly faster (34.3 versus 27.3 ml/min/kg) in rats pretreated with 3-methylcholanthrene.,Pharmacokinetics of 5-fluorouracil in mutant Nagase analbuminemic rats: faster metabolism of 5-fluorouracil via CYP1A. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17230597/),[ml] / [kg·min],34.3,102199,DB00544,Fluorouracil
,17230597,Clnr,The Clnr of 5-fluorouracil was significantly faster (34.3 versus 27.3 ml/min/kg) in rats pretreated with 3-methylcholanthrene.,Pharmacokinetics of 5-fluorouracil in mutant Nagase analbuminemic rats: faster metabolism of 5-fluorouracil via CYP1A. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17230597/),[ml] / [kg·min],27.3,102200,DB00544,Fluorouracil
,18407591,percentages of remaining peritoneal fluid volume,"The mean volumes remaining in the peritoneal cavity were significantly higher with HAES-steri than those with physiologic saline at 1, 6, 12, 18, and 24 h (P = 0.047, 0.009, 0.005, 0.005 and 0.005 respectively, the percentages of remaining peritoneal fluid volume were 89.9 +/- 5.6 vs 83.4 +/- 4.9, 79.9 +/- 2.8 vs 56.2 +/- 15.7, 46.8 +/- 5.5 vs 24.7 +/- 9.7, 23.0 +/- 2.8 vs 0.0 +/- 0.0 and 4.2 +/- 1.7 vs 0.0 +/- 0.0 respectively).",Pharmacokinetics and tissue distribution of intraperitoneal 5-fluorouracil with a novel carrier solution in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18407591/),,89.9,102215,DB00544,Fluorouracil
,18407591,percentages of remaining peritoneal fluid volume,"The mean volumes remaining in the peritoneal cavity were significantly higher with HAES-steri than those with physiologic saline at 1, 6, 12, 18, and 24 h (P = 0.047, 0.009, 0.005, 0.005 and 0.005 respectively, the percentages of remaining peritoneal fluid volume were 89.9 +/- 5.6 vs 83.4 +/- 4.9, 79.9 +/- 2.8 vs 56.2 +/- 15.7, 46.8 +/- 5.5 vs 24.7 +/- 9.7, 23.0 +/- 2.8 vs 0.0 +/- 0.0 and 4.2 +/- 1.7 vs 0.0 +/- 0.0 respectively).",Pharmacokinetics and tissue distribution of intraperitoneal 5-fluorouracil with a novel carrier solution in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18407591/),,83.4,102216,DB00544,Fluorouracil
,18407591,percentages of remaining peritoneal fluid volume,"The mean volumes remaining in the peritoneal cavity were significantly higher with HAES-steri than those with physiologic saline at 1, 6, 12, 18, and 24 h (P = 0.047, 0.009, 0.005, 0.005 and 0.005 respectively, the percentages of remaining peritoneal fluid volume were 89.9 +/- 5.6 vs 83.4 +/- 4.9, 79.9 +/- 2.8 vs 56.2 +/- 15.7, 46.8 +/- 5.5 vs 24.7 +/- 9.7, 23.0 +/- 2.8 vs 0.0 +/- 0.0 and 4.2 +/- 1.7 vs 0.0 +/- 0.0 respectively).",Pharmacokinetics and tissue distribution of intraperitoneal 5-fluorouracil with a novel carrier solution in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18407591/),,79.9,102217,DB00544,Fluorouracil
,18407591,percentages of remaining peritoneal fluid volume,"The mean volumes remaining in the peritoneal cavity were significantly higher with HAES-steri than those with physiologic saline at 1, 6, 12, 18, and 24 h (P = 0.047, 0.009, 0.005, 0.005 and 0.005 respectively, the percentages of remaining peritoneal fluid volume were 89.9 +/- 5.6 vs 83.4 +/- 4.9, 79.9 +/- 2.8 vs 56.2 +/- 15.7, 46.8 +/- 5.5 vs 24.7 +/- 9.7, 23.0 +/- 2.8 vs 0.0 +/- 0.0 and 4.2 +/- 1.7 vs 0.0 +/- 0.0 respectively).",Pharmacokinetics and tissue distribution of intraperitoneal 5-fluorouracil with a novel carrier solution in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18407591/),,56.2,102218,DB00544,Fluorouracil
,18407591,percentages of remaining peritoneal fluid volume,"The mean volumes remaining in the peritoneal cavity were significantly higher with HAES-steri than those with physiologic saline at 1, 6, 12, 18, and 24 h (P = 0.047, 0.009, 0.005, 0.005 and 0.005 respectively, the percentages of remaining peritoneal fluid volume were 89.9 +/- 5.6 vs 83.4 +/- 4.9, 79.9 +/- 2.8 vs 56.2 +/- 15.7, 46.8 +/- 5.5 vs 24.7 +/- 9.7, 23.0 +/- 2.8 vs 0.0 +/- 0.0 and 4.2 +/- 1.7 vs 0.0 +/- 0.0 respectively).",Pharmacokinetics and tissue distribution of intraperitoneal 5-fluorouracil with a novel carrier solution in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18407591/),,46.8,102219,DB00544,Fluorouracil
,18407591,percentages of remaining peritoneal fluid volume,"The mean volumes remaining in the peritoneal cavity were significantly higher with HAES-steri than those with physiologic saline at 1, 6, 12, 18, and 24 h (P = 0.047, 0.009, 0.005, 0.005 and 0.005 respectively, the percentages of remaining peritoneal fluid volume were 89.9 +/- 5.6 vs 83.4 +/- 4.9, 79.9 +/- 2.8 vs 56.2 +/- 15.7, 46.8 +/- 5.5 vs 24.7 +/- 9.7, 23.0 +/- 2.8 vs 0.0 +/- 0.0 and 4.2 +/- 1.7 vs 0.0 +/- 0.0 respectively).",Pharmacokinetics and tissue distribution of intraperitoneal 5-fluorouracil with a novel carrier solution in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18407591/),,24.7,102220,DB00544,Fluorouracil
,18407591,percentages of remaining peritoneal fluid volume,"The mean volumes remaining in the peritoneal cavity were significantly higher with HAES-steri than those with physiologic saline at 1, 6, 12, 18, and 24 h (P = 0.047, 0.009, 0.005, 0.005 and 0.005 respectively, the percentages of remaining peritoneal fluid volume were 89.9 +/- 5.6 vs 83.4 +/- 4.9, 79.9 +/- 2.8 vs 56.2 +/- 15.7, 46.8 +/- 5.5 vs 24.7 +/- 9.7, 23.0 +/- 2.8 vs 0.0 +/- 0.0 and 4.2 +/- 1.7 vs 0.0 +/- 0.0 respectively).",Pharmacokinetics and tissue distribution of intraperitoneal 5-fluorouracil with a novel carrier solution in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18407591/),,23.0,102221,DB00544,Fluorouracil
,18407591,percentages of remaining peritoneal fluid volume,"The mean volumes remaining in the peritoneal cavity were significantly higher with HAES-steri than those with physiologic saline at 1, 6, 12, 18, and 24 h (P = 0.047, 0.009, 0.005, 0.005 and 0.005 respectively, the percentages of remaining peritoneal fluid volume were 89.9 +/- 5.6 vs 83.4 +/- 4.9, 79.9 +/- 2.8 vs 56.2 +/- 15.7, 46.8 +/- 5.5 vs 24.7 +/- 9.7, 23.0 +/- 2.8 vs 0.0 +/- 0.0 and 4.2 +/- 1.7 vs 0.0 +/- 0.0 respectively).",Pharmacokinetics and tissue distribution of intraperitoneal 5-fluorouracil with a novel carrier solution in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18407591/),,0.0,102222,DB00544,Fluorouracil
,18407591,percentages of remaining peritoneal fluid volume,"The mean volumes remaining in the peritoneal cavity were significantly higher with HAES-steri than those with physiologic saline at 1, 6, 12, 18, and 24 h (P = 0.047, 0.009, 0.005, 0.005 and 0.005 respectively, the percentages of remaining peritoneal fluid volume were 89.9 +/- 5.6 vs 83.4 +/- 4.9, 79.9 +/- 2.8 vs 56.2 +/- 15.7, 46.8 +/- 5.5 vs 24.7 +/- 9.7, 23.0 +/- 2.8 vs 0.0 +/- 0.0 and 4.2 +/- 1.7 vs 0.0 +/- 0.0 respectively).",Pharmacokinetics and tissue distribution of intraperitoneal 5-fluorouracil with a novel carrier solution in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18407591/),,4.2,102223,DB00544,Fluorouracil
,6305522,half-lives of,"After IV administration, the mean half-lives of the distribution phase and elimination phase were 1.0 h and 7.6 h, respectively.",Pharmacokinetics of ftorafur after intravenous and oral administration. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6305522/),h,1.0,102420,DB00544,Fluorouracil
,6305522,half-lives of,"After IV administration, the mean half-lives of the distribution phase and elimination phase were 1.0 h and 7.6 h, respectively.",Pharmacokinetics of ftorafur after intravenous and oral administration. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6305522/),h,7.6,102421,DB00544,Fluorouracil
,6305522,Total serum clearance,Total serum clearance was 69 ml/h .,Pharmacokinetics of ftorafur after intravenous and oral administration. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6305522/),[ml] / [h],69,102422,DB00544,Fluorouracil
,6305522,apparent volume of distribution,kg and the apparent volume of distribution was 0.66 l/kg.,Pharmacokinetics of ftorafur after intravenous and oral administration. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6305522/),[l] / [kg],0.66,102423,DB00544,Fluorouracil
,6305522,lag-time,"Following PO administration there was a short lag-time, 11 min, before the appearance of FT in peripheral serum, and the maximum concentration in peripheral serum was achieved in 3.2 h.",Pharmacokinetics of ftorafur after intravenous and oral administration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6305522/),min,11,102424,DB00544,Fluorouracil
,9270007,Extrahepatic clearance,"Extrahepatic clearance of 5-FU was estimated as 0.66 +/- 0.33 liters/min, whereas the hepatic clearance was 0.52 +/- 0.25 liters/min.",Pharmacokinetic analysis of 5-[18F]fluorouracil tissue concentrations measured with positron emission tomography in patients with liver metastases from colorectal adenocarcinoma. ,CLH-Q25,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9270007/),[l] / [min],0.66,102718,DB00544,Fluorouracil
,9270007,hepatic clearance,"Extrahepatic clearance of 5-FU was estimated as 0.66 +/- 0.33 liters/min, whereas the hepatic clearance was 0.52 +/- 0.25 liters/min.",Pharmacokinetic analysis of 5-[18F]fluorouracil tissue concentrations measured with positron emission tomography in patients with liver metastases from colorectal adenocarcinoma. ,CLH-Q25,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9270007/),[l] / [min],0.52,102719,DB00544,Fluorouracil
,9270007,Km,The Michaelis-Menten parameters describing the nonlinear conversion of 5-FU to FBAL were Km = 11.3 +/- 6.4 micromol and Vmax = 147.1 +/- 130.7 micromol/min.,Pharmacokinetic analysis of 5-[18F]fluorouracil tissue concentrations measured with positron emission tomography in patients with liver metastases from colorectal adenocarcinoma. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9270007/),μM,11.3,102720,DB00544,Fluorouracil
,9270007,Vmax,The Michaelis-Menten parameters describing the nonlinear conversion of 5-FU to FBAL were Km = 11.3 +/- 6.4 micromol and Vmax = 147.1 +/- 130.7 micromol/min.,Pharmacokinetic analysis of 5-[18F]fluorouracil tissue concentrations measured with positron emission tomography in patients with liver metastases from colorectal adenocarcinoma. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9270007/),[μM] / [min],147.1,102721,DB00544,Fluorouracil
,17690883,AUC,"At day 4 from the initial preoperative administration of S-1, the AUC of 5-FU was 1,055 +/- 304 ng h/ml.","Effect of gastrectomy on the pharmacokinetics of S-1, an oral fluoropyrimidine, in resectable gastric cancer patients. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17690883/),[h·ng] / [ml],"1,055",105106,DB00544,Fluorouracil
,17690883,concentrations,"In the resected tumor tissues, concentrations of 5-FU were 242 +/- 83 ng/g around 4.5 h and 91.7 +/- 37.0 ng/g around 20 h after the final administration, respectively.","Effect of gastrectomy on the pharmacokinetics of S-1, an oral fluoropyrimidine, in resectable gastric cancer patients. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17690883/),[ng] / [g],242,105107,DB00544,Fluorouracil
,17690883,concentrations,"In the resected tumor tissues, concentrations of 5-FU were 242 +/- 83 ng/g around 4.5 h and 91.7 +/- 37.0 ng/g around 20 h after the final administration, respectively.","Effect of gastrectomy on the pharmacokinetics of S-1, an oral fluoropyrimidine, in resectable gastric cancer patients. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17690883/),[ng] / [g],91.,105108,DB00544,Fluorouracil
,12021636,MAE%,"MPE% ranged between -0.8% and -8.3% and MAE% between 6.1% and 9.5%, depending on the time combination used.",New limited sampling strategy for determining 5-fluorouracil area under the concentration-time curve after rapid intravenous bolus. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12021636/),%,6.1,105318,DB00544,Fluorouracil
,12021636,MAE%,"MPE% ranged between -0.8% and -8.3% and MAE% between 6.1% and 9.5%, depending on the time combination used.",New limited sampling strategy for determining 5-fluorouracil area under the concentration-time curve after rapid intravenous bolus. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12021636/),%,9.5,105319,DB00544,Fluorouracil
,18504211,peak 5-FU concentration (Cmax),Systemic administration of 5-FU resulted in the peak 5-FU concentration (Cmax) and area under curve (AUC) in the liver tissue of 13.79-/+4.56 microg/g and 342.20-/+108.20 microg.min(-1).,[Distribution of 5-FU in rat plasma and liver tissue after local 5-FU infusion]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18504211/),[μg] / [g],13.79,105384,DB00544,Fluorouracil
,18504211,area under curve (AUC),Systemic administration of 5-FU resulted in the peak 5-FU concentration (Cmax) and area under curve (AUC) in the liver tissue of 13.79-/+4.56 microg/g and 342.20-/+108.20 microg.min(-1).,[Distribution of 5-FU in rat plasma and liver tissue after local 5-FU infusion]. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18504211/),[μg] / [min],342.20,105385,DB00544,Fluorouracil
,18504211,plasma Cmax,"g(-1)g-1, with the plasma Cmax and AUC of 36.85-/+5.96 microg/g and 842.00-/+158.00 microg.min(-1).",[Distribution of 5-FU in rat plasma and liver tissue after local 5-FU infusion]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18504211/),[μg] / [g],36.85,105386,DB00544,Fluorouracil
,18504211,AUC,"g(-1)g-1, with the plasma Cmax and AUC of 36.85-/+5.96 microg/g and 842.00-/+158.00 microg.min(-1).",[Distribution of 5-FU in rat plasma and liver tissue after local 5-FU infusion]. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18504211/),[μg] / [min],842.00,105387,DB00544,Fluorouracil
,18504211,Cmax,Local 5-FU administration through the hepatic artery resulted in Cmax and AUC in the liver tissue of 29.58-/+4.30 microg/g and 794.60-/+115.40 microg.min(-1).,[Distribution of 5-FU in rat plasma and liver tissue after local 5-FU infusion]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18504211/),[μg] / [g],29.58,105388,DB00544,Fluorouracil
,18504211,AUC,Local 5-FU administration through the hepatic artery resulted in Cmax and AUC in the liver tissue of 29.58-/+4.30 microg/g and 794.60-/+115.40 microg.min(-1).,[Distribution of 5-FU in rat plasma and liver tissue after local 5-FU infusion]. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18504211/),[μg] / [min],794.60,105389,DB00544,Fluorouracil
,18504211,Cmax,g(-1) and Cmax and AUC in the plasma of 24.39-/+4.63 microg/g and 639.70-/+133.80 microg.min(-1).,[Distribution of 5-FU in rat plasma and liver tissue after local 5-FU infusion]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18504211/),[μg] / [g],24.39,105390,DB00544,Fluorouracil
,18504211,AUC,g(-1) and Cmax and AUC in the plasma of 24.39-/+4.63 microg/g and 639.70-/+133.80 microg.min(-1).,[Distribution of 5-FU in rat plasma and liver tissue after local 5-FU infusion]. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18504211/),[μg] / [min],639.70,105391,DB00544,Fluorouracil
,18504211,Cmax,"After administration through the portal vein, the Cmax and AUC of 5-FU was 28.21-/+4.46 microg/g and 733.60-/+180.3 microg.min(-1).",[Distribution of 5-FU in rat plasma and liver tissue after local 5-FU infusion]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18504211/),[μg] / [g],28.21,105392,DB00544,Fluorouracil
,18504211,AUC,"After administration through the portal vein, the Cmax and AUC of 5-FU was 28.21-/+4.46 microg/g and 733.60-/+180.3 microg.min(-1).",[Distribution of 5-FU in rat plasma and liver tissue after local 5-FU infusion]. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18504211/),[μg] / [min],733.60,105393,DB00544,Fluorouracil
,3498014,survival time,Median survival time for all 28 patients enrolled in the study was 22 weeks.,A phase II trial of 5-fluorouracil and high-dose intravenous leucovorin in gastric carcinoma. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3498014/),weeks,22,106107,DB00544,Fluorouracil
,12451472,Hill constant,"In contrast, there was a highly significant relationship between the mean VRB AUC (days 1-5) and the absolute neutrophil count decrease (Emax model, Hill constant=4.38+/-2.59, EC(50)=508+/-53.2 micro g.h/l, r=0.75, P=0.0013).",The raltitrexed-vinorelbine combination: a phase I pharmacokinetic and pharmacodynamic trial in advanced breast cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12451472/),,4.38,106375,DB00544,Fluorouracil
,12451472,EC(50),"In contrast, there was a highly significant relationship between the mean VRB AUC (days 1-5) and the absolute neutrophil count decrease (Emax model, Hill constant=4.38+/-2.59, EC(50)=508+/-53.2 micro g.h/l, r=0.75, P=0.0013).",The raltitrexed-vinorelbine combination: a phase I pharmacokinetic and pharmacodynamic trial in advanced breast cancer. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12451472/),[h·μg] / [l],508,106376,DB00544,Fluorouracil
,29624242,retention time,The retention time was found to be 4.107 with a flow rate of I mL/min.,REVERSE PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY METHOD FOR DETERMINATION OF 5-FLUOROURACIL IN RABBIT PLASMA. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29624242/),,4.107,107294,DB00544,Fluorouracil
,29624242,flow rate,The retention time was found to be 4.107 with a flow rate of I mL/min.,REVERSE PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY METHOD FOR DETERMINATION OF 5-FLUOROURACIL IN RABBIT PLASMA. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29624242/),[ml] / [min],I,107295,DB00544,Fluorouracil
,31370815,overall response rate,The overall response rate was 55.6%.,Selective TACE with irinotecan-loaded 40 μm microspheres and FOLFIRI for colorectal liver metastases: phase I dose escalation pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31370815/),%,55.6,107632,DB00544,Fluorouracil
,31370815,progression free,"The median progression free and overall survival were 8.1 and 18.2 months, respectively.",Selective TACE with irinotecan-loaded 40 μm microspheres and FOLFIRI for colorectal liver metastases: phase I dose escalation pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31370815/),month,8.1,107633,DB00544,Fluorouracil
,31370815,overall survival,"The median progression free and overall survival were 8.1 and 18.2 months, respectively.",Selective TACE with irinotecan-loaded 40 μm microspheres and FOLFIRI for colorectal liver metastases: phase I dose escalation pharmacokinetic study. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31370815/),month,18.2,107634,DB00544,Fluorouracil
,9815792,clearance,5-FU clearance was higher in 14 cycles with IFN-gamma compared to the patient's prior cycle with the same doses of 5-FU/LV/IFN-alpha: 798 +/- 309 versus 601 +/- 250 ml/min/m2 (mean +/- SD; P = 0.04).,"A pilot study of gamma-1b-interferon in combination with fluorouracil, leucovorin, and alpha-2a-interferon. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9815792/),[ml] / [m2·min],798,108248,DB00544,Fluorouracil
,9815792,clearance,5-FU clearance was higher in 14 cycles with IFN-gamma compared to the patient's prior cycle with the same doses of 5-FU/LV/IFN-alpha: 798 +/- 309 versus 601 +/- 250 ml/min/m2 (mean +/- SD; P = 0.04).,"A pilot study of gamma-1b-interferon in combination with fluorouracil, leucovorin, and alpha-2a-interferon. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9815792/),[ml] / [m2·min],601,108249,DB00544,Fluorouracil
,9815792,clearance,"In these 28 cycles, the median 5-FU clearance was significantly lower in 11 cycles that were complicated by more severe diarrhea: 524 versus 798 ml/min/m2 (grade 2 versus 0-1; P = 0. 0032).","A pilot study of gamma-1b-interferon in combination with fluorouracil, leucovorin, and alpha-2a-interferon. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9815792/),[ml] / [m2·min],524,108250,DB00544,Fluorouracil
,9815792,clearance,"In these 28 cycles, the median 5-FU clearance was significantly lower in 11 cycles that were complicated by more severe diarrhea: 524 versus 798 ml/min/m2 (grade 2 versus 0-1; P = 0. 0032).","A pilot study of gamma-1b-interferon in combination with fluorouracil, leucovorin, and alpha-2a-interferon. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9815792/),[ml] / [m2·min],798,108251,DB00544,Fluorouracil
,9815792,maximum tolerated dose,"Dose reductions of IFN-gamma for chronic fatigue, malaise, or anorexia were ultimately required more frequently with >/=2.4 MU/m2 (P = 0.018), and the maximum tolerated dose of IFN-gamma was considered to be 1.2 MU/m2/ day.","A pilot study of gamma-1b-interferon in combination with fluorouracil, leucovorin, and alpha-2a-interferon. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9815792/),[Mu] / [·d·m2],1.2,108252,DB00544,Fluorouracil
,22201120,Overall response rate,"Overall response rate and median progression-free survival in a total of 61 patients were 43% and 7.5 months, respectively.",Association of ABCC2 genotype with efficacy of first-line FOLFIRI in Japanese patients with advanced colorectal cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22201120/),%,43,108550,DB00544,Fluorouracil
,22201120,progression-free survival,"Overall response rate and median progression-free survival in a total of 61 patients were 43% and 7.5 months, respectively.",Association of ABCC2 genotype with efficacy of first-line FOLFIRI in Japanese patients with advanced colorectal cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22201120/),month,7.5,108551,DB00544,Fluorouracil
>,12707718,half-life,"EU on either schedule decreased 5-FU plasma clearance by 48 to 52-fold, prolonged the half-life to >5 h, and increased the percentage of 5-FU excreted in the urine from 2% to 64-66%.","Pharmacokinetic and pharmacodynamic effects of oral eniluracil, fluorouracil and leucovorin given on a weekly schedule. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12707718/),h,5,108587,DB00544,Fluorouracil
,11192475,maximum tolerated dose (MTD),The maximum tolerated dose (MTD) for the 3-weekly schedule was 3.5 to 4.5 mg/m2 in adults and 6 mg/m2 in a paediatric population.,Clinical and preclinical pharmacokinetics of raltitrexed. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11192475/),[mg] / [m2],3.5 to 4.5,108797,DB00544,Fluorouracil
,11192475,maximum tolerated dose (MTD),The maximum tolerated dose (MTD) for the 3-weekly schedule was 3.5 to 4.5 mg/m2 in adults and 6 mg/m2 in a paediatric population.,Clinical and preclinical pharmacokinetics of raltitrexed. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11192475/),[mg] / [m],6,108798,DB00544,Fluorouracil
,11192475,terminal half-life (t1/2gamma),"The disposition of raltitrexed in patients is best described by a 3-compartment model with a terminal half-life (t1/2gamma) of 260 hours, the latter being subject to significant interpatient variability.",Clinical and preclinical pharmacokinetics of raltitrexed. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11192475/),h,260,108799,DB00544,Fluorouracil
,11192475,clearance,"The average clearance of raltitrexed is 2.4 L/h (40 ml/min), and this value is significantly reduced in patients with compromised renal function (glomerular filtration rate of 25 to 65 ml/min).",Clinical and preclinical pharmacokinetics of raltitrexed. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11192475/),[l] / [h],2.4,108800,DB00544,Fluorouracil
,22260036,relative bioavailability,"The highest peak value of DMF was 1/37 of original value of FU, and the relative bioavailability was 419% to original FU.","[Supra-molecular assembly and magnetic targeted slow-release effect of ""dextran-magnetic layered double hydroxide-fluorouracil"" drug delivery system]. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22260036/),%,419,108897,DB00544,Fluorouracil
,31248179,surface area,"MSNs produced in this study were functionalized with the biocompatible polymers, chitosan, and poly(ethylene)glycol to produce monodisperse NPs of 36-65 nm, with a large surface area of 710.36 m2/g, large pore volume, diameter spanning 9.8 nm, and a favorable zeta potential allowing for stability and enhanced uptake of 5-FU.",Polymeric Mesoporous Silica Nanoparticles for Enhanced Delivery of 5-Fluorouracil In Vitro. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31248179/),[m2] / [g],710.36,109139,DB00544,Fluorouracil
,27067847,area under the curve (AUC),The sample group included 11 patients in whom 5-FU doses were adjusted individually based on pharmacokinetic monitoring according to an algorithm to maintain the area under the curve (AUC) in the range of 20-25 mg·h/L (Group A) and 9 patients in whom 5-FU doses were adjusted conventionally based on body surface area (Group B).,[Individual Dose Adjustment of 5-Fluorouracil Based on Pharmacokinetic Monitoring May Improve the Outcome of FOLFOX for Metastatic Colorectal Cancer]. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27067847/),[h·mg] / [l],20-25,109235,DB00544,Fluorouracil
,27067847,objective response rate,"The objective response rate was 63% and 33% in Group A and Group B, respectively (p=0.174).",[Individual Dose Adjustment of 5-Fluorouracil Based on Pharmacokinetic Monitoring May Improve the Outcome of FOLFOX for Metastatic Colorectal Cancer]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27067847/),%,63,109236,DB00544,Fluorouracil
,27067847,objective response rate,"The objective response rate was 63% and 33% in Group A and Group B, respectively (p=0.174).",[Individual Dose Adjustment of 5-Fluorouracil Based on Pharmacokinetic Monitoring May Improve the Outcome of FOLFOX for Metastatic Colorectal Cancer]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27067847/),%,33,109237,DB00544,Fluorouracil
,27067847,overall survival,"The median overall survival was 34 months and 14 months in Group A and Group B, respectively (p=0.036).",[Individual Dose Adjustment of 5-Fluorouracil Based on Pharmacokinetic Monitoring May Improve the Outcome of FOLFOX for Metastatic Colorectal Cancer]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27067847/),month,34,109238,DB00544,Fluorouracil
,27067847,overall survival,"The median overall survival was 34 months and 14 months in Group A and Group B, respectively (p=0.036).",[Individual Dose Adjustment of 5-Fluorouracil Based on Pharmacokinetic Monitoring May Improve the Outcome of FOLFOX for Metastatic Colorectal Cancer]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27067847/),month,14,109239,DB00544,Fluorouracil
,26117830,progression-free survival,The median progression-free survival was 9.9 (95% CI 6.5-17.1) months.,Phase I/II study of S-1 in combination with sorafenib for metastatic renal cell carcinoma. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26117830/),month,9.9,109490,DB00544,Fluorouracil
,23235319,Dose levels (DLs),"Dose levels (DLs) 1, 2, 3 and 4 were 50, 75, 100 and 125 mg/day, respectively.",Phase I trial of gemcitabine combined with capecitabine and erlotinib in advanced pancreatic cancer: a clinical and pharmacological study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23235319/),,50,109626,DB00544,Fluorouracil
,23235319,Dose levels (DLs),"Dose levels (DLs) 1, 2, 3 and 4 were 50, 75, 100 and 125 mg/day, respectively.",Phase I trial of gemcitabine combined with capecitabine and erlotinib in advanced pancreatic cancer: a clinical and pharmacological study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23235319/),,75,109627,DB00544,Fluorouracil
,23235319,Dose levels (DLs),"Dose levels (DLs) 1, 2, 3 and 4 were 50, 75, 100 and 125 mg/day, respectively.",Phase I trial of gemcitabine combined with capecitabine and erlotinib in advanced pancreatic cancer: a clinical and pharmacological study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23235319/),,100,109628,DB00544,Fluorouracil
,23235319,Dose levels (DLs),"Dose levels (DLs) 1, 2, 3 and 4 were 50, 75, 100 and 125 mg/day, respectively.",Phase I trial of gemcitabine combined with capecitabine and erlotinib in advanced pancreatic cancer: a clinical and pharmacological study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23235319/),,125,109629,DB00544,Fluorouracil
,30262136,progression-free survival,"Objective response (35 [49%] of 71 vs 40 [56%] of 71), clinical benefit (62 [87%] vs 65 [92%]), and progression-free survival (median 10·8 months [95% CI 7·4-11·5] vs 11·1 months [95% CI 8·0-12·8]) were similar in the BEVZ92 and reference bevacizumab groups.","Bevacizumab biosimilar BEVZ92 versus reference bevacizumab in combination with FOLFOX or FOLFIRI as first-line treatment for metastatic colorectal cancer: a multicentre, open-label, randomised controlled trial. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30262136/),month,10·8,109658,DB00544,Fluorouracil
,30262136,progression-free survival,"Objective response (35 [49%] of 71 vs 40 [56%] of 71), clinical benefit (62 [87%] vs 65 [92%]), and progression-free survival (median 10·8 months [95% CI 7·4-11·5] vs 11·1 months [95% CI 8·0-12·8]) were similar in the BEVZ92 and reference bevacizumab groups.","Bevacizumab biosimilar BEVZ92 versus reference bevacizumab in combination with FOLFOX or FOLFIRI as first-line treatment for metastatic colorectal cancer: a multicentre, open-label, randomised controlled trial. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30262136/),month,11·1,109659,DB00544,Fluorouracil
,1607921,Cl,"5-FU Cl values (L/h/m2) showed a wide dispersion for both men (median, 179; range, 29 to 739) and women (median, 155; range, 56 to 466).",Influence of sex and age on fluorouracil clearance. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1607921/),[l] / [h·m2],179,109712,DB00544,Fluorouracil
,1607921,Cl,"5-FU Cl values (L/h/m2) showed a wide dispersion for both men (median, 179; range, 29 to 739) and women (median, 155; range, 56 to 466).",Influence of sex and age on fluorouracil clearance. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1607921/),[l] / [h·m2],155,109713,DB00544,Fluorouracil
,33277781,CLcr,Thirty patients with BSA of 1.14-1.84 m2 and CLcr of 23.8-96.4 mL/min were assessable for pharmacokinetics.,Prospective evaluation and refinement of an S-1 dosage formula based on renal function for clinical application. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33277781/),[ml] / [min],23.8-96.4,109759,DB00544,Fluorouracil
,33277781,AUC,"The observed daily AUC ranged from 712.6 to 2868.7 ng·h/mL, and 18 patients achieved the target AUC (1447.8 ± 545.4 ng·h/mL).",Prospective evaluation and refinement of an S-1 dosage formula based on renal function for clinical application. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33277781/),[h·ng] / [ml],712.6 to 2868.7,109760,DB00544,Fluorouracil
,33277781,AUC,"The observed daily AUC ranged from 712.6 to 2868.7 ng·h/mL, and 18 patients achieved the target AUC (1447.8 ± 545.4 ng·h/mL).",Prospective evaluation and refinement of an S-1 dosage formula based on renal function for clinical application. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33277781/),[h·ng] / [ml],1447.8,109761,DB00544,Fluorouracil
,26955748,Area under curve (AUC),"Area under curve (AUC), maximum plasma concentration (Cmax), mean residence time (MRT) and time to reach maximum plasma concentration Tmax), were observed 4398.1±7.90μgh/mL, 145.45±2.25μg/L, 45.74±0.25h, 72±0.50h, respectively of HAC NPs and 119.92±1.78μgh/mL, 46.38±3.42μg/L, 1.2±0.25h, 0.5±0.02h were observed in plain 5-FU solution.",Hyaluronic acid embedded cellulose acetate phthlate core/shell nanoparticulate carrier of 5-fluorouracil. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26955748/),[μgh] / [ml],4398.1,109784,DB00544,Fluorouracil
,26955748,time to reach maximum plasma concentration Tmax),"Area under curve (AUC), maximum plasma concentration (Cmax), mean residence time (MRT) and time to reach maximum plasma concentration Tmax), were observed 4398.1±7.90μgh/mL, 145.45±2.25μg/L, 45.74±0.25h, 72±0.50h, respectively of HAC NPs and 119.92±1.78μgh/mL, 46.38±3.42μg/L, 1.2±0.25h, 0.5±0.02h were observed in plain 5-FU solution.",Hyaluronic acid embedded cellulose acetate phthlate core/shell nanoparticulate carrier of 5-fluorouracil. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26955748/),h,72,109785,DB00544,Fluorouracil
,26955748,time to reach maximum plasma concentration Tmax),"Area under curve (AUC), maximum plasma concentration (Cmax), mean residence time (MRT) and time to reach maximum plasma concentration Tmax), were observed 4398.1±7.90μgh/mL, 145.45±2.25μg/L, 45.74±0.25h, 72±0.50h, respectively of HAC NPs and 119.92±1.78μgh/mL, 46.38±3.42μg/L, 1.2±0.25h, 0.5±0.02h were observed in plain 5-FU solution.",Hyaluronic acid embedded cellulose acetate phthlate core/shell nanoparticulate carrier of 5-fluorouracil. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26955748/),h,0.5,109786,DB00544,Fluorouracil
> or =,11013283,steady-state concentration,"The mean steady-state concentration of plasma 5-FU was > or = 24 ng/mL, which was 184-fold greater than the minimum effective cytotoxic concentration in vitro.","Phase I assessment of the pharmacokinetics, metabolism, and safety of emitefur in patients with refractory solid tumors. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11013283/),[ng] / [ml],24,110069,DB00544,Fluorouracil
,10873078,MTD,"In conclusion, the MTD of this schedule is 10 mg/day and the DLTs are neutropenia and diarrhea.",Dose-finding and pharmacologic study of chronic oral idarubicin therapy in metastatic breast cancer patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10873078/),,10,110284,DB00544,Fluorouracil
,27200415,entrapment efficiency (E.E),Mean size of pHLNp-5-FU was 164.3 ± 8.4 nm with entrapment efficiency (E.E) of 54.17%.,"Pharmacokinetic, biodistribution and therapeutic efficacy of 5-fluorouracil-loaded pH-sensitive PEGylated liposomal nanoparticles in HCT-116 tumor bearing mouse. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27200415/),%,54.17,110408,DB00544,Fluorouracil
,32478266,loading capacities,"They emphasized excellent 5-Fu loading capacities of 141.2 mg/g (MCM-48), 156.6 mg/g (MCM/ST), 191 mg/g (MCM/CH), and 170 mg/g (MCM/CD), reflecting significant enhancement in the loading capacities.",Insight into the Loading and Release Properties of MCM-48/Biopolymer Composites as Carriers for 5-Fluorouracil: Equilibrium Modeling and Pharmacokinetic Studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32478266/),[mg] / [g],141.2,110506,DB00544,Fluorouracil
,32478266,loading capacities,"They emphasized excellent 5-Fu loading capacities of 141.2 mg/g (MCM-48), 156.6 mg/g (MCM/ST), 191 mg/g (MCM/CH), and 170 mg/g (MCM/CD), reflecting significant enhancement in the loading capacities.",Insight into the Loading and Release Properties of MCM-48/Biopolymer Composites as Carriers for 5-Fluorouracil: Equilibrium Modeling and Pharmacokinetic Studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32478266/),[mg] / [g],156.6,110507,DB00544,Fluorouracil
,32478266,loading capacities,"They emphasized excellent 5-Fu loading capacities of 141.2 mg/g (MCM-48), 156.6 mg/g (MCM/ST), 191 mg/g (MCM/CH), and 170 mg/g (MCM/CD), reflecting significant enhancement in the loading capacities.",Insight into the Loading and Release Properties of MCM-48/Biopolymer Composites as Carriers for 5-Fluorouracil: Equilibrium Modeling and Pharmacokinetic Studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32478266/),[mg] / [g],191,110508,DB00544,Fluorouracil
,32478266,loading capacities,"They emphasized excellent 5-Fu loading capacities of 141.2 mg/g (MCM-48), 156.6 mg/g (MCM/ST), 191 mg/g (MCM/CH), and 170 mg/g (MCM/CD), reflecting significant enhancement in the loading capacities.",Insight into the Loading and Release Properties of MCM-48/Biopolymer Composites as Carriers for 5-Fluorouracil: Equilibrium Modeling and Pharmacokinetic Studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32478266/),[mg] / [g],170,110509,DB00544,Fluorouracil
,32478266,ads,"This was supported by the estimated adsorption energies (0.23 kJ/mol (MCM-48), 0.26 kJ/mol (MCM/ST), 0.3 kJ/mol (MCM/CH), and 0.75 kJ/mol (MCM/CD)) and the thermodynamic parameters of free energy and enthalpy.",Insight into the Loading and Release Properties of MCM-48/Biopolymer Composites as Carriers for 5-Fluorouracil: Equilibrium Modeling and Pharmacokinetic Studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32478266/),[kj] / [mol],0.23,110510,DB00544,Fluorouracil
,32478266,ads,"This was supported by the estimated adsorption energies (0.23 kJ/mol (MCM-48), 0.26 kJ/mol (MCM/ST), 0.3 kJ/mol (MCM/CH), and 0.75 kJ/mol (MCM/CD)) and the thermodynamic parameters of free energy and enthalpy.",Insight into the Loading and Release Properties of MCM-48/Biopolymer Composites as Carriers for 5-Fluorouracil: Equilibrium Modeling and Pharmacokinetic Studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32478266/),[kj] / [mol],0.26,110511,DB00544,Fluorouracil
,32478266,ads,"This was supported by the estimated adsorption energies (0.23 kJ/mol (MCM-48), 0.26 kJ/mol (MCM/ST), 0.3 kJ/mol (MCM/CH), and 0.75 kJ/mol (MCM/CD)) and the thermodynamic parameters of free energy and enthalpy.",Insight into the Loading and Release Properties of MCM-48/Biopolymer Composites as Carriers for 5-Fluorouracil: Equilibrium Modeling and Pharmacokinetic Studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32478266/),[kj] / [mol],0.3,110512,DB00544,Fluorouracil
,32478266,ads,"This was supported by the estimated adsorption energies (0.23 kJ/mol (MCM-48), 0.26 kJ/mol (MCM/ST), 0.3 kJ/mol (MCM/CH), and 0.75 kJ/mol (MCM/CD)) and the thermodynamic parameters of free energy and enthalpy.",Insight into the Loading and Release Properties of MCM-48/Biopolymer Composites as Carriers for 5-Fluorouracil: Equilibrium Modeling and Pharmacokinetic Studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32478266/),[kj] / [mol],0.75,110513,DB00544,Fluorouracil
,12207632,-,"FFM-normalized CL was significantly higher in women than in men (0.030+/-0.008 vs 0.022+/-0.005 l min(-1) kg)(-1); 95% CI of difference 0.012, 0.003; P=0.003), suggesting that FU metabolism is more rapid in females.",Relationships between body composition parameters and fluorouracil pharmacokinetics. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12207632/),[l] / [min],0.030,110790,DB00544,Fluorouracil
,12207632,-,"FFM-normalized CL was significantly higher in women than in men (0.030+/-0.008 vs 0.022+/-0.005 l min(-1) kg)(-1); 95% CI of difference 0.012, 0.003; P=0.003), suggesting that FU metabolism is more rapid in females.",Relationships between body composition parameters and fluorouracil pharmacokinetics. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12207632/),[l] / [min],0.022,110791,DB00544,Fluorouracil
,12207632,normalized CL,"FFM-normalized CL was significantly higher in women than in men (0.030+/-0.008 vs 0.022+/-0.005 l min(-1) kg)(-1); 95% CI of difference 0.012, 0.003; P=0.003), suggesting that FU metabolism is more rapid in females.",Relationships between body composition parameters and fluorouracil pharmacokinetics. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12207632/),[l] / [min],0.030,110792,DB00544,Fluorouracil
,12207632,normalized CL,"FFM-normalized CL was significantly higher in women than in men (0.030+/-0.008 vs 0.022+/-0.005 l min(-1) kg)(-1); 95% CI of difference 0.012, 0.003; P=0.003), suggesting that FU metabolism is more rapid in females.",Relationships between body composition parameters and fluorouracil pharmacokinetics. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12207632/),[l] / [min],0.022,110793,DB00544,Fluorouracil
,24114122,AUCs,"UGT1A1 *1/*28 and *1/*1 patients treated with IRIN (150) had similar AUCs for the active irinotecan metabolite, SN38 (366 +/- 278 and 350 +/- 159 ng/ml*hr, respectively).","UGT1A1 genotype-guided phase I study of irinotecan, oxaliplatin, and capecitabine. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24114122/),[ng] / [h·ml],366,111241,DB00544,Fluorouracil
,24114122,AUCs,"UGT1A1 *1/*28 and *1/*1 patients treated with IRIN (150) had similar AUCs for the active irinotecan metabolite, SN38 (366 +/- 278 and 350 +/- 159 ng/ml*hr, respectively).","UGT1A1 genotype-guided phase I study of irinotecan, oxaliplatin, and capecitabine. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24114122/),[ng] / [h·ml],350,111242,DB00544,Fluorouracil
,24114122,exposures,"UGT1A1 *28/*28 patients (n = 3) treated with a lower IRIN dose (100) had non-significantly higher mean SN38 exposures (604 +/- 289 ng/ml*hr, p = 0.14).","UGT1A1 genotype-guided phase I study of irinotecan, oxaliplatin, and capecitabine. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24114122/),[ng] / [h·ml],604,111243,DB00544,Fluorouracil
,2676149,steady-state plasma concentration,"Eleven patients treated with a 5.5-day continuous i.v. infusion of 500 mg/m2/day of (6R,S)-folinic acid in combination with daily bolus 5-fluorouracil had a median steady-state plasma concentration of 3.25 microM (6S)-folinic acid (the bioactive diastereoisomer).","Pharmacokinetics of diastereoisomers of (6R,S)-folinic acid (leucovorin) in humans during constant high-dose intravenous infusion. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2676149/),μM,3.25,111422,DB00544,Fluorouracil
,2676149,steady-state plasma concentration,"The bioactive metabolite (6S)-5-methyltetrahydrofolic acid, analyzed in six patients, reached a median steady-state plasma concentration of 5.7 microM.","Pharmacokinetics of diastereoisomers of (6R,S)-folinic acid (leucovorin) in humans during constant high-dose intravenous infusion. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2676149/),μM,5.7,111423,DB00544,Fluorouracil
,2676149,lowest plasma concentrations at steady-state,The lowest plasma concentrations at steady-state were 1.86 microM (6S)-folinic acid and 3.12 microM (6S)-5-methyltetrahydrofolic acid.,"Pharmacokinetics of diastereoisomers of (6R,S)-folinic acid (leucovorin) in humans during constant high-dose intravenous infusion. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2676149/),μM,1.86,111424,DB00544,Fluorouracil
,2676149,lowest plasma concentrations at steady-state,The lowest plasma concentrations at steady-state were 1.86 microM (6S)-folinic acid and 3.12 microM (6S)-5-methyltetrahydrofolic acid.,"Pharmacokinetics of diastereoisomers of (6R,S)-folinic acid (leucovorin) in humans during constant high-dose intravenous infusion. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2676149/),μM,3.12,111425,DB00544,Fluorouracil
,2676149,steady-state plasma concentration,"The median steady-state plasma concentration of (6R)-folinic acid was 38.2 microM, more than 10 times the concentration of (6S)-folinic acid.","Pharmacokinetics of diastereoisomers of (6R,S)-folinic acid (leucovorin) in humans during constant high-dose intravenous infusion. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2676149/),μM,38.2,111426,DB00544,Fluorouracil
,2676149,terminal half-lives,"Along with other plasma pharmacokinetic parameters, terminal half-lives were estimated for (6S)-folinic acid (median, 45.4 min), (6R)-folinic acid (median, 388 min), and (6S)-5-methyltetrahydrofolic acid (median, 446 min).","Pharmacokinetics of diastereoisomers of (6R,S)-folinic acid (leucovorin) in humans during constant high-dose intravenous infusion. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2676149/),min,45.4,111427,DB00544,Fluorouracil
,2676149,terminal half-lives,"Along with other plasma pharmacokinetic parameters, terminal half-lives were estimated for (6S)-folinic acid (median, 45.4 min), (6R)-folinic acid (median, 388 min), and (6S)-5-methyltetrahydrofolic acid (median, 446 min).","Pharmacokinetics of diastereoisomers of (6R,S)-folinic acid (leucovorin) in humans during constant high-dose intravenous infusion. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2676149/),min,388,111428,DB00544,Fluorouracil
,2676149,terminal half-lives,"Along with other plasma pharmacokinetic parameters, terminal half-lives were estimated for (6S)-folinic acid (median, 45.4 min), (6R)-folinic acid (median, 388 min), and (6S)-5-methyltetrahydrofolic acid (median, 446 min).","Pharmacokinetics of diastereoisomers of (6R,S)-folinic acid (leucovorin) in humans during constant high-dose intravenous infusion. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2676149/),min,446,111429,DB00544,Fluorouracil
,2676149,renal clearance,"However, the low renal clearance of (6R)-folinic acid (median, 8.2 ml/min/m2) was attributable to the extensive binding of (6R)-folinic acid to plasma proteins (median, 8.7% free), not to reabsorption in the kidney.","Pharmacokinetics of diastereoisomers of (6R,S)-folinic acid (leucovorin) in humans during constant high-dose intravenous infusion. ",CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2676149/),[ml] / [m2·min],8.2,111430,DB00544,Fluorouracil
,23197286,area under the plasma concentration-time curve (AUC),"After rats received 5-FU intravenous (IV) bolus injections, the area under the plasma concentration-time curve (AUC) and elimination half-life (t 1/2) in CRC rats (10.02 ± 0.37 μg h mL(-1), 0.30 ± 0.02 h, respectively) were significantly lower than that in control rats (13.46 ± 1.20 μg h mL(-1), 0.52 ± 0.05 h, respectively), whereas total plasma clearance (CLtot) in CRC rats (2.01 ± 0.07 L h(-1) kg(-1)) was significantly increased compared with that in control rats (1.54 ± 0.14 L h(-1) kg(-1)).","Pharmacokinetics of 5-fluorouracil and increased hepatic dihydropyrimidine dehydrogenase activity levels in 1,2-dimethylhydrazine-induced colorectal cancer model rats. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23197286/),[h·μg] / [ml],10.02,112021,DB00544,Fluorouracil
,23197286,area under the plasma concentration-time curve (AUC),"After rats received 5-FU intravenous (IV) bolus injections, the area under the plasma concentration-time curve (AUC) and elimination half-life (t 1/2) in CRC rats (10.02 ± 0.37 μg h mL(-1), 0.30 ± 0.02 h, respectively) were significantly lower than that in control rats (13.46 ± 1.20 μg h mL(-1), 0.52 ± 0.05 h, respectively), whereas total plasma clearance (CLtot) in CRC rats (2.01 ± 0.07 L h(-1) kg(-1)) was significantly increased compared with that in control rats (1.54 ± 0.14 L h(-1) kg(-1)).","Pharmacokinetics of 5-fluorouracil and increased hepatic dihydropyrimidine dehydrogenase activity levels in 1,2-dimethylhydrazine-induced colorectal cancer model rats. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23197286/),[h·μg] / [ml],13.46,112022,DB00544,Fluorouracil
,23197286,elimination half-life (t 1/2),"After rats received 5-FU intravenous (IV) bolus injections, the area under the plasma concentration-time curve (AUC) and elimination half-life (t 1/2) in CRC rats (10.02 ± 0.37 μg h mL(-1), 0.30 ± 0.02 h, respectively) were significantly lower than that in control rats (13.46 ± 1.20 μg h mL(-1), 0.52 ± 0.05 h, respectively), whereas total plasma clearance (CLtot) in CRC rats (2.01 ± 0.07 L h(-1) kg(-1)) was significantly increased compared with that in control rats (1.54 ± 0.14 L h(-1) kg(-1)).","Pharmacokinetics of 5-fluorouracil and increased hepatic dihydropyrimidine dehydrogenase activity levels in 1,2-dimethylhydrazine-induced colorectal cancer model rats. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/23197286/),h,0.30,112023,DB00544,Fluorouracil
,23197286,elimination half-life (t 1/2),"After rats received 5-FU intravenous (IV) bolus injections, the area under the plasma concentration-time curve (AUC) and elimination half-life (t 1/2) in CRC rats (10.02 ± 0.37 μg h mL(-1), 0.30 ± 0.02 h, respectively) were significantly lower than that in control rats (13.46 ± 1.20 μg h mL(-1), 0.52 ± 0.05 h, respectively), whereas total plasma clearance (CLtot) in CRC rats (2.01 ± 0.07 L h(-1) kg(-1)) was significantly increased compared with that in control rats (1.54 ± 0.14 L h(-1) kg(-1)).","Pharmacokinetics of 5-fluorouracil and increased hepatic dihydropyrimidine dehydrogenase activity levels in 1,2-dimethylhydrazine-induced colorectal cancer model rats. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/23197286/),h,0.52,112024,DB00544,Fluorouracil
,23197286,total plasma clearance (CLtot),"After rats received 5-FU intravenous (IV) bolus injections, the area under the plasma concentration-time curve (AUC) and elimination half-life (t 1/2) in CRC rats (10.02 ± 0.37 μg h mL(-1), 0.30 ± 0.02 h, respectively) were significantly lower than that in control rats (13.46 ± 1.20 μg h mL(-1), 0.52 ± 0.05 h, respectively), whereas total plasma clearance (CLtot) in CRC rats (2.01 ± 0.07 L h(-1) kg(-1)) was significantly increased compared with that in control rats (1.54 ± 0.14 L h(-1) kg(-1)).","Pharmacokinetics of 5-fluorouracil and increased hepatic dihydropyrimidine dehydrogenase activity levels in 1,2-dimethylhydrazine-induced colorectal cancer model rats. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23197286/),[l] / [h·kg],2.01,112025,DB00544,Fluorouracil
,23197286,total plasma clearance (CLtot),"After rats received 5-FU intravenous (IV) bolus injections, the area under the plasma concentration-time curve (AUC) and elimination half-life (t 1/2) in CRC rats (10.02 ± 0.37 μg h mL(-1), 0.30 ± 0.02 h, respectively) were significantly lower than that in control rats (13.46 ± 1.20 μg h mL(-1), 0.52 ± 0.05 h, respectively), whereas total plasma clearance (CLtot) in CRC rats (2.01 ± 0.07 L h(-1) kg(-1)) was significantly increased compared with that in control rats (1.54 ± 0.14 L h(-1) kg(-1)).","Pharmacokinetics of 5-fluorouracil and increased hepatic dihydropyrimidine dehydrogenase activity levels in 1,2-dimethylhydrazine-induced colorectal cancer model rats. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23197286/),[l] / [h·kg],1.54,112026,DB00544,Fluorouracil
,21326246,overall response rate,The overall response rate was 24.5%.,Phase II study of S-1 combined with oxaliplatin as therapy for patients with metastatic biliary tract cancer: influence of the CYP2A6 polymorphism on pharmacokinetics and clinical activity. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21326246/),%,24.5,112283,DB00544,Fluorouracil
,21326246,progression-free,"Median progression-free and overall survival was 3.7 and 8.7 months, respectively.",Phase II study of S-1 combined with oxaliplatin as therapy for patients with metastatic biliary tract cancer: influence of the CYP2A6 polymorphism on pharmacokinetics and clinical activity. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21326246/),month,3.7,112284,DB00544,Fluorouracil
,21326246,overall survival,"Median progression-free and overall survival was 3.7 and 8.7 months, respectively.",Phase II study of S-1 combined with oxaliplatin as therapy for patients with metastatic biliary tract cancer: influence of the CYP2A6 polymorphism on pharmacokinetics and clinical activity. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21326246/),month,8.7,112285,DB00544,Fluorouracil
,18555590,progression free survival,"Patients with > or =6.2 CD34+/vWF+ cells/ml had a shorter progression free survival (3.7 months) as against patients with <6.2 CD34+/vWF+/ml (6.0 months, p = 0.076).",Mobilized CD34+ cells as a biomarker candidate for the efficacy of combined maximal tolerance dose and continuous infusional chemotherapy and G-CSF surge in gastric cancer. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18555590/),month,3.7,112426,DB00544,Fluorouracil
,18555590,progression free survival,"Patients with > or =6.2 CD34+/vWF+ cells/ml had a shorter progression free survival (3.7 months) as against patients with <6.2 CD34+/vWF+/ml (6.0 months, p = 0.076).",Mobilized CD34+ cells as a biomarker candidate for the efficacy of combined maximal tolerance dose and continuous infusional chemotherapy and G-CSF surge in gastric cancer. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18555590/),month,6.0,112427,DB00544,Fluorouracil
,18555590,progression free survival,"Patients with > or =5.8 CD34+ cells/ml had shorter progression free survival (4.0 months) than patients with <5.8 CD34+ cells/ml (6.1 months, p = 0.046).",Mobilized CD34+ cells as a biomarker candidate for the efficacy of combined maximal tolerance dose and continuous infusional chemotherapy and G-CSF surge in gastric cancer. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18555590/),month,4.,112428,DB00544,Fluorouracil
,18555590,progression free survival,"Patients with > or =5.8 CD34+ cells/ml had shorter progression free survival (4.0 months) than patients with <5.8 CD34+ cells/ml (6.1 months, p = 0.046).",Mobilized CD34+ cells as a biomarker candidate for the efficacy of combined maximal tolerance dose and continuous infusional chemotherapy and G-CSF surge in gastric cancer. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18555590/),month,6.1,112429,DB00544,Fluorouracil
,18555590,maximum inhibition (I(max)),"In an ex vivo pharmacokinetic study, the maximum inhibition (I(max)) for HUVEC and YCC3 cells was 13.0 +/- 6.6% and 74.0 +/- 2.0%, respectively.",Mobilized CD34+ cells as a biomarker candidate for the efficacy of combined maximal tolerance dose and continuous infusional chemotherapy and G-CSF surge in gastric cancer. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18555590/),%,13.0,112430,DB00544,Fluorouracil
,18555590,maximum inhibition (I(max)),"In an ex vivo pharmacokinetic study, the maximum inhibition (I(max)) for HUVEC and YCC3 cells was 13.0 +/- 6.6% and 74.0 +/- 2.0%, respectively.",Mobilized CD34+ cells as a biomarker candidate for the efficacy of combined maximal tolerance dose and continuous infusional chemotherapy and G-CSF surge in gastric cancer. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18555590/),%,74.0,112431,DB00544,Fluorouracil
,18555590,time to reach I(max) (T(max)),The time to reach I(max) (T(max)) was 72 h in all HUVEC cells and 0.5 hours in YCC3 cells.,Mobilized CD34+ cells as a biomarker candidate for the efficacy of combined maximal tolerance dose and continuous infusional chemotherapy and G-CSF surge in gastric cancer. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18555590/),h,72,112432,DB00544,Fluorouracil
,18555590,time to reach I(max) (T(max)),The time to reach I(max) (T(max)) was 72 h in all HUVEC cells and 0.5 hours in YCC3 cells.,Mobilized CD34+ cells as a biomarker candidate for the efficacy of combined maximal tolerance dose and continuous infusional chemotherapy and G-CSF surge in gastric cancer. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18555590/),h,0.5,112433,DB00544,Fluorouracil
> or =,9508199,Steady-state concentrations (Css),Steady-state concentrations (Css) of 9-AC L > or = 10 nmol/L (3.6 microg/L) were seen in five of seven patients at 1.65 mg/m2 and five of six patients at 1.9 mg/m2.,Phase I and pharmacologic study of 9-aminocamptothecin colloidal dispersion formulation given as a 24-hour continuous infusion weekly times four every 5 weeks. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9508199/),[nM] / [l],10,113163,DB00544,Fluorouracil
,9508199,Steady-state concentrations (Css),Steady-state concentrations (Css) of 9-AC L > or = 10 nmol/L (3.6 microg/L) were seen in five of seven patients at 1.65 mg/m2 and five of six patients at 1.9 mg/m2.,Phase I and pharmacologic study of 9-aminocamptothecin colloidal dispersion formulation given as a 24-hour continuous infusion weekly times four every 5 weeks. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9508199/),[μg] / [l],3.6,113164,DB00544,Fluorouracil
,28102464,PFS,"Six patients achieved a partial response, and in 15 patients with CRC median PFS was 5.95 months (95% CI: 5.29-8.77).",A phase I and pharmacokinetic study of afilbercept with FOLFIRI: comparison of Chinese and Caucasian populations. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28102464/),month,5.95,113620,DB00544,Fluorouracil
,28102464,Cmax,"The mean free aflibercept values for Cmax (64.8 μg/mL) AUC (291 μg.day/mL), CL (0.92 L/day) and Vss (5.9 L) were similar to those measured in Caucasian patients.",A phase I and pharmacokinetic study of afilbercept with FOLFIRI: comparison of Chinese and Caucasian populations. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28102464/),[μg] / [ml],64.8,113621,DB00544,Fluorouracil
,28102464,AUC,"The mean free aflibercept values for Cmax (64.8 μg/mL) AUC (291 μg.day/mL), CL (0.92 L/day) and Vss (5.9 L) were similar to those measured in Caucasian patients.",A phase I and pharmacokinetic study of afilbercept with FOLFIRI: comparison of Chinese and Caucasian populations. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28102464/),[d·μg] / [ml],291,113622,DB00544,Fluorouracil
,28102464,CL,"The mean free aflibercept values for Cmax (64.8 μg/mL) AUC (291 μg.day/mL), CL (0.92 L/day) and Vss (5.9 L) were similar to those measured in Caucasian patients.",A phase I and pharmacokinetic study of afilbercept with FOLFIRI: comparison of Chinese and Caucasian populations. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28102464/),[l] / [d],0.92,113623,DB00544,Fluorouracil
,28102464,Vss,"The mean free aflibercept values for Cmax (64.8 μg/mL) AUC (291 μg.day/mL), CL (0.92 L/day) and Vss (5.9 L) were similar to those measured in Caucasian patients.",A phase I and pharmacokinetic study of afilbercept with FOLFIRI: comparison of Chinese and Caucasian populations. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28102464/),l,5.9,113624,DB00544,Fluorouracil
,17697758,C(max),"In plasma, the observed mean C(max) from the coated pellets group (3.65+/-2.3microg/mL) was lower than that of the uncoated pellets group (23.54+/-2.9microg/mL).",Study on colon-specific pectin/ethylcellulose film-coated 5-fluorouracil pellets in rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17697758/),[μg] / [ml],3.65,114155,DB00544,Fluorouracil
,17697758,C(max),"In plasma, the observed mean C(max) from the coated pellets group (3.65+/-2.3microg/mL) was lower than that of the uncoated pellets group (23.54+/-2.9microg/mL).",Study on colon-specific pectin/ethylcellulose film-coated 5-fluorouracil pellets in rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17697758/),[μg] / [ml],23.54,114156,DB00544,Fluorouracil
,17697758,AUC,"The AUC values obtained from the uncoated pellets and the coated pellets were 49.08+/-3.1 and 9.06+/-1.2microgh/mL, respectively.",Study on colon-specific pectin/ethylcellulose film-coated 5-fluorouracil pellets in rats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17697758/),[μgh] / [ml],49.08,114157,DB00544,Fluorouracil
,17697758,AUC,"The AUC values obtained from the uncoated pellets and the coated pellets were 49.08+/-3.1 and 9.06+/-1.2microgh/mL, respectively.",Study on colon-specific pectin/ethylcellulose film-coated 5-fluorouracil pellets in rats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17697758/),[μgh] / [ml],9.06,114158,DB00544,Fluorouracil
,2523758,apparent Ki,"6-Benzyl-2-thiouracil, a thymidine phosphorylase-selective inhibitor, and 1-(2'-deoxy-beta-D-glucopyranosyl)thymine, a uridine phosphorylase-selective inhibitor, each decreased the rate of FdUrd disappearance (apparent Ki, 1.4-1.6 and 3.8 mM, respectively) but had no direct effect on FUra disappearance.",Effects of pyrimidine nucleoside phosphorylase inhibitors on hepatic fluoropyrimidine elimination in the rat. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2523758/),mM,1.4-1.6,114298,DB00544,Fluorouracil
,2523758,apparent Ki,"6-Benzyl-2-thiouracil, a thymidine phosphorylase-selective inhibitor, and 1-(2'-deoxy-beta-D-glucopyranosyl)thymine, a uridine phosphorylase-selective inhibitor, each decreased the rate of FdUrd disappearance (apparent Ki, 1.4-1.6 and 3.8 mM, respectively) but had no direct effect on FUra disappearance.",Effects of pyrimidine nucleoside phosphorylase inhibitors on hepatic fluoropyrimidine elimination in the rat. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2523758/),mM,3.8,114299,DB00544,Fluorouracil
,2523758,apparent Ki,"2,6-Dihydroxypyridine, a uridine phosphorylase-selective inhibitor, decreased the rate of FdUrd disappearance (apparent Ki, 12.4-16.2 microM) and directly inhibited FUra elimination (apparent Ki, 4.3-5.3 microM).",Effects of pyrimidine nucleoside phosphorylase inhibitors on hepatic fluoropyrimidine elimination in the rat. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2523758/),μM,12.4-16.2,114300,DB00544,Fluorouracil
,2523758,apparent Ki,"2,6-Dihydroxypyridine, a uridine phosphorylase-selective inhibitor, decreased the rate of FdUrd disappearance (apparent Ki, 12.4-16.2 microM) and directly inhibited FUra elimination (apparent Ki, 4.3-5.3 microM).",Effects of pyrimidine nucleoside phosphorylase inhibitors on hepatic fluoropyrimidine elimination in the rat. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2523758/),μM,4.3-5.3,114301,DB00544,Fluorouracil
,2523758,apparent Ki,"2,4-Dihydroxypyridine, which does not inhibit pyrimidine nucleoside phosphorylases, directly inhibited FUra elimination (apparent Ki, 77 microM) and also decreased the rate of FdUrd disappearance, possibly due to product (FUra) inhibition.",Effects of pyrimidine nucleoside phosphorylase inhibitors on hepatic fluoropyrimidine elimination in the rat. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2523758/),μM,77,114302,DB00544,Fluorouracil
,10472335,AUC,"a) AUC in all patients, at the beginning of the treatment averaged 9.05 +/- 3.115 (range from 3.9 to 16.41).",Individual 5FU-dose adaptation schedule using bimonthly pharmacokinetically modulated LV5FU2 regimen: a feasibility study in patients with advanced colorectal cancer. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10472335/),,9.05,114374,DB00544,Fluorouracil
,11745907,T-HALF,The T-HALF of racemic FT (8.3 h) was comparable to the T-HALF of S-FT (10.3 h) which indicated that the kinetics of the racemate are governed by S-FT.,Stereoselective metabolism and pharmacokinetics of tegafur. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11745907/),h,8.3,114666,DB00544,Fluorouracil
,11745907,T-HALF,The T-HALF of racemic FT (8.3 h) was comparable to the T-HALF of S-FT (10.3 h) which indicated that the kinetics of the racemate are governed by S-FT.,Stereoselective metabolism and pharmacokinetics of tegafur. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11745907/),h,10.3,114667,DB00544,Fluorouracil
,11745907,T-HALF,"The active cytotoxic moiety, 5-FU, exhibited formation rate limited kinetics from R-FT because the T-HALF of 5-FU (3.4 h) was similar to that of R-FT (2.4 h).",Stereoselective metabolism and pharmacokinetics of tegafur. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11745907/),h,3.4,114668,DB00544,Fluorouracil
,11745907,T-HALF,"The active cytotoxic moiety, 5-FU, exhibited formation rate limited kinetics from R-FT because the T-HALF of 5-FU (3.4 h) was similar to that of R-FT (2.4 h).",Stereoselective metabolism and pharmacokinetics of tegafur. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11745907/),h,2.4,114669,DB00544,Fluorouracil
,12761805,V(d),V(d) was 0.266 L/kg of ideal body weight and Cl was 1.21 L/h. kg of total weight following weekly doses.,A Bayesian method for predicting 5-fluorouracil pharmacokinetic parameters following short-term infusion in patients with colorectal cancer. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12761805/),[l] / [kg],0.266,115173,DB00544,Fluorouracil
,12761805,Cl,V(d) was 0.266 L/kg of ideal body weight and Cl was 1.21 L/h. kg of total weight following weekly doses.,A Bayesian method for predicting 5-fluorouracil pharmacokinetic parameters following short-term infusion in patients with colorectal cancer. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12761805/),[l] / [h·kg],1.21,115174,DB00544,Fluorouracil
,26375684,T1/2,"T1/2 of the slow-release 5-fluorouracil implant was 5475.8±136.4 min, whereas Vd was 45275.0±1028.6 l.",Pharmacokinetic study and clinical evaluation of a slow-release 5-fluorouracil implant in pancreatic cancer patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26375684/),min,5475.8,116267,DB00544,Fluorouracil
,26375684,Vd,"T1/2 of the slow-release 5-fluorouracil implant was 5475.8±136.4 min, whereas Vd was 45275.0±1028.6 l.",Pharmacokinetic study and clinical evaluation of a slow-release 5-fluorouracil implant in pancreatic cancer patients. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26375684/),l,45275.0,116268,DB00544,Fluorouracil
,1362949,Maximum plasma levels (Cpmax),"Maximum plasma levels (Cpmax) for Ft, uracil, and 5-FU except in one patient were achieved at 0.6-2.1 hr, 0.6-4.1 hr, and 0.7-2.0 hr, respectively.",Clinical pharmacology of combined oral uracil and ftorafur. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1362949/),h,0.6-2.1,116413,DB00544,Fluorouracil
,1362949,Maximum plasma levels (Cpmax),"Maximum plasma levels (Cpmax) for Ft, uracil, and 5-FU except in one patient were achieved at 0.6-2.1 hr, 0.6-4.1 hr, and 0.7-2.0 hr, respectively.",Clinical pharmacology of combined oral uracil and ftorafur. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1362949/),h,0.6-4.1,116414,DB00544,Fluorouracil
,1362949,Maximum plasma levels (Cpmax),"Maximum plasma levels (Cpmax) for Ft, uracil, and 5-FU except in one patient were achieved at 0.6-2.1 hr, 0.6-4.1 hr, and 0.7-2.0 hr, respectively.",Clinical pharmacology of combined oral uracil and ftorafur. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1362949/),h,0.7-2.0,116415,DB00544,Fluorouracil
,29325686,progression-free survival,"The median progression-free survival and overall survival times were 4.4 months (95% CI = 4.2-8.5) and 17.0 months (95% CI = 11.2-18.7), respectively.",Phase II study of tailored S-1 monotherapy with a 1-week interval after a 2-week dosing period in elderly patients with advanced non-small cell lung cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29325686/),month,4.4,117125,DB00544,Fluorouracil
,29325686,overall survival times,"The median progression-free survival and overall survival times were 4.4 months (95% CI = 4.2-8.5) and 17.0 months (95% CI = 11.2-18.7), respectively.",Phase II study of tailored S-1 monotherapy with a 1-week interval after a 2-week dosing period in elderly patients with advanced non-small cell lung cancer. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29325686/),month,17.0,117126,DB00544,Fluorouracil
,12196374,overall survival,"Of 29 patients with evaluable disease, there was one complete response and six partial responses [24% response rate [95% confidence interval (CI) 10% to 44%]], a median PFS of 22 weeks (95% CI 17-27 weeks) and median overall survival of 34 weeks (95% CI 19-49 weeks).",A phase I and pharmacokinetic study of capecitabine in combination with epirubicin and cisplatin in patients with inoperable oesophago-gastric adenocarcinoma. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12196374/),weeks,34,117162,DB00544,Fluorouracil
,12196374,t(max),"Capecitabine was rapidly absorbed after oral administration, with a t(max) of 1-2 h for capecitabine, DFCR (5'-deoxy-5-fluorocytidine) and DFUR (5'-deoxy-5-fluorouridine).",A phase I and pharmacokinetic study of capecitabine in combination with epirubicin and cisplatin in patients with inoperable oesophago-gastric adenocarcinoma. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12196374/),h,1-2,117163,DB00544,Fluorouracil
,678346,bioavailability,Oral administration of 10 to 15 mg/kg gave variable plasma levels (0 to 10.5 microgram/ml) and bioavailability (0 to 74%; mean 28%).,Fluorouracil therapy in patients with carcinoma of the large bowel: a pharmacokinetic comparison of various rates and routes of administration. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/678346/),%,0 to 74,117242,DB00544,Fluorouracil
,678346,bioavailability,Oral administration of 10 to 15 mg/kg gave variable plasma levels (0 to 10.5 microgram/ml) and bioavailability (0 to 74%; mean 28%).,Fluorouracil therapy in patients with carcinoma of the large bowel: a pharmacokinetic comparison of various rates and routes of administration. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/678346/),%,28,117243,DB00544,Fluorouracil
,18067212,Tumor volume,"Tumor volume of the control animals was 5.8 cm(3) on the 30th day, while in 5-FU with transdermal patch delivery animals it was only 0.23 cm(3) (p <0.05).",Microprocessor-controlled iontophoretic drug delivery of 5-fluorouracil: pharmacodynamic and pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18067212/),cm(3),5.8,117263,DB00544,Fluorouracil
,18067212,Tumor volume,"Tumor volume of the control animals was 5.8 cm(3) on the 30th day, while in 5-FU with transdermal patch delivery animals it was only 0.23 cm(3) (p <0.05).",Microprocessor-controlled iontophoretic drug delivery of 5-fluorouracil: pharmacodynamic and pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18067212/),cm(3),0.23,117264,DB00544,Fluorouracil
,22045498,response rate,"Objective partial responses were reported in 7 patients, yielding a response rate of 43.8% in the all-treated population according to the investigator assessment.",A phase I study of vinflunine in combination with capecitabine in patients with metastatic breast cancer previously treated with anthracyclines and taxanes. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22045498/),%,43.8,118154,DB00544,Fluorouracil
,17216531,progression-free,"Median progression-free and overall survivals were 12.2 and 26.6 months, respectively.","Phase I study of gefitinib, irinotecan, 5-fluorouracil and leucovorin in patients with metastatic colorectal cancer. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17216531/),month,12.2,119214,DB00544,Fluorouracil
,17216531,overall survivals,"Median progression-free and overall survivals were 12.2 and 26.6 months, respectively.","Phase I study of gefitinib, irinotecan, 5-fluorouracil and leucovorin in patients with metastatic colorectal cancer. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17216531/),month,26.6,119215,DB00544,Fluorouracil
,8419064,total run time,"HPLC 1 allows quantification of 5MTHF by absorption at 313 nm; HPLC 2, the quantification of l-FA and d-FA by electrochemical detection in the oxidation mode (total run time 18 min).",HPLC of folinic acid diastereoisomers and 5-methyltetrahydrofolate in plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8419064/),min,18,119499,DB00544,Fluorouracil
>,8419064,Recoveries,Recoveries are > 80%.,HPLC of folinic acid diastereoisomers and 5-methyltetrahydrofolate in plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8419064/),%,80,119500,DB00544,Fluorouracil
,8419064,sensitivity,The sensitivity limit is 50 nmol/L for 5MTHF and 20 nmol/L for l-FA and d-FA.,HPLC of folinic acid diastereoisomers and 5-methyltetrahydrofolate in plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8419064/),[nM] / [l],50,119501,DB00544,Fluorouracil
,8419064,sensitivity,The sensitivity limit is 50 nmol/L for 5MTHF and 20 nmol/L for l-FA and d-FA.,HPLC of folinic acid diastereoisomers and 5-methyltetrahydrofolate in plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8419064/),,20,119502,DB00544,Fluorouracil
,21482491,AUC(0-t),"The AUC(0-t) values of mean concentration curves of total plasma platinum, total ascites platinum, free plasma platinum, and free ascites platinum were 31.15, 7.96, 4.93 and 2.93 mg•h/ml, respectively.",Pharmacokinetics of oxaliplatin in gastrointestinal cancer patients with malignant ascites. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21482491/),[h·mg] / [ml],31.15,119603,DB00544,Fluorouracil
,21482491,AUC(0-t),"The AUC(0-t) values of mean concentration curves of total plasma platinum, total ascites platinum, free plasma platinum, and free ascites platinum were 31.15, 7.96, 4.93 and 2.93 mg•h/ml, respectively.",Pharmacokinetics of oxaliplatin in gastrointestinal cancer patients with malignant ascites. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21482491/),[h·mg] / [ml],7.96,119604,DB00544,Fluorouracil
,21482491,AUC(0-t),"The AUC(0-t) values of mean concentration curves of total plasma platinum, total ascites platinum, free plasma platinum, and free ascites platinum were 31.15, 7.96, 4.93 and 2.93 mg•h/ml, respectively.",Pharmacokinetics of oxaliplatin in gastrointestinal cancer patients with malignant ascites. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21482491/),[h·mg] / [ml],4.93,119605,DB00544,Fluorouracil
,21482491,AUC(0-t),"The AUC(0-t) values of mean concentration curves of total plasma platinum, total ascites platinum, free plasma platinum, and free ascites platinum were 31.15, 7.96, 4.93 and 2.93 mg•h/ml, respectively.",Pharmacokinetics of oxaliplatin in gastrointestinal cancer patients with malignant ascites. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21482491/),[h·mg] / [ml],2.93,119606,DB00544,Fluorouracil
,8784018,total lung FUDR,"Pharmacokinetic evaluation demonstrated that ILP at 21 mg/mL maximally elevated total lung FUDR and 5-fluorouracil levels (508.5 +/- 96.4 micrograms/g lung) in comparison with the ILP 14, ILP 7, and intravenous groups (299.1 +/- 44.8, 116.0 +/- 21.1, and 7.5 +/- 4.1 micrograms/g lung, respectively) (p < 0.05).",Isolated lung perfusion with FUDR in the rat: pharmacokinetics and survival. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8784018/),[μg] / [g],508.5,120396,DB00544,Fluorouracil
,8784018,Ser,"Serum FUDR levels were 10.5 +/- 6.8, 1.3 +/- 0.5, 2.31 +/- 1.1, and 1.2 +/- 0.4 microgram/g lung (p = not significant) for intravenous, ILP 7, ILP 14, and ILP 21 groups, respectively.",Isolated lung perfusion with FUDR in the rat: pharmacokinetics and survival. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8784018/),[μg] / [g·lung],10.5,120397,DB00544,Fluorouracil
,8784018,FUDR,"Serum FUDR levels were 10.5 +/- 6.8, 1.3 +/- 0.5, 2.31 +/- 1.1, and 1.2 +/- 0.4 microgram/g lung (p = not significant) for intravenous, ILP 7, ILP 14, and ILP 21 groups, respectively.",Isolated lung perfusion with FUDR in the rat: pharmacokinetics and survival. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8784018/),[μg] / [g·lung],10.5,120398,DB00544,Fluorouracil
,8784018,FUDR,"Serum FUDR levels were 10.5 +/- 6.8, 1.3 +/- 0.5, 2.31 +/- 1.1, and 1.2 +/- 0.4 microgram/g lung (p = not significant) for intravenous, ILP 7, ILP 14, and ILP 21 groups, respectively.",Isolated lung perfusion with FUDR in the rat: pharmacokinetics and survival. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8784018/),[μg] / [g·lung],1.3,120399,DB00544,Fluorouracil
,8784018,FUDR,"Serum FUDR levels were 10.5 +/- 6.8, 1.3 +/- 0.5, 2.31 +/- 1.1, and 1.2 +/- 0.4 microgram/g lung (p = not significant) for intravenous, ILP 7, ILP 14, and ILP 21 groups, respectively.",Isolated lung perfusion with FUDR in the rat: pharmacokinetics and survival. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8784018/),[μg] / [g·lung],2.31,120400,DB00544,Fluorouracil
,8784018,FUDR,"Serum FUDR levels were 10.5 +/- 6.8, 1.3 +/- 0.5, 2.31 +/- 1.1, and 1.2 +/- 0.4 microgram/g lung (p = not significant) for intravenous, ILP 7, ILP 14, and ILP 21 groups, respectively.",Isolated lung perfusion with FUDR in the rat: pharmacokinetics and survival. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8784018/),[μg] / [g·lung],1.2,120401,DB00544,Fluorouracil
,8784018,maximum dose,Isolated left lung perfusion with FUDR is well tolerated to a maximum dose of 21 mg/mL and results in significantly higher FUDR and 5-fluorouracil lung levels with low serum levels compared with intravenous treatment.,Isolated lung perfusion with FUDR in the rat: pharmacokinetics and survival. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8784018/),[mg] / [ml],21,120402,DB00544,Fluorouracil
,9816174,peritoneal fluid:plasma AUC ratio,"The pharmacokinetics of 5-fluorouracil were not altered by vasopressin; however, vasopressin increased the peritoneal fluid:plasma AUC ratio for CBDCA from 30.6 +/- 5.6 to 70. 6 +/- 7.4 (P < 0.01) and increased the lymph:plasma AUC ratio from 1.1 +/- 0.4 to 2.6 +/- 0.22 (P < 0.05).","Vasopressin modulation of peritoneal, lymphatic, and plasma drug exposure following intraperitoneal administration. ",AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9816174/),,30.6,120412,DB00544,Fluorouracil
,9816174,peritoneal fluid:plasma AUC ratio,"The pharmacokinetics of 5-fluorouracil were not altered by vasopressin; however, vasopressin increased the peritoneal fluid:plasma AUC ratio for CBDCA from 30.6 +/- 5.6 to 70. 6 +/- 7.4 (P < 0.01) and increased the lymph:plasma AUC ratio from 1.1 +/- 0.4 to 2.6 +/- 0.22 (P < 0.05).","Vasopressin modulation of peritoneal, lymphatic, and plasma drug exposure following intraperitoneal administration. ",AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9816174/),,70. 6,120413,DB00544,Fluorouracil
,9816174,lymph:plasma AUC ratio,"The pharmacokinetics of 5-fluorouracil were not altered by vasopressin; however, vasopressin increased the peritoneal fluid:plasma AUC ratio for CBDCA from 30.6 +/- 5.6 to 70. 6 +/- 7.4 (P < 0.01) and increased the lymph:plasma AUC ratio from 1.1 +/- 0.4 to 2.6 +/- 0.22 (P < 0.05).","Vasopressin modulation of peritoneal, lymphatic, and plasma drug exposure following intraperitoneal administration. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9816174/),,1.1,120414,DB00544,Fluorouracil
,9816174,lymph:plasma AUC ratio,"The pharmacokinetics of 5-fluorouracil were not altered by vasopressin; however, vasopressin increased the peritoneal fluid:plasma AUC ratio for CBDCA from 30.6 +/- 5.6 to 70. 6 +/- 7.4 (P < 0.01) and increased the lymph:plasma AUC ratio from 1.1 +/- 0.4 to 2.6 +/- 0.22 (P < 0.05).","Vasopressin modulation of peritoneal, lymphatic, and plasma drug exposure following intraperitoneal administration. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9816174/),,2.6,120415,DB00544,Fluorouracil
,9816174,peritoneal fluid:plasma AUC ratio,"In the case of VP-16, vasopressin increased the peritoneal fluid:plasma AUC ratio from 129 +/- 35 to 350 +/- 76 (P < 0.05) and the lymph:plasma AUC ratio from 2.1 +/- 0.6 to 10.6 +/- 3.5 (P < 0.05).","Vasopressin modulation of peritoneal, lymphatic, and plasma drug exposure following intraperitoneal administration. ",AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9816174/),,129,120416,DB00544,Fluorouracil
,9816174,peritoneal fluid:plasma AUC ratio,"In the case of VP-16, vasopressin increased the peritoneal fluid:plasma AUC ratio from 129 +/- 35 to 350 +/- 76 (P < 0.05) and the lymph:plasma AUC ratio from 2.1 +/- 0.6 to 10.6 +/- 3.5 (P < 0.05).","Vasopressin modulation of peritoneal, lymphatic, and plasma drug exposure following intraperitoneal administration. ",AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9816174/),,350,120417,DB00544,Fluorouracil
,9816174,lymph:plasma AUC ratio,"In the case of VP-16, vasopressin increased the peritoneal fluid:plasma AUC ratio from 129 +/- 35 to 350 +/- 76 (P < 0.05) and the lymph:plasma AUC ratio from 2.1 +/- 0.6 to 10.6 +/- 3.5 (P < 0.05).","Vasopressin modulation of peritoneal, lymphatic, and plasma drug exposure following intraperitoneal administration. ",AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9816174/),,2.1,120418,DB00544,Fluorouracil
,9816174,lymph:plasma AUC ratio,"In the case of VP-16, vasopressin increased the peritoneal fluid:plasma AUC ratio from 129 +/- 35 to 350 +/- 76 (P < 0.05) and the lymph:plasma AUC ratio from 2.1 +/- 0.6 to 10.6 +/- 3.5 (P < 0.05).","Vasopressin modulation of peritoneal, lymphatic, and plasma drug exposure following intraperitoneal administration. ",AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9816174/),,10.6,120419,DB00544,Fluorouracil
,3828961,half-life time (t0.5),"The mean phenazone half-life time (t0.5) was significantly shorter in patients with breast cancer (8.880 +/- 2.5585 h) than in healthy persons (12.024 +/- 3.8486 h, P less than 0.001).",Metabolic efficiency of the liver in patients with breast cancer as determined by pharmacokinetics of phenazone. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3828961/),h,8.880,120567,DB00544,Fluorouracil
,3828961,half-life time (t0.5),"The mean phenazone half-life time (t0.5) was significantly shorter in patients with breast cancer (8.880 +/- 2.5585 h) than in healthy persons (12.024 +/- 3.8486 h, P less than 0.001).",Metabolic efficiency of the liver in patients with breast cancer as determined by pharmacokinetics of phenazone. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3828961/),h,12.024,120568,DB00544,Fluorouracil
,3828961,elimination rate constant (K,"Mean elimination rate constant (K, 0.063 +/- 0.0197 h-1) and mean metabolic clearance rate (MCR, 54.968 +/- 20.3476 ml/min) differed statistically (P less than 0.01) from the same parameters in control group, where K was 0.063 +/- 0.0197 h-1, MCR was 41.832 +/- 14.7153 ml/min.",Metabolic efficiency of the liver in patients with breast cancer as determined by pharmacokinetics of phenazone. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3828961/),1/[h],0.063,120569,DB00544,Fluorouracil
,3828961,metabolic clearance rate (MCR,"Mean elimination rate constant (K, 0.063 +/- 0.0197 h-1) and mean metabolic clearance rate (MCR, 54.968 +/- 20.3476 ml/min) differed statistically (P less than 0.01) from the same parameters in control group, where K was 0.063 +/- 0.0197 h-1, MCR was 41.832 +/- 14.7153 ml/min.",Metabolic efficiency of the liver in patients with breast cancer as determined by pharmacokinetics of phenazone. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3828961/),[ml] / [min],54.968,120570,DB00544,Fluorouracil
,3828961,K,"Mean elimination rate constant (K, 0.063 +/- 0.0197 h-1) and mean metabolic clearance rate (MCR, 54.968 +/- 20.3476 ml/min) differed statistically (P less than 0.01) from the same parameters in control group, where K was 0.063 +/- 0.0197 h-1, MCR was 41.832 +/- 14.7153 ml/min.",Metabolic efficiency of the liver in patients with breast cancer as determined by pharmacokinetics of phenazone. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3828961/),1/[h],0.063,120571,DB00544,Fluorouracil
,3828961,MCR,"Mean elimination rate constant (K, 0.063 +/- 0.0197 h-1) and mean metabolic clearance rate (MCR, 54.968 +/- 20.3476 ml/min) differed statistically (P less than 0.01) from the same parameters in control group, where K was 0.063 +/- 0.0197 h-1, MCR was 41.832 +/- 14.7153 ml/min.",Metabolic efficiency of the liver in patients with breast cancer as determined by pharmacokinetics of phenazone. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3828961/),[ml] / [min],41.832,120572,DB00544,Fluorouracil
,18088503,peak plasma concentration (Cmax),"After oral administration of coated pellets, 5-FU started appearing in the plasma at 7 h, and reached peak plasma concentration (Cmax) of 3.21+/-2.01 microg mL(-1) at 16 h (Tmax); the Cmax for uncoated pellets was 22.21+/-2.60 microg mL(-1) at Tmax 0.75 h.",In-vitro and in-vivo studies of pectin/ethylcellulosefilm-coated pellets of 5-fluorouracil for colonic targeting. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18088503/),[μg] / [ml],3.21,120727,DB00544,Fluorouracil
,18088503,Tmax,"After oral administration of coated pellets, 5-FU started appearing in the plasma at 7 h, and reached peak plasma concentration (Cmax) of 3.21+/-2.01 microg mL(-1) at 16 h (Tmax); the Cmax for uncoated pellets was 22.21+/-2.60 microg mL(-1) at Tmax 0.75 h.",In-vitro and in-vivo studies of pectin/ethylcellulosefilm-coated pellets of 5-fluorouracil for colonic targeting. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18088503/),h,16,120728,DB00544,Fluorouracil
,18088503,Cmax,"After oral administration of coated pellets, 5-FU started appearing in the plasma at 7 h, and reached peak plasma concentration (Cmax) of 3.21+/-2.01 microg mL(-1) at 16 h (Tmax); the Cmax for uncoated pellets was 22.21+/-2.60 microg mL(-1) at Tmax 0.75 h.",In-vitro and in-vivo studies of pectin/ethylcellulosefilm-coated pellets of 5-fluorouracil for colonic targeting. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18088503/),[μg] / [ml],22.21,120729,DB00544,Fluorouracil
,18088503,Tmax,"After oral administration of coated pellets, 5-FU started appearing in the plasma at 7 h, and reached peak plasma concentration (Cmax) of 3.21+/-2.01 microg mL(-1) at 16 h (Tmax); the Cmax for uncoated pellets was 22.21+/-2.60 microg mL(-1) at Tmax 0.75 h.",In-vitro and in-vivo studies of pectin/ethylcellulosefilm-coated pellets of 5-fluorouracil for colonic targeting. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18088503/),h,0,120730,DB00544,Fluorouracil
,26682194,percentage,"The percentage of 5-FU released at the end of 24 h from ECHC3 was 97.83 ± 0.12% in the presence of pectinase whereas in the control study, it was 40.08 ± 0.02%.",Factorial designed 5-fluorouracil-loaded microsponges and calcium pectinate beads plugged in hydroxypropyl methylcellulose capsules for colorectal cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26682194/),%,97.83,121093,DB00544,Fluorouracil
,26682194,percentage,"The percentage of 5-FU released at the end of 24 h from ECHC3 was 97.83 ± 0.12% in the presence of pectinase whereas in the control study, it was 40.08 ± 0.02%.",Factorial designed 5-fluorouracil-loaded microsponges and calcium pectinate beads plugged in hydroxypropyl methylcellulose capsules for colorectal cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26682194/),%,40.08,121094,DB00544,Fluorouracil
,25374410,area under the plasma concentration-time curve (AUC0-8),"The area under the plasma concentration-time curve (AUC0-8) of tegafur (FT), 5-chloro-2, 4-dihydroxypyridine (CDHP), oxonate (Oxo), and 5-fluorouracil (5-FU) was 4,309.2, 716.3, 86.8, and 492.75 ng h/mL, respectively, after S-1 administration.",Safety and pharmacokinetics of S-1 in a recurrent colon cancer patient with chronic myeloid leukemia treated with dasatinib: a case report. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25374410/),[h·ng] / [ml],"4,309.2",121535,DB00544,Fluorouracil
,25374410,area under the plasma concentration-time curve (AUC0-8),"The area under the plasma concentration-time curve (AUC0-8) of tegafur (FT), 5-chloro-2, 4-dihydroxypyridine (CDHP), oxonate (Oxo), and 5-fluorouracil (5-FU) was 4,309.2, 716.3, 86.8, and 492.75 ng h/mL, respectively, after S-1 administration.",Safety and pharmacokinetics of S-1 in a recurrent colon cancer patient with chronic myeloid leukemia treated with dasatinib: a case report. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25374410/),[h·ng] / [ml],716.3,121536,DB00544,Fluorouracil
,25374410,area under the plasma concentration-time curve (AUC0-8),"The area under the plasma concentration-time curve (AUC0-8) of tegafur (FT), 5-chloro-2, 4-dihydroxypyridine (CDHP), oxonate (Oxo), and 5-fluorouracil (5-FU) was 4,309.2, 716.3, 86.8, and 492.75 ng h/mL, respectively, after S-1 administration.",Safety and pharmacokinetics of S-1 in a recurrent colon cancer patient with chronic myeloid leukemia treated with dasatinib: a case report. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25374410/),[h·ng] / [ml],86.8,121537,DB00544,Fluorouracil
,25374410,area under the plasma concentration-time curve (AUC0-8),"The area under the plasma concentration-time curve (AUC0-8) of tegafur (FT), 5-chloro-2, 4-dihydroxypyridine (CDHP), oxonate (Oxo), and 5-fluorouracil (5-FU) was 4,309.2, 716.3, 86.8, and 492.75 ng h/mL, respectively, after S-1 administration.",Safety and pharmacokinetics of S-1 in a recurrent colon cancer patient with chronic myeloid leukemia treated with dasatinib: a case report. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25374410/),[h·ng] / [ml],492.75,121538,DB00544,Fluorouracil
,19551382,time to progression,The median time to progression was 6.6 months (95% CI 4.0-9.2 months) and the median overall survival was 12.5 months (95% CI 9.2-15.9 months).,Phase I/II and pharmacokinetic study of S-1 and oxaliplatin in previously untreated advanced gastric cancer. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19551382/),month,6.6,121768,DB00544,Fluorouracil
,19551382,overall survival,The median time to progression was 6.6 months (95% CI 4.0-9.2 months) and the median overall survival was 12.5 months (95% CI 9.2-15.9 months).,Phase I/II and pharmacokinetic study of S-1 and oxaliplatin in previously untreated advanced gastric cancer. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19551382/),month,12.5,121769,DB00544,Fluorouracil
,2747244,area under the curve,"Mean area under the curve values in microgram/ml X min and the ratios of the systemic/hepatic vein areas following 5-FUra infusion via systemic, portal vein, hepatic artery, or hepatic artery after dearterialization routes were: 975/539 (R = 1.80), 939/748 (R = 1.35), 211/454 (R = 0.46), and 562/1,424 (R = 0.39).",Influence of the routes of continuous intrahepatic infusion of 5-fluorouracil on its pharmacokinetics. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2747244/),μ,975,122465,DB00544,Fluorouracil
,2747244,area under the curve,"Mean area under the curve values in microgram/ml X min and the ratios of the systemic/hepatic vein areas following 5-FUra infusion via systemic, portal vein, hepatic artery, or hepatic artery after dearterialization routes were: 975/539 (R = 1.80), 939/748 (R = 1.35), 211/454 (R = 0.46), and 562/1,424 (R = 0.39).",Influence of the routes of continuous intrahepatic infusion of 5-fluorouracil on its pharmacokinetics. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2747244/),μ,939,122466,DB00544,Fluorouracil
,2747244,area under the curve,"Mean area under the curve values in microgram/ml X min and the ratios of the systemic/hepatic vein areas following 5-FUra infusion via systemic, portal vein, hepatic artery, or hepatic artery after dearterialization routes were: 975/539 (R = 1.80), 939/748 (R = 1.35), 211/454 (R = 0.46), and 562/1,424 (R = 0.39).",Influence of the routes of continuous intrahepatic infusion of 5-fluorouracil on its pharmacokinetics. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2747244/),μ,211,122467,DB00544,Fluorouracil
,2747244,area under the curve,"Mean area under the curve values in microgram/ml X min and the ratios of the systemic/hepatic vein areas following 5-FUra infusion via systemic, portal vein, hepatic artery, or hepatic artery after dearterialization routes were: 975/539 (R = 1.80), 939/748 (R = 1.35), 211/454 (R = 0.46), and 562/1,424 (R = 0.39).",Influence of the routes of continuous intrahepatic infusion of 5-fluorouracil on its pharmacokinetics. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2747244/),μ,562,122468,DB00544,Fluorouracil
,11810570,overall response rate,The overall response rate was 47.2%.,An analysis of the therapeutic efficacy of protracted infusion of low-dose 5-fluorouracil and cisplatin in advanced gastric cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11810570/),%,47.2,122667,DB00544,Fluorouracil
,11810570,survival time (MST),"The median survival time (MST) and 1-year survival rate were 8 months and 36.2%, respectively.",An analysis of the therapeutic efficacy of protracted infusion of low-dose 5-fluorouracil and cisplatin in advanced gastric cancer. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11810570/),month,8,122668,DB00544,Fluorouracil
,19228749,progression-free survival,The median progression-free survival was 9.3 months.,Phase I study of cediranib in combination with oxaliplatin and infusional 5-Fluorouracil in patients with advanced colorectal cancer. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19228749/),month,9.3,123484,DB00544,Fluorouracil
,15229463,area under the plasma concentration-time curve from 0 to 1 hour,"The coadministration of oxaliplatin did not significantly alter 5FU area under the plasma concentration-time curve from 0 to 1 hour, area under the plasma concentration-time curve from time 0 to the last time point, or steady-state concentration in either the de Gramont (11.6 +/- 3.8 mg/L x h(-1), 14.9 +/- 4.2 mg x h/L, and 0.17 +/- 0.06 mg/L, respectively, for 5FU alone versus 9.4 +/- 2.6 mg/L x h(-1), 13.3 +/- 2.3 mg x h/L, and 0.16 +/- 0.04, respectively, for 5FU plus oxaliplatin) or modified de Gramont regimens (13.4 +/- 2.2 mg x h/L, 35.4 +/- 4.2 mg x h/L, and 0.46 +/- 0.08 mg/L, respectively, for 5FU alone versus 13.9 +/- 3.3 mg x h/L, 38.1 +/- 7.4 mg x h/L, and 0.53 +/- 0.12, respectively, for 5FU plus oxaliplatin).",Lack of pharmacokinetic interaction between 5-fluorouracil and oxaliplatin. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15229463/),[l·mg] / [h],11.6,124064,DB00544,Fluorouracil
,15229463,area under the plasma concentration-time curve from time 0 to the last time point,"The coadministration of oxaliplatin did not significantly alter 5FU area under the plasma concentration-time curve from 0 to 1 hour, area under the plasma concentration-time curve from time 0 to the last time point, or steady-state concentration in either the de Gramont (11.6 +/- 3.8 mg/L x h(-1), 14.9 +/- 4.2 mg x h/L, and 0.17 +/- 0.06 mg/L, respectively, for 5FU alone versus 9.4 +/- 2.6 mg/L x h(-1), 13.3 +/- 2.3 mg x h/L, and 0.16 +/- 0.04, respectively, for 5FU plus oxaliplatin) or modified de Gramont regimens (13.4 +/- 2.2 mg x h/L, 35.4 +/- 4.2 mg x h/L, and 0.46 +/- 0.08 mg/L, respectively, for 5FU alone versus 13.9 +/- 3.3 mg x h/L, 38.1 +/- 7.4 mg x h/L, and 0.53 +/- 0.12, respectively, for 5FU plus oxaliplatin).",Lack of pharmacokinetic interaction between 5-fluorouracil and oxaliplatin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15229463/),[h·mg] / [l],14.9,124065,DB00544,Fluorouracil
,15229463,area under the plasma concentration-time curve from time 0 to the last time point,"The coadministration of oxaliplatin did not significantly alter 5FU area under the plasma concentration-time curve from 0 to 1 hour, area under the plasma concentration-time curve from time 0 to the last time point, or steady-state concentration in either the de Gramont (11.6 +/- 3.8 mg/L x h(-1), 14.9 +/- 4.2 mg x h/L, and 0.17 +/- 0.06 mg/L, respectively, for 5FU alone versus 9.4 +/- 2.6 mg/L x h(-1), 13.3 +/- 2.3 mg x h/L, and 0.16 +/- 0.04, respectively, for 5FU plus oxaliplatin) or modified de Gramont regimens (13.4 +/- 2.2 mg x h/L, 35.4 +/- 4.2 mg x h/L, and 0.46 +/- 0.08 mg/L, respectively, for 5FU alone versus 13.9 +/- 3.3 mg x h/L, 38.1 +/- 7.4 mg x h/L, and 0.53 +/- 0.12, respectively, for 5FU plus oxaliplatin).",Lack of pharmacokinetic interaction between 5-fluorouracil and oxaliplatin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15229463/),[h·mg] / [l],13.4,124066,DB00544,Fluorouracil
,15229463,area under the plasma concentration-time curve from time 0 to the last time point,"The coadministration of oxaliplatin did not significantly alter 5FU area under the plasma concentration-time curve from 0 to 1 hour, area under the plasma concentration-time curve from time 0 to the last time point, or steady-state concentration in either the de Gramont (11.6 +/- 3.8 mg/L x h(-1), 14.9 +/- 4.2 mg x h/L, and 0.17 +/- 0.06 mg/L, respectively, for 5FU alone versus 9.4 +/- 2.6 mg/L x h(-1), 13.3 +/- 2.3 mg x h/L, and 0.16 +/- 0.04, respectively, for 5FU plus oxaliplatin) or modified de Gramont regimens (13.4 +/- 2.2 mg x h/L, 35.4 +/- 4.2 mg x h/L, and 0.46 +/- 0.08 mg/L, respectively, for 5FU alone versus 13.9 +/- 3.3 mg x h/L, 38.1 +/- 7.4 mg x h/L, and 0.53 +/- 0.12, respectively, for 5FU plus oxaliplatin).",Lack of pharmacokinetic interaction between 5-fluorouracil and oxaliplatin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15229463/),[h·mg] / [l],35.4,124067,DB00544,Fluorouracil
,15229463,area under the plasma concentration-time curve from time 0 to the last time point,"The coadministration of oxaliplatin did not significantly alter 5FU area under the plasma concentration-time curve from 0 to 1 hour, area under the plasma concentration-time curve from time 0 to the last time point, or steady-state concentration in either the de Gramont (11.6 +/- 3.8 mg/L x h(-1), 14.9 +/- 4.2 mg x h/L, and 0.17 +/- 0.06 mg/L, respectively, for 5FU alone versus 9.4 +/- 2.6 mg/L x h(-1), 13.3 +/- 2.3 mg x h/L, and 0.16 +/- 0.04, respectively, for 5FU plus oxaliplatin) or modified de Gramont regimens (13.4 +/- 2.2 mg x h/L, 35.4 +/- 4.2 mg x h/L, and 0.46 +/- 0.08 mg/L, respectively, for 5FU alone versus 13.9 +/- 3.3 mg x h/L, 38.1 +/- 7.4 mg x h/L, and 0.53 +/- 0.12, respectively, for 5FU plus oxaliplatin).",Lack of pharmacokinetic interaction between 5-fluorouracil and oxaliplatin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15229463/),[h·mg] / [l],13.9,124068,DB00544,Fluorouracil
,15229463,steady-state concentration,"The coadministration of oxaliplatin did not significantly alter 5FU area under the plasma concentration-time curve from 0 to 1 hour, area under the plasma concentration-time curve from time 0 to the last time point, or steady-state concentration in either the de Gramont (11.6 +/- 3.8 mg/L x h(-1), 14.9 +/- 4.2 mg x h/L, and 0.17 +/- 0.06 mg/L, respectively, for 5FU alone versus 9.4 +/- 2.6 mg/L x h(-1), 13.3 +/- 2.3 mg x h/L, and 0.16 +/- 0.04, respectively, for 5FU plus oxaliplatin) or modified de Gramont regimens (13.4 +/- 2.2 mg x h/L, 35.4 +/- 4.2 mg x h/L, and 0.46 +/- 0.08 mg/L, respectively, for 5FU alone versus 13.9 +/- 3.3 mg x h/L, 38.1 +/- 7.4 mg x h/L, and 0.53 +/- 0.12, respectively, for 5FU plus oxaliplatin).",Lack of pharmacokinetic interaction between 5-fluorouracil and oxaliplatin. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15229463/),[mg] / [l],0.17,124069,DB00544,Fluorouracil
,15229463,steady-state concentration,"The coadministration of oxaliplatin did not significantly alter 5FU area under the plasma concentration-time curve from 0 to 1 hour, area under the plasma concentration-time curve from time 0 to the last time point, or steady-state concentration in either the de Gramont (11.6 +/- 3.8 mg/L x h(-1), 14.9 +/- 4.2 mg x h/L, and 0.17 +/- 0.06 mg/L, respectively, for 5FU alone versus 9.4 +/- 2.6 mg/L x h(-1), 13.3 +/- 2.3 mg x h/L, and 0.16 +/- 0.04, respectively, for 5FU plus oxaliplatin) or modified de Gramont regimens (13.4 +/- 2.2 mg x h/L, 35.4 +/- 4.2 mg x h/L, and 0.46 +/- 0.08 mg/L, respectively, for 5FU alone versus 13.9 +/- 3.3 mg x h/L, 38.1 +/- 7.4 mg x h/L, and 0.53 +/- 0.12, respectively, for 5FU plus oxaliplatin).",Lack of pharmacokinetic interaction between 5-fluorouracil and oxaliplatin. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15229463/),[h·mg] / [l],13.4,124070,DB00544,Fluorouracil
,15229463,steady-state concentration,"The coadministration of oxaliplatin did not significantly alter 5FU area under the plasma concentration-time curve from 0 to 1 hour, area under the plasma concentration-time curve from time 0 to the last time point, or steady-state concentration in either the de Gramont (11.6 +/- 3.8 mg/L x h(-1), 14.9 +/- 4.2 mg x h/L, and 0.17 +/- 0.06 mg/L, respectively, for 5FU alone versus 9.4 +/- 2.6 mg/L x h(-1), 13.3 +/- 2.3 mg x h/L, and 0.16 +/- 0.04, respectively, for 5FU plus oxaliplatin) or modified de Gramont regimens (13.4 +/- 2.2 mg x h/L, 35.4 +/- 4.2 mg x h/L, and 0.46 +/- 0.08 mg/L, respectively, for 5FU alone versus 13.9 +/- 3.3 mg x h/L, 38.1 +/- 7.4 mg x h/L, and 0.53 +/- 0.12, respectively, for 5FU plus oxaliplatin).",Lack of pharmacokinetic interaction between 5-fluorouracil and oxaliplatin. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15229463/),[h·mg] / [l],35.4,124071,DB00544,Fluorouracil
,15229463,steady-state concentration,"The coadministration of oxaliplatin did not significantly alter 5FU area under the plasma concentration-time curve from 0 to 1 hour, area under the plasma concentration-time curve from time 0 to the last time point, or steady-state concentration in either the de Gramont (11.6 +/- 3.8 mg/L x h(-1), 14.9 +/- 4.2 mg x h/L, and 0.17 +/- 0.06 mg/L, respectively, for 5FU alone versus 9.4 +/- 2.6 mg/L x h(-1), 13.3 +/- 2.3 mg x h/L, and 0.16 +/- 0.04, respectively, for 5FU plus oxaliplatin) or modified de Gramont regimens (13.4 +/- 2.2 mg x h/L, 35.4 +/- 4.2 mg x h/L, and 0.46 +/- 0.08 mg/L, respectively, for 5FU alone versus 13.9 +/- 3.3 mg x h/L, 38.1 +/- 7.4 mg x h/L, and 0.53 +/- 0.12, respectively, for 5FU plus oxaliplatin).",Lack of pharmacokinetic interaction between 5-fluorouracil and oxaliplatin. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15229463/),[mg] / [l],0.46,124072,DB00544,Fluorouracil
,15229463,steady-state concentration,"The coadministration of oxaliplatin did not significantly alter 5FU area under the plasma concentration-time curve from 0 to 1 hour, area under the plasma concentration-time curve from time 0 to the last time point, or steady-state concentration in either the de Gramont (11.6 +/- 3.8 mg/L x h(-1), 14.9 +/- 4.2 mg x h/L, and 0.17 +/- 0.06 mg/L, respectively, for 5FU alone versus 9.4 +/- 2.6 mg/L x h(-1), 13.3 +/- 2.3 mg x h/L, and 0.16 +/- 0.04, respectively, for 5FU plus oxaliplatin) or modified de Gramont regimens (13.4 +/- 2.2 mg x h/L, 35.4 +/- 4.2 mg x h/L, and 0.46 +/- 0.08 mg/L, respectively, for 5FU alone versus 13.9 +/- 3.3 mg x h/L, 38.1 +/- 7.4 mg x h/L, and 0.53 +/- 0.12, respectively, for 5FU plus oxaliplatin).",Lack of pharmacokinetic interaction between 5-fluorouracil and oxaliplatin. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15229463/),[h·mg] / [l],13.9,124073,DB00544,Fluorouracil
,15229463,steady-state concentration,"The coadministration of oxaliplatin did not significantly alter 5FU area under the plasma concentration-time curve from 0 to 1 hour, area under the plasma concentration-time curve from time 0 to the last time point, or steady-state concentration in either the de Gramont (11.6 +/- 3.8 mg/L x h(-1), 14.9 +/- 4.2 mg x h/L, and 0.17 +/- 0.06 mg/L, respectively, for 5FU alone versus 9.4 +/- 2.6 mg/L x h(-1), 13.3 +/- 2.3 mg x h/L, and 0.16 +/- 0.04, respectively, for 5FU plus oxaliplatin) or modified de Gramont regimens (13.4 +/- 2.2 mg x h/L, 35.4 +/- 4.2 mg x h/L, and 0.46 +/- 0.08 mg/L, respectively, for 5FU alone versus 13.9 +/- 3.3 mg x h/L, 38.1 +/- 7.4 mg x h/L, and 0.53 +/- 0.12, respectively, for 5FU plus oxaliplatin).",Lack of pharmacokinetic interaction between 5-fluorouracil and oxaliplatin. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15229463/),,38.1,124074,DB00544,Fluorouracil
,15229463,maximum velocity,"The inclusion of oxaliplatin coadministration as a covariate in a NONMEM analysis did not result in any change in the objective function or mean values for the following derived parameters: maximum velocity (1590 mg x h(-1)), day 1 Michaelis-Menten constant (7.8 mg x h(-1)), and day 2 Michaelis-Menten constant (11.9 mg x h(-1)).",Lack of pharmacokinetic interaction between 5-fluorouracil and oxaliplatin. ,Vmax velocity-Q2,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15229463/),[mg] / [h],1590,124075,DB00544,Fluorouracil
,15229463,Michaelis-Menten,"The inclusion of oxaliplatin coadministration as a covariate in a NONMEM analysis did not result in any change in the objective function or mean values for the following derived parameters: maximum velocity (1590 mg x h(-1)), day 1 Michaelis-Menten constant (7.8 mg x h(-1)), and day 2 Michaelis-Menten constant (11.9 mg x h(-1)).",Lack of pharmacokinetic interaction between 5-fluorouracil and oxaliplatin. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15229463/),[mg] / [h],7.8,124076,DB00544,Fluorouracil
,15229463,Michaelis-Menten constant,"The inclusion of oxaliplatin coadministration as a covariate in a NONMEM analysis did not result in any change in the objective function or mean values for the following derived parameters: maximum velocity (1590 mg x h(-1)), day 1 Michaelis-Menten constant (7.8 mg x h(-1)), and day 2 Michaelis-Menten constant (11.9 mg x h(-1)).",Lack of pharmacokinetic interaction between 5-fluorouracil and oxaliplatin. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15229463/),[mg] / [h],11.9,124077,DB00544,Fluorouracil
,28431329,half-life,"However, intravenous administration of 5-FU at the dose of 7-12mg/kg exhibits curbs like short half-life (20min) and toxic side-effects on bone marrow cells.","Stealth recombinant human serum albumin nanoparticles conjugating 5-fluorouracil augmented drug delivery and cytotoxicity in human colon cancer, HT-29 cells. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28431329/),min,20,124113,DB00544,Fluorouracil
,28431329,particle size,"The mean particle size of 5-FU-rHSA-NPs was measured to be 44.3±5.8-nm, significantly (P<0.05) lesser than 65.7±7.2-nm of 5-FU-rHSA-PEG-NPs.","Stealth recombinant human serum albumin nanoparticles conjugating 5-fluorouracil augmented drug delivery and cytotoxicity in human colon cancer, HT-29 cells. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28431329/),,44.3,124114,DB00544,Fluorouracil
,28431329,particle size,"The mean particle size of 5-FU-rHSA-NPs was measured to be 44.3±5.8-nm, significantly (P<0.05) lesser than 65.7±7.2-nm of 5-FU-rHSA-PEG-NPs.","Stealth recombinant human serum albumin nanoparticles conjugating 5-fluorouracil augmented drug delivery and cytotoxicity in human colon cancer, HT-29 cells. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28431329/),,65.7,124115,DB00544,Fluorouracil
,28431329,zeta-potential,"In addition, zeta-potential of 5-FU-rHSA-NPs was estimated to be -10.2±2.6-mV significantly (P<0.05) lower than -25.8±3.5-mV of 5-FU-rHSA-PEG-NPs.","Stealth recombinant human serum albumin nanoparticles conjugating 5-fluorouracil augmented drug delivery and cytotoxicity in human colon cancer, HT-29 cells. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28431329/),mv,-,124116,DB00544,Fluorouracil
,28431329,zeta-potential,"In addition, zeta-potential of 5-FU-rHSA-NPs was estimated to be -10.2±2.6-mV significantly (P<0.05) lower than -25.8±3.5-mV of 5-FU-rHSA-PEG-NPs.","Stealth recombinant human serum albumin nanoparticles conjugating 5-fluorouracil augmented drug delivery and cytotoxicity in human colon cancer, HT-29 cells. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28431329/),mv,10.2,124117,DB00544,Fluorouracil
,28431329,zeta-potential,"In addition, zeta-potential of 5-FU-rHSA-NPs was estimated to be -10.2±2.6-mV significantly (P<0.05) lower than -25.8±3.5-mV of 5-FU-rHSA-PEG-NPs.","Stealth recombinant human serum albumin nanoparticles conjugating 5-fluorouracil augmented drug delivery and cytotoxicity in human colon cancer, HT-29 cells. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28431329/),m,-,124118,DB00544,Fluorouracil
,28431329,zeta-potential,"In addition, zeta-potential of 5-FU-rHSA-NPs was estimated to be -10.2±2.6-mV significantly (P<0.05) lower than -25.8±3.5-mV of 5-FU-rHSA-PEG-NPs.","Stealth recombinant human serum albumin nanoparticles conjugating 5-fluorouracil augmented drug delivery and cytotoxicity in human colon cancer, HT-29 cells. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28431329/),m,25.8,124119,DB00544,Fluorouracil
,28431329,IC50,"Furthermore, 5-FU-rHSA-PEG-NPs displayed the IC50 of 3.7-μM significantly (P<0.05) lower than 6.8-μM and 11.2-μM of 5-FU-rHSA-NPs and 5-FU solution, respectively.","Stealth recombinant human serum albumin nanoparticles conjugating 5-fluorouracil augmented drug delivery and cytotoxicity in human colon cancer, HT-29 cells. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28431329/),μM,3.7,124120,DB00544,Fluorouracil
lower,28431329,IC50,"Furthermore, 5-FU-rHSA-PEG-NPs displayed the IC50 of 3.7-μM significantly (P<0.05) lower than 6.8-μM and 11.2-μM of 5-FU-rHSA-NPs and 5-FU solution, respectively.","Stealth recombinant human serum albumin nanoparticles conjugating 5-fluorouracil augmented drug delivery and cytotoxicity in human colon cancer, HT-29 cells. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28431329/),μM,6.8,124121,DB00544,Fluorouracil
,28431329,IC50,"Furthermore, 5-FU-rHSA-PEG-NPs displayed the IC50 of 3.7-μM significantly (P<0.05) lower than 6.8-μM and 11.2-μM of 5-FU-rHSA-NPs and 5-FU solution, respectively.","Stealth recombinant human serum albumin nanoparticles conjugating 5-fluorouracil augmented drug delivery and cytotoxicity in human colon cancer, HT-29 cells. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28431329/),μM,11.2,124122,DB00544,Fluorouracil
,28431329,half-life (t1/2),"One compartmental pharmacokinetic elements indicated that 5-FU-rHSA-PEG-NPs demonstrated the half-life (t1/2) of 5.33±0.15-h significantly (P<0.001) higher than 1.50±0.08-h and 0.30±0.09-h of 5-FU-rHSA-NPs and 5-FU solution, respectively.","Stealth recombinant human serum albumin nanoparticles conjugating 5-fluorouracil augmented drug delivery and cytotoxicity in human colon cancer, HT-29 cells. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28431329/),h,5.33,124123,DB00544,Fluorouracil
,28431329,half-life (t1/2),"One compartmental pharmacokinetic elements indicated that 5-FU-rHSA-PEG-NPs demonstrated the half-life (t1/2) of 5.33±0.15-h significantly (P<0.001) higher than 1.50±0.08-h and 0.30±0.09-h of 5-FU-rHSA-NPs and 5-FU solution, respectively.","Stealth recombinant human serum albumin nanoparticles conjugating 5-fluorouracil augmented drug delivery and cytotoxicity in human colon cancer, HT-29 cells. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28431329/),h,1.50,124124,DB00544,Fluorouracil
,28431329,half-life (t1/2),"One compartmental pharmacokinetic elements indicated that 5-FU-rHSA-PEG-NPs demonstrated the half-life (t1/2) of 5.33±0.15-h significantly (P<0.001) higher than 1.50±0.08-h and 0.30±0.09-h of 5-FU-rHSA-NPs and 5-FU solution, respectively.","Stealth recombinant human serum albumin nanoparticles conjugating 5-fluorouracil augmented drug delivery and cytotoxicity in human colon cancer, HT-29 cells. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28431329/),h,0.30,124125,DB00544,Fluorouracil
,21464401,OS,"With PTK/ZK and placebo, respectively, median OS was 13.1 and 11.9 months (hazard ratio [HR], 1.00; 95% CI, 0.87 to 1.16; P = .957).","Randomized, placebo-controlled, phase III study of oxaliplatin, fluorouracil, and leucovorin with or without PTK787/ZK 222584 in patients with previously treated metastatic colorectal adenocarcinoma. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21464401/),month,13.1,124150,DB00544,Fluorouracil
,21464401,OS,"With PTK/ZK and placebo, respectively, median OS was 13.1 and 11.9 months (hazard ratio [HR], 1.00; 95% CI, 0.87 to 1.16; P = .957).","Randomized, placebo-controlled, phase III study of oxaliplatin, fluorouracil, and leucovorin with or without PTK787/ZK 222584 in patients with previously treated metastatic colorectal adenocarcinoma. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21464401/),month,11.9,124151,DB00544,Fluorouracil
,29493289,zeta potential,"The optimized nanoparticles have the particle size, zeta potential, and entrapment efficiency of 145.6 ± 3.6 nm, -26.9 ± 2.7 mV, and 88.33 ± 3.74%, respectively.","Capecitabine lipid nanoparticles for anti-colon cancer activity in 1,2-dimethylhydrazine-induced colon cancer: preparation, cytotoxic, pharmacokinetic, and pathological evaluation. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29493289/),m,26.9,125351,DB00544,Fluorouracil
,29493289,entrapment efficiency,"The optimized nanoparticles have the particle size, zeta potential, and entrapment efficiency of 145.6 ± 3.6 nm, -26.9 ± 2.7 mV, and 88.33 ± 3.74%, respectively.","Capecitabine lipid nanoparticles for anti-colon cancer activity in 1,2-dimethylhydrazine-induced colon cancer: preparation, cytotoxic, pharmacokinetic, and pathological evaluation. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29493289/),m,26.9,125352,DB00544,Fluorouracil
,29493289,entrapment efficiency,"The optimized nanoparticles have the particle size, zeta potential, and entrapment efficiency of 145.6 ± 3.6 nm, -26.9 ± 2.7 mV, and 88.33 ± 3.74%, respectively.","Capecitabine lipid nanoparticles for anti-colon cancer activity in 1,2-dimethylhydrazine-induced colon cancer: preparation, cytotoxic, pharmacokinetic, and pathological evaluation. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29493289/),%,88.33,125353,DB00544,Fluorouracil
,2328492,steady-state FUra plasma concentration,"At the maximal tolerated dose of FUra, 2300 mg/m2/day x3, mean steady-state FUra plasma concentration and total body clearance were 6.6 microM and 122 liters/h/m2, respectively, for courses of the combination.",Phase I trial of 5-fluorouracil and dipyridamole administered by seventy-two-hour concurrent continuous infusion. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2328492/),μM,6.6,125730,DB00544,Fluorouracil
,2328492,total body clearance,"At the maximal tolerated dose of FUra, 2300 mg/m2/day x3, mean steady-state FUra plasma concentration and total body clearance were 6.6 microM and 122 liters/h/m2, respectively, for courses of the combination.",Phase I trial of 5-fluorouracil and dipyridamole administered by seventy-two-hour concurrent continuous infusion. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2328492/),[l] / [h·m2],122,125731,DB00544,Fluorouracil
,16496681,relative tissue efficiencies,"Following intragastric gavage of PL-FT207 or T-FT207 to rats, AUC was significantly increased in plasma, liver, kidney, colon and lung (P < 0.01) of PL-FT207 group in contrast to that of T-FT207 group, the relative tissue efficiencies of these tissues were 1.36-1.57, the maximum drug concentrations of brain and lung of PL-FT207 group were significantly declined (P < 0.005).",[In vivo distribution of a novel proliposomal preparation of tegafur following intragastric gavage to rats]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16496681/),,1.36-1.57,126010,DB00544,Fluorouracil
,7815285,ratio of peritoneal fluid AUC to serum AUC,The ratio of peritoneal fluid AUC to serum AUC was about 1400 for 5-fluorouracil and 80 for mitomycin C.,Pharmacokinetic characteristics of 5-fluorouracil and mitomycin C in intraperitoneal chemotherapy. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7815285/),,1400,126507,DB00544,Fluorouracil
,7815285,ratio of peritoneal fluid AUC to serum AUC,The ratio of peritoneal fluid AUC to serum AUC was about 1400 for 5-fluorouracil and 80 for mitomycin C.,Pharmacokinetic characteristics of 5-fluorouracil and mitomycin C in intraperitoneal chemotherapy. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7815285/),,80,126508,DB00544,Fluorouracil
,7815285,t1/2p,"The half-life in the peritoneal fluid (t1/2p) and the rate constant from the peritoneal fluid to the systemic circulation (ka) were nearly equal for both 5-fluorouracil and mitomycin C (t1/2p, 1.0 h for 5-fluorouracil and 1.3 h for mitomycin C; ka 0.71 h-1 for 5-fluorouracil and 0.68 h-1 for mitomycin C), although the apparent volume of distribution (Vds/F) and clearance in the peritoneal cavity (CLp) for mitomycin C (78 L m-2 and 1.8 L h-1 m-2) were about twice the values for 5-fluorouracil (149 L m-2 and 0.8 L h-1 m-2).",Pharmacokinetic characteristics of 5-fluorouracil and mitomycin C in intraperitoneal chemotherapy. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7815285/),h,1.0,126509,DB00544,Fluorouracil
,7815285,t1/2p,"The half-life in the peritoneal fluid (t1/2p) and the rate constant from the peritoneal fluid to the systemic circulation (ka) were nearly equal for both 5-fluorouracil and mitomycin C (t1/2p, 1.0 h for 5-fluorouracil and 1.3 h for mitomycin C; ka 0.71 h-1 for 5-fluorouracil and 0.68 h-1 for mitomycin C), although the apparent volume of distribution (Vds/F) and clearance in the peritoneal cavity (CLp) for mitomycin C (78 L m-2 and 1.8 L h-1 m-2) were about twice the values for 5-fluorouracil (149 L m-2 and 0.8 L h-1 m-2).",Pharmacokinetic characteristics of 5-fluorouracil and mitomycin C in intraperitoneal chemotherapy. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7815285/),h,1.3,126510,DB00544,Fluorouracil
,7815285,ka,"The half-life in the peritoneal fluid (t1/2p) and the rate constant from the peritoneal fluid to the systemic circulation (ka) were nearly equal for both 5-fluorouracil and mitomycin C (t1/2p, 1.0 h for 5-fluorouracil and 1.3 h for mitomycin C; ka 0.71 h-1 for 5-fluorouracil and 0.68 h-1 for mitomycin C), although the apparent volume of distribution (Vds/F) and clearance in the peritoneal cavity (CLp) for mitomycin C (78 L m-2 and 1.8 L h-1 m-2) were about twice the values for 5-fluorouracil (149 L m-2 and 0.8 L h-1 m-2).",Pharmacokinetic characteristics of 5-fluorouracil and mitomycin C in intraperitoneal chemotherapy. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7815285/),1/[h],0.71,126511,DB00544,Fluorouracil
,7815285,ka,"The half-life in the peritoneal fluid (t1/2p) and the rate constant from the peritoneal fluid to the systemic circulation (ka) were nearly equal for both 5-fluorouracil and mitomycin C (t1/2p, 1.0 h for 5-fluorouracil and 1.3 h for mitomycin C; ka 0.71 h-1 for 5-fluorouracil and 0.68 h-1 for mitomycin C), although the apparent volume of distribution (Vds/F) and clearance in the peritoneal cavity (CLp) for mitomycin C (78 L m-2 and 1.8 L h-1 m-2) were about twice the values for 5-fluorouracil (149 L m-2 and 0.8 L h-1 m-2).",Pharmacokinetic characteristics of 5-fluorouracil and mitomycin C in intraperitoneal chemotherapy. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7815285/),1/[h],0.68,126512,DB00544,Fluorouracil
,7815285,apparent volume of distribution (Vds/F),"The half-life in the peritoneal fluid (t1/2p) and the rate constant from the peritoneal fluid to the systemic circulation (ka) were nearly equal for both 5-fluorouracil and mitomycin C (t1/2p, 1.0 h for 5-fluorouracil and 1.3 h for mitomycin C; ka 0.71 h-1 for 5-fluorouracil and 0.68 h-1 for mitomycin C), although the apparent volume of distribution (Vds/F) and clearance in the peritoneal cavity (CLp) for mitomycin C (78 L m-2 and 1.8 L h-1 m-2) were about twice the values for 5-fluorouracil (149 L m-2 and 0.8 L h-1 m-2).",Pharmacokinetic characteristics of 5-fluorouracil and mitomycin C in intraperitoneal chemotherapy. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7815285/),[l] / [(m)^2],78,126513,DB00544,Fluorouracil
,7815285,clearance in the peritoneal cavity (CLp),"The half-life in the peritoneal fluid (t1/2p) and the rate constant from the peritoneal fluid to the systemic circulation (ka) were nearly equal for both 5-fluorouracil and mitomycin C (t1/2p, 1.0 h for 5-fluorouracil and 1.3 h for mitomycin C; ka 0.71 h-1 for 5-fluorouracil and 0.68 h-1 for mitomycin C), although the apparent volume of distribution (Vds/F) and clearance in the peritoneal cavity (CLp) for mitomycin C (78 L m-2 and 1.8 L h-1 m-2) were about twice the values for 5-fluorouracil (149 L m-2 and 0.8 L h-1 m-2).",Pharmacokinetic characteristics of 5-fluorouracil and mitomycin C in intraperitoneal chemotherapy. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7815285/),[l] / [(m)^2·h],1.8,126514,DB00544,Fluorouracil
,7815285,clearance in the peritoneal cavity (CLp),"The half-life in the peritoneal fluid (t1/2p) and the rate constant from the peritoneal fluid to the systemic circulation (ka) were nearly equal for both 5-fluorouracil and mitomycin C (t1/2p, 1.0 h for 5-fluorouracil and 1.3 h for mitomycin C; ka 0.71 h-1 for 5-fluorouracil and 0.68 h-1 for mitomycin C), although the apparent volume of distribution (Vds/F) and clearance in the peritoneal cavity (CLp) for mitomycin C (78 L m-2 and 1.8 L h-1 m-2) were about twice the values for 5-fluorouracil (149 L m-2 and 0.8 L h-1 m-2).",Pharmacokinetic characteristics of 5-fluorouracil and mitomycin C in intraperitoneal chemotherapy. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7815285/),[l] / [(m)^2],149,126515,DB00544,Fluorouracil
,7815285,clearance in the peritoneal cavity (CLp),"The half-life in the peritoneal fluid (t1/2p) and the rate constant from the peritoneal fluid to the systemic circulation (ka) were nearly equal for both 5-fluorouracil and mitomycin C (t1/2p, 1.0 h for 5-fluorouracil and 1.3 h for mitomycin C; ka 0.71 h-1 for 5-fluorouracil and 0.68 h-1 for mitomycin C), although the apparent volume of distribution (Vds/F) and clearance in the peritoneal cavity (CLp) for mitomycin C (78 L m-2 and 1.8 L h-1 m-2) were about twice the values for 5-fluorouracil (149 L m-2 and 0.8 L h-1 m-2).",Pharmacokinetic characteristics of 5-fluorouracil and mitomycin C in intraperitoneal chemotherapy. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7815285/),[l] / [(m)^2·h],0.8,126516,DB00544,Fluorouracil
,7497579,AUCFUrd,"Chemotherapy cycles without neutropenia were associated with low AUCFUrd values (mean +/- SEM, 2.9 +/- 0.7 micrograms ml-1 h) and high AUCFdUrd values (14.1 +/- 2.7 micrograms ml-1 h), respectively, whereas courses with myelosuppression (WHO grades 2-4) showed inverse profiles with high AUCFUrd values (16.3 +/- 2.3 micrograms ml-1 h) and low AUCFdUrd values (3.1 +/- 1.0 micrograms ml-1 h), respectively.",Evaluation of plasma 5-fluorouracil nucleoside levels in patients with metastatic breast cancer: relationships with toxicities. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7497579/),[h·μg] / [ml],2.9,127377,DB00544,Fluorouracil
,7497579,AUCFdUrd,"Chemotherapy cycles without neutropenia were associated with low AUCFUrd values (mean +/- SEM, 2.9 +/- 0.7 micrograms ml-1 h) and high AUCFdUrd values (14.1 +/- 2.7 micrograms ml-1 h), respectively, whereas courses with myelosuppression (WHO grades 2-4) showed inverse profiles with high AUCFUrd values (16.3 +/- 2.3 micrograms ml-1 h) and low AUCFdUrd values (3.1 +/- 1.0 micrograms ml-1 h), respectively.",Evaluation of plasma 5-fluorouracil nucleoside levels in patients with metastatic breast cancer: relationships with toxicities. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7497579/),[h·μg] / [ml],14.1,127378,DB00544,Fluorouracil
,7497579,AUCFUrd,"Chemotherapy cycles without neutropenia were associated with low AUCFUrd values (mean +/- SEM, 2.9 +/- 0.7 micrograms ml-1 h) and high AUCFdUrd values (14.1 +/- 2.7 micrograms ml-1 h), respectively, whereas courses with myelosuppression (WHO grades 2-4) showed inverse profiles with high AUCFUrd values (16.3 +/- 2.3 micrograms ml-1 h) and low AUCFdUrd values (3.1 +/- 1.0 micrograms ml-1 h), respectively.",Evaluation of plasma 5-fluorouracil nucleoside levels in patients with metastatic breast cancer: relationships with toxicities. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7497579/),[h·μg] / [ml],16.3,127379,DB00544,Fluorouracil
,7497579,AUCFdUrd,"Chemotherapy cycles without neutropenia were associated with low AUCFUrd values (mean +/- SEM, 2.9 +/- 0.7 micrograms ml-1 h) and high AUCFdUrd values (14.1 +/- 2.7 micrograms ml-1 h), respectively, whereas courses with myelosuppression (WHO grades 2-4) showed inverse profiles with high AUCFUrd values (16.3 +/- 2.3 micrograms ml-1 h) and low AUCFdUrd values (3.1 +/- 1.0 micrograms ml-1 h), respectively.",Evaluation of plasma 5-fluorouracil nucleoside levels in patients with metastatic breast cancer: relationships with toxicities. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7497579/),[h·μg] / [ml],3.1,127380,DB00544,Fluorouracil
,7497579,AUCFdUrd,"A statistically significant difference in AUCFdUrd values was also observed between cycles with and those without mucositis (P = 0.0027), with AUCFdUrd values being 22.6 +/- 5.6 and 7.8 +/- 1.9 micrograms ml-1 h, respectively.",Evaluation of plasma 5-fluorouracil nucleoside levels in patients with metastatic breast cancer: relationships with toxicities. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7497579/),[h·μg] / [ml],22.6,127381,DB00544,Fluorouracil
,7497579,AUCFdUrd,"A statistically significant difference in AUCFdUrd values was also observed between cycles with and those without mucositis (P = 0.0027), with AUCFdUrd values being 22.6 +/- 5.6 and 7.8 +/- 1.9 micrograms ml-1 h, respectively.",Evaluation of plasma 5-fluorouracil nucleoside levels in patients with metastatic breast cancer: relationships with toxicities. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7497579/),[h·μg] / [ml],7.8,127382,DB00544,Fluorouracil
,20463088,MTD,"The MTD of vorinostat in combination with sLV5FU2 is 1,700 mg orally once daily x 3 or 600 mg orally twice daily x 3 days every 2 weeks.","A phase I, pharmacokinetic, and pharmacodynamic study of two schedules of vorinostat in combination with 5-fluorouracil and leucovorin in patients with refractory solid tumors. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20463088/),mg,1,127610,DB00544,Fluorouracil
,25957957,clearance [CL,"The mean uracil clearance [CL 51.7 (SD 6.4) vs. 46.7 (SD 13.0) l/h], area under the curve [AUC0-220min 20.6 (SD 6.4) vs. 21.0 (SD 5.7) h mg/l], elimination half-life [t 1/2 21 (SD 7) vs. 21 (SD 8) min], maximum concentration time [T max 27 (SD 9) vs. 25 (SD 9) min], volume of distribution [V 26.58 (SD 10.11) vs. 21.10 (SD 8.48) l] and the elimination constant [k el 2.01 (SD 0.56) vs. 2.41 (SD 0.72) h(-1)] did not differ significantly (p > 0.05) non-metastatic CRD versus metastatic CRC.",Influence of metastatic disease on the usefulness of uracil pharmacokinetics as a screening tool for DPD activity in colorectal cancer patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25957957/),[l] / [h],51.7,127698,DB00544,Fluorouracil
,25957957,clearance [CL,"The mean uracil clearance [CL 51.7 (SD 6.4) vs. 46.7 (SD 13.0) l/h], area under the curve [AUC0-220min 20.6 (SD 6.4) vs. 21.0 (SD 5.7) h mg/l], elimination half-life [t 1/2 21 (SD 7) vs. 21 (SD 8) min], maximum concentration time [T max 27 (SD 9) vs. 25 (SD 9) min], volume of distribution [V 26.58 (SD 10.11) vs. 21.10 (SD 8.48) l] and the elimination constant [k el 2.01 (SD 0.56) vs. 2.41 (SD 0.72) h(-1)] did not differ significantly (p > 0.05) non-metastatic CRD versus metastatic CRC.",Influence of metastatic disease on the usefulness of uracil pharmacokinetics as a screening tool for DPD activity in colorectal cancer patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25957957/),[l] / [h],46.7,127699,DB00544,Fluorouracil
,25957957,area under the curve [AUC0-220min,"The mean uracil clearance [CL 51.7 (SD 6.4) vs. 46.7 (SD 13.0) l/h], area under the curve [AUC0-220min 20.6 (SD 6.4) vs. 21.0 (SD 5.7) h mg/l], elimination half-life [t 1/2 21 (SD 7) vs. 21 (SD 8) min], maximum concentration time [T max 27 (SD 9) vs. 25 (SD 9) min], volume of distribution [V 26.58 (SD 10.11) vs. 21.10 (SD 8.48) l] and the elimination constant [k el 2.01 (SD 0.56) vs. 2.41 (SD 0.72) h(-1)] did not differ significantly (p > 0.05) non-metastatic CRD versus metastatic CRC.",Influence of metastatic disease on the usefulness of uracil pharmacokinetics as a screening tool for DPD activity in colorectal cancer patients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25957957/),[h·mg] / [l],20.6,127700,DB00544,Fluorouracil
,25957957,area under the curve [AUC0-220min,"The mean uracil clearance [CL 51.7 (SD 6.4) vs. 46.7 (SD 13.0) l/h], area under the curve [AUC0-220min 20.6 (SD 6.4) vs. 21.0 (SD 5.7) h mg/l], elimination half-life [t 1/2 21 (SD 7) vs. 21 (SD 8) min], maximum concentration time [T max 27 (SD 9) vs. 25 (SD 9) min], volume of distribution [V 26.58 (SD 10.11) vs. 21.10 (SD 8.48) l] and the elimination constant [k el 2.01 (SD 0.56) vs. 2.41 (SD 0.72) h(-1)] did not differ significantly (p > 0.05) non-metastatic CRD versus metastatic CRC.",Influence of metastatic disease on the usefulness of uracil pharmacokinetics as a screening tool for DPD activity in colorectal cancer patients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25957957/),[h·mg] / [l],21.0,127701,DB00544,Fluorouracil
,25957957,elimination half-life [t 1/2,"The mean uracil clearance [CL 51.7 (SD 6.4) vs. 46.7 (SD 13.0) l/h], area under the curve [AUC0-220min 20.6 (SD 6.4) vs. 21.0 (SD 5.7) h mg/l], elimination half-life [t 1/2 21 (SD 7) vs. 21 (SD 8) min], maximum concentration time [T max 27 (SD 9) vs. 25 (SD 9) min], volume of distribution [V 26.58 (SD 10.11) vs. 21.10 (SD 8.48) l] and the elimination constant [k el 2.01 (SD 0.56) vs. 2.41 (SD 0.72) h(-1)] did not differ significantly (p > 0.05) non-metastatic CRD versus metastatic CRC.",Influence of metastatic disease on the usefulness of uracil pharmacokinetics as a screening tool for DPD activity in colorectal cancer patients. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/25957957/),min,21,127702,DB00544,Fluorouracil
,25957957,elimination half-life [t 1/2,"The mean uracil clearance [CL 51.7 (SD 6.4) vs. 46.7 (SD 13.0) l/h], area under the curve [AUC0-220min 20.6 (SD 6.4) vs. 21.0 (SD 5.7) h mg/l], elimination half-life [t 1/2 21 (SD 7) vs. 21 (SD 8) min], maximum concentration time [T max 27 (SD 9) vs. 25 (SD 9) min], volume of distribution [V 26.58 (SD 10.11) vs. 21.10 (SD 8.48) l] and the elimination constant [k el 2.01 (SD 0.56) vs. 2.41 (SD 0.72) h(-1)] did not differ significantly (p > 0.05) non-metastatic CRD versus metastatic CRC.",Influence of metastatic disease on the usefulness of uracil pharmacokinetics as a screening tool for DPD activity in colorectal cancer patients. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/25957957/),min,21,127703,DB00544,Fluorouracil
,25957957,maximum concentration time [T max,"The mean uracil clearance [CL 51.7 (SD 6.4) vs. 46.7 (SD 13.0) l/h], area under the curve [AUC0-220min 20.6 (SD 6.4) vs. 21.0 (SD 5.7) h mg/l], elimination half-life [t 1/2 21 (SD 7) vs. 21 (SD 8) min], maximum concentration time [T max 27 (SD 9) vs. 25 (SD 9) min], volume of distribution [V 26.58 (SD 10.11) vs. 21.10 (SD 8.48) l] and the elimination constant [k el 2.01 (SD 0.56) vs. 2.41 (SD 0.72) h(-1)] did not differ significantly (p > 0.05) non-metastatic CRD versus metastatic CRC.",Influence of metastatic disease on the usefulness of uracil pharmacokinetics as a screening tool for DPD activity in colorectal cancer patients. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25957957/),min,27,127704,DB00544,Fluorouracil
,25957957,maximum concentration time [T max,"The mean uracil clearance [CL 51.7 (SD 6.4) vs. 46.7 (SD 13.0) l/h], area under the curve [AUC0-220min 20.6 (SD 6.4) vs. 21.0 (SD 5.7) h mg/l], elimination half-life [t 1/2 21 (SD 7) vs. 21 (SD 8) min], maximum concentration time [T max 27 (SD 9) vs. 25 (SD 9) min], volume of distribution [V 26.58 (SD 10.11) vs. 21.10 (SD 8.48) l] and the elimination constant [k el 2.01 (SD 0.56) vs. 2.41 (SD 0.72) h(-1)] did not differ significantly (p > 0.05) non-metastatic CRD versus metastatic CRC.",Influence of metastatic disease on the usefulness of uracil pharmacokinetics as a screening tool for DPD activity in colorectal cancer patients. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25957957/),min,25,127705,DB00544,Fluorouracil
,25957957,volume of distribution [V,"The mean uracil clearance [CL 51.7 (SD 6.4) vs. 46.7 (SD 13.0) l/h], area under the curve [AUC0-220min 20.6 (SD 6.4) vs. 21.0 (SD 5.7) h mg/l], elimination half-life [t 1/2 21 (SD 7) vs. 21 (SD 8) min], maximum concentration time [T max 27 (SD 9) vs. 25 (SD 9) min], volume of distribution [V 26.58 (SD 10.11) vs. 21.10 (SD 8.48) l] and the elimination constant [k el 2.01 (SD 0.56) vs. 2.41 (SD 0.72) h(-1)] did not differ significantly (p > 0.05) non-metastatic CRD versus metastatic CRC.",Influence of metastatic disease on the usefulness of uracil pharmacokinetics as a screening tool for DPD activity in colorectal cancer patients. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25957957/),l,26.58,127706,DB00544,Fluorouracil
,25957957,volume of distribution [V,"The mean uracil clearance [CL 51.7 (SD 6.4) vs. 46.7 (SD 13.0) l/h], area under the curve [AUC0-220min 20.6 (SD 6.4) vs. 21.0 (SD 5.7) h mg/l], elimination half-life [t 1/2 21 (SD 7) vs. 21 (SD 8) min], maximum concentration time [T max 27 (SD 9) vs. 25 (SD 9) min], volume of distribution [V 26.58 (SD 10.11) vs. 21.10 (SD 8.48) l] and the elimination constant [k el 2.01 (SD 0.56) vs. 2.41 (SD 0.72) h(-1)] did not differ significantly (p > 0.05) non-metastatic CRD versus metastatic CRC.",Influence of metastatic disease on the usefulness of uracil pharmacokinetics as a screening tool for DPD activity in colorectal cancer patients. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25957957/),l,21.10,127707,DB00544,Fluorouracil
,25957957,elimination constant [k el,"The mean uracil clearance [CL 51.7 (SD 6.4) vs. 46.7 (SD 13.0) l/h], area under the curve [AUC0-220min 20.6 (SD 6.4) vs. 21.0 (SD 5.7) h mg/l], elimination half-life [t 1/2 21 (SD 7) vs. 21 (SD 8) min], maximum concentration time [T max 27 (SD 9) vs. 25 (SD 9) min], volume of distribution [V 26.58 (SD 10.11) vs. 21.10 (SD 8.48) l] and the elimination constant [k el 2.01 (SD 0.56) vs. 2.41 (SD 0.72) h(-1)] did not differ significantly (p > 0.05) non-metastatic CRD versus metastatic CRC.",Influence of metastatic disease on the usefulness of uracil pharmacokinetics as a screening tool for DPD activity in colorectal cancer patients. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25957957/),1/[h],2.01,127708,DB00544,Fluorouracil
,25957957,elimination constant [k el,"The mean uracil clearance [CL 51.7 (SD 6.4) vs. 46.7 (SD 13.0) l/h], area under the curve [AUC0-220min 20.6 (SD 6.4) vs. 21.0 (SD 5.7) h mg/l], elimination half-life [t 1/2 21 (SD 7) vs. 21 (SD 8) min], maximum concentration time [T max 27 (SD 9) vs. 25 (SD 9) min], volume of distribution [V 26.58 (SD 10.11) vs. 21.10 (SD 8.48) l] and the elimination constant [k el 2.01 (SD 0.56) vs. 2.41 (SD 0.72) h(-1)] did not differ significantly (p > 0.05) non-metastatic CRD versus metastatic CRC.",Influence of metastatic disease on the usefulness of uracil pharmacokinetics as a screening tool for DPD activity in colorectal cancer patients. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25957957/),1/[h],2.41,127709,DB00544,Fluorouracil
,2786459,Peak total,"Peak total and ultrafiltrate plasma platinum concentrations were 1.15 and 0.172 micrograms/ml for cycle 1 and 1.2 and 0.124 micrograms/ml for cycle 3, respectively.",Pharmacokinetics of cisplatin in patients receiving interleukin-2-containing treatment regimens. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2786459/),[μg] / [ml],1.15,127710,DB00544,Fluorouracil
,2786459,Peak total,"Peak total and ultrafiltrate plasma platinum concentrations were 1.15 and 0.172 micrograms/ml for cycle 1 and 1.2 and 0.124 micrograms/ml for cycle 3, respectively.",Pharmacokinetics of cisplatin in patients receiving interleukin-2-containing treatment regimens. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2786459/),[μg] / [ml],1.2,127711,DB00544,Fluorouracil
,2786459,ultrafiltrate plasma platinum concentrations,"Peak total and ultrafiltrate plasma platinum concentrations were 1.15 and 0.172 micrograms/ml for cycle 1 and 1.2 and 0.124 micrograms/ml for cycle 3, respectively.",Pharmacokinetics of cisplatin in patients receiving interleukin-2-containing treatment regimens. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2786459/),[μg] / [ml],0.172,127712,DB00544,Fluorouracil
,2786459,ultrafiltrate plasma platinum concentrations,"Peak total and ultrafiltrate plasma platinum concentrations were 1.15 and 0.172 micrograms/ml for cycle 1 and 1.2 and 0.124 micrograms/ml for cycle 3, respectively.",Pharmacokinetics of cisplatin in patients receiving interleukin-2-containing treatment regimens. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2786459/),[μg] / [ml],0.124,127713,DB00544,Fluorouracil
,2786459,AUCs,"The AUCs for total and ultrafiltrate plasma platinum were 7.33 and 0.965 micrograms/ml per hour for cycle 1 and 8.48 and 0.924 micrograms/ml per hour for cycle 3, respectively.",Pharmacokinetics of cisplatin in patients receiving interleukin-2-containing treatment regimens. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2786459/),[μg] / [h·ml],7.33,127714,DB00544,Fluorouracil
,2786459,AUCs,"The AUCs for total and ultrafiltrate plasma platinum were 7.33 and 0.965 micrograms/ml per hour for cycle 1 and 8.48 and 0.924 micrograms/ml per hour for cycle 3, respectively.",Pharmacokinetics of cisplatin in patients receiving interleukin-2-containing treatment regimens. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2786459/),[μg] / [h·ml],0.965,127715,DB00544,Fluorouracil
,2786459,AUCs,"The AUCs for total and ultrafiltrate plasma platinum were 7.33 and 0.965 micrograms/ml per hour for cycle 1 and 8.48 and 0.924 micrograms/ml per hour for cycle 3, respectively.",Pharmacokinetics of cisplatin in patients receiving interleukin-2-containing treatment regimens. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2786459/),[μg] / [h·ml],8.48,127716,DB00544,Fluorouracil
,2786459,AUCs,"The AUCs for total and ultrafiltrate plasma platinum were 7.33 and 0.965 micrograms/ml per hour for cycle 1 and 8.48 and 0.924 micrograms/ml per hour for cycle 3, respectively.",Pharmacokinetics of cisplatin in patients receiving interleukin-2-containing treatment regimens. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2786459/),[μg] / [h·ml],0.924,127717,DB00544,Fluorouracil
,2786459,Total body clearances,"Total body clearances for total and ultrafiltrate platinum were 0.051 and 0.525 ml/h for cycle 1 and 0.042 and 0.443 ml/h for cycle 3, respectively.",Pharmacokinetics of cisplatin in patients receiving interleukin-2-containing treatment regimens. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2786459/),[ml] / [h],0.051,127718,DB00544,Fluorouracil
,2786459,Total body clearances,"Total body clearances for total and ultrafiltrate platinum were 0.051 and 0.525 ml/h for cycle 1 and 0.042 and 0.443 ml/h for cycle 3, respectively.",Pharmacokinetics of cisplatin in patients receiving interleukin-2-containing treatment regimens. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2786459/),[ml] / [h],0.525,127719,DB00544,Fluorouracil
,2786459,Total body clearances,"Total body clearances for total and ultrafiltrate platinum were 0.051 and 0.525 ml/h for cycle 1 and 0.042 and 0.443 ml/h for cycle 3, respectively.",Pharmacokinetics of cisplatin in patients receiving interleukin-2-containing treatment regimens. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2786459/),[ml] / [h],0.042,127720,DB00544,Fluorouracil
,2786459,Total body clearances,"Total body clearances for total and ultrafiltrate platinum were 0.051 and 0.525 ml/h for cycle 1 and 0.042 and 0.443 ml/h for cycle 3, respectively.",Pharmacokinetics of cisplatin in patients receiving interleukin-2-containing treatment regimens. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2786459/),[ml] / [h],0.443,127721,DB00544,Fluorouracil
,8137453,area under the curve (AUC),"Before the operation, the area under the curve (AUC) for tegafur, uracil, and 5-fluorouracil (5-FU) was 79.28 +/- 26.88, 4.41 +/- 1.78, and 0.51 +/- 0.20 micrograms h ml-1, respectively.","Effect of gastrectomy on the pharmacokinetics of tegafur, uracil, and 5-fluorouracil after oral administration of a 1:4 tegafur and uracil combination. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8137453/),[h·μg] / [ml],79.28,128101,DB00544,Fluorouracil
,8137453,area under the curve (AUC),"Before the operation, the area under the curve (AUC) for tegafur, uracil, and 5-fluorouracil (5-FU) was 79.28 +/- 26.88, 4.41 +/- 1.78, and 0.51 +/- 0.20 micrograms h ml-1, respectively.","Effect of gastrectomy on the pharmacokinetics of tegafur, uracil, and 5-fluorouracil after oral administration of a 1:4 tegafur and uracil combination. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8137453/),[h·μg] / [ml],4.41,128102,DB00544,Fluorouracil
,8137453,area under the curve (AUC),"Before the operation, the area under the curve (AUC) for tegafur, uracil, and 5-fluorouracil (5-FU) was 79.28 +/- 26.88, 4.41 +/- 1.78, and 0.51 +/- 0.20 micrograms h ml-1, respectively.","Effect of gastrectomy on the pharmacokinetics of tegafur, uracil, and 5-fluorouracil after oral administration of a 1:4 tegafur and uracil combination. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8137453/),[h·μg] / [ml],0.51,128103,DB00544,Fluorouracil
,20859741,compliance rate,"No patients were withdrawn from this study because of the intolerability of curcumin, which met the primary endpoint of the phase II study, and the median compliance rate of oral curcumin was 100% (Range 79-100%).",A phase I/II study of gemcitabine-based chemotherapy plus curcumin for patients with gemcitabine-resistant pancreatic cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20859741/),%,100,128312,DB00544,Fluorouracil
,20859741,survival time,Median survival time after initiation of curcumin was 161 days (95% confidence interval 109-223 days) and 1-year survival rate was 19% (4.4-41.4%).,A phase I/II study of gemcitabine-based chemotherapy plus curcumin for patients with gemcitabine-resistant pancreatic cancer. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20859741/),d,161,128313,DB00544,Fluorouracil
,2118420,area under the curve ratio,Median area under the curve ratio i.p./i.v. was 117 for 5-fluorouracil and 21.6 for mitomycin C.,Early postoperative intraperitoneal chemotherapy as an adjuvant therapy to surgery for peritoneal carcinomatosis from gastrointestinal cancer: pharmacological studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2118420/),,117,129073,DB00544,Fluorouracil
,2118420,area under the curve ratio,Median area under the curve ratio i.p./i.v. was 117 for 5-fluorouracil and 21.6 for mitomycin C.,Early postoperative intraperitoneal chemotherapy as an adjuvant therapy to surgery for peritoneal carcinomatosis from gastrointestinal cancer: pharmacological studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2118420/),,21.6,129074,DB00544,Fluorouracil
,20946314,progression-free survival,"The median progression-free survival and overall survival were 3.7 and 16.6 months, respectively.","Phase I/II study of the pharmacokinetics, safety and efficacy of S-1 in patients with advanced hepatocellular carcinoma. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20946314/),month,3.7,129576,DB00544,Fluorouracil
,20946314,overall survival,"The median progression-free survival and overall survival were 3.7 and 16.6 months, respectively.","Phase I/II study of the pharmacokinetics, safety and efficacy of S-1 in patients with advanced hepatocellular carcinoma. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20946314/),month,16.6,129577,DB00544,Fluorouracil
,2060083,half-life,"The estimated mean half-life was 6.9 +/- 3.9 min for unchanged 5-FU and 225 +/- 352, 7.6 +/- 4, and 9.6 +/- 7.7 min, respectively, for the three measured catabolites dihydrofluorouracil (FUH2), alpha-fluoro-beta-ureidopropionic acid (FUPA), and alpha-fluoro-beta-alanine (FBAL).",A mathematical model of the kinetics of 5-fluorouracil and its metabolites in cancer patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2060083/),min,6.9,130075,DB00544,Fluorouracil
,2060083,half-life,"The estimated mean half-life was 6.9 +/- 3.9 min for unchanged 5-FU and 225 +/- 352, 7.6 +/- 4, and 9.6 +/- 7.7 min, respectively, for the three measured catabolites dihydrofluorouracil (FUH2), alpha-fluoro-beta-ureidopropionic acid (FUPA), and alpha-fluoro-beta-alanine (FBAL).",A mathematical model of the kinetics of 5-fluorouracil and its metabolites in cancer patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2060083/),min,225,130076,DB00544,Fluorouracil
,2060083,half-life,"The estimated mean half-life was 6.9 +/- 3.9 min for unchanged 5-FU and 225 +/- 352, 7.6 +/- 4, and 9.6 +/- 7.7 min, respectively, for the three measured catabolites dihydrofluorouracil (FUH2), alpha-fluoro-beta-ureidopropionic acid (FUPA), and alpha-fluoro-beta-alanine (FBAL).",A mathematical model of the kinetics of 5-fluorouracil and its metabolites in cancer patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2060083/),min,7.6,130077,DB00544,Fluorouracil
,2060083,half-life,"The estimated mean half-life was 6.9 +/- 3.9 min for unchanged 5-FU and 225 +/- 352, 7.6 +/- 4, and 9.6 +/- 7.7 min, respectively, for the three measured catabolites dihydrofluorouracil (FUH2), alpha-fluoro-beta-ureidopropionic acid (FUPA), and alpha-fluoro-beta-alanine (FBAL).",A mathematical model of the kinetics of 5-fluorouracil and its metabolites in cancer patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2060083/),min,9.6,130078,DB00544,Fluorouracil
,9225949,half-life,The half-life of 5-FU in the pericardial space was 168.6 min with a concentration of 0.113 mg/ml still detected at 5 h.,Pharmacokinetics of intrapericardial administration of 5-fluorouracil. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9225949/),min,168.6,130662,DB00544,Fluorouracil
,9225949,area under the curve (AUC),The area under the curve (AUC) was estimated to be 4.739 mg h/ml.,Pharmacokinetics of intrapericardial administration of 5-fluorouracil. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9225949/),[h·mg] / [ml],4.739,130663,DB00544,Fluorouracil
,9225949,half-life,"We conclude that pericardial infusion of 5-FU allowed a high concentration of 5-FU to be achieved within the pericardial sac with a greatly increased half-life over that of systemic 5-FU treatment (168 min vs 6-20 min), and with little systemic toxicity.",Pharmacokinetics of intrapericardial administration of 5-fluorouracil. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9225949/),min,168,130664,DB00544,Fluorouracil
,9225949,half-life,"We conclude that pericardial infusion of 5-FU allowed a high concentration of 5-FU to be achieved within the pericardial sac with a greatly increased half-life over that of systemic 5-FU treatment (168 min vs 6-20 min), and with little systemic toxicity.",Pharmacokinetics of intrapericardial administration of 5-fluorouracil. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9225949/),min,6-20,130665,DB00544,Fluorouracil
,8173197,survival time,"Moreover, although dose reduction was often performed, the clinical response was not affected (42-44%), neither was the median survival time (8.8 months-14.1 months in control and adapted groups respectively).",[Pharmacokinetic monitoring with dosage adjustment of 5 fluorouracil administered by continuous infusion]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8173197/),month,8.8,130754,DB00544,Fluorouracil
,8173197,survival time,"Moreover, although dose reduction was often performed, the clinical response was not affected (42-44%), neither was the median survival time (8.8 months-14.1 months in control and adapted groups respectively).",[Pharmacokinetic monitoring with dosage adjustment of 5 fluorouracil administered by continuous infusion]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8173197/),month,14.1,130755,DB00544,Fluorouracil
,32115568,total platinum (Pt) concentration (Pt_total),"The total platinum (Pt) concentration (Pt_total) and free Pt concentration (Pt_free) 2 h after completion of HD were 0.4 μg/mL and 0.3 μg/mL, respectively.",[A Case of Advanced Esophageal Cancer Treated with Nedaplatin in a Patient Undergoing Maintenance Hemodialysis]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32115568/),[μg] / [ml],0.4,131456,DB00544,Fluorouracil
,32115568,free Pt concentration (Pt_free),"The total platinum (Pt) concentration (Pt_total) and free Pt concentration (Pt_free) 2 h after completion of HD were 0.4 μg/mL and 0.3 μg/mL, respectively.",[A Case of Advanced Esophageal Cancer Treated with Nedaplatin in a Patient Undergoing Maintenance Hemodialysis]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32115568/),[μg] / [ml],0.3,131457,DB00544,Fluorouracil
,32115568,removal rates,"The removal rates of Pt_total and Pt_free by the dialyzer were 76.5% and 84.6%, respectively.",[A Case of Advanced Esophageal Cancer Treated with Nedaplatin in a Patient Undergoing Maintenance Hemodialysis]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32115568/),%,76.5,131458,DB00544,Fluorouracil
,32115568,removal rates,"The removal rates of Pt_total and Pt_free by the dialyzer were 76.5% and 84.6%, respectively.",[A Case of Advanced Esophageal Cancer Treated with Nedaplatin in a Patient Undergoing Maintenance Hemodialysis]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32115568/),%,84.6,131459,DB00544,Fluorouracil
,32115568,AUC0-24,"Pt_free within the range of the recommended CDGP target AUC0-24 was 8-10 μg/mL•h, the AUC0-24 of Pt_total and Pt_free were 16.5 μg/mL•h and 8.8 μg/mL•h, respectively.",[A Case of Advanced Esophageal Cancer Treated with Nedaplatin in a Patient Undergoing Maintenance Hemodialysis]. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32115568/),[μg] / [h·ml],8-10,131460,DB00544,Fluorouracil
,32115568,AUC0-24,"Pt_free within the range of the recommended CDGP target AUC0-24 was 8-10 μg/mL•h, the AUC0-24 of Pt_total and Pt_free were 16.5 μg/mL•h and 8.8 μg/mL•h, respectively.",[A Case of Advanced Esophageal Cancer Treated with Nedaplatin in a Patient Undergoing Maintenance Hemodialysis]. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32115568/),[μg] / [h·ml],16.5,131461,DB00544,Fluorouracil
,32115568,AUC0-24,"Pt_free within the range of the recommended CDGP target AUC0-24 was 8-10 μg/mL•h, the AUC0-24 of Pt_total and Pt_free were 16.5 μg/mL•h and 8.8 μg/mL•h, respectively.",[A Case of Advanced Esophageal Cancer Treated with Nedaplatin in a Patient Undergoing Maintenance Hemodialysis]. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32115568/),[μg] / [h·ml],8.8,131462,DB00544,Fluorouracil
,26541630,maximal concentration,"At 500 mg/m(2), the median 5-FU maximal concentration, AUC0-∞, and alpha half-life were 825 µM, 205 µM × h, and 9.9 min, respectively.",Phase I study of 5-fluorouracil in children and young adults with recurrent ependymoma. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26541630/),μM,825,131470,DB00544,Fluorouracil
,26541630,AUC0-∞,"At 500 mg/m(2), the median 5-FU maximal concentration, AUC0-∞, and alpha half-life were 825 µM, 205 µM × h, and 9.9 min, respectively.",Phase I study of 5-fluorouracil in children and young adults with recurrent ependymoma. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26541630/),h·μM,205,131471,DB00544,Fluorouracil
,26541630,alpha half-life,"At 500 mg/m(2), the median 5-FU maximal concentration, AUC0-∞, and alpha half-life were 825 µM, 205 µM × h, and 9.9 min, respectively.",Phase I study of 5-fluorouracil in children and young adults with recurrent ependymoma. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26541630/),min,9.9,131472,DB00544,Fluorouracil
,28667466,overall response rate,"Among the 11 patients with measurable disease, overall response rate and disease control rate were 45.5% and 100.0%, respectively.","Safety, pharmacokinetic, and clinical activity profiles of ramucirumab in combination with three platinum/fluoropyrimidine doublets in Japanese patients with chemotherapy-naïve metastatic gastric/gastroesophageal junction cancer. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28667466/),%,45.5,133613,DB00544,Fluorouracil
,28667466,disease control rate,"Among the 11 patients with measurable disease, overall response rate and disease control rate were 45.5% and 100.0%, respectively.","Safety, pharmacokinetic, and clinical activity profiles of ramucirumab in combination with three platinum/fluoropyrimidine doublets in Japanese patients with chemotherapy-naïve metastatic gastric/gastroesophageal junction cancer. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28667466/),%,100.0,133614,DB00544,Fluorouracil
,28667466,progression-free survival,Median progression-free survival (95% CI) was 7.6 months (6.0 to not estimable).,"Safety, pharmacokinetic, and clinical activity profiles of ramucirumab in combination with three platinum/fluoropyrimidine doublets in Japanese patients with chemotherapy-naïve metastatic gastric/gastroesophageal junction cancer. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28667466/),month,7.6,133615,DB00544,Fluorouracil
,22490854,plasma concentrations,"The average plasma concentrations of fluorouracil of the three groups were (23.48 ± 1.95) ng/ml, (31.47 ± 2.33) ng/ml and (39.89 ± 3.87) ng/ml, respectively (P < 0.01).",[Role of pharmacokinetic monitoring of serum fluorouracil concentration in patients with local advanced and metastatic colorectal cancer and further improving efficacy of fluorouracil-based chemotherapy]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22490854/),[ng] / [ml],23.48,133672,DB00544,Fluorouracil
,22490854,plasma concentrations,"The average plasma concentrations of fluorouracil of the three groups were (23.48 ± 1.95) ng/ml, (31.47 ± 2.33) ng/ml and (39.89 ± 3.87) ng/ml, respectively (P < 0.01).",[Role of pharmacokinetic monitoring of serum fluorouracil concentration in patients with local advanced and metastatic colorectal cancer and further improving efficacy of fluorouracil-based chemotherapy]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22490854/),[ng] / [ml],31.47,133673,DB00544,Fluorouracil
,22490854,plasma concentrations,"The average plasma concentrations of fluorouracil of the three groups were (23.48 ± 1.95) ng/ml, (31.47 ± 2.33) ng/ml and (39.89 ± 3.87) ng/ml, respectively (P < 0.01).",[Role of pharmacokinetic monitoring of serum fluorouracil concentration in patients with local advanced and metastatic colorectal cancer and further improving efficacy of fluorouracil-based chemotherapy]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22490854/),[ng] / [ml],39.89,133674,DB00544,Fluorouracil
,22490854,OS,"As for therapeutic efficacy, the median OS of the groups 2 and 3 were 18.0 and 17.5 months, significantly higher than that in the group 1 (13.0 months, P < 0.01).",[Role of pharmacokinetic monitoring of serum fluorouracil concentration in patients with local advanced and metastatic colorectal cancer and further improving efficacy of fluorouracil-based chemotherapy]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22490854/),month,18.0,133675,DB00544,Fluorouracil
,22490854,OS,"As for therapeutic efficacy, the median OS of the groups 2 and 3 were 18.0 and 17.5 months, significantly higher than that in the group 1 (13.0 months, P < 0.01).",[Role of pharmacokinetic monitoring of serum fluorouracil concentration in patients with local advanced and metastatic colorectal cancer and further improving efficacy of fluorouracil-based chemotherapy]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22490854/),month,17.5,133676,DB00544,Fluorouracil
,22490854,OS,"As for therapeutic efficacy, the median OS of the groups 2 and 3 were 18.0 and 17.5 months, significantly higher than that in the group 1 (13.0 months, P < 0.01).",[Role of pharmacokinetic monitoring of serum fluorouracil concentration in patients with local advanced and metastatic colorectal cancer and further improving efficacy of fluorouracil-based chemotherapy]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22490854/),month,13.0,133677,DB00544,Fluorouracil
,22490854,PFS,"The PFS were 4.5, 7.5 and 8.0 months, respectively (P < 0.01).",[Role of pharmacokinetic monitoring of serum fluorouracil concentration in patients with local advanced and metastatic colorectal cancer and further improving efficacy of fluorouracil-based chemotherapy]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22490854/),month,4.5,133678,DB00544,Fluorouracil
,22490854,PFS,"The PFS were 4.5, 7.5 and 8.0 months, respectively (P < 0.01).",[Role of pharmacokinetic monitoring of serum fluorouracil concentration in patients with local advanced and metastatic colorectal cancer and further improving efficacy of fluorouracil-based chemotherapy]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22490854/),month,7.5,133679,DB00544,Fluorouracil
,22490854,PFS,"The PFS were 4.5, 7.5 and 8.0 months, respectively (P < 0.01).",[Role of pharmacokinetic monitoring of serum fluorouracil concentration in patients with local advanced and metastatic colorectal cancer and further improving efficacy of fluorouracil-based chemotherapy]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22490854/),month,8.0,133680,DB00544,Fluorouracil
,27538461,drug,"Capecitabine, an anti cancer drug, has a very short drug elimination half-life (0.49 to 0.89 h).",Cell Line and Augument Cellular Uptake Study of Statistically Optimized Sustained Release Capecitabine Loaded Eudragit S100/PLGA(poly(lacticco- glycolic acid)) Nanoparticles for Colon Targeting. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/27538461/),h,0.49 to 0.89,133773,DB00544,Fluorouracil
,27538461,elimination half-life,"Capecitabine, an anti cancer drug, has a very short drug elimination half-life (0.49 to 0.89 h).",Cell Line and Augument Cellular Uptake Study of Statistically Optimized Sustained Release Capecitabine Loaded Eudragit S100/PLGA(poly(lacticco- glycolic acid)) Nanoparticles for Colon Targeting. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/27538461/),h,0.49 to 0.89,133774,DB00544,Fluorouracil
,10100600,exposure ratios,"Pelvic isolation of drug was demonstrated by the pelvic-systemic drug exposure ratios of 6.0:1 for cis-platinum, 8.4:1 for 5-fluorouracil and 9.0:1 for mitomycin-C.","A pharmacokinetic model and the clinical pharmacology of cis-platinum, 5-fluorouracil and mitomycin-C in isolated pelvic perfusion. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10100600/),:1,6.0,133775,DB00544,Fluorouracil
,10100600,exposure ratios,"Pelvic isolation of drug was demonstrated by the pelvic-systemic drug exposure ratios of 6.0:1 for cis-platinum, 8.4:1 for 5-fluorouracil and 9.0:1 for mitomycin-C.","A pharmacokinetic model and the clinical pharmacology of cis-platinum, 5-fluorouracil and mitomycin-C in isolated pelvic perfusion. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10100600/),:1,8.4,133776,DB00544,Fluorouracil
,10100600,exposure ratios,"Pelvic isolation of drug was demonstrated by the pelvic-systemic drug exposure ratios of 6.0:1 for cis-platinum, 8.4:1 for 5-fluorouracil and 9.0:1 for mitomycin-C.","A pharmacokinetic model and the clinical pharmacology of cis-platinum, 5-fluorouracil and mitomycin-C in isolated pelvic perfusion. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10100600/),:1,9.0,133777,DB00544,Fluorouracil
,22966260,objective response rate,The objective response rate was 31.4% and the tumour stabilization rate was 85.7%.,Multicentre phase II study of leucovorin plus pharmacokinetic modulating chemotherapy for metastatic colorectal cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22966260/),%,31.4,134669,DB00544,Fluorouracil
,22966260,t,The objective response rate was 31.4% and the tumour stabilization rate was 85.7%.,Multicentre phase II study of leucovorin plus pharmacokinetic modulating chemotherapy for metastatic colorectal cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22966260/),%,85.,134670,DB00544,Fluorouracil
,16062072,AUC,"Patients received carboplatin (AUC = 2) on days 1 and 8, docetaxel (35-40 mg/m2) on days 1 and 8, and capecitabine (500-2000 mg/m2) on days 1 to 10.","Phase I study of docetaxel, capecitabine, and carboplatin in metastatic esophagogastric cancer. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16062072/),,2,134671,DB00544,Fluorouracil
,16062072,AUC,"The MTD was docetaxel, 40 mg/m2 days 1 and 8; carboplatin, AUC = 2 days 1 and 8; and capecitabine, 1500 to 2000 mg/m2 days 1 to 10 in a 21-day cycle.","Phase I study of docetaxel, capecitabine, and carboplatin in metastatic esophagogastric cancer. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16062072/),,2,134672,DB00544,Fluorouracil
,7825979,AUC,"In addition, AUC values of 37000 ng.h.ml-1 and 21000 ng.h.ml-1 for the entire cycle and the half-cycle respectively were found to be predictive of toxicity.",Pharmacodynamics of 5-fluorouracil combined with carboplatin in patients with head and neck cancer. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7825979/),[h·ng] / [ml],37000,135135,DB00544,Fluorouracil
,7825979,AUC,"In addition, AUC values of 37000 ng.h.ml-1 and 21000 ng.h.ml-1 for the entire cycle and the half-cycle respectively were found to be predictive of toxicity.",Pharmacodynamics of 5-fluorouracil combined with carboplatin in patients with head and neck cancer. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7825979/),[h·ng] / [ml],21000,135136,DB00544,Fluorouracil
,11106122,terminal half-life,"Mean values for terminal half-life, systemic clearance, and apparent volume of distribution for oral 5-FU during treatments A/B/C were 5.5/5.6/5.6 hours, 6.6/6.6/6.5 liters/hour, and 50.7/51.5/50.0 liters, respectively.","Pharmacokinetics and bioequivalence of a combined oral formulation of eniluracil, an inactivator of dihydropyrimidine dehydrogenase, and 5-fluorouracil in patients with advanced solid malignancies. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11106122/),h,5.5,136377,DB00544,Fluorouracil
,11106122,systemic clearance,"Mean values for terminal half-life, systemic clearance, and apparent volume of distribution for oral 5-FU during treatments A/B/C were 5.5/5.6/5.6 hours, 6.6/6.6/6.5 liters/hour, and 50.7/51.5/50.0 liters, respectively.","Pharmacokinetics and bioequivalence of a combined oral formulation of eniluracil, an inactivator of dihydropyrimidine dehydrogenase, and 5-fluorouracil in patients with advanced solid malignancies. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11106122/),[l] / [h],6.6,136378,DB00544,Fluorouracil
,11106122,apparent volume of distribution,"Mean values for terminal half-life, systemic clearance, and apparent volume of distribution for oral 5-FU during treatments A/B/C were 5.5/5.6/5.6 hours, 6.6/6.6/6.5 liters/hour, and 50.7/51.5/50.0 liters, respectively.","Pharmacokinetics and bioequivalence of a combined oral formulation of eniluracil, an inactivator of dihydropyrimidine dehydrogenase, and 5-fluorouracil in patients with advanced solid malignancies. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11106122/),[l] / [h],6.6,136379,DB00544,Fluorouracil
,11106122,apparent volume of distribution,"Mean values for terminal half-life, systemic clearance, and apparent volume of distribution for oral 5-FU during treatments A/B/C were 5.5/5.6/5.6 hours, 6.6/6.6/6.5 liters/hour, and 50.7/51.5/50.0 liters, respectively.","Pharmacokinetics and bioequivalence of a combined oral formulation of eniluracil, an inactivator of dihydropyrimidine dehydrogenase, and 5-fluorouracil in patients with advanced solid malignancies. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11106122/),l,50.7,136380,DB00544,Fluorouracil
,11106122,urinary excretion,"The urinary excretion of unchanged 5-FU over 24 hours following treatments A, B, and C averaged 52.2%, 56.1%, and 50.8'%, of the administered dose of 5-FU, respectively.","Pharmacokinetics and bioequivalence of a combined oral formulation of eniluracil, an inactivator of dihydropyrimidine dehydrogenase, and 5-fluorouracil in patients with advanced solid malignancies. ",ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11106122/),%,52.2,136381,DB00544,Fluorouracil
,11106122,urinary excretion,"The urinary excretion of unchanged 5-FU over 24 hours following treatments A, B, and C averaged 52.2%, 56.1%, and 50.8'%, of the administered dose of 5-FU, respectively.","Pharmacokinetics and bioequivalence of a combined oral formulation of eniluracil, an inactivator of dihydropyrimidine dehydrogenase, and 5-fluorouracil in patients with advanced solid malignancies. ",ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11106122/),%,56.1,136382,DB00544,Fluorouracil
,11106122,urinary excretion,"The urinary excretion of unchanged 5-FU over 24 hours following treatments A, B, and C averaged 52.2%, 56.1%, and 50.8'%, of the administered dose of 5-FU, respectively.","Pharmacokinetics and bioequivalence of a combined oral formulation of eniluracil, an inactivator of dihydropyrimidine dehydrogenase, and 5-fluorouracil in patients with advanced solid malignancies. ",ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11106122/),'%,50.8,136383,DB00544,Fluorouracil
,9614438,total AUC,"The highest AUC of total and free Pt and the lowest Cmax of free Pt were observed in the daily continuous infusion (total AUC; 162.53 +/- 18.39 micrograms h/ml, free AUC; 5.50 +/- 0.9 micrograms h/ml, free Cmax; 0.07 +/- 0.01 microgram/ml, mean +/- SEM).",Pharmacokinetics of cisplatin in combined cisplatin and 5-fluorouracil therapy: a comparative study of three different schedules of cisplatin administration. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9614438/),[h·μg] / [ml],162.53,136397,DB00544,Fluorouracil
,9614438,AUC,"The highest AUC of total and free Pt and the lowest Cmax of free Pt were observed in the daily continuous infusion (total AUC; 162.53 +/- 18.39 micrograms h/ml, free AUC; 5.50 +/- 0.9 micrograms h/ml, free Cmax; 0.07 +/- 0.01 microgram/ml, mean +/- SEM).",Pharmacokinetics of cisplatin in combined cisplatin and 5-fluorouracil therapy: a comparative study of three different schedules of cisplatin administration. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9614438/),[h·μg] / [ml],5.50,136398,DB00544,Fluorouracil
,9614438,Cmax,"The highest AUC of total and free Pt and the lowest Cmax of free Pt were observed in the daily continuous infusion (total AUC; 162.53 +/- 18.39 micrograms h/ml, free AUC; 5.50 +/- 0.9 micrograms h/ml, free Cmax; 0.07 +/- 0.01 microgram/ml, mean +/- SEM).",Pharmacokinetics of cisplatin in combined cisplatin and 5-fluorouracil therapy: a comparative study of three different schedules of cisplatin administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9614438/),[μg] / [ml],0.07,136399,DB00544,Fluorouracil
,25810324,absorption lag,The only difference in the final pharmacokinetic model around gastrectomy was the presence of an absorption lag of 0.23 hours before surgery.,Postgastrectomy pharmacokinetic changes of S-1 in patients with localized advanced gastric cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25810324/),h,0.23,136480,DB00544,Fluorouracil
,24920908,zeta potential,The lyophilized TFU-LNS had a mean particle size of 180.03±3.11 nm and zeta potential of -8.02±1.43 mV and showed no discernible changes after storage at 4°C for 3 months.,Preclinical studies of N₃-O-toluyl-fluorouracil-loaded lipid-based nanosuspensions in H₂₂-bearing mice. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24920908/),mv,-8.02,136676,DB00544,Fluorouracil
,19940007,Response rates,"Response rates in the cetuximab monotherapy and combination therapy phases were 15% and 42%, respectively.",Cetuximab administered once every second week to patients with metastatic colorectal cancer: a two-part pharmacokinetic/pharmacodynamic phase I dose-escalation study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19940007/),%,15,137032,DB00544,Fluorouracil
,19940007,Response rates,"Response rates in the cetuximab monotherapy and combination therapy phases were 15% and 42%, respectively.",Cetuximab administered once every second week to patients with metastatic colorectal cancer: a two-part pharmacokinetic/pharmacodynamic phase I dose-escalation study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19940007/),%,42,137033,DB00544,Fluorouracil
,23864305,initial clearance half-time,LuTate demonstrated biexponential blood clearance with an initial clearance half-time of 21 min.,Rapid blood clearance and lack of long-term renal toxicity of 177Lu-DOTATATE enables shortening of renoprotective amino acid infusion. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23864305/),min,21,137149,DB00544,Fluorouracil
,21499694,areas under the curves (AUC),"The areas under the curves (AUC) for free platinum were 17.6, 23.6, and 32.6 μg h/mL after doses of 60, 70, and 85 mg/m(2) oxaliplatin, respectively.",Pharmacokinetics of oxaliplatin in a hemodialytic patient treated with modified FOLFOX-6 plus bevacizumab therapy. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21499694/),[h·μg] / [ml],17.6,137182,DB00544,Fluorouracil
,21499694,areas under the curves (AUC),"The areas under the curves (AUC) for free platinum were 17.6, 23.6, and 32.6 μg h/mL after doses of 60, 70, and 85 mg/m(2) oxaliplatin, respectively.",Pharmacokinetics of oxaliplatin in a hemodialytic patient treated with modified FOLFOX-6 plus bevacizumab therapy. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21499694/),[h·μg] / [ml],23.6,137183,DB00544,Fluorouracil
,21499694,areas under the curves (AUC),"The areas under the curves (AUC) for free platinum were 17.6, 23.6, and 32.6 μg h/mL after doses of 60, 70, and 85 mg/m(2) oxaliplatin, respectively.",Pharmacokinetics of oxaliplatin in a hemodialytic patient treated with modified FOLFOX-6 plus bevacizumab therapy. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21499694/),[h·μg] / [ml],32.6,137184,DB00544,Fluorouracil
,6225866,blood clearances,"The respective blood clearances of FU and dFUR were 44 and 18 ml X kg-1 X min-1 after i.v. bolus injections, which were significantly lower than the 108 and 26 ml X kg-1 X min-1 after infusion.",Pharmacokinetic studies of 5-fluorouracil and 5'-deoxy-5-fluorouridine in rats. ,CLb-Q23,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6225866/),[ml] / [kg·min],44,137661,DB00544,Fluorouracil
,6225866,blood clearances,"The respective blood clearances of FU and dFUR were 44 and 18 ml X kg-1 X min-1 after i.v. bolus injections, which were significantly lower than the 108 and 26 ml X kg-1 X min-1 after infusion.",Pharmacokinetic studies of 5-fluorouracil and 5'-deoxy-5-fluorouridine in rats. ,CLb-Q23,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6225866/),[ml] / [kg·min],18,137662,DB00544,Fluorouracil
,6225866,blood clearances,"The respective blood clearances of FU and dFUR were 44 and 18 ml X kg-1 X min-1 after i.v. bolus injections, which were significantly lower than the 108 and 26 ml X kg-1 X min-1 after infusion.",Pharmacokinetic studies of 5-fluorouracil and 5'-deoxy-5-fluorouridine in rats. ,CLb-Q23,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6225866/),[ml] / [kg·min],108,137663,DB00544,Fluorouracil
,6225866,blood clearances,"The respective blood clearances of FU and dFUR were 44 and 18 ml X kg-1 X min-1 after i.v. bolus injections, which were significantly lower than the 108 and 26 ml X kg-1 X min-1 after infusion.",Pharmacokinetic studies of 5-fluorouracil and 5'-deoxy-5-fluorouridine in rats. ,CLb-Q23,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6225866/),[ml] / [kg·min],26,137664,DB00544,Fluorouracil
,18221066,maximum survival time,The increase in the life span (ILS) was 87.05% with maximum survival time of 30.5+/-1.87 days.,Transdermal delivery of 5-fluorouracil for induced ehrlich ascites carcinoma tumor in BALB/c mice and pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18221066/),d,30.5,137814,DB00544,Fluorouracil
,18221066,half-life,"Pharmacokinetic studies of 5-FU transdermal patch in rabbits showed half-life 95+/-0.5 min, C(max) (ng/ml) 863.25,AUC(0-infinity) (ng/ml/h)1567+/-36 and T(max) (h) 1.5 with controlled release for 24 h which was very significant (p<0.001) compared to intravenous route.",Transdermal delivery of 5-fluorouracil for induced ehrlich ascites carcinoma tumor in BALB/c mice and pharmacokinetic study. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18221066/),min,95,137815,DB00544,Fluorouracil
,18221066,C(max),"Pharmacokinetic studies of 5-FU transdermal patch in rabbits showed half-life 95+/-0.5 min, C(max) (ng/ml) 863.25,AUC(0-infinity) (ng/ml/h)1567+/-36 and T(max) (h) 1.5 with controlled release for 24 h which was very significant (p<0.001) compared to intravenous route.",Transdermal delivery of 5-fluorouracil for induced ehrlich ascites carcinoma tumor in BALB/c mice and pharmacokinetic study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18221066/),[ng] / [ml],863.25,137816,DB00544,Fluorouracil
,18221066,AUC(0-infinity),"Pharmacokinetic studies of 5-FU transdermal patch in rabbits showed half-life 95+/-0.5 min, C(max) (ng/ml) 863.25,AUC(0-infinity) (ng/ml/h)1567+/-36 and T(max) (h) 1.5 with controlled release for 24 h which was very significant (p<0.001) compared to intravenous route.",Transdermal delivery of 5-fluorouracil for induced ehrlich ascites carcinoma tumor in BALB/c mice and pharmacokinetic study. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18221066/),[ng] / [h·ml],1567,137817,DB00544,Fluorouracil
,18221066,T(max),"Pharmacokinetic studies of 5-FU transdermal patch in rabbits showed half-life 95+/-0.5 min, C(max) (ng/ml) 863.25,AUC(0-infinity) (ng/ml/h)1567+/-36 and T(max) (h) 1.5 with controlled release for 24 h which was very significant (p<0.001) compared to intravenous route.",Transdermal delivery of 5-fluorouracil for induced ehrlich ascites carcinoma tumor in BALB/c mice and pharmacokinetic study. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18221066/),h,1.5,137818,DB00544,Fluorouracil
,12904894,activity,"In samples of these tissues, collected 6 days after the last eniluracil dose, DPD activity approached baseline in normal mucosa, normal liver and primary tumor (28+/-12, 94+/-23 and 20+/-8 pmol/min per mg protein, respectively).",Dihydropyrimidine dehydrogenase (DPD) rapidly regenerates after inactivation by eniluracil (GW776C85) in primary and metastatic colorectal cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12904894/),[pM] / [mg·min],28,137895,DB00544,Fluorouracil
,12904894,activity,"In samples of these tissues, collected 6 days after the last eniluracil dose, DPD activity approached baseline in normal mucosa, normal liver and primary tumor (28+/-12, 94+/-23 and 20+/-8 pmol/min per mg protein, respectively).",Dihydropyrimidine dehydrogenase (DPD) rapidly regenerates after inactivation by eniluracil (GW776C85) in primary and metastatic colorectal cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12904894/),[pM] / [mg·min],94,137896,DB00544,Fluorouracil
,12904894,activity,"In samples of these tissues, collected 6 days after the last eniluracil dose, DPD activity approached baseline in normal mucosa, normal liver and primary tumor (28+/-12, 94+/-23 and 20+/-8 pmol/min per mg protein, respectively).",Dihydropyrimidine dehydrogenase (DPD) rapidly regenerates after inactivation by eniluracil (GW776C85) in primary and metastatic colorectal cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12904894/),[pM] / [mg·min],20,137897,DB00544,Fluorouracil
,9552054,area under the concentration-time curve at 0 to 8 hours [AUC0-8],"In a previous study with 5-FU stepwise dose escalation in a weekly regimen, and pharmacokinetic monitoring, we defined a therapeutic range for 5-FU plasma levels: 2,000 to 3,000 microg/L (area under the concentration-time curve at 0 to 8 hours [AUC0-8], 16 to 24 mg x h/L).",Long-term weekly treatment of colorectal metastatic cancer with fluorouracil and leucovorin: results of a multicentric prospective trial of fluorouracil dosage optimization by pharmacokinetic monitoring in 152 patients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9552054/),[h·mg] / [l],16 to 24,138082,DB00544,Fluorouracil
,9552054,overall survival time,Median overall survival time was 19 months.,Long-term weekly treatment of colorectal metastatic cancer with fluorouracil and leucovorin: results of a multicentric prospective trial of fluorouracil dosage optimization by pharmacokinetic monitoring in 152 patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9552054/),month,19,138083,DB00544,Fluorouracil
,16395593,C (max),"The C (max) of oxaliplatin was observed at the end of infusion, with mean values of 4.66, 0.84, and 2.69 microg/ml for total plasma, plasma ultrafiltrate, and RBC samples, respectively.",Clinical pharmacokinetics of oxaliplatin and 5-fluorouracil administered in combination with leucovorin in Korean patients with advanced colorectal cancer. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16395593/),[μg] / [ml],4.66,138085,DB00544,Fluorouracil
,16395593,C (max),"The C (max) of oxaliplatin was observed at the end of infusion, with mean values of 4.66, 0.84, and 2.69 microg/ml for total plasma, plasma ultrafiltrate, and RBC samples, respectively.",Clinical pharmacokinetics of oxaliplatin and 5-fluorouracil administered in combination with leucovorin in Korean patients with advanced colorectal cancer. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16395593/),[μg] / [ml],0.84,138086,DB00544,Fluorouracil
,16395593,C (max),"The C (max) of oxaliplatin was observed at the end of infusion, with mean values of 4.66, 0.84, and 2.69 microg/ml for total plasma, plasma ultrafiltrate, and RBC samples, respectively.",Clinical pharmacokinetics of oxaliplatin and 5-fluorouracil administered in combination with leucovorin in Korean patients with advanced colorectal cancer. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16395593/),[μg] / [ml],2.69,138087,DB00544,Fluorouracil
,16395593,C (max),"The C (max) of plasma 5-FU ranged from 23.9 to 533.8 ng/ml, indicating large inter-patient pharmacokinetic variations.",Clinical pharmacokinetics of oxaliplatin and 5-fluorouracil administered in combination with leucovorin in Korean patients with advanced colorectal cancer. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16395593/),[ng] / [ml],23.9 to 533.8,138088,DB00544,Fluorouracil
,3789759,Vmax,The Vmax (nmol/mg protein/min) of DHU (dihydrouracil dehydrogenase) in the liver homogenate from normal mice was 1.18 and found to be 0.70 in CCl4-treated mice.,"[Dose, administration time and route and hepatic function-dependent metabolism of 5-FU in mice]. ",Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3789759/),[nM] / [·mg·min],1.18,138131,DB00544,Fluorouracil
,3789759,Vmax,The Vmax (nmol/mg protein/min) of DHU (dihydrouracil dehydrogenase) in the liver homogenate from normal mice was 1.18 and found to be 0.70 in CCl4-treated mice.,"[Dose, administration time and route and hepatic function-dependent metabolism of 5-FU in mice]. ",Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3789759/),[nM] / [·mg·min],0.70,138132,DB00544,Fluorouracil
,15729602,MTD,The MTD of continuous oral capecitabine over 6 weeks was 1255 mg/m2 twice daily.,A Japanese phase I study of continuous oral capecitabine in patients with malignant solid tumors. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15729602/),[mg] / [m2],1255,138416,DB00544,Fluorouracil
,21958858,AUC((0→∞)),"In pharmacokinetics, the AUC((0→∞)), MRT((0→∞)) and Cl of (188)Re-liposome in blood via intravenous route were 998 h %ID/ml, 28.7 h and 0.1 ml/h, respectively.","Pharmacokinetics, dosimetry and comparative efficacy of 188Re-liposome and 5-FU in a CT26-luc lung-metastatic mice model. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21958858/),[%id·h] / [ml],998,138500,DB00544,Fluorouracil
,21958858,MRT((0→∞)),"In pharmacokinetics, the AUC((0→∞)), MRT((0→∞)) and Cl of (188)Re-liposome in blood via intravenous route were 998 h %ID/ml, 28.7 h and 0.1 ml/h, respectively.","Pharmacokinetics, dosimetry and comparative efficacy of 188Re-liposome and 5-FU in a CT26-luc lung-metastatic mice model. ",MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21958858/),h,28.7,138501,DB00544,Fluorouracil
,21958858,Cl,"In pharmacokinetics, the AUC((0→∞)), MRT((0→∞)) and Cl of (188)Re-liposome in blood via intravenous route were 998 h %ID/ml, 28.7 h and 0.1 ml/h, respectively.","Pharmacokinetics, dosimetry and comparative efficacy of 188Re-liposome and 5-FU in a CT26-luc lung-metastatic mice model. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21958858/),[ml] / [h],0.1,138502,DB00544,Fluorouracil
,21958858,total excreted fractions,"The total excreted fractions of feces and urine were 0.61 and 0.26, respectively.","Pharmacokinetics, dosimetry and comparative efficacy of 188Re-liposome and 5-FU in a CT26-luc lung-metastatic mice model. ",fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21958858/),,0.61,138503,DB00544,Fluorouracil
,21958858,total excreted fractions,"The total excreted fractions of feces and urine were 0.61 and 0.26, respectively.","Pharmacokinetics, dosimetry and comparative efficacy of 188Re-liposome and 5-FU in a CT26-luc lung-metastatic mice model. ",fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21958858/),,0.26,138504,DB00544,Fluorouracil
,21958858,Absorbed doses,"Absorbed doses for (188)Re-liposome in the liver and red marrow were 0.31 and 0.08 mSv/MBq, respectively.","Pharmacokinetics, dosimetry and comparative efficacy of 188Re-liposome and 5-FU in a CT26-luc lung-metastatic mice model. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21958858/),[msv] / [Mbq],0.31,138505,DB00544,Fluorouracil
,21958858,Absorbed doses,"Absorbed doses for (188)Re-liposome in the liver and red marrow were 0.31 and 0.08 mSv/MBq, respectively.","Pharmacokinetics, dosimetry and comparative efficacy of 188Re-liposome and 5-FU in a CT26-luc lung-metastatic mice model. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21958858/),[msv] / [Mbq],0.08,138506,DB00544,Fluorouracil
,21958858,Tumor-absorbed doses,Tumor-absorbed doses for (188)Re-liposome ranged from 48.4 to 1.73 mGy/MBq at 10 to 300 g tumor spheres.,"Pharmacokinetics, dosimetry and comparative efficacy of 188Re-liposome and 5-FU in a CT26-luc lung-metastatic mice model. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21958858/),[mgy] / [Mbq],48.4 to 1.73,138507,DB00544,Fluorouracil
,3918800,total-body clearance,"Over the range of 3-480 mg/m2/h, total-body clearance of 5-FU decreases from 600 ml/min/m2 to less than 90 ml/min/m2.",Pharmacokinetics of 5-fluorouracil infusions in the rat: comparison with man and other species. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3918800/),[ml] / [m2·min],600,138999,DB00544,Fluorouracil
less,3918800,total-body clearance,"Over the range of 3-480 mg/m2/h, total-body clearance of 5-FU decreases from 600 ml/min/m2 to less than 90 ml/min/m2.",Pharmacokinetics of 5-fluorouracil infusions in the rat: comparison with man and other species. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3918800/),[ml] / [m2·min],90,139000,DB00544,Fluorouracil
,10894878,plasma peak concentrations,"Plasma pharmacokinetics of 5-FU were linear; at the highest S-1 dose level, 5-FU plasma peak concentrations reached 1 to 2 micromol/L, and the half-life of 5-FU was 3 to 4 hours.",Phase I clinical and pharmacokinetic study of oral S-1 in patients with advanced solid tumors. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10894878/),[μM] / [l],1 to 2,139168,DB00544,Fluorouracil
,10894878,half-life,"Plasma pharmacokinetics of 5-FU were linear; at the highest S-1 dose level, 5-FU plasma peak concentrations reached 1 to 2 micromol/L, and the half-life of 5-FU was 3 to 4 hours.",Phase I clinical and pharmacokinetic study of oral S-1 in patients with advanced solid tumors. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10894878/),h,3 to 4,139169,DB00544,Fluorouracil
,8622018,peak AZT plasma concentration,The peak AZT plasma concentration increased from 21.9 to 995.6 micromol/L.,Intravenous azidothymidine with fluorouracil and leucovorin: a phase I-II study in previously untreated metastatic colorectal cancer patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8622018/),[μM] / [l],21.9,139452,DB00544,Fluorouracil
,8622018,peak AZT plasma concentration,The peak AZT plasma concentration increased from 21.9 to 995.6 micromol/L.,Intravenous azidothymidine with fluorouracil and leucovorin: a phase I-II study in previously untreated metastatic colorectal cancer patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8622018/),[μM] / [l],995.6,139453,DB00544,Fluorouracil
,8622018,area under the concentration/time curve (AUC),"The area under the concentration/time curve (AUC) also showed a progressive, but not linear increase from 40.34 to 3,108 h x micromol/L.",Intravenous azidothymidine with fluorouracil and leucovorin: a phase I-II study in previously untreated metastatic colorectal cancer patients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8622018/),[h·μM] / [l],40.34,139454,DB00544,Fluorouracil
,8622018,area under the concentration/time curve (AUC),"The area under the concentration/time curve (AUC) also showed a progressive, but not linear increase from 40.34 to 3,108 h x micromol/L.",Intravenous azidothymidine with fluorouracil and leucovorin: a phase I-II study in previously untreated metastatic colorectal cancer patients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8622018/),[h·μM] / [l],"3,108",139455,DB00544,Fluorouracil
,23155289,area under the time concentration curve (AUC)(0-8),"The mean area under the time concentration curve (AUC)(0-8), half-life (t(1/2)), and maximum drug concentration (C(max)) obtained by the two methods were as follows: GC-MS, 847.9 μg/ml/hr, 2.76 h, and 186.6 ng/ml; and immunoassay, 1311.2 μg/ml/hr, 3.5 h, and 259.8 ng/ml.",An immunoassay method for the pharmacokinetics of 5-fluorouracil in patients with gastric cancer administered adjuvant chemotherapy. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23155289/),[μg] / [h·ml],847.9,139540,DB00544,Fluorouracil
,23155289,half-life (t(1/2)),"The mean area under the time concentration curve (AUC)(0-8), half-life (t(1/2)), and maximum drug concentration (C(max)) obtained by the two methods were as follows: GC-MS, 847.9 μg/ml/hr, 2.76 h, and 186.6 ng/ml; and immunoassay, 1311.2 μg/ml/hr, 3.5 h, and 259.8 ng/ml.",An immunoassay method for the pharmacokinetics of 5-fluorouracil in patients with gastric cancer administered adjuvant chemotherapy. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23155289/),h,2.76,139541,DB00544,Fluorouracil
,23155289,maximum drug concentration (C(max)),"The mean area under the time concentration curve (AUC)(0-8), half-life (t(1/2)), and maximum drug concentration (C(max)) obtained by the two methods were as follows: GC-MS, 847.9 μg/ml/hr, 2.76 h, and 186.6 ng/ml; and immunoassay, 1311.2 μg/ml/hr, 3.5 h, and 259.8 ng/ml.",An immunoassay method for the pharmacokinetics of 5-fluorouracil in patients with gastric cancer administered adjuvant chemotherapy. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23155289/),[ng] / [ml],186.6,139542,DB00544,Fluorouracil
,23155289,maximum drug concentration (C(max)),"The mean area under the time concentration curve (AUC)(0-8), half-life (t(1/2)), and maximum drug concentration (C(max)) obtained by the two methods were as follows: GC-MS, 847.9 μg/ml/hr, 2.76 h, and 186.6 ng/ml; and immunoassay, 1311.2 μg/ml/hr, 3.5 h, and 259.8 ng/ml.",An immunoassay method for the pharmacokinetics of 5-fluorouracil in patients with gastric cancer administered adjuvant chemotherapy. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23155289/),[μg] / [h·ml],1311.2,139543,DB00544,Fluorouracil
,23155289,maximum drug concentration (C(max)),"The mean area under the time concentration curve (AUC)(0-8), half-life (t(1/2)), and maximum drug concentration (C(max)) obtained by the two methods were as follows: GC-MS, 847.9 μg/ml/hr, 2.76 h, and 186.6 ng/ml; and immunoassay, 1311.2 μg/ml/hr, 3.5 h, and 259.8 ng/ml.",An immunoassay method for the pharmacokinetics of 5-fluorouracil in patients with gastric cancer administered adjuvant chemotherapy. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23155289/),h,3.5,139544,DB00544,Fluorouracil
,23155289,maximum drug concentration (C(max)),"The mean area under the time concentration curve (AUC)(0-8), half-life (t(1/2)), and maximum drug concentration (C(max)) obtained by the two methods were as follows: GC-MS, 847.9 μg/ml/hr, 2.76 h, and 186.6 ng/ml; and immunoassay, 1311.2 μg/ml/hr, 3.5 h, and 259.8 ng/ml.",An immunoassay method for the pharmacokinetics of 5-fluorouracil in patients with gastric cancer administered adjuvant chemotherapy. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23155289/),[ng] / [ml],259.8,139545,DB00544,Fluorouracil
,3200235,T/C,"By using these AUC-T/C correlations, the concentration of 5-FU in the clonogenic assay to predict the T/C of the maximum tolerated dose in mouse was calculated to be 3 micrograms/ml mathematically.",[Pharmacodynamic study of the in vitro clonogenic assay--with reference to dose levels]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3200235/),[μg] / [ml],3,140481,DB00544,Fluorouracil
,3335642,elimination half-life,"After administration of a ""test"" dose of FUra (25 mg/m2, 600 microCi[6-3H]FUra by intravenous bolus) to a patient who had previously developed neurotoxicity after FUra, a markedly prolonged elimination half-life (159 min) was observed with no evidence of FUra catabolites in plasma or cerebrospinal fluid and with 89.7% of the administered dose being excreted into the urine as unchanged FUra.",Familial deficiency of dihydropyrimidine dehydrogenase. Biochemical basis for familial pyrimidinemia and severe 5-fluorouracil-induced toxicity. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3335642/),min,159,141005,DB00544,Fluorouracil
,21409383,t (½),The V (ss) and CL did not differ between the two regimens; t (½) during the PK cycle was also similar for both arms at approximately 16 days.,"A multicenter, randomized, open-label study to assess the steady-state pharmacokinetics of bevacizumab given with either XELOX or FOLFOX-4 in patients with metastatic colorectal cancer. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21409383/),d,16,141601,DB00544,Fluorouracil
,20037436,survival time (MST),"The median survival time (MST) of A-group was 78.9 months, and of B-group was 74.3 months.",[Effects of pharmacokinetic modulation chemotherapy (PMC) using oral UFT and venous 5-FU infusion as adjuvant chemotherapy for intrahepatic cholangiocellular carcinoma]. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20037436/),month,78.9,141949,DB00544,Fluorouracil
,20037436,survival time (MST),"The median survival time (MST) of A-group was 78.9 months, and of B-group was 74.3 months.",[Effects of pharmacokinetic modulation chemotherapy (PMC) using oral UFT and venous 5-FU infusion as adjuvant chemotherapy for intrahepatic cholangiocellular carcinoma]. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20037436/),month,74.3,141950,DB00544,Fluorouracil
,20037436,cumulative survival rates,"Five-year cumulative survival rates of A-and B-group were 59.4%, 59%,and disease free survival rates were 37.5%, 25%,respectively.",[Effects of pharmacokinetic modulation chemotherapy (PMC) using oral UFT and venous 5-FU infusion as adjuvant chemotherapy for intrahepatic cholangiocellular carcinoma]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20037436/),%,59.4,141951,DB00544,Fluorouracil
,20037436,cumulative survival rates,"Five-year cumulative survival rates of A-and B-group were 59.4%, 59%,and disease free survival rates were 37.5%, 25%,respectively.",[Effects of pharmacokinetic modulation chemotherapy (PMC) using oral UFT and venous 5-FU infusion as adjuvant chemotherapy for intrahepatic cholangiocellular carcinoma]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20037436/),%,59,141952,DB00544,Fluorouracil
,29527010,objective response rate,"Fifteen patients had a partial response (objective response rate, 17.6%).",A phase 1 dose-escalation study of veliparib with bimonthly FOLFIRI in patients with advanced solid tumours. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29527010/),%,17.6,143147,DB00544,Fluorouracil
,27325685,PFS,"Median PFS and OS were 3.3 and 6.3 months, respectively.",A Phase II Biomarker-Embedded Study of Lapatinib plus Capecitabine as First-line Therapy in Patients with Advanced or Metastatic Gastric Cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27325685/),month,3.3,143563,DB00544,Fluorouracil
,27325685,PFS,"Median PFS and OS were 3.3 and 6.3 months, respectively.",A Phase II Biomarker-Embedded Study of Lapatinib plus Capecitabine as First-line Therapy in Patients with Advanced or Metastatic Gastric Cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27325685/),month,6.3,143564,DB00544,Fluorouracil
,27325685,OS,"Median PFS and OS were 3.3 and 6.3 months, respectively.",A Phase II Biomarker-Embedded Study of Lapatinib plus Capecitabine as First-line Therapy in Patients with Advanced or Metastatic Gastric Cancer. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27325685/),month,6.3,143565,DB00544,Fluorouracil
,6704976,steady-state arterial level,BrdUrd steady-state arterial levels are described for three different infusional rates: 1.6 mumol/sq m/min (350 mg/sq m/12 hr) produced a steady-state arterial level of 0.7 microM; 3.2 mumol/sq m/min (700 mg/sq m/12 hr) resulted in 2.1 microM; 5.9 mumol/sq m/min (650 mg/sq m/6 hr) showed a level of 3.9 microM.,Pharmacological evaluation of intravenous delivery of 5-bromodeoxyuridine to patients with brain tumors. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6704976/),μM,0.7,143857,DB00544,Fluorouracil
,6704976,steady-state arterial level,BrdUrd steady-state arterial levels are described for three different infusional rates: 1.6 mumol/sq m/min (350 mg/sq m/12 hr) produced a steady-state arterial level of 0.7 microM; 3.2 mumol/sq m/min (700 mg/sq m/12 hr) resulted in 2.1 microM; 5.9 mumol/sq m/min (650 mg/sq m/6 hr) showed a level of 3.9 microM.,Pharmacological evaluation of intravenous delivery of 5-bromodeoxyuridine to patients with brain tumors. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6704976/),[μM] / [m·min·sq],3.2,143858,DB00544,Fluorouracil
,6704976,steady-state arterial level,BrdUrd steady-state arterial levels are described for three different infusional rates: 1.6 mumol/sq m/min (350 mg/sq m/12 hr) produced a steady-state arterial level of 0.7 microM; 3.2 mumol/sq m/min (700 mg/sq m/12 hr) resulted in 2.1 microM; 5.9 mumol/sq m/min (650 mg/sq m/6 hr) showed a level of 3.9 microM.,Pharmacological evaluation of intravenous delivery of 5-bromodeoxyuridine to patients with brain tumors. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6704976/),μM,2.1,143859,DB00544,Fluorouracil
,6704976,steady-state arterial level,BrdUrd steady-state arterial levels are described for three different infusional rates: 1.6 mumol/sq m/min (350 mg/sq m/12 hr) produced a steady-state arterial level of 0.7 microM; 3.2 mumol/sq m/min (700 mg/sq m/12 hr) resulted in 2.1 microM; 5.9 mumol/sq m/min (650 mg/sq m/6 hr) showed a level of 3.9 microM.,Pharmacological evaluation of intravenous delivery of 5-bromodeoxyuridine to patients with brain tumors. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6704976/),[μM] / [m·min·sq],5.9,143860,DB00544,Fluorouracil
,21931273,AUC,"Six-of-eleven patients with normalized tumor TS mRNA levels < 4.0 had a 5-FU AUC of 20 mg.h/L or greater, and 80% of patients (4 of 5) with TS levels > 4.0 had a plasma 5-FU AUC of less than or equal to 20 mg.h/L.",Preliminary observations indicate variable patterns of plasma 5-fluorouracil (5-FU) levels during dose optimization of infusional 5-FU in colorectal cancer patients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21931273/),[h·mg] / [l],20,144656,DB00544,Fluorouracil
less,21931273,AUC,"Six-of-eleven patients with normalized tumor TS mRNA levels < 4.0 had a 5-FU AUC of 20 mg.h/L or greater, and 80% of patients (4 of 5) with TS levels > 4.0 had a plasma 5-FU AUC of less than or equal to 20 mg.h/L.",Preliminary observations indicate variable patterns of plasma 5-fluorouracil (5-FU) levels during dose optimization of infusional 5-FU in colorectal cancer patients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21931273/),[h·mg] / [l],20,144657,DB00544,Fluorouracil
,2525077,t.1/2 alpha,"Plasma TMTX elimination was biexponential, with a mean t.1/2 alpha of 0.23 h and a t.1/2 beta of 16.7 h.",Phase I clinical and pharmacologic trial of trimetrexate in combination with 5-fluorouracil. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2525077/),h,0.23,145968,DB00544,Fluorouracil
,2525077,t.1/2 beta,"Plasma TMTX elimination was biexponential, with a mean t.1/2 alpha of 0.23 h and a t.1/2 beta of 16.7 h.",Phase I clinical and pharmacologic trial of trimetrexate in combination with 5-fluorouracil. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2525077/),h,16.7,145969,DB00544,Fluorouracil
,2525077,Total plasma TMTX clearance,Total plasma TMTX clearance (mean +/- SD) was 14.3 +/- 5.9 ml/min per m2.,Phase I clinical and pharmacologic trial of trimetrexate in combination with 5-fluorouracil. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2525077/),[ml] / [m2·min],14.3,145970,DB00544,Fluorouracil
,2967734,perfusion,"At a perfusion rate of 20 ml/min, the apparent Vmax and Km for FdUrd disappearance were 14-19 nmol/ml/min and 161-194 microM, respectively.",5-Fluoro-2'-deoxyuridine elimination by the isolated perfused rat liver. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2967734/),[nM] / [min·ml],14-19,146802,DB00544,Fluorouracil
,2967734,apparent Vmax,"At a perfusion rate of 20 ml/min, the apparent Vmax and Km for FdUrd disappearance were 14-19 nmol/ml/min and 161-194 microM, respectively.",5-Fluoro-2'-deoxyuridine elimination by the isolated perfused rat liver. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2967734/),[nM] / [min·ml],14-19,146803,DB00544,Fluorouracil
,2967734,Km,"At a perfusion rate of 20 ml/min, the apparent Vmax and Km for FdUrd disappearance were 14-19 nmol/ml/min and 161-194 microM, respectively.",5-Fluoro-2'-deoxyuridine elimination by the isolated perfused rat liver. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2967734/),μM,161-194,146804,DB00544,Fluorouracil
,2967734,clearance during first-order elimination,FdUrd clearance during first-order elimination was 8-11 ml/min.,5-Fluoro-2'-deoxyuridine elimination by the isolated perfused rat liver. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2967734/),[ml] / [min],8-11,146805,DB00544,Fluorouracil
,2967734,half-life,"After FdUrd administration, 5-fluorouracil concentration reached 10-15% of the initial FdUrd concentration, then decreased with a half-life of 4-7 min.",5-Fluoro-2'-deoxyuridine elimination by the isolated perfused rat liver. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2967734/),min,4-7,146806,DB00544,Fluorouracil
,2967734,first-order clearance,"At a dose of 20 mg, first-order clearance of FdUrd increased from 7 to 12 ml/min as hepatic flow increased from 10 to 30 ml/min.",5-Fluoro-2'-deoxyuridine elimination by the isolated perfused rat liver. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2967734/),[ml] / [min],7 to 12,146807,DB00544,Fluorouracil
,2967734,hepatic flow,"At a dose of 20 mg, first-order clearance of FdUrd increased from 7 to 12 ml/min as hepatic flow increased from 10 to 30 ml/min.",5-Fluoro-2'-deoxyuridine elimination by the isolated perfused rat liver. ,QH-Q55,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2967734/),[ml] / [min],10 to 30,146808,DB00544,Fluorouracil
,7577097,plasma protein binding,Docetaxel exhibited linear pharmacokinetics and long tumour retention in tumour-bearing mice; plasma protein binding ranged from 76 to 89%.,Preclinical pharmacology of docetaxel. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7577097/),%,76 to 89,147082,DB00544,Fluorouracil
,15866500,Retention times,"Retention times were 7.5 and 12.5 min for 2'-deoxyuridine and 5-iodo-2'-deoxyuridine, an iodinated analogue internal standard (IS), respectively.",Rapid quantitation of plasma 2'-deoxyuridine by high-performance liquid chromatography/atmospheric pressure chemical ionization mass spectrometry and its application to pharmacodynamic studies in cancer patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15866500/),min,7.5,147463,DB00544,Fluorouracil
,15866500,Retention times,"Retention times were 7.5 and 12.5 min for 2'-deoxyuridine and 5-iodo-2'-deoxyuridine, an iodinated analogue internal standard (IS), respectively.",Rapid quantitation of plasma 2'-deoxyuridine by high-performance liquid chromatography/atmospheric pressure chemical ionization mass spectrometry and its application to pharmacodynamic studies in cancer patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15866500/),min,12.5,147464,DB00544,Fluorouracil
,15866500,recovery,"The average recovery was 81.5% and 78.6% for 2'-deoxyuridine and 5-iodo-deoxyuridine, respectively.",Rapid quantitation of plasma 2'-deoxyuridine by high-performance liquid chromatography/atmospheric pressure chemical ionization mass spectrometry and its application to pharmacodynamic studies in cancer patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15866500/),%,81.5,147465,DB00544,Fluorouracil
,15866500,recovery,"The average recovery was 81.5% and 78.6% for 2'-deoxyuridine and 5-iodo-deoxyuridine, respectively.",Rapid quantitation of plasma 2'-deoxyuridine by high-performance liquid chromatography/atmospheric pressure chemical ionization mass spectrometry and its application to pharmacodynamic studies in cancer patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15866500/),%,78.6,147466,DB00544,Fluorouracil
,16044967,area under the blood concentration time curve (AUC),"The area under the blood concentration time curve (AUC) of nedaplatin was 15.85 microg/ml, which was slightly low compared with that after infusion of 80 mg/m2 in patients with normal renal function.",[Chemotherapy for an esophageal cancer patient undergoing continuous ambulatory peritoneal dialysis for chronic renal failure and measurement of plasma concentration of the drug]. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16044967/),[μg] / [ml],15.85,148280,DB00544,Fluorouracil
,16141295,MTD,"The MTD of CPT-11 was considered to be 100 mg/m(2), because 50% of the patients (3/6) developed DLTs, diarrhea and rash.",Phase I study of S-1 combined with irinotecan (CPT-11) in patients with advanced gastric cancer (OGSG 0002). ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16141295/),,100,148323,DB00544,Fluorouracil
,16187114,MTD,The MTD of 5-FU was 100 mg/kg/week whereas the MTD of 5-FU + PN401 was 200 mg/kg/week.,5-Fluorouracil dose escalation enabled with PN401 (triacetyluridine): toxicity reduction and increased antitumor activity in mice. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16187114/),[mg] / [kg·week],200,148340,DB00544,Fluorouracil
,23575907,AUC0-60 min,"IHP exposures (AUC0-60 min) were 10.9 ± 4.5 μgPt h/mL, 49.3 ± 30.7 μg h/mL 5-FU (DL1), and 70.5 ± 35.5 μg h/mL 5-FU (DL2).",A phase I trial of isolated hepatic perfusion (IHP) using 5-FU and oxaliplatin in patients with unresectable isolated liver metastases from colorectal cancer. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23575907/),[h·μgpt] / [ml],10.9,148386,DB00544,Fluorouracil
,23575907,AUC0-60 min,"IHP exposures (AUC0-60 min) were 10.9 ± 4.5 μgPt h/mL, 49.3 ± 30.7 μg h/mL 5-FU (DL1), and 70.5 ± 35.5 μg h/mL 5-FU (DL2).",A phase I trial of isolated hepatic perfusion (IHP) using 5-FU and oxaliplatin in patients with unresectable isolated liver metastases from colorectal cancer. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23575907/),[h·μg] / [ml],49.3,148387,DB00544,Fluorouracil
,23575907,AUC0-60 min,"IHP exposures (AUC0-60 min) were 10.9 ± 4.5 μgPt h/mL, 49.3 ± 30.7 μg h/mL 5-FU (DL1), and 70.5 ± 35.5 μg h/mL 5-FU (DL2).",A phase I trial of isolated hepatic perfusion (IHP) using 5-FU and oxaliplatin in patients with unresectable isolated liver metastases from colorectal cancer. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23575907/),[h·μg] / [ml],70.5,148388,DB00544,Fluorouracil
,23575907,AUC0-inf,Systemic exposure (AUC0-inf) relative to IHP exposure was negligible for both platinum (1.1 ± 1.5 %) and 5-FU (0.09 ± 0.10 %).,A phase I trial of isolated hepatic perfusion (IHP) using 5-FU and oxaliplatin in patients with unresectable isolated liver metastases from colorectal cancer. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23575907/),%,1.1,148389,DB00544,Fluorouracil
,23575907,AUC0-inf,Systemic exposure (AUC0-inf) relative to IHP exposure was negligible for both platinum (1.1 ± 1.5 %) and 5-FU (0.09 ± 0.10 %).,A phase I trial of isolated hepatic perfusion (IHP) using 5-FU and oxaliplatin in patients with unresectable isolated liver metastases from colorectal cancer. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23575907/),%,0.09,148390,DB00544,Fluorouracil
,23575907,MTD,The MTD for IHP was 200 mg/m(2) 5-FU with 40 mg/m(2) oxaliplatin.,A phase I trial of isolated hepatic perfusion (IHP) using 5-FU and oxaliplatin in patients with unresectable isolated liver metastases from colorectal cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23575907/),,200,148391,DB00544,Fluorouracil
,1519925,effective concentration,"The 5-FU remained at an effective concentration of 0.05 microgram/ml, 4 hours after a single dose of 100 mg HCFU.",[Serum concentration of HCFU and 5-FU after oral administration of HCFU in postoperative digestive cancer patients]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1519925/),[μg] / [ml],0.05,148792,DB00544,Fluorouracil
,25389968,loading efficiency,"The PEG-based prodrug obtained in this study possessed an exceedingly high 5-FA loading efficiency of 10.58%, much higher than the maximum drug loading efficiency of unmodified PEG with the same molecular weight, which was 0.98% theoretically.",A polymeric prodrug of 5-fluorouracil-1-acetic acid using a multi-hydroxyl polyethylene glycol derivative as the drug carrier. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25389968/),%,10.58,148954,DB00544,Fluorouracil
,25389968,maximum drug loading efficiency,"The PEG-based prodrug obtained in this study possessed an exceedingly high 5-FA loading efficiency of 10.58%, much higher than the maximum drug loading efficiency of unmodified PEG with the same molecular weight, which was 0.98% theoretically.",A polymeric prodrug of 5-fluorouracil-1-acetic acid using a multi-hydroxyl polyethylene glycol derivative as the drug carrier. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25389968/),%,0.98,148955,DB00544,Fluorouracil
,10632324,duration of response,Median duration of response in colorectal cancer patients was 12 months.,Phase I and pharmacokinetic study of tomudex combined with 5-fluorouracil plus levofolinic acid in advanced head and neck cancer and colorectal cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10632324/),month,12,149163,DB00544,Fluorouracil
,8053919,steady-state plasma 5-FU concentration,5-FU at 40 mg/kg/24 hr resulted in a steady-state plasma 5-FU concentration of 1.3 microM and was fatal with dogs dying from apparent neurotoxicity.,5-Ethynyluracil (776C85): protection from 5-fluorouracil-induced neurotoxicity in dogs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8053919/),μM,1.3,149785,DB00544,Fluorouracil
,8053919,total clearance,5-Ethynyluracil lowered the total clearance of 5-FU from 9.9 to 0.2 L/hr/kg and enabled 1.6 mg/kg/24 hr 5-FU to achieve a steady-state plasma 5-FU concentration of 2.4 microM with no apparent toxicity.,5-Ethynyluracil (776C85): protection from 5-fluorouracil-induced neurotoxicity in dogs. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8053919/),[l] / [h·kg],9.9 to 0.2,149786,DB00544,Fluorouracil
,8053919,steady-state plasma 5-FU concentration,5-Ethynyluracil lowered the total clearance of 5-FU from 9.9 to 0.2 L/hr/kg and enabled 1.6 mg/kg/24 hr 5-FU to achieve a steady-state plasma 5-FU concentration of 2.4 microM with no apparent toxicity.,5-Ethynyluracil (776C85): protection from 5-fluorouracil-induced neurotoxicity in dogs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8053919/),μM,2.4,149787,DB00544,Fluorouracil
,8053919,steady-state plasma 5-FU concentration,5-FU at 4 mg/kg/24 hr achieved a steady-state plasma 5-FU concentration of 5.3 microM and produced only mild gastrointestinal disturbances in 5-ethynyluracil-treated dogs.,5-Ethynyluracil (776C85): protection from 5-fluorouracil-induced neurotoxicity in dogs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8053919/),μM,5.3,149788,DB00544,Fluorouracil
,12546525,objective response rates,"The objective response rates were 23%, 39% and 28%, respectively (p = 0.02).",Dose-effect relationship of bolus 5-fluorouracil in the treatment of advanced colorectal cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12546525/),%,23,151150,DB00544,Fluorouracil
,12546525,objective response rates,"The objective response rates were 23%, 39% and 28%, respectively (p = 0.02).",Dose-effect relationship of bolus 5-fluorouracil in the treatment of advanced colorectal cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12546525/),%,39,151151,DB00544,Fluorouracil
,12546525,objective response rates,"The objective response rates were 23%, 39% and 28%, respectively (p = 0.02).",Dose-effect relationship of bolus 5-fluorouracil in the treatment of advanced colorectal cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12546525/),%,28,151152,DB00544,Fluorouracil
,3260621,peak plasma concentration,"Following the two-hour infusion of dl-CF, mean peak plasma concentration and elimination half-life of I-5-formyltetrahydrofolic acid (I-CF) were 24 +/- 6 mumol/L and 0.8 +/- 0.1 hour, respectively.",Plasma and tumor tissue pharmacology of high-dose intravenous leucovorin calcium in combination with fluorouracil in patients with advanced colorectal carcinoma. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3260621/),[μM] / [l],24,151438,DB00544,Fluorouracil
,3260621,elimination half-life,"Following the two-hour infusion of dl-CF, mean peak plasma concentration and elimination half-life of I-5-formyltetrahydrofolic acid (I-CF) were 24 +/- 6 mumol/L and 0.8 +/- 0.1 hour, respectively.",Plasma and tumor tissue pharmacology of high-dose intravenous leucovorin calcium in combination with fluorouracil in patients with advanced colorectal carcinoma. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3260621/),h,0.8,151439,DB00544,Fluorouracil
,3260621,steady-state plasma level,CI of dl-CF over five days yielded a mean steady-state plasma level of I-CF of only 1.2 +/- 0.5 mumol/L.,Plasma and tumor tissue pharmacology of high-dose intravenous leucovorin calcium in combination with fluorouracil in patients with advanced colorectal carcinoma. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3260621/),[μM] / [l],1.2,151440,DB00544,Fluorouracil
,3260621,Peak,Peak and steady-state plasma concentrations of the metabolite 5-methyl tetrahydrofolic acid were comparable in the two schedules (17 +/- 8 mumol/L for the two-hour infusion and 12 +/- 5 mumol/L for the CI).,Plasma and tumor tissue pharmacology of high-dose intravenous leucovorin calcium in combination with fluorouracil in patients with advanced colorectal carcinoma. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3260621/),[μM] / [l],17,151441,DB00544,Fluorouracil
,3260621,steady-state plasma concentrations,Peak and steady-state plasma concentrations of the metabolite 5-methyl tetrahydrofolic acid were comparable in the two schedules (17 +/- 8 mumol/L for the two-hour infusion and 12 +/- 5 mumol/L for the CI).,Plasma and tumor tissue pharmacology of high-dose intravenous leucovorin calcium in combination with fluorouracil in patients with advanced colorectal carcinoma. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3260621/),[μM] / [l],12,151442,DB00544,Fluorouracil
,3260621,Areas under the concentration v time curve (AUC),Areas under the concentration v time curve (AUC) of total reduced folates were significantly greater under conditions of CI: 89.0 v 16.7 mmol/L/min for the two-hour infusion.,Plasma and tumor tissue pharmacology of high-dose intravenous leucovorin calcium in combination with fluorouracil in patients with advanced colorectal carcinoma. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3260621/),,89,151443,DB00544,Fluorouracil
,3260621,Areas under the concentration v time curve (AUC),Areas under the concentration v time curve (AUC) of total reduced folates were significantly greater under conditions of CI: 89.0 v 16.7 mmol/L/min for the two-hour infusion.,Plasma and tumor tissue pharmacology of high-dose intravenous leucovorin calcium in combination with fluorouracil in patients with advanced colorectal carcinoma. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3260621/),,16.7,151444,DB00544,Fluorouracil
,10778943,terminal elimination phase (t1/2,"The pharmacokinetics (PKs) of unbound platinum in plasma ultrafiltrate after oxaliplatin administration was triphasic, characterized by a short initial distribution phase and a long terminal elimination phase (t1/2, 252-273 h).",Clinical pharmacokinetics of oxaliplatin: a critical review. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10778943/),h,252-273,151863,DB00544,Fluorouracil
,10778943,Urinary excretion,"Urinary excretion (53.8 +/- 9.1%) was the predominant route of platinum elimination, with fecal excretion accounting for only 2.1 +/- 1.9% of the administered dose 5 days postadministration.",Clinical pharmacokinetics of oxaliplatin: a critical review. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10778943/),%,53.8,151864,DB00544,Fluorouracil
,1304835,activity,"The average DPD activity measured in lymphocytes was 0.186 +/- 0.068 nmol/min/mg protein (range 0.058-0.357) and the average 5-FU clearance (Cl) was 2,523 +/- 684 ml/min/m2 (range 1,052-4,029).",[Dihydropyrimidine dehydrogenase activity in lymphocytes: predictive factor for 5-fluorouracil clearance]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1304835/),[nM] / [mg·min],0.186,152502,DB00544,Fluorouracil
,1304835,clearance (Cl),"The average DPD activity measured in lymphocytes was 0.186 +/- 0.068 nmol/min/mg protein (range 0.058-0.357) and the average 5-FU clearance (Cl) was 2,523 +/- 684 ml/min/m2 (range 1,052-4,029).",[Dihydropyrimidine dehydrogenase activity in lymphocytes: predictive factor for 5-fluorouracil clearance]. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1304835/),[ml] / [m2·min],"2,523",152503,DB00544,Fluorouracil
>,28278081,progression free survival,"Of the *1/*1 -*1/*1 genotype combination, the median progression free survival of the CSN-38 1.5 h > 50.24 ng/ml subset was remarkably longer than that of the CSN-38 1.5 h ≤ 50.24 ng/ml subset.",Correlative analysis of plasma SN-38 levels and DPD activity with outcomes of FOLFIRI regimen for metastatic colorectal cancer with UGT1A1 *28 and *6 wild type and its implication for individualized chemotherapy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28278081/),[ng] / [ml],50.24,152655,DB00544,Fluorouracil
,28278081,progression free survival,"Of the *1/*1 -*1/*1 genotype combination, the median progression free survival of the CSN-38 1.5 h > 50.24 ng/ml subset was remarkably longer than that of the CSN-38 1.5 h ≤ 50.24 ng/ml subset.",Correlative analysis of plasma SN-38 levels and DPD activity with outcomes of FOLFIRI regimen for metastatic colorectal cancer with UGT1A1 *28 and *6 wild type and its implication for individualized chemotherapy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28278081/),,1,152656,DB00544,Fluorouracil
≤,28278081,progression free survival,"Of the *1/*1 -*1/*1 genotype combination, the median progression free survival of the CSN-38 1.5 h > 50.24 ng/ml subset was remarkably longer than that of the CSN-38 1.5 h ≤ 50.24 ng/ml subset.",Correlative analysis of plasma SN-38 levels and DPD activity with outcomes of FOLFIRI regimen for metastatic colorectal cancer with UGT1A1 *28 and *6 wild type and its implication for individualized chemotherapy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28278081/),[ng] / [ml],50.24,152657,DB00544,Fluorouracil
,15087023,half-life time,5-Fluorouracil (5-FU) belongs to antimetabolic anticancer drugs and its half-life time in vivo is only about 5 minutes.,"[Studies on 5-FU/PEG-PBLG nano-micelles: preparation, characteristics, and drug releasing in vivo]. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15087023/),min,5,152659,DB00544,Fluorouracil
,15087023,entrapment efficiency,The entrapment efficiency was (29.5+/-0.015)%.,"[Studies on 5-FU/PEG-PBLG nano-micelles: preparation, characteristics, and drug releasing in vivo]. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15087023/),%,29.5,152660,DB00544,Fluorouracil
,15087023,half-life,"In control group, 5-FU is one-compartment in vivo; its half-life was 5.3 minutes; the maximum plasma concentration (C(max)) was 17047.3 microg/L; T(max) was the time of attaining C(max) of the end of infusion; the area under the plasma concentration-time curve (AUC) was 6263.7 microg/L x min.","[Studies on 5-FU/PEG-PBLG nano-micelles: preparation, characteristics, and drug releasing in vivo]. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15087023/),min,5.3,152661,DB00544,Fluorouracil
,15087023,maximum plasma concentration (C(max)),"In control group, 5-FU is one-compartment in vivo; its half-life was 5.3 minutes; the maximum plasma concentration (C(max)) was 17047.3 microg/L; T(max) was the time of attaining C(max) of the end of infusion; the area under the plasma concentration-time curve (AUC) was 6263.7 microg/L x min.","[Studies on 5-FU/PEG-PBLG nano-micelles: preparation, characteristics, and drug releasing in vivo]. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15087023/),[μg] / [l],17047.3,152662,DB00544,Fluorouracil
,15087023,area under the plasma concentration-time curve (AUC),"In control group, 5-FU is one-compartment in vivo; its half-life was 5.3 minutes; the maximum plasma concentration (C(max)) was 17047.3 microg/L; T(max) was the time of attaining C(max) of the end of infusion; the area under the plasma concentration-time curve (AUC) was 6263.7 microg/L x min.","[Studies on 5-FU/PEG-PBLG nano-micelles: preparation, characteristics, and drug releasing in vivo]. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15087023/),[μg] / [l·min],6263.7,152663,DB00544,Fluorouracil
,15087023,t(1/2),"However, the model of nano-micelles in vivo was typical release-drug of nano-micelles namely abrupt release-slow release; its t(1/2) was 63.2 minutes; C(max) was 4563.5 microg/L; T(max) was 1.25 hours; AUC was 5794.5 microg/Lxmin.","[Studies on 5-FU/PEG-PBLG nano-micelles: preparation, characteristics, and drug releasing in vivo]. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15087023/),min,63.2,152664,DB00544,Fluorouracil
,15087023,C(max),"However, the model of nano-micelles in vivo was typical release-drug of nano-micelles namely abrupt release-slow release; its t(1/2) was 63.2 minutes; C(max) was 4563.5 microg/L; T(max) was 1.25 hours; AUC was 5794.5 microg/Lxmin.","[Studies on 5-FU/PEG-PBLG nano-micelles: preparation, characteristics, and drug releasing in vivo]. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15087023/),[μg] / [l],4563.5,152665,DB00544,Fluorouracil
,15087023,T(max),"However, the model of nano-micelles in vivo was typical release-drug of nano-micelles namely abrupt release-slow release; its t(1/2) was 63.2 minutes; C(max) was 4563.5 microg/L; T(max) was 1.25 hours; AUC was 5794.5 microg/Lxmin.","[Studies on 5-FU/PEG-PBLG nano-micelles: preparation, characteristics, and drug releasing in vivo]. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15087023/),h,1.25,152666,DB00544,Fluorouracil
,15087023,AUC,"However, the model of nano-micelles in vivo was typical release-drug of nano-micelles namely abrupt release-slow release; its t(1/2) was 63.2 minutes; C(max) was 4563.5 microg/L; T(max) was 1.25 hours; AUC was 5794.5 microg/Lxmin.","[Studies on 5-FU/PEG-PBLG nano-micelles: preparation, characteristics, and drug releasing in vivo]. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15087023/),[μg] / [l·min],5794.5,152667,DB00544,Fluorouracil
,16912527,response rate,The response rate was 25.0% (3 PR/12).,[A phase-I clinical study of a combination therapy of vinorelbine and capecitabine in patients with advanced/recurrent breast cancer]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16912527/),%,25.0,152993,DB00544,Fluorouracil
,8729951,steady-state total plasma reduced folate concentrations,"Based on pharmacokinetics at higher doses, steady-state total plasma reduced folate concentrations of 1 microM would be expected from the administration of leucovorin 50 mg/m2 by 24 h infusion.",A phase II trial of weekly infusional 5-fluorouracil in combination with low-dose leucovorin in patients with advanced colorectal cancer. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8729951/),μM,1,153821,DB00544,Fluorouracil
,8729951,total response rate,"Among the 32 evaluable patients, there were 14 partial remissions for a total response rate of 44% (95% confidence interval 27-61%).",A phase II trial of weekly infusional 5-fluorouracil in combination with low-dose leucovorin in patients with advanced colorectal cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8729951/),%,44,153822,DB00544,Fluorouracil
,7857100,inhibition rate,"2) TS inhibition rate in the tumor tissue was 66.8% in UFTL group and 53.2% in UFT group, and there was a significant difference between these two groups.",[Pharmacokinetic study in biochemical modulation therapy of UFT with leucovorin tablet]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7857100/),%,66.8,153862,DB00544,Fluorouracil
,7857100,inhibition rate,"2) TS inhibition rate in the tumor tissue was 66.8% in UFTL group and 53.2% in UFT group, and there was a significant difference between these two groups.",[Pharmacokinetic study in biochemical modulation therapy of UFT with leucovorin tablet]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7857100/),%,53.2,153863,DB00544,Fluorouracil
,9229329,maximum tolerated dose (MTD),The maximum tolerated dose (MTD) was 115 mg/m2 in the daily schedule and 145 mg/m2 in the weekly schedule.,CPT-11: the European clinical development. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9229329/),[mg] / [m2],115,154289,DB00544,Fluorouracil
,9229329,maximum tolerated dose (MTD),The maximum tolerated dose (MTD) was 115 mg/m2 in the daily schedule and 145 mg/m2 in the weekly schedule.,CPT-11: the European clinical development. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9229329/),[mg] / [m2],145,154290,DB00544,Fluorouracil
,10680979,uptake clearance,"The uptake clearance following nasal perfusion (8.65 microl/min/g tissue) was significantly large (p < 0.001) in comparison with that following intravenous infusion (6.20 microl/min/g tissue), while that following nasal instillation (6.94 microl/min/g tissue) was not.",Transnasal delivery of 5-fluorouracil to the brain in the rat. ,Uptake Volume-Q9,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10680979/),[μl] / [g·min·tissue],8.65,154414,DB00544,Fluorouracil
,10680979,uptake clearance,"The uptake clearance following nasal perfusion (8.65 microl/min/g tissue) was significantly large (p < 0.001) in comparison with that following intravenous infusion (6.20 microl/min/g tissue), while that following nasal instillation (6.94 microl/min/g tissue) was not.",Transnasal delivery of 5-fluorouracil to the brain in the rat. ,Uptake Volume-Q9,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10680979/),[μl] / [g·min·tissue],6.20,154415,DB00544,Fluorouracil
,10680979,uptake clearance,"The uptake clearance following nasal perfusion (8.65 microl/min/g tissue) was significantly large (p < 0.001) in comparison with that following intravenous infusion (6.20 microl/min/g tissue), while that following nasal instillation (6.94 microl/min/g tissue) was not.",Transnasal delivery of 5-fluorouracil to the brain in the rat. ,Uptake Volume-Q9,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10680979/),[μl] / [g·min·tissue],6.94,154416,DB00544,Fluorouracil
,9735391,rate of cumulative local recurrence,"However, the rate of cumulative local recurrence in the CT group was 0%, while that in the NCT group was 28.6% (p=0.0392).",Effects of pharmacokinetic modulating chemotherapy using oral UFT and continuous venous 5FU infusion on the prognosis of irradiated rectal carcinomas with p53 overexpression. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9735391/),%,0,154522,DB00544,Fluorouracil
,9735391,rate of cumulative local recurrence,"However, the rate of cumulative local recurrence in the CT group was 0%, while that in the NCT group was 28.6% (p=0.0392).",Effects of pharmacokinetic modulating chemotherapy using oral UFT and continuous venous 5FU infusion on the prognosis of irradiated rectal carcinomas with p53 overexpression. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9735391/),%,28.,154523,DB00544,Fluorouracil
,9735391,distant recurrence rate,"The distant recurrence rate in the CT group was also significantly lower than that in the NCT group (7.1% vs. 42.9%, p=0.0376).",Effects of pharmacokinetic modulating chemotherapy using oral UFT and continuous venous 5FU infusion on the prognosis of irradiated rectal carcinomas with p53 overexpression. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9735391/),%,7.1,154524,DB00544,Fluorouracil
,9735391,distant recurrence rate,"The distant recurrence rate in the CT group was also significantly lower than that in the NCT group (7.1% vs. 42.9%, p=0.0376).",Effects of pharmacokinetic modulating chemotherapy using oral UFT and continuous venous 5FU infusion on the prognosis of irradiated rectal carcinomas with p53 overexpression. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9735391/),%,42.9,154525,DB00544,Fluorouracil
,8285607,half-life at alpha phase,"Plasma clearance of 10 mg of FTC per kg of body weight was biexponential in rats, with a half-life at alpha phase of 4.7 +/- 1.1 min (mean +/- standard deviation) and a half-life at beta phase of 44 +/- 8.8 min (n = 5).","Pharmacokinetics, oral bioavailability, and metabolic disposition in rats of (-)-cis-5-fluoro-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl] cytosine, a nucleoside analog active against human immunodeficiency virus and hepatitis B virus. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8285607/),min,4.7,154604,DB00544,Fluorouracil
,8285607,half-life at beta phase,"Plasma clearance of 10 mg of FTC per kg of body weight was biexponential in rats, with a half-life at alpha phase of 4.7 +/- 1.1 min (mean +/- standard deviation) and a half-life at beta phase of 44 +/- 8.8 min (n = 5).","Pharmacokinetics, oral bioavailability, and metabolic disposition in rats of (-)-cis-5-fluoro-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl] cytosine, a nucleoside analog active against human immunodeficiency virus and hepatitis B virus. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8285607/),min,44,154605,DB00544,Fluorouracil
,8285607,total body clearance,"The total body clearance of FTC was 1.8 +/- 0.1 liters/h/kg, and the oral bioavailability was 90% +/- 8%.","Pharmacokinetics, oral bioavailability, and metabolic disposition in rats of (-)-cis-5-fluoro-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl] cytosine, a nucleoside analog active against human immunodeficiency virus and hepatitis B virus. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8285607/),[l] / [h·kg],1.8,154606,DB00544,Fluorouracil
,8285607,oral bioavailability,"The total body clearance of FTC was 1.8 +/- 0.1 liters/h/kg, and the oral bioavailability was 90% +/- 8%.","Pharmacokinetics, oral bioavailability, and metabolic disposition in rats of (-)-cis-5-fluoro-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl] cytosine, a nucleoside analog active against human immunodeficiency virus and hepatitis B virus. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8285607/),%,90,154607,DB00544,Fluorouracil
,8285607,volume of distribution at steady state (Vss),The volume of distribution at steady state (Vss) was 1.5 +/- 0.1 liters/kg.,"Pharmacokinetics, oral bioavailability, and metabolic disposition in rats of (-)-cis-5-fluoro-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl] cytosine, a nucleoside analog active against human immunodeficiency virus and hepatitis B virus. ",Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8285607/),[l] / [kg],1.5,154608,DB00544,Fluorouracil
,8285607,clearance,"Increasing the dose to 100 mg/kg slowed clearance to 1.5 +/- 0.2 liters/kg/h, lowered the Vss to 1.2 +/- 0.2 liters/kg, and reduced the oral bioavailability to 65% +/- 15%.","Pharmacokinetics, oral bioavailability, and metabolic disposition in rats of (-)-cis-5-fluoro-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl] cytosine, a nucleoside analog active against human immunodeficiency virus and hepatitis B virus. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8285607/),[l] / [h·kg],1.5,154609,DB00544,Fluorouracil
,8285607,Vss,"Increasing the dose to 100 mg/kg slowed clearance to 1.5 +/- 0.2 liters/kg/h, lowered the Vss to 1.2 +/- 0.2 liters/kg, and reduced the oral bioavailability to 65% +/- 15%.","Pharmacokinetics, oral bioavailability, and metabolic disposition in rats of (-)-cis-5-fluoro-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl] cytosine, a nucleoside analog active against human immunodeficiency virus and hepatitis B virus. ",Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8285607/),[l] / [kg],1.2,154610,DB00544,Fluorouracil
,8285607,oral bioavailability,"Increasing the dose to 100 mg/kg slowed clearance to 1.5 +/- 0.2 liters/kg/h, lowered the Vss to 1.2 +/- 0.2 liters/kg, and reduced the oral bioavailability to 65% +/- 15%.","Pharmacokinetics, oral bioavailability, and metabolic disposition in rats of (-)-cis-5-fluoro-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl] cytosine, a nucleoside analog active against human immunodeficiency virus and hepatitis B virus. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8285607/),%,65,154611,DB00544,Fluorouracil
,8285607,urinary,"The urinary and fecal recoveries of unchanged FTC after a 10-mg/kg intravenous dose were 87% +/- 3% and 5% +/- 1.6%, respectively.","Pharmacokinetics, oral bioavailability, and metabolic disposition in rats of (-)-cis-5-fluoro-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl] cytosine, a nucleoside analog active against human immunodeficiency virus and hepatitis B virus. ",fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8285607/),%,87,154612,DB00544,Fluorouracil
,8285607,fecal recoveries,"The urinary and fecal recoveries of unchanged FTC after a 10-mg/kg intravenous dose were 87% +/- 3% and 5% +/- 1.6%, respectively.","Pharmacokinetics, oral bioavailability, and metabolic disposition in rats of (-)-cis-5-fluoro-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl] cytosine, a nucleoside analog active against human immunodeficiency virus and hepatitis B virus. ",fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8285607/),%,5,154613,DB00544,Fluorouracil
,8285607,urinary,"After a 10-mg/kg oral dose, respective urinary and fecal recoveries were 70% +/- 2.5% and 25% +/- 1.6%.","Pharmacokinetics, oral bioavailability, and metabolic disposition in rats of (-)-cis-5-fluoro-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl] cytosine, a nucleoside analog active against human immunodeficiency virus and hepatitis B virus. ",fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8285607/),%,70,154614,DB00544,Fluorouracil
,8285607,f,"After a 10-mg/kg oral dose, respective urinary and fecal recoveries were 70% +/- 2.5% and 25% +/- 1.6%.","Pharmacokinetics, oral bioavailability, and metabolic disposition in rats of (-)-cis-5-fluoro-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl] cytosine, a nucleoside analog active against human immunodeficiency virus and hepatitis B virus. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8285607/),%,70,154615,DB00544,Fluorouracil
,8285607,recoveries,"After a 10-mg/kg oral dose, respective urinary and fecal recoveries were 70% +/- 2.5% and 25% +/- 1.6%.","Pharmacokinetics, oral bioavailability, and metabolic disposition in rats of (-)-cis-5-fluoro-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl] cytosine, a nucleoside analog active against human immunodeficiency virus and hepatitis B virus. ",fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8285607/),%,25,154616,DB00544,Fluorouracil
,10561369,objective response rate,"Antitumor activity was observed at almost all dose levels, with an objective response rate of 22%.","Irinotecan combined with bolus fluorouracil, continuous infusion fluorouracil, and high-dose leucovorin every two weeks (LV5FU2 regimen): a clinical dose-finding and pharmacokinetic study in patients with pretreated metastatic colorectal cancer. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10561369/),%,22,156071,DB00544,Fluorouracil
,10561369,time to progression,Median time to progression was 6.3 months and overall survival was 15 months.,"Irinotecan combined with bolus fluorouracil, continuous infusion fluorouracil, and high-dose leucovorin every two weeks (LV5FU2 regimen): a clinical dose-finding and pharmacokinetic study in patients with pretreated metastatic colorectal cancer. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10561369/),month,6.3,156072,DB00544,Fluorouracil
,10561369,overall survival,Median time to progression was 6.3 months and overall survival was 15 months.,"Irinotecan combined with bolus fluorouracil, continuous infusion fluorouracil, and high-dose leucovorin every two weeks (LV5FU2 regimen): a clinical dose-finding and pharmacokinetic study in patients with pretreated metastatic colorectal cancer. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10561369/),month,15,156073,DB00544,Fluorouracil
,31605153,liver regeneration rate,"The liver regeneration rate was significantly lower in the HC group than in the H group (67.3 ± 7.4 vs 33.0 ± 5.7%, p < 0.001).",Pharmacokinetic and toxicodynamic evaluation of 5-fluorouracil administration after major hepatectomy in a rat model. ,QH-Q55,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31605153/),%,67.3,156295,DB00544,Fluorouracil
,31605153,liver regeneration rate,"The liver regeneration rate was significantly lower in the HC group than in the H group (67.3 ± 7.4 vs 33.0 ± 5.7%, p < 0.001).",Pharmacokinetic and toxicodynamic evaluation of 5-fluorouracil administration after major hepatectomy in a rat model. ,QH-Q55,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31605153/),%,33.0,156296,DB00544,Fluorouracil
,31605153,villous height,"The HC group had a significantly lower ileal villous height than the CC group (253 ± 40 μm vs. 318 ± 36 μm, p < 0.05).",Pharmacokinetic and toxicodynamic evaluation of 5-fluorouracil administration after major hepatectomy in a rat model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31605153/),μm,253,156297,DB00544,Fluorouracil
,31605153,villous height,"The HC group had a significantly lower ileal villous height than the CC group (253 ± 40 μm vs. 318 ± 36 μm, p < 0.05).",Pharmacokinetic and toxicodynamic evaluation of 5-fluorouracil administration after major hepatectomy in a rat model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31605153/),μm,318,156298,DB00544,Fluorouracil
,20085906,area under the curve,"The free platinum area under the curve was 15.7-18.9 microg h/ml when 40 mg/m(2) of oxaliplatin was administered, which was comparable to the area under the curve at 85 mg/m(2) in patient with normal renal function.",Drug monitoring during FOLFOX6 therapy in a rectal cancer patient on chronic hemodialysis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20085906/),[h·μg] / [ml],15.7-18.9,156299,DB00544,Fluorouracil
,9605432,AUCs,"In the three susceptible models, 5-FUra AUCs in tumors after capecitabine administration were 210 to 303 nmol x hr/g, whereas those after 5-FUra administration were 8.54 to 13.1 nmol x hr/g.","Tumor selective delivery of 5-fluorouracil by capecitabine, a new oral fluoropyrimidine carbamate, in human cancer xenografts. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9605432/),[h·nM] / [g],210 to 303,156816,DB00544,Fluorouracil
,9605432,AUCs,"In the three susceptible models, 5-FUra AUCs in tumors after capecitabine administration were 210 to 303 nmol x hr/g, whereas those after 5-FUra administration were 8.54 to 13.1 nmol x hr/g.","Tumor selective delivery of 5-fluorouracil by capecitabine, a new oral fluoropyrimidine carbamate, in human cancer xenografts. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9605432/),[h·nM] / [g],8.54 to 13.1,156817,DB00544,Fluorouracil
,9605432,AUC,"In the refractory model, WiDr, 5-FUra AUC in tumors after capecitabine administration was only 62.8 nmol x hr/g, although the level of the intermediate metabolite 5'-dFUrd was high (AUC: 695 nmol x hr/g).","Tumor selective delivery of 5-fluorouracil by capecitabine, a new oral fluoropyrimidine carbamate, in human cancer xenografts. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9605432/),[h·nM] / [g],62.8,156818,DB00544,Fluorouracil
,9605432,AUC,"In the refractory model, WiDr, 5-FUra AUC in tumors after capecitabine administration was only 62.8 nmol x hr/g, although the level of the intermediate metabolite 5'-dFUrd was high (AUC: 695 nmol x hr/g).","Tumor selective delivery of 5-fluorouracil by capecitabine, a new oral fluoropyrimidine carbamate, in human cancer xenografts. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9605432/),[h·nM] / [g],695,156819,DB00544,Fluorouracil
,29159476,area-under-the-concentration-time-curve (AUC),"No significant differences in first cycle 5FU area-under-the-concentration-time-curve (AUC) were found between sarcopenic and non-sarcopenic patients (17.3 vs. 19.3 AUC, p = 0.43).",The impact of skeletal muscle on the pharmacokinetics and toxicity of 5-fluorouracil in colorectal cancer. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29159476/),auc,17.3,156991,DB00544,Fluorouracil
,29159476,area-under-the-concentration-time-curve (AUC),"No significant differences in first cycle 5FU area-under-the-concentration-time-curve (AUC) were found between sarcopenic and non-sarcopenic patients (17.3 vs. 19.3 AUC, p = 0.43).",The impact of skeletal muscle on the pharmacokinetics and toxicity of 5-fluorouracil in colorectal cancer. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29159476/),auc,19.3,156992,DB00544,Fluorouracil
,16303861,time to progression,"Median time to progression was 9.9 months [lower 95% confidence limit (CL) 7.9, upper 95% CL not reached].",Cetuximab and irinotecan/5-fluorouracil/folinic acid is a safe combination for the first-line treatment of patients with epidermal growth factor receptor expressing metastatic colorectal carcinoma. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16303861/),month,9.9,157278,DB00544,Fluorouracil
,11432616,terminal half-life,"The mean PK parameters were: terminal half-life of ultrafiltrable platin, 17.75 +/- 9.29 hours; renal elimination, 48.7% +/- 14.1% of the applied dose; renal clearance 135.55 +/- 45.32 ml/min.",Phase I and pharmacokinetic study of hepatic arterial infusion with oxaliplatin in combination with folinic acid and 5-fluorouracil in patients with hepatic metastases from colorectal cancer. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11432616/),h,17.75,157854,DB00544,Fluorouracil
,11432616,renal elimination,"The mean PK parameters were: terminal half-life of ultrafiltrable platin, 17.75 +/- 9.29 hours; renal elimination, 48.7% +/- 14.1% of the applied dose; renal clearance 135.55 +/- 45.32 ml/min.",Phase I and pharmacokinetic study of hepatic arterial infusion with oxaliplatin in combination with folinic acid and 5-fluorouracil in patients with hepatic metastases from colorectal cancer. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11432616/),%,48.7,157855,DB00544,Fluorouracil
,11432616,renal clearance,"The mean PK parameters were: terminal half-life of ultrafiltrable platin, 17.75 +/- 9.29 hours; renal elimination, 48.7% +/- 14.1% of the applied dose; renal clearance 135.55 +/- 45.32 ml/min.",Phase I and pharmacokinetic study of hepatic arterial infusion with oxaliplatin in combination with folinic acid and 5-fluorouracil in patients with hepatic metastases from colorectal cancer. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11432616/),[ml] / [min],135.55,157856,DB00544,Fluorouracil
,11432616,area under the plasma-concentration curve (AUC),The mean area under the plasma-concentration curve (AUC) increased linearly from 3.22 +/- 0.61 microg x h/ml to 18.45 +/- 8.90 microg x h/ml through the first five dose levels (P = 0.0004).,Phase I and pharmacokinetic study of hepatic arterial infusion with oxaliplatin in combination with folinic acid and 5-fluorouracil in patients with hepatic metastases from colorectal cancer. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11432616/),[h·μg] / [ml],3.22,157857,DB00544,Fluorouracil
,11432616,area under the plasma-concentration curve (AUC),The mean area under the plasma-concentration curve (AUC) increased linearly from 3.22 +/- 0.61 microg x h/ml to 18.45 +/- 8.90 microg x h/ml through the first five dose levels (P = 0.0004).,Phase I and pharmacokinetic study of hepatic arterial infusion with oxaliplatin in combination with folinic acid and 5-fluorouracil in patients with hepatic metastases from colorectal cancer. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11432616/),[h·μg] / [ml],18.45,157858,DB00544,Fluorouracil
,15799730,half-life,A mathematical model is presented that can explain the measured data if the clearance of 5-FU from the vitreous water phase follows first order kinetics with a half-life of 20 min.,Pharmacokinetics of intravitreal 5-fluorouracil prodrugs in silicone oil: experimental studies in pigs. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15799730/),min,20,158556,DB00544,Fluorouracil
,15799730,specific release rate constant,The model analysis indicates that an alkoxycarbonyl 5-FU prodrug with a specific release rate constant of 10.7 microg/square root h cm(2) can maintain an intravitreal 5-FU concentration above 1 microg/ml for 5 days in the porcine eye.,Pharmacokinetics of intravitreal 5-fluorouracil prodrugs in silicone oil: experimental studies in pigs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15799730/),[h·root·square·μg] / [cm(2],10.7,158557,DB00544,Fluorouracil
,3652033,Vmax,"Vmax and Km were 6-11 nmol/ml/min and 33-45 microM, respectively.",Dose and flow dependence of 5-fluorouracil elimination by the isolated perfused rat liver. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3652033/),[nM] / [min·ml],6-11,158763,DB00544,Fluorouracil
,3652033,Km,"Vmax and Km were 6-11 nmol/ml/min and 33-45 microM, respectively.",Dose and flow dependence of 5-fluorouracil elimination by the isolated perfused rat liver. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3652033/),μM,33-45,158764,DB00544,Fluorouracil
,3652033,Hepatic clearance during first-order elimination,Hepatic clearance during first-order elimination was close to 20 ml/min.,Dose and flow dependence of 5-fluorouracil elimination by the isolated perfused rat liver. ,CLH-Q25,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3652033/),[ml] / [min],20,158765,DB00544,Fluorouracil
,3652033,Km,"As hepatic blood flow increased from 10 to 30 ml/min, Vmax was unchanged but Km decreased progressively from 84 to 32 microM, and clearance increased from 12 to 29 ml/min.",Dose and flow dependence of 5-fluorouracil elimination by the isolated perfused rat liver. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3652033/),μM,84,158766,DB00544,Fluorouracil
,3652033,Km,"As hepatic blood flow increased from 10 to 30 ml/min, Vmax was unchanged but Km decreased progressively from 84 to 32 microM, and clearance increased from 12 to 29 ml/min.",Dose and flow dependence of 5-fluorouracil elimination by the isolated perfused rat liver. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3652033/),μM,32,158767,DB00544,Fluorouracil
,3652033,clearance,"As hepatic blood flow increased from 10 to 30 ml/min, Vmax was unchanged but Km decreased progressively from 84 to 32 microM, and clearance increased from 12 to 29 ml/min.",Dose and flow dependence of 5-fluorouracil elimination by the isolated perfused rat liver. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3652033/),[ml] / [min],12 to 29,158768,DB00544,Fluorouracil
,18212800,maximum plasma concentration,"Furthermore, patients with the CYP2A6*4C allele had a significantly lower maximum plasma concentration (102.6 +/- 32.9 ng/ml) for 5-FU than patients without the CYP2A6*4C allele (157.0 +/- 65.5 ng/ml, P < 0.05).",The CYP2A6*4 allele is determinant of S-1 pharmacokinetics in Japanese patients with non-small-cell lung cancer. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18212800/),[ng] / [ml],102.6,159556,DB00544,Fluorouracil
,18212800,maximum plasma concentration,"Furthermore, patients with the CYP2A6*4C allele had a significantly lower maximum plasma concentration (102.6 +/- 32.9 ng/ml) for 5-FU than patients without the CYP2A6*4C allele (157.0 +/- 65.5 ng/ml, P < 0.05).",The CYP2A6*4 allele is determinant of S-1 pharmacokinetics in Japanese patients with non-small-cell lung cancer. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18212800/),[ng] / [ml],157.0,159557,DB00544,Fluorouracil
,22865703,maximum encapsulation efficiency,"We found that when 5-FU and GC were mixed at the mass ratio of 10:1, the nanoparticle reached a maximum encapsulation efficiency of 81.82% ± 5.32%, with a drug loading of 6.12% ± 1.36%, a particle size of 35.19 ± 9.50 nm, and a Zeta potential of +10.34 ± 1.43 mV.","Synthesis of galactosylated chitosan/5-fluorouracil nanoparticles and its characteristics, in vitro and in vivo release studies. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22865703/),%,81.82,161775,DB00544,Fluorouracil
,22865703,Zeta potential,"We found that when 5-FU and GC were mixed at the mass ratio of 10:1, the nanoparticle reached a maximum encapsulation efficiency of 81.82% ± 5.32%, with a drug loading of 6.12% ± 1.36%, a particle size of 35.19 ± 9.50 nm, and a Zeta potential of +10.34 ± 1.43 mV.","Synthesis of galactosylated chitosan/5-fluorouracil nanoparticles and its characteristics, in vitro and in vivo release studies. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22865703/),mv,+,161776,DB00544,Fluorouracil
,22865703,Zeta potential,"We found that when 5-FU and GC were mixed at the mass ratio of 10:1, the nanoparticle reached a maximum encapsulation efficiency of 81.82% ± 5.32%, with a drug loading of 6.12% ± 1.36%, a particle size of 35.19 ± 9.50 nm, and a Zeta potential of +10.34 ± 1.43 mV.","Synthesis of galactosylated chitosan/5-fluorouracil nanoparticles and its characteristics, in vitro and in vivo release studies. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22865703/),mv,10.34,161777,DB00544,Fluorouracil
,27807652,area under the concentration-time curve,"The median initial area under the concentration-time curve for FU was 23 mg h/L. Twenty-nine patients (60%) achieved the target concentration at the first cycle, and all 48 achieved it within the fourth cycle.",Pharmacokinetic dose adjustment of 5-FU in modified FOLFOX7 plus bevacizumab for metastatic colorectal cancer in Japanese patients: a-JUST phase II clinical trial. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27807652/),[h·mg] / [l],23,161866,DB00544,Fluorouracil
,27807652,overall response rate,The overall response rate was 48% (95% confidence intervals = 34-62%).,Pharmacokinetic dose adjustment of 5-FU in modified FOLFOX7 plus bevacizumab for metastatic colorectal cancer in Japanese patients: a-JUST phase II clinical trial. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27807652/),%,48,161867,DB00544,Fluorouracil
,27807652,progression-free,"The median progression-free and overall survival rates were 11.3 and 24.1 months, respectively.",Pharmacokinetic dose adjustment of 5-FU in modified FOLFOX7 plus bevacizumab for metastatic colorectal cancer in Japanese patients: a-JUST phase II clinical trial. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27807652/),month,11.3,161868,DB00544,Fluorouracil
,27807652,overall survival rates,"The median progression-free and overall survival rates were 11.3 and 24.1 months, respectively.",Pharmacokinetic dose adjustment of 5-FU in modified FOLFOX7 plus bevacizumab for metastatic colorectal cancer in Japanese patients: a-JUST phase II clinical trial. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27807652/),month,24.1,161869,DB00544,Fluorouracil
,7929872,Absolute bioavailability,"Absolute bioavailability after the oral dosing on day 1 was 87.5 +/- 31.3%, and on day 5 was 85.2 +/- 22.1% (P > .05).",Oral ondansetron pharmacokinetics: the effect of chemotherapy. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7929872/),%,87.5,162420,DB00544,Fluorouracil
,7929872,Absolute bioavailability,"Absolute bioavailability after the oral dosing on day 1 was 87.5 +/- 31.3%, and on day 5 was 85.2 +/- 22.1% (P > .05).",Oral ondansetron pharmacokinetics: the effect of chemotherapy. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7929872/),%,85.2,162421,DB00544,Fluorouracil
,7929872,AUC,"Mean values of AUC, Cmax, Tmax, and half life on days 1 and 5 were 399 +/- 275 and 381 +/- 222 ng.hour/mL, 53.3 +/- 26.8 and 43.6 +/- 21.7 ng/mL, 1.9 +/- 1.4 and 2 +/- 1.4 hours, and 5.21 +/- 1.78 and 6.19 +/- 1.99 hours, respectively.",Oral ondansetron pharmacokinetics: the effect of chemotherapy. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7929872/),[h·ng] / [ml],399,162422,DB00544,Fluorouracil
,7929872,Cmax,"Mean values of AUC, Cmax, Tmax, and half life on days 1 and 5 were 399 +/- 275 and 381 +/- 222 ng.hour/mL, 53.3 +/- 26.8 and 43.6 +/- 21.7 ng/mL, 1.9 +/- 1.4 and 2 +/- 1.4 hours, and 5.21 +/- 1.78 and 6.19 +/- 1.99 hours, respectively.",Oral ondansetron pharmacokinetics: the effect of chemotherapy. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7929872/),[h·ng] / [ml],381,162423,DB00544,Fluorouracil
,7929872,Cmax,"Mean values of AUC, Cmax, Tmax, and half life on days 1 and 5 were 399 +/- 275 and 381 +/- 222 ng.hour/mL, 53.3 +/- 26.8 and 43.6 +/- 21.7 ng/mL, 1.9 +/- 1.4 and 2 +/- 1.4 hours, and 5.21 +/- 1.78 and 6.19 +/- 1.99 hours, respectively.",Oral ondansetron pharmacokinetics: the effect of chemotherapy. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7929872/),h,1.9,162424,DB00544,Fluorouracil
,7929872,Tmax,"Mean values of AUC, Cmax, Tmax, and half life on days 1 and 5 were 399 +/- 275 and 381 +/- 222 ng.hour/mL, 53.3 +/- 26.8 and 43.6 +/- 21.7 ng/mL, 1.9 +/- 1.4 and 2 +/- 1.4 hours, and 5.21 +/- 1.78 and 6.19 +/- 1.99 hours, respectively.",Oral ondansetron pharmacokinetics: the effect of chemotherapy. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7929872/),[h·ng] / [ml],381,162425,DB00544,Fluorouracil
,7929872,Tmax,"Mean values of AUC, Cmax, Tmax, and half life on days 1 and 5 were 399 +/- 275 and 381 +/- 222 ng.hour/mL, 53.3 +/- 26.8 and 43.6 +/- 21.7 ng/mL, 1.9 +/- 1.4 and 2 +/- 1.4 hours, and 5.21 +/- 1.78 and 6.19 +/- 1.99 hours, respectively.",Oral ondansetron pharmacokinetics: the effect of chemotherapy. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7929872/),h,1.9,162426,DB00544,Fluorouracil
,7929872,half life,"Mean values of AUC, Cmax, Tmax, and half life on days 1 and 5 were 399 +/- 275 and 381 +/- 222 ng.hour/mL, 53.3 +/- 26.8 and 43.6 +/- 21.7 ng/mL, 1.9 +/- 1.4 and 2 +/- 1.4 hours, and 5.21 +/- 1.78 and 6.19 +/- 1.99 hours, respectively.",Oral ondansetron pharmacokinetics: the effect of chemotherapy. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7929872/),h,2,162427,DB00544,Fluorouracil
,7929872,half life,"Mean values of AUC, Cmax, Tmax, and half life on days 1 and 5 were 399 +/- 275 and 381 +/- 222 ng.hour/mL, 53.3 +/- 26.8 and 43.6 +/- 21.7 ng/mL, 1.9 +/- 1.4 and 2 +/- 1.4 hours, and 5.21 +/- 1.78 and 6.19 +/- 1.99 hours, respectively.",Oral ondansetron pharmacokinetics: the effect of chemotherapy. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7929872/),h,5.21,162428,DB00544,Fluorouracil
,7929872,half life,"Mean values of AUC, Cmax, Tmax, and half life on days 1 and 5 were 399 +/- 275 and 381 +/- 222 ng.hour/mL, 53.3 +/- 26.8 and 43.6 +/- 21.7 ng/mL, 1.9 +/- 1.4 and 2 +/- 1.4 hours, and 5.21 +/- 1.78 and 6.19 +/- 1.99 hours, respectively.",Oral ondansetron pharmacokinetics: the effect of chemotherapy. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7929872/),h,6.19,162429,DB00544,Fluorouracil
lower,21452098,IC₅₀,"Interestingly, all of the compounds showed selective inhibitory activities against BGC-823, with IC₅₀ values lower than 0.1 µmol, which is more potent than CPT-11 (2).",Design and synthesis of novel camptothecin/5-fluorouracil conjugates as cytotoxic agents. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21452098/),μM,0.1,162797,DB00544,Fluorouracil
,16897970,area under the curve (AUC0-10h),"The area under the curve (AUC0-10h) of 5-FU on day 5 was 728 +/- 113 ng x hr/ml for PVI of 5-FU and 1,364 +/- 374 ng x hr/ml for S-1.","[Plasma concentrations of 5-fluorouracil and F-beta-alanine following oral administration of S-1, a dihydropyrimidine dehydrogenase inhibitory fluoropyrimidine, as compared with protracted venous infusion of 5-fluorouracil]. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16897970/),[h·ng] / [ml],728,163169,DB00544,Fluorouracil
,16897970,area under the curve (AUC0-10h),"The area under the curve (AUC0-10h) of 5-FU on day 5 was 728 +/- 113 ng x hr/ml for PVI of 5-FU and 1,364 +/- 374 ng x hr/ml for S-1.","[Plasma concentrations of 5-fluorouracil and F-beta-alanine following oral administration of S-1, a dihydropyrimidine dehydrogenase inhibitory fluoropyrimidine, as compared with protracted venous infusion of 5-fluorouracil]. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16897970/),[h·ng] / [ml],"1,364",163170,DB00544,Fluorouracil
,16897970,AUC0-10h,"The AUC0-10h of FBAL on day 5 of PVI of 5-FU was 9,465 +/- 3,225 ng x hr/ml, AUC0-10h, as compared with 1,725 +/- 605 ng x hr/ml on day 5 of S-1 treatment.","[Plasma concentrations of 5-fluorouracil and F-beta-alanine following oral administration of S-1, a dihydropyrimidine dehydrogenase inhibitory fluoropyrimidine, as compared with protracted venous infusion of 5-fluorouracil]. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16897970/),[h·ng] / [ml],"9,465",163171,DB00544,Fluorouracil
,16897970,AUC0-10h,"The AUC0-10h of FBAL on day 5 of PVI of 5-FU was 9,465 +/- 3,225 ng x hr/ml, AUC0-10h, as compared with 1,725 +/- 605 ng x hr/ml on day 5 of S-1 treatment.","[Plasma concentrations of 5-fluorouracil and F-beta-alanine following oral administration of S-1, a dihydropyrimidine dehydrogenase inhibitory fluoropyrimidine, as compared with protracted venous infusion of 5-fluorouracil]. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16897970/),[h·ng] / [ml],"1,725",163172,DB00544,Fluorouracil
,16897970,AUC0-10h,"The AUC0-10h of uracil on day 5 was 252 +/- 60 ng x hr/ml with PVI of 5-FU and 12,582 +/- 3,060 ng x hr/ml with S-1.","[Plasma concentrations of 5-fluorouracil and F-beta-alanine following oral administration of S-1, a dihydropyrimidine dehydrogenase inhibitory fluoropyrimidine, as compared with protracted venous infusion of 5-fluorouracil]. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16897970/),[h·ng] / [ml],252,163173,DB00544,Fluorouracil
,16897970,AUC0-10h,"The AUC0-10h of uracil on day 5 was 252 +/- 60 ng x hr/ml with PVI of 5-FU and 12,582 +/- 3,060 ng x hr/ml with S-1.","[Plasma concentrations of 5-fluorouracil and F-beta-alanine following oral administration of S-1, a dihydropyrimidine dehydrogenase inhibitory fluoropyrimidine, as compared with protracted venous infusion of 5-fluorouracil]. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16897970/),[h·ng] / [ml],"12,582",163174,DB00544,Fluorouracil
,17656482,overall response rate,"The overall response rate was 9% (5/57, 95% CI: 4-19%).",Phase II study of oxaliplatin in japanese patients with metastatic colorectal cancer refractory to fluoropyrimidines. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17656482/),%,9,163216,DB00544,Fluorouracil
,17656482,time to progression,"The median time to progression was 2.7 months, and the median survival time was 11.1 months.",Phase II study of oxaliplatin in japanese patients with metastatic colorectal cancer refractory to fluoropyrimidines. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17656482/),month,2.7,163217,DB00544,Fluorouracil
,17656482,survival time,"The median time to progression was 2.7 months, and the median survival time was 11.1 months.",Phase II study of oxaliplatin in japanese patients with metastatic colorectal cancer refractory to fluoropyrimidines. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17656482/),month,11.1,163218,DB00544,Fluorouracil
,6950156,elimination half-line,"The mean FUra elimination half-line in plasma was 7.11 +/- 0.84 minutes (SEM), which is no different from that reported for FUra alone.",Phase I-phase II trial of N-phosphonacetyl-L-aspartic acid given by intravenous infusion and 5-fluorouracil given by bolus injection. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6950156/),min,7.11,164786,DB00544,Fluorouracil
,21184205,area under the plasma concentration-time curve (AUC),"All data were subsequently processed by using the computer program 3P97, and the values were showed as follows: the area under the plasma concentration-time curve (AUC) value was 321.88 (μg/ml) × day, and the mean residence time (MRT) value was 23.05 days.",The biodegradation of zein in vitro and in vivo and its application in implants. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21184205/),[μg] / [d·ml)],321.88,164843,DB00544,Fluorouracil
,21184205,mean residence time (MRT),"All data were subsequently processed by using the computer program 3P97, and the values were showed as follows: the area under the plasma concentration-time curve (AUC) value was 321.88 (μg/ml) × day, and the mean residence time (MRT) value was 23.05 days.",The biodegradation of zein in vitro and in vivo and its application in implants. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21184205/),d,23.05,164844,DB00544,Fluorouracil
,18525298,MTD,The MTD of epirubicin was 50 mg/m2.,"Phase I dose escalation study with irinotecan, capecitabine, epirubicin, and granulocyte colony-stimulating factor support for patients with solid malignancies. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18525298/),[mg] / [m2],50,165644,DB00544,Fluorouracil
,17289892,Maximum tolerated dose,Maximum tolerated dose of irinotecan in FOLFIRI schedule with celecoxib is 200 mg/m2.,"Celecoxib and mucosal protection: translation from an animal model to a phase I clinical trial of celecoxib, irinotecan, and 5-fluorouracil. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17289892/),mg,200,166306,DB00544,Fluorouracil
,26503235,mesor,"The mesor, amplitude and acrophase of Cosinor model were estimated as 1.93 L/h/kg, 0.10 L/h/kg and 2.02 h, respectively.",Population pharmacokinetic modelling and simulation of 5-fluorouracil incorporating a circadian rhythm in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26503235/),[l] / [h·kg],1.93,166743,DB00544,Fluorouracil
,26503235,amplitude,"The mesor, amplitude and acrophase of Cosinor model were estimated as 1.93 L/h/kg, 0.10 L/h/kg and 2.02 h, respectively.",Population pharmacokinetic modelling and simulation of 5-fluorouracil incorporating a circadian rhythm in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26503235/),[l] / [h·kg],0.10,166744,DB00544,Fluorouracil
,26503235,acrophase,"The mesor, amplitude and acrophase of Cosinor model were estimated as 1.93 L/h/kg, 0.10 L/h/kg and 2.02 h, respectively.",Population pharmacokinetic modelling and simulation of 5-fluorouracil incorporating a circadian rhythm in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26503235/),h,2.02,166745,DB00544,Fluorouracil
,1643698,steady-state FUra concentrations,Limited pharmacokinetic sampling at levels 3 and 4 revealed mean steady-state FUra concentrations of around 1.0 microM with infusions of FUra/LV+DP.,"A phase I trial of 5-fluorouracil, leucovorin, and dipyridamole given by concurrent 120-h continuous infusions. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1643698/),μM,1.0,167173,DB00544,Fluorouracil
,4009218,half-life,The mean half-life of 5-FU in the isolated circuit was 18.5 minutes.,Pharmacokinetics of 5-fluorouracil during hyperthermic pelvic isolation-perfusion. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4009218/),min,18.5,167641,DB00544,Fluorouracil
,7468228,systemic availability,"The systemic availability of oral antipyrine after cyclophosphamide pretreatment (0.88) was not changed, but the metabolic clearance of the drug was reduced.",The effect of antineoplastic drugs on the pharmacokinetics of antipyrine in the rat. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7468228/),,0.88,167737,DB00544,Fluorouracil
,24829073,Response rate,"Response rate, disease control rate, median time to progression, and median overall survival were 27.8 %, 61.1 %, 5.3 months, and 12.8 months, respectively.","Phase I study on the safety, pharmacokinetic profile, and efficacy of the combination of TSU-68, an oral antiangiogenic agent, and S-1 in patients with advanced hepatocellular carcinoma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24829073/),%,27.8,167978,DB00544,Fluorouracil
,24829073,disease control rate,"Response rate, disease control rate, median time to progression, and median overall survival were 27.8 %, 61.1 %, 5.3 months, and 12.8 months, respectively.","Phase I study on the safety, pharmacokinetic profile, and efficacy of the combination of TSU-68, an oral antiangiogenic agent, and S-1 in patients with advanced hepatocellular carcinoma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24829073/),%,61.1,167979,DB00544,Fluorouracil
,24829073,disease control rate,"Response rate, disease control rate, median time to progression, and median overall survival were 27.8 %, 61.1 %, 5.3 months, and 12.8 months, respectively.","Phase I study on the safety, pharmacokinetic profile, and efficacy of the combination of TSU-68, an oral antiangiogenic agent, and S-1 in patients with advanced hepatocellular carcinoma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24829073/),month,5.3,167980,DB00544,Fluorouracil
,24829073,time to progression,"Response rate, disease control rate, median time to progression, and median overall survival were 27.8 %, 61.1 %, 5.3 months, and 12.8 months, respectively.","Phase I study on the safety, pharmacokinetic profile, and efficacy of the combination of TSU-68, an oral antiangiogenic agent, and S-1 in patients with advanced hepatocellular carcinoma. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24829073/),%,61.1,167981,DB00544,Fluorouracil
,24829073,time to progression,"Response rate, disease control rate, median time to progression, and median overall survival were 27.8 %, 61.1 %, 5.3 months, and 12.8 months, respectively.","Phase I study on the safety, pharmacokinetic profile, and efficacy of the combination of TSU-68, an oral antiangiogenic agent, and S-1 in patients with advanced hepatocellular carcinoma. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24829073/),month,5.3,167982,DB00544,Fluorouracil
,24829073,overall survival,"Response rate, disease control rate, median time to progression, and median overall survival were 27.8 %, 61.1 %, 5.3 months, and 12.8 months, respectively.","Phase I study on the safety, pharmacokinetic profile, and efficacy of the combination of TSU-68, an oral antiangiogenic agent, and S-1 in patients with advanced hepatocellular carcinoma. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24829073/),month,12.8,167983,DB00544,Fluorouracil
,1617631,peak plasma concentration,"Pharmacokinetic studies indicated a rapid clearance of L-histidinol following a bolus dose (250 mg/kg i.p.), peak plasma concentration of 200 micrograms/ml (1.4 mM), and beta phase t1/2 of 12.6 min.",L-histidinol: preclinical therapeutic studies in combination with antitumor agents and pharmacokinetic studies in mice. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1617631/),[μg] / [ml],200,168290,DB00544,Fluorouracil
,1617631,beta phase t1/2,"Pharmacokinetic studies indicated a rapid clearance of L-histidinol following a bolus dose (250 mg/kg i.p.), peak plasma concentration of 200 micrograms/ml (1.4 mM), and beta phase t1/2 of 12.6 min.",L-histidinol: preclinical therapeutic studies in combination with antitumor agents and pharmacokinetic studies in mice. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1617631/),min,12.6,168291,DB00544,Fluorouracil
no greater,1617631,Maximum tolerable plasma steady state concentrations,Maximum tolerable plasma steady state concentrations with a 24-h infusion (2000 mg/kg/24 h) were no greater than 25 micrograms/ml (0.18 mM).,L-histidinol: preclinical therapeutic studies in combination with antitumor agents and pharmacokinetic studies in mice. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1617631/),[μg] / [ml],25,168292,DB00544,Fluorouracil
,1617631,Maximum tolerable plasma steady state concentrations,Maximum tolerable plasma steady state concentrations with a 24-h infusion (2000 mg/kg/24 h) were no greater than 25 micrograms/ml (0.18 mM).,L-histidinol: preclinical therapeutic studies in combination with antitumor agents and pharmacokinetic studies in mice. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1617631/),mM,0.18,168293,DB00544,Fluorouracil
,24709212,bioavailability,In vivo pellet coating led to reduced drug bioavailability and enhanced drug accumulation at colon (179.13 μg 5-FU/g rat colon content vs 4.66 μg/g of conventional in vitro film-coated pellets at 15 mg/kg dose).,Oral 5-fluorouracil colon-specific delivery through in vivo pellet coating for colon cancer and aberrant crypt foci treatment. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24709212/),μg,179.13,168459,DB00544,Fluorouracil
,24709212,bioavailability,In vivo pellet coating led to reduced drug bioavailability and enhanced drug accumulation at colon (179.13 μg 5-FU/g rat colon content vs 4.66 μg/g of conventional in vitro film-coated pellets at 15 mg/kg dose).,Oral 5-fluorouracil colon-specific delivery through in vivo pellet coating for colon cancer and aberrant crypt foci treatment. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24709212/),[μg] / [g],4.66,168460,DB00544,Fluorouracil
,7748192,bioavailability,The bioavailability of 5-FP given orally was 100% at a dosage of 25 mg/kg and 78% at a dosage of 50 mg/kg.,"5-Fluoro-2-pyrimidinone, a liver aldehyde oxidase-activated prodrug of 5-fluorouracil. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7748192/),%,100,170033,DB00544,Fluorouracil
,7748192,bioavailability,The bioavailability of 5-FP given orally was 100% at a dosage of 25 mg/kg and 78% at a dosage of 50 mg/kg.,"5-Fluoro-2-pyrimidinone, a liver aldehyde oxidase-activated prodrug of 5-fluorouracil. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7748192/),%,78,170034,DB00544,Fluorouracil
,7748192,steady-state level,"The resulting 5-FU was measured at a steady-state level of 40-70 microM in plasma, at a dosage of 25 mg/kg, that was sustained for at least 4 hr.","5-Fluoro-2-pyrimidinone, a liver aldehyde oxidase-activated prodrug of 5-fluorouracil. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7748192/),μM,40-70,170035,DB00544,Fluorouracil
,28220020,OS,"Median OS was 67.4 weeks on RAM + CAP, 62.1 weeks on ICR + CAP, and 71.6 weeks on CAP (HRs: 1.833, p = .0283, RAM + CAP versus CAP; 1.468, p = .1550, ICR + CAP versus CAP).",Randomized Phase II Study of Ramucirumab or Icrucumab in Combination with Capecitabine in Patients with Previously Treated Locally Advanced or Metastatic Breast Cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28220020/),weeks,67.4,170229,DB00544,Fluorouracil
,28220020,OS,"Median OS was 67.4 weeks on RAM + CAP, 62.1 weeks on ICR + CAP, and 71.6 weeks on CAP (HRs: 1.833, p = .0283, RAM + CAP versus CAP; 1.468, p = .1550, ICR + CAP versus CAP).",Randomized Phase II Study of Ramucirumab or Icrucumab in Combination with Capecitabine in Patients with Previously Treated Locally Advanced or Metastatic Breast Cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28220020/),weeks,62.1,170230,DB00544,Fluorouracil
,28220020,OS,"Median OS was 67.4 weeks on RAM + CAP, 62.1 weeks on ICR + CAP, and 71.6 weeks on CAP (HRs: 1.833, p = .0283, RAM + CAP versus CAP; 1.468, p = .1550, ICR + CAP versus CAP).",Randomized Phase II Study of Ramucirumab or Icrucumab in Combination with Capecitabine in Patients with Previously Treated Locally Advanced or Metastatic Breast Cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28220020/),weeks,71.6,170231,DB00544,Fluorouracil
,28804517,progression-free survival,"It is the first, second-line treatment approved by the US Food and Drug Administration to treat patients with MPC based on results of the NAnoliPOsomaL Irinotecan (NAPOLI-1) study, which showed that this regimen significantly prolonged progression-free survival (3.1 months versus 1.5 months) and overall survival (6.2 months versus 4.1 months) compared with 5-FU/folinic acid alone.",Update on the role of nanoliposomal irinotecan in the treatment of metastatic pancreatic cancer. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28804517/),month,3.1,170253,DB00544,Fluorouracil
,28804517,progression-free survival,"It is the first, second-line treatment approved by the US Food and Drug Administration to treat patients with MPC based on results of the NAnoliPOsomaL Irinotecan (NAPOLI-1) study, which showed that this regimen significantly prolonged progression-free survival (3.1 months versus 1.5 months) and overall survival (6.2 months versus 4.1 months) compared with 5-FU/folinic acid alone.",Update on the role of nanoliposomal irinotecan in the treatment of metastatic pancreatic cancer. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28804517/),month,1.5,170254,DB00544,Fluorouracil
,28804517,overall survival,"It is the first, second-line treatment approved by the US Food and Drug Administration to treat patients with MPC based on results of the NAnoliPOsomaL Irinotecan (NAPOLI-1) study, which showed that this regimen significantly prolonged progression-free survival (3.1 months versus 1.5 months) and overall survival (6.2 months versus 4.1 months) compared with 5-FU/folinic acid alone.",Update on the role of nanoliposomal irinotecan in the treatment of metastatic pancreatic cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28804517/),month,6.2,170255,DB00544,Fluorouracil
,28804517,overall survival,"It is the first, second-line treatment approved by the US Food and Drug Administration to treat patients with MPC based on results of the NAnoliPOsomaL Irinotecan (NAPOLI-1) study, which showed that this regimen significantly prolonged progression-free survival (3.1 months versus 1.5 months) and overall survival (6.2 months versus 4.1 months) compared with 5-FU/folinic acid alone.",Update on the role of nanoliposomal irinotecan in the treatment of metastatic pancreatic cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28804517/),month,4.1,170256,DB00544,Fluorouracil
,24452393,elimination half-life,The elimination half-life was approximately 2 h.,"First-in-human, phase I dose-escalation study of single and multiple doses of a first-in-class enhancer of fluoropyrimidines, a dUTPase inhibitor (TAS-114) in healthy male volunteers. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/24452393/),h,2,170307,DB00544,Fluorouracil
,20482808,mean residence time (MRT),"In the pharmacokinetic study, the 5-FU-loaded PEG-hydrogel gave a mean residence time (MRT) of 8.0 h and the elimination half-life of 0.9 h; these values were 14- and 6-fold, respectively, longer than those for the free solution of 5-FU (p < 0.05).",Pharmacokinetic properties and antitumor efficacy of the 5-fluorouracil loaded PEG-hydrogel. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20482808/),h,8.0,170624,DB00544,Fluorouracil
,20482808,elimination half-life,"In the pharmacokinetic study, the 5-FU-loaded PEG-hydrogel gave a mean residence time (MRT) of 8.0 h and the elimination half-life of 0.9 h; these values were 14- and 6-fold, respectively, longer than those for the free solution of 5-FU (p < 0.05).",Pharmacokinetic properties and antitumor efficacy of the 5-fluorouracil loaded PEG-hydrogel. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/20482808/),h,0.9,170625,DB00544,Fluorouracil
,12942110,area under the curve (AUC(0-10 h)),The area under the curve (AUC(0-10 h)) of 5-FU on day 5 was 728+/-113 ng h ml(-1) for PVI of 5-FU and 1364+/-374 ng h ml(-1) for S-1.,"Plasma concentrations of 5-fluorouracil and F-beta-alanine following oral administration of S-1, a dihydropyrimidine dehydrogenase inhibitory fluoropyrimidine, as compared with protracted venous infusion of 5-fluorouracil. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12942110/),[h·ng] / [ml],728,170962,DB00544,Fluorouracil
,12942110,area under the curve (AUC(0-10 h)),The area under the curve (AUC(0-10 h)) of 5-FU on day 5 was 728+/-113 ng h ml(-1) for PVI of 5-FU and 1364+/-374 ng h ml(-1) for S-1.,"Plasma concentrations of 5-fluorouracil and F-beta-alanine following oral administration of S-1, a dihydropyrimidine dehydrogenase inhibitory fluoropyrimidine, as compared with protracted venous infusion of 5-fluorouracil. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12942110/),[h·ng] / [ml],1364,170963,DB00544,Fluorouracil
,12942110,ratio of the AUC(0-10 h),The median 5-FU PVI : S-1 ratio of the AUC(0-10 h) of 5-FU was 1.9.,"Plasma concentrations of 5-fluorouracil and F-beta-alanine following oral administration of S-1, a dihydropyrimidine dehydrogenase inhibitory fluoropyrimidine, as compared with protracted venous infusion of 5-fluorouracil. ",AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12942110/),,1.9,170964,DB00544,Fluorouracil
,12942110,AUC(0-10 h),"The AUC(0-10 h) of FBAL on day 5 of PVI of 5-FU was 9465+/-3225 ng h ml(-1), AUC(0-10 h), as compared with 1725+/-605 ng h ml(-1) on day 5 of S-1 treatment.","Plasma concentrations of 5-fluorouracil and F-beta-alanine following oral administration of S-1, a dihydropyrimidine dehydrogenase inhibitory fluoropyrimidine, as compared with protracted venous infusion of 5-fluorouracil. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12942110/),[h·ng] / [ml],9465,170965,DB00544,Fluorouracil
,12942110,AUC(0-10 h),"The AUC(0-10 h) of FBAL on day 5 of PVI of 5-FU was 9465+/-3225 ng h ml(-1), AUC(0-10 h), as compared with 1725+/-605 ng h ml(-1) on day 5 of S-1 treatment.","Plasma concentrations of 5-fluorouracil and F-beta-alanine following oral administration of S-1, a dihydropyrimidine dehydrogenase inhibitory fluoropyrimidine, as compared with protracted venous infusion of 5-fluorouracil. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12942110/),[h·ng] / [ml],1725,170966,DB00544,Fluorouracil
,12942110,AUC(0-10 h),The AUC(0-10 h) of uracil on day 5 was 252+/-60 ng h ml(-1) with PVI of 5-FU and 12 582+/-3060 ng h ml(-1) with S-1.,"Plasma concentrations of 5-fluorouracil and F-beta-alanine following oral administration of S-1, a dihydropyrimidine dehydrogenase inhibitory fluoropyrimidine, as compared with protracted venous infusion of 5-fluorouracil. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12942110/),[h·ng] / [ml],252,170967,DB00544,Fluorouracil
,12942110,AUC(0-10 h),The AUC(0-10 h) of uracil on day 5 was 252+/-60 ng h ml(-1) with PVI of 5-FU and 12 582+/-3060 ng h ml(-1) with S-1.,"Plasma concentrations of 5-fluorouracil and F-beta-alanine following oral administration of S-1, a dihydropyrimidine dehydrogenase inhibitory fluoropyrimidine, as compared with protracted venous infusion of 5-fluorouracil. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12942110/),[h·ng] / [ml],12 582,170968,DB00544,Fluorouracil
,7825967,overall,The overall CT-scan response rate of 85% was obtained with a haematological dose-limiting toxicity: neutropenia and thrombopenia grade 3-4 of 23% and 30% respectively.,"Pharmacokinetic study in carboplatin, cisplatin and 5-fluorouracil regimen for advanced oesophageal cancer. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7825967/),%,85,170998,DB00544,Fluorouracil
,3971391,plasma beta-half-lives,"In pharmacokinetic studies in five patients, both schedules produced prolonged plasma beta-half-lives of 5-FU (96-189 minutes).",Phase I evaluation and pharmacokinetic study of weekly iv thymidine and 5-FU in patients with advanced colorectal carcinoma. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3971391/),min,96-189,171199,DB00544,Fluorouracil
,17348458,survival,"Median survival was 15.5 months for colorectal cancer, 12.","Phase II study of regional chemotherapy using the hypoxic abdominal perfusion technique in advanced abdominal carcinoma. 5-FU pharmacokinetics, complications and outcome. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17348458/),month,15.5,171319,DB00544,Fluorouracil
,7964939,activity,"Mean and median DPD activity values were 0.222 and 0.211 nmol/min/mg protein, respectively (range, 0.065 to 0.559).",Population study of dihydropyrimidine dehydrogenase in cancer patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7964939/),[nM] / [mg·min],0.222,171631,DB00544,Fluorouracil
,7964939,activity,"Mean and median DPD activity values were 0.222 and 0.211 nmol/min/mg protein, respectively (range, 0.065 to 0.559).",Population study of dihydropyrimidine dehydrogenase in cancer patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7964939/),[nM] / [mg·min],0.211,171632,DB00544,Fluorouracil
,21695438,PFS,"After a median follow-up duration of 8.6 months (range, 3.7-14.2 months), median PFS was 3.9 months (95% CI, 0.8-7.0 months) and median OS was 10.4 months (95% CI, 0-22.4 months).",Phase 1 trial of S-1 in combination with sorafenib for patients with advanced hepatocellular carcinoma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21695438/),month,3.9,171646,DB00544,Fluorouracil
,21695438,OS,"After a median follow-up duration of 8.6 months (range, 3.7-14.2 months), median PFS was 3.9 months (95% CI, 0.8-7.0 months) and median OS was 10.4 months (95% CI, 0-22.4 months).",Phase 1 trial of S-1 in combination with sorafenib for patients with advanced hepatocellular carcinoma. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21695438/),month,10,171647,DB00544,Fluorouracil
,9554592,MTD,The MTD of oral levamisole was 100 mg/m2 administered three times a day concurrently with 450 mg/m2 per day intravenous 5-FU for 5 consecutive days.,Clinical and pharmacokinetic studies of high-dose levamisole in combination with 5-fluorouracil in patients with advanced cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9554592/),[mg] / [m2],100,172837,DB00544,Fluorouracil
,9554592,Peak plasma concentrations,Peak plasma concentrations of 1 microg/ml (range 0.6-1.3 microg/ml) were achieved 90 min (range 60-360 min) after an oral dose of 100 mg/m2 levamisole with a 3.5-fold accumulation noted following 4 days of administration.,Clinical and pharmacokinetic studies of high-dose levamisole in combination with 5-fluorouracil in patients with advanced cancer. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9554592/),[μg] / [ml],1,172838,DB00544,Fluorouracil
,10637237,half-life (t(1/2)),The intratumoral half-life (t(1/2)) of 5-FU in these tumors ranged from 18.8 minutes to 42.3 minutes.,Enhancement of fluorouracil uptake in human colorectal and gastric cancers by interferon or by high-dose methotrexate: An in vivo human study using noninvasive (19)F-magnetic resonance spectroscopy. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10637237/),min,18.8,173094,DB00544,Fluorouracil
,10637237,half-life (t(1/2)),The intratumoral half-life (t(1/2)) of 5-FU in these tumors ranged from 18.8 minutes to 42.3 minutes.,Enhancement of fluorouracil uptake in human colorectal and gastric cancers by interferon or by high-dose methotrexate: An in vivo human study using noninvasive (19)F-magnetic resonance spectroscopy. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10637237/),min,42.3,173095,DB00544,Fluorouracil
,22565063,Material,"Material recoveries from the liquid-liquid extraction technique were 97-110% and 86-91% for tegafur and 5-FU, respectively.",Development and utilization of a combined LC-UV and LC-MS/MS method for the simultaneous analysis of tegafur and 5-fluorouracil in human plasma to support a phase I clinical study of oral UFT®/leucovorin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22565063/),%,97-110,173148,DB00544,Fluorouracil
,22565063,recoveries,"Material recoveries from the liquid-liquid extraction technique were 97-110% and 86-91% for tegafur and 5-FU, respectively.",Development and utilization of a combined LC-UV and LC-MS/MS method for the simultaneous analysis of tegafur and 5-fluorouracil in human plasma to support a phase I clinical study of oral UFT®/leucovorin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22565063/),%,97-110,173149,DB00544,Fluorouracil
,22565063,recoveries,"Material recoveries from the liquid-liquid extraction technique were 97-110% and 86-91% for tegafur and 5-FU, respectively.",Development and utilization of a combined LC-UV and LC-MS/MS method for the simultaneous analysis of tegafur and 5-fluorouracil in human plasma to support a phase I clinical study of oral UFT®/leucovorin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22565063/),%,86-91,173150,DB00544,Fluorouracil
,30599225,entrapment efficiency,"The LC-POSS MIPs had extended release of the template molecules over 13.4 h with entrapment efficiency of 20.53%, diffusion coefficient of 2.83 × 10-11 cm2 s-1, and diffusion exponent of 0.84.",Floating molecularly imprinted polymers based on liquid crystalline and polyhedral oligomeric silsesquioxanes for capecitabine sustained release. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30599225/),%,20.53,173664,DB00544,Fluorouracil
,30599225,diffusion coefficient,"The LC-POSS MIPs had extended release of the template molecules over 13.4 h with entrapment efficiency of 20.53%, diffusion coefficient of 2.83 × 10-11 cm2 s-1, and diffusion exponent of 0.84.",Floating molecularly imprinted polymers based on liquid crystalline and polyhedral oligomeric silsesquioxanes for capecitabine sustained release. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30599225/),[cm2] / [s],2.83 × 10-11,173665,DB00544,Fluorouracil
,30599225,diffusion exponent,"The LC-POSS MIPs had extended release of the template molecules over 13.4 h with entrapment efficiency of 20.53%, diffusion coefficient of 2.83 × 10-11 cm2 s-1, and diffusion exponent of 0.84.",Floating molecularly imprinted polymers based on liquid crystalline and polyhedral oligomeric silsesquioxanes for capecitabine sustained release. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30599225/),,0.84,173666,DB00544,Fluorouracil
,8130783,half-lives (t1/2),"The half-lives (t1/2) of 5'-DFUR and 5-FU in plasma were 16.8 and 11.5 min, respectively.","Differential effects of acyclothymidine, a potent pyrimidine nucleoside phosphorylase inhibitor, on the pharmacokinetics of doxifluridine in rabbits via oral administration. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8130783/),min,16.8,174094,DB00544,Fluorouracil
,8130783,half-lives (t1/2),"The half-lives (t1/2) of 5'-DFUR and 5-FU in plasma were 16.8 and 11.5 min, respectively.","Differential effects of acyclothymidine, a potent pyrimidine nucleoside phosphorylase inhibitor, on the pharmacokinetics of doxifluridine in rabbits via oral administration. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8130783/),min,11.5,174095,DB00544,Fluorouracil
,8130783,AUC (area under the plasma concentration-time curve),AUC (area under the plasma concentration-time curve) of 5'-DFUR and 5-FU following the oral administration of 5'-DFUR (50 mg/kg) was 1710 and 24.3 micrograms.,"Differential effects of acyclothymidine, a potent pyrimidine nucleoside phosphorylase inhibitor, on the pharmacokinetics of doxifluridine in rabbits via oral administration. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8130783/),μg,1710,174096,DB00544,Fluorouracil
,8130783,AUC (area under the plasma concentration-time curve),AUC (area under the plasma concentration-time curve) of 5'-DFUR and 5-FU following the oral administration of 5'-DFUR (50 mg/kg) was 1710 and 24.3 micrograms.,"Differential effects of acyclothymidine, a potent pyrimidine nucleoside phosphorylase inhibitor, on the pharmacokinetics of doxifluridine in rabbits via oral administration. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8130783/),μg,24.3,174097,DB00544,Fluorouracil
,8130783,AUC,"After the oral co-administration of 5'-DFUR and AcyT (at a molar ratio of 1:1), the AUC values for 5'-DFUR and 5-FU increased to 2680 and to 121.1 micrograms.","Differential effects of acyclothymidine, a potent pyrimidine nucleoside phosphorylase inhibitor, on the pharmacokinetics of doxifluridine in rabbits via oral administration. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8130783/),μg,2680,174098,DB00544,Fluorouracil
,8130783,AUC,"After the oral co-administration of 5'-DFUR and AcyT (at a molar ratio of 1:1), the AUC values for 5'-DFUR and 5-FU increased to 2680 and to 121.1 micrograms.","Differential effects of acyclothymidine, a potent pyrimidine nucleoside phosphorylase inhibitor, on the pharmacokinetics of doxifluridine in rabbits via oral administration. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8130783/),μg,121.1,174099,DB00544,Fluorouracil
,23517808,MTD,The MTD of capecitabine was determined to be 825 mg/m(2) b.i.d.,Simultaneous integrated boost-intensity modulated radiation therapy with concomitant capecitabine and mitomycin C for locally advanced anal carcinoma: a phase 1 study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23517808/),[mg] / [m],825,174735,DB00544,Fluorouracil
,8336197,MTD,The MTD of PCI 5-FU by our criteria that could be combined with IFN-alpha was 250 mg/m2/d.,"Phase I trial of low-dose, prolonged continuous infusion fluorouracil plus interferon-alfa: evidence for enhanced fluorouracil toxicity without pharmacokinetic perturbation. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8336197/),mg,250,174986,DB00544,Fluorouracil
,2231760,alpha half-life,"A dose-related increase in peak plasma levels of AZT was observed, and the alpha half-life of AZT in plasma (75 min) was unaffected by these high doses.","Oral zidovudine, continuous-infusion fluorouracil, and oral leucovorin calcium: a phase I study. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2231760/),min,75,175020,DB00544,Fluorouracil
,27417318,half-,"The half-life after the end of the infusion (t 1/2, 4-8 h) of 5-FU in the rats given the bolus injection was significantly longer than in those that had been given saline, and it increased with increasing 5-FU bolus injection dosage (r = 0.801, p < 0.01).",Effects of a bolus injection of 5-fluorouracil on dihydropyrimidine dehydrogenase activity in rats receiving continuous infusion of 5-fluorouracil. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27417318/),h,4-8,175256,DB00544,Fluorouracil
,12114411,maximum tolerated dose,The maximum tolerated dose was 50 mg/m(2)/day.,Phase I and pharmacokinetic study of once daily oral administration of S-1 in patients with advanced cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12114411/),mg,50,175613,DB00544,Fluorouracil
,18357738,excretion,"The excretion of 5-Fu in urine and feces amounted to 0.0065% and 0.063% of the dose, respectively.",[Tissue distribution and excretion of 5-fluorouracil from indomethacin 5-fluorouracil-1-ylmethylester in rats]. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18357738/),%,0.0065,175633,DB00544,Fluorouracil
,18357738,excretion,"The excretion of 5-Fu in urine and feces amounted to 0.0065% and 0.063% of the dose, respectively.",[Tissue distribution and excretion of 5-fluorouracil from indomethacin 5-fluorouracil-1-ylmethylester in rats]. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18357738/),%,0.063,175634,DB00544,Fluorouracil
,22696869,t1/2alpha,"There were significant differences in the pharmacokinetic parameters of 5-FU and CP between in depression model rats group and in the normal control group (p < 0.05), except t1/2alpha (p > 0.05) for CP pharmacokinetics in depression model rats group and in the normal control rats group, with the value of those was 0.07 and 0.09 h.",Pharmacokinetics of 5-fluorouracil and cyclophosphamide in depression rats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22696869/),h,0.07,176248,DB00544,Fluorouracil
,22696869,t1/2alpha,"There were significant differences in the pharmacokinetic parameters of 5-FU and CP between in depression model rats group and in the normal control group (p < 0.05), except t1/2alpha (p > 0.05) for CP pharmacokinetics in depression model rats group and in the normal control rats group, with the value of those was 0.07 and 0.09 h.",Pharmacokinetics of 5-fluorouracil and cyclophosphamide in depression rats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22696869/),h,0.09,176249,DB00544,Fluorouracil
,24960402,Cmin,Mean pertuzumab Cmin at day 43 was 40.0 μg ml(-1) (s.d.: 17.3) in Arm A and 62.7 μg ml(-1) (29.1) in Arm B.,"A phase IIa dose-finding and safety study of first-line pertuzumab in combination with trastuzumab, capecitabine and cisplatin in patients with HER2-positive advanced gastric cancer. ",Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24960402/),[μg] / [ml],40.0,176260,DB00544,Fluorouracil
,24960402,Cmin,Mean pertuzumab Cmin at day 43 was 40.0 μg ml(-1) (s.d.: 17.3) in Arm A and 62.7 μg ml(-1) (29.1) in Arm B.,"A phase IIa dose-finding and safety study of first-line pertuzumab in combination with trastuzumab, capecitabine and cisplatin in patients with HER2-positive advanced gastric cancer. ",Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24960402/),[μg] / [ml],62.7,176261,DB00544,Fluorouracil
,12877360,Cmax,"Comparing day 1 with day 4, Cmax of platinum in PUF was significantly increased (84 +/- 13 ng/ml vs. 131 +/- 22 ng/ml, P = 0.012) as well as AUC0-24h of platinum in PUF (0.97 +/- 0.29 microg x h/ml vs. 1.90 +/- 0.44 microg x h/ml, P = 0.018).",Pharmacokinetics of oxaliplatin during chronomodulated infusion in metastatic gastrointestinal cancer patients: a pilot investigation with preliminary results. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12877360/),[ng] / [ml],84,177425,DB00544,Fluorouracil
,12877360,Cmax,"Comparing day 1 with day 4, Cmax of platinum in PUF was significantly increased (84 +/- 13 ng/ml vs. 131 +/- 22 ng/ml, P = 0.012) as well as AUC0-24h of platinum in PUF (0.97 +/- 0.29 microg x h/ml vs. 1.90 +/- 0.44 microg x h/ml, P = 0.018).",Pharmacokinetics of oxaliplatin during chronomodulated infusion in metastatic gastrointestinal cancer patients: a pilot investigation with preliminary results. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12877360/),[ng] / [ml],131,177426,DB00544,Fluorouracil
,12877360,AUC0-24h,"Comparing day 1 with day 4, Cmax of platinum in PUF was significantly increased (84 +/- 13 ng/ml vs. 131 +/- 22 ng/ml, P = 0.012) as well as AUC0-24h of platinum in PUF (0.97 +/- 0.29 microg x h/ml vs. 1.90 +/- 0.44 microg x h/ml, P = 0.018).",Pharmacokinetics of oxaliplatin during chronomodulated infusion in metastatic gastrointestinal cancer patients: a pilot investigation with preliminary results. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12877360/),[h·μg] / [ml],0.97,177427,DB00544,Fluorouracil
,12877360,AUC0-24h,"Comparing day 1 with day 4, Cmax of platinum in PUF was significantly increased (84 +/- 13 ng/ml vs. 131 +/- 22 ng/ml, P = 0.012) as well as AUC0-24h of platinum in PUF (0.97 +/- 0.29 microg x h/ml vs. 1.90 +/- 0.44 microg x h/ml, P = 0.018).",Pharmacokinetics of oxaliplatin during chronomodulated infusion in metastatic gastrointestinal cancer patients: a pilot investigation with preliminary results. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12877360/),[h·μg] / [ml],1.90,177428,DB00544,Fluorouracil
,20567127,serum ultrafiltrate concentrations,"The serum ultrafiltrate concentrations of platinum were 800, 1, 000, 300, <200, and <200 ng/mLat 1, 2, 3 hr, 1 week, and 2 weeks after the start of infusion, respectively, which were closely comparable with the population pharmacokinetic data in Japanese patients with normal renal function.",[Nephrotoxicity induced by repeated cycles of oxaliplatin in a Japanese colorectal cancer patient with moderate renal impairment]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20567127/),[ng] / [ml],800,177568,DB00544,Fluorouracil
,20567127,serum ultrafiltrate concentrations,"The serum ultrafiltrate concentrations of platinum were 800, 1, 000, 300, <200, and <200 ng/mLat 1, 2, 3 hr, 1 week, and 2 weeks after the start of infusion, respectively, which were closely comparable with the population pharmacokinetic data in Japanese patients with normal renal function.",[Nephrotoxicity induced by repeated cycles of oxaliplatin in a Japanese colorectal cancer patient with moderate renal impairment]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20567127/),[ng] / [ml],"1, 000",177569,DB00544,Fluorouracil
,20567127,serum ultrafiltrate concentrations,"The serum ultrafiltrate concentrations of platinum were 800, 1, 000, 300, <200, and <200 ng/mLat 1, 2, 3 hr, 1 week, and 2 weeks after the start of infusion, respectively, which were closely comparable with the population pharmacokinetic data in Japanese patients with normal renal function.",[Nephrotoxicity induced by repeated cycles of oxaliplatin in a Japanese colorectal cancer patient with moderate renal impairment]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20567127/),[ng] / [ml],300,177570,DB00544,Fluorouracil
<,20567127,serum ultrafiltrate concentrations,"The serum ultrafiltrate concentrations of platinum were 800, 1, 000, 300, <200, and <200 ng/mLat 1, 2, 3 hr, 1 week, and 2 weeks after the start of infusion, respectively, which were closely comparable with the population pharmacokinetic data in Japanese patients with normal renal function.",[Nephrotoxicity induced by repeated cycles of oxaliplatin in a Japanese colorectal cancer patient with moderate renal impairment]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20567127/),[ng] / [ml],200,177571,DB00544,Fluorouracil
,16283312,Response rate,"Response rate was 30%, and disease stabilization rate was 64% (all dose levels included).",Combination vinorelbine and capecitabine for metastatic breast cancer using a non-body surface area dosing scheme. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16283312/),%,30,177794,DB00544,Fluorouracil
,1798712,absolute bioavailability,"The absolute bioavailability, was 78% for p.o. and 57% for the i.a. administration of 1 respectively, and 98% for p.o. and 61% for the i.a. administration of 1 (given as 2), Accordingly, p.o. administration of both substances leads to therapeutical sufficiently high plasma levels with a steady state of css = 2.9 micrograms/ml/tss = 14 min for 1 and css = 3.5 micrograms/ml/tss = 20 min for 2.","[Comparative bioavailability of fluorouracil and its prodrug, ftorafur, following intra-arterial, intravenous and preoral administration]. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1798712/),%,78,178400,DB00544,Fluorouracil
,1798712,absolute bioavailability,"The absolute bioavailability, was 78% for p.o. and 57% for the i.a. administration of 1 respectively, and 98% for p.o. and 61% for the i.a. administration of 1 (given as 2), Accordingly, p.o. administration of both substances leads to therapeutical sufficiently high plasma levels with a steady state of css = 2.9 micrograms/ml/tss = 14 min for 1 and css = 3.5 micrograms/ml/tss = 20 min for 2.","[Comparative bioavailability of fluorouracil and its prodrug, ftorafur, following intra-arterial, intravenous and preoral administration]. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1798712/),%,57,178401,DB00544,Fluorouracil
,1798712,absolute bioavailability,"The absolute bioavailability, was 78% for p.o. and 57% for the i.a. administration of 1 respectively, and 98% for p.o. and 61% for the i.a. administration of 1 (given as 2), Accordingly, p.o. administration of both substances leads to therapeutical sufficiently high plasma levels with a steady state of css = 2.9 micrograms/ml/tss = 14 min for 1 and css = 3.5 micrograms/ml/tss = 20 min for 2.","[Comparative bioavailability of fluorouracil and its prodrug, ftorafur, following intra-arterial, intravenous and preoral administration]. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1798712/),%,98,178402,DB00544,Fluorouracil
,1798712,absolute bioavailability,"The absolute bioavailability, was 78% for p.o. and 57% for the i.a. administration of 1 respectively, and 98% for p.o. and 61% for the i.a. administration of 1 (given as 2), Accordingly, p.o. administration of both substances leads to therapeutical sufficiently high plasma levels with a steady state of css = 2.9 micrograms/ml/tss = 14 min for 1 and css = 3.5 micrograms/ml/tss = 20 min for 2.","[Comparative bioavailability of fluorouracil and its prodrug, ftorafur, following intra-arterial, intravenous and preoral administration]. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1798712/),%,61,178403,DB00544,Fluorouracil
,1798712,steady state of css,"The absolute bioavailability, was 78% for p.o. and 57% for the i.a. administration of 1 respectively, and 98% for p.o. and 61% for the i.a. administration of 1 (given as 2), Accordingly, p.o. administration of both substances leads to therapeutical sufficiently high plasma levels with a steady state of css = 2.9 micrograms/ml/tss = 14 min for 1 and css = 3.5 micrograms/ml/tss = 20 min for 2.","[Comparative bioavailability of fluorouracil and its prodrug, ftorafur, following intra-arterial, intravenous and preoral administration]. ",Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1798712/),[μg] / [ml·t],2.9,178404,DB00544,Fluorouracil
,1798712,css,"The absolute bioavailability, was 78% for p.o. and 57% for the i.a. administration of 1 respectively, and 98% for p.o. and 61% for the i.a. administration of 1 (given as 2), Accordingly, p.o. administration of both substances leads to therapeutical sufficiently high plasma levels with a steady state of css = 2.9 micrograms/ml/tss = 14 min for 1 and css = 3.5 micrograms/ml/tss = 20 min for 2.","[Comparative bioavailability of fluorouracil and its prodrug, ftorafur, following intra-arterial, intravenous and preoral administration]. ",Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1798712/),[μg] / [ml·t],3.5,178405,DB00544,Fluorouracil
,6867473,degradation half-life,"The degradation half-life of DFUG was 4.04 min when DFUG was incubated in rat plasma at 37 degrees C, though DFUG was considerably stable in buffers having different pH values, pH 1, 5 and 7.4.",Conversion of a novel 5-fluorouracil (5-FU) derivative to 5-FU in rats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6867473/),min,4.04,179309,DB00544,Fluorouracil
,16291583,response rate,"The response rate was 17% (95% CI 10-23), median time to progression (TTP) was 5.4 months (95% CI 4.6-6.4) and median survival 9.5 months (95% CI 8.5-11.2).",Short-time infusion of oxaliplatin in combination with capecitabine (XELOX30) as second-line therapy in patients with advanced colorectal cancer after failure to irinotecan and 5-fluorouracil. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16291583/),%,17,179683,DB00544,Fluorouracil
,16291583,time to progression (TTP),"The response rate was 17% (95% CI 10-23), median time to progression (TTP) was 5.4 months (95% CI 4.6-6.4) and median survival 9.5 months (95% CI 8.5-11.2).",Short-time infusion of oxaliplatin in combination with capecitabine (XELOX30) as second-line therapy in patients with advanced colorectal cancer after failure to irinotecan and 5-fluorouracil. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16291583/),month,5.4,179684,DB00544,Fluorouracil
,16291583,survival,"The response rate was 17% (95% CI 10-23), median time to progression (TTP) was 5.4 months (95% CI 4.6-6.4) and median survival 9.5 months (95% CI 8.5-11.2).",Short-time infusion of oxaliplatin in combination with capecitabine (XELOX30) as second-line therapy in patients with advanced colorectal cancer after failure to irinotecan and 5-fluorouracil. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16291583/),month,9.5,179685,DB00544,Fluorouracil
,1451233,half-life,"After a 10-mg intraventricular dose, the disappearance of the drug from ventricular cerebrospinal fluid was monoexponential, the half-life being 51 min; the area under the concentration-time curve (AUC) being greater than 18 mM h-1; and the peak ventricular 5FU concentrations ranging between 10 and 15 mM.",Intrathecal 5-fluorouracil in the rhesus monkey. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1451233/),min,51,180083,DB00544,Fluorouracil
greater,1451233,area under the concentration-time curve (AUC),"After a 10-mg intraventricular dose, the disappearance of the drug from ventricular cerebrospinal fluid was monoexponential, the half-life being 51 min; the area under the concentration-time curve (AUC) being greater than 18 mM h-1; and the peak ventricular 5FU concentrations ranging between 10 and 15 mM.",Intrathecal 5-fluorouracil in the rhesus monkey. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1451233/),[mM] / [h],18,180084,DB00544,Fluorouracil
,1451233,peak ventricular 5FU concentrations,"After a 10-mg intraventricular dose, the disappearance of the drug from ventricular cerebrospinal fluid was monoexponential, the half-life being 51 min; the area under the concentration-time curve (AUC) being greater than 18 mM h-1; and the peak ventricular 5FU concentrations ranging between 10 and 15 mM.",Intrathecal 5-fluorouracil in the rhesus monkey. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1451233/),mM,10 and 15,180085,DB00544,Fluorouracil
,1451233,AUC,"After a 1-mg intralumbar dose, the AUC was 1235 microM h-1.",Intrathecal 5-fluorouracil in the rhesus monkey. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1451233/),[μM] / [h],1235,180086,DB00544,Fluorouracil
>,8840990,E(H),"BrdUrd and FUra were found to be highly extracted across the liver (E(H) > or = 0.65) at the regional dose rates studied, resulting in low values for the fraction of drug escaping presystemic hepatic elimination (F(H) < or = 0.35).",Regional pharmacokinetics of 5-bromo-2'-deoxyuridine and 5-fluorouracil in dogs: hepatic arterial versus portal venous infusions. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8840990/),,0.65,180408,DB00544,Fluorouracil
<,8840990,F(H),"BrdUrd and FUra were found to be highly extracted across the liver (E(H) > or = 0.65) at the regional dose rates studied, resulting in low values for the fraction of drug escaping presystemic hepatic elimination (F(H) < or = 0.35).",Regional pharmacokinetics of 5-bromo-2'-deoxyuridine and 5-fluorouracil in dogs: hepatic arterial versus portal venous infusions. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8840990/),,0.35,180409,DB00544,Fluorouracil
,8478667,steady-state plasma concentration (Css,"Interpatient pharmacokinetics showed that rIFN-a did not alter steady-state plasma concentration (Css; range, 0.77 +/- 0.35 mumol/L to 1.85 +/- 0.48 mumol/L), elimination half-life (t1/2; mean, 9.7 +/- 4.3 minutes), area under the concentration-versus-time curve (AUC; range, 93 to 224 mumol/L x hours), total-body clearance (CI; range, 1,172 to 3,236 mL/min), or volume of distribution (range, 11.9 to 49.2 L) of FUra.",Phase I and plasma pharmacokinetic study of infusional fluorouracil combined with recombinant interferon alfa-2b in patients with advanced cancer. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8478667/),[μM] / [l],0.77,180527,DB00544,Fluorouracil
,8478667,steady-state plasma concentration (Css,"Interpatient pharmacokinetics showed that rIFN-a did not alter steady-state plasma concentration (Css; range, 0.77 +/- 0.35 mumol/L to 1.85 +/- 0.48 mumol/L), elimination half-life (t1/2; mean, 9.7 +/- 4.3 minutes), area under the concentration-versus-time curve (AUC; range, 93 to 224 mumol/L x hours), total-body clearance (CI; range, 1,172 to 3,236 mL/min), or volume of distribution (range, 11.9 to 49.2 L) of FUra.",Phase I and plasma pharmacokinetic study of infusional fluorouracil combined with recombinant interferon alfa-2b in patients with advanced cancer. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8478667/),[μM] / [l],1.85,180528,DB00544,Fluorouracil
,8478667,elimination half-life (t1/2,"Interpatient pharmacokinetics showed that rIFN-a did not alter steady-state plasma concentration (Css; range, 0.77 +/- 0.35 mumol/L to 1.85 +/- 0.48 mumol/L), elimination half-life (t1/2; mean, 9.7 +/- 4.3 minutes), area under the concentration-versus-time curve (AUC; range, 93 to 224 mumol/L x hours), total-body clearance (CI; range, 1,172 to 3,236 mL/min), or volume of distribution (range, 11.9 to 49.2 L) of FUra.",Phase I and plasma pharmacokinetic study of infusional fluorouracil combined with recombinant interferon alfa-2b in patients with advanced cancer. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8478667/),min,9.7,180529,DB00544,Fluorouracil
,8478667,area under the concentration-versus-time curve (AUC,"Interpatient pharmacokinetics showed that rIFN-a did not alter steady-state plasma concentration (Css; range, 0.77 +/- 0.35 mumol/L to 1.85 +/- 0.48 mumol/L), elimination half-life (t1/2; mean, 9.7 +/- 4.3 minutes), area under the concentration-versus-time curve (AUC; range, 93 to 224 mumol/L x hours), total-body clearance (CI; range, 1,172 to 3,236 mL/min), or volume of distribution (range, 11.9 to 49.2 L) of FUra.",Phase I and plasma pharmacokinetic study of infusional fluorouracil combined with recombinant interferon alfa-2b in patients with advanced cancer. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8478667/),[μM] / [h·l],93 to 224,180530,DB00544,Fluorouracil
,8478667,total-body clearance (CI,"Interpatient pharmacokinetics showed that rIFN-a did not alter steady-state plasma concentration (Css; range, 0.77 +/- 0.35 mumol/L to 1.85 +/- 0.48 mumol/L), elimination half-life (t1/2; mean, 9.7 +/- 4.3 minutes), area under the concentration-versus-time curve (AUC; range, 93 to 224 mumol/L x hours), total-body clearance (CI; range, 1,172 to 3,236 mL/min), or volume of distribution (range, 11.9 to 49.2 L) of FUra.",Phase I and plasma pharmacokinetic study of infusional fluorouracil combined with recombinant interferon alfa-2b in patients with advanced cancer. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8478667/),[ml] / [min],"1,172 to 3,236",180531,DB00544,Fluorouracil
,8478667,volume of distribution,"Interpatient pharmacokinetics showed that rIFN-a did not alter steady-state plasma concentration (Css; range, 0.77 +/- 0.35 mumol/L to 1.85 +/- 0.48 mumol/L), elimination half-life (t1/2; mean, 9.7 +/- 4.3 minutes), area under the concentration-versus-time curve (AUC; range, 93 to 224 mumol/L x hours), total-body clearance (CI; range, 1,172 to 3,236 mL/min), or volume of distribution (range, 11.9 to 49.2 L) of FUra.",Phase I and plasma pharmacokinetic study of infusional fluorouracil combined with recombinant interferon alfa-2b in patients with advanced cancer. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8478667/),l,11.9 to 49.2,180532,DB00544,Fluorouracil
,8478667,Css,"The mean FUra Css after rIFN-a administration (1.31 mumol/L) was greater than that before rIFN-a administration (1.02 mumol/L, P < .0001).",Phase I and plasma pharmacokinetic study of infusional fluorouracil combined with recombinant interferon alfa-2b in patients with advanced cancer. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8478667/),[μM] / [l],1.31,180533,DB00544,Fluorouracil
,8478667,Css,"The mean FUra Css after rIFN-a administration (1.31 mumol/L) was greater than that before rIFN-a administration (1.02 mumol/L, P < .0001).",Phase I and plasma pharmacokinetic study of infusional fluorouracil combined with recombinant interferon alfa-2b in patients with advanced cancer. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8478667/),[μM] / [l],1.02,180534,DB00544,Fluorouracil
,1999851,maximum tolerated dose (MTD),The maximum tolerated dose (MTD) was 10 to 12 g/m2 for a single dose of uridine and 5 g/m2 for the multiple-dose regimen.,Clinical and pharmacologic study of orally administered uridine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1999851/),[g] / [m2],10 to 12,180578,DB00544,Fluorouracil
,1999851,maximum tolerated dose (MTD),The maximum tolerated dose (MTD) was 10 to 12 g/m2 for a single dose of uridine and 5 g/m2 for the multiple-dose regimen.,Clinical and pharmacologic study of orally administered uridine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1999851/),,5,180579,DB00544,Fluorouracil
,1999851,bioavailability,"At these doses, bioavailability of oral uridine ranged from 5.8% to 9.9%.",Clinical and pharmacologic study of orally administered uridine. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1999851/),%,5.8,180580,DB00544,Fluorouracil
,1999851,bioavailability,"At these doses, bioavailability of oral uridine ranged from 5.8% to 9.9%.",Clinical and pharmacologic study of orally administered uridine. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1999851/),%,9.9,180581,DB00544,Fluorouracil
,1999851,steady-state plasma uridine levels,"At the MTD of 5 g/m2 in the multiple-dose uridine schedule, steady-state plasma uridine levels of approximately 50 microM were achieved.",Clinical and pharmacologic study of orally administered uridine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1999851/),μM,50,180582,DB00544,Fluorouracil
,17695429,Overall response,"Overall response and disease control rates were 20% and 80%, respectively.",Phase I study of combination therapy with S-1 and weekly docetaxel for advanced gastric cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17695429/),%,20,180688,DB00544,Fluorouracil
,17695429,disease control rates,"Overall response and disease control rates were 20% and 80%, respectively.",Phase I study of combination therapy with S-1 and weekly docetaxel for advanced gastric cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17695429/),%,80,180689,DB00544,Fluorouracil
,17695429,response rate,The response rate at the RD (level 2) was 50%.,Phase I study of combination therapy with S-1 and weekly docetaxel for advanced gastric cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17695429/),%,50,180690,DB00544,Fluorouracil
,17695429,Overall survival,Overall survival was 9.4 months.,Phase I study of combination therapy with S-1 and weekly docetaxel for advanced gastric cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17695429/),month,9.4,180691,DB00544,Fluorouracil
,26718616,FUTP,"FUTP levels ranged between <LOD and 1.0 μM on day 1, and from 0.64 to 14 μM on day 14.",Exploring the intracellular pharmacokinetics of the 5-fluorouracil nucleotides during capecitabine treatment. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26718616/),μM,1.0,181324,DB00544,Fluorouracil
,26718616,FUTP,"FUTP levels ranged between <LOD and 1.0 μM on day 1, and from 0.64 to 14 μM on day 14.",Exploring the intracellular pharmacokinetics of the 5-fluorouracil nucleotides during capecitabine treatment. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26718616/),μM,0.64 to 14,181325,DB00544,Fluorouracil
,26718616,area under the FUTP concentration-time curve,The area under the FUTP concentration-time curve was significantly increased on day 14 of the treatment compared to day 1 (mean ± SD: 28 ± 19 μM h vs. 2.0 ± 1.9 μM h).,Exploring the intracellular pharmacokinetics of the 5-fluorouracil nucleotides during capecitabine treatment. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26718616/),h·μM,28,181326,DB00544,Fluorouracil
,26718616,area under the FUTP concentration-time curve,The area under the FUTP concentration-time curve was significantly increased on day 14 of the treatment compared to day 1 (mean ± SD: 28 ± 19 μM h vs. 2.0 ± 1.9 μM h).,Exploring the intracellular pharmacokinetics of the 5-fluorouracil nucleotides during capecitabine treatment. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26718616/),h·μM,2.0,181327,DB00544,Fluorouracil
,30121935,MTD,The MTD of paclitaxel was 90 mg/m2.,Phase I study of S-1 plus paclitaxel combination therapy as a first-line treatment in elderly patients with advanced non-small cell lung cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30121935/),[mg] / [m2],90,181464,DB00544,Fluorouracil
,30121935,RD,The RD for both S-1 and paclitaxel was 80 mg/m2 (DL 3).,Phase I study of S-1 plus paclitaxel combination therapy as a first-line treatment in elderly patients with advanced non-small cell lung cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30121935/),[mg] / [m2],80,181465,DB00544,Fluorouracil
,30121935,response rate,The response rate was 45.5% (8 of 15 patients achieved a partial response).,Phase I study of S-1 plus paclitaxel combination therapy as a first-line treatment in elderly patients with advanced non-small cell lung cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30121935/),%,45.5,181466,DB00544,Fluorouracil
,30121935,RD,"In conclusion, the RD of both S-1 and paclitaxel was 80 mg/m2 in the combination therapy for chemotherapy-naïve patients with advanced NSCLC.",Phase I study of S-1 plus paclitaxel combination therapy as a first-line treatment in elderly patients with advanced non-small cell lung cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30121935/),[mg] / [m2],80,181467,DB00544,Fluorouracil
,11840401,extraction ratios,"In contrast, the final 5-FU catabolite alpha-fluoro-beta-alanine (FBAL) accumulated to a concentration of 276 micromol/L on day 5 (approximately twofold higher than expected from the literature) despite good removal by hemodialysis with extraction ratios of 0.6 to 0.85 over the filter membrane.",Pharmacokinetics of 5-fluorouracil and its catabolites determined by 19F nuclear magnetic resonance spectroscopy for a patient on chronic hemodialysis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11840401/),,0.6 to 0.85,182968,DB00544,Fluorouracil
,2311173,rapid,"With a mean of 56.5 min, 1-CHO-THF exhibits a rapid body clearance of 222 ml/min, about 60% of which is caused by metabolism to CH3-THF and 40%, by renal excretion.","Pharmacokinetics of reduced folates after short-term infusion of d, 1-folinic acid. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2311173/),[ml] / [min],222,183012,DB00544,Fluorouracil
,2311173,body clearance,"With a mean of 56.5 min, 1-CHO-THF exhibits a rapid body clearance of 222 ml/min, about 60% of which is caused by metabolism to CH3-THF and 40%, by renal excretion.","Pharmacokinetics of reduced folates after short-term infusion of d, 1-folinic acid. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2311173/),[ml] / [min],222,183013,DB00544,Fluorouracil
,2311173,terminal half-life,"CH3-THF has a terminal half-life of 208 min and a total body clearance of 88.9 ml/min, which is essentially the same as the renal clearance.","Pharmacokinetics of reduced folates after short-term infusion of d, 1-folinic acid. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2311173/),min,208,183014,DB00544,Fluorouracil
,2311173,total body clearance,"CH3-THF has a terminal half-life of 208 min and a total body clearance of 88.9 ml/min, which is essentially the same as the renal clearance.","Pharmacokinetics of reduced folates after short-term infusion of d, 1-folinic acid. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2311173/),[ml] / [min],88.9,183015,DB00544,Fluorouracil
,2311173,AUC,"Due to the lower clearance of CH3-THF, its AUC (2,132 microM x min) exceeds that of 1-CHO-THF (1445 microM x min) by approximately 50%.","Pharmacokinetics of reduced folates after short-term infusion of d, 1-folinic acid. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2311173/),min·μM,"2,132",183016,DB00544,Fluorouracil
,2311173,AUC,"Due to the lower clearance of CH3-THF, its AUC (2,132 microM x min) exceeds that of 1-CHO-THF (1445 microM x min) by approximately 50%.","Pharmacokinetics of reduced folates after short-term infusion of d, 1-folinic acid. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2311173/),min·μM,1445,183017,DB00544,Fluorouracil
,2311173,total body,"In contrast to that of the reduced 1-folates, the total body and renal clearance of d-CHO-THF is very low, with values of 13.2 and 12.9 ml/min, respectively.","Pharmacokinetics of reduced folates after short-term infusion of d, 1-folinic acid. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2311173/),[ml] / [min],13.2,183018,DB00544,Fluorouracil
,2311173,renal clearance,"In contrast to that of the reduced 1-folates, the total body and renal clearance of d-CHO-THF is very low, with values of 13.2 and 12.9 ml/min, respectively.","Pharmacokinetics of reduced folates after short-term infusion of d, 1-folinic acid. ",CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2311173/),[ml] / [min],12.9,183019,DB00544,Fluorouracil
,2311173,AUC,"This results in a very high AUC of 24, 269 microM x min, which is higher by factors of 17 and 11 than those of 1-CHO-THF and CH3-THF, respectively.","Pharmacokinetics of reduced folates after short-term infusion of d, 1-folinic acid. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2311173/),min·μM,"24, 269",183020,DB00544,Fluorouracil
,27378205,AUC,"Pharmacokinetic parameters were also determined in blood after IV administration of HEP NPs: AUC, Cmax, MRT, and Tmax values are 6096.075 ± 5.90 μg h/mL, 144.38 ± 1.52 μg/L, 58.71 ± 0.25 h, 96 ± 0.50 h, respectively and 117.92 ± 1.78, 45.35 ± 3.00, 1.2 ± 0.25, 0.5 ± 0.02 in plain 5-FU solution.",Heparin-appended polycaprolactone core/corona nanoparticles for site specific delivery of 5-fluorouracil. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27378205/),[h·μg] / [ml],6096.075,183753,DB00544,Fluorouracil
,27378205,Cmax,"Pharmacokinetic parameters were also determined in blood after IV administration of HEP NPs: AUC, Cmax, MRT, and Tmax values are 6096.075 ± 5.90 μg h/mL, 144.38 ± 1.52 μg/L, 58.71 ± 0.25 h, 96 ± 0.50 h, respectively and 117.92 ± 1.78, 45.35 ± 3.00, 1.2 ± 0.25, 0.5 ± 0.02 in plain 5-FU solution.",Heparin-appended polycaprolactone core/corona nanoparticles for site specific delivery of 5-fluorouracil. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27378205/),[μg] / [l],144.38,183754,DB00544,Fluorouracil
,27378205,Cmax,"Pharmacokinetic parameters were also determined in blood after IV administration of HEP NPs: AUC, Cmax, MRT, and Tmax values are 6096.075 ± 5.90 μg h/mL, 144.38 ± 1.52 μg/L, 58.71 ± 0.25 h, 96 ± 0.50 h, respectively and 117.92 ± 1.78, 45.35 ± 3.00, 1.2 ± 0.25, 0.5 ± 0.02 in plain 5-FU solution.",Heparin-appended polycaprolactone core/corona nanoparticles for site specific delivery of 5-fluorouracil. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27378205/),h,58.71,183755,DB00544,Fluorouracil
,27378205,MRT,"Pharmacokinetic parameters were also determined in blood after IV administration of HEP NPs: AUC, Cmax, MRT, and Tmax values are 6096.075 ± 5.90 μg h/mL, 144.38 ± 1.52 μg/L, 58.71 ± 0.25 h, 96 ± 0.50 h, respectively and 117.92 ± 1.78, 45.35 ± 3.00, 1.2 ± 0.25, 0.5 ± 0.02 in plain 5-FU solution.",Heparin-appended polycaprolactone core/corona nanoparticles for site specific delivery of 5-fluorouracil. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27378205/),[μg] / [l],144.38,183756,DB00544,Fluorouracil
,27378205,MRT,"Pharmacokinetic parameters were also determined in blood after IV administration of HEP NPs: AUC, Cmax, MRT, and Tmax values are 6096.075 ± 5.90 μg h/mL, 144.38 ± 1.52 μg/L, 58.71 ± 0.25 h, 96 ± 0.50 h, respectively and 117.92 ± 1.78, 45.35 ± 3.00, 1.2 ± 0.25, 0.5 ± 0.02 in plain 5-FU solution.",Heparin-appended polycaprolactone core/corona nanoparticles for site specific delivery of 5-fluorouracil. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27378205/),h,58.71,183757,DB00544,Fluorouracil
,27378205,Tmax,"Pharmacokinetic parameters were also determined in blood after IV administration of HEP NPs: AUC, Cmax, MRT, and Tmax values are 6096.075 ± 5.90 μg h/mL, 144.38 ± 1.52 μg/L, 58.71 ± 0.25 h, 96 ± 0.50 h, respectively and 117.92 ± 1.78, 45.35 ± 3.00, 1.2 ± 0.25, 0.5 ± 0.02 in plain 5-FU solution.",Heparin-appended polycaprolactone core/corona nanoparticles for site specific delivery of 5-fluorouracil. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27378205/),h,96,183758,DB00544,Fluorouracil
,10856097,response duration,"Median response duration was 14 months (range, 10 to 18+ months).",Low-dose oral fluorouracil with eniluracil as first-line chemotherapy against advanced breast cancer: a phase II study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10856097/),month,14,183926,DB00544,Fluorouracil
,17352269,total body clearance,"The total body clearance for cisplatin was 1.25 L/(hxm2) for the liposomal formulation, compared to 0.62 L/(hxm2) for conventional cisplatin.",Pharmacokinetics of liposomal cisplatin (lipoplatin) in combination with 5-FU in patients with advanced head and neck cancer: first results of a phase III study. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17352269/),[l] / [h·m2],1.25,184137,DB00544,Fluorouracil
,17352269,total body clearance,"The total body clearance for cisplatin was 1.25 L/(hxm2) for the liposomal formulation, compared to 0.62 L/(hxm2) for conventional cisplatin.",Pharmacokinetics of liposomal cisplatin (lipoplatin) in combination with 5-FU in patients with advanced head and neck cancer: first results of a phase III study. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17352269/),[l] / [h·m2],0.62,184138,DB00544,Fluorouracil
,17352269,terminal half life,The terminal half life was half as long for lipoplatin (10.98 h) as compared to cisplatin (24.5h).,Pharmacokinetics of liposomal cisplatin (lipoplatin) in combination with 5-FU in patients with advanced head and neck cancer: first results of a phase III study. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/17352269/),h,10.98,184139,DB00544,Fluorouracil
,17352269,terminal half life,The terminal half life was half as long for lipoplatin (10.98 h) as compared to cisplatin (24.5h).,Pharmacokinetics of liposomal cisplatin (lipoplatin) in combination with 5-FU in patients with advanced head and neck cancer: first results of a phase III study. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/17352269/),h,24.5,184140,DB00544,Fluorouracil
,17352269,area under the concentration time-curve (AUC),"Even though the maximum observed concentration in the plasma (C(max) was greater for lipoplatin than for cisplatin, the area under the concentration time-curve (AUC) was less (6.5 microg/ml vs. 4.07 microg/ml and 66.85 microg/h/ml vs. 130.33 microg/h/ml, respectively).",Pharmacokinetics of liposomal cisplatin (lipoplatin) in combination with 5-FU in patients with advanced head and neck cancer: first results of a phase III study. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17352269/),[μg] / [ml],6.5,184141,DB00544,Fluorouracil
,17352269,area under the concentration time-curve (AUC),"Even though the maximum observed concentration in the plasma (C(max) was greater for lipoplatin than for cisplatin, the area under the concentration time-curve (AUC) was less (6.5 microg/ml vs. 4.07 microg/ml and 66.85 microg/h/ml vs. 130.33 microg/h/ml, respectively).",Pharmacokinetics of liposomal cisplatin (lipoplatin) in combination with 5-FU in patients with advanced head and neck cancer: first results of a phase III study. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17352269/),[μg] / [ml],4.07,184142,DB00544,Fluorouracil
,17352269,area under the concentration time-curve (AUC),"Even though the maximum observed concentration in the plasma (C(max) was greater for lipoplatin than for cisplatin, the area under the concentration time-curve (AUC) was less (6.5 microg/ml vs. 4.07 microg/ml and 66.85 microg/h/ml vs. 130.33 microg/h/ml, respectively).",Pharmacokinetics of liposomal cisplatin (lipoplatin) in combination with 5-FU in patients with advanced head and neck cancer: first results of a phase III study. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17352269/),[μg] / [h·ml],66.85,184143,DB00544,Fluorouracil
,17352269,area under the concentration time-curve (AUC),"Even though the maximum observed concentration in the plasma (C(max) was greater for lipoplatin than for cisplatin, the area under the concentration time-curve (AUC) was less (6.5 microg/ml vs. 4.07 microg/ml and 66.85 microg/h/ml vs. 130.33 microg/h/ml, respectively).",Pharmacokinetics of liposomal cisplatin (lipoplatin) in combination with 5-FU in patients with advanced head and neck cancer: first results of a phase III study. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17352269/),[μg] / [h·ml],130.33,184144,DB00544,Fluorouracil
,3609119,half-life,The mean 5-FU half-life following the high dose was nearly twice as long as that observed for the low dose (12.3 versus 6.2 min).,Nonlinear pharmacokinetic characteristics of 5-fluorouracil (5-FU) in colorectal cancer patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3609119/),min,12.3,184217,DB00544,Fluorouracil
,3609119,half-life,The mean 5-FU half-life following the high dose was nearly twice as long as that observed for the low dose (12.3 versus 6.2 min).,Nonlinear pharmacokinetic characteristics of 5-fluorouracil (5-FU) in colorectal cancer patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3609119/),min,6.2,184218,DB00544,Fluorouracil
,17218488,MTD,The MTD was 1250 mg daily with dizziness being the most frequent dose-limiting toxicity (DLT).,"A phase IB, open-label dose-escalating study of the oral angiogenesis inhibitor PTK787/ZK 222584 (PTK/ZK), in combination with FOLFOX4 chemotherapy in patients with advanced colorectal cancer. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17218488/),,125,184670,DB00544,Fluorouracil
,17218488,progression-free survival,Median progression-free survival was 11.4 months.,"A phase IB, open-label dose-escalating study of the oral angiogenesis inhibitor PTK787/ZK 222584 (PTK/ZK), in combination with FOLFOX4 chemotherapy in patients with advanced colorectal cancer. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17218488/),month,11.4,184671,DB00544,Fluorouracil
,17218488,MTD,The MTD of PTK/ZK in combination with FOLFOX4 in this patient population is 1250 mg daily.,"A phase IB, open-label dose-escalating study of the oral angiogenesis inhibitor PTK787/ZK 222584 (PTK/ZK), in combination with FOLFOX4 chemotherapy in patients with advanced colorectal cancer. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17218488/),mg,1250,184672,DB00544,Fluorouracil
,24710768,overall response rate,"The overall response rate was 55.9%, including 2 complete responses (CRs).","Platinum-based chemotherapy plus cetuximab first-line for Asian patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck: Results of an open-label, single-arm, multicenter trial. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24710768/),%,55.9,185047,DB00544,Fluorouracil
,24710768,overall survival (OS),Median overall survival (OS) was 12.6 months and median progression-free survival (PFS) was 6.6 months.,"Platinum-based chemotherapy plus cetuximab first-line for Asian patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck: Results of an open-label, single-arm, multicenter trial. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24710768/),month,12.6,185048,DB00544,Fluorouracil
,24710768,progression-free survival (PFS),Median overall survival (OS) was 12.6 months and median progression-free survival (PFS) was 6.6 months.,"Platinum-based chemotherapy plus cetuximab first-line for Asian patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck: Results of an open-label, single-arm, multicenter trial. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24710768/),month,6.6,185049,DB00544,Fluorouracil
,25342290,C(max) ratio,"The Modufolin® to Isovorin® C(max) ratio for methyleneTHF was 113 at 200 mg/m² and 52 at 60 mg/m²; the AUC(last) ratios were 17 and 9, respectively.",A pharmacokinetic and pharmacodynamic investigation of Modufolin® compared to Isovorin® after single dose intravenous administration to patients with colon cancer: a randomized study. ,Cmax ratio-Q33,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25342290/),,113,185291,DB00544,Fluorouracil
,25342290,C(max) ratio,"The Modufolin® to Isovorin® C(max) ratio for methyleneTHF was 113 at 200 mg/m² and 52 at 60 mg/m²; the AUC(last) ratios were 17 and 9, respectively.",A pharmacokinetic and pharmacodynamic investigation of Modufolin® compared to Isovorin® after single dose intravenous administration to patients with colon cancer: a randomized study. ,Cmax ratio-Q33,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25342290/),,52,185292,DB00544,Fluorouracil
,25342290,AUC(last) ratios,"The Modufolin® to Isovorin® C(max) ratio for methyleneTHF was 113 at 200 mg/m² and 52 at 60 mg/m²; the AUC(last) ratios were 17 and 9, respectively.",A pharmacokinetic and pharmacodynamic investigation of Modufolin® compared to Isovorin® after single dose intravenous administration to patients with colon cancer: a randomized study. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25342290/),,17,185293,DB00544,Fluorouracil
,25342290,AUC(last) ratios,"The Modufolin® to Isovorin® C(max) ratio for methyleneTHF was 113 at 200 mg/m² and 52 at 60 mg/m²; the AUC(last) ratios were 17 and 9, respectively.",A pharmacokinetic and pharmacodynamic investigation of Modufolin® compared to Isovorin® after single dose intravenous administration to patients with colon cancer: a randomized study. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25342290/),,9,185294,DB00544,Fluorouracil
,25342290,C(max) ratio,"The THF plasma concentrations were also higher after Modufolin® administration (C(max) ratio 23, AUC(last) ratio 13 at 200 mg/m²; C(max) ratio 15, AUC(last) ratio 11 at 60 mg/m²).",A pharmacokinetic and pharmacodynamic investigation of Modufolin® compared to Isovorin® after single dose intravenous administration to patients with colon cancer: a randomized study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25342290/),,23,185295,DB00544,Fluorouracil
,25342290,AUC(last) ratio,"The THF plasma concentrations were also higher after Modufolin® administration (C(max) ratio 23, AUC(last) ratio 13 at 200 mg/m²; C(max) ratio 15, AUC(last) ratio 11 at 60 mg/m²).",A pharmacokinetic and pharmacodynamic investigation of Modufolin® compared to Isovorin® after single dose intravenous administration to patients with colon cancer: a randomized study. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25342290/),,13,185296,DB00544,Fluorouracil
,25342290,C(max) ratio,"The THF plasma concentrations were also higher after Modufolin® administration (C(max) ratio 23, AUC(last) ratio 13 at 200 mg/m²; C(max) ratio 15, AUC(last) ratio 11 at 60 mg/m²).",A pharmacokinetic and pharmacodynamic investigation of Modufolin® compared to Isovorin® after single dose intravenous administration to patients with colon cancer: a randomized study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25342290/),,15,185297,DB00544,Fluorouracil
,25342290,AUC(last) ratio,"The THF plasma concentrations were also higher after Modufolin® administration (C(max) ratio 23, AUC(last) ratio 13 at 200 mg/m²; C(max) ratio 15, AUC(last) ratio 11 at 60 mg/m²).",A pharmacokinetic and pharmacodynamic investigation of Modufolin® compared to Isovorin® after single dose intravenous administration to patients with colon cancer: a randomized study. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25342290/),,11,185298,DB00544,Fluorouracil
,8523062,Css,"A Css of 2.2 +/- 0.8 mumol/L for 5-FU was achieved on the recommended schedule, which compares favorably with conventional IV 5-FU regimens.",Phase I clinical and pharmacokinetic study of leucovorin and infusional hepatic arterial fluorouracil. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8523062/),[μM] / [l],2.2,186105,DB00544,Fluorouracil
higher,34347254,maximum plasma concentration (Cmax),"Reference scaled maximum plasma concentration (Cmax) was higher than 0.294, permitting use of RSABE.","Pharmacokinetic and Safety Comparison of Two Capecitabine Tablets in Patients with Colorectal or Breast Cancer Under Fed Conditions: A Multicenter, Randomized, Open-Label, Three-Period, and Reference-Replicated Crossover Study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34347254/),,0.294,186374,DB00544,Fluorouracil
,3358790,therapeutic index (LD50/ED50),"The therapeutic index (LD50/ED50) for the combination of BVDU plus 5-FU was 8.1 and 3.9 upon intraperitoneal (i.p.) or oral (p.o.) administration, respectively.",Enhancing effect of bromovinyldeoxyuridine on antitumor activity of 5-fluorouracil against adenocarcinoma 755 in mice. Increased therapeutic index and correlation with increased plasma 5-fluorouracil levels. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3358790/),,8.1,186690,DB00544,Fluorouracil
,3358790,therapeutic index (LD50/ED50),"The therapeutic index (LD50/ED50) for the combination of BVDU plus 5-FU was 8.1 and 3.9 upon intraperitoneal (i.p.) or oral (p.o.) administration, respectively.",Enhancing effect of bromovinyldeoxyuridine on antitumor activity of 5-fluorouracil against adenocarcinoma 755 in mice. Increased therapeutic index and correlation with increased plasma 5-fluorouracil levels. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3358790/),,3.9,186691,DB00544,Fluorouracil
,10448274,half-life of the rapid phase,"The half-life of the rapid phase averaged 8.0 min, and was of the same order of magnitude as the 5-FU elimination half-life determined from plasma data.",Plasma and salivary pharmacokinetics of 5-fluorouracil (5-FU) in patients with metastatic colorectal cancer receiving 5-FU bolus plus continuous infusion with high-dose folinic acid. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10448274/),min,8.0,186797,DB00544,Fluorouracil
,10448274,half-life of the terminal part of the,"The half-life of the terminal part of the curve averaged 8 h; such decrease in salivary concentrations could be due to changes in salivary gland function caused by 5-FU, which results in reduced salivary flow rate.",Plasma and salivary pharmacokinetics of 5-fluorouracil (5-FU) in patients with metastatic colorectal cancer receiving 5-FU bolus plus continuous infusion with high-dose folinic acid. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10448274/),h,8,186798,DB00544,Fluorouracil
,16475204,response rate,The response rate was 40.9%.,Phase I/II study of S-1 combined with carboplatin in recurrent and/or metastatic head and neck cancer as outpatient chemotherapy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16475204/),%,40.9,187957,DB00544,Fluorouracil
,21925254,en,The encapsulation efficiency of 5-FU in PPD nanocarriers was as high as 92.5% through the pH transition.,A 5-fluorouracil-loaded pH-responsive dendrimer nanocarrier for tumor targeting. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21925254/),,92,188151,DB00544,Fluorouracil
,1336946,terminal half-life,The terminal half-life of FTC was independent of the route of administration and averaged 1.34 +/- 0.18 h (mean +/- standard deviation).,"Pharmacokinetics and metabolism of racemic 2',3'-dideoxy-5-fluoro-3'-thiacytidine in rhesus monkeys. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1336946/),h,1.34,190148,DB00544,Fluorouracil
,1336946,Total clearance,"Total clearance of FTC was moderate to high, averaging 1.49 +/- 0.24 liters/h/kg.","Pharmacokinetics and metabolism of racemic 2',3'-dideoxy-5-fluoro-3'-thiacytidine in rhesus monkeys. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1336946/),[l] / [h·kg],1.49,190149,DB00544,Fluorouracil
,1336946,steady-state volume of distribution,"The steady-state volume of distribution of FTC in serum averaged 2.23 +/- 0.42 liters/kg, and the nucleoside analog was distributed into the cerebrospinal fluid, which suggests that this drug penetrated the blood-brain barrier.","Pharmacokinetics and metabolism of racemic 2',3'-dideoxy-5-fluoro-3'-thiacytidine in rhesus monkeys. ",Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1336946/),[l] / [kg],2.23,190150,DB00544,Fluorouracil
,1336946,bioavailability,"Absorption of FTC after oral administration was rapid, with bioavailability averaging 73 +/- 6%.","Pharmacokinetics and metabolism of racemic 2',3'-dideoxy-5-fluoro-3'-thiacytidine in rhesus monkeys. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1336946/),%,73,190151,DB00544,Fluorouracil
over,3940221,C X T,"A close relationship was demonstrated between elevated 5-FU C X T values (over 30 000 ng h ml-1) and the frequency of cycles in which signs of toxicity (myelosuppression, mucositis, diarrhea) were observed.",Clinical pharmacokinetic study of 5-FU in continuous 5-day infusions for head and neck cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3940221/),[h·ng] / [ml],30 000,190306,DB00544,Fluorouracil
,7917936,half-life,Drug concentrations in both peritoneal and plasma compartments followed a first-order model with similar half-life value of 1.3 h.,Pharmacokinetic study of 5-fluorouracil in a novel dialysate solution: a long-term intraperitoneal treatment approach for advanced colorectal carcinoma. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7917936/),h,1.3,191401,DB00544,Fluorouracil
,26489552,in,"Since the levels of tumor markers increased, the 5-FU dose was increased from 2,700 to 3,000 mg/m2 using a Jackson-type pump and an extended infusion time of 53 hours.",[Improved Response to 5-FU Using Dose Adjustment and Elastomeric Pump Selection Based on Monitoring of the 5-FU Level--A Case Report]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26489552/),,53,191430,DB00544,Fluorouracil
,26489552,areas under the concentration vs. time curve (AUC mg,"The areas under the concentration vs. time curve (AUC mg・h/L)were 21 and 44 mg・h/L for the Jackson- and bottle-type pumps, respectively.",[Improved Response to 5-FU Using Dose Adjustment and Elastomeric Pump Selection Based on Monitoring of the 5-FU Level--A Case Report]. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26489552/),[mg・h] / [l],21,191431,DB00544,Fluorouracil
,26489552,areas under the concentration vs. time curve (AUC mg,"The areas under the concentration vs. time curve (AUC mg・h/L)were 21 and 44 mg・h/L for the Jackson- and bottle-type pumps, respectively.",[Improved Response to 5-FU Using Dose Adjustment and Elastomeric Pump Selection Based on Monitoring of the 5-FU Level--A Case Report]. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26489552/),[mg・h] / [l],44,191432,DB00544,Fluorouracil
,26489552,AUC,"The AUC decreased to 27 mg・h/L, but the liver metastases were reduced and the adverse effects subsided to Grade 1.",[Improved Response to 5-FU Using Dose Adjustment and Elastomeric Pump Selection Based on Monitoring of the 5-FU Level--A Case Report]. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26489552/),[mg・h] / [l],27,191433,DB00544,Fluorouracil
,9815764,Cmax,"The platinum concentration curves were quite similar from one course to another, with a high peak value 2 h after administration (day 1, Cmax = 3201 +/- 609 microgram/liter) and a rapid decrease (day 8, 443 +/- 99 microgram/liter).","Cumulative pharmacokinetic study of oxaliplatin, administered every three weeks, combined with 5-fluorouracil in colorectal cancer patients. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9815764/),[μg] / [l],3201,192024,DB00544,Fluorouracil
,9815764,Cmax,"The platinum concentration curves were quite similar from one course to another, with a high peak value 2 h after administration (day 1, Cmax = 3201 +/- 609 microgram/liter) and a rapid decrease (day 8, 443 +/- 99 microgram/liter).","Cumulative pharmacokinetic study of oxaliplatin, administered every three weeks, combined with 5-fluorouracil in colorectal cancer patients. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9815764/),[μg] / [l],443,192025,DB00544,Fluorouracil
,9815764,total platinum half-life,The mean total platinum half-life in plasma was 9 days.,"Cumulative pharmacokinetic study of oxaliplatin, administered every three weeks, combined with 5-fluorouracil in colorectal cancer patients. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9815764/),d,9,192026,DB00544,Fluorouracil
,9815764,UC:total platinum ratio,"The mean UC:total platinum ratio was 15% at day 1 and 5% at days 8, 15, and 22 in the 3-week treatment course.","Cumulative pharmacokinetic study of oxaliplatin, administered every three weeks, combined with 5-fluorouracil in colorectal cancer patients. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9815764/),%,15,192027,DB00544,Fluorouracil
,9815764,UC:total platinum ratio,"The mean UC:total platinum ratio was 15% at day 1 and 5% at days 8, 15, and 22 in the 3-week treatment course.","Cumulative pharmacokinetic study of oxaliplatin, administered every three weeks, combined with 5-fluorouracil in colorectal cancer patients. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9815764/),%,5,192028,DB00544,Fluorouracil
,9815765,peak concentration,"The disposition of FUR was biphasic, with a peak concentration of 8.8 microgram/ml and a clearance of 127 ml/min/kg.",Bladder tissue pharmacokinetics and antitumor effect of intravesical 5-fluorouridine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9815765/),[μg] / [ml],8.8,192092,DB00544,Fluorouracil
,9815765,clearance,"The disposition of FUR was biphasic, with a peak concentration of 8.8 microgram/ml and a clearance of 127 ml/min/kg.",Bladder tissue pharmacokinetics and antitumor effect of intravesical 5-fluorouridine. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9815765/),[ml] / [kg·min],127,192093,DB00544,Fluorouracil
,9815765,peak concentration,"5-Fluorouracil was the major circulating metabolite, reaching a peak concentration of 3.2 microgram/ml.",Bladder tissue pharmacokinetics and antitumor effect of intravesical 5-fluorouridine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9815765/),[μg] / [ml],3.2,192094,DB00544,Fluorouracil
,9815765,FUR concentrations (IC50s),"The FUR concentrations (IC50s) required to produce 50% inhibition of DNA precursor ([3H]thymidine or bromodeoxyuridine) incorporation in human superficial bladder tumors (i.e., Ta and T1 tumors, n = 4) and muscle-invading tumors (i.e., T3 and T4 tumors, n = 4) were 9 and 22 microgram/ml, respectively.",Bladder tissue pharmacokinetics and antitumor effect of intravesical 5-fluorouridine. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9815765/),[μg] / [ml],9,192095,DB00544,Fluorouracil
,9815765,FUR concentrations (IC50s),"The FUR concentrations (IC50s) required to produce 50% inhibition of DNA precursor ([3H]thymidine or bromodeoxyuridine) incorporation in human superficial bladder tumors (i.e., Ta and T1 tumors, n = 4) and muscle-invading tumors (i.e., T3 and T4 tumors, n = 4) were 9 and 22 microgram/ml, respectively.",Bladder tissue pharmacokinetics and antitumor effect of intravesical 5-fluorouridine. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9815765/),[μg] / [ml],22,192096,DB00544,Fluorouracil
,10785589,"plasma area under the curve, (AUC(0-105h)","Platinum pharmacokinetics (total and ultrafilterable plasma platinum concentration measured 16 h after CP administration) and 5-FU pharmacokinetics (full-cycle plasma area under the curve, (AUC(0-105h)30 g/l) occurred in 15 patients (38%) and 3 of them also received a blood transfusion.",An analysis of potential factors allowing an individual prediction of cisplatin-induced anaemia. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10785589/),[g] / [l],30,192187,DB00544,Fluorouracil
,18408443,AUC,AUC was 5.67-10.21 mg/L x h.,[Modified FOLFOX6 in a patient on hemodialysis with metastatic colorectal cancer]. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18408443/),[mg] / [h·l],5.67-10.21,192374,DB00544,Fluorouracil
,18408443,dial,The dialysis removal rate was 84.0%.,[Modified FOLFOX6 in a patient on hemodialysis with metastatic colorectal cancer]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18408443/),%,84.0,192375,DB00544,Fluorouracil
,18408443,removal rate,The dialysis removal rate was 84.0%.,[Modified FOLFOX6 in a patient on hemodialysis with metastatic colorectal cancer]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18408443/),%,84.0,192376,DB00544,Fluorouracil
,32152679,total clearance,Population estimate for total clearance was 249 L/h.,Prediction of exposure-driven myelotoxicity of continuous infusion 5-fluorouracil by a semi-physiological pharmacokinetic-pharmacodynamic model in gastrointestinal cancer patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32152679/),[l] / [h],249,192417,DB00544,Fluorouracil
,32152679,central,"5FU central and peripheral volumes of distribution were 5.56 L and 28.5 L, respectively.",Prediction of exposure-driven myelotoxicity of continuous infusion 5-fluorouracil by a semi-physiological pharmacokinetic-pharmacodynamic model in gastrointestinal cancer patients. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32152679/),l,5.56,192418,DB00544,Fluorouracil
,32152679,peripheral volumes of distribution,"5FU central and peripheral volumes of distribution were 5.56 L and 28.5 L, respectively.",Prediction of exposure-driven myelotoxicity of continuous infusion 5-fluorouracil by a semi-physiological pharmacokinetic-pharmacodynamic model in gastrointestinal cancer patients. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32152679/),l,28.5,192419,DB00544,Fluorouracil
,32152679,clearance,"Estimated 5FUH2 clearance and volume of distribution were 121 L/h and 96.7 L, respectively.",Prediction of exposure-driven myelotoxicity of continuous infusion 5-fluorouracil by a semi-physiological pharmacokinetic-pharmacodynamic model in gastrointestinal cancer patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32152679/),[l] / [h],121,192420,DB00544,Fluorouracil
,32152679,volume of distribution,"Estimated 5FUH2 clearance and volume of distribution were 121 L/h and 96.7 L, respectively.",Prediction of exposure-driven myelotoxicity of continuous infusion 5-fluorouracil by a semi-physiological pharmacokinetic-pharmacodynamic model in gastrointestinal cancer patients. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32152679/),l,96.7,192421,DB00544,Fluorouracil
,32152679,leukocyte transit time,"Baseline leukocyte count of 6.86 × 109/L, as well as mean leukocyte transit time of 281 h accounting for time delay between proliferating and circulating cells, was estimated.",Prediction of exposure-driven myelotoxicity of continuous infusion 5-fluorouracil by a semi-physiological pharmacokinetic-pharmacodynamic model in gastrointestinal cancer patients. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32152679/),h,281,192422,DB00544,Fluorouracil
,8422689,Peak plasma concentrations,Peak plasma concentrations (300-500 microM) of 5FU were comparable in human and murine plasma.,Prolonged retention of high concentrations of 5-fluorouracil in human and murine tumors as compared with plasma. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8422689/),μM,300-500,192924,DB00544,Fluorouracil
,8422689,half-life of plasma elimination,"The half-life of plasma elimination (during the period from 15 to 120 min) in both mouse and man ranged from 10 to 20 min, whereas at between 2 and 8 h, plasma concentrations varied from 0.1 to 1 microM, the half-life being about 100 min.",Prolonged retention of high concentrations of 5-fluorouracil in human and murine tumors as compared with plasma. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8422689/),min,10 to 20,192925,DB00544,Fluorouracil
,8422689,half-life,"The half-life of plasma elimination (during the period from 15 to 120 min) in both mouse and man ranged from 10 to 20 min, whereas at between 2 and 8 h, plasma concentrations varied from 0.1 to 1 microM, the half-life being about 100 min.",Prolonged retention of high concentrations of 5-fluorouracil in human and murine tumors as compared with plasma. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8422689/),min,100,192926,DB00544,Fluorouracil
,8422689,tumor concentrations,"5FU tumor concentrations varied between 0.78-21.6, 0.44-6.1, and 0.17-10.8 mumol/kg wet wt., respectively.",Prolonged retention of high concentrations of 5-fluorouracil in human and murine tumors as compared with plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8422689/),[μM] / [kg·wet·wt],0.78-21.6,192927,DB00544,Fluorouracil
,8422689,tumor concentrations,"5FU tumor concentrations varied between 0.78-21.6, 0.44-6.1, and 0.17-10.8 mumol/kg wet wt., respectively.",Prolonged retention of high concentrations of 5-fluorouracil in human and murine tumors as compared with plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8422689/),[μM] / [kg·wet·wt],0.44-6.1,192928,DB00544,Fluorouracil
,8422689,tumor concentrations,"5FU tumor concentrations varied between 0.78-21.6, 0.44-6.1, and 0.17-10.8 mumol/kg wet wt., respectively.",Prolonged retention of high concentrations of 5-fluorouracil in human and murine tumors as compared with plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8422689/),[μM] / [kg·wet·wt],0.17-10.8,192929,DB00544,Fluorouracil
,8422689,tissue concentration/plasma concentration ratio,"At between 4 and 48 h, the tissue concentration/plasma concentration ratio was at least 10.",Prolonged retention of high concentrations of 5-fluorouracil in human and murine tumors as compared with plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8422689/),,10,192930,DB00544,Fluorouracil
,10861418,concentrations,"The 5-FU concentrations of 1, 2, and plasma at 15 minutes/60 minutes after injection in the nongastrectomized group were 7.75 x 10(3)/227 ng/g, 7.58 x 10(3)/439 ng/g, and 7.24 x 10(3)/417 ng/mL, respectively.",Influence of gastrectomy on the distribution of intravenously administered 5-fluorouracil to regional lymph nodes in an animal model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10861418/),[ng] / [g],7.75 x,193032,DB00544,Fluorouracil
,10861418,concentrations,"The 5-FU concentrations of 1, 2, and plasma at 15 minutes/60 minutes after injection in the nongastrectomized group were 7.75 x 10(3)/227 ng/g, 7.58 x 10(3)/439 ng/g, and 7.24 x 10(3)/417 ng/mL, respectively.",Influence of gastrectomy on the distribution of intravenously administered 5-fluorouracil to regional lymph nodes in an animal model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10861418/),[ng] / [g],227,193033,DB00544,Fluorouracil
,10861418,concentrations,"The 5-FU concentrations of 1, 2, and plasma at 15 minutes/60 minutes after injection in the nongastrectomized group were 7.75 x 10(3)/227 ng/g, 7.58 x 10(3)/439 ng/g, and 7.24 x 10(3)/417 ng/mL, respectively.",Influence of gastrectomy on the distribution of intravenously administered 5-fluorouracil to regional lymph nodes in an animal model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10861418/),[ng] / [g],7.58 x 10,193034,DB00544,Fluorouracil
,10861418,concentrations,"The 5-FU concentrations of 1, 2, and plasma at 15 minutes/60 minutes after injection in the nongastrectomized group were 7.75 x 10(3)/227 ng/g, 7.58 x 10(3)/439 ng/g, and 7.24 x 10(3)/417 ng/mL, respectively.",Influence of gastrectomy on the distribution of intravenously administered 5-fluorouracil to regional lymph nodes in an animal model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10861418/),[ng] / [g],439,193035,DB00544,Fluorouracil
,10861418,concentrations,"The 5-FU concentrations of 1, 2, and plasma at 15 minutes/60 minutes after injection in the nongastrectomized group were 7.75 x 10(3)/227 ng/g, 7.58 x 10(3)/439 ng/g, and 7.24 x 10(3)/417 ng/mL, respectively.",Influence of gastrectomy on the distribution of intravenously administered 5-fluorouracil to regional lymph nodes in an animal model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10861418/),[ng] / [ml],7.24 x 10(3,193036,DB00544,Fluorouracil
,10861418,concentrations,"The 5-FU concentrations of 1, 2, and plasma at 15 minutes/60 minutes after injection in the nongastrectomized group were 7.75 x 10(3)/227 ng/g, 7.58 x 10(3)/439 ng/g, and 7.24 x 10(3)/417 ng/mL, respectively.",Influence of gastrectomy on the distribution of intravenously administered 5-fluorouracil to regional lymph nodes in an animal model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10861418/),[ng] / [ml],417,193037,DB00544,Fluorouracil
,1747791,response rate,Phase II studies in metastatic colorectal cancer in 345 patients have demonstrated an average response rate of 36% (range 15-59%) and a prospective randomized study performed by the Mid-Atlantic Oncology Program (MAOP) has confirmed a higher response rate with 5FU infusion compared with a bolus schedule.,5-Fluorouracil by protracted venous infusion: a review of recent clinical studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1747791/),%,36,194732,DB00544,Fluorouracil
,9193347,MTD,"The MTD of FU given in this fashion with PN401 rescue was 1,000 mg/m2, at which level two of six patients had neutropenic fever.","Phase I trial of PN401, an oral prodrug of uridine, to prevent toxicity from fluorouracil in patients with advanced cancer. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9193347/),[mg] / [m2],"1,000",194919,DB00544,Fluorouracil
,9193347,MTD,"The MTD of FU with PN401 rescue is 1,000 mg/m2 and the recommended dose for phase II trials is 800 mg/m2 given weekly for 6 weeks with dose escalation.","Phase I trial of PN401, an oral prodrug of uridine, to prevent toxicity from fluorouracil in patients with advanced cancer. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9193347/),[mg] / [m2],"1,000",194920,DB00544,Fluorouracil
,1346985,half-lives,"Plasma disappearance curves for FBAL could be described by the sum of three exponentials, with half-lives of 0.26, 12.1, and 8426 min.",Pharmacokinetics and tissue distribution of 2-fluoro-beta-alanine in rats. Potential relevance to toxicity pattern of 5-fluorouracil. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1346985/),min,0.26,195078,DB00544,Fluorouracil
,1346985,half-lives,"Plasma disappearance curves for FBAL could be described by the sum of three exponentials, with half-lives of 0.26, 12.1, and 8426 min.",Pharmacokinetics and tissue distribution of 2-fluoro-beta-alanine in rats. Potential relevance to toxicity pattern of 5-fluorouracil. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1346985/),min,12.1,195079,DB00544,Fluorouracil
,1346985,half-lives,"Plasma disappearance curves for FBAL could be described by the sum of three exponentials, with half-lives of 0.26, 12.1, and 8426 min.",Pharmacokinetics and tissue distribution of 2-fluoro-beta-alanine in rats. Potential relevance to toxicity pattern of 5-fluorouracil. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1346985/),min,8426,195080,DB00544,Fluorouracil
>,12171874,peak FUra concentrations,Serial plasma samples revealed peak FUra concentrations of >100 micro M; at 100 micro g/m2 IFN-gamma plasma concentrations >5 units/ml persisted for 6.5 h and >1 unit/ml for 28.5 h.,"Modulation of the Fas signaling pathway by IFN-gamma in therapy of colon cancer: phase I trial and correlative studies of IFN-gamma, 5-fluorouracil, and leucovorin. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12171874/),μM,100,195641,DB00544,Fluorouracil
,9529293,maximum standardized uptake,"Metastases reached the highest 18F-FU concentrations after intra-arterial administration, with a maximum standardized uptake values of 18.75 for the FU influx and of 5.03 for FU trapping.",Intravenous and intra-arterial oxygen-15-labeled water and fluorine-18-labeled fluorouracil in patients with liver metastases from colorectal carcinoma. ,Uptake Volume-Q9,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9529293/),,18.75,195924,DB00544,Fluorouracil
,9529293,maximum standardized uptake,"Metastases reached the highest 18F-FU concentrations after intra-arterial administration, with a maximum standardized uptake values of 18.75 for the FU influx and of 5.03 for FU trapping.",Intravenous and intra-arterial oxygen-15-labeled water and fluorine-18-labeled fluorouracil in patients with liver metastases from colorectal carcinoma. ,Uptake Volume-Q9,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9529293/),,5.03,195925,DB00544,Fluorouracil
,23049254,half-maximal inhibitory concentration [IC(50)],"After 72 hours of treatment, both the FVS (half-maximal inhibitory concentration [IC(50)] = 11.99 μg · mL(-1)) and the standard anticancer drug, 5-fluorouracil (IC(50) = 0.88 μg · mL(-1)) exhibited strong in vitro antiproliferative activity against SGC cells, with IC(50) > 30.0 μg · mL(-1); but the FVS performed poorly against LoVo cells (IC(50) > 40.0 μg · mL(-1)).","Enhanced oral bioavailability of a sterol-loaded microemulsion formulation of Flammulina velutipes, a potential antitumor drug. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23049254/),[μg] / [ml],11.99,196170,DB00544,Fluorouracil
,23049254,IC(50),"After 72 hours of treatment, both the FVS (half-maximal inhibitory concentration [IC(50)] = 11.99 μg · mL(-1)) and the standard anticancer drug, 5-fluorouracil (IC(50) = 0.88 μg · mL(-1)) exhibited strong in vitro antiproliferative activity against SGC cells, with IC(50) > 30.0 μg · mL(-1); but the FVS performed poorly against LoVo cells (IC(50) > 40.0 μg · mL(-1)).","Enhanced oral bioavailability of a sterol-loaded microemulsion formulation of Flammulina velutipes, a potential antitumor drug. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23049254/),[μg] / [ml],0.88,196171,DB00544,Fluorouracil
>,23049254,IC(50),"After 72 hours of treatment, both the FVS (half-maximal inhibitory concentration [IC(50)] = 11.99 μg · mL(-1)) and the standard anticancer drug, 5-fluorouracil (IC(50) = 0.88 μg · mL(-1)) exhibited strong in vitro antiproliferative activity against SGC cells, with IC(50) > 30.0 μg · mL(-1); but the FVS performed poorly against LoVo cells (IC(50) > 40.0 μg · mL(-1)).","Enhanced oral bioavailability of a sterol-loaded microemulsion formulation of Flammulina velutipes, a potential antitumor drug. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23049254/),[μg] / [ml],30.0,196172,DB00544,Fluorouracil
>,23049254,IC(50),"After 72 hours of treatment, both the FVS (half-maximal inhibitory concentration [IC(50)] = 11.99 μg · mL(-1)) and the standard anticancer drug, 5-fluorouracil (IC(50) = 0.88 μg · mL(-1)) exhibited strong in vitro antiproliferative activity against SGC cells, with IC(50) > 30.0 μg · mL(-1); but the FVS performed poorly against LoVo cells (IC(50) > 40.0 μg · mL(-1)).","Enhanced oral bioavailability of a sterol-loaded microemulsion formulation of Flammulina velutipes, a potential antitumor drug. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23049254/),[μg] / [ml],40.0,196173,DB00544,Fluorouracil
,23049254,solubility,"The optimal FVSMs prescription consisted of 3.0% medium chain triglycerides, 5.0% ethanol, 21.0% Cremophor EL and 71.0% water (w/w) with associated solubility of FVS being 0.680 mg · mL(-1) as compared to free FVS (0.67 μg · mL(-1)).","Enhanced oral bioavailability of a sterol-loaded microemulsion formulation of Flammulina velutipes, a potential antitumor drug. ",Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23049254/),[mg] / [ml],0.680,196174,DB00544,Fluorouracil
,23049254,solubility,"The optimal FVSMs prescription consisted of 3.0% medium chain triglycerides, 5.0% ethanol, 21.0% Cremophor EL and 71.0% water (w/w) with associated solubility of FVS being 0.680 mg · mL(-1) as compared to free FVS (0.67 μg · mL(-1)).","Enhanced oral bioavailability of a sterol-loaded microemulsion formulation of Flammulina velutipes, a potential antitumor drug. ",Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23049254/),[μg] / [ml],0.67,196175,DB00544,Fluorouracil
,29285832,Maximum-tolerated dose,Maximum-tolerated dose was estimated to be at least 200 mg/wk and the dose was not escalated to level 2.,Nimotuzumab combined with concurrent chemoradiotherapy in Japanese patients with esophageal cancer: A phase I study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29285832/),mg,200,197174,DB00544,Fluorouracil
,29285832,Complete response rate,Complete response rate was 50%.,Nimotuzumab combined with concurrent chemoradiotherapy in Japanese patients with esophageal cancer: A phase I study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29285832/),%,50,197175,DB00544,Fluorouracil
,29285832,Progression-free survival,Progression-free survival was 13.9 months.,Nimotuzumab combined with concurrent chemoradiotherapy in Japanese patients with esophageal cancer: A phase I study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29285832/),month,13.9,197176,DB00544,Fluorouracil
,9187406,detection limit,"A HPLC assay method was modified and validated for the determination of 5-fluorouracil in human red blood cells, plasma and whole blood with a two-fold increased sensitivity (detection limit=10 ng/ml).","High-performance liquid chromatographic assay of 5-fluorouracil in human erythrocytes, plasma and whole blood. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9187406/),[ng] / [ml],10,197385,DB00544,Fluorouracil
,1891168,clearance,Average clearance decreased from 1.3 l/min for 320 to 0.7 l/min for 960 mg FU/m2.,"Relative importance of dose, body surface area, sex, and age for 5-fluorouracil clearance. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1891168/),[l] / [min],1.3,197449,DB00544,Fluorouracil
,1891168,clearance,Average clearance decreased from 1.3 l/min for 320 to 0.7 l/min for 960 mg FU/m2.,"Relative importance of dose, body surface area, sex, and age for 5-fluorouracil clearance. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1891168/),[l] / [min],0.7,197450,DB00544,Fluorouracil
,28177438,concentrations,Mean 5-FU concentrations in plasma were 1.9 ± 2.6 ng/ml and 56 ± 30 ng/g in tumors.,Vectorized gene therapy of liver tumors: proof-of-concept of TG4023 (MVA-FCU1) in combination with flucytosine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28177438/),[ng] / [ml],1.9,197813,DB00544,Fluorouracil
,28177438,concentrations,Mean 5-FU concentrations in plasma were 1.9 ± 2.6 ng/ml and 56 ± 30 ng/g in tumors.,Vectorized gene therapy of liver tumors: proof-of-concept of TG4023 (MVA-FCU1) in combination with flucytosine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28177438/),[ng] / [g],56,197814,DB00544,Fluorouracil
,28177438,MTD,This phase I study demonstrated that IT injections of TG4023 were feasible and well tolerated; MTD was defined as 4 × 108 p.f.u.,Vectorized gene therapy of liver tumors: proof-of-concept of TG4023 (MVA-FCU1) in combination with flucytosine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28177438/),p,4 ×,197815,DB00544,Fluorouracil
,15073108,elimination half-life (t(1/2)),"Ro 09-4889 has a short elimination half-life (t(1/2)) of 0.5 h, followed by metabolites 5'-deoxy-5-vinyluridine (5'-DVUR), 5'-deoxy-5-vinylcytidine (5'-DVCR), and 5-VU with t(1/2) of 1.3, 1.2, and 2 h, respectively.","Single ascending dose tolerability, pharmacokinetic-pharmacodynamic study of dihydropyrimidine dehydrogenase inhibitor Ro 09-4889. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15073108/),h,0.5,198018,DB00544,Fluorouracil
,15073108,t(1/2),"Ro 09-4889 has a short elimination half-life (t(1/2)) of 0.5 h, followed by metabolites 5'-deoxy-5-vinyluridine (5'-DVUR), 5'-deoxy-5-vinylcytidine (5'-DVCR), and 5-VU with t(1/2) of 1.3, 1.2, and 2 h, respectively.","Single ascending dose tolerability, pharmacokinetic-pharmacodynamic study of dihydropyrimidine dehydrogenase inhibitor Ro 09-4889. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15073108/),h,1.3,198019,DB00544,Fluorouracil
,15073108,t(1/2),"Ro 09-4889 has a short elimination half-life (t(1/2)) of 0.5 h, followed by metabolites 5'-deoxy-5-vinyluridine (5'-DVUR), 5'-deoxy-5-vinylcytidine (5'-DVCR), and 5-VU with t(1/2) of 1.3, 1.2, and 2 h, respectively.","Single ascending dose tolerability, pharmacokinetic-pharmacodynamic study of dihydropyrimidine dehydrogenase inhibitor Ro 09-4889. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15073108/),h,1.2,198020,DB00544,Fluorouracil
,15073108,t(1/2),"Ro 09-4889 has a short elimination half-life (t(1/2)) of 0.5 h, followed by metabolites 5'-deoxy-5-vinyluridine (5'-DVUR), 5'-deoxy-5-vinylcytidine (5'-DVCR), and 5-VU with t(1/2) of 1.3, 1.2, and 2 h, respectively.","Single ascending dose tolerability, pharmacokinetic-pharmacodynamic study of dihydropyrimidine dehydrogenase inhibitor Ro 09-4889. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15073108/),h,2,198021,DB00544,Fluorouracil
,15073108,ED(50),The model-predicted ED(50) value was 100 mg.,"Single ascending dose tolerability, pharmacokinetic-pharmacodynamic study of dihydropyrimidine dehydrogenase inhibitor Ro 09-4889. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15073108/),mg,100,198022,DB00544,Fluorouracil
,15081940,flow rate,"The drug and the internal standard were eluted from a Genesis C(18) analytical column at ambient temperature with mobile phase consisting of methanol:water (10:90, v/v) adjusted to pH 3.2 with perchloric acid at a flow rate of 1.0 ml/min.",Validated liquid chromatographic determination of 5-fluorouracil in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15081940/),[ml] / [min],1.0,198082,DB00544,Fluorouracil
,15081940,retention times,"The retention times for 5-flurorouracil, uracil, and thymine were 4.5, 6.0, and 9.0, respectively.",Validated liquid chromatographic determination of 5-fluorouracil in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15081940/),,4.5,198083,DB00544,Fluorouracil
,15081940,retention times,"The retention times for 5-flurorouracil, uracil, and thymine were 4.5, 6.0, and 9.0, respectively.",Validated liquid chromatographic determination of 5-fluorouracil in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15081940/),,6.0,198084,DB00544,Fluorouracil
,15081940,retention times,"The retention times for 5-flurorouracil, uracil, and thymine were 4.5, 6.0, and 9.0, respectively.",Validated liquid chromatographic determination of 5-fluorouracil in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15081940/),,9.0,198085,DB00544,Fluorouracil
,15081940,relative,The relative and absolute recoveries varied from 96 to 101%.,Validated liquid chromatographic determination of 5-fluorouracil in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15081940/),%,96 to 101,198086,DB00544,Fluorouracil
,15081940,absolute recoveries,The relative and absolute recoveries varied from 96 to 101%.,Validated liquid chromatographic determination of 5-fluorouracil in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15081940/),%,96 to 101,198087,DB00544,Fluorouracil
,9788400,Total RT dose,Total RT dose was 80.4 Gy on the oropharynx and 75.6 Gy on the hypopharynx.,Concomitant b.i.d. radiotherapy and chemotherapy with cisplatin and 5-fluorouracil in unresectable squamous-cell carcinoma of the pharynx: clinical and pharmacological data of a French multicenter phase II study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9788400/),gy,80.4,198390,DB00544,Fluorouracil
,9788400,Total RT dose,Total RT dose was 80.4 Gy on the oropharynx and 75.6 Gy on the hypopharynx.,Concomitant b.i.d. radiotherapy and chemotherapy with cisplatin and 5-fluorouracil in unresectable squamous-cell carcinoma of the pharynx: clinical and pharmacological data of a French multicenter phase II study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9788400/),g,75.6,198391,DB00544,Fluorouracil
,9660536,area under the curve (AUC),"The median values of the area under the curve (AUC) and maximum concentration (Cmax) of 5-FU in IS and CS were 187.7 and 263.2 ng/ml/h, 57.1 and 93.0 ng/ml, respectively.",A crossover study of oral administration of UFT in chronic liver disease: comparison of continuous and intermittent schedules. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9660536/),[ng] / [h·ml],187.7,198454,DB00544,Fluorouracil
,9660536,area under the curve (AUC),"The median values of the area under the curve (AUC) and maximum concentration (Cmax) of 5-FU in IS and CS were 187.7 and 263.2 ng/ml/h, 57.1 and 93.0 ng/ml, respectively.",A crossover study of oral administration of UFT in chronic liver disease: comparison of continuous and intermittent schedules. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9660536/),[ng] / [ml],57.1,198455,DB00544,Fluorouracil
,9660536,maximum concentration (Cmax),"The median values of the area under the curve (AUC) and maximum concentration (Cmax) of 5-FU in IS and CS were 187.7 and 263.2 ng/ml/h, 57.1 and 93.0 ng/ml, respectively.",A crossover study of oral administration of UFT in chronic liver disease: comparison of continuous and intermittent schedules. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9660536/),[ng] / [ml],93.0,198456,DB00544,Fluorouracil
,28708227,area under the curve (AUC),The 5-FU levels ranged between 103 and 4311 µg/L and area under the curve (AUC) measurements ranged between 4.5 and 189.7 mg min/L.,A correlation study of fluorouracil pharmacodynamics with clinical efficacy and toxicity. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28708227/),[mg·min] / [l],4.5 and 189.7,198537,DB00544,Fluorouracil
,11697844,clearance (CL),"5-FU clearance (CL) was lower (range 14.12-25.17 l/h/m2), and the area under the curve (AUC) was higher (range 14.70-26.20 h x microg/ml) than those observed in 84 patients with mild toxicities (CL, 56.30 +/- 3.60 l/h/M2; AUC, 7.91 +/- 0.44 h x microg/ml).","Relationship between 5-fluorouracil disposition, toxicity and dihydropyrimidine dehydrogenase activity in cancer patients. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11697844/),[l] / [h·m2],14.12-25.17,198817,DB00544,Fluorouracil
,11697844,area under the curve (AUC),"5-FU clearance (CL) was lower (range 14.12-25.17 l/h/m2), and the area under the curve (AUC) was higher (range 14.70-26.20 h x microg/ml) than those observed in 84 patients with mild toxicities (CL, 56.30 +/- 3.60 l/h/M2; AUC, 7.91 +/- 0.44 h x microg/ml).","Relationship between 5-fluorouracil disposition, toxicity and dihydropyrimidine dehydrogenase activity in cancer patients. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11697844/),[h·μg] / [ml],14.70-26.20,198818,DB00544,Fluorouracil
,11697844,CL,"5-FU clearance (CL) was lower (range 14.12-25.17 l/h/m2), and the area under the curve (AUC) was higher (range 14.70-26.20 h x microg/ml) than those observed in 84 patients with mild toxicities (CL, 56.30 +/- 3.60 l/h/M2; AUC, 7.91 +/- 0.44 h x microg/ml).","Relationship between 5-fluorouracil disposition, toxicity and dihydropyrimidine dehydrogenase activity in cancer patients. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11697844/),[l] / [M2·h],56.30,198819,DB00544,Fluorouracil
,11697844,AUC,"5-FU clearance (CL) was lower (range 14.12-25.17 l/h/m2), and the area under the curve (AUC) was higher (range 14.70-26.20 h x microg/ml) than those observed in 84 patients with mild toxicities (CL, 56.30 +/- 3.60 l/h/M2; AUC, 7.91 +/- 0.44 h x microg/ml).","Relationship between 5-fluorouracil disposition, toxicity and dihydropyrimidine dehydrogenase activity in cancer patients. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11697844/),[h·μg] / [ml],7.91,198820,DB00544,Fluorouracil
,33983544,z,"The taurine-modified graphene oxide carrier (Tau-GO) was synthesized by chemical method to obtain Tau-GO that has a good dispersibility and stability in water, with a zeta potential of - 38.8 mV and a particle size of 242 nm.",Fabrication and Characterization of Taurine Functionalized Graphene Oxide with 5-Fluorouracil as Anticancer Drug Delivery Systems. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33983544/),m,38.8,199282,DB00544,Fluorouracil
,33983544,IC50,"In addition, the inhibition of HepG2 cells that was measured by the MTT assay, showed that the IC50 value of 5-FU was 196 ± 8.73 μg/mL, and the IC50 value of 5-FU-Tau-GO was 65.2 ± 0.7 μg/mL, indicating that 5- FU-Tau-GO is more potent against HepG2 cells and has a stronger inhibitory effect on cancer cells.",Fabrication and Characterization of Taurine Functionalized Graphene Oxide with 5-Fluorouracil as Anticancer Drug Delivery Systems. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33983544/),[μg] / [ml],196,199283,DB00544,Fluorouracil
,33983544,IC50,"In addition, the inhibition of HepG2 cells that was measured by the MTT assay, showed that the IC50 value of 5-FU was 196 ± 8.73 μg/mL, and the IC50 value of 5-FU-Tau-GO was 65.2 ± 0.7 μg/mL, indicating that 5- FU-Tau-GO is more potent against HepG2 cells and has a stronger inhibitory effect on cancer cells.",Fabrication and Characterization of Taurine Functionalized Graphene Oxide with 5-Fluorouracil as Anticancer Drug Delivery Systems. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33983544/),[μg] / [ml],65.2,199284,DB00544,Fluorouracil
,11431319,K(I),"Using this novel approach, we report for the first time that the net clearance of 5-[(18)F]FU from plasma into tumors (liver metastases and pancreatic tumor) of patients is low (K(I) = 0.0033 +/- 0.0005 ml plasma/ml tissue/min).",Extraction of 5-fluorouracil by tumor and liver: a noninvasive positron emission tomography study of patients with gastrointestinal cancer. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11431319/),[ml·plasma] / [min·ml·tissue],0.0033,199290,DB00544,Fluorouracil
,11431319,K(I),"In contrast, the initial (up to 10 min) clearance through catabolism in liver was high (K(I) = 0.7313 +/- 0.092 ml plasma/ml tissue/min).",Extraction of 5-fluorouracil by tumor and liver: a noninvasive positron emission tomography study of patients with gastrointestinal cancer. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11431319/),[ml·plasma] / [min·ml·tissue],0.7313,199291,DB00544,Fluorouracil
,7143586,renal clearance,5-fluorouracil was given orally and the renal clearance of active 5-fluorouracil was approximately 40 ml.,Oral administration of 5-fluorouracil: renal clearance and urinary concentration in man. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7143586/),ml,40,199694,DB00544,Fluorouracil
,7143586,maximum serum,"The maximum serum (1,100 ng./ml. serum) and urinary concentrations (49,000 ng./ml. urine) of 5-fluorouracil occurred 20 and 40 minutes after administration, respectively.",Oral administration of 5-fluorouracil: renal clearance and urinary concentration in man. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7143586/),[ng] / [ml·serum],"1,100",199695,DB00544,Fluorouracil
,7143586,urinary concentrations,"The maximum serum (1,100 ng./ml. serum) and urinary concentrations (49,000 ng./ml. urine) of 5-fluorouracil occurred 20 and 40 minutes after administration, respectively.",Oral administration of 5-fluorouracil: renal clearance and urinary concentration in man. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7143586/),[ng] / [ml·urine],"49,000",199696,DB00544,Fluorouracil
,29175408,t1/2,"The maximum and minimum mean t1/2 values of 5-fluorouracil were obtained when the drug was administered at 07:00h (23 HALO: 3.1±1.2h) and 13:00h (5 HALO: 1.5±0.6h), respectively.",Circadian variations in the pharmacokinetics of capecitabine and its metabolites in rats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29175408/),h,1.5,199781,DB00544,Fluorouracil
,29175408,AUC0-∞,The AUC0-∞ value of 5-fluorouracil at 07:00h (23 HALO: 533.9±195.7μmol∙h/L) was 1.8-fold higher than the value at 13:00h (5 HALO: 302.5±157.1μmol∙h/L).,Circadian variations in the pharmacokinetics of capecitabine and its metabolites in rats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29175408/),[7μmol∙h] / [l],533.9,199782,DB00544,Fluorouracil
,29175408,AUC0-∞,The AUC0-∞ value of 5-fluorouracil at 07:00h (23 HALO: 533.9±195.7μmol∙h/L) was 1.8-fold higher than the value at 13:00h (5 HALO: 302.5±157.1μmol∙h/L).,Circadian variations in the pharmacokinetics of capecitabine and its metabolites in rats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29175408/),[1μmol∙h] / [l],302.5,199783,DB00544,Fluorouracil
,18445839,area under the curve,FU doses were adjusted weekly in arm B based on a single-point measurement of FU plasma concentrations at steady state until the therapeutic range (targeted area under the curve 20-25 mg x h x L(-1)) previously established in other studies was reached.,Individual fluorouracil dose adjustment based on pharmacokinetic follow-up compared with conventional dosage: results of a multicenter randomized trial of patients with metastatic colorectal cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18445839/),[h·mg] / [l],20-25,199994,DB00544,Fluorouracil
,18445839,objective response rate,An intent-to-treat analysis of the 208 patients showed the objective response rate was 18.3% in arm A and 33.7% in arm B (P = .004).,Individual fluorouracil dose adjustment based on pharmacokinetic follow-up compared with conventional dosage: results of a multicenter randomized trial of patients with metastatic colorectal cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18445839/),%,18.3,199995,DB00544,Fluorouracil
,18445839,objective response rate,An intent-to-treat analysis of the 208 patients showed the objective response rate was 18.3% in arm A and 33.7% in arm B (P = .004).,Individual fluorouracil dose adjustment based on pharmacokinetic follow-up compared with conventional dosage: results of a multicenter randomized trial of patients with metastatic colorectal cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18445839/),%,33.7,199996,DB00544,Fluorouracil
,18445839,overall survival,Median overall survival was 16 months in arm A and 22 months in arm B (P = .08).,Individual fluorouracil dose adjustment based on pharmacokinetic follow-up compared with conventional dosage: results of a multicenter randomized trial of patients with metastatic colorectal cancer. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18445839/),month,16,199997,DB00544,Fluorouracil
,18445839,overall survival,Median overall survival was 16 months in arm A and 22 months in arm B (P = .08).,Individual fluorouracil dose adjustment based on pharmacokinetic follow-up compared with conventional dosage: results of a multicenter randomized trial of patients with metastatic colorectal cancer. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18445839/),month,22,199998,DB00544,Fluorouracil
,2969304,maximal blood concentration,The UR dose produced a maximal blood concentration of 80 micrograms/ml for UR and 100 micrograms/ml for its metabolite uracil (U).,Effect of uridine coadministration on 5'-deoxy-5-fluorouridine disposition in rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2969304/),[μg] / [ml],80,200139,DB00544,Fluorouracil
,2969304,maximal blood concentration,The UR dose produced a maximal blood concentration of 80 micrograms/ml for UR and 100 micrograms/ml for its metabolite uracil (U).,Effect of uridine coadministration on 5'-deoxy-5-fluorouridine disposition in rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2969304/),[μg] / [ml],100,200140,DB00544,Fluorouracil
,2969304,absolute oral bioavailability,"UR did not alter the Cl of dFUR, but reduced the absorption rate of dFUR from the gastrointestinal tract and significantly reduced the absolute oral bioavailability of dFUR from 55.2% to 33.4%.",Effect of uridine coadministration on 5'-deoxy-5-fluorouridine disposition in rats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2969304/),%,55.2,200141,DB00544,Fluorouracil
,2969304,absolute oral bioavailability,"UR did not alter the Cl of dFUR, but reduced the absorption rate of dFUR from the gastrointestinal tract and significantly reduced the absolute oral bioavailability of dFUR from 55.2% to 33.4%.",Effect of uridine coadministration on 5'-deoxy-5-fluorouridine disposition in rats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2969304/),%,33.4,200142,DB00544,Fluorouracil
,6487480,peak plasma concentration,The peak plasma concentration after oral 5FU was increased by 74% from 18.7 +/- 4.5 micrograms/ml (mean +/- s.e. mean) to 32.6 +/- 4.4 micrograms/ml (P less than 0.05) and AUC was increased by 72% from 528 +/- 133 micrograms/ml-1 min (mean +/- s.e. mean) to 911 +/- 152 micrograms ml-1 min (P less than 0.05).,The influence of cimetidine on the pharmacokinetics of 5-fluorouracil. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6487480/),[μg] / [ml],18.7,200235,DB00544,Fluorouracil
,6487480,peak plasma concentration,The peak plasma concentration after oral 5FU was increased by 74% from 18.7 +/- 4.5 micrograms/ml (mean +/- s.e. mean) to 32.6 +/- 4.4 micrograms/ml (P less than 0.05) and AUC was increased by 72% from 528 +/- 133 micrograms/ml-1 min (mean +/- s.e. mean) to 911 +/- 152 micrograms ml-1 min (P less than 0.05).,The influence of cimetidine on the pharmacokinetics of 5-fluorouracil. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6487480/),[μg] / [ml],32.6,200236,DB00544,Fluorouracil
,6487480,AUC,The peak plasma concentration after oral 5FU was increased by 74% from 18.7 +/- 4.5 micrograms/ml (mean +/- s.e. mean) to 32.6 +/- 4.4 micrograms/ml (P less than 0.05) and AUC was increased by 72% from 528 +/- 133 micrograms/ml-1 min (mean +/- s.e. mean) to 911 +/- 152 micrograms ml-1 min (P less than 0.05).,The influence of cimetidine on the pharmacokinetics of 5-fluorouracil. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6487480/),[μg] / [ml],528,200237,DB00544,Fluorouracil
,6487480,AUC,The peak plasma concentration after oral 5FU was increased by 74% from 18.7 +/- 4.5 micrograms/ml (mean +/- s.e. mean) to 32.6 +/- 4.4 micrograms/ml (P less than 0.05) and AUC was increased by 72% from 528 +/- 133 micrograms/ml-1 min (mean +/- s.e. mean) to 911 +/- 152 micrograms ml-1 min (P less than 0.05).,The influence of cimetidine on the pharmacokinetics of 5-fluorouracil. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6487480/),[min·μg] / [ml],911,200238,DB00544,Fluorouracil
,6487480,AUC,"After intravenous 5FU, AUC was increased by 27% from 977 +/- 96 micrograms ml-1 min (mean +/- s.e. mean) to 1353 +/- 124 micrograms ml-1 min (P less than 0.01).",The influence of cimetidine on the pharmacokinetics of 5-fluorouracil. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6487480/),[min·μg] / [ml],977,200239,DB00544,Fluorouracil
,6487480,AUC,"After intravenous 5FU, AUC was increased by 27% from 977 +/- 96 micrograms ml-1 min (mean +/- s.e. mean) to 1353 +/- 124 micrograms ml-1 min (P less than 0.01).",The influence of cimetidine on the pharmacokinetics of 5-fluorouracil. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6487480/),[min·μg] / [ml],1353,200240,DB00544,Fluorouracil
,6487480,Total body clearance,Total body clearance for 5FU following intravenous administration was decreased by 28% from 987 +/- 116 ml/min (mean +/- s.e. mean) to 711 +/- 87 ml/min (P less than 0.01).,The influence of cimetidine on the pharmacokinetics of 5-fluorouracil. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6487480/),[ml] / [min],987,200241,DB00544,Fluorouracil
,6487480,Total body clearance,Total body clearance for 5FU following intravenous administration was decreased by 28% from 987 +/- 116 ml/min (mean +/- s.e. mean) to 711 +/- 87 ml/min (P less than 0.01).,The influence of cimetidine on the pharmacokinetics of 5-fluorouracil. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6487480/),[ml] / [min],711,200242,DB00544,Fluorouracil
,25073394,total,"The use of voriconazole as the internal standard, combined with gradient elution and on-line wavelength switching, assured very high within- and between-run precision of results (relative standard deviation < 7.1% for lower limit of quantification) and enabled the reduction of the total chromatographic run time to 8 min.",Rapid and simplified HPLC-UV method with on-line wavelengths switching for determination of capecitabine in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25073394/),,8,200334,DB00544,Fluorouracil
,9252705,steady-state plasma concentration,"The steady-state plasma concentration averaged 0.31 +/- 0.11 microgram/ml (i.e., 2.4 microM).",Pharmacokinetics of 5-fluorouracil (5-FUra) in patients with metastatic colorectal cancer receiving 5-FUra bolus plus continuous infusion with high dose folinic acid (LV5FU2). ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9252705/),[μg] / [ml],0.31,200847,DB00544,Fluorouracil
,9252705,steady-state plasma concentration,"The steady-state plasma concentration averaged 0.31 +/- 0.11 microgram/ml (i.e., 2.4 microM).",Pharmacokinetics of 5-fluorouracil (5-FUra) in patients with metastatic colorectal cancer receiving 5-FUra bolus plus continuous infusion with high dose folinic acid (LV5FU2). ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9252705/),μ,2.4,200848,DB00544,Fluorouracil
,9252705,apparent elimination half-life,5-FUra plasma levels declined rapidly after the end of infusion with an apparent elimination half-life of 7.08 +/- 3.21 minutes.,Pharmacokinetics of 5-fluorouracil (5-FUra) in patients with metastatic colorectal cancer receiving 5-FUra bolus plus continuous infusion with high dose folinic acid (LV5FU2). ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9252705/),min,7.08,200849,DB00544,Fluorouracil
,9252705,Clearance,Clearance ranged from 776 to 3023 ml/min/m2.,Pharmacokinetics of 5-fluorouracil (5-FUra) in patients with metastatic colorectal cancer receiving 5-FUra bolus plus continuous infusion with high dose folinic acid (LV5FU2). ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9252705/),[ml] / [m2·min],776 to 3023,200850,DB00544,Fluorouracil
,24610670,terminal half-life,"HY administration resulted in a longer terminal half-life (2.1 ± 0.7 vs 1.0 ± 0.2 days, p < 0.05), a reduced area under the plasma concentration-time curve from 0 to 2 hours (AUC0-2h) [0.08 ± 0.009 vs 0.12 ± 0.017 g/L•min, p < 0.01], and an increased volume of distribution, both initially (11.7 ± 3.4 vs 6.6 ± 2.1L, p < 0.05) and at steady-state (43.0 ± 10.8 vs 22.1 ± 8.8L, p < 0.05), for total Pt.",Effect of hyaluronidase on the pharmacokinetics of free and total platinum species after intra-arterial Cisplatin in refractory patients with colorectal liver metastases. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/24610670/),d,2.1,201349,DB00544,Fluorouracil
,24610670,terminal half-life,"HY administration resulted in a longer terminal half-life (2.1 ± 0.7 vs 1.0 ± 0.2 days, p < 0.05), a reduced area under the plasma concentration-time curve from 0 to 2 hours (AUC0-2h) [0.08 ± 0.009 vs 0.12 ± 0.017 g/L•min, p < 0.01], and an increased volume of distribution, both initially (11.7 ± 3.4 vs 6.6 ± 2.1L, p < 0.05) and at steady-state (43.0 ± 10.8 vs 22.1 ± 8.8L, p < 0.05), for total Pt.",Effect of hyaluronidase on the pharmacokinetics of free and total platinum species after intra-arterial Cisplatin in refractory patients with colorectal liver metastases. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/24610670/),d,1.0,201350,DB00544,Fluorouracil
,24610670,area under the plasma concentration-time curve from 0 to 2 hours (AUC0-2h),"HY administration resulted in a longer terminal half-life (2.1 ± 0.7 vs 1.0 ± 0.2 days, p < 0.05), a reduced area under the plasma concentration-time curve from 0 to 2 hours (AUC0-2h) [0.08 ± 0.009 vs 0.12 ± 0.017 g/L•min, p < 0.01], and an increased volume of distribution, both initially (11.7 ± 3.4 vs 6.6 ± 2.1L, p < 0.05) and at steady-state (43.0 ± 10.8 vs 22.1 ± 8.8L, p < 0.05), for total Pt.",Effect of hyaluronidase on the pharmacokinetics of free and total platinum species after intra-arterial Cisplatin in refractory patients with colorectal liver metastases. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24610670/),[g] / [l·min],0.08,201351,DB00544,Fluorouracil
,24610670,area under the plasma concentration-time curve from 0 to 2 hours (AUC0-2h),"HY administration resulted in a longer terminal half-life (2.1 ± 0.7 vs 1.0 ± 0.2 days, p < 0.05), a reduced area under the plasma concentration-time curve from 0 to 2 hours (AUC0-2h) [0.08 ± 0.009 vs 0.12 ± 0.017 g/L•min, p < 0.01], and an increased volume of distribution, both initially (11.7 ± 3.4 vs 6.6 ± 2.1L, p < 0.05) and at steady-state (43.0 ± 10.8 vs 22.1 ± 8.8L, p < 0.05), for total Pt.",Effect of hyaluronidase on the pharmacokinetics of free and total platinum species after intra-arterial Cisplatin in refractory patients with colorectal liver metastases. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24610670/),[g] / [l·min],0.12,201352,DB00544,Fluorouracil
,24610670,volume of distribution,"HY administration resulted in a longer terminal half-life (2.1 ± 0.7 vs 1.0 ± 0.2 days, p < 0.05), a reduced area under the plasma concentration-time curve from 0 to 2 hours (AUC0-2h) [0.08 ± 0.009 vs 0.12 ± 0.017 g/L•min, p < 0.01], and an increased volume of distribution, both initially (11.7 ± 3.4 vs 6.6 ± 2.1L, p < 0.05) and at steady-state (43.0 ± 10.8 vs 22.1 ± 8.8L, p < 0.05), for total Pt.",Effect of hyaluronidase on the pharmacokinetics of free and total platinum species after intra-arterial Cisplatin in refractory patients with colorectal liver metastases. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24610670/),l,11.7,201353,DB00544,Fluorouracil
,24610670,volume of distribution,"HY administration resulted in a longer terminal half-life (2.1 ± 0.7 vs 1.0 ± 0.2 days, p < 0.05), a reduced area under the plasma concentration-time curve from 0 to 2 hours (AUC0-2h) [0.08 ± 0.009 vs 0.12 ± 0.017 g/L•min, p < 0.01], and an increased volume of distribution, both initially (11.7 ± 3.4 vs 6.6 ± 2.1L, p < 0.05) and at steady-state (43.0 ± 10.8 vs 22.1 ± 8.8L, p < 0.05), for total Pt.",Effect of hyaluronidase on the pharmacokinetics of free and total platinum species after intra-arterial Cisplatin in refractory patients with colorectal liver metastases. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24610670/),l,6.6,201354,DB00544,Fluorouracil
,24610670,volume of distribution,"HY administration resulted in a longer terminal half-life (2.1 ± 0.7 vs 1.0 ± 0.2 days, p < 0.05), a reduced area under the plasma concentration-time curve from 0 to 2 hours (AUC0-2h) [0.08 ± 0.009 vs 0.12 ± 0.017 g/L•min, p < 0.01], and an increased volume of distribution, both initially (11.7 ± 3.4 vs 6.6 ± 2.1L, p < 0.05) and at steady-state (43.0 ± 10.8 vs 22.1 ± 8.8L, p < 0.05), for total Pt.",Effect of hyaluronidase on the pharmacokinetics of free and total platinum species after intra-arterial Cisplatin in refractory patients with colorectal liver metastases. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24610670/),l,43.0,201355,DB00544,Fluorouracil
,24610670,volume of distribution,"HY administration resulted in a longer terminal half-life (2.1 ± 0.7 vs 1.0 ± 0.2 days, p < 0.05), a reduced area under the plasma concentration-time curve from 0 to 2 hours (AUC0-2h) [0.08 ± 0.009 vs 0.12 ± 0.017 g/L•min, p < 0.01], and an increased volume of distribution, both initially (11.7 ± 3.4 vs 6.6 ± 2.1L, p < 0.05) and at steady-state (43.0 ± 10.8 vs 22.1 ± 8.8L, p < 0.05), for total Pt.",Effect of hyaluronidase on the pharmacokinetics of free and total platinum species after intra-arterial Cisplatin in refractory patients with colorectal liver metastases. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24610670/),l,22.1,201356,DB00544,Fluorouracil
,11237378,response rate,The response rate was 26% (33% stable disease) and median survival was 11 months.,5-fluorouracil steady state pharmacokinetics and outcome in patients receiving protracted venous infusion for advanced colorectal cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11237378/),%,26,201840,DB00544,Fluorouracil
,11237378,Css,Variability in 5FU(300)Css was considerably less than previously reported; 94 +/- 25 ng ml(-1)(CV = 27%).,5-fluorouracil steady state pharmacokinetics and outcome in patients receiving protracted venous infusion for advanced colorectal cancer. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11237378/),[ng] / [ml],94,201841,DB00544,Fluorouracil
,19297278,response rate,Objective responses were seen in five patients (response rate 33%).,A phase I study of TS-1 plus carboplatin in patients with advanced non-small-cell lung cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19297278/),%,33,201997,DB00544,Fluorouracil
,1557647,steady-state serum levels,"Mean steady-state serum levels of 5-FU at 500 mg/m2 given as a 4-hour infusion were 16.55 +/- 9.34 mumol/L and 18.23 +/- 12.77 mumol/L with and without IFN, respectively.",A phase I trial of interferon alpha-2b with folinic acid and 5-fluorouracil administered by 4-hour infusion in metastatic colorectal carcinoma. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1557647/),[μM] / [l],16.55,202136,DB00544,Fluorouracil
,1557647,steady-state serum levels,"Mean steady-state serum levels of 5-FU at 500 mg/m2 given as a 4-hour infusion were 16.55 +/- 9.34 mumol/L and 18.23 +/- 12.77 mumol/L with and without IFN, respectively.",A phase I trial of interferon alpha-2b with folinic acid and 5-fluorouracil administered by 4-hour infusion in metastatic colorectal carcinoma. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1557647/),[μM] / [l],18.23,202137,DB00544,Fluorouracil
,1557647,area under the curve,"Mean area under the curve (mumol/L x min) was 4,008 +/- 2,133 and 5,114 +/- 2,567 with and without interferon, respectively.",A phase I trial of interferon alpha-2b with folinic acid and 5-fluorouracil administered by 4-hour infusion in metastatic colorectal carcinoma. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1557647/),[μM] / [l·min],"4,008",202138,DB00544,Fluorouracil
,1557647,area under the curve,"Mean area under the curve (mumol/L x min) was 4,008 +/- 2,133 and 5,114 +/- 2,567 with and without interferon, respectively.",A phase I trial of interferon alpha-2b with folinic acid and 5-fluorouracil administered by 4-hour infusion in metastatic colorectal carcinoma. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1557647/),[μM] / [l·min],"5,114",202139,DB00544,Fluorouracil
,16770096,survival time,The median survival time of the 13 patients was 17 months.,[Second-line chemotherapy with pharmacokinetic modulating chemotherapy for unresectable colorectal carcinoma recurrences resistant to 5-FU-based chemotherapy]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16770096/),month,17,203732,DB00544,Fluorouracil
,1097091,half-life,"Injections of 5-fu at 15, 40, and 90 mg/kg in rats resulted in an alpha-phase of elimination from plasma with a half-life of 10-18 minutes.",Determination of 5-fluorouracil (NSC-19893) plasma levels in rats and man by isotope dilution-mass fragmentography. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1097091/),min,10-18,204118,DB00544,Fluorouracil
,1097091,beta-phase,The beta-phase could only be measured after the injection of 90 mg/kg of 5-FU and amounted to about 20 hours in two rats.,Determination of 5-fluorouracil (NSC-19893) plasma levels in rats and man by isotope dilution-mass fragmentography. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1097091/),h,20,204119,DB00544,Fluorouracil
,1097091,Plasma elimination half-lives,Plasma elimination half-lives after intravenous doses were 12 minutes and dropped below measurable levels 2 hours after administration in three patients.,Determination of 5-fluorouracil (NSC-19893) plasma levels in rats and man by isotope dilution-mass fragmentography. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1097091/),min,12,204120,DB00544,Fluorouracil
,1097091,peak plasma levels,"After oral administration, peak plasma levels of 5-FU varied between 0.8 and 60 mug/ml of 5-FU in three patients after 10 minutes to 2 hours.",Determination of 5-fluorouracil (NSC-19893) plasma levels in rats and man by isotope dilution-mass fragmentography. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1097091/),[μg] / [ml],0.8 and 60,204121,DB00544,Fluorouracil
,21208844,progression-free survival,"The Response Evaluation Criteria in Solid Tumors response rate was 11 of 14 (78%), median progression-free survival was 9.5 months, and median overall survival was 30 months.","Phase I trial of oxaliplatin, infusional 5-fluorouracil, and leucovorin (FOLFOX4) with erlotinib and bevacizumab in colorectal cancer. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21208844/),month,9.5,204548,DB00544,Fluorouracil
,21208844,overall survival,"The Response Evaluation Criteria in Solid Tumors response rate was 11 of 14 (78%), median progression-free survival was 9.5 months, and median overall survival was 30 months.","Phase I trial of oxaliplatin, infusional 5-fluorouracil, and leucovorin (FOLFOX4) with erlotinib and bevacizumab in colorectal cancer. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21208844/),month,30,204549,DB00544,Fluorouracil
,21208844,MTD,The MTD of erlotinib with FOLFOX4 with or without bevacizumab is 100 mg daily.,"Phase I trial of oxaliplatin, infusional 5-fluorouracil, and leucovorin (FOLFOX4) with erlotinib and bevacizumab in colorectal cancer. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21208844/),mg,100,204550,DB00544,Fluorouracil
,1733436,area under the plasma concentration--time curve,"The mean area under the plasma concentration--time curve, the peak plasma concentration and the steady state volume of distribution were 163 micrograms ml-1 h-1 (SD 41), 18.5 micrograms ml-1 (SD 1.2) and 7.41 m-2 (SD 0.44) respectively following intravenous administration of folinic acid compared with 142 micrograms ml-1 h-1 (SD 45), 14.8 micrograms ml-1 (SD 2.4) and 11.21 m-2 (SD 1.22) following intra-hepatic arterial administration (P less than 0.05).",A pharmacokinetic comparison of intravenous versus intra-arterial folinic acid. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1733436/),[μg] / [h·ml],163,205844,DB00544,Fluorouracil
,1733436,peak plasma concentration,"The mean area under the plasma concentration--time curve, the peak plasma concentration and the steady state volume of distribution were 163 micrograms ml-1 h-1 (SD 41), 18.5 micrograms ml-1 (SD 1.2) and 7.41 m-2 (SD 0.44) respectively following intravenous administration of folinic acid compared with 142 micrograms ml-1 h-1 (SD 45), 14.8 micrograms ml-1 (SD 2.4) and 11.21 m-2 (SD 1.22) following intra-hepatic arterial administration (P less than 0.05).",A pharmacokinetic comparison of intravenous versus intra-arterial folinic acid. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1733436/),[μg] / [ml],18.5,205845,DB00544,Fluorouracil
,1733436,steady state volume of distribution,"The mean area under the plasma concentration--time curve, the peak plasma concentration and the steady state volume of distribution were 163 micrograms ml-1 h-1 (SD 41), 18.5 micrograms ml-1 (SD 1.2) and 7.41 m-2 (SD 0.44) respectively following intravenous administration of folinic acid compared with 142 micrograms ml-1 h-1 (SD 45), 14.8 micrograms ml-1 (SD 2.4) and 11.21 m-2 (SD 1.22) following intra-hepatic arterial administration (P less than 0.05).",A pharmacokinetic comparison of intravenous versus intra-arterial folinic acid. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1733436/),1/[(m)^2],7.41,205846,DB00544,Fluorouracil
,1733436,steady state volume of distribution,"The mean area under the plasma concentration--time curve, the peak plasma concentration and the steady state volume of distribution were 163 micrograms ml-1 h-1 (SD 41), 18.5 micrograms ml-1 (SD 1.2) and 7.41 m-2 (SD 0.44) respectively following intravenous administration of folinic acid compared with 142 micrograms ml-1 h-1 (SD 45), 14.8 micrograms ml-1 (SD 2.4) and 11.21 m-2 (SD 1.22) following intra-hepatic arterial administration (P less than 0.05).",A pharmacokinetic comparison of intravenous versus intra-arterial folinic acid. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1733436/),1/[(m)^2],11.21,205847,DB00544,Fluorouracil
,15939714,Response rate,Response rate in the phase II cohort was 42% [95% confidence interval (CI) 29% to 56%].,A phase I/II and pharmacokinetic study of irinotecan in combination with capecitabine as first-line therapy for advanced colorectal cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15939714/),%,42,206007,DB00544,Fluorouracil
,15939714,duration of response,Median duration of response was 7.7 months (95% CI 7.5-8.9).,A phase I/II and pharmacokinetic study of irinotecan in combination with capecitabine as first-line therapy for advanced colorectal cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15939714/),month,7.7,206008,DB00544,Fluorouracil
,15939714,time to progression,Median time to progression was 8.3 months (95% CI 5.8-10).,A phase I/II and pharmacokinetic study of irinotecan in combination with capecitabine as first-line therapy for advanced colorectal cancer. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15939714/),month,8.3,206009,DB00544,Fluorouracil
,23524118,IC50,"In vitro cytotoxicity assay of FVS against U251 cells and HeLa cells showed that at 72h treatment, the FVS (IC50=23.42μg/mL) exhibited strong inhibitory effect against U251 cells, even overwhelmed the standard anti-tumor drug (5-fluorouracil) to an extent, while the HeLa cells were not significantly susceptible to the FVS.",Cytotoxic effect of novel Flammulina velutipes sterols and its oral bioavailability via mixed micellar nanoformulation. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23524118/),[μg] / [ml],23.42,206771,DB00544,Fluorouracil
,8996532,plasma clearance rate,The plasma clearance rate of a bolus dose of 100 mg/kg 5-FU was significantly reduced from 54 to 28 ml/min per kg and the elimination half-life was increased from 6.9 to 12.2 min by prior administration of morphine.,Opiate effects on 5-fluorouracil disposition in mice. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8996532/),[ml] / [kg·min],54 to 28,206813,DB00544,Fluorouracil
,8996532,elimination half-life,The plasma clearance rate of a bolus dose of 100 mg/kg 5-FU was significantly reduced from 54 to 28 ml/min per kg and the elimination half-life was increased from 6.9 to 12.2 min by prior administration of morphine.,Opiate effects on 5-fluorouracil disposition in mice. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8996532/),min,6.9 to 12.2,206814,DB00544,Fluorouracil
,8996532,plasma clearance rate,"When 5-FU was infused at 0.5 mg/kg per min, morphine reduced its plasma clearance rate from 145 to 94 ml/min per kg.",Opiate effects on 5-fluorouracil disposition in mice. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8996532/),[ml] / [kg·min],145,206815,DB00544,Fluorouracil
,8996532,plasma clearance rate,"When 5-FU was infused at 0.5 mg/kg per min, morphine reduced its plasma clearance rate from 145 to 94 ml/min per kg.",Opiate effects on 5-fluorouracil disposition in mice. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8996532/),[ml] / [kg·min],94,206816,DB00544,Fluorouracil
,1568210,steady-state plasma concentrations,"The mean steady-state plasma concentrations of (6S)-folinic acid and its principal metabolite (6S)-5-methyltetrahydrofolate at the 250 mg/m2/day dose were 2.7 and 5.1 microM, respectively.",Pharmacokinetics and toxicity of continuous infusion (6S)-folinic acid and bolus 5-fluorouracil in patients with advanced cancer. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1568210/),μM,2.7,207014,DB00544,Fluorouracil
,1568210,steady-state plasma concentrations,"The mean steady-state plasma concentrations of (6S)-folinic acid and its principal metabolite (6S)-5-methyltetrahydrofolate at the 250 mg/m2/day dose were 2.7 and 5.1 microM, respectively.",Pharmacokinetics and toxicity of continuous infusion (6S)-folinic acid and bolus 5-fluorouracil in patients with advanced cancer. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1568210/),μM,5.1,207015,DB00544,Fluorouracil
,19151579,peak concentration,"Serum 5-FU levels were higher at night, and the peak concentration of 5-FU was / 398 ng/mL.",[Pharmacokinetic monitoring of 5-fluorouracil may improve the clinical benefit with an individualized regimen-a case report]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19151579/),[ng] / [ml],/ 398,207321,DB00544,Fluorouracil
,7738622,objective response rate,An objective response rate of 15% (one complete response [CR] and 13 partial responses [PRs]) for 5-FU/FA and 13% (two CRs and nine PRs) for 5-FU/FA/DP was observed.,Failure of orally administered dipyridamole to enhance the antineoplastic activity of fluorouracil in combination with leucovorin in patients with advanced colorectal cancer: a prospective randomized trial. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7738622/),%,15,207980,DB00544,Fluorouracil
,7738622,objective response rate,An objective response rate of 15% (one complete response [CR] and 13 partial responses [PRs]) for 5-FU/FA and 13% (two CRs and nine PRs) for 5-FU/FA/DP was observed.,Failure of orally administered dipyridamole to enhance the antineoplastic activity of fluorouracil in combination with leucovorin in patients with advanced colorectal cancer: a prospective randomized trial. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7738622/),%,13,207981,DB00544,Fluorouracil
,7738622,time to progression,"The median time to progression (P = .8) and the median survival time (11.6 months for 5-FU/FA v 9.3 months for 5-FU/FA/DP; P = .14, log-rank test) were not different between treatment arms.",Failure of orally administered dipyridamole to enhance the antineoplastic activity of fluorouracil in combination with leucovorin in patients with advanced colorectal cancer: a prospective randomized trial. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7738622/),month,11.6,207982,DB00544,Fluorouracil
,7738622,survival time,"The median time to progression (P = .8) and the median survival time (11.6 months for 5-FU/FA v 9.3 months for 5-FU/FA/DP; P = .14, log-rank test) were not different between treatment arms.",Failure of orally administered dipyridamole to enhance the antineoplastic activity of fluorouracil in combination with leucovorin in patients with advanced colorectal cancer: a prospective randomized trial. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7738622/),month,9.3,207983,DB00544,Fluorouracil
,10955781,area under the curve,"Plasma pharmacokinetic parameters of patients given 250 mg/m2 5-FU were significantly different from those receiving 370 mg/m2; main differences were observed in the trapezoidal areas under the plasma levels-versus-time curve from to to the last measurable concentration (area under the curve, 3.77+/-0.21 versus 13.61+/-2.3 h x microg/ml), peak plasma concentration (Cmax, 18.15+/-1.35 versus 48.41+/-7.69 microg/ml), and total body clearance (CL(TB), 54.64+/-3.54 versus 25.43+/-2.3 l/h/m2).","Comparative pharmacokinetic analysis of 5-fluorouracil and its major metabolite 5-fluoro-5,6-dihydrouracil after conventional and reduced test dose in cancer patients. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10955781/),[h·μg] / [ml],3.77,208373,DB00544,Fluorouracil
,10955781,area under the curve,"Plasma pharmacokinetic parameters of patients given 250 mg/m2 5-FU were significantly different from those receiving 370 mg/m2; main differences were observed in the trapezoidal areas under the plasma levels-versus-time curve from to to the last measurable concentration (area under the curve, 3.77+/-0.21 versus 13.61+/-2.3 h x microg/ml), peak plasma concentration (Cmax, 18.15+/-1.35 versus 48.41+/-7.69 microg/ml), and total body clearance (CL(TB), 54.64+/-3.54 versus 25.43+/-2.3 l/h/m2).","Comparative pharmacokinetic analysis of 5-fluorouracil and its major metabolite 5-fluoro-5,6-dihydrouracil after conventional and reduced test dose in cancer patients. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10955781/),[h·μg] / [ml],13.61,208374,DB00544,Fluorouracil
,10955781,peak plasma concentration (Cmax,"Plasma pharmacokinetic parameters of patients given 250 mg/m2 5-FU were significantly different from those receiving 370 mg/m2; main differences were observed in the trapezoidal areas under the plasma levels-versus-time curve from to to the last measurable concentration (area under the curve, 3.77+/-0.21 versus 13.61+/-2.3 h x microg/ml), peak plasma concentration (Cmax, 18.15+/-1.35 versus 48.41+/-7.69 microg/ml), and total body clearance (CL(TB), 54.64+/-3.54 versus 25.43+/-2.3 l/h/m2).","Comparative pharmacokinetic analysis of 5-fluorouracil and its major metabolite 5-fluoro-5,6-dihydrouracil after conventional and reduced test dose in cancer patients. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10955781/),[μg] / [ml],18.15,208375,DB00544,Fluorouracil
,10955781,peak plasma concentration (Cmax,"Plasma pharmacokinetic parameters of patients given 250 mg/m2 5-FU were significantly different from those receiving 370 mg/m2; main differences were observed in the trapezoidal areas under the plasma levels-versus-time curve from to to the last measurable concentration (area under the curve, 3.77+/-0.21 versus 13.61+/-2.3 h x microg/ml), peak plasma concentration (Cmax, 18.15+/-1.35 versus 48.41+/-7.69 microg/ml), and total body clearance (CL(TB), 54.64+/-3.54 versus 25.43+/-2.3 l/h/m2).","Comparative pharmacokinetic analysis of 5-fluorouracil and its major metabolite 5-fluoro-5,6-dihydrouracil after conventional and reduced test dose in cancer patients. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10955781/),[μg] / [ml],48.41,208376,DB00544,Fluorouracil
,10955781,total body clearance (CL(TB),"Plasma pharmacokinetic parameters of patients given 250 mg/m2 5-FU were significantly different from those receiving 370 mg/m2; main differences were observed in the trapezoidal areas under the plasma levels-versus-time curve from to to the last measurable concentration (area under the curve, 3.77+/-0.21 versus 13.61+/-2.3 h x microg/ml), peak plasma concentration (Cmax, 18.15+/-1.35 versus 48.41+/-7.69 microg/ml), and total body clearance (CL(TB), 54.64+/-3.54 versus 25.43+/-2.3 l/h/m2).","Comparative pharmacokinetic analysis of 5-fluorouracil and its major metabolite 5-fluoro-5,6-dihydrouracil after conventional and reduced test dose in cancer patients. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10955781/),[l] / [h·m2],54.64,208377,DB00544,Fluorouracil
,10955781,total body clearance (CL(TB),"Plasma pharmacokinetic parameters of patients given 250 mg/m2 5-FU were significantly different from those receiving 370 mg/m2; main differences were observed in the trapezoidal areas under the plasma levels-versus-time curve from to to the last measurable concentration (area under the curve, 3.77+/-0.21 versus 13.61+/-2.3 h x microg/ml), peak plasma concentration (Cmax, 18.15+/-1.35 versus 48.41+/-7.69 microg/ml), and total body clearance (CL(TB), 54.64+/-3.54 versus 25.43+/-2.3 l/h/m2).","Comparative pharmacokinetic analysis of 5-fluorouracil and its major metabolite 5-fluoro-5,6-dihydrouracil after conventional and reduced test dose in cancer patients. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10955781/),[l] / [h·m2],25.43,208378,DB00544,Fluorouracil
,10955781,area under the curve from to to 4 h,"Significant differences were also observed in the main pharmacokinetic parameters of 5-FDHU after 250 and 370 mg/m2 5-FU including the area under the curve from to to 4 h (5.39+/-0.32 versus 8.75+/-1.24 h x microg/ml), Cmax (3.60+/-0.16 versus 5.26+/-0.55 microg/ml) and time to Cmax (Tmax, 0.45+/-0.03 versus 0.69+/-0.06 h).","Comparative pharmacokinetic analysis of 5-fluorouracil and its major metabolite 5-fluoro-5,6-dihydrouracil after conventional and reduced test dose in cancer patients. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10955781/),[h·μg] / [ml],5.39,208379,DB00544,Fluorouracil
,10955781,area under the curve from to to 4 h,"Significant differences were also observed in the main pharmacokinetic parameters of 5-FDHU after 250 and 370 mg/m2 5-FU including the area under the curve from to to 4 h (5.39+/-0.32 versus 8.75+/-1.24 h x microg/ml), Cmax (3.60+/-0.16 versus 5.26+/-0.55 microg/ml) and time to Cmax (Tmax, 0.45+/-0.03 versus 0.69+/-0.06 h).","Comparative pharmacokinetic analysis of 5-fluorouracil and its major metabolite 5-fluoro-5,6-dihydrouracil after conventional and reduced test dose in cancer patients. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10955781/),[h·μg] / [ml],8.75,208380,DB00544,Fluorouracil
,10955781,Cmax,"Significant differences were also observed in the main pharmacokinetic parameters of 5-FDHU after 250 and 370 mg/m2 5-FU including the area under the curve from to to 4 h (5.39+/-0.32 versus 8.75+/-1.24 h x microg/ml), Cmax (3.60+/-0.16 versus 5.26+/-0.55 microg/ml) and time to Cmax (Tmax, 0.45+/-0.03 versus 0.69+/-0.06 h).","Comparative pharmacokinetic analysis of 5-fluorouracil and its major metabolite 5-fluoro-5,6-dihydrouracil after conventional and reduced test dose in cancer patients. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10955781/),[μg] / [ml],3.60,208381,DB00544,Fluorouracil
,10955781,Cmax,"Significant differences were also observed in the main pharmacokinetic parameters of 5-FDHU after 250 and 370 mg/m2 5-FU including the area under the curve from to to 4 h (5.39+/-0.32 versus 8.75+/-1.24 h x microg/ml), Cmax (3.60+/-0.16 versus 5.26+/-0.55 microg/ml) and time to Cmax (Tmax, 0.45+/-0.03 versus 0.69+/-0.06 h).","Comparative pharmacokinetic analysis of 5-fluorouracil and its major metabolite 5-fluoro-5,6-dihydrouracil after conventional and reduced test dose in cancer patients. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10955781/),[μg] / [ml],5.26,208382,DB00544,Fluorouracil
,10955781,time to Cmax (Tmax,"Significant differences were also observed in the main pharmacokinetic parameters of 5-FDHU after 250 and 370 mg/m2 5-FU including the area under the curve from to to 4 h (5.39+/-0.32 versus 8.75+/-1.24 h x microg/ml), Cmax (3.60+/-0.16 versus 5.26+/-0.55 microg/ml) and time to Cmax (Tmax, 0.45+/-0.03 versus 0.69+/-0.06 h).","Comparative pharmacokinetic analysis of 5-fluorouracil and its major metabolite 5-fluoro-5,6-dihydrouracil after conventional and reduced test dose in cancer patients. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10955781/),h,0.45,208383,DB00544,Fluorouracil
,10955781,time to Cmax (Tmax,"Significant differences were also observed in the main pharmacokinetic parameters of 5-FDHU after 250 and 370 mg/m2 5-FU including the area under the curve from to to 4 h (5.39+/-0.32 versus 8.75+/-1.24 h x microg/ml), Cmax (3.60+/-0.16 versus 5.26+/-0.55 microg/ml) and time to Cmax (Tmax, 0.45+/-0.03 versus 0.69+/-0.06 h).","Comparative pharmacokinetic analysis of 5-fluorouracil and its major metabolite 5-fluoro-5,6-dihydrouracil after conventional and reduced test dose in cancer patients. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10955781/),h,0.69,208384,DB00544,Fluorouracil
,10955781,activity,"The mean DPD activity in PBMCs in this group of patients was 205.7+/-36.4 pmol of 5-FDHU/min/mg of protein and was within the normal range; however, no significant correlations were found between 5-FU or 5-FDHU pharmacokinetic parameters at two dose levels and DPD activity of PBMCs.","Comparative pharmacokinetic analysis of 5-fluorouracil and its major metabolite 5-fluoro-5,6-dihydrouracil after conventional and reduced test dose in cancer patients. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10955781/),pM,205.7,208385,DB00544,Fluorouracil
,7917928,Michaelis constant (KM),"With the Michaelis constant (KM) set at 15 microM, values were derived for the volume of distribution (Vd), the maximum rate of non-linear elimination (Vmax) and the first-order elimination rate constant (K1.e).",Lack of effect of interferon alpha 2a upon fluorouracil pharmacokinetics. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7917928/),μM,15,208699,DB00544,Fluorouracil
,7917928,Vd,"Mean (+/- s.d.) values in control (no IFN-alpha) patients were: Vd 10.4 (+/- 1.9) l m-2, Vmax 182 (+/- 59) mumol l-1 h-1 and k1.e 4.35 (+/- 0.58) h-1.",Lack of effect of interferon alpha 2a upon fluorouracil pharmacokinetics. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7917928/),[l] / [(m)^2],10.4,208700,DB00544,Fluorouracil
,7917928,Vmax,"Mean (+/- s.d.) values in control (no IFN-alpha) patients were: Vd 10.4 (+/- 1.9) l m-2, Vmax 182 (+/- 59) mumol l-1 h-1 and k1.e 4.35 (+/- 0.58) h-1.",Lack of effect of interferon alpha 2a upon fluorouracil pharmacokinetics. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7917928/),[μM] / [h·l],182,208701,DB00544,Fluorouracil
,7917928,k1.e,"Mean (+/- s.d.) values in control (no IFN-alpha) patients were: Vd 10.4 (+/- 1.9) l m-2, Vmax 182 (+/- 59) mumol l-1 h-1 and k1.e 4.35 (+/- 0.58) h-1.",Lack of effect of interferon alpha 2a upon fluorouracil pharmacokinetics. ,"K12, K21-Q48",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7917928/),1/[h],4.35,208702,DB00544,Fluorouracil
,7917928,Vd,"No significant differences were detected in patients receiving IFN-alpha, in whom the equivalent mean values were Vd 10.0 (+/- 0.9) l m-2, Vmax 141 (+/- 27) mumol l-1 h-1 and k1.e 3.96 (+/- 0.5) h-1.",Lack of effect of interferon alpha 2a upon fluorouracil pharmacokinetics. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7917928/),[l] / [(m)^2],10.0,208703,DB00544,Fluorouracil
,7917928,Vmax,"No significant differences were detected in patients receiving IFN-alpha, in whom the equivalent mean values were Vd 10.0 (+/- 0.9) l m-2, Vmax 141 (+/- 27) mumol l-1 h-1 and k1.e 3.96 (+/- 0.5) h-1.",Lack of effect of interferon alpha 2a upon fluorouracil pharmacokinetics. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7917928/),[μM] / [h·l],141,208704,DB00544,Fluorouracil
,7917928,k1.e,"No significant differences were detected in patients receiving IFN-alpha, in whom the equivalent mean values were Vd 10.0 (+/- 0.9) l m-2, Vmax 141 (+/- 27) mumol l-1 h-1 and k1.e 3.96 (+/- 0.5) h-1.",Lack of effect of interferon alpha 2a upon fluorouracil pharmacokinetics. ,"K12, K21-Q48",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7917928/),1/[h],3.96,208705,DB00544,Fluorouracil
,7917928,AUC0-22 h,"Mean trapezoidal AUC0-22 h was similar in the two groups (control patients 116 microM h, IFN-alpha patients 125 microM h).",Lack of effect of interferon alpha 2a upon fluorouracil pharmacokinetics. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7917928/),h·μM,116,208706,DB00544,Fluorouracil
,7917928,AUC0-22 h,"Mean trapezoidal AUC0-22 h was similar in the two groups (control patients 116 microM h, IFN-alpha patients 125 microM h).",Lack of effect of interferon alpha 2a upon fluorouracil pharmacokinetics. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7917928/),h·μM,125,208707,DB00544,Fluorouracil
,27390048,50% inhibitory,"The 50% inhibitory 5-FU concentration for CYP2C9 synthesis and the degradation rate constant of CYP2C9 were estimated to be 0.00310 ng/mL and 0.0768 day-1, respectively.",Pharmacokinetic model analysis of interaction between phenytoin and capecitabine. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27390048/),[ng] / [ml],0.00310,208880,DB00544,Fluorouracil
,27390048,degradation rate constant,"The 50% inhibitory 5-FU concentration for CYP2C9 synthesis and the degradation rate constant of CYP2C9 were estimated to be 0.00310 ng/mL and 0.0768 day-1, respectively.",Pharmacokinetic model analysis of interaction between phenytoin and capecitabine. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27390048/),1/[d],0.0768,208881,DB00544,Fluorouracil
,29373094,bpCR rates,"The bpCR rates were 51.7% and 42.0% with SB3 and TRZ, respectively.","Phase III, Randomized, Double-Blind Study Comparing the Efficacy, Safety, and Immunogenicity of SB3 (Trastuzumab Biosimilar) and Reference Trastuzumab in Patients Treated With Neoadjuvant Therapy for Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29373094/),%,51.7,209179,DB00544,Fluorouracil
,29373094,bpCR rates,"The bpCR rates were 51.7% and 42.0% with SB3 and TRZ, respectively.","Phase III, Randomized, Double-Blind Study Comparing the Efficacy, Safety, and Immunogenicity of SB3 (Trastuzumab Biosimilar) and Reference Trastuzumab in Patients Treated With Neoadjuvant Therapy for Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29373094/),%,42.0,209180,DB00544,Fluorouracil
,29373094,total pathologic complete response rates,"The total pathologic complete response rates were 45.8% and 35.8% and the overall response rates were 96.3% and 91.2% with SB3 and TRZ, respectively.","Phase III, Randomized, Double-Blind Study Comparing the Efficacy, Safety, and Immunogenicity of SB3 (Trastuzumab Biosimilar) and Reference Trastuzumab in Patients Treated With Neoadjuvant Therapy for Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29373094/),%,45.8,209181,DB00544,Fluorouracil
,29373094,total pathologic complete response rates,"The total pathologic complete response rates were 45.8% and 35.8% and the overall response rates were 96.3% and 91.2% with SB3 and TRZ, respectively.","Phase III, Randomized, Double-Blind Study Comparing the Efficacy, Safety, and Immunogenicity of SB3 (Trastuzumab Biosimilar) and Reference Trastuzumab in Patients Treated With Neoadjuvant Therapy for Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29373094/),%,35.8,209182,DB00544,Fluorouracil
,29373094,overall response rates,"The total pathologic complete response rates were 45.8% and 35.8% and the overall response rates were 96.3% and 91.2% with SB3 and TRZ, respectively.","Phase III, Randomized, Double-Blind Study Comparing the Efficacy, Safety, and Immunogenicity of SB3 (Trastuzumab Biosimilar) and Reference Trastuzumab in Patients Treated With Neoadjuvant Therapy for Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29373094/),%,96.3,209183,DB00544,Fluorouracil
,29373094,overall response rates,"The total pathologic complete response rates were 45.8% and 35.8% and the overall response rates were 96.3% and 91.2% with SB3 and TRZ, respectively.","Phase III, Randomized, Double-Blind Study Comparing the Efficacy, Safety, and Immunogenicity of SB3 (Trastuzumab Biosimilar) and Reference Trastuzumab in Patients Treated With Neoadjuvant Therapy for Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29373094/),%,91.2,209184,DB00544,Fluorouracil
,22528576,minimal detectable levels,"Pharmacokinetic data has demonstrated minimal detectable levels of irinotecan (18.6, 21, and 18.6 ng/ml) and SN-38 (1.06, 1.47, and 1.55 ng/ml) after the first, second, and third DEBIRI treatments, respectively.",Irinotecan drug-eluting beads in the treatment of chemo-naive unresectable colorectal liver metastasis with concomitant systemic fluorouracil and oxaliplatin: results of pharmacokinetics and phase I trial. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22528576/),[ng] / [ml],18.6,209363,DB00544,Fluorouracil
,22528576,minimal detectable levels,"Pharmacokinetic data has demonstrated minimal detectable levels of irinotecan (18.6, 21, and 18.6 ng/ml) and SN-38 (1.06, 1.47, and 1.55 ng/ml) after the first, second, and third DEBIRI treatments, respectively.",Irinotecan drug-eluting beads in the treatment of chemo-naive unresectable colorectal liver metastasis with concomitant systemic fluorouracil and oxaliplatin: results of pharmacokinetics and phase I trial. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22528576/),[ng] / [ml],21,209364,DB00544,Fluorouracil
,22528576,minimal detectable levels,"Pharmacokinetic data has demonstrated minimal detectable levels of irinotecan (18.6, 21, and 18.6 ng/ml) and SN-38 (1.06, 1.47, and 1.55 ng/ml) after the first, second, and third DEBIRI treatments, respectively.",Irinotecan drug-eluting beads in the treatment of chemo-naive unresectable colorectal liver metastasis with concomitant systemic fluorouracil and oxaliplatin: results of pharmacokinetics and phase I trial. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22528576/),[ng] / [ml],1.06,209365,DB00544,Fluorouracil
,22528576,minimal detectable levels,"Pharmacokinetic data has demonstrated minimal detectable levels of irinotecan (18.6, 21, and 18.6 ng/ml) and SN-38 (1.06, 1.47, and 1.55 ng/ml) after the first, second, and third DEBIRI treatments, respectively.",Irinotecan drug-eluting beads in the treatment of chemo-naive unresectable colorectal liver metastasis with concomitant systemic fluorouracil and oxaliplatin: results of pharmacokinetics and phase I trial. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22528576/),[ng] / [ml],1.47,209366,DB00544,Fluorouracil
,22528576,minimal detectable levels,"Pharmacokinetic data has demonstrated minimal detectable levels of irinotecan (18.6, 21, and 18.6 ng/ml) and SN-38 (1.06, 1.47, and 1.55 ng/ml) after the first, second, and third DEBIRI treatments, respectively.",Irinotecan drug-eluting beads in the treatment of chemo-naive unresectable colorectal liver metastasis with concomitant systemic fluorouracil and oxaliplatin: results of pharmacokinetics and phase I trial. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22528576/),[ng] / [ml],1.55,209367,DB00544,Fluorouracil
,22528576,overall survival,Four (40 %) patients were successfully downstaged to resection and/or ablation with a median overall survival of 15.2 months.,Irinotecan drug-eluting beads in the treatment of chemo-naive unresectable colorectal liver metastasis with concomitant systemic fluorouracil and oxaliplatin: results of pharmacokinetics and phase I trial. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22528576/),month,15.2,209368,DB00544,Fluorouracil
,31138588,progression-free survival (PFS),The median progression-free survival (PFS) was 22.1 months (95% CI: 9.0-26.2 months).,"Safety, Efficacy, and Biomarker Analysis of Pyrotinib in Combination with Capecitabine in HER2-Positive Metastatic Breast Cancer Patients: A Phase I Clinical Trial. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31138588/),month,22.1,210109,DB00544,Fluorouracil
,11014408,maximum rate of elimination,"On day 1 the mean values (with interindividual variability as expressed by the coefficient of variation) were 1390 mg x h(-1) (20%), and 5.57 mg x L(-1) (22%) for the maximum rate of elimination, and the half-saturating plasma concentration.",Dose and time dependencies of 5-fluorouracil pharmacokinetics. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11014408/),[mg] / [h],1390,210381,DB00544,Fluorouracil
,11014408,half-saturating plasma concentration,"On day 1 the mean values (with interindividual variability as expressed by the coefficient of variation) were 1390 mg x h(-1) (20%), and 5.57 mg x L(-1) (22%) for the maximum rate of elimination, and the half-saturating plasma concentration.",Dose and time dependencies of 5-fluorouracil pharmacokinetics. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11014408/),[mg] / [h],1390,210382,DB00544,Fluorouracil
,11014408,maximum rate of elimination,"On day 1 the mean values (with interindividual variability as expressed by the coefficient of variation) were 1390 mg x h(-1) (20%), and 5.57 mg x L(-1) (22%) for the maximum rate of elimination, and the half-saturating plasma concentration.",Dose and time dependencies of 5-fluorouracil pharmacokinetics. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11014408/),[mg] / [l],5.57,210383,DB00544,Fluorouracil
,11014408,half-saturating plasma concentration,"On day 1 the mean values (with interindividual variability as expressed by the coefficient of variation) were 1390 mg x h(-1) (20%), and 5.57 mg x L(-1) (22%) for the maximum rate of elimination, and the half-saturating plasma concentration.",Dose and time dependencies of 5-fluorouracil pharmacokinetics. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11014408/),[mg] / [l],5.57,210384,DB00544,Fluorouracil
,10037174,maximum tolerated doses (MTDs),"The maximum tolerated doses (MTDs) of S-1, FT, and FUra were 31.5, 200, and 25 mg/kg/d for 7 days and 22.5, 150, and 12.5 mg/kg/d for 28 days, respectively.","Persistent induction of apoptosis and suppression of mitosis as the basis for curative therapy with S-1, an oral 5-fluorouracil prodrug in a colorectal tumor model. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10037174/),,31.5,210888,DB00544,Fluorouracil
,10037174,maximum tolerated doses (MTDs),"The maximum tolerated doses (MTDs) of S-1, FT, and FUra were 31.5, 200, and 25 mg/kg/d for 7 days and 22.5, 150, and 12.5 mg/kg/d for 28 days, respectively.","Persistent induction of apoptosis and suppression of mitosis as the basis for curative therapy with S-1, an oral 5-fluorouracil prodrug in a colorectal tumor model. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10037174/),,22.5,210889,DB00544,Fluorouracil
,21174225,objective response rate,"The objective response rate was 30.0% (95% confidence interval [CI], 14.7%-49.4%) and the disease control rate (complete response, partial response, or stable disease) was 76.7% (95% CI, 57.7%-90.0%).","Phase II study of combination chemotherapy with biweekly cetuximab and irinotecan for wild-type KRAS metastatic colorectal cancer refractory to irinotecan, oxaliplatin, and fluoropyrimidines. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21174225/),%,30.,210925,DB00544,Fluorouracil
,21174225,progression-free survival,The median progression-free survival was 5.3 months and median overall survival was 10.8 months.,"Phase II study of combination chemotherapy with biweekly cetuximab and irinotecan for wild-type KRAS metastatic colorectal cancer refractory to irinotecan, oxaliplatin, and fluoropyrimidines. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21174225/),month,5.3,210926,DB00544,Fluorouracil
,21174225,overall survival,The median progression-free survival was 5.3 months and median overall survival was 10.8 months.,"Phase II study of combination chemotherapy with biweekly cetuximab and irinotecan for wild-type KRAS metastatic colorectal cancer refractory to irinotecan, oxaliplatin, and fluoropyrimidines. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21174225/),month,10.8,210927,DB00544,Fluorouracil
,27871319,MTD,The MTD of PEP02 was determined as 80 mg/m2.,A phase I dose-escalation study of PEP02 (irinotecan liposome injection) in combination with 5-fluorouracil and leucovorin in advanced solid tumors. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27871319/),[mg] / [m2],80,212352,DB00544,Fluorouracil
,27871319,MTD,"The MTD of PEP02 on day 1 in combination with 24-h infusion of 5-FU and LV on days 1 and 8, every 3 weeks was 80 mg/m2, which will be the recommended dose for future studies.",A phase I dose-escalation study of PEP02 (irinotecan liposome injection) in combination with 5-fluorouracil and leucovorin in advanced solid tumors. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27871319/),mg,80,212353,DB00544,Fluorouracil
,2974418,terminal half-lives,Plasma concentrations of 5'dFUR fell rapidly with terminal half-lives ranging from 16.1 to 27.7 min.,The pharmacokinetics of doxifluridine and 5-fluorouracil after single intravenous infusions of doxifluridine to patients with colorectal cancer. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2974418/),min,16.1 to 27.7,212892,DB00544,Fluorouracil
,2974418,nonrenal clearance,Doubling the dose resulted in a 40% decrease in nonrenal clearance (0.60 to 0.37 l.min-1) but no apparent change in renal clearance (0.32 to 0.29 l.min-1) or steady-state apparent volume of distribution (19.8 to 20.4 l).,The pharmacokinetics of doxifluridine and 5-fluorouracil after single intravenous infusions of doxifluridine to patients with colorectal cancer. ,CLH-Q25,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2974418/),[l] / [min],0.60 to 0.37,212893,DB00544,Fluorouracil
,2974418,renal clearance,Doubling the dose resulted in a 40% decrease in nonrenal clearance (0.60 to 0.37 l.min-1) but no apparent change in renal clearance (0.32 to 0.29 l.min-1) or steady-state apparent volume of distribution (19.8 to 20.4 l).,The pharmacokinetics of doxifluridine and 5-fluorouracil after single intravenous infusions of doxifluridine to patients with colorectal cancer. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2974418/),[l] / [min],0.32 to 0.29,212894,DB00544,Fluorouracil
,2974418,steady-state apparent volume of distribution,Doubling the dose resulted in a 40% decrease in nonrenal clearance (0.60 to 0.37 l.min-1) but no apparent change in renal clearance (0.32 to 0.29 l.min-1) or steady-state apparent volume of distribution (19.8 to 20.4 l).,The pharmacokinetics of doxifluridine and 5-fluorouracil after single intravenous infusions of doxifluridine to patients with colorectal cancer. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2974418/),l,19.8 to 20.4,212895,DB00544,Fluorouracil
,10668856,distribution half-life,The distribution half-life of ultrafiltrated plasma platinum ranges from 10 to 25 minutes and its terminal elimination half-life is 26 hours (determined with FAAS) or 270 hours (ICP-MS).,Oxaliplatin: pharmacokinetics and chronopharmacological aspects. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10668856/),min,10 to 25,213128,DB00544,Fluorouracil
,10668856,terminal elimination half-life,The distribution half-life of ultrafiltrated plasma platinum ranges from 10 to 25 minutes and its terminal elimination half-life is 26 hours (determined with FAAS) or 270 hours (ICP-MS).,Oxaliplatin: pharmacokinetics and chronopharmacological aspects. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10668856/),h,26,213129,DB00544,Fluorouracil
,10668856,terminal elimination half-life,The distribution half-life of ultrafiltrated plasma platinum ranges from 10 to 25 minutes and its terminal elimination half-life is 26 hours (determined with FAAS) or 270 hours (ICP-MS).,Oxaliplatin: pharmacokinetics and chronopharmacological aspects. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10668856/),h,270,213130,DB00544,Fluorouracil
,10668856,elimination half-life,"The elimination half-life of erythrocytic platinum is 12 to 50 days, close to that of erythrocytes.",Oxaliplatin: pharmacokinetics and chronopharmacological aspects. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10668856/),d,12 to 50,213131,DB00544,Fluorouracil
,2948036,half-life,"The average half-life of HCFUf and 5-FUra were 1.05 and 1.31 hours, and the average areas under the curves (AUC) of the plasma concentration were 6.51 hr X mcg/ml and 0.46 hr X mcg/ml, respectively.",[The determination of thymidylate synthetase inhibition for testing fluoropyrimidines--pharmacokinetics and metabolism of carmofur (HCFU) in patients with gynecologic malignancies--Tokai HCFU Study Group for Gynecologic Malignancies]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2948036/),h,1.05,213186,DB00544,Fluorouracil
,2948036,half-life,"The average half-life of HCFUf and 5-FUra were 1.05 and 1.31 hours, and the average areas under the curves (AUC) of the plasma concentration were 6.51 hr X mcg/ml and 0.46 hr X mcg/ml, respectively.",[The determination of thymidylate synthetase inhibition for testing fluoropyrimidines--pharmacokinetics and metabolism of carmofur (HCFU) in patients with gynecologic malignancies--Tokai HCFU Study Group for Gynecologic Malignancies]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2948036/),h,1.31,213187,DB00544,Fluorouracil
,2948036,areas under the curves (AUC),"The average half-life of HCFUf and 5-FUra were 1.05 and 1.31 hours, and the average areas under the curves (AUC) of the plasma concentration were 6.51 hr X mcg/ml and 0.46 hr X mcg/ml, respectively.",[The determination of thymidylate synthetase inhibition for testing fluoropyrimidines--pharmacokinetics and metabolism of carmofur (HCFU) in patients with gynecologic malignancies--Tokai HCFU Study Group for Gynecologic Malignancies]. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2948036/),[h·mcg] / [ml],6.51,213188,DB00544,Fluorouracil
,2948036,areas under the curves (AUC),"The average half-life of HCFUf and 5-FUra were 1.05 and 1.31 hours, and the average areas under the curves (AUC) of the plasma concentration were 6.51 hr X mcg/ml and 0.46 hr X mcg/ml, respectively.",[The determination of thymidylate synthetase inhibition for testing fluoropyrimidines--pharmacokinetics and metabolism of carmofur (HCFU) in patients with gynecologic malignancies--Tokai HCFU Study Group for Gynecologic Malignancies]. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2948036/),[h·mcg] / [ml],0.46,213189,DB00544,Fluorouracil
,2948036,FdUMP: dUMP ratio,"The average FdUMP: dUMP ratio was 3.44 X 10(3), However, more than 80% inhibitions of TS were observed in nine cases (21.4%).",[The determination of thymidylate synthetase inhibition for testing fluoropyrimidines--pharmacokinetics and metabolism of carmofur (HCFU) in patients with gynecologic malignancies--Tokai HCFU Study Group for Gynecologic Malignancies]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2948036/),,3.44 X 10(3),213190,DB00544,Fluorouracil
,24946270,zeta potential,"The 5-FU-TCS-NPs (size: 150±40nm, zeta potential: +48.2±5mV) and CRC-TCS-NPs (size: 150±20nm, zeta potential: +35.7±3mV) were proven to be compatible with blood.",Combinatorial anticancer effects of curcumin and 5-fluorouracil loaded thiolated chitosan nanoparticles towards colon cancer treatment. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24946270/),m,48.2,213302,DB00544,Fluorouracil
,24946270,zeta potential,"The 5-FU-TCS-NPs (size: 150±40nm, zeta potential: +48.2±5mV) and CRC-TCS-NPs (size: 150±20nm, zeta potential: +35.7±3mV) were proven to be compatible with blood.",Combinatorial anticancer effects of curcumin and 5-fluorouracil loaded thiolated chitosan nanoparticles towards colon cancer treatment. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24946270/),m,35.7,213303,DB00544,Fluorouracil
,10944598,terminal half-life,Pharmakokinetic analysis showed a terminal half-life of approximately 2 days.,"A phase I study of a new polyamine biosynthesis inhibitor, SAM486A, in cancer patients with solid tumours. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10944598/),d,2,213978,DB00544,Fluorouracil
,23067100,mean residence time [MRT],"Pharmacokinetics of (188)Re-liposome showed the properties of high circulation time and high bioavailability (mean residence time [MRT]=18.8 hours, area under the curve [AUC]=1371%ID/g·h).",Comparative therapeutic efficacy of rhenium-188 radiolabeled-liposome and 5-fluorouracil in LS-174T human colon carcinoma solid tumor xenografts. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23067100/),h,18.8,216242,DB00544,Fluorouracil
,23067100,area under the curve [AUC],"Pharmacokinetics of (188)Re-liposome showed the properties of high circulation time and high bioavailability (mean residence time [MRT]=18.8 hours, area under the curve [AUC]=1371%ID/g·h).",Comparative therapeutic efficacy of rhenium-188 radiolabeled-liposome and 5-fluorouracil in LS-174T human colon carcinoma solid tumor xenografts. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23067100/),[%id] / [g·h],1371,216243,DB00544,Fluorouracil
,23067100,survival time,The median survival time for mice treated with (188)Re-liposome (58.5 days; p<0.05) was significantly better than those of 5-FU (48.25 days; p>0.05) and normal saline-treated mice (43.63 days).,Comparative therapeutic efficacy of rhenium-188 radiolabeled-liposome and 5-fluorouracil in LS-174T human colon carcinoma solid tumor xenografts. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23067100/),d,58.5,216244,DB00544,Fluorouracil
,23067100,survival time,The median survival time for mice treated with (188)Re-liposome (58.5 days; p<0.05) was significantly better than those of 5-FU (48.25 days; p>0.05) and normal saline-treated mice (43.63 days).,Comparative therapeutic efficacy of rhenium-188 radiolabeled-liposome and 5-fluorouracil in LS-174T human colon carcinoma solid tumor xenografts. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23067100/),d,48.25,216245,DB00544,Fluorouracil
,23067100,survival time,The median survival time for mice treated with (188)Re-liposome (58.5 days; p<0.05) was significantly better than those of 5-FU (48.25 days; p>0.05) and normal saline-treated mice (43.63 days).,Comparative therapeutic efficacy of rhenium-188 radiolabeled-liposome and 5-fluorouracil in LS-174T human colon carcinoma solid tumor xenografts. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23067100/),d,43.63,216246,DB00544,Fluorouracil
,27743200,overall response rates,"The overall response rates in the 10- and 20-µg/m2/d groups were 50 % (6/12) and 33.3 % (4/12), respectively, and the overall response rates of the ESCC and GC patients were 66.7 % (8/12) and 16.7 % (2/12), respectively.",A phase IIa study of rhLTα-Da in combination with cisplatin and fluorouracil for patients with metastatic esophageal squamous cell carcinoma or gastric adenocarcinoma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27743200/),%,50,216692,DB00544,Fluorouracil
,27743200,overall response rates,"The overall response rates in the 10- and 20-µg/m2/d groups were 50 % (6/12) and 33.3 % (4/12), respectively, and the overall response rates of the ESCC and GC patients were 66.7 % (8/12) and 16.7 % (2/12), respectively.",A phase IIa study of rhLTα-Da in combination with cisplatin and fluorouracil for patients with metastatic esophageal squamous cell carcinoma or gastric adenocarcinoma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27743200/),%,33.3,216693,DB00544,Fluorouracil
,27743200,overall response rates,"The overall response rates in the 10- and 20-µg/m2/d groups were 50 % (6/12) and 33.3 % (4/12), respectively, and the overall response rates of the ESCC and GC patients were 66.7 % (8/12) and 16.7 % (2/12), respectively.",A phase IIa study of rhLTα-Da in combination with cisplatin and fluorouracil for patients with metastatic esophageal squamous cell carcinoma or gastric adenocarcinoma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27743200/),%,66.7,216694,DB00544,Fluorouracil
,27743200,overall response rates,"The overall response rates in the 10- and 20-µg/m2/d groups were 50 % (6/12) and 33.3 % (4/12), respectively, and the overall response rates of the ESCC and GC patients were 66.7 % (8/12) and 16.7 % (2/12), respectively.",A phase IIa study of rhLTα-Da in combination with cisplatin and fluorouracil for patients with metastatic esophageal squamous cell carcinoma or gastric adenocarcinoma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27743200/),%,16.7,216695,DB00544,Fluorouracil
,8529282,maximum tolerated dose,The maximum tolerated dose of 5-FU in this combination was 2600 mg/m2.,Phase I trial of fluorouracil modulation by N-phosphonacetyl-L-aspartate and 6-methylmercaptopurine ribonucleoside. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8529282/),[mg] / [m2],2600,217023,DB00544,Fluorouracil
,11286326,time to reach peak concentration (tmax),"After oral administration of 1250 mg/m2, capecitabine is rapidly and extensively absorbed from the gastrointestinal tract [with a time to reach peak concentration (tmax) of 2 hours and peak plasma drug concentration (Cmax) of 3 to 4 mg/L] and has a relatively short elimination half-life (t(1/2)) [0.55 to 0.89 h].",Clinical pharmacokinetics of capecitabine. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11286326/),h,2,217445,DB00544,Fluorouracil
,11286326,peak plasma drug concentration (Cmax),"After oral administration of 1250 mg/m2, capecitabine is rapidly and extensively absorbed from the gastrointestinal tract [with a time to reach peak concentration (tmax) of 2 hours and peak plasma drug concentration (Cmax) of 3 to 4 mg/L] and has a relatively short elimination half-life (t(1/2)) [0.55 to 0.89 h].",Clinical pharmacokinetics of capecitabine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11286326/),[mg] / [l],3 to 4,217446,DB00544,Fluorouracil
,11286326,elimination half-life (t(1/2)),"After oral administration of 1250 mg/m2, capecitabine is rapidly and extensively absorbed from the gastrointestinal tract [with a time to reach peak concentration (tmax) of 2 hours and peak plasma drug concentration (Cmax) of 3 to 4 mg/L] and has a relatively short elimination half-life (t(1/2)) [0.55 to 0.89 h].",Clinical pharmacokinetics of capecitabine. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11286326/),h,0.55 to 0.89,217447,DB00544,Fluorouracil
,11286326,Recovery,Recovery of drug-related material in urine and faeces is nearly 100%.,Clinical pharmacokinetics of capecitabine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11286326/),%,100,217448,DB00544,Fluorouracil
,11286326,Cmax,Plasma concentrations of the cytotoxic moiety fluorouracil are very low [with a Cmax of 0.22 to 0.31 mg/L and area under the concentration-time curve (AUC) of 0.461 to 0.698 mg x h/L].,Clinical pharmacokinetics of capecitabine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11286326/),[mg] / [l],0.22 to 0.31,217449,DB00544,Fluorouracil
,11286326,area under the concentration-time curve (AUC),Plasma concentrations of the cytotoxic moiety fluorouracil are very low [with a Cmax of 0.22 to 0.31 mg/L and area under the concentration-time curve (AUC) of 0.461 to 0.698 mg x h/L].,Clinical pharmacokinetics of capecitabine. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11286326/),[h·mg] / [l],0.461 to 0.698,217450,DB00544,Fluorouracil
,9563484,pulmonary clearance,"Although only 17% of the drug was extracted by the lungs at the lowest dose rate, pulmonary clearance (16.0 ml/min/kg) was on the order of splanchnic clearance (13.5 ml/min/kg), or larger.","Regional pharmacokinetics of 5-fluorouracil in dogs: role of the liver, gastrointestinal tract, and lungs. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9563484/),[ml] / [kg·min],16.0,217648,DB00544,Fluorouracil
,9563484,clearance,"Although only 17% of the drug was extracted by the lungs at the lowest dose rate, pulmonary clearance (16.0 ml/min/kg) was on the order of splanchnic clearance (13.5 ml/min/kg), or larger.","Regional pharmacokinetics of 5-fluorouracil in dogs: role of the liver, gastrointestinal tract, and lungs. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9563484/),[ml] / [kg·min],13.5,217649,DB00544,Fluorouracil
,27042001,"area under curve, [AUC](0-t)","Pharmacokinetic studies demonstrated that 5-FU hollow microspheres significantly enhanced oral bioavailability (area under curve, [AUC](0-t): 12.53±1.65 mg/L(*)h vs 7.80±0.83 and 5.82±0.83 mg/L(*)h) with longer elimination half-life (t1/2) (15.43±2.12 hours vs 2.25±0.22 and 1.43±0.18 hours) and mean residence time (7.65±0.97 hours vs 3.61±0.41 and 2.34±0.35 hours), in comparison with its solid microspheres and powder.","A 5-fluorouracil-loaded floating gastroretentive hollow microsphere: development, pharmacokinetic in rabbits, and biodistribution in tumor-bearing mice. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27042001/),[mg] / [)h·l(],12.53,217760,DB00544,Fluorouracil
,27042001,"area under curve, [AUC](0-t)","Pharmacokinetic studies demonstrated that 5-FU hollow microspheres significantly enhanced oral bioavailability (area under curve, [AUC](0-t): 12.53±1.65 mg/L(*)h vs 7.80±0.83 and 5.82±0.83 mg/L(*)h) with longer elimination half-life (t1/2) (15.43±2.12 hours vs 2.25±0.22 and 1.43±0.18 hours) and mean residence time (7.65±0.97 hours vs 3.61±0.41 and 2.34±0.35 hours), in comparison with its solid microspheres and powder.","A 5-fluorouracil-loaded floating gastroretentive hollow microsphere: development, pharmacokinetic in rabbits, and biodistribution in tumor-bearing mice. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27042001/),[mg] / [)h·l(],7.80,217761,DB00544,Fluorouracil
,27042001,"area under curve, [AUC](0-t)","Pharmacokinetic studies demonstrated that 5-FU hollow microspheres significantly enhanced oral bioavailability (area under curve, [AUC](0-t): 12.53±1.65 mg/L(*)h vs 7.80±0.83 and 5.82±0.83 mg/L(*)h) with longer elimination half-life (t1/2) (15.43±2.12 hours vs 2.25±0.22 and 1.43±0.18 hours) and mean residence time (7.65±0.97 hours vs 3.61±0.41 and 2.34±0.35 hours), in comparison with its solid microspheres and powder.","A 5-fluorouracil-loaded floating gastroretentive hollow microsphere: development, pharmacokinetic in rabbits, and biodistribution in tumor-bearing mice. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27042001/),[mg] / [)h·l(],5.82,217762,DB00544,Fluorouracil
,27042001,elimination half-life (t1/2),"Pharmacokinetic studies demonstrated that 5-FU hollow microspheres significantly enhanced oral bioavailability (area under curve, [AUC](0-t): 12.53±1.65 mg/L(*)h vs 7.80±0.83 and 5.82±0.83 mg/L(*)h) with longer elimination half-life (t1/2) (15.43±2.12 hours vs 2.25±0.22 and 1.43±0.18 hours) and mean residence time (7.65±0.97 hours vs 3.61±0.41 and 2.34±0.35 hours), in comparison with its solid microspheres and powder.","A 5-fluorouracil-loaded floating gastroretentive hollow microsphere: development, pharmacokinetic in rabbits, and biodistribution in tumor-bearing mice. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/27042001/),h,15.43,217763,DB00544,Fluorouracil
,27042001,elimination half-life (t1/2),"Pharmacokinetic studies demonstrated that 5-FU hollow microspheres significantly enhanced oral bioavailability (area under curve, [AUC](0-t): 12.53±1.65 mg/L(*)h vs 7.80±0.83 and 5.82±0.83 mg/L(*)h) with longer elimination half-life (t1/2) (15.43±2.12 hours vs 2.25±0.22 and 1.43±0.18 hours) and mean residence time (7.65±0.97 hours vs 3.61±0.41 and 2.34±0.35 hours), in comparison with its solid microspheres and powder.","A 5-fluorouracil-loaded floating gastroretentive hollow microsphere: development, pharmacokinetic in rabbits, and biodistribution in tumor-bearing mice. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/27042001/),h,2.25,217764,DB00544,Fluorouracil
,27042001,elimination half-life (t1/2),"Pharmacokinetic studies demonstrated that 5-FU hollow microspheres significantly enhanced oral bioavailability (area under curve, [AUC](0-t): 12.53±1.65 mg/L(*)h vs 7.80±0.83 and 5.82±0.83 mg/L(*)h) with longer elimination half-life (t1/2) (15.43±2.12 hours vs 2.25±0.22 and 1.43±0.18 hours) and mean residence time (7.65±0.97 hours vs 3.61±0.41 and 2.34±0.35 hours), in comparison with its solid microspheres and powder.","A 5-fluorouracil-loaded floating gastroretentive hollow microsphere: development, pharmacokinetic in rabbits, and biodistribution in tumor-bearing mice. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/27042001/),h,1.43,217765,DB00544,Fluorouracil
,27042001,mean residence time,"Pharmacokinetic studies demonstrated that 5-FU hollow microspheres significantly enhanced oral bioavailability (area under curve, [AUC](0-t): 12.53±1.65 mg/L(*)h vs 7.80±0.83 and 5.82±0.83 mg/L(*)h) with longer elimination half-life (t1/2) (15.43±2.12 hours vs 2.25±0.22 and 1.43±0.18 hours) and mean residence time (7.65±0.97 hours vs 3.61±0.41 and 2.34±0.35 hours), in comparison with its solid microspheres and powder.","A 5-fluorouracil-loaded floating gastroretentive hollow microsphere: development, pharmacokinetic in rabbits, and biodistribution in tumor-bearing mice. ",MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27042001/),h,7.65,217766,DB00544,Fluorouracil
,27042001,mean residence time,"Pharmacokinetic studies demonstrated that 5-FU hollow microspheres significantly enhanced oral bioavailability (area under curve, [AUC](0-t): 12.53±1.65 mg/L(*)h vs 7.80±0.83 and 5.82±0.83 mg/L(*)h) with longer elimination half-life (t1/2) (15.43±2.12 hours vs 2.25±0.22 and 1.43±0.18 hours) and mean residence time (7.65±0.97 hours vs 3.61±0.41 and 2.34±0.35 hours), in comparison with its solid microspheres and powder.","A 5-fluorouracil-loaded floating gastroretentive hollow microsphere: development, pharmacokinetic in rabbits, and biodistribution in tumor-bearing mice. ",MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27042001/),h,3.61,217767,DB00544,Fluorouracil
,27042001,mean residence time,"Pharmacokinetic studies demonstrated that 5-FU hollow microspheres significantly enhanced oral bioavailability (area under curve, [AUC](0-t): 12.53±1.65 mg/L(*)h vs 7.80±0.83 and 5.82±0.83 mg/L(*)h) with longer elimination half-life (t1/2) (15.43±2.12 hours vs 2.25±0.22 and 1.43±0.18 hours) and mean residence time (7.65±0.97 hours vs 3.61±0.41 and 2.34±0.35 hours), in comparison with its solid microspheres and powder.","A 5-fluorouracil-loaded floating gastroretentive hollow microsphere: development, pharmacokinetic in rabbits, and biodistribution in tumor-bearing mice. ",MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27042001/),h,2.34,217768,DB00544,Fluorouracil
,3731137,Total urinary excretion,"Total urinary excretion of uridine was 15%-40% of the dose, while uracil excretion in urine was 2%-17%.",Clinical and pharmacokinetic studies of prolonged administration of high-dose uridine intended for rescue from 5-FU toxicity. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3731137/),%,15,217804,DB00544,Fluorouracil
,3731137,excretion,"Total urinary excretion of uridine was 15%-40% of the dose, while uracil excretion in urine was 2%-17%.",Clinical and pharmacokinetic studies of prolonged administration of high-dose uridine intended for rescue from 5-FU toxicity. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3731137/),%,2,217805,DB00544,Fluorouracil
,10656433,maximum tolerated dose,The maximum tolerated dose determined during the first cycle was 1000 mg/m2/day for 5 days of 5FU with either 75 or 85 mg/m2 docetaxel.,A phase I and pharmacokinetic study of docetaxel administered in combination with continuous intravenous infusion of 5-fluorouracil in patients with advanced solid tumors. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10656433/),,1000,219020,DB00544,Fluorouracil
,7600920,Total urinary excretion,"Total urinary excretion was 14.3 +/- 1.4% (SE) of the dose, with unchanged taxol and an unknown polar metabolite as the main excretion products.",Taxol metabolism and disposition in cancer patients. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7600920/),%,14.3,219146,DB00544,Fluorouracil
,7600920,Total fecal excretion,"Total fecal excretion was 71.1 +/- 8.2%, with 6 alpha-hydroxytaxol being the largest component by far.",Taxol metabolism and disposition in cancer patients. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7600920/),%,71.1,219147,DB00544,Fluorouracil
,7600920,area under the curve,The plasma area under the curve for unchanged taxol was 20.5 +/- 2.3 microM.hr and that for total taxol metabolites was 14.2 +/- 4.5 microM.hr.,Taxol metabolism and disposition in cancer patients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7600920/),h·μM,20.5,219148,DB00544,Fluorouracil
,7600920,area under the curve,The plasma area under the curve for unchanged taxol was 20.5 +/- 2.3 microM.hr and that for total taxol metabolites was 14.2 +/- 4.5 microM.hr.,Taxol metabolism and disposition in cancer patients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7600920/),h·μM,14.2,219149,DB00544,Fluorouracil
,7600920,half-life,"The half-life of total metabolites (5.6 +/- 0.4 hr), however, greatly exceeded that of unchanged taxol (2.9 +/- 0.3 hr).",Taxol metabolism and disposition in cancer patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7600920/),h,5.6,219150,DB00544,Fluorouracil
,7600920,half-life,"The half-life of total metabolites (5.6 +/- 0.4 hr), however, greatly exceeded that of unchanged taxol (2.9 +/- 0.3 hr).",Taxol metabolism and disposition in cancer patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7600920/),h,2.9,219151,DB00544,Fluorouracil
,11818199,area under the plasma concentration curve (AUC),"The area under the plasma concentration curve (AUC) for 5-FU after UFT administration was 113 microM x min on day 8, 114 on day 15 and 98 on day 28; the peak levels (Cmax) were 1.2, 1.3 and 1.0 microM, respectively.",Patient preference and pharmacokinetics of oral modulated UFT versus intravenous fluorouracil and leucovorin: a randomised crossover trial in advanced colorectal cancer. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11818199/),min·μM,113,219549,DB00544,Fluorouracil
,11818199,area under the plasma concentration curve (AUC),"The area under the plasma concentration curve (AUC) for 5-FU after UFT administration was 113 microM x min on day 8, 114 on day 15 and 98 on day 28; the peak levels (Cmax) were 1.2, 1.3 and 1.0 microM, respectively.",Patient preference and pharmacokinetics of oral modulated UFT versus intravenous fluorouracil and leucovorin: a randomised crossover trial in advanced colorectal cancer. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11818199/),,114,219550,DB00544,Fluorouracil
,11818199,area under the plasma concentration curve (AUC),"The area under the plasma concentration curve (AUC) for 5-FU after UFT administration was 113 microM x min on day 8, 114 on day 15 and 98 on day 28; the peak levels (Cmax) were 1.2, 1.3 and 1.0 microM, respectively.",Patient preference and pharmacokinetics of oral modulated UFT versus intravenous fluorouracil and leucovorin: a randomised crossover trial in advanced colorectal cancer. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11818199/),,98,219551,DB00544,Fluorouracil
,11818199,peak levels (Cmax),"The area under the plasma concentration curve (AUC) for 5-FU after UFT administration was 113 microM x min on day 8, 114 on day 15 and 98 on day 28; the peak levels (Cmax) were 1.2, 1.3 and 1.0 microM, respectively.",Patient preference and pharmacokinetics of oral modulated UFT versus intravenous fluorouracil and leucovorin: a randomised crossover trial in advanced colorectal cancer. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11818199/),μM,1.2,219552,DB00544,Fluorouracil
,11818199,peak levels (Cmax),"The area under the plasma concentration curve (AUC) for 5-FU after UFT administration was 113 microM x min on day 8, 114 on day 15 and 98 on day 28; the peak levels (Cmax) were 1.2, 1.3 and 1.0 microM, respectively.",Patient preference and pharmacokinetics of oral modulated UFT versus intravenous fluorouracil and leucovorin: a randomised crossover trial in advanced colorectal cancer. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11818199/),μM,1.3,219553,DB00544,Fluorouracil
,11818199,peak levels (Cmax),"The area under the plasma concentration curve (AUC) for 5-FU after UFT administration was 113 microM x min on day 8, 114 on day 15 and 98 on day 28; the peak levels (Cmax) were 1.2, 1.3 and 1.0 microM, respectively.",Patient preference and pharmacokinetics of oral modulated UFT versus intravenous fluorouracil and leucovorin: a randomised crossover trial in advanced colorectal cancer. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11818199/),μM,1.0,219554,DB00544,Fluorouracil
,11818199,AUC,The AUC for the 5-FU/LV courses was 3083 microM x min for day 1 and 3809 for day 5 (P=0.002).,Patient preference and pharmacokinetics of oral modulated UFT versus intravenous fluorouracil and leucovorin: a randomised crossover trial in advanced colorectal cancer. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11818199/),min·μM,3083,219555,DB00544,Fluorouracil
,11818199,AUC,The AUC for the 5-FU/LV courses was 3083 microM x min for day 1 and 3809 for day 5 (P=0.002).,Patient preference and pharmacokinetics of oral modulated UFT versus intravenous fluorouracil and leucovorin: a randomised crossover trial in advanced colorectal cancer. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11818199/),,3809,219556,DB00544,Fluorouracil
,11818199,Cmax,"The Cmax was 170.1 and 196.2 microM (P=0.06) and the clearance 2.6 and 1.9 l/min, respectively (P=0.002).",Patient preference and pharmacokinetics of oral modulated UFT versus intravenous fluorouracil and leucovorin: a randomised crossover trial in advanced colorectal cancer. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11818199/),μM,170.1,219557,DB00544,Fluorouracil
,11818199,Cmax,"The Cmax was 170.1 and 196.2 microM (P=0.06) and the clearance 2.6 and 1.9 l/min, respectively (P=0.002).",Patient preference and pharmacokinetics of oral modulated UFT versus intravenous fluorouracil and leucovorin: a randomised crossover trial in advanced colorectal cancer. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11818199/),μM,196.2,219558,DB00544,Fluorouracil
,11818199,clearance,"The Cmax was 170.1 and 196.2 microM (P=0.06) and the clearance 2.6 and 1.9 l/min, respectively (P=0.002).",Patient preference and pharmacokinetics of oral modulated UFT versus intravenous fluorouracil and leucovorin: a randomised crossover trial in advanced colorectal cancer. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11818199/),[l] / [min],2.6,219559,DB00544,Fluorouracil
,11818199,clearance,"The Cmax was 170.1 and 196.2 microM (P=0.06) and the clearance 2.6 and 1.9 l/min, respectively (P=0.002).",Patient preference and pharmacokinetics of oral modulated UFT versus intravenous fluorouracil and leucovorin: a randomised crossover trial in advanced colorectal cancer. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11818199/),[l] / [min],1.9,219560,DB00544,Fluorouracil
,11002805,clearance,"The clearance of the i.v. tracer dose of [6-3H]dFUR was 18.5 +/- 2.5 mL.kg-1.min-1 (mean +/- SD, n = 5).",Disposition and availability of 5-fluorouracil prodrug 5'-deoxy-5-fluorouridine after oral administration in rats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11002805/),[ml] / [kg·min],18.5,219576,DB00544,Fluorouracil
,11002805,oral bioavailability,"The oral bioavailability, calculated using the clearance of [6-3H]dFUR and the area under the blood concentration-time curve (AUC) of unlabeled dFUR, was 63.4 +/- 16.9%.",Disposition and availability of 5-fluorouracil prodrug 5'-deoxy-5-fluorouridine after oral administration in rats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11002805/),%,63.4,219577,DB00544,Fluorouracil
,15235341,area under the curve [AUC],"We present long-term results of a phase II trial of induction chemotherapy (IC) with uracilftegafur (UFT) 200 mg/m orally days 1 to 21, vinorelbine 25 mg/m intravenously (IV) days 1 and 8, and cisplatin 100 mg/m IV day 1 (UFTVP) each for 21 days for 4 courses, followed by radiotherapy concomitant with UFT 100 mg/m orally daily and carboplatin (area under the curve [AUC] = 0.5 IV weekly) (RT/ UFTJ), without surgery to the primary site if response, in patients (pts) with resectable locally advanced squamous cell carcinoma of the larynx and hypopharynx.","Long-term results of a phase II trial of induction chemotherapy with uracil-ftegafur (UFT), vinorelbine, and cisplatin (UFTVP) followed by radiotherapy concomitant with UFT and carboplatin (RT/UFTJ) in a primary site preservation setting for resectable locally advanced squamous cell carcinoma of larynx and hypopharynx. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15235341/),,0.5,219630,DB00544,Fluorouracil
,26163340,duration of response,2 patients (22 %) achieved partial response with the duration of response were 112 and 799 days.,Phase I study of TAS-102 and irinotecan combination therapy in Japanese patients with advanced colorectal cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26163340/),d,112,219831,DB00544,Fluorouracil
,26163340,duration of response,2 patients (22 %) achieved partial response with the duration of response were 112 and 799 days.,Phase I study of TAS-102 and irinotecan combination therapy in Japanese patients with advanced colorectal cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26163340/),d,799,219832,DB00544,Fluorouracil
,19727730,overall response rate,"The overall response rate in 33 patients was 21.2% (95% CI, 10.7-37.8%), and median progression-free survival was 3.9 months, with a median overall survival of 15.7 months.",Phase II study of S-1 as first-line treatment for elderly patients over 75 years of age with advanced gastric cancer: the Tokyo Cooperative Oncology Group study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19727730/),%,21.2,221104,DB00544,Fluorouracil
,19727730,progression-free survival,"The overall response rate in 33 patients was 21.2% (95% CI, 10.7-37.8%), and median progression-free survival was 3.9 months, with a median overall survival of 15.7 months.",Phase II study of S-1 as first-line treatment for elderly patients over 75 years of age with advanced gastric cancer: the Tokyo Cooperative Oncology Group study. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19727730/),month,3.9,221105,DB00544,Fluorouracil
,19727730,overall survival,"The overall response rate in 33 patients was 21.2% (95% CI, 10.7-37.8%), and median progression-free survival was 3.9 months, with a median overall survival of 15.7 months.",Phase II study of S-1 as first-line treatment for elderly patients over 75 years of age with advanced gastric cancer: the Tokyo Cooperative Oncology Group study. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19727730/),month,15,221106,DB00544,Fluorouracil
,11173134,enhancement ratio,The enhancement ratio of OFU001 in the TCD-50 assay was 1.2.,"In vivo evaluation of a novel antitumor prodrug, 1-(2'-oxopropyl)-5-fluorouracil (OFU001), which releases 5-fluorouracil upon hypoxic irradiation. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11173134/),,1.2,221868,DB00544,Fluorouracil
,11081572,half-life,New DPD is synthesized with a half-life of 2.6 days.,Preclinical development of eniluracil: enhancing the therapeutic index and dosing convenience of 5-fluorouracil. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11081572/),d,2.6,222119,DB00544,Fluorouracil
,21383342,clearance,5-FU clearance was significantly lower on day 5 (62.64 ± 20.16 L/h/m(2)) than on day 1 (74.83 ± 31.61 L/h/m(2)).,Time-dependent pharmacokinetics of 5-fluorouracil and association with treatment tolerability in the adjuvant setting of colorectal cancer. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21383342/),[h·l] / [m(2],62.64,222609,DB00544,Fluorouracil
,21383342,clearance,5-FU clearance was significantly lower on day 5 (62.64 ± 20.16 L/h/m(2)) than on day 1 (74.83 ± 31.61 L/h/m(2)).,Time-dependent pharmacokinetics of 5-fluorouracil and association with treatment tolerability in the adjuvant setting of colorectal cancer. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21383342/),[h·l] / [m(2],74.83,222610,DB00544,Fluorouracil
,12239603,retention time,"The retention time of 5-FU using this method is 4.7 min with a limit of detection of 5 ng/ml, and an extraction yield of 96.2+/-0.5% (SE).",An HPLC method for the measurement of 5-fluorouracil in human plasma with a low detection limit and a high extraction yield. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12239603/),min,4.7,222710,DB00544,Fluorouracil
,12239603,extraction yield,"The retention time of 5-FU using this method is 4.7 min with a limit of detection of 5 ng/ml, and an extraction yield of 96.2+/-0.5% (SE).",An HPLC method for the measurement of 5-fluorouracil in human plasma with a low detection limit and a high extraction yield. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12239603/),%,96.2,222711,DB00544,Fluorouracil
,12506476,survival period,The mean survival period of these cases was 12.5 +/- 4.2 months.,[Modified pharmacokinetic modulation chemotherapy (PMC) with medication of UFT and intraarterial infusion of 5-FU for advanced unresectable HCC]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12506476/),month,12.5,222891,DB00544,Fluorouracil
,12452753,elimination half-life,The elimination half-life of both drugs is 0.5-0.7 hours.,Fluorouracil for allergic reactions to capecitabine. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12452753/),h,0.5-0.7,222981,DB00544,Fluorouracil
,23982118,objective tumor response rate,"In 22 efficacy-evaluable patients, the objective tumor response rate was 59.1 % (75 % for both MCRC and MGC in the first-line setting) and the disease control rate was 100 %.",Phase I clinical and pharmacokinetic/pharmacogenetic study of a triplet regimen of S-1/irinotecan/oxaliplatin in patients with metastatic colorectal or gastric cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23982118/),%,59.1,223209,DB00544,Fluorouracil
,23982118,objective tumor response rate,"In 22 efficacy-evaluable patients, the objective tumor response rate was 59.1 % (75 % for both MCRC and MGC in the first-line setting) and the disease control rate was 100 %.",Phase I clinical and pharmacokinetic/pharmacogenetic study of a triplet regimen of S-1/irinotecan/oxaliplatin in patients with metastatic colorectal or gastric cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23982118/),%,75,223210,DB00544,Fluorouracil
,8996526,clearance,"Based on allometric analysis, the estimated clearance of 5-FU (10.9 l/h) in humans with DPD deficiency was comparable to the observed values in humans lacking DPD activity due to genetic predisposition (10.1 l/h), or treatment with 776C85 (7.0 l/h) or (E)-5-(2-bromovinyl)-2'-deoxyuridine (BVdUrd, 6.6 l/h).","Dihydropyrimidine dehydrogenase inactivation and 5-fluorouracil pharmacokinetics: allometric scaling of animal data, pharmacokinetics and toxicodynamics of 5-fluorouracil in humans. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8996526/),[l] / [h],10.9,223221,DB00544,Fluorouracil
,8996526,clearance,"Based on allometric analysis, the estimated clearance of 5-FU (10.9 l/h) in humans with DPD deficiency was comparable to the observed values in humans lacking DPD activity due to genetic predisposition (10.1 l/h), or treatment with 776C85 (7.0 l/h) or (E)-5-(2-bromovinyl)-2'-deoxyuridine (BVdUrd, 6.6 l/h).","Dihydropyrimidine dehydrogenase inactivation and 5-fluorouracil pharmacokinetics: allometric scaling of animal data, pharmacokinetics and toxicodynamics of 5-fluorouracil in humans. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8996526/),[l] / [h],10.1,223222,DB00544,Fluorouracil
,8996526,clearance,"Based on allometric analysis, the estimated clearance of 5-FU (10.9 l/h) in humans with DPD deficiency was comparable to the observed values in humans lacking DPD activity due to genetic predisposition (10.1 l/h), or treatment with 776C85 (7.0 l/h) or (E)-5-(2-bromovinyl)-2'-deoxyuridine (BVdUrd, 6.6 l/h).","Dihydropyrimidine dehydrogenase inactivation and 5-fluorouracil pharmacokinetics: allometric scaling of animal data, pharmacokinetics and toxicodynamics of 5-fluorouracil in humans. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8996526/),[l] / [h],7.0,223223,DB00544,Fluorouracil
,8996526,clearance,"Based on allometric analysis, the estimated clearance of 5-FU (10.9 l/h) in humans with DPD deficiency was comparable to the observed values in humans lacking DPD activity due to genetic predisposition (10.1 l/h), or treatment with 776C85 (7.0 l/h) or (E)-5-(2-bromovinyl)-2'-deoxyuridine (BVdUrd, 6.6 l/h).","Dihydropyrimidine dehydrogenase inactivation and 5-fluorouracil pharmacokinetics: allometric scaling of animal data, pharmacokinetics and toxicodynamics of 5-fluorouracil in humans. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8996526/),[l] / [h],6.6,223224,DB00544,Fluorouracil
,8996526,MTD,"Based on allometric analysis, the estimated values for the MTD in humans treated with 776C85 and receiving 5-FU as a single i.v. bolus dose, and 5-day and 12-day continuous infusions were about 110, 50 and 30 mg/m2 of 5-FU, respectively.","Dihydropyrimidine dehydrogenase inactivation and 5-fluorouracil pharmacokinetics: allometric scaling of animal data, pharmacokinetics and toxicodynamics of 5-fluorouracil in humans. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8996526/),[mg] / [m2],110,223225,DB00544,Fluorouracil
,8996526,MTD,"Based on allometric analysis, the estimated values for the MTD in humans treated with 776C85 and receiving 5-FU as a single i.v. bolus dose, and 5-day and 12-day continuous infusions were about 110, 50 and 30 mg/m2 of 5-FU, respectively.","Dihydropyrimidine dehydrogenase inactivation and 5-fluorouracil pharmacokinetics: allometric scaling of animal data, pharmacokinetics and toxicodynamics of 5-fluorouracil in humans. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8996526/),[mg] / [m2],50,223226,DB00544,Fluorouracil
,8996526,MTD,"Based on allometric analysis, the estimated values for the MTD in humans treated with 776C85 and receiving 5-FU as a single i.v. bolus dose, and 5-day and 12-day continuous infusions were about 110, 50 and 30 mg/m2 of 5-FU, respectively.","Dihydropyrimidine dehydrogenase inactivation and 5-fluorouracil pharmacokinetics: allometric scaling of animal data, pharmacokinetics and toxicodynamics of 5-fluorouracil in humans. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8996526/),[mg] / [m2],30,223227,DB00544,Fluorouracil
,29453635,Trough plasma concentrations,Trough plasma concentrations ranged from 0.04 to 1.22 µg/ml after day 1 and from 0.01 to 2.4 µg/ml in the long-term assessment.,Monitoring of erlotinib in pancreatic cancer patients during long-time administration and comparison to a physiologically based pharmacokinetic model. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29453635/),[μg] / [ml],0.04 to 1.22,224474,DB00544,Fluorouracil
,29453635,Trough plasma concentrations,Trough plasma concentrations ranged from 0.04 to 1.22 µg/ml after day 1 and from 0.01 to 2.4 µg/ml in the long-term assessment.,Monitoring of erlotinib in pancreatic cancer patients during long-time administration and comparison to a physiologically based pharmacokinetic model. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29453635/),[μg] / [ml],0.01 to 2.4,224475,DB00544,Fluorouracil
,2230874,half-life (T1/2),"The half-life (T1/2) of this tumor pool of ""trapped"" 5FU was 0.33 to 1.3 hours (20 to 78 minutes), much longer than the T1/2 of 5FU in blood (5 to 15 minutes).",Human tumor fluorouracil trapping: clinical correlations of in vivo 19F nuclear magnetic resonance spectroscopy pharmacokinetics. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2230874/),h,0.33 to 1.3,224542,DB00544,Fluorouracil
,2230874,half-life (T1/2),"The half-life (T1/2) of this tumor pool of ""trapped"" 5FU was 0.33 to 1.3 hours (20 to 78 minutes), much longer than the T1/2 of 5FU in blood (5 to 15 minutes).",Human tumor fluorouracil trapping: clinical correlations of in vivo 19F nuclear magnetic resonance spectroscopy pharmacokinetics. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2230874/),min,20 to 78,224543,DB00544,Fluorouracil
,2230874,T1/2,"The half-life (T1/2) of this tumor pool of ""trapped"" 5FU was 0.33 to 1.3 hours (20 to 78 minutes), much longer than the T1/2 of 5FU in blood (5 to 15 minutes).",Human tumor fluorouracil trapping: clinical correlations of in vivo 19F nuclear magnetic resonance spectroscopy pharmacokinetics. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2230874/),min,5 to 15,224544,DB00544,Fluorouracil
,7670132,elimination half-life,There was a good tumor retention with a 22 h elimination half-life.,Docetaxel (Taxotere): a review of preclinical and clinical experience. Part I: Preclinical experience. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7670132/),h,22,225080,DB00544,Fluorouracil
,7670132,Plasma protein binding,Plasma protein binding ranged from 76 to 89%.,Docetaxel (Taxotere): a review of preclinical and clinical experience. Part I: Preclinical experience. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7670132/),%,76 to 89,225081,DB00544,Fluorouracil
,1893377,maximum plasma concentration (Cmax),"The maximum plasma concentration (Cmax) of TBAF was 821 +/- 97 (SE) nM, occurring at a median of 8 h; the Cmax of (6S)-leucovorin was 77 +/- 11 nM, occurring at 4 h.",Pharmacology and phase I trial of high-dose oral leucovorin plus 5-fluorouracil in children with refractory cancer: a report from the Children's Cancer Study Group. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1893377/),nM,821,225312,DB00544,Fluorouracil
,1893377,Cmax,"The maximum plasma concentration (Cmax) of TBAF was 821 +/- 97 (SE) nM, occurring at a median of 8 h; the Cmax of (6S)-leucovorin was 77 +/- 11 nM, occurring at 4 h.",Pharmacology and phase I trial of high-dose oral leucovorin plus 5-fluorouracil in children with refractory cancer: a report from the Children's Cancer Study Group. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1893377/),nM,77,225313,DB00544,Fluorouracil
,1893377,TBAF,The TBAF concentration fell to 146 +/- 42 nM by 24 h.,Pharmacology and phase I trial of high-dose oral leucovorin plus 5-fluorouracil in children with refractory cancer: a report from the Children's Cancer Study Group. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1893377/),nM,146,225314,DB00544,Fluorouracil
,1893377,concentration,The TBAF concentration fell to 146 +/- 42 nM by 24 h.,Pharmacology and phase I trial of high-dose oral leucovorin plus 5-fluorouracil in children with refractory cancer: a report from the Children's Cancer Study Group. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1893377/),nM,146,225315,DB00544,Fluorouracil
,27913881,PFS,"The median PFS, TTF, and OS were 4.13, 3.70, and 11.40 months.",Phase II trial of S-1 plus leucovorin in patients with advanced gastric cancer and clinical prediction by S-1 pharmacogenetic pathway. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27913881/),month,4.13,226375,DB00544,Fluorouracil
,27913881,TTF,"The median PFS, TTF, and OS were 4.13, 3.70, and 11.40 months.",Phase II trial of S-1 plus leucovorin in patients with advanced gastric cancer and clinical prediction by S-1 pharmacogenetic pathway. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27913881/),month,3.70,226376,DB00544,Fluorouracil
,27913881,TTF,"The median PFS, TTF, and OS were 4.13, 3.70, and 11.40 months.",Phase II trial of S-1 plus leucovorin in patients with advanced gastric cancer and clinical prediction by S-1 pharmacogenetic pathway. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27913881/),month,11.40,226377,DB00544,Fluorouracil
,27913881,OS,"The median PFS, TTF, and OS were 4.13, 3.70, and 11.40 months.",Phase II trial of S-1 plus leucovorin in patients with advanced gastric cancer and clinical prediction by S-1 pharmacogenetic pathway. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27913881/),month,11.40,226378,DB00544,Fluorouracil
,31788317,area under the curve [AUC],"These studies were multicenter, open-label phase II trials designed to evaluate the drug-drug interactions between cetuximab (400 mg m-2 initial dose) and cisplatin (JXBA; 100 mg m-2) or carboplatin (JXBB; area under the curve [AUC] = 5 mg × min mL-1) with or without 5-fluorouracil (5FU) in patients with advanced solid tumors.",Evaluation of pharmacokinetics and safety of cetuximab with cisplatin/carboplatin in patients with advanced solid tumor: Result from phase II studies. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31788317/),[mg·min] / [ml],5,226887,DB00544,Fluorouracil
,31788317,"C max, t max","The C max, t max and overall AUC for the cetuximab group (194 µg mL-1, 2.0 hour, 14 900 µg × h mL-1) and the cetuximab and cisplatin combination group (192 µg mL-1, 1.99 hour, 16 300 µg × h mL-1) were similar.",Evaluation of pharmacokinetics and safety of cetuximab with cisplatin/carboplatin in patients with advanced solid tumor: Result from phase II studies. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31788317/),[μg] / [ml],194,226888,DB00544,Fluorouracil
,31788317,"C max, t max","The C max, t max and overall AUC for the cetuximab group (194 µg mL-1, 2.0 hour, 14 900 µg × h mL-1) and the cetuximab and cisplatin combination group (192 µg mL-1, 1.99 hour, 16 300 µg × h mL-1) were similar.",Evaluation of pharmacokinetics and safety of cetuximab with cisplatin/carboplatin in patients with advanced solid tumor: Result from phase II studies. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31788317/),h,2.0,226889,DB00544,Fluorouracil
,31788317,"C max, t max","The C max, t max and overall AUC for the cetuximab group (194 µg mL-1, 2.0 hour, 14 900 µg × h mL-1) and the cetuximab and cisplatin combination group (192 µg mL-1, 1.99 hour, 16 300 µg × h mL-1) were similar.",Evaluation of pharmacokinetics and safety of cetuximab with cisplatin/carboplatin in patients with advanced solid tumor: Result from phase II studies. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31788317/),[μg] / [ml],192,226890,DB00544,Fluorouracil
,31788317,"C max, t max","The C max, t max and overall AUC for the cetuximab group (194 µg mL-1, 2.0 hour, 14 900 µg × h mL-1) and the cetuximab and cisplatin combination group (192 µg mL-1, 1.99 hour, 16 300 µg × h mL-1) were similar.",Evaluation of pharmacokinetics and safety of cetuximab with cisplatin/carboplatin in patients with advanced solid tumor: Result from phase II studies. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31788317/),h,1.99,226891,DB00544,Fluorouracil
,31788317,overall AUC,"The C max, t max and overall AUC for the cetuximab group (194 µg mL-1, 2.0 hour, 14 900 µg × h mL-1) and the cetuximab and cisplatin combination group (192 µg mL-1, 1.99 hour, 16 300 µg × h mL-1) were similar.",Evaluation of pharmacokinetics and safety of cetuximab with cisplatin/carboplatin in patients with advanced solid tumor: Result from phase II studies. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31788317/),[h·μg] / [ml],14 900,226892,DB00544,Fluorouracil
,31788317,overall AUC,"The C max, t max and overall AUC for the cetuximab group (194 µg mL-1, 2.0 hour, 14 900 µg × h mL-1) and the cetuximab and cisplatin combination group (192 µg mL-1, 1.99 hour, 16 300 µg × h mL-1) were similar.",Evaluation of pharmacokinetics and safety of cetuximab with cisplatin/carboplatin in patients with advanced solid tumor: Result from phase II studies. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31788317/),[h·μg] / [ml],16 300,226893,DB00544,Fluorouracil
,31788317,"C max, t max","The C max, t max and overall AUC for the cetuximab group (199 µg mL-1, 1.15 hour, 17 200 µg × h mL-1) and the cetuximab and carboplatin combination group (199 µg mL-1, 3.17 h, 16 800 µg × h mL-1) were similar.",Evaluation of pharmacokinetics and safety of cetuximab with cisplatin/carboplatin in patients with advanced solid tumor: Result from phase II studies. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31788317/),[μg] / [ml],199,226894,DB00544,Fluorouracil
,31788317,"C max, t max","The C max, t max and overall AUC for the cetuximab group (199 µg mL-1, 1.15 hour, 17 200 µg × h mL-1) and the cetuximab and carboplatin combination group (199 µg mL-1, 3.17 h, 16 800 µg × h mL-1) were similar.",Evaluation of pharmacokinetics and safety of cetuximab with cisplatin/carboplatin in patients with advanced solid tumor: Result from phase II studies. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31788317/),h,1.15,226895,DB00544,Fluorouracil
,31788317,"C max, t max","The C max, t max and overall AUC for the cetuximab group (199 µg mL-1, 1.15 hour, 17 200 µg × h mL-1) and the cetuximab and carboplatin combination group (199 µg mL-1, 3.17 h, 16 800 µg × h mL-1) were similar.",Evaluation of pharmacokinetics and safety of cetuximab with cisplatin/carboplatin in patients with advanced solid tumor: Result from phase II studies. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31788317/),h,3.17,226896,DB00544,Fluorouracil
,31788317,overall AUC,"The C max, t max and overall AUC for the cetuximab group (199 µg mL-1, 1.15 hour, 17 200 µg × h mL-1) and the cetuximab and carboplatin combination group (199 µg mL-1, 3.17 h, 16 800 µg × h mL-1) were similar.",Evaluation of pharmacokinetics and safety of cetuximab with cisplatin/carboplatin in patients with advanced solid tumor: Result from phase II studies. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31788317/),[h·μg] / [ml],17 200,226897,DB00544,Fluorouracil
,31788317,overall AUC,"The C max, t max and overall AUC for the cetuximab group (199 µg mL-1, 1.15 hour, 17 200 µg × h mL-1) and the cetuximab and carboplatin combination group (199 µg mL-1, 3.17 h, 16 800 µg × h mL-1) were similar.",Evaluation of pharmacokinetics and safety of cetuximab with cisplatin/carboplatin in patients with advanced solid tumor: Result from phase II studies. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31788317/),[h·μg] / [ml],16 800,226898,DB00544,Fluorouracil
,14523056,F-RNA,"F-RNA, ranging from 27 to 36 ng/mg RNA, was detected in the tumor of the rabbits that were administered a total dose of 8 mg/kg.",Pharmacokinetics of 5-fluorouracil following hepatic intra-arterial infusion in a VX2 hepatic metastasis model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14523056/),[ng] / [mg·rna],27 to 36,227039,DB00544,Fluorouracil
,30077713,trough,We found that the area under the plasma concentration-time curves (AUC0-∞) of 5‑fluorouracil depended on the UFT dosing time of day with a 2.4-fold difference between the peak (at 19:00: 13.7 ± 1.4 μmol·h/L) and trough (at 13:00: 5.6 ± 1.3 μmol·h/L).,Circadian variations in the pharmacokinetics of the oral anticancer agent tegafur-uracil (UFT) and its metabolites in rats. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30077713/),[h·μM] / [l],5.6,227845,DB00544,Fluorouracil
,16303864,response rate,"Objective responses were reported in 18 patients (three complete responses and 15 partial responses), yielding a response rate of 40.9% in the intention-to-treat population according to the investigator assessment.",Dose-finding and pharmacokinetic study of an all-oral combination regimen of oral vinorelbine and capecitabine for patients with metastatic breast cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16303864/),%,40.9,227968,DB00544,Fluorouracil
,10223231,response rate,"Two complete responses and 15 partial responses were observed (response rate of 47.2%; 95% confidence interval, 30.1-64.4%).",A simplified regimen of weekly high dose 5-fluorouracil and leucovorin as a 24-hour infusion in patients with advanced colorectal carcinoma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10223231/),%,47.2,228049,DB00544,Fluorouracil
,10223231,response duration,The median response duration was 9.6 months.,A simplified regimen of weekly high dose 5-fluorouracil and leucovorin as a 24-hour infusion in patients with advanced colorectal carcinoma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10223231/),month,9.6,228050,DB00544,Fluorouracil
,10223231,survival,"The median survival and time to progression were 11.9 months and 7.1 months, respectively.",A simplified regimen of weekly high dose 5-fluorouracil and leucovorin as a 24-hour infusion in patients with advanced colorectal carcinoma. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10223231/),month,11.9,228051,DB00544,Fluorouracil
,10223231,time to progression,"The median survival and time to progression were 11.9 months and 7.1 months, respectively.",A simplified regimen of weekly high dose 5-fluorouracil and leucovorin as a 24-hour infusion in patients with advanced colorectal carcinoma. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10223231/),month,7.1,228052,DB00544,Fluorouracil
,9877235,elimination half-life,The elimination half-life of 5-FU following UFT administration is approximately 7 h compared with 0.2 h with i.v. 5-FU.,UFT and leucovorin: a review of its clinical development and therapeutic potential in the oral treatment of cancer. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9877235/),h,7,228378,DB00544,Fluorouracil
,9877235,elimination half-life,The elimination half-life of 5-FU following UFT administration is approximately 7 h compared with 0.2 h with i.v. 5-FU.,UFT and leucovorin: a review of its clinical development and therapeutic potential in the oral treatment of cancer. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9877235/),h,0.2,228379,DB00544,Fluorouracil
,9877235,response rates,"In phase II studies of UFT plus oral leucovorin for the treatment of advanced colorectal cancer, response rates ranged from 25 to 42%.",UFT and leucovorin: a review of its clinical development and therapeutic potential in the oral treatment of cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9877235/),%,25 to 42,228380,DB00544,Fluorouracil
,8001446,rate of encap,"5-Fu polyphase liposome was prepared by fusing the drug with lecithin and cholesterol, the rate of encapsulation being 52%, and 97% of the particles were less than 2 microns in diameter and stable against heat and cold.",[A pharmacokinetic study of subconjunctival polyphase liposome 5-fluorouracil]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8001446/),%,52,228444,DB00544,Fluorouracil
no less,8001446,ID50,"The concentrations of 5-Fu in the conjunctiva, the sclera, and the conjunctiva-Tenen's capsule-sclera en bloc 180 degrees from the site of injection were measured by the scintillation method 12, 24, 48, 72 and 96 hours after injection to be no less than 0.2 microgram, the ID50 of fibroblast proliferation.",[A pharmacokinetic study of subconjunctival polyphase liposome 5-fluorouracil]. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8001446/),μg,0.2,228445,DB00544,Fluorouracil
,10755317,concentration ratio,"The mean liver metastasis/healthy tissue 5-FU concentration ratio was 1.4 (P = 0.49, not statistically different).",Preferential activation of capecitabine in tumor following oral administration to colorectal cancer patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10755317/),,1.4,228855,DB00544,Fluorouracil
exceeded,10755317,concentration ratios,The mean tissue/plasma 5-FU concentration ratios exceeded 20 for colorectal tumor and ranged from 8 to 10 for other tissues.,Preferential activation of capecitabine in tumor following oral administration to colorectal cancer patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10755317/),,20,228856,DB00544,Fluorouracil
exceeded,10755317,concentration ratios,The mean tissue/plasma 5-FU concentration ratios exceeded 20 for colorectal tumor and ranged from 8 to 10 for other tissues.,Preferential activation of capecitabine in tumor following oral administration to colorectal cancer patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10755317/),,8 to 10,228857,DB00544,Fluorouracil
,22382460,AUC,"Because individual factors other than dose change may also affect the change in AUC, longitudinal PK monitoring in all cycles and dose adjustment to ensure AUC in the desired range of 20-30 mg · h/L are recommended.",Modeling the 5-fluorouracil area under the curve versus dose relationship to develop a pharmacokinetic dosing algorithm for colorectal cancer patients receiving FOLFOX6. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22382460/),[h·mg] / [l],20-30,228886,DB00544,Fluorouracil
,10217332,activity,The mean of the activity was 0.28 +/- 0.16 nmol/min/mg protein.,Dihydropyrimidine dehydrogenase activity in a Korean population. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10217332/),[nM] / [mg·min],0.28,229163,DB00544,Fluorouracil
,8639317,AUC,The AUC after bolus injection was 6158 +/- 874 micromol/l*min compared to 3355 +/- 428 micromol/l*min after short-time infusion of 5-fluorouracil (p < 0.01).,Different intravenous administration techniques for 5-fluorouracil. Pharmacokinetics and pharmacodynamic effects. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8639317/),[μM] / [l·min],6158,229506,DB00544,Fluorouracil
,8639317,AUC,The AUC after bolus injection was 6158 +/- 874 micromol/l*min compared to 3355 +/- 428 micromol/l*min after short-time infusion of 5-fluorouracil (p < 0.01).,Different intravenous administration techniques for 5-fluorouracil. Pharmacokinetics and pharmacodynamic effects. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8639317/),[μM] / [l·min],3355,229507,DB00544,Fluorouracil
,8639317,peak-level,The mean peak-level after bolus injection was 341 +/- 34 microM versus 161 +/- 17 microM after a short-time infusion (p < 0.01).,Different intravenous administration techniques for 5-fluorouracil. Pharmacokinetics and pharmacodynamic effects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8639317/),μM,341,229508,DB00544,Fluorouracil
,8639317,peak-level,The mean peak-level after bolus injection was 341 +/- 34 microM versus 161 +/- 17 microM after a short-time infusion (p < 0.01).,Different intravenous administration techniques for 5-fluorouracil. Pharmacokinetics and pharmacodynamic effects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8639317/),μM,161,229509,DB00544,Fluorouracil
,1428724,Cmax,Non tumour-bearing and MAC26 bearing mice gave almost identical plasma profiles after i.p. administration with the Cmax being 29.8 and 30.4 micrograms ml-1 and t1/2 16 and 15 min.,"Pharmacokinetics and cytotoxicity of B.3839, a molecular combination of 5-fluorouracil and N-(2-chloroethyl)-N-nitrosourea, in a mouse model. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1428724/),[μg] / [ml],29.8,230752,DB00544,Fluorouracil
,1428724,Cmax,Non tumour-bearing and MAC26 bearing mice gave almost identical plasma profiles after i.p. administration with the Cmax being 29.8 and 30.4 micrograms ml-1 and t1/2 16 and 15 min.,"Pharmacokinetics and cytotoxicity of B.3839, a molecular combination of 5-fluorouracil and N-(2-chloroethyl)-N-nitrosourea, in a mouse model. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1428724/),[μg] / [ml],30.4,230753,DB00544,Fluorouracil
,1428724,t1/2,Non tumour-bearing and MAC26 bearing mice gave almost identical plasma profiles after i.p. administration with the Cmax being 29.8 and 30.4 micrograms ml-1 and t1/2 16 and 15 min.,"Pharmacokinetics and cytotoxicity of B.3839, a molecular combination of 5-fluorouracil and N-(2-chloroethyl)-N-nitrosourea, in a mouse model. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1428724/),min,16,230754,DB00544,Fluorouracil
,1428724,t1/2,Non tumour-bearing and MAC26 bearing mice gave almost identical plasma profiles after i.p. administration with the Cmax being 29.8 and 30.4 micrograms ml-1 and t1/2 16 and 15 min.,"Pharmacokinetics and cytotoxicity of B.3839, a molecular combination of 5-fluorouracil and N-(2-chloroethyl)-N-nitrosourea, in a mouse model. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1428724/),min,15,230755,DB00544,Fluorouracil
,1428724,AUCs,The AUCs were 15.3 and 13.9 micrograms h ml-1 suggesting tumour load had no influence over plasma levels.,"Pharmacokinetics and cytotoxicity of B.3839, a molecular combination of 5-fluorouracil and N-(2-chloroethyl)-N-nitrosourea, in a mouse model. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1428724/),[h·μg] / [ml],15.3,230756,DB00544,Fluorouracil
,1428724,AUCs,The AUCs were 15.3 and 13.9 micrograms h ml-1 suggesting tumour load had no influence over plasma levels.,"Pharmacokinetics and cytotoxicity of B.3839, a molecular combination of 5-fluorouracil and N-(2-chloroethyl)-N-nitrosourea, in a mouse model. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1428724/),[h·μg] / [ml],13.9,230757,DB00544,Fluorouracil
,1428724,Cmax,Oral administration gave a much lower Cmax of 8.0 micrograms ml-1 but an AUC of 15.2 micrograms h ml-1 due to a longer terminal t1/2 (94 min) giving 99% bioavailability.,"Pharmacokinetics and cytotoxicity of B.3839, a molecular combination of 5-fluorouracil and N-(2-chloroethyl)-N-nitrosourea, in a mouse model. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1428724/),[μg] / [ml],8.0,230758,DB00544,Fluorouracil
,1428724,AUC,Oral administration gave a much lower Cmax of 8.0 micrograms ml-1 but an AUC of 15.2 micrograms h ml-1 due to a longer terminal t1/2 (94 min) giving 99% bioavailability.,"Pharmacokinetics and cytotoxicity of B.3839, a molecular combination of 5-fluorouracil and N-(2-chloroethyl)-N-nitrosourea, in a mouse model. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1428724/),[h·μg] / [ml],15.2,230759,DB00544,Fluorouracil
,1428724,terminal t1/2,Oral administration gave a much lower Cmax of 8.0 micrograms ml-1 but an AUC of 15.2 micrograms h ml-1 due to a longer terminal t1/2 (94 min) giving 99% bioavailability.,"Pharmacokinetics and cytotoxicity of B.3839, a molecular combination of 5-fluorouracil and N-(2-chloroethyl)-N-nitrosourea, in a mouse model. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1428724/),min,94,230760,DB00544,Fluorouracil
,1428724,bioavailability,Oral administration gave a much lower Cmax of 8.0 micrograms ml-1 but an AUC of 15.2 micrograms h ml-1 due to a longer terminal t1/2 (94 min) giving 99% bioavailability.,"Pharmacokinetics and cytotoxicity of B.3839, a molecular combination of 5-fluorouracil and N-(2-chloroethyl)-N-nitrosourea, in a mouse model. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1428724/),%,99,230761,DB00544,Fluorouracil
,1428724,IC70,"Cytotoxicity assays in vitro against the MAC lines gave IC70 values of 5.3, 13.8 and 8.6 micrograms ml-1 for MAC 26, 13 and 15A respectively after a one hour exposure.","Pharmacokinetics and cytotoxicity of B.3839, a molecular combination of 5-fluorouracil and N-(2-chloroethyl)-N-nitrosourea, in a mouse model. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1428724/),[μg] / [ml],5.3,230762,DB00544,Fluorouracil
,1428724,IC70,"Cytotoxicity assays in vitro against the MAC lines gave IC70 values of 5.3, 13.8 and 8.6 micrograms ml-1 for MAC 26, 13 and 15A respectively after a one hour exposure.","Pharmacokinetics and cytotoxicity of B.3839, a molecular combination of 5-fluorouracil and N-(2-chloroethyl)-N-nitrosourea, in a mouse model. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1428724/),[μg] / [ml],13.8,230763,DB00544,Fluorouracil
,1428724,IC70,"Cytotoxicity assays in vitro against the MAC lines gave IC70 values of 5.3, 13.8 and 8.6 micrograms ml-1 for MAC 26, 13 and 15A respectively after a one hour exposure.","Pharmacokinetics and cytotoxicity of B.3839, a molecular combination of 5-fluorouracil and N-(2-chloroethyl)-N-nitrosourea, in a mouse model. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1428724/),[μg] / [ml],8.6,230764,DB00544,Fluorouracil
,10725316,k(inact),"The kinetic parameters obtained for inactivation represented by k(inact) and K'(app) were 2.05 +/- 1.52 min(-1), 69.2 +/- 60.8 microM (rat hepatic cytosol), 2.39 +/- 0.13 min(-1), 48.6 +/- 11.8 microM (human hepatic cytosol), and 0.574 +/- 0.121 min(-1), 2.20 +/- 0.57 microM (human recombinant DPD).",Prediction of in vivo drug-drug interactions based on mechanism-based inhibition from in vitro data: inhibition of 5-fluorouracil metabolism by (E)-5-(2-Bromovinyl)uracil. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10725316/),1/[min],2.05,231522,DB00544,Fluorouracil
,10725316,K'(app),"The kinetic parameters obtained for inactivation represented by k(inact) and K'(app) were 2.05 +/- 1.52 min(-1), 69.2 +/- 60.8 microM (rat hepatic cytosol), 2.39 +/- 0.13 min(-1), 48.6 +/- 11.8 microM (human hepatic cytosol), and 0.574 +/- 0.121 min(-1), 2.20 +/- 0.57 microM (human recombinant DPD).",Prediction of in vivo drug-drug interactions based on mechanism-based inhibition from in vitro data: inhibition of 5-fluorouracil metabolism by (E)-5-(2-Bromovinyl)uracil. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10725316/),μM,48.6,231523,DB00544,Fluorouracil
,10725316,K'(app),"The kinetic parameters obtained for inactivation represented by k(inact) and K'(app) were 2.05 +/- 1.52 min(-1), 69.2 +/- 60.8 microM (rat hepatic cytosol), 2.39 +/- 0.13 min(-1), 48.6 +/- 11.8 microM (human hepatic cytosol), and 0.574 +/- 0.121 min(-1), 2.20 +/- 0.57 microM (human recombinant DPD).",Prediction of in vivo drug-drug interactions based on mechanism-based inhibition from in vitro data: inhibition of 5-fluorouracil metabolism by (E)-5-(2-Bromovinyl)uracil. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10725316/),1/[min],0.574,231524,DB00544,Fluorouracil
,10725316,K'(app),"The kinetic parameters obtained for inactivation represented by k(inact) and K'(app) were 2.05 +/- 1.52 min(-1), 69.2 +/- 60.8 microM (rat hepatic cytosol), 2.39 +/- 0.13 min(-1), 48.6 +/- 11.8 microM (human hepatic cytosol), and 0.574 +/- 0.121 min(-1), 2.20 +/- 0.57 microM (human recombinant DPD).",Prediction of in vivo drug-drug interactions based on mechanism-based inhibition from in vitro data: inhibition of 5-fluorouracil metabolism by (E)-5-(2-Bromovinyl)uracil. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10725316/),μM,2.20,231525,DB00544,Fluorouracil
,18990017,maximum survival time,"In mice, increase in the life span (ILS) by 87.1% with a maximum survival time of 30.5+/-1.87 days was found with EAC cell-induced tumors, with an ILS of 88.1% and a maximum survival time of 39.5+/-1.87 days for DLA cell-induced lesions with 5-FU transdermal patches.",Clinical evaluation of 5-fluorouracil from transdermal patches on EAC and DLA cell-induced tumors in mice. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18990017/),d,30.5,231800,DB00544,Fluorouracil
,18990017,maximum survival time,"In mice, increase in the life span (ILS) by 87.1% with a maximum survival time of 30.5+/-1.87 days was found with EAC cell-induced tumors, with an ILS of 88.1% and a maximum survival time of 39.5+/-1.87 days for DLA cell-induced lesions with 5-FU transdermal patches.",Clinical evaluation of 5-fluorouracil from transdermal patches on EAC and DLA cell-induced tumors in mice. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18990017/),d,39.5,231801,DB00544,Fluorouracil
,18990017,t1/2,"Pharmacokinetic studies in rabbits showed a t1/2 of 29+/-6 min, a Cmax (ng/ml) of 978.23, an AUC0-infinity (ng/ml/h) of 1213.73 +/-14 and a Tmax (h) of 0.5.",Clinical evaluation of 5-fluorouracil from transdermal patches on EAC and DLA cell-induced tumors in mice. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18990017/),min,29,231802,DB00544,Fluorouracil
,18990017,Cmax,"Pharmacokinetic studies in rabbits showed a t1/2 of 29+/-6 min, a Cmax (ng/ml) of 978.23, an AUC0-infinity (ng/ml/h) of 1213.73 +/-14 and a Tmax (h) of 0.5.",Clinical evaluation of 5-fluorouracil from transdermal patches on EAC and DLA cell-induced tumors in mice. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18990017/),[ng] / [ml],978.23,231803,DB00544,Fluorouracil
,18990017,AUC0-infinity,"Pharmacokinetic studies in rabbits showed a t1/2 of 29+/-6 min, a Cmax (ng/ml) of 978.23, an AUC0-infinity (ng/ml/h) of 1213.73 +/-14 and a Tmax (h) of 0.5.",Clinical evaluation of 5-fluorouracil from transdermal patches on EAC and DLA cell-induced tumors in mice. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18990017/),[ng] / [h·ml],1213.73,231804,DB00544,Fluorouracil
,18990017,Tmax,"Pharmacokinetic studies in rabbits showed a t1/2 of 29+/-6 min, a Cmax (ng/ml) of 978.23, an AUC0-infinity (ng/ml/h) of 1213.73 +/-14 and a Tmax (h) of 0.5.",Clinical evaluation of 5-fluorouracil from transdermal patches on EAC and DLA cell-induced tumors in mice. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18990017/),h,0.5,231805,DB00544,Fluorouracil
,18990017,half-life,"5-FU from transdermal patches exhibited a half-life of 95+/-0.5 min, a Cmax (ng/ml) of 863.25, an AUC0-infinity (ng/ml/h) of 1567+/-36 and a Tmax (h) of 1.5.",Clinical evaluation of 5-fluorouracil from transdermal patches on EAC and DLA cell-induced tumors in mice. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18990017/),min,95,231806,DB00544,Fluorouracil
,18990017,Cmax,"5-FU from transdermal patches exhibited a half-life of 95+/-0.5 min, a Cmax (ng/ml) of 863.25, an AUC0-infinity (ng/ml/h) of 1567+/-36 and a Tmax (h) of 1.5.",Clinical evaluation of 5-fluorouracil from transdermal patches on EAC and DLA cell-induced tumors in mice. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18990017/),[ng] / [ml],863.25,231807,DB00544,Fluorouracil
,18990017,AUC0-infinity,"5-FU from transdermal patches exhibited a half-life of 95+/-0.5 min, a Cmax (ng/ml) of 863.25, an AUC0-infinity (ng/ml/h) of 1567+/-36 and a Tmax (h) of 1.5.",Clinical evaluation of 5-fluorouracil from transdermal patches on EAC and DLA cell-induced tumors in mice. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18990017/),[ng] / [h·ml],1567,231808,DB00544,Fluorouracil
,18990017,Tmax,"5-FU from transdermal patches exhibited a half-life of 95+/-0.5 min, a Cmax (ng/ml) of 863.25, an AUC0-infinity (ng/ml/h) of 1567+/-36 and a Tmax (h) of 1.5.",Clinical evaluation of 5-fluorouracil from transdermal patches on EAC and DLA cell-induced tumors in mice. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18990017/),h,1.5,231809,DB00544,Fluorouracil
,9932161,MTD,The median MTD was 475 mg/m2/day (95% CI: 450-500) in the FU bolus arm with stomatitis +/- diarrhea being the most common DLT.,5-methyltetrahydrofolate for biochemical modulation of fluorouracil (FU) in patients with advanced colorectal cancer: a randomized phase I-II study of two different FU administration schedules. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9932161/),[mg] / [d·m2],475,231829,DB00544,Fluorouracil
,9932161,MTD,"Gastrointestinal side effects were also dose-limiting in the two-hour infusion arm; however, the median MTD was 600 mg/m2/day (95% CI: 568-632).",5-methyltetrahydrofolate for biochemical modulation of fluorouracil (FU) in patients with advanced colorectal cancer: a randomized phase I-II study of two different FU administration schedules. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9932161/),mg,600,231830,DB00544,Fluorouracil
,9932161,overall response rates,The overall response rates were 27.5% (95% CI: 15-44%; 1 CR and 10 PR) for patients treated in the bolus arm and 14.5% (95% CI: 5-28%; 1 CR and 5 PR) for those treated in the two-hour infusion arm.,5-methyltetrahydrofolate for biochemical modulation of fluorouracil (FU) in patients with advanced colorectal cancer: a randomized phase I-II study of two different FU administration schedules. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9932161/),%,27.5,231831,DB00544,Fluorouracil
,9932161,overall response rates,The overall response rates were 27.5% (95% CI: 15-44%; 1 CR and 10 PR) for patients treated in the bolus arm and 14.5% (95% CI: 5-28%; 1 CR and 5 PR) for those treated in the two-hour infusion arm.,5-methyltetrahydrofolate for biochemical modulation of fluorouracil (FU) in patients with advanced colorectal cancer: a randomized phase I-II study of two different FU administration schedules. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9932161/),%,14.5,231832,DB00544,Fluorouracil
,9932161,time to progression,"Analogous to recorded response, median time to progression (8.5 vs. 6.25) and overall survival time (14.0 vs. 11.0) tended to be superior in the FU bolus arm.",5-methyltetrahydrofolate for biochemical modulation of fluorouracil (FU) in patients with advanced colorectal cancer: a randomized phase I-II study of two different FU administration schedules. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9932161/),,8.5,231833,DB00544,Fluorouracil
,9932161,time to progression,"Analogous to recorded response, median time to progression (8.5 vs. 6.25) and overall survival time (14.0 vs. 11.0) tended to be superior in the FU bolus arm.",5-methyltetrahydrofolate for biochemical modulation of fluorouracil (FU) in patients with advanced colorectal cancer: a randomized phase I-II study of two different FU administration schedules. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9932161/),,6.25,231834,DB00544,Fluorouracil
,9932161,overall survival time,"Analogous to recorded response, median time to progression (8.5 vs. 6.25) and overall survival time (14.0 vs. 11.0) tended to be superior in the FU bolus arm.",5-methyltetrahydrofolate for biochemical modulation of fluorouracil (FU) in patients with advanced colorectal cancer: a randomized phase I-II study of two different FU administration schedules. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9932161/),,14.0,231835,DB00544,Fluorouracil
,9932161,overall survival time,"Analogous to recorded response, median time to progression (8.5 vs. 6.25) and overall survival time (14.0 vs. 11.0) tended to be superior in the FU bolus arm.",5-methyltetrahydrofolate for biochemical modulation of fluorouracil (FU) in patients with advanced colorectal cancer: a randomized phase I-II study of two different FU administration schedules. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9932161/),,11.0,231836,DB00544,Fluorouracil
,27270460,progression-free survival (PFS),The median progression-free survival (PFS) was 10 months (range 2-36 months).,Chronomodulated oxaliplatin plus Capecitabine (XELOX) as a first line chemotherapy in metastatic colorectal cancer: A Phase II Brunch regimen study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27270460/),month,10,231854,DB00544,Fluorouracil
,22382585,progression free survival (PFS),"Median progression free survival (PFS) and overall survival (OS) were 2.7 ms (95% CI, 1.6-3.9 ms) and 7.1 ms (95% CI, 4.3-9.9 ms), respectively.","Clinical, pharmacokinetic and pharmacodynamic evaluations of metronomic UFT and cyclophosphamide plus celecoxib in patients with advanced refractory gastrointestinal cancers. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22382585/),ms,2.7,232046,DB00544,Fluorouracil
,22382585,overall survival (OS),"Median progression free survival (PFS) and overall survival (OS) were 2.7 ms (95% CI, 1.6-3.9 ms) and 7.1 ms (95% CI, 4.3-9.9 ms), respectively.","Clinical, pharmacokinetic and pharmacodynamic evaluations of metronomic UFT and cyclophosphamide plus celecoxib in patients with advanced refractory gastrointestinal cancers. ",AUCSS-Q18,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22382585/),ms,7.1,232047,DB00544,Fluorouracil
greater,22382585,AUC,"Pharmacokinetics of 27 patients (13/14, SD/progressive disease, PD) after the first treatment of UFT revealed that 5-FU AUC and C(max) values greater than 1.313 h × μg/ml and 0.501 μg/ml, respectively, were statistically correlated with stabilization of disease and prolonged PFS/OS.","Clinical, pharmacokinetic and pharmacodynamic evaluations of metronomic UFT and cyclophosphamide plus celecoxib in patients with advanced refractory gastrointestinal cancers. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22382585/),[h·μg] / [ml],1.313,232048,DB00544,Fluorouracil
,22382585,C(max),"Pharmacokinetics of 27 patients (13/14, SD/progressive disease, PD) after the first treatment of UFT revealed that 5-FU AUC and C(max) values greater than 1.313 h × μg/ml and 0.501 μg/ml, respectively, were statistically correlated with stabilization of disease and prolonged PFS/OS.","Clinical, pharmacokinetic and pharmacodynamic evaluations of metronomic UFT and cyclophosphamide plus celecoxib in patients with advanced refractory gastrointestinal cancers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22382585/),[μg] / [ml],0.501,232049,DB00544,Fluorouracil
,23179335,response rate,"The response rate and progression-free survival at 4.0 mg/kg was 8.3 % and 7.59 months, respectively.",A phase I study of intravenous aflibercept with FOLFIRI in Japanese patients with previously treated metastatic colorectal cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23179335/),%,8.3,232228,DB00544,Fluorouracil
,23179335,progression-free survival,"The response rate and progression-free survival at 4.0 mg/kg was 8.3 % and 7.59 months, respectively.",A phase I study of intravenous aflibercept with FOLFIRI in Japanese patients with previously treated metastatic colorectal cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23179335/),month,7.59,232229,DB00544,Fluorouracil
,23179335,RPTD,The RPTD of aflibercept in combination with FOLFIRI for Japanese patients with mCRC was determined to be 4.0 mg/kg every 2 weeks.,A phase I study of intravenous aflibercept with FOLFIRI in Japanese patients with previously treated metastatic colorectal cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23179335/),[mg] / [kg],4.0,232230,DB00544,Fluorouracil
,33252721,AUC,"The values reported for LDC (AUC = 19.37 ± 0.09 µg/mL h and VD 2.4 ± 0.24 mL) and pure drug (AUC = 8.37 ± 0.04 µg/mL h and VD = 5.24 ± 0.29 mL) indicate higher concentrations of LDC in systemic circulation, while pure 5-FU was found to be largely available in tissue rather than blood circulation.",Enhanced brain targeting efficiency using 5-FU (fluorouracil) lipid-drug conjugated nanoparticles in brain cancer therapy. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33252721/),[μg] / [h·ml],19.37,233253,DB00544,Fluorouracil
,33252721,VD,"The values reported for LDC (AUC = 19.37 ± 0.09 µg/mL h and VD 2.4 ± 0.24 mL) and pure drug (AUC = 8.37 ± 0.04 µg/mL h and VD = 5.24 ± 0.29 mL) indicate higher concentrations of LDC in systemic circulation, while pure 5-FU was found to be largely available in tissue rather than blood circulation.",Enhanced brain targeting efficiency using 5-FU (fluorouracil) lipid-drug conjugated nanoparticles in brain cancer therapy. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33252721/),ml,2.4,233254,DB00544,Fluorouracil
,33252721,AUC,"The values reported for LDC (AUC = 19.37 ± 0.09 µg/mL h and VD 2.4 ± 0.24 mL) and pure drug (AUC = 8.37 ± 0.04 µg/mL h and VD = 5.24 ± 0.29 mL) indicate higher concentrations of LDC in systemic circulation, while pure 5-FU was found to be largely available in tissue rather than blood circulation.",Enhanced brain targeting efficiency using 5-FU (fluorouracil) lipid-drug conjugated nanoparticles in brain cancer therapy. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33252721/),[μg] / [h·ml],8.37,233255,DB00544,Fluorouracil
,33252721,VD,"The values reported for LDC (AUC = 19.37 ± 0.09 µg/mL h and VD 2.4 ± 0.24 mL) and pure drug (AUC = 8.37 ± 0.04 µg/mL h and VD = 5.24 ± 0.29 mL) indicate higher concentrations of LDC in systemic circulation, while pure 5-FU was found to be largely available in tissue rather than blood circulation.",Enhanced brain targeting efficiency using 5-FU (fluorouracil) lipid-drug conjugated nanoparticles in brain cancer therapy. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33252721/),ml,5.24,233256,DB00544,Fluorouracil
,33252721,MRT,"The t1/2 for LDC represents an approximate rise by ninefold, while MRT (12.10 ± 0.44 h) denotes 12-fold rise than pure 5-FU indicating the prolonged circulation of LDC.",Enhanced brain targeting efficiency using 5-FU (fluorouracil) lipid-drug conjugated nanoparticles in brain cancer therapy. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33252721/),h,12.10,233257,DB00544,Fluorouracil
,33252721,concentration in,"Free 5-FU concentration in the brain was maximum (5.24 ± 0.01 μg/g) after 3 h, while for the optimized formulation of LDC it was twofold greater estimated as 11.52 ± 0.32 μg/g.",Enhanced brain targeting efficiency using 5-FU (fluorouracil) lipid-drug conjugated nanoparticles in brain cancer therapy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33252721/),[μg] / [g],5.24,233258,DB00544,Fluorouracil
,8032956,time of distribution (t1/2 alpha,"When leucovorin was administered, the time of distribution (t1/2 alpha for 5-FU increased from 8.9 +/- 2.4 to 12.8 +/- 2.5 min (p < 0.0005) and the volume of distribution (Vd) increased from 0.129 +/- 0.039 to 0.237 +/- 0.033 L/kg (p < 0.03).",5-Fluorouracil pharmacokinetics in patients with metastatic colorectal carcinoma after high-dose leucovorin. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8032956/),min,8.9,233379,DB00544,Fluorouracil
,8032956,time of distribution (t1/2 alpha,"When leucovorin was administered, the time of distribution (t1/2 alpha for 5-FU increased from 8.9 +/- 2.4 to 12.8 +/- 2.5 min (p < 0.0005) and the volume of distribution (Vd) increased from 0.129 +/- 0.039 to 0.237 +/- 0.033 L/kg (p < 0.03).",5-Fluorouracil pharmacokinetics in patients with metastatic colorectal carcinoma after high-dose leucovorin. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8032956/),min,12.8,233380,DB00544,Fluorouracil
,8032956,volume of distribution (Vd),"When leucovorin was administered, the time of distribution (t1/2 alpha for 5-FU increased from 8.9 +/- 2.4 to 12.8 +/- 2.5 min (p < 0.0005) and the volume of distribution (Vd) increased from 0.129 +/- 0.039 to 0.237 +/- 0.033 L/kg (p < 0.03).",5-Fluorouracil pharmacokinetics in patients with metastatic colorectal carcinoma after high-dose leucovorin. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8032956/),[l] / [kg],0.129,233381,DB00544,Fluorouracil
,8032956,volume of distribution (Vd),"When leucovorin was administered, the time of distribution (t1/2 alpha for 5-FU increased from 8.9 +/- 2.4 to 12.8 +/- 2.5 min (p < 0.0005) and the volume of distribution (Vd) increased from 0.129 +/- 0.039 to 0.237 +/- 0.033 L/kg (p < 0.03).",5-Fluorouracil pharmacokinetics in patients with metastatic colorectal carcinoma after high-dose leucovorin. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8032956/),[l] / [kg],0.237,233382,DB00544,Fluorouracil
,19935361,Time to first result,"Time to first result was 10 minutes, and 400 samples per hour could be quantitated from a standard curve stored for >30 days.",Multicenter evaluation of a novel nanoparticle immunoassay for 5-fluorouracil on the Olympus AU400 analyzer. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19935361/),min,10,233740,DB00544,Fluorouracil
,19935361,Time to first result,"Time to first result was 10 minutes, and 400 samples per hour could be quantitated from a standard curve stored for >30 days.",Multicenter evaluation of a novel nanoparticle immunoassay for 5-fluorouracil on the Olympus AU400 analyzer. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19935361/),[samples] / [h],400,233741,DB00544,Fluorouracil
<,19935361,Cross-reactivities,"Cross-reactivities for dihydro-5-FU, uracil, capecitabine, and tegafur were <1%, 9.9%, 0.05%, and 0.23%, respectively.",Multicenter evaluation of a novel nanoparticle immunoassay for 5-fluorouracil on the Olympus AU400 analyzer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19935361/),%,1,233742,DB00544,Fluorouracil
,19935361,Cross-reactivities,"Cross-reactivities for dihydro-5-FU, uracil, capecitabine, and tegafur were <1%, 9.9%, 0.05%, and 0.23%, respectively.",Multicenter evaluation of a novel nanoparticle immunoassay for 5-fluorouracil on the Olympus AU400 analyzer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19935361/),%,9.9,233743,DB00544,Fluorouracil
,19935361,Cross-reactivities,"Cross-reactivities for dihydro-5-FU, uracil, capecitabine, and tegafur were <1%, 9.9%, 0.05%, and 0.23%, respectively.",Multicenter evaluation of a novel nanoparticle immunoassay for 5-fluorouracil on the Olympus AU400 analyzer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19935361/),%,0.05,233744,DB00544,Fluorouracil
,19935361,Cross-reactivities,"Cross-reactivities for dihydro-5-FU, uracil, capecitabine, and tegafur were <1%, 9.9%, 0.05%, and 0.23%, respectively.",Multicenter evaluation of a novel nanoparticle immunoassay for 5-fluorouracil on the Olympus AU400 analyzer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19935361/),%,0.23,233745,DB00544,Fluorouracil
,19935361,limit of detection,The limit of detection was 52 ng/mL with a lower limit of quantitation of 86 ng/mL.,Multicenter evaluation of a novel nanoparticle immunoassay for 5-fluorouracil on the Olympus AU400 analyzer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19935361/),[ng] / [ml],52,233746,DB00544,Fluorouracil
,8521418,area under the plasma 5-FU concentration versus the time curve,"The area under the plasma 5-FU concentration versus the time curve generated from UFT, FT, and 776C/FT at their maximum tolerated dose was 140, 50, and 27 microM.h, respectively.","5-Ethynyluracil (776C85): effects on the antitumor activity and pharmacokinetics of tegafur, a prodrug of 5-fluorouracil. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8521418/),h·μM,140,236215,DB00544,Fluorouracil
,8521418,area under the plasma 5-FU concentration versus the time curve,"The area under the plasma 5-FU concentration versus the time curve generated from UFT, FT, and 776C/FT at their maximum tolerated dose was 140, 50, and 27 microM.h, respectively.","5-Ethynyluracil (776C85): effects on the antitumor activity and pharmacokinetics of tegafur, a prodrug of 5-fluorouracil. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8521418/),h·μM,50,236216,DB00544,Fluorouracil
,8521418,area under the plasma 5-FU concentration versus the time curve,"The area under the plasma 5-FU concentration versus the time curve generated from UFT, FT, and 776C/FT at their maximum tolerated dose was 140, 50, and 27 microM.h, respectively.","5-Ethynyluracil (776C85): effects on the antitumor activity and pharmacokinetics of tegafur, a prodrug of 5-fluorouracil. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8521418/),h·μM,27,236217,DB00544,Fluorouracil
,10555122,tmax,"Based on the radioactivity measurements of drug-related material, absorption is rapid (tmax 0.25-1.5 hours) followed by a rapid biphasic decline.",A human capecitabine excretion balance and pharmacokinetic study after administration of a single oral dose of 14C-labelled drug. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10555122/),h,0.25-1.5,236321,DB00544,Fluorouracil
,9748123,steady state,"Following 1 h of CIFU, the plasma 5-FU levels reached a steady state of 0.6+/-0.2 microM (mean+/-SD; day 1), which was maintained for the entire 5-day infusion period (0.6+/-0.1 microM).",Comparison of 5-fluorouracil pharmacokinetics in patients receiving continuous 5-fluorouracil infusion and oral uracil plus N1-(2'-tetrahydrofuryl)-5-fluorouracil. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9748123/),μM,0.6,237095,DB00544,Fluorouracil
,9748123,steady state,"Following 1 h of CIFU, the plasma 5-FU levels reached a steady state of 0.6+/-0.2 microM (mean+/-SD; day 1), which was maintained for the entire 5-day infusion period (0.6+/-0.1 microM).",Comparison of 5-fluorouracil pharmacokinetics in patients receiving continuous 5-fluorouracil infusion and oral uracil plus N1-(2'-tetrahydrofuryl)-5-fluorouracil. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9748123/),μM,0.6,237096,DB00544,Fluorouracil
,9748123,maximum 5-FU concentrations (Cpmax),"In contrast, the maximum 5-FU concentrations (Cpmax) generated from oral UFT at 1 h after dose administration on days 1 and 5 were 2.1+/-1.5 microM and 2.3+/-1.9 microM, respectively, which were higher than the steady-state levels during CIFU.",Comparison of 5-fluorouracil pharmacokinetics in patients receiving continuous 5-fluorouracil infusion and oral uracil plus N1-(2'-tetrahydrofuryl)-5-fluorouracil. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9748123/),μM,2.1,237097,DB00544,Fluorouracil
,9748123,maximum 5-FU concentrations (Cpmax),"In contrast, the maximum 5-FU concentrations (Cpmax) generated from oral UFT at 1 h after dose administration on days 1 and 5 were 2.1+/-1.5 microM and 2.3+/-1.9 microM, respectively, which were higher than the steady-state levels during CIFU.",Comparison of 5-fluorouracil pharmacokinetics in patients receiving continuous 5-fluorouracil infusion and oral uracil plus N1-(2'-tetrahydrofuryl)-5-fluorouracil. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9748123/),μM,2.3,237098,DB00544,Fluorouracil
,9748123,"apparent elimination half-life (tl/2,beta)","These high 5-FU levels disappeared with an apparent elimination half-life (tl/2,beta) of 5.2+/-2.4 h (day 1) and 7.2+/-3.9 h (day 5).",Comparison of 5-fluorouracil pharmacokinetics in patients receiving continuous 5-fluorouracil infusion and oral uracil plus N1-(2'-tetrahydrofuryl)-5-fluorouracil. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9748123/),h,5.2,237099,DB00544,Fluorouracil
,9748123,"apparent elimination half-life (tl/2,beta)","These high 5-FU levels disappeared with an apparent elimination half-life (tl/2,beta) of 5.2+/-2.4 h (day 1) and 7.2+/-3.9 h (day 5).",Comparison of 5-fluorouracil pharmacokinetics in patients receiving continuous 5-fluorouracil infusion and oral uracil plus N1-(2'-tetrahydrofuryl)-5-fluorouracil. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9748123/),h,7.2,237100,DB00544,Fluorouracil
,9748123,area under the concentration versus time curve (AUC0-8h),"On day 1 of both regimens, CIFU patients had significantly larger 5-FU area under the concentration versus time curve (AUC0-8h) values (4.4+/-1.3 microM.h) than the AUC value when they received the UFT regimen (2.6+/-1.7 microM.h; P = 0.02).",Comparison of 5-fluorouracil pharmacokinetics in patients receiving continuous 5-fluorouracil infusion and oral uracil plus N1-(2'-tetrahydrofuryl)-5-fluorouracil. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9748123/),h·μM,4.4,237101,DB00544,Fluorouracil
,9748123,AUC,"On day 1 of both regimens, CIFU patients had significantly larger 5-FU area under the concentration versus time curve (AUC0-8h) values (4.4+/-1.3 microM.h) than the AUC value when they received the UFT regimen (2.6+/-1.7 microM.h; P = 0.02).",Comparison of 5-fluorouracil pharmacokinetics in patients receiving continuous 5-fluorouracil infusion and oral uracil plus N1-(2'-tetrahydrofuryl)-5-fluorouracil. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9748123/),h·μM,2.6,237102,DB00544,Fluorouracil
,9748123,AUC0-8 h,"However, by day 5, there were no significant differences between AUC0-8 h values in patients receiving CIFU and UFT, respectively (4.8+/-1.5 microM.h versus 3.8+/-2.2 microM.h; P = 0.30)].",Comparison of 5-fluorouracil pharmacokinetics in patients receiving continuous 5-fluorouracil infusion and oral uracil plus N1-(2'-tetrahydrofuryl)-5-fluorouracil. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9748123/),h·μM,4.8,237103,DB00544,Fluorouracil
,9748123,AUC0-8 h,"However, by day 5, there were no significant differences between AUC0-8 h values in patients receiving CIFU and UFT, respectively (4.8+/-1.5 microM.h versus 3.8+/-2.2 microM.h; P = 0.30)].",Comparison of 5-fluorouracil pharmacokinetics in patients receiving continuous 5-fluorouracil infusion and oral uracil plus N1-(2'-tetrahydrofuryl)-5-fluorouracil. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9748123/),h·μM,3.8,237104,DB00544,Fluorouracil
,9748123,"concentration of the metabolite 5-FU at steady-state (Css,aver)","On day 5, the average concentration of the metabolite 5-FU at steady-state (Css,aver) within dose interval of 8 h (0.48+/-0.28 microM) for the oral UFT treatment is comparable with the Cpss values of 5-FU from CIFU-treated patients.",Comparison of 5-fluorouracil pharmacokinetics in patients receiving continuous 5-fluorouracil infusion and oral uracil plus N1-(2'-tetrahydrofuryl)-5-fluorouracil. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9748123/),μM,0.48,237105,DB00544,Fluorouracil
>,17015056,half-life [t(1/2 beta)],"Of 188 patients, 3 (1.6%) had marked alterations of 5-FU/5-FDHU pharmacokinetics (ie, 5-FU half-life [t(1/2 beta)] >5 hours, 5-FU total body clearance [CL(TB)] <1 L x h(-1) x m(-2), and 5-FDHU time to reach maximum plasma concentration [t max] > or = 45 minutes); they were excluded from 5-FU treatments and treated with irinotecan, which was well tolerated.",A pharmacokinetic-based test to prevent severe 5-fluorouracil toxicity. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17015056/),h,5,237401,DB00544,Fluorouracil
<,17015056,total body clearance [CL(TB)],"Of 188 patients, 3 (1.6%) had marked alterations of 5-FU/5-FDHU pharmacokinetics (ie, 5-FU half-life [t(1/2 beta)] >5 hours, 5-FU total body clearance [CL(TB)] <1 L x h(-1) x m(-2), and 5-FDHU time to reach maximum plasma concentration [t max] > or = 45 minutes); they were excluded from 5-FU treatments and treated with irinotecan, which was well tolerated.",A pharmacokinetic-based test to prevent severe 5-fluorouracil toxicity. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17015056/),[l] / [(m)^2·h],1,237402,DB00544,Fluorouracil
> or =,17015056,time to reach maximum plasma concentration [t max],"Of 188 patients, 3 (1.6%) had marked alterations of 5-FU/5-FDHU pharmacokinetics (ie, 5-FU half-life [t(1/2 beta)] >5 hours, 5-FU total body clearance [CL(TB)] <1 L x h(-1) x m(-2), and 5-FDHU time to reach maximum plasma concentration [t max] > or = 45 minutes); they were excluded from 5-FU treatments and treated with irinotecan, which was well tolerated.",A pharmacokinetic-based test to prevent severe 5-fluorouracil toxicity. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17015056/),min,45,237403,DB00544,Fluorouracil
,17015056,area under the curve (AUC),"The plasma disposition of 5-FU in the remaining 185 patients revealed an area under the curve (AUC) of 3.73 +/- 2.18 h x microg/mL (mean +/- SD), maximum plasma concentration (Cmax) of 16.78 +/- 8.61 microg/mL, and t(1/2 beta) of 0.16 +/- 0.15 hour, whereas the CL(TB) was 65.67 +/- 31.86 L x h(-1) x m(-2).",A pharmacokinetic-based test to prevent severe 5-fluorouracil toxicity. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17015056/),[h·μg] / [ml],3.73,237404,DB00544,Fluorouracil
,17015056,maximum plasma concentration (Cmax),"The plasma disposition of 5-FU in the remaining 185 patients revealed an area under the curve (AUC) of 3.73 +/- 2.18 h x microg/mL (mean +/- SD), maximum plasma concentration (Cmax) of 16.78 +/- 8.61 microg/mL, and t(1/2 beta) of 0.16 +/- 0.15 hour, whereas the CL(TB) was 65.67 +/- 31.86 L x h(-1) x m(-2).",A pharmacokinetic-based test to prevent severe 5-fluorouracil toxicity. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17015056/),[μg] / [ml],16.78,237405,DB00544,Fluorouracil
,17015056,t(1/2 beta),"The plasma disposition of 5-FU in the remaining 185 patients revealed an area under the curve (AUC) of 3.73 +/- 2.18 h x microg/mL (mean +/- SD), maximum plasma concentration (Cmax) of 16.78 +/- 8.61 microg/mL, and t(1/2 beta) of 0.16 +/- 0.15 hour, whereas the CL(TB) was 65.67 +/- 31.86 L x h(-1) x m(-2).",A pharmacokinetic-based test to prevent severe 5-fluorouracil toxicity. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/17015056/),h,0.16,237406,DB00544,Fluorouracil
,17015056,CL(TB),"The plasma disposition of 5-FU in the remaining 185 patients revealed an area under the curve (AUC) of 3.73 +/- 2.18 h x microg/mL (mean +/- SD), maximum plasma concentration (Cmax) of 16.78 +/- 8.61 microg/mL, and t(1/2 beta) of 0.16 +/- 0.15 hour, whereas the CL(TB) was 65.67 +/- 31.86 L x h(-1) x m(-2).",A pharmacokinetic-based test to prevent severe 5-fluorouracil toxicity. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17015056/),[l] / [(m)^2·h],65.67,237407,DB00544,Fluorouracil
,17015056,Cmax,"The 5-FDHU plasma profile showed a Cmax value of 3.64 +/- 1.94 microg/mL, whereas the t max value was 26.63 +/- 10.06 minutes, with an AUC value of 3.71 +/- 1.90 h x microg/mL.",A pharmacokinetic-based test to prevent severe 5-fluorouracil toxicity. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17015056/),[μg] / [ml],3.64,237408,DB00544,Fluorouracil
,17015056,t max,"The 5-FDHU plasma profile showed a Cmax value of 3.64 +/- 1.94 microg/mL, whereas the t max value was 26.63 +/- 10.06 minutes, with an AUC value of 3.71 +/- 1.90 h x microg/mL.",A pharmacokinetic-based test to prevent severe 5-fluorouracil toxicity. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17015056/),min,26.63,237409,DB00544,Fluorouracil
,17015056,AUC,"The 5-FDHU plasma profile showed a Cmax value of 3.64 +/- 1.94 microg/mL, whereas the t max value was 26.63 +/- 10.06 minutes, with an AUC value of 3.71 +/- 1.90 h x microg/mL.",A pharmacokinetic-based test to prevent severe 5-fluorouracil toxicity. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17015056/),[h·μg] / [ml],3.71,237410,DB00544,Fluorouracil
,17015056,activity,"The PBMC DPD activity was 202.15 +/- 141.14 pmol 5-FDHU x min(-1) x mg(-1) protein (95% confidence interval, 165-239.3 pmol 5-FDHU x min(-1) x mg(-1) protein).",A pharmacokinetic-based test to prevent severe 5-fluorouracil toxicity. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17015056/),[5-fdhu·pM] / [mg·min],202.15,237411,DB00544,Fluorouracil
greater,17015056,t max,"Interestingly, no relationships between PBMC DPD activity and common toxicities were found, whereas 5-FDHU t max values greater than 30 minutes were associated with the risk of moderate to severe neutropenia and diarrhea (P = .0323 and P = .0138, respectively; chi-square test).",A pharmacokinetic-based test to prevent severe 5-fluorouracil toxicity. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17015056/),min,30,237412,DB00544,Fluorouracil
,3513684,Response rates,"Response rates were 45% on tamoxifen and 38% on CMF, with median durations of 10.4 and 7.9 months, respectively.",Combination chemotherapy compared to tamoxifen as initial therapy for stage IV breast cancer in elderly women. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3513684/),%,45,237457,DB00544,Fluorouracil
,3513684,Response rates,"Response rates were 45% on tamoxifen and 38% on CMF, with median durations of 10.4 and 7.9 months, respectively.",Combination chemotherapy compared to tamoxifen as initial therapy for stage IV breast cancer in elderly women. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3513684/),%,38,237458,DB00544,Fluorouracil
,30544058,response rate,The response rate was 42.3% (95% confidence interval (CI) 28.7-56.8%) with 7.7% complete and 34.6% partial responses.,Hepatic arterial therapy with oxaliplatin and systemic capecitabine for patients with liver metastases from breast cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30544058/),%,42.3,238236,DB00544,Fluorouracil
,30544058,progression free survival,Median progression free survival was 10.8 months (95% CI 6.9-14.7 months) and median overall survival 27.6 months (95% CI 20.4-34.8 months).,Hepatic arterial therapy with oxaliplatin and systemic capecitabine for patients with liver metastases from breast cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30544058/),month,10.8,238237,DB00544,Fluorouracil
,30544058,overall survival,Median progression free survival was 10.8 months (95% CI 6.9-14.7 months) and median overall survival 27.6 months (95% CI 20.4-34.8 months).,Hepatic arterial therapy with oxaliplatin and systemic capecitabine for patients with liver metastases from breast cancer. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30544058/),month,27.6,238238,DB00544,Fluorouracil
,6211226,plasma clearance,Concurrent dThd administration reduced the plasma clearance of FUra at steady state from 389.1 +/- 153.5 (S.D.) to 56.0 +/- 36.4 liters/kg/day.,Clinical pharmacological studies of concurrent infusion of 5-fluorouracil and thymidine in treatment of colorectal carcinomas. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6211226/),[l] / [d·kg],389.1,238977,DB00544,Fluorouracil
,6211226,plasma clearance,Concurrent dThd administration reduced the plasma clearance of FUra at steady state from 389.1 +/- 153.5 (S.D.) to 56.0 +/- 36.4 liters/kg/day.,Clinical pharmacological studies of concurrent infusion of 5-fluorouracil and thymidine in treatment of colorectal carcinomas. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6211226/),[l] / [d·kg],56.0,238978,DB00544,Fluorouracil
,6211226,steady-state plasma concentration,The mean steady-state plasma concentration of FUra in patients receiving FUra alone was 0.38 microM and was significantly lower than the 1.30 microM in patients receiving FUra-dThd.,Clinical pharmacological studies of concurrent infusion of 5-fluorouracil and thymidine in treatment of colorectal carcinomas. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6211226/),μM,0.38,238979,DB00544,Fluorouracil
,6211226,steady-state plasma concentration,The mean steady-state plasma concentration of FUra in patients receiving FUra alone was 0.38 microM and was significantly lower than the 1.30 microM in patients receiving FUra-dThd.,Clinical pharmacological studies of concurrent infusion of 5-fluorouracil and thymidine in treatment of colorectal carcinomas. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6211226/),μM,1.30,238980,DB00544,Fluorouracil
,6211226,plasma clearance,The plasma clearance of FUra in the toxic population was 32.0 +/- 16.8 liters/kg/day and was significantly lower than the clearance of 72.0 +/- 37.3 liters/kg/day in the nontoxic population (p less than 0.001).,Clinical pharmacological studies of concurrent infusion of 5-fluorouracil and thymidine in treatment of colorectal carcinomas. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6211226/),[l] / [d·kg],32.0,238981,DB00544,Fluorouracil
,6211226,clearance,The plasma clearance of FUra in the toxic population was 32.0 +/- 16.8 liters/kg/day and was significantly lower than the clearance of 72.0 +/- 37.3 liters/kg/day in the nontoxic population (p less than 0.001).,Clinical pharmacological studies of concurrent infusion of 5-fluorouracil and thymidine in treatment of colorectal carcinomas. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6211226/),[l] / [d·kg],72.0,238982,DB00544,Fluorouracil
,6211226,critical toxic steady-state FUra plasma concentration,The corresponding critical toxic steady-state FUra plasma concentration was 1.5 microM.,Clinical pharmacological studies of concurrent infusion of 5-fluorouracil and thymidine in treatment of colorectal carcinomas. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6211226/),μM,1.5,238983,DB00544,Fluorouracil
,7463330,peak plasma level,"In five patients who received intravenous fluorouracil, the mean peak plasma level of unchanged drug was 13.4 microgram/ml, the elimination half-life was 6.3 min, and the plasma clearance was 1410 ml/min.",Pharmacokinetics of oral and intravenous fluorouracil in humans. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7463330/),[μg] / [ml],13.4,239063,DB00544,Fluorouracil
,7463330,elimination half-life,"In five patients who received intravenous fluorouracil, the mean peak plasma level of unchanged drug was 13.4 microgram/ml, the elimination half-life was 6.3 min, and the plasma clearance was 1410 ml/min.",Pharmacokinetics of oral and intravenous fluorouracil in humans. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7463330/),min,6.3,239064,DB00544,Fluorouracil
,7463330,plasma clearance,"In five patients who received intravenous fluorouracil, the mean peak plasma level of unchanged drug was 13.4 microgram/ml, the elimination half-life was 6.3 min, and the plasma clearance was 1410 ml/min.",Pharmacokinetics of oral and intravenous fluorouracil in humans. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7463330/),[ml] / [min],1410,239065,DB00544,Fluorouracil
,7463330,peak value,"In six patients who received oral fluorouracil, the mean peak value of unchanged drug in plasma, which occurred within 20 min of dosing, was 8.3 microgram/ml, and the fluorouracil elimination half-life was 7.2 min.",Pharmacokinetics of oral and intravenous fluorouracil in humans. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7463330/),[μg] / [ml],8.3,239066,DB00544,Fluorouracil
,7463330,elimination half-life,"In six patients who received oral fluorouracil, the mean peak value of unchanged drug in plasma, which occurred within 20 min of dosing, was 8.3 microgram/ml, and the fluorouracil elimination half-life was 7.2 min.",Pharmacokinetics of oral and intravenous fluorouracil in humans. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7463330/),min,7.2,239067,DB00544,Fluorouracil
,7463330,overall bioavailability,"The overall bioavailability of oral fluorouracil as unchanged drug was 28%, and the variation in plasma drug levels between individuals was similar following oral and intravenous doses.",Pharmacokinetics of oral and intravenous fluorouracil in humans. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7463330/),%,28,239068,DB00544,Fluorouracil
,27933371,response rate,S-1 has shown a response rate of 35% in chemonaïve patients with metastatic colorectal cancer (mCRC).,Phase I clinical and pharmacokinetic study of S-1 plus oral leucovorin in patients with metastatic colorectal cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27933371/),%,35,239202,DB00544,Fluorouracil
,27933371,overall response rate,"The overall response rate was 67% (95% confidence interval, 38-88%).",Phase I clinical and pharmacokinetic study of S-1 plus oral leucovorin in patients with metastatic colorectal cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27933371/),%,67,239203,DB00544,Fluorouracil
,22683364,objective response rate,"The objective response rate was 69.7% in the PK-adjusted arm, and median overall survival and median progression-free survival were 28 and 16 months, respectively.","Individual fluorouracil dose adjustment in FOLFOX based on pharmacokinetic follow-up compared with conventional body-area-surface dosing: a phase II, proof-of-concept study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22683364/),%,69.7,239461,DB00544,Fluorouracil
,22683364,overall survival,"The objective response rate was 69.7% in the PK-adjusted arm, and median overall survival and median progression-free survival were 28 and 16 months, respectively.","Individual fluorouracil dose adjustment in FOLFOX based on pharmacokinetic follow-up compared with conventional body-area-surface dosing: a phase II, proof-of-concept study. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22683364/),month,28,239462,DB00544,Fluorouracil
,22683364,progression-free survival,"The objective response rate was 69.7% in the PK-adjusted arm, and median overall survival and median progression-free survival were 28 and 16 months, respectively.","Individual fluorouracil dose adjustment in FOLFOX based on pharmacokinetic follow-up compared with conventional body-area-surface dosing: a phase II, proof-of-concept study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22683364/),month,16,239463,DB00544,Fluorouracil
,22683364,objective response rate,"In the traditional patients who received BSA dosage, objective response rate was 46%, and overall survival and progression-free survival were 22 and 10 months, respectively.","Individual fluorouracil dose adjustment in FOLFOX based on pharmacokinetic follow-up compared with conventional body-area-surface dosing: a phase II, proof-of-concept study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22683364/),%,46,239464,DB00544,Fluorouracil
,22683364,overall survival,"In the traditional patients who received BSA dosage, objective response rate was 46%, and overall survival and progression-free survival were 22 and 10 months, respectively.","Individual fluorouracil dose adjustment in FOLFOX based on pharmacokinetic follow-up compared with conventional body-area-surface dosing: a phase II, proof-of-concept study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22683364/),month,22,239465,DB00544,Fluorouracil
,22683364,overall survival,"In the traditional patients who received BSA dosage, objective response rate was 46%, and overall survival and progression-free survival were 22 and 10 months, respectively.","Individual fluorouracil dose adjustment in FOLFOX based on pharmacokinetic follow-up compared with conventional body-area-surface dosing: a phase II, proof-of-concept study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22683364/),month,10,239466,DB00544,Fluorouracil
,22683364,progression-free survival,"In the traditional patients who received BSA dosage, objective response rate was 46%, and overall survival and progression-free survival were 22 and 10 months, respectively.","Individual fluorouracil dose adjustment in FOLFOX based on pharmacokinetic follow-up compared with conventional body-area-surface dosing: a phase II, proof-of-concept study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22683364/),month,10,239467,DB00544,Fluorouracil
,22683364,Grade 3/4 toxicity,"Grade 3/4 toxicity was 1.7% for diarrhea, 0.8% for mucositis, and 18% for neutropenia in the dose-monitored group; they were 12%, 15%, and 25%, respectively, in the BSA group.","Individual fluorouracil dose adjustment in FOLFOX based on pharmacokinetic follow-up compared with conventional body-area-surface dosing: a phase II, proof-of-concept study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22683364/),%,1.7,239468,DB00544,Fluorouracil
,22683364,Grade 3/4 toxicity,"Grade 3/4 toxicity was 1.7% for diarrhea, 0.8% for mucositis, and 18% for neutropenia in the dose-monitored group; they were 12%, 15%, and 25%, respectively, in the BSA group.","Individual fluorouracil dose adjustment in FOLFOX based on pharmacokinetic follow-up compared with conventional body-area-surface dosing: a phase II, proof-of-concept study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22683364/),%,0.8,239469,DB00544,Fluorouracil
,22683364,Grade 3/4 toxicity,"Grade 3/4 toxicity was 1.7% for diarrhea, 0.8% for mucositis, and 18% for neutropenia in the dose-monitored group; they were 12%, 15%, and 25%, respectively, in the BSA group.","Individual fluorouracil dose adjustment in FOLFOX based on pharmacokinetic follow-up compared with conventional body-area-surface dosing: a phase II, proof-of-concept study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22683364/),%,12,239470,DB00544,Fluorouracil
,22683364,Grade 3/4 toxicity,"Grade 3/4 toxicity was 1.7% for diarrhea, 0.8% for mucositis, and 18% for neutropenia in the dose-monitored group; they were 12%, 15%, and 25%, respectively, in the BSA group.","Individual fluorouracil dose adjustment in FOLFOX based on pharmacokinetic follow-up compared with conventional body-area-surface dosing: a phase II, proof-of-concept study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22683364/),%,15,239471,DB00544,Fluorouracil
,22683364,Grade 3/4 toxicity,"Grade 3/4 toxicity was 1.7% for diarrhea, 0.8% for mucositis, and 18% for neutropenia in the dose-monitored group; they were 12%, 15%, and 25%, respectively, in the BSA group.","Individual fluorouracil dose adjustment in FOLFOX based on pharmacokinetic follow-up compared with conventional body-area-surface dosing: a phase II, proof-of-concept study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22683364/),%,25,239472,DB00544,Fluorouracil
,14981990,AUC,Pharmacokinetic analysis revealed an AUC value of 85.3 micrograms x min/ml after HAI.,"Hepatic artery infusion using oxaliplatin in combination with 5-fluorouracil, folinic acid and mitomycin C: oxaliplatin pharmacokinetics and feasibility. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14981990/),[min·μg] / [ml],85.3,239494,DB00544,Fluorouracil
,14981990,AUC,Recalculating these values with the previously reported AUC value for systemic administration (161 micrograms x min/ml) revealed a liver extraction ratio of 0.47 for Oxa.,"Hepatic artery infusion using oxaliplatin in combination with 5-fluorouracil, folinic acid and mitomycin C: oxaliplatin pharmacokinetics and feasibility. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14981990/),[min·μg] / [ml],161,239495,DB00544,Fluorouracil
,14981990,liver extraction ratio,Recalculating these values with the previously reported AUC value for systemic administration (161 micrograms x min/ml) revealed a liver extraction ratio of 0.47 for Oxa.,"Hepatic artery infusion using oxaliplatin in combination with 5-fluorouracil, folinic acid and mitomycin C: oxaliplatin pharmacokinetics and feasibility. ",E-Q38,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14981990/),,0.47,239496,DB00544,Fluorouracil
,7398191,half-saturating concentration (KM),A half-saturating concentration (KM) of 15 microM was determined by comparison of model simulations with literature data.,Nonlinear pharmacokinetic models for 5-fluorouracil in man: intravenous and intraperitoneal routes. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7398191/),μM,15,239561,DB00544,Fluorouracil
,20037758,Area under the concentration-time curve (AUC),Area under the concentration-time curve (AUC)of 5-FU was 2647.2 ng h/mL after administration of S-1 of 23.5 mg/m(2) (40 mg/body).,"Safety, efficacy and pharmacokinetics of S-1 in a hemodialysis patient with advanced gastric cancer. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20037758/),[h·ng] / [ml],2647.2,239792,DB00544,Fluorouracil
,22884505,C(trough),The geometric mean presurgery C(trough) was 51·8 μg/mL (coefficient of variation 52·5%) in the intravenous group and 69·0 μg/mL (55·8%) in the subcutaneous group.,"Subcutaneous versus intravenous administration of (neo)adjuvant trastuzumab in patients with HER2-positive, clinical stage I-III breast cancer (HannaH study): a phase 3, open-label, multicentre, randomised trial. ",Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22884505/),[μg] / [ml],51·8,240404,DB00544,Fluorouracil
,22884505,C(trough),The geometric mean presurgery C(trough) was 51·8 μg/mL (coefficient of variation 52·5%) in the intravenous group and 69·0 μg/mL (55·8%) in the subcutaneous group.,"Subcutaneous versus intravenous administration of (neo)adjuvant trastuzumab in patients with HER2-positive, clinical stage I-III breast cancer (HannaH study): a phase 3, open-label, multicentre, randomised trial. ",Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22884505/),[μg] / [ml],69·0,240405,DB00544,Fluorouracil
,2532072,response rate,"This relatively low response rate (15%), which is similar to that achieved with FUDR alone, may be explained by the low steady-state plasma concentrations of free DP achieved in our patients.",Effect of dipyridamole on fluorodeoxyuridine cytotoxicity in vitro and in cancer patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2532072/),%,15,240812,DB00544,Fluorouracil
,10473078,Cmax,"Pharmacokinetic parameters of plasma 5-FU were as follows: Cmax, 128.5 +/- 41.5 ng/ml; Tmax, 3.5 +/- 1.7 h; AUC(0-14), 723.9 +/- 272.7 ng x h/ml; and T(1/2), 1.9 +/- 0.4 h.","Pharmacokinetic study of S-1, a novel oral fluorouracil antitumor drug. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10473078/),[ng] / [ml],128.5,241502,DB00544,Fluorouracil
,10473078,Tmax,"Pharmacokinetic parameters of plasma 5-FU were as follows: Cmax, 128.5 +/- 41.5 ng/ml; Tmax, 3.5 +/- 1.7 h; AUC(0-14), 723.9 +/- 272.7 ng x h/ml; and T(1/2), 1.9 +/- 0.4 h.","Pharmacokinetic study of S-1, a novel oral fluorouracil antitumor drug. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10473078/),h,3.5,241503,DB00544,Fluorouracil
,10473078,AUC(0-14),"Pharmacokinetic parameters of plasma 5-FU were as follows: Cmax, 128.5 +/- 41.5 ng/ml; Tmax, 3.5 +/- 1.7 h; AUC(0-14), 723.9 +/- 272.7 ng x h/ml; and T(1/2), 1.9 +/- 0.4 h.","Pharmacokinetic study of S-1, a novel oral fluorouracil antitumor drug. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10473078/),[h·ng] / [ml],723.9,241504,DB00544,Fluorouracil
,10473078,T(1/2),"Pharmacokinetic parameters of plasma 5-FU were as follows: Cmax, 128.5 +/- 41.5 ng/ml; Tmax, 3.5 +/- 1.7 h; AUC(0-14), 723.9 +/- 272.7 ng x h/ml; and T(1/2), 1.9 +/- 0.4 h.","Pharmacokinetic study of S-1, a novel oral fluorouracil antitumor drug. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10473078/),h,1.9,241505,DB00544,Fluorouracil
,22615059,MTD,The MTD of sunitinib was established as 25 mg/day on Schedule 2/1.,"A phase I, dose-finding study of sunitinib combined with cisplatin and 5-fluorouracil in patients with advanced gastric cancer. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22615059/),[mg] / [d],25,241763,DB00544,Fluorouracil
,21150775,maximum tolerated dose,The maximum tolerated dose of 5-FU was 3750 mg/m²/48 h/week with this tri-monthly schedule.,"Phase I, pharmacokinetic, and bone marrow drug-level studies of tri-monthly 48-h infusion of high-dose 5-fluorouracil and leucovorin in patients with metastatic colorectal cancers. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21150775/),[mg] / [48·h·m²·week],375,242234,DB00544,Fluorouracil
,21150775,progression-free survival,"Median progression-free survival and overall survival were 4.1 months (range: 1.8-12.5) and 10.5 months (range: 2.7-32.1), respectively.","Phase I, pharmacokinetic, and bone marrow drug-level studies of tri-monthly 48-h infusion of high-dose 5-fluorouracil and leucovorin in patients with metastatic colorectal cancers. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21150775/),month,4.1,242235,DB00544,Fluorouracil
,21150775,overall survival,"Median progression-free survival and overall survival were 4.1 months (range: 1.8-12.5) and 10.5 months (range: 2.7-32.1), respectively.","Phase I, pharmacokinetic, and bone marrow drug-level studies of tri-monthly 48-h infusion of high-dose 5-fluorouracil and leucovorin in patients with metastatic colorectal cancers. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21150775/),month,10.5,242236,DB00544,Fluorouracil
,24091982,progression-free survival,"At the MTDs, median progression-free survival was 6.4 months and 5.5-8.0 months for sunitinib/XP and sunitinib/XELOX, respectively; and the objective response rate was 46.7% and 43.5-45.5% for sunitinib/XP and sunitinib/XELOX, respectively.",Phase I study of sunitinib plus capecitabine/cisplatin or capecitabine/oxaliplatin in advanced gastric cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24091982/),month,6.4,242929,DB00544,Fluorouracil
,24091982,progression-free survival,"At the MTDs, median progression-free survival was 6.4 months and 5.5-8.0 months for sunitinib/XP and sunitinib/XELOX, respectively; and the objective response rate was 46.7% and 43.5-45.5% for sunitinib/XP and sunitinib/XELOX, respectively.",Phase I study of sunitinib plus capecitabine/cisplatin or capecitabine/oxaliplatin in advanced gastric cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24091982/),month,5.5-8.0,242930,DB00544,Fluorouracil
,24091982,objective response rate,"At the MTDs, median progression-free survival was 6.4 months and 5.5-8.0 months for sunitinib/XP and sunitinib/XELOX, respectively; and the objective response rate was 46.7% and 43.5-45.5% for sunitinib/XP and sunitinib/XELOX, respectively.",Phase I study of sunitinib plus capecitabine/cisplatin or capecitabine/oxaliplatin in advanced gastric cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24091982/),%,46.7,242931,DB00544,Fluorouracil
,24091982,objective response rate,"At the MTDs, median progression-free survival was 6.4 months and 5.5-8.0 months for sunitinib/XP and sunitinib/XELOX, respectively; and the objective response rate was 46.7% and 43.5-45.5% for sunitinib/XP and sunitinib/XELOX, respectively.",Phase I study of sunitinib plus capecitabine/cisplatin or capecitabine/oxaliplatin in advanced gastric cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24091982/),%,43.5-45.5,242932,DB00544,Fluorouracil
,15729584,oral bioavailability,PTAU is fully absorbed after oral administration with 100% oral bioavailability.,5-(Phenylthio)acyclouridine: a powerful enhancer of oral uridine bioavailability: relevance to chemotherapy with 5-fluorouracil and other uridine rescue regimens. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15729584/),%,100,243129,DB00544,Fluorouracil
,15729584,plasma half-life,"Oral PTAU at 30, 45, 60, 120 and 240 mg/kg has a prolonged plasma half-life of 2-3 h, and peak plasma PTAU concentrations (C(max)) of 41, 51, 74, 126 and 161 microM with AUCs of 70, 99, 122, 173 and 225 micromol h/l, respectively.",5-(Phenylthio)acyclouridine: a powerful enhancer of oral uridine bioavailability: relevance to chemotherapy with 5-fluorouracil and other uridine rescue regimens. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15729584/),h,2-3,243130,DB00544,Fluorouracil
,15729584,peak plasma PTAU concentrations (C(max)),"Oral PTAU at 30, 45, 60, 120 and 240 mg/kg has a prolonged plasma half-life of 2-3 h, and peak plasma PTAU concentrations (C(max)) of 41, 51, 74, 126 and 161 microM with AUCs of 70, 99, 122, 173 and 225 micromol h/l, respectively.",5-(Phenylthio)acyclouridine: a powerful enhancer of oral uridine bioavailability: relevance to chemotherapy with 5-fluorouracil and other uridine rescue regimens. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15729584/),μM,41,243131,DB00544,Fluorouracil
,15729584,peak plasma PTAU concentrations (C(max)),"Oral PTAU at 30, 45, 60, 120 and 240 mg/kg has a prolonged plasma half-life of 2-3 h, and peak plasma PTAU concentrations (C(max)) of 41, 51, 74, 126 and 161 microM with AUCs of 70, 99, 122, 173 and 225 micromol h/l, respectively.",5-(Phenylthio)acyclouridine: a powerful enhancer of oral uridine bioavailability: relevance to chemotherapy with 5-fluorouracil and other uridine rescue regimens. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15729584/),μM,51,243132,DB00544,Fluorouracil
,15729584,peak plasma PTAU concentrations (C(max)),"Oral PTAU at 30, 45, 60, 120 and 240 mg/kg has a prolonged plasma half-life of 2-3 h, and peak plasma PTAU concentrations (C(max)) of 41, 51, 74, 126 and 161 microM with AUCs of 70, 99, 122, 173 and 225 micromol h/l, respectively.",5-(Phenylthio)acyclouridine: a powerful enhancer of oral uridine bioavailability: relevance to chemotherapy with 5-fluorouracil and other uridine rescue regimens. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15729584/),μM,74,243133,DB00544,Fluorouracil
,15729584,peak plasma PTAU concentrations (C(max)),"Oral PTAU at 30, 45, 60, 120 and 240 mg/kg has a prolonged plasma half-life of 2-3 h, and peak plasma PTAU concentrations (C(max)) of 41, 51, 74, 126 and 161 microM with AUCs of 70, 99, 122, 173 and 225 micromol h/l, respectively.",5-(Phenylthio)acyclouridine: a powerful enhancer of oral uridine bioavailability: relevance to chemotherapy with 5-fluorouracil and other uridine rescue regimens. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15729584/),μM,126,243134,DB00544,Fluorouracil
,15729584,peak plasma PTAU concentrations (C(max)),"Oral PTAU at 30, 45, 60, 120 and 240 mg/kg has a prolonged plasma half-life of 2-3 h, and peak plasma PTAU concentrations (C(max)) of 41, 51, 74, 126 and 161 microM with AUCs of 70, 99, 122, 173 and 225 micromol h/l, respectively.",5-(Phenylthio)acyclouridine: a powerful enhancer of oral uridine bioavailability: relevance to chemotherapy with 5-fluorouracil and other uridine rescue regimens. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15729584/),μM,161,243135,DB00544,Fluorouracil
,15729584,AUCs,"Oral PTAU at 30, 45, 60, 120 and 240 mg/kg has a prolonged plasma half-life of 2-3 h, and peak plasma PTAU concentrations (C(max)) of 41, 51, 74, 126 and 161 microM with AUCs of 70, 99, 122, 173 and 225 micromol h/l, respectively.",5-(Phenylthio)acyclouridine: a powerful enhancer of oral uridine bioavailability: relevance to chemotherapy with 5-fluorouracil and other uridine rescue regimens. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15729584/),[h·μM] / [l],70,243136,DB00544,Fluorouracil
,15729584,AUCs,"Oral PTAU at 30, 45, 60, 120 and 240 mg/kg has a prolonged plasma half-life of 2-3 h, and peak plasma PTAU concentrations (C(max)) of 41, 51, 74, 126 and 161 microM with AUCs of 70, 99, 122, 173 and 225 micromol h/l, respectively.",5-(Phenylthio)acyclouridine: a powerful enhancer of oral uridine bioavailability: relevance to chemotherapy with 5-fluorouracil and other uridine rescue regimens. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15729584/),[h·μM] / [l],99,243137,DB00544,Fluorouracil
,15729584,AUCs,"Oral PTAU at 30, 45, 60, 120 and 240 mg/kg has a prolonged plasma half-life of 2-3 h, and peak plasma PTAU concentrations (C(max)) of 41, 51, 74, 126 and 161 microM with AUCs of 70, 99, 122, 173 and 225 micromol h/l, respectively.",5-(Phenylthio)acyclouridine: a powerful enhancer of oral uridine bioavailability: relevance to chemotherapy with 5-fluorouracil and other uridine rescue regimens. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15729584/),[h·μM] / [l],122,243138,DB00544,Fluorouracil
,15729584,AUCs,"Oral PTAU at 30, 45, 60, 120 and 240 mg/kg has a prolonged plasma half-life of 2-3 h, and peak plasma PTAU concentrations (C(max)) of 41, 51, 74, 126 and 161 microM with AUCs of 70, 99, 122, 173 and 225 micromol h/l, respectively.",5-(Phenylthio)acyclouridine: a powerful enhancer of oral uridine bioavailability: relevance to chemotherapy with 5-fluorouracil and other uridine rescue regimens. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15729584/),[h·μM] / [l],173,243139,DB00544,Fluorouracil
,15729584,AUCs,"Oral PTAU at 30, 45, 60, 120 and 240 mg/kg has a prolonged plasma half-life of 2-3 h, and peak plasma PTAU concentrations (C(max)) of 41, 51, 74, 126 and 161 microM with AUCs of 70, 99, 122, 173 and 225 micromol h/l, respectively.",5-(Phenylthio)acyclouridine: a powerful enhancer of oral uridine bioavailability: relevance to chemotherapy with 5-fluorouracil and other uridine rescue regimens. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15729584/),[h·μM] / [l],225,243140,DB00544,Fluorouracil
,15729584,oral bioavailability,"Coadministration of PTAU at 30, 45, 60, 120 and 240 mg/kg improved the low oral bioavailability (7.7%) of uridine administered at 1320 mg/kg by 4.3-, 5.9-, 9.9-, 11.7- and 12.5-fold, respectively, and reduced the AUC of plasma uracil (1227.8 micromol h/l) by 5.7-, 6.8-, 8.2-, 6.3-, and 6.9-fold, respectively.",5-(Phenylthio)acyclouridine: a powerful enhancer of oral uridine bioavailability: relevance to chemotherapy with 5-fluorouracil and other uridine rescue regimens. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15729584/),%,7.7,243141,DB00544,Fluorouracil
,15729584,AUC,"Coadministration of PTAU at 30, 45, 60, 120 and 240 mg/kg improved the low oral bioavailability (7.7%) of uridine administered at 1320 mg/kg by 4.3-, 5.9-, 9.9-, 11.7- and 12.5-fold, respectively, and reduced the AUC of plasma uracil (1227.8 micromol h/l) by 5.7-, 6.8-, 8.2-, 6.3-, and 6.9-fold, respectively.",5-(Phenylthio)acyclouridine: a powerful enhancer of oral uridine bioavailability: relevance to chemotherapy with 5-fluorouracil and other uridine rescue regimens. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15729584/),[h·μM] / [l],1227.8,243142,DB00544,Fluorouracil
,30699067,AUC,A 5-FU AUC range between 20 and 30 [mg×h×L] is recommended.,Therapeutic drug monitoring (TDM) of 5-fluorouracil (5-FU): new preanalytic aspects. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30699067/),h·l·mg,20 and 30,243543,DB00544,Fluorouracil
,30699067,AUC,Calculated median AUC was 23.3 for the right arm (range 5.8-59.4) and a median of 23.4 for the left arm (range 5.3-61.0).,Therapeutic drug monitoring (TDM) of 5-fluorouracil (5-FU): new preanalytic aspects. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30699067/),,23.3,243544,DB00544,Fluorouracil
,30699067,AUC,Calculated median AUC was 23.3 for the right arm (range 5.8-59.4) and a median of 23.4 for the left arm (range 5.3-61.0).,Therapeutic drug monitoring (TDM) of 5-fluorouracil (5-FU): new preanalytic aspects. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30699067/),,23.4,243545,DB00544,Fluorouracil
,30699067,AUC,"In all, these results confirm that a high percentage of patients are not treated with 5-FU doses reaching suggested AUC levels of 20-30.",Therapeutic drug monitoring (TDM) of 5-fluorouracil (5-FU): new preanalytic aspects. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30699067/),,20-30,243546,DB00544,Fluorouracil
,8862717,maximum tolerated dose,The maximum tolerated dose of IFN was 18 MU/m2.,"A phase I trial of 5-fluorouracil, leucovorin and interferon-alpha 2b administered by 24 h infusion in metastatic colorectal carcinoma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8862717/),[Mu] / [m2],18,246204,DB00544,Fluorouracil
,14648016,apparent IFN-gamma clearance,The median (range) apparent IFN-gamma clearance was 46 l/m(2) per hour (2.6-92 l/m(2) per hour).,Interferon-gamma pharmacokinetics and pharmacodynamics in patients with colorectal cancer. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14648016/),[l] / [h·m(2)],46,246402,DB00544,Fluorouracil
above,14648016,AUC(0--> infinity ),"IFN-gamma AUC(0--> infinity ) and time above 33.3 pg/ml significantly correlated with Fas upregulation in several PBMC compartments, but dosage was significantly correlated with this pharmacodynamic marker only in CD4(+) and CD56(+) cells.",Interferon-gamma pharmacokinetics and pharmacodynamics in patients with colorectal cancer. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14648016/),[pg] / [ml],33.3,246403,DB00544,Fluorouracil
above,14648016,time,"IFN-gamma AUC(0--> infinity ) and time above 33.3 pg/ml significantly correlated with Fas upregulation in several PBMC compartments, but dosage was significantly correlated with this pharmacodynamic marker only in CD4(+) and CD56(+) cells.",Interferon-gamma pharmacokinetics and pharmacodynamics in patients with colorectal cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14648016/),[pg] / [ml],33.3,246404,DB00544,Fluorouracil
,34154593,terminal elimination half-life,"In three healthy Beagle dogs receiving 100 mg/kg of 5-fluorocytosine twice daily for 14 days by oral route, non-compartmental pharmacokinetics revealed a terminal elimination half-life of 164.5 ± 22.5 min at day 1 and of 179.2 ± 11.5 min, after 7 days of administration.",Pharmacokinetics and tolerance of repeated oral administration of 5-fluorocytosine in healthy dogs. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/34154593/),min,164.5,246474,DB00544,Fluorouracil
,34154593,terminal elimination half-life,"In three healthy Beagle dogs receiving 100 mg/kg of 5-fluorocytosine twice daily for 14 days by oral route, non-compartmental pharmacokinetics revealed a terminal elimination half-life of 164.5 ± 22.5 min at day 1 and of 179.2 ± 11.5 min, after 7 days of administration.",Pharmacokinetics and tolerance of repeated oral administration of 5-fluorocytosine in healthy dogs. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/34154593/),min,179.2,246475,DB00544,Fluorouracil
,34154593,Clearance,"Clearance was significantly decreased between day 1 and day 7 with 0.386 ± 0.031 and 0.322 ± 0.027 ml/min/kg, respectively.",Pharmacokinetics and tolerance of repeated oral administration of 5-fluorocytosine in healthy dogs. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34154593/),[ml] / [kg·min],0.386,246476,DB00544,Fluorouracil
,34154593,Clearance,"Clearance was significantly decreased between day 1 and day 7 with 0.386 ± 0.031 and 0.322 ± 0.027 ml/min/kg, respectively.",Pharmacokinetics and tolerance of repeated oral administration of 5-fluorocytosine in healthy dogs. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34154593/),[ml] / [kg·min],0.322,246477,DB00544,Fluorouracil
below,34154593,Maximal plasma concentration,"Maximal plasma concentration values were below 100 µg/ml, which is considered within the therapeutic margin for human patients.",Pharmacokinetics and tolerance of repeated oral administration of 5-fluorocytosine in healthy dogs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34154593/),[μg] / [ml],100,246478,DB00544,Fluorouracil
,30964613,sampling times,"The optimal sampling times were 0.546, 0.892, 1.562, 4.736 and 8 hours after the administration of the drug.",Mining Small Routine Clinical Data: A Population Pharmacokinetic Model and Optimal Sampling Times of Capecitabine and its Metabolites. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30964613/),h,0.546,246562,DB00544,Fluorouracil
,30964613,sampling times,"The optimal sampling times were 0.546, 0.892, 1.562, 4.736 and 8 hours after the administration of the drug.",Mining Small Routine Clinical Data: A Population Pharmacokinetic Model and Optimal Sampling Times of Capecitabine and its Metabolites. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30964613/),h,0.892,246563,DB00544,Fluorouracil
,30964613,sampling times,"The optimal sampling times were 0.546, 0.892, 1.562, 4.736 and 8 hours after the administration of the drug.",Mining Small Routine Clinical Data: A Population Pharmacokinetic Model and Optimal Sampling Times of Capecitabine and its Metabolites. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30964613/),h,1.562,246564,DB00544,Fluorouracil
,30964613,sampling times,"The optimal sampling times were 0.546, 0.892, 1.562, 4.736 and 8 hours after the administration of the drug.",Mining Small Routine Clinical Data: A Population Pharmacokinetic Model and Optimal Sampling Times of Capecitabine and its Metabolites. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30964613/),h,4.736,246565,DB00544,Fluorouracil
,30964613,sampling times,"The optimal sampling times were 0.546, 0.892, 1.562, 4.736 and 8 hours after the administration of the drug.",Mining Small Routine Clinical Data: A Population Pharmacokinetic Model and Optimal Sampling Times of Capecitabine and its Metabolites. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30964613/),h,8,246566,DB00544,Fluorouracil
,26687170,clearance,"Following systemic administration, clearance of ultrafilterable (active) platinum over the first 6 h was 20.8 L/h, which is lower than previously reported clearance levels of ultrafilterable platinum.",A pharmacokinetic analysis of cisplatin and 5-fluorouracil in a patient with esophageal cancer on peritoneal dialysis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26687170/),[l] / [h],20.8,247478,DB00544,Fluorouracil
,26687170,AUC,"Total platinum AUC was 131 μg h/mL, also higher than an AUC previously reported for total platinum in patients with normal renal function.",A pharmacokinetic analysis of cisplatin and 5-fluorouracil in a patient with esophageal cancer on peritoneal dialysis. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26687170/),[h·μg] / [ml],131,247479,DB00544,Fluorouracil
,32559325,Circ0,"System- (Circ0 = 3.54 × 109 cells/mL, MTT = 204 hours and γ = 6.0 × 10-2 ) and drug-related (slope [SLP] = 3.1 × 10-2 mL/mg).",Evaluation of ABC gene polymorphisms on the pharmacokinetics and pharmacodynamics of capecitabine in colorectal patients: Implications for dosing recommendations. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32559325/),[cells] / [ml],3.54 ×,247806,DB00544,Fluorouracil
,32559325,MTT,"System- (Circ0 = 3.54 × 109 cells/mL, MTT = 204 hours and γ = 6.0 × 10-2 ) and drug-related (slope [SLP] = 3.1 × 10-2 mL/mg).",Evaluation of ABC gene polymorphisms on the pharmacokinetics and pharmacodynamics of capecitabine in colorectal patients: Implications for dosing recommendations. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32559325/),h,204,247807,DB00544,Fluorouracil
,8173194,ratio AUC peritoneum,The pharmacokinetic advantage of 5-FU-ip was confirmed in our study (ratio AUC peritoneum/plasma between 160 and 328).,[Continuous double administration of 5 fluorouracil (intravenous and intraperitoneal) modulated by folinic acid: phase I clinical study and pharmacokinetics in patients with intra-abdominal developing cancers]. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8173194/),,160 and 328,248004,DB00544,Fluorouracil
,8173194,plasmatic AUC,The systemic exposure to 5-FU (plasmatic AUC ranging from 73.4 to 173.21 microM) and to AF were found in efficacious ranges.,[Continuous double administration of 5 fluorouracil (intravenous and intraperitoneal) modulated by folinic acid: phase I clinical study and pharmacokinetics in patients with intra-abdominal developing cancers]. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8173194/),μM,73.4 to 173.21,248005,DB00544,Fluorouracil
,1628371,plasma peak platinum concentrations (cmax),"The plasma peak platinum concentrations (cmax) and the areas under the curve for total platinum concentration versus time (AUC) during i.a. infusions were lower than the i.v. cmax (mean, 1.92 +/- 0.28 and 4.08 +/- 2.80 mg/l, for i.a. and i.v. infusions, respectively) and AUC values (mean, 22.55 +/- 4.96 and 40.66 +/- 10.71 mg h-1 l-1 for i.a. and i.v. treatment, respectively), suggesting a first-passage extraction of the drug by the tumor mass during i.a. infusion.",Pharmacokinetics and tumor concentration of intraarterial and intravenous cisplatin in patients with head and neck squamous cancer. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1628371/),[mg] / [l],1.92,248094,DB00544,Fluorouracil
,1628371,areas under the curve for total platinum concentration versus time (AUC),"The plasma peak platinum concentrations (cmax) and the areas under the curve for total platinum concentration versus time (AUC) during i.a. infusions were lower than the i.v. cmax (mean, 1.92 +/- 0.28 and 4.08 +/- 2.80 mg/l, for i.a. and i.v. infusions, respectively) and AUC values (mean, 22.55 +/- 4.96 and 40.66 +/- 10.71 mg h-1 l-1 for i.a. and i.v. treatment, respectively), suggesting a first-passage extraction of the drug by the tumor mass during i.a. infusion.",Pharmacokinetics and tumor concentration of intraarterial and intravenous cisplatin in patients with head and neck squamous cancer. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1628371/),[mg] / [l],4.08,248095,DB00544,Fluorouracil
,1628371,AUC,"The plasma peak platinum concentrations (cmax) and the areas under the curve for total platinum concentration versus time (AUC) during i.a. infusions were lower than the i.v. cmax (mean, 1.92 +/- 0.28 and 4.08 +/- 2.80 mg/l, for i.a. and i.v. infusions, respectively) and AUC values (mean, 22.55 +/- 4.96 and 40.66 +/- 10.71 mg h-1 l-1 for i.a. and i.v. treatment, respectively), suggesting a first-passage extraction of the drug by the tumor mass during i.a. infusion.",Pharmacokinetics and tumor concentration of intraarterial and intravenous cisplatin in patients with head and neck squamous cancer. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1628371/),[mg] / [h·l],22.55,248096,DB00544,Fluorouracil
,1628371,AUC,"The plasma peak platinum concentrations (cmax) and the areas under the curve for total platinum concentration versus time (AUC) during i.a. infusions were lower than the i.v. cmax (mean, 1.92 +/- 0.28 and 4.08 +/- 2.80 mg/l, for i.a. and i.v. infusions, respectively) and AUC values (mean, 22.55 +/- 4.96 and 40.66 +/- 10.71 mg h-1 l-1 for i.a. and i.v. treatment, respectively), suggesting a first-passage extraction of the drug by the tumor mass during i.a. infusion.",Pharmacokinetics and tumor concentration of intraarterial and intravenous cisplatin in patients with head and neck squamous cancer. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1628371/),[mg] / [h·l],40.66,248097,DB00544,Fluorouracil
,33417061,first-order elimination (ke,"The PK of intracellular FUTP was described by an one-compartment model with first-order elimination (ke,FUTP was 0.028 h-1 (95% confidence interval 0.022-0.039)) where the FUTP influx rate was proportional to the 5-FU plasma concentrations.",Population Pharmacokinetics of Intracellular 5-Fluorouridine 5'-Triphosphate and its Relationship with Hand-and-Foot Syndrome in Patients Treated with Capecitabine. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33417061/),1/[h],0.028,248439,DB00544,Fluorouracil
,10367751,half-lives,"Local drug disposition was biexponential in four of six tumors where the half-lives of the fast and slow components of disposition ranged from 4 to 26 and from 33 to 289 min, respectively.",Local disposition kinetics of floxuridine after intratumoral and subcutaneous injection as monitored by [19F]-nuclear magnetic resonance spectroscopy in vivo. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10367751/),min,4 to 26,248478,DB00544,Fluorouracil
,10367751,half-lives,"Local drug disposition was biexponential in four of six tumors where the half-lives of the fast and slow components of disposition ranged from 4 to 26 and from 33 to 289 min, respectively.",Local disposition kinetics of floxuridine after intratumoral and subcutaneous injection as monitored by [19F]-nuclear magnetic resonance spectroscopy in vivo. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10367751/),min,33 to 289,248479,DB00544,Fluorouracil
,10367751,half-lives,"It was monoexponential in the remaining two tumors (half-lives 49 and 128 min) and in the s.c. injection experiments (n = 4, half-life 6-9 min).",Local disposition kinetics of floxuridine after intratumoral and subcutaneous injection as monitored by [19F]-nuclear magnetic resonance spectroscopy in vivo. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10367751/),min,49,248480,DB00544,Fluorouracil
,10367751,half-lives,"It was monoexponential in the remaining two tumors (half-lives 49 and 128 min) and in the s.c. injection experiments (n = 4, half-life 6-9 min).",Local disposition kinetics of floxuridine after intratumoral and subcutaneous injection as monitored by [19F]-nuclear magnetic resonance spectroscopy in vivo. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10367751/),min,128,248481,DB00544,Fluorouracil
,10367751,half-life,"It was monoexponential in the remaining two tumors (half-lives 49 and 128 min) and in the s.c. injection experiments (n = 4, half-life 6-9 min).",Local disposition kinetics of floxuridine after intratumoral and subcutaneous injection as monitored by [19F]-nuclear magnetic resonance spectroscopy in vivo. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10367751/),min,6-9,248482,DB00544,Fluorouracil
,10367751,fraction,5-Fluorouracil could be quantitated in three of six tumors; the estimated fraction of floxuridine converted intratumorally into 5-fluorouracil was 11-23%.,Local disposition kinetics of floxuridine after intratumoral and subcutaneous injection as monitored by [19F]-nuclear magnetic resonance spectroscopy in vivo. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10367751/),,11-23,248483,DB00544,Fluorouracil
,8617578,overall response rate,The overall response rate was 40% (C.I. 23-60%).,A phase II and pharmacokinetic study of 6S-leucovorin plus 5-fluorouracil in patient with colorectal carcinoma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8617578/),%,40,249848,DB00544,Fluorouracil
,1605719,vascular availability,"The vascular availability of 1 is influenced by erythrocytes at 38.6 +/- 7.2% (calculated as AUC0-60-values), the coefficient of partition is 0.65 +/- 0.18.",[Pharmacokinetics of 5-fluorouracil in erythrocytes following i.v. administration]. ,Q-Q54,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1605719/),%,38.6,249860,DB00544,Fluorouracil
,1605719,coefficient of partition,"The vascular availability of 1 is influenced by erythrocytes at 38.6 +/- 7.2% (calculated as AUC0-60-values), the coefficient of partition is 0.65 +/- 0.18.",[Pharmacokinetics of 5-fluorouracil in erythrocytes following i.v. administration]. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1605719/),,0.65,249861,DB00544,Fluorouracil
,1998989,Km,"A concentration-dependent 5-FU elimination was observed, indicating saturation of 5-FU elimination according to Michaelis-Menten kinetics (Km 14-22 microM).",Measurement of in vitro cellular pharmacokinetics of 5-fluorouracil in human and rat cancer cell lines and rat hepatocytes using a flow-through system. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1998989/),μM,14-22,249962,DB00544,Fluorouracil
,1998989,maximal velocity (Vmax),The maximal velocity (Vmax) values ranged from 0.025 to 0.13 nmol 5-FU/10(6) cells per minute.,Measurement of in vitro cellular pharmacokinetics of 5-fluorouracil in human and rat cancer cell lines and rat hepatocytes using a flow-through system. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1998989/),nM,0.025 to 0.13,249963,DB00544,Fluorouracil
,8983929,percentage AUC-ratios,"The extent of biotransformation of CHO-THFA into CH3-THFA, which takes place in the blood, is not influenced by IFN because percentage AUC-ratios CHO-THFA:CH3-THFA were 89.5:10.5% for the control group and 88.8:11.2% for the IFN group.",Disposition of 5-formyl- and 5-methyltetrahydrofolic acid in serum after i.v. bolus of calcium folinate: pharmacokinetic drug interaction with preadministered interferon-alpha-2b. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8983929/),%,89.5,250515,DB00544,Fluorouracil
,8983929,percentage AUC-ratios,"The extent of biotransformation of CHO-THFA into CH3-THFA, which takes place in the blood, is not influenced by IFN because percentage AUC-ratios CHO-THFA:CH3-THFA were 89.5:10.5% for the control group and 88.8:11.2% for the IFN group.",Disposition of 5-formyl- and 5-methyltetrahydrofolic acid in serum after i.v. bolus of calcium folinate: pharmacokinetic drug interaction with preadministered interferon-alpha-2b. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8983929/),%,10.5,250516,DB00544,Fluorouracil
,8983929,percentage AUC-ratios,"The extent of biotransformation of CHO-THFA into CH3-THFA, which takes place in the blood, is not influenced by IFN because percentage AUC-ratios CHO-THFA:CH3-THFA were 89.5:10.5% for the control group and 88.8:11.2% for the IFN group.",Disposition of 5-formyl- and 5-methyltetrahydrofolic acid in serum after i.v. bolus of calcium folinate: pharmacokinetic drug interaction with preadministered interferon-alpha-2b. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8983929/),%,88.8,250517,DB00544,Fluorouracil
,11157039,area under the curve,"rhuMAbVEGF, 3 mg/kg IV, was administered weekly for 8 weeks with (1) doxorubicin 50 mg/m(2) every 4 weeks; (2) carboplatin at area under the curve of 6 plus paclitaxel 175 mg/m(2) every 4 weeks; and (3) fluorouracil (5-FU) 500 mg/m(2) with leucovorin 20 mg/m(2) weekly, weeks 1 to 6 every 8 weeks.",Phase Ib trial of intravenous recombinant humanized monoclonal antibody to vascular endothelial growth factor in combination with chemotherapy in patients with advanced cancer: pharmacologic and long-term safety data. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11157039/),,6,250656,DB00544,Fluorouracil
,11157039,peak serum level,"The mean (+/- SD) peak serum level of rhuMAbVEGF was 167 +/- 46 microg/mL, and the mean terminal half-life was 13 days.",Phase Ib trial of intravenous recombinant humanized monoclonal antibody to vascular endothelial growth factor in combination with chemotherapy in patients with advanced cancer: pharmacologic and long-term safety data. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11157039/),[μg] / [ml],167,250657,DB00544,Fluorouracil
,11157039,terminal half-life,"The mean (+/- SD) peak serum level of rhuMAbVEGF was 167 +/- 46 microg/mL, and the mean terminal half-life was 13 days.",Phase Ib trial of intravenous recombinant humanized monoclonal antibody to vascular endothelial growth factor in combination with chemotherapy in patients with advanced cancer: pharmacologic and long-term safety data. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11157039/),d,13,250658,DB00544,Fluorouracil
<,23139054,area-under-the concentration-time curve of 5FU (AUC(5FU)),"The area-under-the concentration-time curve of 5FU (AUC(5FU)) was found to be <20 mg h/L in 33 occasions (58 %), between 20 and 30 mg h/L in 17 occasions (30 %) and >30 mg h/L in 7 occasions (12 %).",Gender-specific elimination of continuous-infusional 5-fluorouracil in patients with gastrointestinal malignancies: results from a prospective population pharmacokinetic study. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23139054/),[h·mg] / [l],20,252101,DB00544,Fluorouracil
,23139054,area-under-the concentration-time curve of 5FU (AUC(5FU)),"The area-under-the concentration-time curve of 5FU (AUC(5FU)) was found to be <20 mg h/L in 33 occasions (58 %), between 20 and 30 mg h/L in 17 occasions (30 %) and >30 mg h/L in 7 occasions (12 %).",Gender-specific elimination of continuous-infusional 5-fluorouracil in patients with gastrointestinal malignancies: results from a prospective population pharmacokinetic study. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23139054/),[h·mg] / [l],20 and 30,252102,DB00544,Fluorouracil
>,23139054,area-under-the concentration-time curve of 5FU (AUC(5FU)),"The area-under-the concentration-time curve of 5FU (AUC(5FU)) was found to be <20 mg h/L in 33 occasions (58 %), between 20 and 30 mg h/L in 17 occasions (30 %) and >30 mg h/L in 7 occasions (12 %).",Gender-specific elimination of continuous-infusional 5-fluorouracil in patients with gastrointestinal malignancies: results from a prospective population pharmacokinetic study. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23139054/),[h·mg] / [l],30,252103,DB00544,Fluorouracil
,23139054,AUC(5FU),"Accordingly, women had a higher AUC(5FU) compared to men (22 vs. 18 mg h/L, p = 0.04).",Gender-specific elimination of continuous-infusional 5-fluorouracil in patients with gastrointestinal malignancies: results from a prospective population pharmacokinetic study. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23139054/),[h·mg] / [l],22,252104,DB00544,Fluorouracil
,23139054,AUC(5FU),"Accordingly, women had a higher AUC(5FU) compared to men (22 vs. 18 mg h/L, p = 0.04).",Gender-specific elimination of continuous-infusional 5-fluorouracil in patients with gastrointestinal malignancies: results from a prospective population pharmacokinetic study. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23139054/),[h·mg] / [l],18,252105,DB00544,Fluorouracil
,10430071,Total urinary recovery,Total urinary recovery of capecitabine and its metabolites was 71% of the administered dose in patients with normal hepatic function and 77% in patients with hepatic impairment.,Effect of hepatic dysfunction due to liver metastases on the pharmacokinetics of capecitabine and its metabolites. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10430071/),%,71,252127,DB00544,Fluorouracil
,10430071,Total urinary recovery,Total urinary recovery of capecitabine and its metabolites was 71% of the administered dose in patients with normal hepatic function and 77% in patients with hepatic impairment.,Effect of hepatic dysfunction due to liver metastases on the pharmacokinetics of capecitabine and its metabolites. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10430071/),%,77,252128,DB00544,Fluorouracil
,10430071,absolute bioavailability,The absolute bioavailability of 5'-deoxy-5-fluorouridine was estimated as 42% in patients with normal hepatic function and 62% in patients with impaired hepatic function.,Effect of hepatic dysfunction due to liver metastases on the pharmacokinetics of capecitabine and its metabolites. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10430071/),%,42,252129,DB00544,Fluorouracil
,10430071,absolute bioavailability,The absolute bioavailability of 5'-deoxy-5-fluorouridine was estimated as 42% in patients with normal hepatic function and 62% in patients with impaired hepatic function.,Effect of hepatic dysfunction due to liver metastases on the pharmacokinetics of capecitabine and its metabolites. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10430071/),%,62,252130,DB00544,Fluorouracil
,17520810,C(max),"Plasma concentration-time curves of free 5-Fu, 5-Fu-MAD and 5-Fu-MAD plus the magnetic frame (MF) conformed to two compartment model of first order absorption and they had C(max) of 34.9, 7.95 and 5.97 mg x L(-1); T1/2 (Ke) of 22.26, 76.0 and 124.6 min, V(d) of 3.28, 30.7 and 66.1 L x kg; AUC(0-t), of 233.9, 78.3 and 50.2 mg x min x L(-1); AUC(0-infinity) of 237.2, 89.3 and 68.1 mg x min x L(-1), respectively.",[Pharmacokinetics and distribution of 5-Fu magnetic albumin deuto-microsphere in normal and tumor-bearing mice]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17520810/),[mg] / [l],34.9,252145,DB00544,Fluorouracil
,17520810,C(max),"Plasma concentration-time curves of free 5-Fu, 5-Fu-MAD and 5-Fu-MAD plus the magnetic frame (MF) conformed to two compartment model of first order absorption and they had C(max) of 34.9, 7.95 and 5.97 mg x L(-1); T1/2 (Ke) of 22.26, 76.0 and 124.6 min, V(d) of 3.28, 30.7 and 66.1 L x kg; AUC(0-t), of 233.9, 78.3 and 50.2 mg x min x L(-1); AUC(0-infinity) of 237.2, 89.3 and 68.1 mg x min x L(-1), respectively.",[Pharmacokinetics and distribution of 5-Fu magnetic albumin deuto-microsphere in normal and tumor-bearing mice]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17520810/),[mg] / [l],7.95,252146,DB00544,Fluorouracil
,17520810,C(max),"Plasma concentration-time curves of free 5-Fu, 5-Fu-MAD and 5-Fu-MAD plus the magnetic frame (MF) conformed to two compartment model of first order absorption and they had C(max) of 34.9, 7.95 and 5.97 mg x L(-1); T1/2 (Ke) of 22.26, 76.0 and 124.6 min, V(d) of 3.28, 30.7 and 66.1 L x kg; AUC(0-t), of 233.9, 78.3 and 50.2 mg x min x L(-1); AUC(0-infinity) of 237.2, 89.3 and 68.1 mg x min x L(-1), respectively.",[Pharmacokinetics and distribution of 5-Fu magnetic albumin deuto-microsphere in normal and tumor-bearing mice]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17520810/),[mg] / [l],5.97,252147,DB00544,Fluorouracil
,17520810,T1/2 (Ke),"Plasma concentration-time curves of free 5-Fu, 5-Fu-MAD and 5-Fu-MAD plus the magnetic frame (MF) conformed to two compartment model of first order absorption and they had C(max) of 34.9, 7.95 and 5.97 mg x L(-1); T1/2 (Ke) of 22.26, 76.0 and 124.6 min, V(d) of 3.28, 30.7 and 66.1 L x kg; AUC(0-t), of 233.9, 78.3 and 50.2 mg x min x L(-1); AUC(0-infinity) of 237.2, 89.3 and 68.1 mg x min x L(-1), respectively.",[Pharmacokinetics and distribution of 5-Fu magnetic albumin deuto-microsphere in normal and tumor-bearing mice]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17520810/),min,22.26,252148,DB00544,Fluorouracil
,17520810,T1/2 (Ke),"Plasma concentration-time curves of free 5-Fu, 5-Fu-MAD and 5-Fu-MAD plus the magnetic frame (MF) conformed to two compartment model of first order absorption and they had C(max) of 34.9, 7.95 and 5.97 mg x L(-1); T1/2 (Ke) of 22.26, 76.0 and 124.6 min, V(d) of 3.28, 30.7 and 66.1 L x kg; AUC(0-t), of 233.9, 78.3 and 50.2 mg x min x L(-1); AUC(0-infinity) of 237.2, 89.3 and 68.1 mg x min x L(-1), respectively.",[Pharmacokinetics and distribution of 5-Fu magnetic albumin deuto-microsphere in normal and tumor-bearing mice]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17520810/),min,76.0,252149,DB00544,Fluorouracil
,17520810,T1/2 (Ke),"Plasma concentration-time curves of free 5-Fu, 5-Fu-MAD and 5-Fu-MAD plus the magnetic frame (MF) conformed to two compartment model of first order absorption and they had C(max) of 34.9, 7.95 and 5.97 mg x L(-1); T1/2 (Ke) of 22.26, 76.0 and 124.6 min, V(d) of 3.28, 30.7 and 66.1 L x kg; AUC(0-t), of 233.9, 78.3 and 50.2 mg x min x L(-1); AUC(0-infinity) of 237.2, 89.3 and 68.1 mg x min x L(-1), respectively.",[Pharmacokinetics and distribution of 5-Fu magnetic albumin deuto-microsphere in normal and tumor-bearing mice]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17520810/),min,124.6,252150,DB00544,Fluorouracil
,17520810,V(d),"Plasma concentration-time curves of free 5-Fu, 5-Fu-MAD and 5-Fu-MAD plus the magnetic frame (MF) conformed to two compartment model of first order absorption and they had C(max) of 34.9, 7.95 and 5.97 mg x L(-1); T1/2 (Ke) of 22.26, 76.0 and 124.6 min, V(d) of 3.28, 30.7 and 66.1 L x kg; AUC(0-t), of 233.9, 78.3 and 50.2 mg x min x L(-1); AUC(0-infinity) of 237.2, 89.3 and 68.1 mg x min x L(-1), respectively.",[Pharmacokinetics and distribution of 5-Fu magnetic albumin deuto-microsphere in normal and tumor-bearing mice]. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17520810/),kg·l,3.28,252151,DB00544,Fluorouracil
,17520810,V(d),"Plasma concentration-time curves of free 5-Fu, 5-Fu-MAD and 5-Fu-MAD plus the magnetic frame (MF) conformed to two compartment model of first order absorption and they had C(max) of 34.9, 7.95 and 5.97 mg x L(-1); T1/2 (Ke) of 22.26, 76.0 and 124.6 min, V(d) of 3.28, 30.7 and 66.1 L x kg; AUC(0-t), of 233.9, 78.3 and 50.2 mg x min x L(-1); AUC(0-infinity) of 237.2, 89.3 and 68.1 mg x min x L(-1), respectively.",[Pharmacokinetics and distribution of 5-Fu magnetic albumin deuto-microsphere in normal and tumor-bearing mice]. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17520810/),kg·l,30.7,252152,DB00544,Fluorouracil
,17520810,V(d),"Plasma concentration-time curves of free 5-Fu, 5-Fu-MAD and 5-Fu-MAD plus the magnetic frame (MF) conformed to two compartment model of first order absorption and they had C(max) of 34.9, 7.95 and 5.97 mg x L(-1); T1/2 (Ke) of 22.26, 76.0 and 124.6 min, V(d) of 3.28, 30.7 and 66.1 L x kg; AUC(0-t), of 233.9, 78.3 and 50.2 mg x min x L(-1); AUC(0-infinity) of 237.2, 89.3 and 68.1 mg x min x L(-1), respectively.",[Pharmacokinetics and distribution of 5-Fu magnetic albumin deuto-microsphere in normal and tumor-bearing mice]. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17520810/),kg·l,66.1,252153,DB00544,Fluorouracil
,17520810,AUC(0-t),"Plasma concentration-time curves of free 5-Fu, 5-Fu-MAD and 5-Fu-MAD plus the magnetic frame (MF) conformed to two compartment model of first order absorption and they had C(max) of 34.9, 7.95 and 5.97 mg x L(-1); T1/2 (Ke) of 22.26, 76.0 and 124.6 min, V(d) of 3.28, 30.7 and 66.1 L x kg; AUC(0-t), of 233.9, 78.3 and 50.2 mg x min x L(-1); AUC(0-infinity) of 237.2, 89.3 and 68.1 mg x min x L(-1), respectively.",[Pharmacokinetics and distribution of 5-Fu magnetic albumin deuto-microsphere in normal and tumor-bearing mice]. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17520810/),[mg·min] / [l],233.9,252154,DB00544,Fluorouracil
,17520810,AUC(0-t),"Plasma concentration-time curves of free 5-Fu, 5-Fu-MAD and 5-Fu-MAD plus the magnetic frame (MF) conformed to two compartment model of first order absorption and they had C(max) of 34.9, 7.95 and 5.97 mg x L(-1); T1/2 (Ke) of 22.26, 76.0 and 124.6 min, V(d) of 3.28, 30.7 and 66.1 L x kg; AUC(0-t), of 233.9, 78.3 and 50.2 mg x min x L(-1); AUC(0-infinity) of 237.2, 89.3 and 68.1 mg x min x L(-1), respectively.",[Pharmacokinetics and distribution of 5-Fu magnetic albumin deuto-microsphere in normal and tumor-bearing mice]. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17520810/),[mg·min] / [l],78.3,252155,DB00544,Fluorouracil
,17520810,AUC(0-t),"Plasma concentration-time curves of free 5-Fu, 5-Fu-MAD and 5-Fu-MAD plus the magnetic frame (MF) conformed to two compartment model of first order absorption and they had C(max) of 34.9, 7.95 and 5.97 mg x L(-1); T1/2 (Ke) of 22.26, 76.0 and 124.6 min, V(d) of 3.28, 30.7 and 66.1 L x kg; AUC(0-t), of 233.9, 78.3 and 50.2 mg x min x L(-1); AUC(0-infinity) of 237.2, 89.3 and 68.1 mg x min x L(-1), respectively.",[Pharmacokinetics and distribution of 5-Fu magnetic albumin deuto-microsphere in normal and tumor-bearing mice]. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17520810/),[mg·min] / [l],50.2,252156,DB00544,Fluorouracil
,17520810,AUC(0-infinity),"Plasma concentration-time curves of free 5-Fu, 5-Fu-MAD and 5-Fu-MAD plus the magnetic frame (MF) conformed to two compartment model of first order absorption and they had C(max) of 34.9, 7.95 and 5.97 mg x L(-1); T1/2 (Ke) of 22.26, 76.0 and 124.6 min, V(d) of 3.28, 30.7 and 66.1 L x kg; AUC(0-t), of 233.9, 78.3 and 50.2 mg x min x L(-1); AUC(0-infinity) of 237.2, 89.3 and 68.1 mg x min x L(-1), respectively.",[Pharmacokinetics and distribution of 5-Fu magnetic albumin deuto-microsphere in normal and tumor-bearing mice]. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17520810/),[mg·min] / [l],237.2,252157,DB00544,Fluorouracil
,17520810,AUC(0-infinity),"Plasma concentration-time curves of free 5-Fu, 5-Fu-MAD and 5-Fu-MAD plus the magnetic frame (MF) conformed to two compartment model of first order absorption and they had C(max) of 34.9, 7.95 and 5.97 mg x L(-1); T1/2 (Ke) of 22.26, 76.0 and 124.6 min, V(d) of 3.28, 30.7 and 66.1 L x kg; AUC(0-t), of 233.9, 78.3 and 50.2 mg x min x L(-1); AUC(0-infinity) of 237.2, 89.3 and 68.1 mg x min x L(-1), respectively.",[Pharmacokinetics and distribution of 5-Fu magnetic albumin deuto-microsphere in normal and tumor-bearing mice]. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17520810/),[mg·min] / [l],89.3,252158,DB00544,Fluorouracil
,17520810,AUC(0-infinity),"Plasma concentration-time curves of free 5-Fu, 5-Fu-MAD and 5-Fu-MAD plus the magnetic frame (MF) conformed to two compartment model of first order absorption and they had C(max) of 34.9, 7.95 and 5.97 mg x L(-1); T1/2 (Ke) of 22.26, 76.0 and 124.6 min, V(d) of 3.28, 30.7 and 66.1 L x kg; AUC(0-t), of 233.9, 78.3 and 50.2 mg x min x L(-1); AUC(0-infinity) of 237.2, 89.3 and 68.1 mg x min x L(-1), respectively.",[Pharmacokinetics and distribution of 5-Fu magnetic albumin deuto-microsphere in normal and tumor-bearing mice]. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17520810/),[mg·min] / [l],68.1,252159,DB00544,Fluorouracil
,8353044,bioavailability,The mean +/- s.d. bioavailability of s.c. 5-FU was 0.89 +/- 0.23.,Bioavailability and feasibility of subcutaneous 5-fluorouracil. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8353044/),,0.89,252213,DB00544,Fluorouracil
,12351598,objective response rate,"In five patients (11.9%) a complete and in 25 (59.5%) a partial response was demonstrated, for an objective response rate of 71.4% (95% confidence interval, 47% to 83%).","Biweekly chemotherapy with oxaliplatin, irinotecan, infusional Fluorouracil, and leucovorin: a pilot study in patients with metastatic colorectal cancer. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12351598/),%,71.4,253135,DB00544,Fluorouracil
,12351598,progression-free,"Median progression-free and overall survival times were 10.4 and 26.5 months, respectively.","Biweekly chemotherapy with oxaliplatin, irinotecan, infusional Fluorouracil, and leucovorin: a pilot study in patients with metastatic colorectal cancer. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12351598/),month,10.4,253136,DB00544,Fluorouracil
,12351598,overall survival times,"Median progression-free and overall survival times were 10.4 and 26.5 months, respectively.","Biweekly chemotherapy with oxaliplatin, irinotecan, infusional Fluorouracil, and leucovorin: a pilot study in patients with metastatic colorectal cancer. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12351598/),month,26.5,253137,DB00544,Fluorouracil
,17639391,half-life,"5-FU plasma concentrations at therapeutic doses were above the Km and a single compartment kinetic model was best used to fit the kinetics, with a mean half-life of 8.6 min.",Plasma pharmacokinetic evaluation of cytotoxic agents radiolabelled with positron emitting radioisotopes. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17639391/),min,8.6,253156,DB00544,Fluorouracil
,17639391,clearance,"Mean (SE) clearance was 1,421(144), ml min(-1) and 1,319 (119) ml min(-1) and the mean (SE) Vd was 17.3 (1.8) l and 16.3 (1.9) l by the model-independent method and model-dependent methods, respectively.",Plasma pharmacokinetic evaluation of cytotoxic agents radiolabelled with positron emitting radioisotopes. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17639391/),[ml] / [min],"1,421",253157,DB00544,Fluorouracil
,17639391,clearance,"Mean (SE) clearance was 1,421(144), ml min(-1) and 1,319 (119) ml min(-1) and the mean (SE) Vd was 17.3 (1.8) l and 16.3 (1.9) l by the model-independent method and model-dependent methods, respectively.",Plasma pharmacokinetic evaluation of cytotoxic agents radiolabelled with positron emitting radioisotopes. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17639391/),[ml] / [min],"1,319",253158,DB00544,Fluorouracil
,17639391,Vd,"Mean (SE) clearance was 1,421(144), ml min(-1) and 1,319 (119) ml min(-1) and the mean (SE) Vd was 17.3 (1.8) l and 16.3 (1.9) l by the model-independent method and model-dependent methods, respectively.",Plasma pharmacokinetic evaluation of cytotoxic agents radiolabelled with positron emitting radioisotopes. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17639391/),l,17.3,253159,DB00544,Fluorouracil
,17639391,Vd,"Mean (SE) clearance was 1,421(144), ml min(-1) and 1,319 (119) ml min(-1) and the mean (SE) Vd was 17.3 (1.8) l and 16.3 (1.9) l by the model-independent method and model-dependent methods, respectively.",Plasma pharmacokinetic evaluation of cytotoxic agents radiolabelled with positron emitting radioisotopes. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17639391/),l,16.3,253160,DB00544,Fluorouracil
,17639391,half-life,"In contrast, with 1 mg/m2, plasma concentrations of 5-FU were less than the Km and a two-compartment model was used to best fit the kinetics, with the mean 5-FU half-life of 6.5 min.",Plasma pharmacokinetic evaluation of cytotoxic agents radiolabelled with positron emitting radioisotopes. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17639391/),min,6.5,253161,DB00544,Fluorouracil
,17639391,clearances,"The mean (SE) clearances obtained by the model-independent method and model-dependent methods were 3,089 (314) ml min(-1) and 2,225 (200) ml min(-1), respectively and the mean (SE) Vd were 27.9 (7.0) l and 2.3 (0.4) l, by the model independent and dependent methods, respectively.",Plasma pharmacokinetic evaluation of cytotoxic agents radiolabelled with positron emitting radioisotopes. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17639391/),[ml] / [min],"3,089",253162,DB00544,Fluorouracil
,17639391,clearances,"The mean (SE) clearances obtained by the model-independent method and model-dependent methods were 3,089 (314) ml min(-1) and 2,225 (200) ml min(-1), respectively and the mean (SE) Vd were 27.9 (7.0) l and 2.3 (0.4) l, by the model independent and dependent methods, respectively.",Plasma pharmacokinetic evaluation of cytotoxic agents radiolabelled with positron emitting radioisotopes. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17639391/),[ml] / [min],"2,225",253163,DB00544,Fluorouracil
,17639391,Vd,"The mean (SE) clearances obtained by the model-independent method and model-dependent methods were 3,089 (314) ml min(-1) and 2,225 (200) ml min(-1), respectively and the mean (SE) Vd were 27.9 (7.0) l and 2.3 (0.4) l, by the model independent and dependent methods, respectively.",Plasma pharmacokinetic evaluation of cytotoxic agents radiolabelled with positron emitting radioisotopes. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17639391/),l,27.9,253164,DB00544,Fluorouracil
,17639391,Vd,"The mean (SE) clearances obtained by the model-independent method and model-dependent methods were 3,089 (314) ml min(-1) and 2,225 (200) ml min(-1), respectively and the mean (SE) Vd were 27.9 (7.0) l and 2.3 (0.4) l, by the model independent and dependent methods, respectively.",Plasma pharmacokinetic evaluation of cytotoxic agents radiolabelled with positron emitting radioisotopes. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17639391/),l,2.3,253165,DB00544,Fluorouracil
,17639391,half-life,A two-compartment model with a mean half-life of 42.1 min was used to best fit the kinetics of DACA; considerable extrapolation (mean 26%) was required to obtain AUC0-infinity from AUC0-Clast.,Plasma pharmacokinetic evaluation of cytotoxic agents radiolabelled with positron emitting radioisotopes. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17639391/),min,42.1,253166,DB00544,Fluorouracil
,17639391,clearance,"Mean (SE) clearance of DACA was 1,920 (269) ml min(-1), with the model-independent method and 1,627 (287) ml min(-1) with the model-dependent method.",Plasma pharmacokinetic evaluation of cytotoxic agents radiolabelled with positron emitting radioisotopes. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17639391/),[ml] / [min],"1,920",253167,DB00544,Fluorouracil
,17639391,clearance,"Mean (SE) clearance of DACA was 1,920 (269) ml min(-1), with the model-independent method and 1,627 (287) ml min(-1) with the model-dependent method.",Plasma pharmacokinetic evaluation of cytotoxic agents radiolabelled with positron emitting radioisotopes. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17639391/),[ml] / [min],"1,627",253168,DB00544,Fluorouracil
,17639391,Vd,"Similarly, Vd [mean (SE)] of DACA with the model-independent and model-dependent methods were 118 (22) l and 50 (15) l, respectively.",Plasma pharmacokinetic evaluation of cytotoxic agents radiolabelled with positron emitting radioisotopes. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17639391/),l,118,253169,DB00544,Fluorouracil
,17639391,Vd,"Similarly, Vd [mean (SE)] of DACA with the model-independent and model-dependent methods were 118 (22) l and 50 (15) l, respectively.",Plasma pharmacokinetic evaluation of cytotoxic agents radiolabelled with positron emitting radioisotopes. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17639391/),l,50,253170,DB00544,Fluorouracil
,16717293,area,"Treatment comprised cetuximab (initial dose 400 mg/m2 with subsequent weekly doses of 250 mg/m2) in combination with 3-week cycles of either cisplatin (100 mg/m2) or carboplatin (area under the curve, 5), each in combination with a 5-day infusion of fluorouracil (FU) at escalating doses of 600, 800, and 1,000 mg/m2/d.",Phase I/II study of cetuximab in combination with cisplatin or carboplatin and fluorouracil in patients with recurrent or metastatic squamous cell carcinoma of the head and neck. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16717293/),,5,253304,DB00544,Fluorouracil
,16717293,overall response rate,"The overall response rate among patients was 36%, with no clear trend toward an increased efficacy at the highest dose of FU, and no impact of the concomitant chemotherapy regimens on cetuximab pharmacokinetics.",Phase I/II study of cetuximab in combination with cisplatin or carboplatin and fluorouracil in patients with recurrent or metastatic squamous cell carcinoma of the head and neck. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16717293/),%,36,253305,DB00544,Fluorouracil
,15961435,maximum tolerated dose (MTD),The maximum tolerated dose (MTD) for this regimen was 90 mg/m2/week of paclitaxel for 3 weeks plus 600 mg/m2/day of continuous 5-FU for 5 days.,Phase I evaluation of continuous 5-fluorouracil infusion followed by weekly paclitaxel in patients with advanced or recurrent gastric cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15961435/),mg,90,254608,DB00544,Fluorouracil
,15277535,response rate,"The response rate for the Japanese patients and the patients in the United States was 36.4% (95% CI, 22.4% to 52.2%) and 34.1% (95% CI, 20.5% to 49.9%), respectively.","Comparison of the efficacy, toxicity, and pharmacokinetics of a uracil/tegafur (UFT) plus oral leucovorin (LV) regimen between Japanese and American patients with advanced colorectal cancer: joint United States and Japan study of UFT/LV. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15277535/),%,36.4,255007,DB00544,Fluorouracil
,15277535,response rate,"The response rate for the Japanese patients and the patients in the United States was 36.4% (95% CI, 22.4% to 52.2%) and 34.1% (95% CI, 20.5% to 49.9%), respectively.","Comparison of the efficacy, toxicity, and pharmacokinetics of a uracil/tegafur (UFT) plus oral leucovorin (LV) regimen between Japanese and American patients with advanced colorectal cancer: joint United States and Japan study of UFT/LV. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15277535/),%,34.1,255008,DB00544,Fluorouracil
,16006754,survival time,The median survival time was 5.6 months with a one-year survival rate of 15.8%.,An early phase II study of S-1 in patients with metastatic pancreatic cancer. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16006754/),month,5.6,255277,DB00544,Fluorouracil
,10673535,terminal half-life,"Mean (SD) values for terminal half-life, apparent volume of distribution, and systemic clearance of 4.5 hours (0.83 hours), 19 L/m(2) (3.0 L/m(2)), and 51 mL/min/m(2) (13 mL/min/m(2)), respectively.",Phase I and pharmacologic study of oral fluorouracil on a chronic daily schedule in combination with the dihydropyrimidine dehydrogenase inactivator eniluracil. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10673535/),h,4.5,256338,DB00544,Fluorouracil
,10673535,apparent volume of distribution,"Mean (SD) values for terminal half-life, apparent volume of distribution, and systemic clearance of 4.5 hours (0.83 hours), 19 L/m(2) (3.0 L/m(2)), and 51 mL/min/m(2) (13 mL/min/m(2)), respectively.",Phase I and pharmacologic study of oral fluorouracil on a chronic daily schedule in combination with the dihydropyrimidine dehydrogenase inactivator eniluracil. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10673535/),[l] / [m(2],19,256339,DB00544,Fluorouracil
,10673535,systemic clearance,"Mean (SD) values for terminal half-life, apparent volume of distribution, and systemic clearance of 4.5 hours (0.83 hours), 19 L/m(2) (3.0 L/m(2)), and 51 mL/min/m(2) (13 mL/min/m(2)), respectively.",Phase I and pharmacologic study of oral fluorouracil on a chronic daily schedule in combination with the dihydropyrimidine dehydrogenase inactivator eniluracil. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10673535/),[min·ml] / [m(2],51,256340,DB00544,Fluorouracil
,10673535,"C(SS,min)","The mean (range) 5-FU C(SS,min) values achieved at the 1.0 mg/m(2) dose level were 22 ng/mL (8 to 38 ng/mL).",Phase I and pharmacologic study of oral fluorouracil on a chronic daily schedule in combination with the dihydropyrimidine dehydrogenase inactivator eniluracil. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10673535/),[ng] / [ml],22,256341,DB00544,Fluorouracil
,10388099,objective response rate,"In a phase II trial in advanced colorectal cancer, UFT plus oral leucovorin produced an objective response rate of 42%, with survival similar to weekly i.v. 5-FU plus leucovorin.",UFT Plus Oral Leucovorin: A New Oral Treatment for Colorectal Cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10388099/),%,42,256413,DB00544,Fluorouracil
,15674819,area under the plasma concentration-time curve from time zero to time infinity (AUC),"In DMIS rats, the area under the plasma concentration-time curve from time zero to time infinity (AUC) was significantly smaller (603 versus 909 microg min/ml) due to the significantly faster total body clearance (Cl; 47.8 versus 33.0 ml/min/kg).",Pharmacokinetics of 5-fluorouracil in rats with diabetes mellitus induced by streptozotocin. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15674819/),[min·μg] / [ml],603,256651,DB00544,Fluorouracil
,15674819,area under the plasma concentration-time curve from time zero to time infinity (AUC),"In DMIS rats, the area under the plasma concentration-time curve from time zero to time infinity (AUC) was significantly smaller (603 versus 909 microg min/ml) due to the significantly faster total body clearance (Cl; 47.8 versus 33.0 ml/min/kg).",Pharmacokinetics of 5-fluorouracil in rats with diabetes mellitus induced by streptozotocin. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15674819/),[min·μg] / [ml],909,256652,DB00544,Fluorouracil
,15674819,total body clearance (Cl,"In DMIS rats, the area under the plasma concentration-time curve from time zero to time infinity (AUC) was significantly smaller (603 versus 909 microg min/ml) due to the significantly faster total body clearance (Cl; 47.8 versus 33.0 ml/min/kg).",Pharmacokinetics of 5-fluorouracil in rats with diabetes mellitus induced by streptozotocin. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15674819/),[ml] / [kg·min],47.8,256653,DB00544,Fluorouracil
,15674819,total body clearance (Cl,"In DMIS rats, the area under the plasma concentration-time curve from time zero to time infinity (AUC) was significantly smaller (603 versus 909 microg min/ml) due to the significantly faster total body clearance (Cl; 47.8 versus 33.0 ml/min/kg).",Pharmacokinetics of 5-fluorouracil in rats with diabetes mellitus induced by streptozotocin. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15674819/),[ml] / [kg·min],33.0,256654,DB00544,Fluorouracil
,15674819,renal,The faster Cl was due to the significantly faster renal (8.54 versus 4.02 ml/min/kg) and nonrenal (38.5 versus 28.7 ml/min/kg) clearances.,Pharmacokinetics of 5-fluorouracil in rats with diabetes mellitus induced by streptozotocin. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15674819/),[ml] / [kg·min],8.54,256655,DB00544,Fluorouracil
,15674819,renal,The faster Cl was due to the significantly faster renal (8.54 versus 4.02 ml/min/kg) and nonrenal (38.5 versus 28.7 ml/min/kg) clearances.,Pharmacokinetics of 5-fluorouracil in rats with diabetes mellitus induced by streptozotocin. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15674819/),[ml] / [kg·min],4.02,256656,DB00544,Fluorouracil
,15674819,renal,The faster Cl was due to the significantly faster renal (8.54 versus 4.02 ml/min/kg) and nonrenal (38.5 versus 28.7 ml/min/kg) clearances.,Pharmacokinetics of 5-fluorouracil in rats with diabetes mellitus induced by streptozotocin. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15674819/),[ml] / [kg·min],38.5,256657,DB00544,Fluorouracil
,15674819,renal,The faster Cl was due to the significantly faster renal (8.54 versus 4.02 ml/min/kg) and nonrenal (38.5 versus 28.7 ml/min/kg) clearances.,Pharmacokinetics of 5-fluorouracil in rats with diabetes mellitus induced by streptozotocin. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15674819/),[ml] / [kg·min],28.7,256658,DB00544,Fluorouracil
,9788577,AUCs,"Median AUCs of cyclophosphamide in patients receiving ondansetron (73.6 mg/ml x min) were lower than those of the control patients (88.3 mg/ml x min, n = 75, P = 0.0004), but the median cisplatin AUC was approximately 10% higher and no difference in the disposition of carmustine was demonstrated.",Pharmacokinetic interaction between ondansetron and cyclophosphamide during high-dose chemotherapy for breast cancer. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9788577/),[mg] / [min·ml],73.6,256672,DB00544,Fluorouracil
,9788577,AUCs,"Median AUCs of cyclophosphamide in patients receiving ondansetron (73.6 mg/ml x min) were lower than those of the control patients (88.3 mg/ml x min, n = 75, P = 0.0004), but the median cisplatin AUC was approximately 10% higher and no difference in the disposition of carmustine was demonstrated.",Pharmacokinetic interaction between ondansetron and cyclophosphamide during high-dose chemotherapy for breast cancer. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9788577/),[mg] / [min·ml],88.3,256673,DB00544,Fluorouracil
,17922560,AUC(24) ratio,"The bid : tid AUC(24) ratio (90% CI) was 1.8 (1.55, 2.10) with fluorouracil, 2.0 (1.59, 2.57) with uracil and 1.2 (1.02, 1.36) with tegafur, indicating that the bid and tid schedules were not bioequivalent.",A clinical pharmacokinetic analysis of tegafur-uracil (UFT) plus leucovorin given in a new twice-daily oral administration schedule. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17922560/),,1,257071,DB00544,Fluorouracil
,17922560,AUC(24) ratio,"The bid : tid AUC(24) ratio (90% CI) was 1.8 (1.55, 2.10) with fluorouracil, 2.0 (1.59, 2.57) with uracil and 1.2 (1.02, 1.36) with tegafur, indicating that the bid and tid schedules were not bioequivalent.",A clinical pharmacokinetic analysis of tegafur-uracil (UFT) plus leucovorin given in a new twice-daily oral administration schedule. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17922560/),,2,257072,DB00544,Fluorouracil
,30783204,MTD,The MTD of eribulin was 1.6 mg/m2 day 1 for schedule 1 and 1.4 mg/m2 days 1 and 8 for schedule 2.,"A phase 1b/2, open-label, dose-escalation, and dose-confirmation study of eribulin mesilate in combination with capecitabine. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30783204/),[mg] / [m2],1.6,257361,DB00544,Fluorouracil
,30783204,MTD,The MTD of eribulin was 1.6 mg/m2 day 1 for schedule 1 and 1.4 mg/m2 days 1 and 8 for schedule 2.,"A phase 1b/2, open-label, dose-escalation, and dose-confirmation study of eribulin mesilate in combination with capecitabine. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30783204/),mg,1.4,257362,DB00544,Fluorouracil
,30783204,ORR,"ORR in phase 2 (eribulin 1.4 mg/m2 days 1, 8 plus capecitabine) was 43% and median PFS 7.2 months.","A phase 1b/2, open-label, dose-escalation, and dose-confirmation study of eribulin mesilate in combination with capecitabine. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30783204/),%,43,257363,DB00544,Fluorouracil
,30783204,PFS,"ORR in phase 2 (eribulin 1.4 mg/m2 days 1, 8 plus capecitabine) was 43% and median PFS 7.2 months.","A phase 1b/2, open-label, dose-escalation, and dose-confirmation study of eribulin mesilate in combination with capecitabine. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30783204/),month,7,257364,DB00544,Fluorouracil
,18412945,drug loading capacity,The drug loading capacity was 27.1% and the drug encapsulation was 61.5%.,Pharmacokinetic characteristics and anticancer effects of 5-fluorouracil loaded nanoparticles. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18412945/),%,27.1,257454,DB00544,Fluorouracil
,18412945,elimination half-life (t1/2,"Compared with 5-FU, 5-FU/PEG-PBLG nanoparticles had a longer elimination half-life (t1/2, 33.3 h vs. 5 min), lower peak concentration (C, 4563.5 microg/L vs. 17047.3 microg/L), and greater distribution volume (VD, 0.114 L vs. 0.069 L).",Pharmacokinetic characteristics and anticancer effects of 5-fluorouracil loaded nanoparticles. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/18412945/),h,33.3,257455,DB00544,Fluorouracil
,18412945,elimination half-life (t1/2,"Compared with 5-FU, 5-FU/PEG-PBLG nanoparticles had a longer elimination half-life (t1/2, 33.3 h vs. 5 min), lower peak concentration (C, 4563.5 microg/L vs. 17047.3 microg/L), and greater distribution volume (VD, 0.114 L vs. 0.069 L).",Pharmacokinetic characteristics and anticancer effects of 5-fluorouracil loaded nanoparticles. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/18412945/),min,5,257456,DB00544,Fluorouracil
,18412945,peak concentration (C,"Compared with 5-FU, 5-FU/PEG-PBLG nanoparticles had a longer elimination half-life (t1/2, 33.3 h vs. 5 min), lower peak concentration (C, 4563.5 microg/L vs. 17047.3 microg/L), and greater distribution volume (VD, 0.114 L vs. 0.069 L).",Pharmacokinetic characteristics and anticancer effects of 5-fluorouracil loaded nanoparticles. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18412945/),[μg] / [l],4563.5,257457,DB00544,Fluorouracil
,18412945,peak concentration (C,"Compared with 5-FU, 5-FU/PEG-PBLG nanoparticles had a longer elimination half-life (t1/2, 33.3 h vs. 5 min), lower peak concentration (C, 4563.5 microg/L vs. 17047.3 microg/L), and greater distribution volume (VD, 0.114 L vs. 0.069 L).",Pharmacokinetic characteristics and anticancer effects of 5-fluorouracil loaded nanoparticles. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18412945/),[μg] / [l],17047.3,257458,DB00544,Fluorouracil
,18412945,distribution volume (VD,"Compared with 5-FU, 5-FU/PEG-PBLG nanoparticles had a longer elimination half-life (t1/2, 33.3 h vs. 5 min), lower peak concentration (C, 4563.5 microg/L vs. 17047.3 microg/L), and greater distribution volume (VD, 0.114 L vs. 0.069 L).",Pharmacokinetic characteristics and anticancer effects of 5-fluorouracil loaded nanoparticles. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18412945/),l,0.114,257459,DB00544,Fluorouracil
,18412945,distribution volume (VD,"Compared with 5-FU, 5-FU/PEG-PBLG nanoparticles had a longer elimination half-life (t1/2, 33.3 h vs. 5 min), lower peak concentration (C, 4563.5 microg/L vs. 17047.3 microg/L), and greater distribution volume (VD, 0.114 L vs. 0.069 L).",Pharmacokinetic characteristics and anticancer effects of 5-fluorouracil loaded nanoparticles. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18412945/),l,0.069,257460,DB00544,Fluorouracil
,17195945,T(max),"However, SN-38 T(max) was longer on Day 8 (0.88 h vs. 1.23 h, p = 0.012).",Pharmacokinetic and safety study of weekly irinotecan and oral capecitabine in patients with advanced solid cancers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17195945/),h,0.88,257590,DB00544,Fluorouracil
,17195945,T(max),"However, SN-38 T(max) was longer on Day 8 (0.88 h vs. 1.23 h, p = 0.012).",Pharmacokinetic and safety study of weekly irinotecan and oral capecitabine in patients with advanced solid cancers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17195945/),h,1.23,257591,DB00544,Fluorouracil
,25772756,objective response rate,"The primary endpoint, objective response rate in patients with measurable disease by RECIST, was 20 % overall and was higher among patients receiving first-line (27 % overall; FOLFOX, 24 %; FOLFIRI, 27 %) compared with second-line therapy (14 % overall; FOLFOX, 0 %; FOLFIRI, 20 %).",Motesanib with or without panitumumab plus FOLFIRI or FOLFOX for the treatment of metastatic colorectal cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25772756/),%,20,257868,DB00544,Fluorouracil
,25772756,objective response rate,"The primary endpoint, objective response rate in patients with measurable disease by RECIST, was 20 % overall and was higher among patients receiving first-line (27 % overall; FOLFOX, 24 %; FOLFIRI, 27 %) compared with second-line therapy (14 % overall; FOLFOX, 0 %; FOLFIRI, 20 %).",Motesanib with or without panitumumab plus FOLFIRI or FOLFOX for the treatment of metastatic colorectal cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25772756/),%,27,257869,DB00544,Fluorouracil
,25772756,objective response rate,"The primary endpoint, objective response rate in patients with measurable disease by RECIST, was 20 % overall and was higher among patients receiving first-line (27 % overall; FOLFOX, 24 %; FOLFIRI, 27 %) compared with second-line therapy (14 % overall; FOLFOX, 0 %; FOLFIRI, 20 %).",Motesanib with or without panitumumab plus FOLFIRI or FOLFOX for the treatment of metastatic colorectal cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25772756/),%,24,257870,DB00544,Fluorouracil
,25772756,objective response rate,"The primary endpoint, objective response rate in patients with measurable disease by RECIST, was 20 % overall and was higher among patients receiving first-line (27 % overall; FOLFOX, 24 %; FOLFIRI, 27 %) compared with second-line therapy (14 % overall; FOLFOX, 0 %; FOLFIRI, 20 %).",Motesanib with or without panitumumab plus FOLFIRI or FOLFOX for the treatment of metastatic colorectal cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25772756/),,27,257871,DB00544,Fluorouracil
,25772756,objective response rate,"The primary endpoint, objective response rate in patients with measurable disease by RECIST, was 20 % overall and was higher among patients receiving first-line (27 % overall; FOLFOX, 24 %; FOLFIRI, 27 %) compared with second-line therapy (14 % overall; FOLFOX, 0 %; FOLFIRI, 20 %).",Motesanib with or without panitumumab plus FOLFIRI or FOLFOX for the treatment of metastatic colorectal cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25772756/),%,14,257872,DB00544,Fluorouracil
,25772756,objective response rate,"The primary endpoint, objective response rate in patients with measurable disease by RECIST, was 20 % overall and was higher among patients receiving first-line (27 % overall; FOLFOX, 24 %; FOLFIRI, 27 %) compared with second-line therapy (14 % overall; FOLFOX, 0 %; FOLFIRI, 20 %).",Motesanib with or without panitumumab plus FOLFIRI or FOLFOX for the treatment of metastatic colorectal cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25772756/),,0,257873,DB00544,Fluorouracil
,22114492,tumor to muscle ratio,"In biodistribution, the highest uptake of (188)Re-liposomes in tumor tissues (7.91% ± 2.02% of the injected dose per gram of tissue [%ID/g]) and a high tumor to muscle ratio (25.8 ± 6.1) were observed at 24 hours after intravenous administration.",Biodistribution and pharmacokinetics of 188Re-liposomes and their comparative therapeutic efficacy with 5-fluorouracil in C26 colonic peritoneal carcinomatosis mice. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22114492/),,25.8,257912,DB00544,Fluorouracil
,22114492,mean residence time [MRT],"The pharmacokinetics of (188)Re-liposomes showed high circulation time and high bioavailability (mean residence time [MRT] = 19.2 hours, area under the curve [AUC] = 820.4%ID/g*h).",Biodistribution and pharmacokinetics of 188Re-liposomes and their comparative therapeutic efficacy with 5-fluorouracil in C26 colonic peritoneal carcinomatosis mice. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22114492/),h,19.2,257913,DB00544,Fluorouracil
,22114492,area under the curve [AUC],"The pharmacokinetics of (188)Re-liposomes showed high circulation time and high bioavailability (mean residence time [MRT] = 19.2 hours, area under the curve [AUC] = 820.4%ID/g*h).",Biodistribution and pharmacokinetics of 188Re-liposomes and their comparative therapeutic efficacy with 5-fluorouracil in C26 colonic peritoneal carcinomatosis mice. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22114492/),[%id] / [g·h],820.4,257914,DB00544,Fluorouracil
,8527281,elimination half-life,The elimination of [S]-5-MTHF from plasma was considerably faster than that of the [R]-isomer (elimination half-life: 3.1 +/- 1.0 h vs 8.3 +/- 3.2 h).,Stereospecific pharmacokinetics of rac-5-methyltetrahydrofolic acid in patients with advanced colorectal cancer. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8527281/),h,3.1,257989,DB00544,Fluorouracil
,8527281,elimination half-life,The elimination of [S]-5-MTHF from plasma was considerably faster than that of the [R]-isomer (elimination half-life: 3.1 +/- 1.0 h vs 8.3 +/- 3.2 h).,Stereospecific pharmacokinetics of rac-5-methyltetrahydrofolic acid in patients with advanced colorectal cancer. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8527281/),h,8.3,257990,DB00544,Fluorouracil
,8527281,plasma,"3. The plasma protein binding was stereoselective ([R]-5-MTHF bound: 88.2 +/- 2.7%; [S]-5-MTHF bound: 59.9 +/- 6.8%; P < 0.001), causing a significantly higher renal clearance for [S]-5-MTHF when compared with the [R]-isomer (37.5 +/- 23.7 ml min-1 vs 12.7 +/- 11.2 ml min-1, P < 0.001).",Stereospecific pharmacokinetics of rac-5-methyltetrahydrofolic acid in patients with advanced colorectal cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8527281/),%,88.2,257991,DB00544,Fluorouracil
,8527281,plasma,"3. The plasma protein binding was stereoselective ([R]-5-MTHF bound: 88.2 +/- 2.7%; [S]-5-MTHF bound: 59.9 +/- 6.8%; P < 0.001), causing a significantly higher renal clearance for [S]-5-MTHF when compared with the [R]-isomer (37.5 +/- 23.7 ml min-1 vs 12.7 +/- 11.2 ml min-1, P < 0.001).",Stereospecific pharmacokinetics of rac-5-methyltetrahydrofolic acid in patients with advanced colorectal cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8527281/),%,59.9,257992,DB00544,Fluorouracil
,8527281,renal clearance,"3. The plasma protein binding was stereoselective ([R]-5-MTHF bound: 88.2 +/- 2.7%; [S]-5-MTHF bound: 59.9 +/- 6.8%; P < 0.001), causing a significantly higher renal clearance for [S]-5-MTHF when compared with the [R]-isomer (37.5 +/- 23.7 ml min-1 vs 12.7 +/- 11.2 ml min-1, P < 0.001).",Stereospecific pharmacokinetics of rac-5-methyltetrahydrofolic acid in patients with advanced colorectal cancer. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8527281/),[ml] / [min],37.5,257993,DB00544,Fluorouracil
,8527281,renal clearance,"3. The plasma protein binding was stereoselective ([R]-5-MTHF bound: 88.2 +/- 2.7%; [S]-5-MTHF bound: 59.9 +/- 6.8%; P < 0.001), causing a significantly higher renal clearance for [S]-5-MTHF when compared with the [R]-isomer (37.5 +/- 23.7 ml min-1 vs 12.7 +/- 11.2 ml min-1, P < 0.001).",Stereospecific pharmacokinetics of rac-5-methyltetrahydrofolic acid in patients with advanced colorectal cancer. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8527281/),[ml] / [min],12.7,257994,DB00544,Fluorouracil
,8527281,CLren[R,"There was no dose dependence, but gender influenced renal clearance (CLren[R]-5-MTHF: male vs female: 20.5 +/- 14.5 ml min-1 vs 7.8 +/- 4.7 min-1, P = 0.03; CLren [S]-5-MTHF: male vs female: 57.2 +/- 21.7 ml min-1 vs 25.7 +/- 16.2 ml min-1, P = 0.006).",Stereospecific pharmacokinetics of rac-5-methyltetrahydrofolic acid in patients with advanced colorectal cancer. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8527281/),[ml] / [min],20.5,257995,DB00544,Fluorouracil
,8527281,CLren[R,"There was no dose dependence, but gender influenced renal clearance (CLren[R]-5-MTHF: male vs female: 20.5 +/- 14.5 ml min-1 vs 7.8 +/- 4.7 min-1, P = 0.03; CLren [S]-5-MTHF: male vs female: 57.2 +/- 21.7 ml min-1 vs 25.7 +/- 16.2 ml min-1, P = 0.006).",Stereospecific pharmacokinetics of rac-5-methyltetrahydrofolic acid in patients with advanced colorectal cancer. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8527281/),1/[min],7.8,257996,DB00544,Fluorouracil
,8527281,CLren [S],"There was no dose dependence, but gender influenced renal clearance (CLren[R]-5-MTHF: male vs female: 20.5 +/- 14.5 ml min-1 vs 7.8 +/- 4.7 min-1, P = 0.03; CLren [S]-5-MTHF: male vs female: 57.2 +/- 21.7 ml min-1 vs 25.7 +/- 16.2 ml min-1, P = 0.006).",Stereospecific pharmacokinetics of rac-5-methyltetrahydrofolic acid in patients with advanced colorectal cancer. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8527281/),[ml] / [min],57.2,257997,DB00544,Fluorouracil
,8527281,CLren [S],"There was no dose dependence, but gender influenced renal clearance (CLren[R]-5-MTHF: male vs female: 20.5 +/- 14.5 ml min-1 vs 7.8 +/- 4.7 min-1, P = 0.03; CLren [S]-5-MTHF: male vs female: 57.2 +/- 21.7 ml min-1 vs 25.7 +/- 16.2 ml min-1, P = 0.006).",Stereospecific pharmacokinetics of rac-5-methyltetrahydrofolic acid in patients with advanced colorectal cancer. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8527281/),[ml] / [min],25.7,257998,DB00544,Fluorouracil
,11592340,oral bioavailability,Linear pharmacokinetics and oral bioavailability of approximately 25% were observed at the dose levels used in this study.,"Bioavailability study of oral and intravenous OGT 719, a novel nucleoside analogue with preferential activity in the liver. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11592340/),%,25,259305,DB00544,Fluorouracil
,11592340,half-life,The mean half-life for oral doses was 4 h.,"Bioavailability study of oral and intravenous OGT 719, a novel nucleoside analogue with preferential activity in the liver. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11592340/),h,4,259306,DB00544,Fluorouracil
,10938396,objective response rate,"The objective response rate was 87%, with 50% complete response (CR) and 37% partial response.","Phase II trial of cisplatin, 5-fluorouracil and folinic acid using a weekly 24-h infusion schedule for locally advanced head and neck cancer: a pharmacokinetic and clinical survey. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10938396/),%,87,259576,DB00544,Fluorouracil
,10938396,Failure rate,Failure rate was 13% (stable disease).,"Phase II trial of cisplatin, 5-fluorouracil and folinic acid using a weekly 24-h infusion schedule for locally advanced head and neck cancer: a pharmacokinetic and clinical survey. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10938396/),%,13,259577,DB00544,Fluorouracil
,10938396,peak plasma levels,"The average peak plasma levels for the 6 courses of CDDP, 5-FU, dl-FA and mTHF were 4.9+/-0.76 microM, 4.1+/-0.54 microM, 29.1+/-2.4 microM and 4.8+/-0.31 microM respectively.","Phase II trial of cisplatin, 5-fluorouracil and folinic acid using a weekly 24-h infusion schedule for locally advanced head and neck cancer: a pharmacokinetic and clinical survey. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10938396/),μM,4.9,259578,DB00544,Fluorouracil
,10938396,peak plasma levels,"The average peak plasma levels for the 6 courses of CDDP, 5-FU, dl-FA and mTHF were 4.9+/-0.76 microM, 4.1+/-0.54 microM, 29.1+/-2.4 microM and 4.8+/-0.31 microM respectively.","Phase II trial of cisplatin, 5-fluorouracil and folinic acid using a weekly 24-h infusion schedule for locally advanced head and neck cancer: a pharmacokinetic and clinical survey. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10938396/),μM,4.1,259579,DB00544,Fluorouracil
,10938396,peak plasma levels,"The average peak plasma levels for the 6 courses of CDDP, 5-FU, dl-FA and mTHF were 4.9+/-0.76 microM, 4.1+/-0.54 microM, 29.1+/-2.4 microM and 4.8+/-0.31 microM respectively.","Phase II trial of cisplatin, 5-fluorouracil and folinic acid using a weekly 24-h infusion schedule for locally advanced head and neck cancer: a pharmacokinetic and clinical survey. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10938396/),μM,29.1,259580,DB00544,Fluorouracil
,10938396,peak plasma levels,"The average peak plasma levels for the 6 courses of CDDP, 5-FU, dl-FA and mTHF were 4.9+/-0.76 microM, 4.1+/-0.54 microM, 29.1+/-2.4 microM and 4.8+/-0.31 microM respectively.","Phase II trial of cisplatin, 5-fluorouracil and folinic acid using a weekly 24-h infusion schedule for locally advanced head and neck cancer: a pharmacokinetic and clinical survey. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10938396/),μM,4.8,259581,DB00544,Fluorouracil
,9181456,encapsulation efficiency,"The main observations were as follows: (a) The mean encapsulation efficiency, as determined by bioassays, was 49-79%, depending on the formulation, for GM-CSF, and 48% for TNF-alpha; (b) some of the entrapped cytokine preparations displayed high stability at 4 degrees C, with < 30% loss of biologic activity during a 4-month period; (c) release of TNF-alpha, but not of GM-CSF, from the liposomes was required for their biological activity in vitro; (d) plasma half-lives (t1/2 alpha, t1/2 beta) and the area under the curve (AUC) of the entrapped cytokines were 10-20 times greater than those of the soluble cytokines; (e) the toxicity of liposomal TNF-alpha was one-third and one-seventh that of soluble TNF-alpha in normal and tumor-bearing mice, respectively; (f) administration of liposomal GM-CSF (5 x 10(4)-2 x 10(5) U, one to five times) to normal and 5-fluorouracil-treated mice led to a two- to fourfold increase in the absolute number of peritoneal and spleen leukocytes and of GM colony-forming cells in the spleen, as compared with the levels obtained using soluble GM-CSF; and (g) under the experimental conditions used, neither free nor liposomal GM-CSF significantly increased the absolute number of blood leukocytes, although liposomal GM-CSF markedly (threefold) enhanced the level of blood granulocytes.",Delivery of cytokines by liposomes. Liposome-encapsulated GM-CSF and TNF-alpha show improved pharmacokinetics and biological activity and reduced toxicity in mice. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9181456/),%,49-79,260497,DB00544,Fluorouracil
,9181456,encapsulation efficiency,"The main observations were as follows: (a) The mean encapsulation efficiency, as determined by bioassays, was 49-79%, depending on the formulation, for GM-CSF, and 48% for TNF-alpha; (b) some of the entrapped cytokine preparations displayed high stability at 4 degrees C, with < 30% loss of biologic activity during a 4-month period; (c) release of TNF-alpha, but not of GM-CSF, from the liposomes was required for their biological activity in vitro; (d) plasma half-lives (t1/2 alpha, t1/2 beta) and the area under the curve (AUC) of the entrapped cytokines were 10-20 times greater than those of the soluble cytokines; (e) the toxicity of liposomal TNF-alpha was one-third and one-seventh that of soluble TNF-alpha in normal and tumor-bearing mice, respectively; (f) administration of liposomal GM-CSF (5 x 10(4)-2 x 10(5) U, one to five times) to normal and 5-fluorouracil-treated mice led to a two- to fourfold increase in the absolute number of peritoneal and spleen leukocytes and of GM colony-forming cells in the spleen, as compared with the levels obtained using soluble GM-CSF; and (g) under the experimental conditions used, neither free nor liposomal GM-CSF significantly increased the absolute number of blood leukocytes, although liposomal GM-CSF markedly (threefold) enhanced the level of blood granulocytes.",Delivery of cytokines by liposomes. Liposome-encapsulated GM-CSF and TNF-alpha show improved pharmacokinetics and biological activity and reduced toxicity in mice. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9181456/),%,48,260498,DB00544,Fluorouracil
,25173708,Tg,"CM-zein showed a new FTIR peak of C-O-C bond at 1080 cm(-1), with a new signal region appearing at 4.0-4.05 ppm that assigned to the protons of the CH2 group from a carboxymethyl on (1)H NMR and a Tg of 168.0 °C by thermal analysis.","Preparation, characterization and application of a novel biodegradable macromolecule: carboxymethyl zein. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25173708/),°c,168.0,261009,DB00544,Fluorouracil
,26421292,complete response rate,"The complete response rate was increased with dose escalation (35.3%, 50.0%, and 72.2% in each group) and also showed the tendency for decreasing moderate-to-severe CINV.","A Randomized, Double-Blind Pilot Study of Dose Comparison of Ramosetron to Prevent Chemotherapy-Induced Nausea and Vomiting. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26421292/),%,35.3,261272,DB00544,Fluorouracil
,26421292,complete response rate,"The complete response rate was increased with dose escalation (35.3%, 50.0%, and 72.2% in each group) and also showed the tendency for decreasing moderate-to-severe CINV.","A Randomized, Double-Blind Pilot Study of Dose Comparison of Ramosetron to Prevent Chemotherapy-Induced Nausea and Vomiting. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26421292/),%,50.0,261273,DB00544,Fluorouracil
,26421292,complete response rate,"The complete response rate was increased with dose escalation (35.3%, 50.0%, and 72.2% in each group) and also showed the tendency for decreasing moderate-to-severe CINV.","A Randomized, Double-Blind Pilot Study of Dose Comparison of Ramosetron to Prevent Chemotherapy-Induced Nausea and Vomiting. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26421292/),%,72.2,261274,DB00544,Fluorouracil
,15236381,T1's,"The determined T1's for 5FU and FNuc (2.3 +/- 0.1 s and 1.3 +/- 0.1 s, respectively) represent the first reported in vivo measurements for these metabolites in tumor.",In vivo 5-fluorouracil and fluoronucleotide T1 relaxation time measurements using the variable nutation angle method. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15236381/),s,2.3,261988,DB00544,Fluorouracil
,15236381,T1's,"The determined T1's for 5FU and FNuc (2.3 +/- 0.1 s and 1.3 +/- 0.1 s, respectively) represent the first reported in vivo measurements for these metabolites in tumor.",In vivo 5-fluorouracil and fluoronucleotide T1 relaxation time measurements using the variable nutation angle method. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15236381/),s,1.3,261989,DB00544,Fluorouracil
,25851942,clinical response rate,"The clinical response rate by RECIST was 74.4 % (95 % CI, 61.4-87.4 %), and the R0 resection rate was 97.7 %.",A phase II study of perioperative S-1 combined with weekly docetaxel in patients with locally advanced gastric carcinoma: clinical outcomes and clinicopathological and pharmacogenetic predictors for survival. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25851942/),%,74,262330,DB00544,Fluorouracil
,2136810,ClR,"The mean (+/- SD) ClR of 5'-dFUR was 108.9 +/- 53.6 ml/min per m2 (range, 45.7-210 ml/min per m2), and the ClNR was 728 +/- 181 ml/min per m2 (range, 444-1,119 ml/min per m2).",Pharmacokinetic study of doxifluridine given by 5-day stepped-dose infusion. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2136810/),[ml] / [m2·min],108.9,262499,DB00544,Fluorouracil
,2136810,ClNR,"The mean (+/- SD) ClR of 5'-dFUR was 108.9 +/- 53.6 ml/min per m2 (range, 45.7-210 ml/min per m2), and the ClNR was 728 +/- 181 ml/min per m2 (range, 444-1,119 ml/min per m2).",Pharmacokinetic study of doxifluridine given by 5-day stepped-dose infusion. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2136810/),[ml] / [m2·min],728,262500,DB00544,Fluorouracil
,2136810,renal clearance,"The mean renal clearance of 5-FU was 100.8 +/- 48.6 ml/min per m2 (range, 23.5-198 ml/min per m2).",Pharmacokinetic study of doxifluridine given by 5-day stepped-dose infusion. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2136810/),[ml] / [m2·min],100.8,262501,DB00544,Fluorouracil
,33046724,zeta potential,"Among the all the formulations, 5FU-SLN4 was the most effective with particle size of was 263 ± 3 nm, zeta potential was 0.1 ± 0.02 and entrapment efficiency of 81 ± 10%.",Application of smart solid lipid nanoparticles to enhance the efficacy of 5-fluorouracil in the treatment of colorectal cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33046724/),,0.1,262769,DB00544,Fluorouracil
,33046724,entrapment efficiency,"Among the all the formulations, 5FU-SLN4 was the most effective with particle size of was 263 ± 3 nm, zeta potential was 0.1 ± 0.02 and entrapment efficiency of 81 ± 10%.",Application of smart solid lipid nanoparticles to enhance the efficacy of 5-fluorouracil in the treatment of colorectal cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33046724/),%,81,262770,DB00544,Fluorouracil
,33046724,IC50,The IC50 value of 5FU-SLN4 (7.4 ± 0.02 µM) was 2.3 fold low compared with 5-FU (17.7 ± 0.03 µM).,Application of smart solid lipid nanoparticles to enhance the efficacy of 5-fluorouracil in the treatment of colorectal cancer. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33046724/),μM,7.4,262771,DB00544,Fluorouracil
,33046724,IC50,The IC50 value of 5FU-SLN4 (7.4 ± 0.02 µM) was 2.3 fold low compared with 5-FU (17.7 ± 0.03 µM).,Application of smart solid lipid nanoparticles to enhance the efficacy of 5-fluorouracil in the treatment of colorectal cancer. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33046724/),μM,17.7,262772,DB00544,Fluorouracil
,25808944,extraction recoveries,"The mean extraction recoveries were within 105-115%, 92.6-101%, 94.0-100%, and 85.1-99.9% for Cape, DFCR, DFUR, and 5-FU, respectively.",Simultaneous determination of capecitabine and its three nucleoside metabolites in human plasma by high performance liquid chromatography-tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25808944/),%,105-115,263258,DB00544,Fluorouracil
,25808944,extraction recoveries,"The mean extraction recoveries were within 105-115%, 92.6-101%, 94.0-100%, and 85.1-99.9% for Cape, DFCR, DFUR, and 5-FU, respectively.",Simultaneous determination of capecitabine and its three nucleoside metabolites in human plasma by high performance liquid chromatography-tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25808944/),%,92.6-101,263259,DB00544,Fluorouracil
,25808944,extraction recoveries,"The mean extraction recoveries were within 105-115%, 92.6-101%, 94.0-100%, and 85.1-99.9% for Cape, DFCR, DFUR, and 5-FU, respectively.",Simultaneous determination of capecitabine and its three nucleoside metabolites in human plasma by high performance liquid chromatography-tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25808944/),%,94.0-100,263260,DB00544,Fluorouracil
,25808944,extraction recoveries,"The mean extraction recoveries were within 105-115%, 92.6-101%, 94.0-100%, and 85.1-99.9% for Cape, DFCR, DFUR, and 5-FU, respectively.",Simultaneous determination of capecitabine and its three nucleoside metabolites in human plasma by high performance liquid chromatography-tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25808944/),%,85.1-99.9,263261,DB00544,Fluorouracil
,7651979,AUC-,"Mean AUC-values increase from 5454 ng/ml.h (day 1) to 12069 ng/ml.h (day 3, p < 0.05) and subsequently to 14919 ng/ml.h on day 5 (p < 0.005).",[Drug interactions between interferon alpha 2b and 5-fluorouracil during continuous intravenous 5FU infusion]. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7651979/),[ng] / [h·ml],5454,263542,DB00544,Fluorouracil
,7651979,AUC-,"Mean AUC-values increase from 5454 ng/ml.h (day 1) to 12069 ng/ml.h (day 3, p < 0.05) and subsequently to 14919 ng/ml.h on day 5 (p < 0.005).",[Drug interactions between interferon alpha 2b and 5-fluorouracil during continuous intravenous 5FU infusion]. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7651979/),[ng] / [h·ml],12069,263543,DB00544,Fluorouracil
,7651979,AUC-,"Mean AUC-values increase from 5454 ng/ml.h (day 1) to 12069 ng/ml.h (day 3, p < 0.05) and subsequently to 14919 ng/ml.h on day 5 (p < 0.005).",[Drug interactions between interferon alpha 2b and 5-fluorouracil during continuous intravenous 5FU infusion]. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7651979/),[ng] / [h·ml],14919,263544,DB00544,Fluorouracil
,7651979,total body clearance,"IFN causes an decrease of the total body clearance from 2949 ml/h (day 1) to 1959 ml/h on day 3 and to 1258 ml/h on day 5 (p < 0.008), respectively.",[Drug interactions between interferon alpha 2b and 5-fluorouracil during continuous intravenous 5FU infusion]. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7651979/),[ml] / [h],2949,263545,DB00544,Fluorouracil
,7651979,total body clearance,"IFN causes an decrease of the total body clearance from 2949 ml/h (day 1) to 1959 ml/h on day 3 and to 1258 ml/h on day 5 (p < 0.008), respectively.",[Drug interactions between interferon alpha 2b and 5-fluorouracil during continuous intravenous 5FU infusion]. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7651979/),[ml] / [h],1959,263546,DB00544,Fluorouracil
,7651979,total body clearance,"IFN causes an decrease of the total body clearance from 2949 ml/h (day 1) to 1959 ml/h on day 3 and to 1258 ml/h on day 5 (p < 0.008), respectively.",[Drug interactions between interferon alpha 2b and 5-fluorouracil during continuous intravenous 5FU infusion]. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7651979/),[ml] / [h],1258,263547,DB00544,Fluorouracil
,21590448,C (max),"In subjects with normal DPD status, 500 mg/m(2) uracil resulted in uracil C (max) levels of 14.4 ± 4.7 mg/L at T (max) = 30.0 ± 11.6 min, and in DPD-deficient subjects, 20.0 ± 4.5 mg/L at 31.5 ± 1.1 min.","Pharmacokinetics of orally administered uracil in healthy volunteers and in DPD-deficient patients, a possible tool for screening of DPD deficiency. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21590448/),[mg] / [l],14.4,263909,DB00544,Fluorouracil
,21590448,T (max),"In subjects with normal DPD status, 500 mg/m(2) uracil resulted in uracil C (max) levels of 14.4 ± 4.7 mg/L at T (max) = 30.0 ± 11.6 min, and in DPD-deficient subjects, 20.0 ± 4.5 mg/L at 31.5 ± 1.1 min.","Pharmacokinetics of orally administered uracil in healthy volunteers and in DPD-deficient patients, a possible tool for screening of DPD deficiency. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21590448/),min,30.0,263910,DB00544,Fluorouracil
,21590448,T (max),"In subjects with normal DPD status, 500 mg/m(2) uracil resulted in uracil C (max) levels of 14.4 ± 4.7 mg/L at T (max) = 30.0 ± 11.6 min, and in DPD-deficient subjects, 20.0 ± 4.5 mg/L at 31.5 ± 1.1 min.","Pharmacokinetics of orally administered uracil in healthy volunteers and in DPD-deficient patients, a possible tool for screening of DPD deficiency. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21590448/),[mg] / [l],20.0,263911,DB00544,Fluorouracil
,21590448,AUC(0>180),"The uracil AUC(0>180) was 31.2 ± 5.1 mg L/h in DPD-deficient subjects, which was significantly higher (P < 0.05) than in the subjects with normal DPD status (13.8 ± 3.9 mg L/h).","Pharmacokinetics of orally administered uracil in healthy volunteers and in DPD-deficient patients, a possible tool for screening of DPD deficiency. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21590448/),[l·mg] / [h],31.2,263912,DB00544,Fluorouracil
,21590448,AUC(0>180),"The uracil AUC(0>180) was 31.2 ± 5.1 mg L/h in DPD-deficient subjects, which was significantly higher (P < 0.05) than in the subjects with normal DPD status (13.8 ± 3.9 mg L/h).","Pharmacokinetics of orally administered uracil in healthy volunteers and in DPD-deficient patients, a possible tool for screening of DPD deficiency. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21590448/),[l·mg] / [h],13.8,263913,DB00544,Fluorouracil
over,2783879,survival,The median survival for CR patients was over 26.7 months and 16.5 months for the PR patients.,Efficacy of high-dose oral leucovorin and 5-fluorouracil in advanced colorectal carcinoma. Plasma and tissue pharmacokinetics. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2783879/),month,26.7,264310,DB00544,Fluorouracil
,2783879,survival,The median survival for CR patients was over 26.7 months and 16.5 months for the PR patients.,Efficacy of high-dose oral leucovorin and 5-fluorouracil in advanced colorectal carcinoma. Plasma and tissue pharmacokinetics. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2783879/),month,16.5,264311,DB00544,Fluorouracil
,2783879,survival,The median survival for stable patients was 9.5 months and 5.5 months for patients with progressive disease.,Efficacy of high-dose oral leucovorin and 5-fluorouracil in advanced colorectal carcinoma. Plasma and tissue pharmacokinetics. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2783879/),month,9.5,264312,DB00544,Fluorouracil
,2783879,survival,The median survival for stable patients was 9.5 months and 5.5 months for patients with progressive disease.,Efficacy of high-dose oral leucovorin and 5-fluorouracil in advanced colorectal carcinoma. Plasma and tissue pharmacokinetics. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2783879/),month,5.5,264313,DB00544,Fluorouracil
,1831736,terminal half-life,The mean terminal half-life for PF FdUrd was found to be 115 min and mean peritoneal clearance was 25 ml/min.,Phase I and pharmacologic evaluation of intraperitoneal 5-fluoro-2'-deoxyuridine. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1831736/),min,115,266249,DB00544,Fluorouracil
,1831736,peritoneal clearance,The mean terminal half-life for PF FdUrd was found to be 115 min and mean peritoneal clearance was 25 ml/min.,Phase I and pharmacologic evaluation of intraperitoneal 5-fluoro-2'-deoxyuridine. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1831736/),[ml] / [min],25,266250,DB00544,Fluorouracil
,25687867,response duration,Median response duration was 9.1 months; median progression-free survival was 3.8 months.,Phase I Study of Axitinib in Combination with Cisplatin and Capecitabine in Patients with Previously Untreated Advanced Gastric Cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25687867/),month,9.1,266502,DB00544,Fluorouracil
,25687867,progression-free survival,Median response duration was 9.1 months; median progression-free survival was 3.8 months.,Phase I Study of Axitinib in Combination with Cisplatin and Capecitabine in Patients with Previously Untreated Advanced Gastric Cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25687867/),month,3.8,266503,DB00544,Fluorouracil
,15905808,Recoveries,"Recoveries ranged between 81% to 85% for all compounds, and the method proved to be linear, with a coefficient of linearity of 0.999.","Improved analysis of 5-Fluorouracil and 5,6-dihydro-5-Fluorouracil by HPLC with diode array detection for determination of cellular dihydropyrimidine dehydrogenase activity and pharmacokinetic profiling. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15905808/),%,81,266939,DB00544,Fluorouracil
,15905808,Recoveries,"Recoveries ranged between 81% to 85% for all compounds, and the method proved to be linear, with a coefficient of linearity of 0.999.","Improved analysis of 5-Fluorouracil and 5,6-dihydro-5-Fluorouracil by HPLC with diode array detection for determination of cellular dihydropyrimidine dehydrogenase activity and pharmacokinetic profiling. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15905808/),%,85,266940,DB00544,Fluorouracil
,10085788,Polydispersity,Polydispersity was estimated to be 0.37.,Lipid grafts of egg-box complex: a new supramolecular biovector for 5-fluorouracil delivery. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10085788/),,0.37,267232,DB00544,Fluorouracil
,10085788,zeta potential,Overall zeta potential was -21.3 mV.,Lipid grafts of egg-box complex: a new supramolecular biovector for 5-fluorouracil delivery. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10085788/),mv,-,267233,DB00544,Fluorouracil
,10085788,zeta potential,Overall zeta potential was -21.3 mV.,Lipid grafts of egg-box complex: a new supramolecular biovector for 5-fluorouracil delivery. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10085788/),mv,21.3,267234,DB00544,Fluorouracil
,10085788,encap,"The drug loading capacity and encapsulation efficiency was found to be 10.0% and 97.9%, respectively.",Lipid grafts of egg-box complex: a new supramolecular biovector for 5-fluorouracil delivery. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10085788/),%,10.0,267235,DB00544,Fluorouracil
,10085788,encap,"The drug loading capacity and encapsulation efficiency was found to be 10.0% and 97.9%, respectively.",Lipid grafts of egg-box complex: a new supramolecular biovector for 5-fluorouracil delivery. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10085788/),%,97.9,267236,DB00544,Fluorouracil
,28973403,progression-free survival,"In Part 2, five of eight patients (63%) with measureable disease at baseline had a partial response and two patients (25%) had stable disease; median (95% CI) progression-free survival was 7.0 (2.4-15.4) months; overall survival was 18.2 (5.6-20.4) months.",A Phase 1/1b tolerability study of rilotumumab alone or in combination with cisplatin and capecitabine in Japanese patients with gastric cancer. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28973403/),month,7.0,267854,DB00544,Fluorouracil
,28973403,overall survival,"In Part 2, five of eight patients (63%) with measureable disease at baseline had a partial response and two patients (25%) had stable disease; median (95% CI) progression-free survival was 7.0 (2.4-15.4) months; overall survival was 18.2 (5.6-20.4) months.",A Phase 1/1b tolerability study of rilotumumab alone or in combination with cisplatin and capecitabine in Japanese patients with gastric cancer. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28973403/),month,18.2,267855,DB00544,Fluorouracil
,3170680,minimum detectable concentration,The minimum detectable concentration in plasma and urine samples is ca. 6 ng/ml.,Bioanalysis of (E)-5-(2-bromovinyl)-2'-deoxyuridine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3170680/),[ng] / [ml],6,268817,DB00544,Fluorouracil
,3170680,recovery,"The recovery after deproteination of plasma samples is 75%, while after liquid-liquid extraction of urine the recovery amounts 92%.",Bioanalysis of (E)-5-(2-bromovinyl)-2'-deoxyuridine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3170680/),%,75,268818,DB00544,Fluorouracil
,3170680,recovery,"The recovery after deproteination of plasma samples is 75%, while after liquid-liquid extraction of urine the recovery amounts 92%.",Bioanalysis of (E)-5-(2-bromovinyl)-2'-deoxyuridine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3170680/),%,92,268819,DB00544,Fluorouracil
,3170680,protein binding,"The degree of protein binding of the analyte, measured by ultrafiltration, is found to be 97%.",Bioanalysis of (E)-5-(2-bromovinyl)-2'-deoxyuridine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3170680/),%,97,268820,DB00544,Fluorouracil
,28744667,OS,"Median OS was 11.5, 12.9, 16.4, and 16.7, and 12.4 months for ramucirumab C min,ss Q1, Q2, Q3, Q4, and placebo group, respectively.",Exposure-response relationship of ramucirumab in patients with advanced second-line colorectal cancer: exploratory analysis of the RAISE trial. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28744667/),month,11.5,269160,DB00544,Fluorouracil
,28744667,OS,"Median OS was 11.5, 12.9, 16.4, and 16.7, and 12.4 months for ramucirumab C min,ss Q1, Q2, Q3, Q4, and placebo group, respectively.",Exposure-response relationship of ramucirumab in patients with advanced second-line colorectal cancer: exploratory analysis of the RAISE trial. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28744667/),month,12.9,269161,DB00544,Fluorouracil
,28744667,OS,"Median OS was 11.5, 12.9, 16.4, and 16.7, and 12.4 months for ramucirumab C min,ss Q1, Q2, Q3, Q4, and placebo group, respectively.",Exposure-response relationship of ramucirumab in patients with advanced second-line colorectal cancer: exploratory analysis of the RAISE trial. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28744667/),month,16.4,269162,DB00544,Fluorouracil
,28744667,OS,"Median OS was 11.5, 12.9, 16.4, and 16.7, and 12.4 months for ramucirumab C min,ss Q1, Q2, Q3, Q4, and placebo group, respectively.",Exposure-response relationship of ramucirumab in patients with advanced second-line colorectal cancer: exploratory analysis of the RAISE trial. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28744667/),month,16.7,269163,DB00544,Fluorouracil
,28744667,OS,"Median OS was 11.5, 12.9, 16.4, and 16.7, and 12.4 months for ramucirumab C min,ss Q1, Q2, Q3, Q4, and placebo group, respectively.",Exposure-response relationship of ramucirumab in patients with advanced second-line colorectal cancer: exploratory analysis of the RAISE trial. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28744667/),month,12.4,269164,DB00544,Fluorouracil
,28744667,PFS,"Median PFS was 5.4, 4.6, 6.8, 8.5, and 5.2 months for ramucirumab C min,ss Q1, Q2, Q3, Q4, and placebo group, respectively.",Exposure-response relationship of ramucirumab in patients with advanced second-line colorectal cancer: exploratory analysis of the RAISE trial. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28744667/),month,5.4,269165,DB00544,Fluorouracil
,28744667,PFS,"Median PFS was 5.4, 4.6, 6.8, 8.5, and 5.2 months for ramucirumab C min,ss Q1, Q2, Q3, Q4, and placebo group, respectively.",Exposure-response relationship of ramucirumab in patients with advanced second-line colorectal cancer: exploratory analysis of the RAISE trial. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28744667/),month,4.6,269166,DB00544,Fluorouracil
,28744667,PFS,"Median PFS was 5.4, 4.6, 6.8, 8.5, and 5.2 months for ramucirumab C min,ss Q1, Q2, Q3, Q4, and placebo group, respectively.",Exposure-response relationship of ramucirumab in patients with advanced second-line colorectal cancer: exploratory analysis of the RAISE trial. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28744667/),month,6.8,269167,DB00544,Fluorouracil
,28744667,PFS,"Median PFS was 5.4, 4.6, 6.8, 8.5, and 5.2 months for ramucirumab C min,ss Q1, Q2, Q3, Q4, and placebo group, respectively.",Exposure-response relationship of ramucirumab in patients with advanced second-line colorectal cancer: exploratory analysis of the RAISE trial. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28744667/),month,8.5,269168,DB00544,Fluorouracil
,28744667,PFS,"Median PFS was 5.4, 4.6, 6.8, 8.5, and 5.2 months for ramucirumab C min,ss Q1, Q2, Q3, Q4, and placebo group, respectively.",Exposure-response relationship of ramucirumab in patients with advanced second-line colorectal cancer: exploratory analysis of the RAISE trial. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28744667/),month,5.2,269169,DB00544,Fluorouracil
,25758191,PFS,"The median PFS and OS after NIPP therapy were 11.0 (95 % confidence interval [CI] 6.6-15.4) and 25.1 (95 % CI 17.1-33.1) months, respectively.",Feasibility and Safety of Negative-Balance Isolated Pelvic Perfusion in Patients with Pretreated Recurrent or Persistent Uterine Cervical Cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25758191/),month,11.0,269225,DB00544,Fluorouracil
,25758191,OS,"The median PFS and OS after NIPP therapy were 11.0 (95 % confidence interval [CI] 6.6-15.4) and 25.1 (95 % CI 17.1-33.1) months, respectively.",Feasibility and Safety of Negative-Balance Isolated Pelvic Perfusion in Patients with Pretreated Recurrent or Persistent Uterine Cervical Cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25758191/),month,25.1,269226,DB00544,Fluorouracil
,25758191,Survival rates,"Survival rates at 1, 2, and 3 years after initial NIPP therapy were 65.2, 50.4, and 13.4 %, respectively.",Feasibility and Safety of Negative-Balance Isolated Pelvic Perfusion in Patients with Pretreated Recurrent or Persistent Uterine Cervical Cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25758191/),%,65,269227,DB00544,Fluorouracil
,25758191,Survival rates,"Survival rates at 1, 2, and 3 years after initial NIPP therapy were 65.2, 50.4, and 13.4 %, respectively.",Feasibility and Safety of Negative-Balance Isolated Pelvic Perfusion in Patients with Pretreated Recurrent or Persistent Uterine Cervical Cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25758191/),%,50.4,269228,DB00544,Fluorouracil
,25758191,Survival rates,"Survival rates at 1, 2, and 3 years after initial NIPP therapy were 65.2, 50.4, and 13.4 %, respectively.",Feasibility and Safety of Negative-Balance Isolated Pelvic Perfusion in Patients with Pretreated Recurrent or Persistent Uterine Cervical Cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25758191/),%,13.4,269229,DB00544,Fluorouracil
,25758191,plasma pelvic-to-systemic exposure ratios,"The plasma pelvic-to-systemic exposure ratios were 15.4 and 15.8, based on the maximum concentration and the concentration-time curve, respectively.",Feasibility and Safety of Negative-Balance Isolated Pelvic Perfusion in Patients with Pretreated Recurrent or Persistent Uterine Cervical Cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25758191/),,15.4,269230,DB00544,Fluorouracil
,25758191,plasma pelvic-to-systemic exposure ratios,"The plasma pelvic-to-systemic exposure ratios were 15.4 and 15.8, based on the maximum concentration and the concentration-time curve, respectively.",Feasibility and Safety of Negative-Balance Isolated Pelvic Perfusion in Patients with Pretreated Recurrent or Persistent Uterine Cervical Cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25758191/),,15.8,269231,DB00544,Fluorouracil
,16047145,complete response,One complete response (54.1+ months) and 2 partial responses were observed.,Phase I/II trial of intraperitoneal 5-Fluorouracil with and without intravenous vasopressin in non-resectable pancreas cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16047145/),month,54,269519,DB00544,Fluorouracil
,16047145,Time to progression,"Time to progression was 4.4 months (0.8-54.1+), and median survival was 8.0 months (0.8-54.1+).",Phase I/II trial of intraperitoneal 5-Fluorouracil with and without intravenous vasopressin in non-resectable pancreas cancer. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16047145/),month,4.4,269520,DB00544,Fluorouracil
,16047145,survival,"Time to progression was 4.4 months (0.8-54.1+), and median survival was 8.0 months (0.8-54.1+).",Phase I/II trial of intraperitoneal 5-Fluorouracil with and without intravenous vasopressin in non-resectable pancreas cancer. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16047145/),month,8.0,269521,DB00544,Fluorouracil
,16047145,Cmax,"There was a significant reduction of 5-FU Cmax in plasma the second day of treatment if vasopressin was used (3.4+/-2.5 and 6.1+/-5.4 mumol/l, respectively, p<0.05).",Phase I/II trial of intraperitoneal 5-Fluorouracil with and without intravenous vasopressin in non-resectable pancreas cancer. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16047145/),[μM] / [l],3.4,269522,DB00544,Fluorouracil
,16047145,Cmax,"There was a significant reduction of 5-FU Cmax in plasma the second day of treatment if vasopressin was used (3.4+/-2.5 and 6.1+/-5.4 mumol/l, respectively, p<0.05).",Phase I/II trial of intraperitoneal 5-Fluorouracil with and without intravenous vasopressin in non-resectable pancreas cancer. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16047145/),[μM] / [l],6.1,269523,DB00544,Fluorouracil
,16047145,Tumour response,Tumour response was 4.4% and median survival time 8.0 months.,Phase I/II trial of intraperitoneal 5-Fluorouracil with and without intravenous vasopressin in non-resectable pancreas cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16047145/),%,4.4,269524,DB00544,Fluorouracil
,16047145,survival time,Tumour response was 4.4% and median survival time 8.0 months.,Phase I/II trial of intraperitoneal 5-Fluorouracil with and without intravenous vasopressin in non-resectable pancreas cancer. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16047145/),month,8.0,269525,DB00544,Fluorouracil
,17982652,terminal half-life (t(1/2)),"The estimated pharmacokinetic parameters of irinotecan [terminal half-life (t(1/2)), 11.5 h; total clearance (CL), 25.0 l h(-1); area under curve (AUC), 14.9 mg x h l(-1)] and SN-38 (terminal t(1/2), 32.2 h; AUC, 0.42 mg x h l(-1)) were similar to those determined in other studies.","A limited sampling strategy to estimate the pharmacokinetic parameters of irinotecan and its active metabolite, SN-38, in patients with metastatic digestive cancer receiving the FOLFIRI regimen. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/17982652/),h,11.5,269647,DB00544,Fluorouracil
,17982652,total clearance (CL),"The estimated pharmacokinetic parameters of irinotecan [terminal half-life (t(1/2)), 11.5 h; total clearance (CL), 25.0 l h(-1); area under curve (AUC), 14.9 mg x h l(-1)] and SN-38 (terminal t(1/2), 32.2 h; AUC, 0.42 mg x h l(-1)) were similar to those determined in other studies.","A limited sampling strategy to estimate the pharmacokinetic parameters of irinotecan and its active metabolite, SN-38, in patients with metastatic digestive cancer receiving the FOLFIRI regimen. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17982652/),[l] / [h],25.0,269648,DB00544,Fluorouracil
,17982652,area under curve (AUC),"The estimated pharmacokinetic parameters of irinotecan [terminal half-life (t(1/2)), 11.5 h; total clearance (CL), 25.0 l h(-1); area under curve (AUC), 14.9 mg x h l(-1)] and SN-38 (terminal t(1/2), 32.2 h; AUC, 0.42 mg x h l(-1)) were similar to those determined in other studies.","A limited sampling strategy to estimate the pharmacokinetic parameters of irinotecan and its active metabolite, SN-38, in patients with metastatic digestive cancer receiving the FOLFIRI regimen. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17982652/),[h·mg] / [l],14.9,269649,DB00544,Fluorouracil
,17982652,terminal t(1/2),"The estimated pharmacokinetic parameters of irinotecan [terminal half-life (t(1/2)), 11.5 h; total clearance (CL), 25.0 l h(-1); area under curve (AUC), 14.9 mg x h l(-1)] and SN-38 (terminal t(1/2), 32.2 h; AUC, 0.42 mg x h l(-1)) were similar to those determined in other studies.","A limited sampling strategy to estimate the pharmacokinetic parameters of irinotecan and its active metabolite, SN-38, in patients with metastatic digestive cancer receiving the FOLFIRI regimen. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/17982652/),h,32.2,269650,DB00544,Fluorouracil
,17982652,AUC,"The estimated pharmacokinetic parameters of irinotecan [terminal half-life (t(1/2)), 11.5 h; total clearance (CL), 25.0 l h(-1); area under curve (AUC), 14.9 mg x h l(-1)] and SN-38 (terminal t(1/2), 32.2 h; AUC, 0.42 mg x h l(-1)) were similar to those determined in other studies.","A limited sampling strategy to estimate the pharmacokinetic parameters of irinotecan and its active metabolite, SN-38, in patients with metastatic digestive cancer receiving the FOLFIRI regimen. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17982652/),[h·mg] / [l],0.42,269651,DB00544,Fluorouracil
,6883317,Css,"Following i.v. infusion to low-microM steady-state plasma levels (Css = 7.6 to 12 microM), each compound alone demonstrated an elimination half-life (t1/2) between 2 and 20 min.","Nonlinear pharmacokinetics of thymidine, thymine, and fluorouracil and their kinetic interactions in normal dogs. ",Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6883317/),μM,7.6 to 12,269657,DB00544,Fluorouracil
,6883317,elimination half-life (t1/2),"Following i.v. infusion to low-microM steady-state plasma levels (Css = 7.6 to 12 microM), each compound alone demonstrated an elimination half-life (t1/2) between 2 and 20 min.","Nonlinear pharmacokinetics of thymidine, thymine, and fluorouracil and their kinetic interactions in normal dogs. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6883317/),min,2 and 20,269658,DB00544,Fluorouracil
,6883317,Css,"When Css was increased to near 1000 microM, the elimination of dThd, thymine, and FUra was markedly slower and no longer followed first-order kinetics.","Nonlinear pharmacokinetics of thymidine, thymine, and fluorouracil and their kinetic interactions in normal dogs. ",Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6883317/),μM,1000,269659,DB00544,Fluorouracil
,6883317,Km,"Using equations based on Michaelis-Menten kinetics, in vivo values of Km and Vmax were determined: Km (in microM): dThd, 45.5; thymine, 82.5; FUra, 39.8; Vmax (in mumol/min/kg): dThd, 2.45; Thymine, 2.55; FUra, 2.16.","Nonlinear pharmacokinetics of thymidine, thymine, and fluorouracil and their kinetic interactions in normal dogs. ",Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6883317/),μM,45.5,269660,DB00544,Fluorouracil
,6883317,Km,"Using equations based on Michaelis-Menten kinetics, in vivo values of Km and Vmax were determined: Km (in microM): dThd, 45.5; thymine, 82.5; FUra, 39.8; Vmax (in mumol/min/kg): dThd, 2.45; Thymine, 2.55; FUra, 2.16.","Nonlinear pharmacokinetics of thymidine, thymine, and fluorouracil and their kinetic interactions in normal dogs. ",Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6883317/),μM,82.5,269661,DB00544,Fluorouracil
,6883317,Km,"Using equations based on Michaelis-Menten kinetics, in vivo values of Km and Vmax were determined: Km (in microM): dThd, 45.5; thymine, 82.5; FUra, 39.8; Vmax (in mumol/min/kg): dThd, 2.45; Thymine, 2.55; FUra, 2.16.","Nonlinear pharmacokinetics of thymidine, thymine, and fluorouracil and their kinetic interactions in normal dogs. ",Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6883317/),μM,39.8,269662,DB00544,Fluorouracil
,6883317,Vmax,"Using equations based on Michaelis-Menten kinetics, in vivo values of Km and Vmax were determined: Km (in microM): dThd, 45.5; thymine, 82.5; FUra, 39.8; Vmax (in mumol/min/kg): dThd, 2.45; Thymine, 2.55; FUra, 2.16.","Nonlinear pharmacokinetics of thymidine, thymine, and fluorouracil and their kinetic interactions in normal dogs. ",Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6883317/),[μM] / [kg·min],2.45,269663,DB00544,Fluorouracil
,6883317,Vmax,"Using equations based on Michaelis-Menten kinetics, in vivo values of Km and Vmax were determined: Km (in microM): dThd, 45.5; thymine, 82.5; FUra, 39.8; Vmax (in mumol/min/kg): dThd, 2.45; Thymine, 2.55; FUra, 2.16.","Nonlinear pharmacokinetics of thymidine, thymine, and fluorouracil and their kinetic interactions in normal dogs. ",Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6883317/),[μM] / [kg·min],2.55,269664,DB00544,Fluorouracil
,6883317,Vmax,"Using equations based on Michaelis-Menten kinetics, in vivo values of Km and Vmax were determined: Km (in microM): dThd, 45.5; thymine, 82.5; FUra, 39.8; Vmax (in mumol/min/kg): dThd, 2.45; Thymine, 2.55; FUra, 2.16.","Nonlinear pharmacokinetics of thymidine, thymine, and fluorouracil and their kinetic interactions in normal dogs. ",Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6883317/),[μM] / [kg·min],2.16,269665,DB00544,Fluorouracil
,6883317,Ki,"Assuming competitive enzymatic inhibition, in vivo Ki values for dThd and thymine effects on FUra metabolism were 24.2 and 17.4 microM, respectively.","Nonlinear pharmacokinetics of thymidine, thymine, and fluorouracil and their kinetic interactions in normal dogs. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6883317/),μM,24.2,269666,DB00544,Fluorouracil
,6883317,Ki,"Assuming competitive enzymatic inhibition, in vivo Ki values for dThd and thymine effects on FUra metabolism were 24.2 and 17.4 microM, respectively.","Nonlinear pharmacokinetics of thymidine, thymine, and fluorouracil and their kinetic interactions in normal dogs. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6883317/),μM,17.4,269667,DB00544,Fluorouracil
,1919632,overall response rate,"In 22 patients without prior 5-FU therapy, three complete (13.6%) and seven partial (31.8%) responses were seen, for an overall response rate of 45.4% (95% confidence interval, 24.4% to 67.8%).",A pilot study of interferon alfa-2a in combination with fluorouracil plus high-dose leucovorin in metastatic gastrointestinal carcinoma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1919632/),%,45.4,269680,DB00544,Fluorouracil
,8622075,maximal rate of elimination (Vmax),"The data for 5-FU were best described by a one-compartment model with nonlinear elimination, where the maximal rate of elimination (Vmax) and the concentration at which the elimination was half-maximal (Km) were 105 mg/L.h and 27 mg/L, respectively.","Lack of relationship between systemic exposure for the component drug of the fluorouracil, epirubicin, and 4-hydroxycyclophosphamide regimen in breast cancer patients. ",Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8622075/),[mg] / [h·l],105,269720,DB00544,Fluorouracil
,8622075,concentration at which the elimination was half-maximal (Km),"The data for 5-FU were best described by a one-compartment model with nonlinear elimination, where the maximal rate of elimination (Vmax) and the concentration at which the elimination was half-maximal (Km) were 105 mg/L.h and 27 mg/L, respectively.","Lack of relationship between systemic exposure for the component drug of the fluorouracil, epirubicin, and 4-hydroxycyclophosphamide regimen in breast cancer patients. ",Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8622075/),[mg] / [l],27,269721,DB00544,Fluorouracil
,8622075,terminal half-life,"EPI concentration-time profiles showed a triexponential decline, with a mean terminal half-life of 24 hours and a clearance (CL) of 59 L/h.","Lack of relationship between systemic exposure for the component drug of the fluorouracil, epirubicin, and 4-hydroxycyclophosphamide regimen in breast cancer patients. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8622075/),h,24,269722,DB00544,Fluorouracil
,8622075,clearance (CL),"EPI concentration-time profiles showed a triexponential decline, with a mean terminal half-life of 24 hours and a clearance (CL) of 59 L/h.","Lack of relationship between systemic exposure for the component drug of the fluorouracil, epirubicin, and 4-hydroxycyclophosphamide regimen in breast cancer patients. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8622075/),[l] / [h],59,269723,DB00544,Fluorouracil
,8622075,half-life,"The elimination of 4-OHCP was monoexponential, with a mean half-life of 7 hours.","Lack of relationship between systemic exposure for the component drug of the fluorouracil, epirubicin, and 4-hydroxycyclophosphamide regimen in breast cancer patients. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8622075/),h,7,269724,DB00544,Fluorouracil
,9051137,response duration,"The mean response duration and survival period for the eleven patients were 13 and 21 months, respectively, and one- and two year survival rates were 82% and 27%.","[Clinical effects of postoperative immunochemotherapy with a combination of 5-FU, CDDP and lentinan for stage IVb gastric carcinoma and long-term pharmacokinetic studies on CDDP and 5-FU]. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9051137/),month,13,269948,DB00544,Fluorouracil
,9051137,survival period,"The mean response duration and survival period for the eleven patients were 13 and 21 months, respectively, and one- and two year survival rates were 82% and 27%.","[Clinical effects of postoperative immunochemotherapy with a combination of 5-FU, CDDP and lentinan for stage IVb gastric carcinoma and long-term pharmacokinetic studies on CDDP and 5-FU]. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9051137/),month,21,269949,DB00544,Fluorouracil
,9051137,survival,"The mean response duration and survival period for the eleven patients were 13 and 21 months, respectively, and one- and two year survival rates were 82% and 27%.","[Clinical effects of postoperative immunochemotherapy with a combination of 5-FU, CDDP and lentinan for stage IVb gastric carcinoma and long-term pharmacokinetic studies on CDDP and 5-FU]. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9051137/),%,27,269950,DB00544,Fluorouracil
,7909867,half-life,"We defined an intratumoral half-life of fluorouracil of 20 min or more as indicating trapping of the drug, based on the blood half-life of 8-12 min.",Association of intratumoral pharmacokinetics of fluorouracil with clinical response. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7909867/),min,20,270858,DB00544,Fluorouracil
,7909867,blood half-life,"We defined an intratumoral half-life of fluorouracil of 20 min or more as indicating trapping of the drug, based on the blood half-life of 8-12 min.",Association of intratumoral pharmacokinetics of fluorouracil with clinical response. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7909867/),min,8-12,270859,DB00544,Fluorouracil
less,7909867,half-lives,"19 patients had intratumoral half-lives indicating trapping of fluorouracil, 27 had half-lives less than 20 min, and 11 had no detectable fluorouracil in their tumours.",Association of intratumoral pharmacokinetics of fluorouracil with clinical response. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7909867/),min,20,270860,DB00544,Fluorouracil
,6488155,area under the concentration versus time curves ratio,"For continuous infusion of 5-FUra, the area under the concentration versus time curves ratio for CSF:plasma was 20 or 11%, depending upon the infusion rate.",Effect of intravenous dose and schedule on cerebrospinal fluid pharmacokinetics of 5-fluorouracil in the monkey. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6488155/),%,20,271019,DB00544,Fluorouracil
,6488155,area under the concentration versus time curves ratio,"For continuous infusion of 5-FUra, the area under the concentration versus time curves ratio for CSF:plasma was 20 or 11%, depending upon the infusion rate.",Effect of intravenous dose and schedule on cerebrospinal fluid pharmacokinetics of 5-fluorouracil in the monkey. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6488155/),%,11,271020,DB00544,Fluorouracil
,15756033,K(d),"By use of XenoMouse technology, we generated CP-751,871, a fully human IgG2 antibody with high affinity (K(d) = 1.5 nmol/L) for human IGF-1R and evaluated its biological, pharmacologic, and antitumor properties.","Combination therapy enhances the inhibition of tumor growth with the fully human anti-type 1 insulin-like growth factor receptor monoclonal antibody CP-751,871. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15756033/),[nM] / [l],1.5,272311,DB00544,Fluorouracil
,15756033,IC(50),"This antibody blocks binding of IGF-1 to its receptor (IC(50) 1.8 nmol/L), IGF-1-induced receptor autophosphorylation (IC(50) 0.42 nmol/L) and induced the down-regulation of IGF-1R in vitro and in tumor xenografts.","Combination therapy enhances the inhibition of tumor growth with the fully human anti-type 1 insulin-like growth factor receptor monoclonal antibody CP-751,871. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15756033/),[nM] / [l],1.8,272312,DB00544,Fluorouracil
,15756033,IC(50),"This antibody blocks binding of IGF-1 to its receptor (IC(50) 1.8 nmol/L), IGF-1-induced receptor autophosphorylation (IC(50) 0.42 nmol/L) and induced the down-regulation of IGF-1R in vitro and in tumor xenografts.","Combination therapy enhances the inhibition of tumor growth with the fully human anti-type 1 insulin-like growth factor receptor monoclonal antibody CP-751,871. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15756033/),[nM] / [l],0.42,272313,DB00544,Fluorouracil
,32104354,maximum drug loading,"Here, we found that when the mass ratio of 5-fluorouracil and chitosan was 1:1, the maximum drug loading of nanoparticles was 20.13 ± 0.007%, the encapsulation efficiency was 44.28 ± 1.69%, the particle size was 283.9 ± 5.25 nm and the zeta potential was 45.3 ± 3.23 mV.",Preparation of 5-fluorouracil-loaded chitosan nanoparticles and study of the sustained release in vitro and in vivo. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32104354/),%,20.13,272361,DB00544,Fluorouracil
,32104354,encapsulation efficiency,"Here, we found that when the mass ratio of 5-fluorouracil and chitosan was 1:1, the maximum drug loading of nanoparticles was 20.13 ± 0.007%, the encapsulation efficiency was 44.28 ± 1.69%, the particle size was 283.9 ± 5.25 nm and the zeta potential was 45.3 ± 3.23 mV.",Preparation of 5-fluorouracil-loaded chitosan nanoparticles and study of the sustained release in vitro and in vivo. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32104354/),%,44.28,272362,DB00544,Fluorouracil
,32104354,zeta potential,"Here, we found that when the mass ratio of 5-fluorouracil and chitosan was 1:1, the maximum drug loading of nanoparticles was 20.13 ± 0.007%, the encapsulation efficiency was 44.28 ± 1.69%, the particle size was 283.9 ± 5.25 nm and the zeta potential was 45.3 ± 3.23 mV.",Preparation of 5-fluorouracil-loaded chitosan nanoparticles and study of the sustained release in vitro and in vivo. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32104354/),mv,45.3,272363,DB00544,Fluorouracil
,15381932,time to treatment failure,"No significant differences in efficacy across the four arms were observed, although a shorter time to treatment failure was noted for arm D (1.7 months; P=0.02).",A randomised phase II multicentre trial of irinotecan (CPT-11) using four different schedules in patients with metastatic colorectal cancer. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15381932/),month,1.7,272562,DB00544,Fluorouracil
,15381932,Overall response rates,Overall response rates were in the range 5-11%.,A randomised phase II multicentre trial of irinotecan (CPT-11) using four different schedules in patients with metastatic colorectal cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15381932/),%,5-11,272563,DB00544,Fluorouracil
,15381932,time to progression,"Secondary end points included median survival (6.4-9.4 months), and time to progression (2.7-3.8 months) and treatment failure (1.7-3.2 months).",A randomised phase II multicentre trial of irinotecan (CPT-11) using four different schedules in patients with metastatic colorectal cancer. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15381932/),month,2.7-3.8,272564,DB00544,Fluorouracil
,15381932,treatment failure,"Secondary end points included median survival (6.4-9.4 months), and time to progression (2.7-3.8 months) and treatment failure (1.7-3.2 months).",A randomised phase II multicentre trial of irinotecan (CPT-11) using four different schedules in patients with metastatic colorectal cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15381932/),month,1.7-3.2,272565,DB00544,Fluorouracil
,16305582,elimination half-life,"The elimination half-life of [2-(13)C]5,6-dihydrouracil was 0.9-1.4 h, whereas that of [2-(13)C]uracil was 0.2-0.3 h.",Physiologically based pharmacokinetic modelling of the three-step metabolism of pyrimidine using C-uracil as an in vivo probe. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/16305582/),h,0.9-1.4,273572,DB00544,Fluorouracil
,16305582,elimination half-life,"The elimination half-life of [2-(13)C]5,6-dihydrouracil was 0.9-1.4 h, whereas that of [2-(13)C]uracil was 0.2-0.3 h.",Physiologically based pharmacokinetic modelling of the three-step metabolism of pyrimidine using C-uracil as an in vivo probe. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/16305582/),h,0.2-0.3,273573,DB00544,Fluorouracil
,29488048,Maximum plasma concentrations (Cmax),"Maximum plasma concentrations (Cmax) of capecitabine (11.51 ± 9.73 μg/ml) occurred at 0.5 h, whereas the Cmax of 5'-deoxy-5-fluorocytidine (5'-DFCR; 2.45 ± 2.93 μg/ml), 5'-deoxy-5-fluorouridine (5'-DFUR; 6.43 ± 8.2 μg/ml), and 5-fluorouracil (5-FU; 0.24 ± 0.16 μg/ml) were found at 1 h, 1.5 h and 1 h, respectively.",Pharmacokinetic analysis of metronomic capecitabine in refractory metastatic colorectal cancer patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29488048/),[μg] / [ml],11.51,273614,DB00544,Fluorouracil
,29488048,Cmax,"Maximum plasma concentrations (Cmax) of capecitabine (11.51 ± 9.73 μg/ml) occurred at 0.5 h, whereas the Cmax of 5'-deoxy-5-fluorocytidine (5'-DFCR; 2.45 ± 2.93 μg/ml), 5'-deoxy-5-fluorouridine (5'-DFUR; 6.43 ± 8.2 μg/ml), and 5-fluorouracil (5-FU; 0.24 ± 0.16 μg/ml) were found at 1 h, 1.5 h and 1 h, respectively.",Pharmacokinetic analysis of metronomic capecitabine in refractory metastatic colorectal cancer patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29488048/),[μg] / [ml],2.45,273615,DB00544,Fluorouracil
,29488048,Cmax,"Maximum plasma concentrations (Cmax) of capecitabine (11.51 ± 9.73 μg/ml) occurred at 0.5 h, whereas the Cmax of 5'-deoxy-5-fluorocytidine (5'-DFCR; 2.45 ± 2.93 μg/ml), 5'-deoxy-5-fluorouridine (5'-DFUR; 6.43 ± 8.2 μg/ml), and 5-fluorouracil (5-FU; 0.24 ± 0.16 μg/ml) were found at 1 h, 1.5 h and 1 h, respectively.",Pharmacokinetic analysis of metronomic capecitabine in refractory metastatic colorectal cancer patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29488048/),[μg] / [ml],6.43,273616,DB00544,Fluorouracil
,29488048,Cmax,"Maximum plasma concentrations (Cmax) of capecitabine (11.51 ± 9.73 μg/ml) occurred at 0.5 h, whereas the Cmax of 5'-deoxy-5-fluorocytidine (5'-DFCR; 2.45 ± 2.93 μg/ml), 5'-deoxy-5-fluorouridine (5'-DFUR; 6.43 ± 8.2 μg/ml), and 5-fluorouracil (5-FU; 0.24 ± 0.16 μg/ml) were found at 1 h, 1.5 h and 1 h, respectively.",Pharmacokinetic analysis of metronomic capecitabine in refractory metastatic colorectal cancer patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29488048/),[μg] / [ml],0.24,273617,DB00544,Fluorouracil
,29488048,AUCs,"Capecitabine, 5'-DFCR, 5'-DFUR and 5-FU AUCs at day 1 were 21.30 ± 10.78, 5.2 ± 4.6, 19.59 ± 3.83 and 0.66 ± 0.77 hxμg/ml, respectively.",Pharmacokinetic analysis of metronomic capecitabine in refractory metastatic colorectal cancer patients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29488048/),[h·μg] / [ml],21.30,273618,DB00544,Fluorouracil
,29488048,AUCs,"Capecitabine, 5'-DFCR, 5'-DFUR and 5-FU AUCs at day 1 were 21.30 ± 10.78, 5.2 ± 4.6, 19.59 ± 3.83 and 0.66 ± 0.77 hxμg/ml, respectively.",Pharmacokinetic analysis of metronomic capecitabine in refractory metastatic colorectal cancer patients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29488048/),[h·μg] / [ml],5.2,273619,DB00544,Fluorouracil
,29488048,AUCs,"Capecitabine, 5'-DFCR, 5'-DFUR and 5-FU AUCs at day 1 were 21.30 ± 10.78, 5.2 ± 4.6, 19.59 ± 3.83 and 0.66 ± 0.77 hxμg/ml, respectively.",Pharmacokinetic analysis of metronomic capecitabine in refractory metastatic colorectal cancer patients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29488048/),[h·μg] / [ml],19.59,273620,DB00544,Fluorouracil
,29488048,AUCs,"Capecitabine, 5'-DFCR, 5'-DFUR and 5-FU AUCs at day 1 were 21.30 ± 10.78, 5.2 ± 4.6, 19.59 ± 3.83 and 0.66 ± 0.77 hxμg/ml, respectively.",Pharmacokinetic analysis of metronomic capecitabine in refractory metastatic colorectal cancer patients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29488048/),[h·μg] / [ml],0.66,273621,DB00544,Fluorouracil
